"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03765957","Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells",,"Recruiting","No Results Available","Psoriasis","Biological: Mesenchymal Stem Cells","Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement|Number of Participants Achieving a Physician Global Assessment (PGA) of (0, 1)|Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score|Adverse event","Central South University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-MSC/CSU/PS","February 20, 2019","July 31, 2020","June 1, 2021","December 5, 2018",,"September 23, 2020","Xiangya Hospital, Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03765957"
2,"NCT04447833","Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome","ARDS-MSC-205","Active, not recruiting","No Results Available","ARDS, Human|COVID","Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205","The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test","Uppsala University|Uppsala University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-02238","June 17, 2020","January 30, 2021","June 30, 2025","June 25, 2020",,"March 4, 2021","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04447833"
3,"NCT04073472","Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's","IPAAF","Withdrawn","No Results Available","Crohn's Disease|Fistula|Anal Fistula|Pouch, Ileal|Pouches, Ileoanal","Drug: mesenchymal stem cells (MSCs)","Safety and Feasibility: Number Of Adverse Events|Radiographic Healing|Clinical Healing","The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment",,"June 1, 2021","June 1, 2022","June 1, 2023","August 29, 2019",,"November 5, 2021",,,"https://ClinicalTrials.gov/show/NCT04073472"
4,"NCT03558334","Human Mesenchymal Stem Cells For Bronchopulmonary Dysplasia",,"Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: Transplantation of mesenchymal stem cell|Drug: No transplantation of mesenchymal stem cell","Number of participants with adverse reactions related to infusion after treatment|Changes of high-resolution chest CT in participants|Changes of temperature in participants|Changes of blood pressure in participants|Changes of heart rate in participants|Changes of respiratory rate in participants|Changes of oxygen saturation in participants|Growth velocity (Z-score) in participants","Children's Hospital of Chongqing Medical University","All","Child, Adult, Older Adult","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XYunqiu","June 28, 2018","December 31, 2021","June 30, 2022","June 15, 2018",,"May 21, 2019","Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03558334"
5,"NCT02824393","Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria",,"Completed","No Results Available","Urticaria|Autoimmune Diseases|Immune System Diseases|Skin Diseases","Biological: Autologous mesenchymal stem cell","Change from baseline in weekly urticaria activity scores.|Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.|The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.|The changes in ratios of peripheral blood inflammatory and anti-inflammatory cytokines.|The changes in the levels of peripheral blood anti-FcεRI autoantibody","Celal Bayar University|The Scientific and Technological Research Council of Turkey|Acıbadem Labcell","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TUBITAK-1001-215S612","March 3, 2017","May 15, 2018","July 15, 2018","July 6, 2016",,"July 18, 2018","Celal Bayar University, Medical School, Manisa, Turkey",,"https://ClinicalTrials.gov/show/NCT02824393"
6,"NCT01221428","Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis",,"Unknown status","No Results Available","Ulcerative Colitis|Mesenchymal Stem Cells|Umbilical Cord","Biological: Umbilical Cord Mesenchymal Stem Cells","the result of enteroscopy and pathological report|the clinical symptom (including stomachache,abdominal distention,bloody purulent stool)","Qingdao University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCKJ004","September 2010","September 2012","December 2012","October 15, 2010",,"October 15, 2010","Stem Cell Research Center of Medical School Hospital of Qingdao University, Qingdao, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01221428"
7,"NCT02247973","Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.",,"Unknown status","No Results Available","Severe Aplastic Anemia","Biological: mesenchymal stem cells","survival rate|acute GVHD|chronic GVHD|Transplant-related mortality|Rates of relapse|The implantation","Guangzhou General Hospital of Guangzhou Military Command|Guangzhou First People's Hospital|Nanfang Hospital of Southern Medical University|Southern Medical University, China|First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital, Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Fifth Affiliated Hospital, Sun Yat-Sen University|Guangdong Provincial People's Hospital|The Second People's Hospital of GuangDong Province|First Affiliated Hospital of Jinan University|The First Affiliated Hospital of Guangzhou Medical University|Second Affiliated Hospital of Guangzhou Medical University|Peking University Shenzhen Hospital|Shenzhen Second People's Hospital","All","14 Years to 50 Years   (Child, Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-alternative donor SCT-SAA","February 2013","February 2017","February 2018","September 25, 2014",,"September 25, 2014","Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02247973"
8,"NCT01219465","Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus",,"Unknown status","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 1|Mesenchymal Stem Cells|Umbilical Cord","Biological: umbilical cord mesenchymal stem cells","C peptide release test|Exogenous insulin dose|blood glucose|glycosylated Hemoglobin A1c|Number of severe and documented hypoglycemic events|Immunologic reconstitution parameters","Qingdao University","All","3 Years to 35 Years   (Child, Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCT1DM003","September 2010","September 2012","December 2012","October 13, 2010",,"October 13, 2010","Stem Cell Research Center of Medical School Hospital of Qingdao University, Qingdao, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01219465"
9,"NCT02387151","Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients","Neptune","Completed","No Results Available","Rejection|Graft Loss","Drug: mesenchymal stromal cells","biopsy proven acute rejection / graft loss|Comparison of fibrosis by quantitative Sirius Red scoring|Serious adverse events|Renal function measured by cGFR (MDRD formula) and iohexol clearance|CMV, BK infection (viremia, disease and syndrome; and subtypes of BK viremia) and other opportunistic infections|Development of de novo donor specific antibodies (DSA) and immunological responses","Leiden University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL4724400013|2013-005407-14","March 2015","November 2018","November 2018","March 12, 2015",,"July 2, 2019","Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02387151"
10,"NCT01219452","Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy",,"Unknown status","No Results Available","Dilated Cardiomyopathy","Biological: umbilical cord mesenchymal stem cells","echocardiography|24h HOLTER|The level of serum BNP,TNI,HGF、LIF and G/M-CSF|The expression level of c-kit,CD31,CD133 on peripheral blood mononuclear cells","Qingdao University","All","1 Year to 14 Years   (Child)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCKX002","October 2010","November 2012","December 2012","October 13, 2010",,"October 28, 2010","Stem Cell Research Center of Medical School Hospital of Qingdao University, Qingdao, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01219452"
11,"NCT02409940","To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients",,"Unknown status","No Results Available","Renal Transplant Rejection","Biological: Mesenchymal Stem Cells","Expansion of regulatory T cell compartment of the patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Normalization of serum creatinine levels of the patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|T cell proliferation changes in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in regulatory T cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in memory T cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in B cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in cytokine profile in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.","Postgraduate Institute of Medical Education and Research","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IFA-LSBM-11","September 2013","September 2016","March 2017","April 7, 2015",,"November 8, 2016","Translational and Regenerative Medicine, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT02409940"
12,"NCT01589549","Mesenchymal Stromal Cells for Acute Graft Versus Host Disease",,"Unknown status","No Results Available","Acute GVH Disease","Biological: Mesenchymal stromal cell therapy","Survival at one year after onset of graft versus host disease|Response at 14 days after commencement of treatment for acute graft versus host disease|Response at 28 days after commencement of treatment of acute graft versus host disease|Incidence of severe infection|Disease free survival at one year|Time to treatment failure, requiring salvage therapy","R.P.Herrmann|Royal Perth Hospital","All","18 Years to 55 Years   (Adult)","Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011/128|CTN 2012/0174","April 2012","December 2015","December 2016","May 2, 2012",,"June 9, 2015","Royal Perth Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01589549"
13,"NCT02326935","Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis",,"Terminated","No Results Available","Multiple Sclerosis","Biological: Autologous adipose derived mesenchymal cells","Standard Complication Questionnaire|MS Impact Scale - MSIS-29|Modified SF-36 Cell-Based Therapy Follow Up|Physical Evaluation","American CryoStem Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRYO-MS-ADSC-006","November 2014","May 18, 2018","May 18, 2018","December 30, 2014",,"May 22, 2018","The Da Vinci Center, George Town, Cayman Islands",,"https://ClinicalTrials.gov/show/NCT02326935"
14,"NCT03863002","Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure",,"Not yet recruiting","No Results Available","Liver Failure, Acute on Chronic","Biological: Mesenchymal Stem Cell","survival rate|Adverse reactions|White blood cell|Platelet|Hemoglobin|Creatinine|ALT|ALB|TBil|INRs|AFP|MELD scores|Tumor formation|Liver failure-associated serious complications","Tianjin Weikai Bioeng., Ltd.|Tianjin Nankai Hospital","All","16 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Tianjin Weikai Bioeng., Ltd","October 1, 2019","October 1, 2021","October 1, 2022","March 5, 2019",,"March 20, 2019","Tianjin Weikai Bioeng., Ltd., Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT03863002"
15,"NCT02172885","Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta","TERCELOI","Completed","No Results Available","Osteogenesis Imperfecta","Biological: Mesenchymal Stem Cells","Adverse Events as a Measure of Safety|bone mineral density|fracture rate|growth velocity|change from baseline in degree of functionality|change from baseline in well-being","Hospital de Cruces|Hospital Universitario Getafe|Hospital Infantil Universitario Niño Jesús, Madrid, Spain","All","6 Months to 12 Years   (Child)","Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT Number:2012-002553-38|Health Department of Spain","April 2014","December 2018","December 2018","June 24, 2014",,"March 26, 2019","Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain|Hospital Universitario Getafe, Getafe, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02172885"
16,"NCT02057965","Mesenchymal Stromal Cell Therapy in Renal Recipients","MSCs","Active, not recruiting","No Results Available","Renal Transplant Rejection|Fibrosis","Drug: Mesenchymal Stromal Cells","Fibrosis by quantitative Sirius Red scoring of MSC treated and untreated groups|Renal function and proteinuria|Number of participants with CMV and BK infection an other opportunistic infections between groups|Number of participants with adverse events|composite end point efficacy failure (biopsy proven acute rejection, graft loss or death)|Presence of donor specific antibodies and immunologic monitoring|Progression of subclinical cardiovascular disease in the different treatment groups bij assessing echocardiographic parameters","Leiden University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL43712.000.13|2013-000819-25","March 2014","January 2020","January 2022","February 7, 2014",,"September 17, 2020","Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02057965"
17,"NCT02285673","Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy",,"Unknown status","No Results Available","Duchenne Muscular Dystrophy","Biological: Umbilical Cord Mesenchymal Stem Cell","Duchenne muscular dystrophy gene expression","Acibadem University","Male","7 Years to 20 Years   (Child, Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DMD-UC-MSC-1","November 2013","February 2015","November 2015","November 7, 2014",,"November 7, 2014","Acibadem Labcell, Istanbul, Uskudar, Turkey",,"https://ClinicalTrials.gov/show/NCT02285673"
18,"NCT04125329","Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy",,"Recruiting","No Results Available","Mesenchymal Stem Cells|Diabetic Nephropathy","Drug: Human umbilical cord mesenchymal stem cells","Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient|Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment","Yan'an Affiliated Hospital of Kunming Medical University","All","18 Years to 60 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","43136152-9","April 1, 2020","September 1, 2024","September 1, 2024","October 14, 2019",,"April 21, 2021","Yan'an Hospital of Kunming City, Kunming, China",,"https://ClinicalTrials.gov/show/NCT04125329"
19,"NCT01956903","Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.","CSM/EICH2010","Completed","No Results Available","Chronic Graft-Versus-Host Disease","Genetic: Allogenic Mesenchymal Stem Cell","Adverse effects|efficacy","Grupo Espanol de trasplantes hematopoyeticos y terapia celular","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/EICH2010|2010-020947-11","January 2010","September 2013","September 2013","October 8, 2013",,"October 8, 2013","Grupo Espanol de trasplantes hematopoyeticos y terapia celular, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01956903"
20,"NCT02482194","Autologous Mesenchymal Stem Cells Transplantation for Spinal Cord Injury- A Phase I Clinical Study",,"Completed","No Results Available","Spinal Cord Injury","Biological: mesenchymal stem cells","Number of adverse events|Sensory and motor strength|Functional Independence|Muscle strength assessment","National Institute of Blood and Marrow Transplant (NIBMT), Pakistan|Armed Forces Institute of Regenerative Medicine","All","18 Years to 50 Years   (Adult)","Phase 1","9","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFBMTC-SCI-2013","June 2013","January 2016","March 2016","June 26, 2015",,"June 29, 2016","Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan",,"https://ClinicalTrials.gov/show/NCT02482194"
21,"NCT03601416","Human Mesenchymal Stem Cells For Moderate and Severe Bronchopulmonary Dysplasia",,"Not yet recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: Transplantation of mesenchymal stem cell|Drug: No Transplantation of Mesenchymal Stem Cell","the accumulative duration of oxygen therapy|Changes of blood pressure in participants|Changes of heart rate in participants","Children's Hospital of Chongqing Medical University","All","up to 1 Year   (Child)","Phase 2","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Xia Yunqiu","July 1, 2019","June 1, 2021","December 31, 2021","July 26, 2018",,"January 15, 2019","Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03601416"
22,"NCT01941394","Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation",,"Unknown status","No Results Available","Graft-versus-host Disease|Relapse","Biological: Mesenchymal stem cells","GVHD|Overall survival|Relapse-free survival|Infection rate","National Research Center for Hematology, Russia","All","18 Years to 60 Years   (Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NRCH-MSC","October 2007","October 2014","October 2014","September 13, 2013",,"September 13, 2013","BMT department, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01941394"
23,"NCT02824653","Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD",,"Completed","No Results Available","Graft Versus Host Disease","Biological: Mesenchymal Stem Cells","Incidence of treatment-emergent adverse events and complications [Safety and Tolerability]|Acute GVHD-restaging [Efficacy]|Chronic GVHD-restaging [Efficacy]|Survival analysis at six months after MSC infusion|Incidence free survival at six months after MSC infusion","National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","All","1 Year to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFBMTC-GVHD-2015","January 2015","July 2016","December 2016","July 7, 2016",,"January 25, 2017","Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT02824653"
24,"NCT04414592","Human Umbilical Cord Mesenchymal Stem Cells For the Treatment of Lumbar Disc Degeneration Disease",,"Recruiting","No Results Available","Lumbar Disc Degeneration|Lumbar Disc Herniation","Other: human umbilical cord mesenchymal stem cells","Lumbar disc signaling values from magnetic resonance imaging|Visual Analogue Scale (VAS) (0-10 scores, the higher scores mean a worse outcome)|Oswestry Disability Index(ODI) (0-50 scores, the higher scores mean a worse outcome)|The Short Form (36) Health survey (SF36) (0-100 scores, the higher scores mean a better outcome)|Disc Height Index (DHI) from X ray|Size of herniated nucleus pulposus from magnetic resonance imaging|Number of participants with treatment-related adverse events by CTCAE v4.0","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 60 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QFu","August 2020","March 2022","March 2023","June 4, 2020",,"June 4, 2020","Shanghai General Hospital, Shanghai, Shanghai, China|Shanghai General Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04414592"
25,"NCT04791878","Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease",,"Recruiting","No Results Available","Perianal Fistula Due to Crohn's Disease (Disorder)","Drug: Mesenchymal stem cells","Treatment related adverse events|Complete clinical healing|Partial clinical healing|Lack of response|Worsening of disease","Amy Lightner|The Cleveland Clinic","All","13 Years to 17 Years   (Child)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Peds-PF","April 1, 2021","April 1, 2023","April 1, 2023","March 10, 2021",,"April 19, 2021","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04791878"
26,"NCT02755922","Bone Regeneration With Mesenchymal Stem Cells",,"Completed","No Results Available","Mandibular Fractures","Biological: Application of autologous mesenchymal stem cells","Change of bone quality|Number of patients with infection ( increase of local temperature, tenderness, leukocyte count >10,000/ µL, confirmed by Gram stain and blood culture).|Number of patients with bleeding after surgery (Persistent bleeding, ineffectiveness stopping bleeding using dressings)|Number of patients with surgical wound dehiscence (subcutaneous tissue , bone or osteosynthesis material exposed and seen through opened skin )","Instituto Mexicano del Seguro Social","All","17 Years to 59 Years   (Child, Adult)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2010-1301-27","April 2010","September 2010","December 2010","April 29, 2016",,"April 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02755922"
27,"NCT04501354","Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients",,"Recruiting","No Results Available","Osteoporosis","Drug: Mesenchymal Stem Cell","Bone Mass Density (BMD)|Visual Analog Scale (VAS)","Ahmad Jabir Rahyussalim|Indonesia University","All","40 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-08-1018","August 2020","December 2020","December 2020","August 6, 2020",,"August 7, 2020","Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04501354"
28,"NCT00504803","Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease",,"Completed","No Results Available","Hematological Malignancies","Procedure: Mesenchymal stem cell infusion","Day-100 incidence of non-relapse mortality|1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution","University of Liege","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TJB0601","December 2006","December 2010","December 2010","July 20, 2007",,"September 2, 2011","CHU Sart Tilman, Liege, Belgium",,"https://ClinicalTrials.gov/show/NCT00504803"
29,"NCT01763086","Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant",,"Unknown status","No Results Available","Stem Cell Transplantation, Hematopoietic|Mesenchymal Stem Cells|Poor Graft Function|Hematological Diseases","Biological: Mesenchymal stem cells","hematopoietic recovery|infections, primary underlying disease relapse and any toxic side effects of MSCs treatment","Nanfang Hospital of Southern Medical University|Peking University People's Hospital|Sun Yat-sen University|Guangdong Provincial People's Hospital|Guangzhou General Hospital of Guangzhou Military Command|Southern Medical University, China|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People's Hospital|Zhongshan People's Hospital, Guangdong, China","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-MSC-allo-HSCT-2013","January 2013","January 2015","January 2016","January 8, 2013",,"January 16, 2013","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01763086"
30,"NCT02440074","Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)","MSV-DISC","Withdrawn","No Results Available","Degenerative Disc Disease","Other: Autologous bone marrow mesenchymal stem cells","Pain relief","Red de Terapia Celular|Instituto de Salud Carlos III|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Eudra-CT2008-001191-68|MSV-DISC-2008-01","June 2011","November 2012","December 2012","May 12, 2015",,"May 12, 2015",,,"https://ClinicalTrials.gov/show/NCT02440074"
31,"NCT02570932","Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries",,"Completed","No Results Available","Spinal Cord Injury","Biological: Autologous Mesenchymal Bone Marrow Cell","Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation.|Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment|Changes in PENN score are considerate for the motor and sensory functions evaluation|Changes in VAS score are considerate for quantification of pain|Changes in BDS score are considerate for the Assessment of the functional status|Changes in GEFFNER score are considerate for the Assessment of the functional status","Puerta de Hierro University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM3|2014-005613-24","July 2015","December 4, 2017","December 4, 2017","October 7, 2015",,"April 5, 2018","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02570932"
32,"NCT03509870","Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds","REDDSTAR","Terminated","No Results Available","Diabetic Foot Ulcer","Biological: mesenchymal stromal cells","serious adverse events attributable to intervention|healing","Steno Diabetes Center Copenhagen|Leiden University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-005580-16","June 1, 2018","April 1, 2020","April 1, 2020","April 26, 2018",,"August 19, 2020","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT03509870"
33,"NCT01874015","Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease",,"Unknown status","No Results Available","Crohn's Disease","Biological: mesenchymal cell transplantation|Biological: mesenchymal cell and fibroblast injection","fistula closure|CDAI","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Royan-GI-003","February 2013","December 2017","February 2018","June 10, 2013",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01874015"
34,"NCT01763099","Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure",,"Unknown status","No Results Available","Hematopoietic Stem Cell Transplantation|Mesenchymal Stem Cells|Umbilical Cord Blood|Graft Failure|Hematological Diseases","Biological: Mesenchymal stem cells|Biological: Mesenchymal stem cells and cord blood","hematopoietic recovery|infections, primary underlying disease relapse and any toxic side effects of MSCs treatment","Nanfang Hospital of Southern Medical University|Peking University People's Hospital|Sun Yat-sen University|Guangdong Provincial People's Hospital|Guangzhou General Hospital of Guangzhou Military Command|Southern Medical University, China|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People's Hospital|Zhongshan People's Hospital, Guangdong, China","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-MSC-auto-HSCT-2013","January 2013","January 2015","January 2016","January 8, 2013",,"January 16, 2013","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01763099"
35,"NCT02118519","Mesenchymal Stem Cells in Knee Cartilage Injuries",,"Completed","No Results Available","Articular Cartilage Disorder of Knee|Osteoarthritis, Knee","Biological: Autologous Mesenchymal Stem Cells","Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.|Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.","University of Jordan","All","40 Years to 68 Years   (Adult, Older Adult)","Phase 2","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KneeUJCTC","January 2014","August 2015","August 2015","April 21, 2014",,"February 24, 2016","Cell Therapy Center, Jordan University Hospital, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02118519"
36,"NCT02112500","Mesenchymal Stem Cell in Patients With Acute Severe Respiratory Failure","STELLAR","Unknown status","No Results Available","Respiratory Distress Syndrome, Adult","Biological: Mesenchymal Stem Cell","Oxygen index at 3 days after mesenchymal stem cell infusion|Lung mechanics|Hemodynamic parameters|Mortality|Plasma cytokines|Markers for inflammation and infection|Ventilator weaning parameters|ICU and hospital stay","Asan Medical Center","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STELLAR-Pilot","February 2014","December 2016","December 2016","April 14, 2014",,"January 11, 2016","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02112500"
37,"NCT03219801","Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus",,"Unknown status","No Results Available","Systemic Lupus Erythematosus","Biological: mesenchymal stem cells","The change of Complement levels(C3 and C4) in peripheral blood|Erythrocyte sedimentation rate|C-reactive protein|adverse reaction","Hebei Medical University","All","14 Years to 60 Years   (Child, Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17277787D-SLE","August 1, 2017","December 30, 2018","December 30, 2019","July 18, 2017",,"July 18, 2017","the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",,"https://ClinicalTrials.gov/show/NCT03219801"
38,"NCT03068988","Clinical Study on Mesenchymal Stem Cells Used in the Reconstruction Surgery of the Supraspinatus Muscle Lesions",,"Active, not recruiting","No Results Available","Rotator Cuff Tear","Biological: mesenchymal stem cells|Procedure: without mesenchymal stem cells","The supraspinatus tendon re-rupture rate|visual analogue scale|ASES score- American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form|Constant score","Hospital Znojmo","All","18 Years to 60 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2016/05/25/09","January 1, 2012","December 31, 2014","December 31, 2021","March 3, 2017",,"September 7, 2017","Petr Šmíd, Znojmo, Czech Republic, Czechia",,"https://ClinicalTrials.gov/show/NCT03068988"
39,"NCT02166489","Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease",,"Completed","No Results Available","Chronic Renal Failure|Polycystic Kidney Disease","Biological: Intravenous injection autologous mesenchymal stem cells","Mass formation|Glomerular Filtration Rate (GFR)","Royan Institute","All","18 Years to 60 Years   (Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Kidney-003","March 2014","December 2015","January 2016","June 18, 2014",,"January 5, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02166489"
40,"NCT00781872","Mesenchymal Stem Cells for the Treatment of MS",,"Completed","No Results Available","Multiple Sclerosis","Biological: Injection of autologous bone marrow derived mesenchymal stem cells","Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis|Clinical effects in terms of changes in the expended disability status scale (EDSS) at 3-6 month intervals|Immunological effects of treatment with MSC in MS","Hadassah Medical Organization","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS22MSC-HMO-CTIL","October 2006","December 2009","December 2009","October 29, 2008",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT00781872"
41,"NCT04351932","Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis",,"Not yet recruiting","No Results Available","Osteo Arthritis Knee","Biological: bone marrow mesenchymal stem cells|Biological: Adipose Mesenchymal stem cells|Biological: bone marrow & adipose mesenchymal stem cells injection","knee pain assessed by Visual Analogue Scale.|knee function assessed by WOMAC (Wester Ontario McMaster Osteoarthritis Index). quosteionary.|Quantitative T2-Mapping Evaluation of Changes in Cartilage Matrix","Universidad Catolica Santiago de Guayaquil|Maastricht University Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCSantiagodeGuayaquil001","June 7, 2020","June 7, 2021","September 7, 2021","April 17, 2020",,"April 17, 2020","Omnihospital, Guayaquil, Guayas, Ecuador","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT04351932/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04351932"
42,"NCT04302519","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","COVID-19","Biological: Dental pulp mesenchymal stem cells","Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen","CAR-T (Shanghai) Biotechnology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KT005HB001","March 5, 2020","June 30, 2021","July 30, 2021","March 10, 2020",,"March 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04302519"
43,"NCT02116634","Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis",,"Withdrawn","No Results Available","Amyotrophic Lateral Sclerosis","Biological: mesenchymal stem cell","Effect of Intrathecal injection of autologous mesenchymal stem cells in improving the symptoms of ALS|ALS-FRS(functional rating scale) score and EMG scale|FVC (forced vital capacity)and DWSE±QoL score","Alzahra Hospital, Iran","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","rokhsareh|stem cell injection in ALS","May 2015","May 2017","May 2017","April 17, 2014",,"January 14, 2016","Neurosciences Research Center, Isfahan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02116634"
44,"NCT02387749","Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .",,"Completed","Has Results","Diabetic Peripheral Neuropathy","Genetic: mesenchymal stem cells","Measurement of b-FGF, v-EGF MEASURED BY ELISA|Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.|Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study|Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.|Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion|Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %","Cairo University","All","18 Years to 45 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FACULTY OF MEDICINE,CAIRO U","May 2014","August 2016","December 2016","March 13, 2015","October 11, 2017","July 3, 2018",,,"https://ClinicalTrials.gov/show/NCT02387749"
45,"NCT01224327","Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients",,"Unknown status","No Results Available","Liver Cirrhosis|Radiology|Mesenchymal Stem Cells|Umbilical Cord","Biological: umbilical cord Mesenchymal Stem Cells|Drug: Conserved therapy","The result of liver function and liver histological improvement.|The disappearance or reduction of abdominal dropsy|The clinical symptom improve(including food appetite,debilitation,abdominal distension,edema of lower limbs )","Qingdao University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCHC005","October 2010","October 2012","December 2012","October 20, 2010",,"October 20, 2010","Stem Cell Research Center of Medical School Hospital of Qingdao University, Qingdao, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01224327"
46,"NCT03055078","Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia",,"Unknown status","No Results Available","Aplastic Anemia","Biological: mesenchymal stem cells","Hemoglobin levels in peripheral blood|The number of red blood cell in peripheral blood|The number of granulocyte in peripheral blood|The number of white blood cell in peripheral blood|The evaluation of bone marrow megakaryocytic series|adverse reaction","Hebei Medical University","All","14 Years to 60 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17277787D-AA","January 2017","December 2018","December 2019","February 16, 2017",,"April 7, 2017","the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",,"https://ClinicalTrials.gov/show/NCT03055078"
47,"NCT03956719","Treatment of Early Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells",,"Active, not recruiting","No Results Available","Knee Osteoarthritis","Drug: Autologous adipose-derived mesenchymal stem cells|Procedure: abdominal liposuction","Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Evaluation of cartilage repair under MRI postoperative 3 month|Evaluation of cartilage repair under MRI postoperative 6 month|Degree of meniscus injury under MRI postoperative 3 month|Degree of meniscus injury under MRI postoperative 6 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Satisfaction of patients postoperative 1 month|Satisfaction of patients postoperative 3 month|Satisfaction of patients postoperative 6 month","Qilu Hospital of Shandong University","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019042","March 2, 2019","September 9, 2020","November 1, 2020","May 21, 2019",,"September 16, 2020","Qilu hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03956719"
48,"NCT01694927","Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients","MSC-SCI","Unknown status","No Results Available","Spinal Cord Injury","Procedure: Autologous Mesenchymal Stem Cells","Safety of Autologous Expanded Mesenchymal Stem Cells transplantation in SCI patients|Functional improvement in muscle strength|Functional Improvement in sphincters control|Functional improvement in spasticity control","Clínica Las Condes. LIT INNOVA CORFO|Clinica las Condes, Chile","All","2 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LIT-2012-ACF-001","January 2012","December 2013","June 2014","September 27, 2012",,"July 3, 2013","Clínica Las Condes, Santiago, RM, Chile",,"https://ClinicalTrials.gov/show/NCT01694927"
49,"NCT03358654","Evaluating Safety and Efficacy of Mesenchymal Stem Cells From Umbilical Cord",,"Unknown status","No Results Available","Umbilical Cord Bleeding|Knee Osteoarthritis","Drug: mesenchymal stem cells from umbilical cord","Unexplained local and systemic symptoms or death","Peking University People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PUPH20170911","January 1, 2018","June 1, 2020","December 1, 2020","November 30, 2017",,"November 30, 2017",,,"https://ClinicalTrials.gov/show/NCT03358654"
50,"NCT01877759","A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Biological: Mesenchymal stem cell","Improvement in Liver function tests|Changes in liver function according to Child-Pugh|Changes in liver function according to MELD Score|Improvement in QUALITY OF LIFE SCALE (QOL)","Chaitanya Hospital, Pune","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSCC/BM/2013/LS/01","December 2013","December 2014","December 2014","June 14, 2013",,"October 9, 2013","Chaitanya Hospital, Pune,, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01877759"
51,"NCT04366271","Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19","MESCEL-COVID19","Withdrawn","No Results Available","COVID","Biological: Mesenchymal cells|Drug: Standard of care","Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MESCEL-COVID19|2020-001450-22","May 7, 2020","July 31, 2020","May 31, 2021","April 28, 2020",,"August 27, 2021","Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Complejo Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04366271"
52,"NCT03778333","Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden",,"Completed","No Results Available","Autologous Mesenchymal Stem Cells|Multiple Sclerosis","Biological: Autologous mesenchymal stem cells","To evaluate number of participants with an adverse event related to the treatment.|To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions.|To evaluate effects on MS disease activity measured by change in EDSS (expanded disability status scale).|To evaluate effect on peripheral blood immune cell populations.","Karolinska Institutet","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-progressive MS","December 1, 2012","December 2016","December 31, 2016","December 19, 2018",,"December 19, 2018","Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03778333"
53,"NCT02344849","Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: mesenchymal stem cell","Number and severity of adverse events|Change From Baseline in the International Index of Erectile Function(IIEF)|Penile Doppler Sonography, PDS|Change From Baseline in Sexual Encounter Profile (SEP) Question 2|Global Assessment Question (GAQ)","Pharmicell Co., Ltd.","Male","20 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellgram-ED","July 2015","January 31, 2018","April 2018","January 26, 2015",,"January 9, 2019","Asan medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02344849"
54,"NCT02492516","Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: mesenchymal stem cells","fever|Unconsciousness|The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)|FVC","Royan Institute","All","18 Years to 55 Years   (Adult)","Phase 1","19","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Nerve-008","September 2014","March 2017","April 2017","July 8, 2015",,"April 28, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02492516"
55,"NCT04446897","Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction",,"Completed","No Results Available","Periodontitis, Chronic","Biological: mesenchymal stem cells|Other: standard treatment","number of patients cured","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education","All","70 Years to 70 Years   (Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(periodontitis)","August 3, 2020","December 31, 2020","December 31, 2020","June 25, 2020",,"February 9, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04446897"
56,"NCT01068951","Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells",,"Completed","No Results Available","Type 1 Diabetes","Biological: Mesenchymal stem cells","The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells","Uppsala University Hospital","All","18 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AS2010-0180","June 2010","September 2013","September 2013","February 17, 2010",,"February 5, 2014","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01068951"
57,"NCT02460770","Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device","MESAD","Withdrawn","No Results Available","Chronic Myocardial Ischemia","Drug: Autologous mesenchymal stem cells","Feasibility of the full procedure|Ejection Fraction|Maximal Oxygen consumption|Walking distance in 6 minutes|weaning procedure|Quality of life|Measure of heart pressures|Brain natriuretic peptide|Troponin|Major bleeding|Systemic embolism|Deaths","University Hospital, Toulouse|Thoratec Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13 150 03","June 2015","June 2017","June 2017","June 2, 2015",,"January 5, 2018","Cardiology Department of Rangueil Hospital - Rangueil Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02460770"
58,"NCT02055625","Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease",,"Withdrawn","No Results Available","Graft -Versus-host-disease","Biological: Mesenchymal stromal cells","Change in disease activity according to National Institutes of Health criteria for oral graft-versus-host disease|Change in self-assessed disease activity and quality of life|Safety","Karolinska Institutet|Region Stockholm","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013/1241-31/1","January 2014","August 2019","August 2019","February 5, 2014",,"August 14, 2019","Oral and Maxillofacial Surgery, Karolinska Univeristy Hospital, Stockholm, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT02055625"
59,"NCT02414295","Sperm Production in Kleinfelter Syndrome Patients After Mesenchymal Stem Cell Injection",,"Completed","No Results Available","Klinefelter Syndrome|Azoospermia","Drug: Mesenchymal stem cell injection","Sperm detection|Hormonal profile","Man Clinic for Andrology, Male Infertility and Sexual Dysfunction","Male","20 Years to 50 Years   (Adult)","Not Applicable","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","6714","August 2013","August 2014","August 2014","April 10, 2015",,"April 10, 2015","Man Clinic for Andrology and male infertility, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02414295"
60,"NCT02749448","Mesenchymal Stem Cells Therapy for Treatment of Airway Remodeling in Mustard Patients",,"Unknown status","No Results Available","Pulmonary Disease","Other: mesenchymal stem cell","pulmonary function testing (PFT)|St. George's Respiratory Questionnaire (SGRQ)|6 minute walk test (6MWT)","Dr. Mostafa Ghanei|Baqiyatallah Medical Sciences University","Male","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRCT2015110524890N1","February 2015","November 2016","February 2017","April 25, 2016",,"July 25, 2016",,,"https://ClinicalTrials.gov/show/NCT02749448"
61,"NCT02472002","Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients","MESHT","Suspended","No Results Available","Coronary Disease|Heart Transplant","Biological: Mesenchymal cell therapy","myocardial perfusion measured in MRI.|complications of catheterization|complications of endomyocardial injection|systolic function|diastolic function|immunomodulation induced MSCs in the blood|immunomodulation induced MSCs in myocardial biopsy","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 100102","January 2014","January 2018","January 2018","June 15, 2015",,"February 23, 2017","Département de cardiologie du Pr Michel KOMADJA, Paris, France",,"https://ClinicalTrials.gov/show/NCT02472002"
62,"NCT02834858","Umbilical Cord Mesenchymal Stem Cells Infusion for Diabetes Related Vascular Complications",,"Unknown status","No Results Available","Peripheral Vascular Disease|Ischemia|Diabetic Foot","Biological: Umbilical Cord Mesenchymal Stem Cells|Biological: saline","Area of diabetic foot ulcers|Improvement of transcutaneous oxygen partial pressure (TcPO2)|Improvement of microvascular cutaneous reactivity by laser Doppler perfusion monitoring (LDPM)|Pain (Visual-Analog Scale)|Walking distance (treadmill) if possible","Jie Shen|Nanfang Hospital of Southern Medical University|Academy Military Medical Science, China|The Fifth Affiliated Hospital of Southern Medical University|Southern Medical University, China|The Third Affiliated Hospital of Southern Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ThirdSouthernMedical1","January 2016","December 2018","December 2019","July 15, 2016",,"April 6, 2017","the Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02834858"
63,"NCT03130374","Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells",,"Completed","No Results Available","Tracheal Stenosis|Laryngeal Stenosis|Mesenchymal Stem Cells","Biological: Olfactory mucosa-derived mesenchymal stem cells","Number of patients who didn't require the repeated surgical interventions|Tracheostomy decannulation","The Republican Research and Practical Center for Epidemiology and Microbiology|Belarusian Medical Academy of Post-Graduate Education|The Republican Center for Research and Practice in Otolaryngology","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RRPCEM_MSC1","January 3, 2017","January 4, 2019","May 20, 2019","April 26, 2017",,"June 7, 2019","The Republican Center for Research and Practice in Otolaryngology, Minsk, Belarus|The Republican Research and Practical Center for Epidemiology and Microbiology, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT03130374"
64,"NCT04432467","Fertility Restoration Using Autologous Mesenchymal Stem Cells",,"Enrolling by invitation","No Results Available","Chronic Endometritis|Uterus; Scar|Uterine Synechiae|Fallopian Tube Obstruction","Biological: Autologous mesenchymal stem cells|Other: standard treatment","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education","Female","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(Fertility)","October 1, 2020","September 30, 2021","September 30, 2021","June 16, 2020",,"December 8, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04432467"
65,"NCT03346967","Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency","MSCSHD","Unknown status","No Results Available","Hormone Deficiency","Combination Product: adipose-derived mesenchymal stem cells","Serum levels of follicle-stimulating hormone (FSH), Anti-Mullerian Hormone (AMH) and estradiol (E2) for female and testosterone level for male","Vinmec Research Institute of Stem Cell and Gene Technology","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VinmecRISCGT72","November 1, 2017","February 28, 2020","March 30, 2020","November 20, 2017",,"November 26, 2018","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03346967"
66,"NCT01946048","Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy",,"Unknown status","No Results Available","Ischemic Cardiomyopathy","Biological: mesenchymal stem cells","The examination of heart function|all-cause mortality|all-cause morbidity|major adverse cardiac and cerebrovascular events","Hebei Medical University","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12276102D-Cardiac Disease","October 2013","October 2013","December 2014","September 19, 2013",,"October 8, 2013","the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",,"https://ClinicalTrials.gov/show/NCT01946048"
67,"NCT01207661","Articular Cartilage Resurfacing With Mesenchymal Stem Cells In Osteoarthritis Of Knee Joint",,"Completed","No Results Available","Osteoarthritis","Biological: Mesenchymal Injection","Pain relief","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-002","August 2009","July 2010","November 2010","September 23, 2010",,"January 5, 2012","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01207661"
68,"NCT03668171","Mesenchymal Stem Cell Transplantation for Acute-on-chronic Liver Failure",,"Unknown status","No Results Available","Acute-On-Chronic Liver Failure","Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein","Efficacy: 12 week mortality rate|Clinical remission rate at week 12","Xijing Hospital of Digestive Diseases","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KY20172049-1","December 10, 2017","December 31, 2019","December 31, 2020","September 12, 2018",,"September 12, 2018","Changcun Guo, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03668171"
69,"NCT01962233","Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy",,"Unknown status","No Results Available","Hypoxic Ischemic Encephalopathy","Biological: mesenchymal stem cells","National Institutes of Health Stroke Scale (NIHSS) scores.|The Barthel Index|The Mini-Mental State Examination (MMSE)|The Montreal Cognitive Assessment(MoCA)|Unified Parkinson's Disease Rating Scale (UPDRS)|adverse reaction","Hebei Medical University","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12276102D-Neurologic Disorder","September 2013","December 2013","December 2014","October 14, 2013",,"October 14, 2013","the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",,"https://ClinicalTrials.gov/show/NCT01962233"
70,"NCT04519671","Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease","PFCD","Recruiting","No Results Available","Perianal Crohn Disease|Perianal Fistula|Crohn Disease","Drug: Mesenchymal Stem Cells|Other: Placebo","Treatment related adverse events|Complete clinical healing","Amy Lightner|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CCF-Stem Cells IBD-001","November 19, 2020","November 2022","November 2022","August 20, 2020",,"March 19, 2021","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04519671"
71,"NCT01809769","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Mesenchymal stem cells low-dose group|Biological: Mesenchymal stem cells mid-dose group|Biological: Mesenchymal stem cells high-dose group","Recording of Adverse Events and Serious Adverse Events|Electrocardiogram|Vital signs|Physical examination|WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Laboratory tests|SF-36|NRS-11|The volume of articular cartilage","Cellular Biomedicine Group Ltd.|RenJi Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBMG-KOA-1.1","March 2013","March 2015","July 2015","March 13, 2013",,"April 4, 2016","Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01809769"
72,"NCT03668145","Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis",,"Unknown status","No Results Available","Primary Biliary Cirrhosis","Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein","Change of alkaline phosphatase (ALP)|Change of other liver function indices|Change of liver histology","Xijing Hospital of Digestive Diseases","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KY20172050-1","November 8, 2017","December 31, 2019","December 31, 2020","September 12, 2018",,"September 12, 2018","Changcun Guo, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03668145"
73,"NCT02140528","Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures",,"Completed","No Results Available","Tibial Fracture","Biological: Mesenchymal stem cell injection|Biological: Placebo","Number of patients with union after transplantation of mesenchymal stem cell in case group in comparison with control group","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royan-Bone-012","August 2013","March 2016","April 2016","May 16, 2014",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02140528"
74,"NCT04519697","Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease","RVF","Recruiting","No Results Available","Rectovaginal Fistula|Crohn Disease|Crohn Disease of Vulva|Rectolabial; Fistula","Drug: Mesenchymal Stem Cells|Other: Placebo","Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease","Amy Lightner|The Cleveland Clinic","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CCF-Stem Cells IBD-003","October 28, 2020","October 2022","October 2022","August 20, 2020",,"March 19, 2021","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04519697"
75,"NCT04208646","Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Mesenchymal progenitor cells|Biological: No mesenchymal progenitor cells","WOMAC Score|MRI quantitative analysis of articular cartilage|VAS Score|SF-36|Adverse Events and Serious Adverse Events|Changes of laboratory test indexes and vital signs","Cellular Biomedicine Group Ltd.|RenJi Hospital|Shanghai 6th People's Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Second Affiliated Hospital, School of Medicine, Zhejiang University|China-Japan Friendship Hospital|Huashan Hospital|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","108","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBM-ALAM.1-01","May 16, 2020","December 2021","January 2022","December 23, 2019",,"November 4, 2020","China-Japan Friendship Hospital, Beijing, China|The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, China|Huashan Hospital Affiliated to Fudan University, Shanghai, China|Shanghai General Hospital, Shanghai, China|Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, China|Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04208646"
76,"NCT02763423","Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis","UCMSCDKA","Unknown status","No Results Available","Ketoacidosis, Diabetic","Procedure: umbilical cord mesenchymal stem cell","Changes from baseline exogenous insulin dose at different time points post treatment|C-peptide level|HbA1c level|titres of islet antigen antibodies","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","12 Years to 35 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NJGYNFM-SC-02","January 2009","December 2019","December 2019","May 5, 2016",,"May 5, 2016","The affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02763423"
77,"NCT03645525","Intratracheal Umbilical Cord-derived Mesenchymal Stem Cell for the Treatment of Bronchopulmonary Dysplasia (BPD)","IUMTB","Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: Human Umbilical Cord-derived Mesenchymal stem cell|Drug: placebo","Oxygen requirement 3 days after transplantation|Oxygen requirement 7 days after transplantation|Duration of ventilator dependence|Incidence of severe BPD|Survival rate|Temperature|Heart rate|Respiratory rate|Duration of CPAP treatment|Percentage of participants treated with steroids for weaning from ventilator|Growth velocity (Z-score)|bronohoalveolar lavage (BAL) cytokine level|The severity of BPD in X-ray patterns","Children's Hospital of Fudan University","All","up to 3 Weeks   (Child)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EKYYIUMTB","December 1, 2019","October 30, 2022","April 1, 2023","August 24, 2018",,"September 9, 2021","Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China|Children's Hospital of Fudan University, Shanghai, Shanghai, China|Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03645525"
78,"NCT02963727","Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis",,"Recruiting","No Results Available","Knee Osteoarthrosis","Biological: Wharton Jelly derived mesenchymal stem cell","Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of WJMSC","Hanan Jafar|University of Jordan","All","42 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AlloKneeUJCTC","January 27, 2017","October 2021","December 2021","November 15, 2016",,"April 28, 2021","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02963727"
79,"NCT02966951","Use of Adipose Tissue Derived Mesenchymal Stem Cells for Knee Osteoarthrosis",,"Recruiting","No Results Available","Knee Osteoarthrosis","Biological: Adipose tissue derived mesenchymal stem cell","Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of ATMSC","Hanan Jafar|University of Jordan","All","42 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATKneeUJCTC","January 17, 2017","September 2021","December 2021","November 17, 2016",,"April 28, 2021","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02966951"
80,"NCT02291770","Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells","MSC-cGvHD","Unknown status","No Results Available","Chronic Graft-Versus-Host Disease","Biological: Mesenchymal Stromal Cells","Proportion of patients responding to treatment of cGvHD with MSC|Overall survival|Progression-free survival|Time without systemic immunosuppression|Cumulative incidents of non-relapse mortality|Adverse events","Guangdong Provincial People's Hospital|Sun Yat-sen University|Nanfang Hospital of Southern Medical University|Guangzhou General Hospital of Guangzhou Military Command|Third Affiliated Hospital, Sun Yat-Sen University|Guangzhou First People's Hospital|Academy Military Medical Science, China","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","130","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","No.GRDEC 2014210H","October 2014","November 2015","December 2019","November 14, 2014",,"November 14, 2014","Xin Du, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02291770"
81,"NCT03268603","Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)",,"Recruiting","No Results Available","ALS|Amyotrophic Lateral Sclerosis","Drug: Autologous Adipose-derived Mesenchymal Stromal Cells","Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R)","Mayo Clinic|State of Minnesota Regenerative Medicine Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-008008|UL1TR000135","October 10, 2017","December 2022","December 2022","August 31, 2017",,"May 6, 2021","Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03268603"
82,"NCT04446884","Treatment of Stress Urinary Incontinence in Women With Autologous Adipose-derived Mesenchymal Stem Cells",,"Completed","No Results Available","Stress Urinary Incontinence","Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(UIW)","March 1, 2018","December 31, 2019","December 31, 2019","June 25, 2020",,"June 25, 2020","Hrodna City Clinical Hospital, Hrodna, Belarus",,"https://ClinicalTrials.gov/show/NCT04446884"
83,"NCT03171194","Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus",,"Completed","No Results Available","System; Lupus Erythematosus","Drug: Low Dose Mesenchymal Stem Cells (MSCs)","Frequency of Grade 3 or higher adverse events|Frequency of All Adverse Events|Change in Disease Activity|Change in Patient Reported Outcomes - Life|Change in Patient Reported Outcomes - Fatigue|Change in Patient Reported Outcomes - Pain|Change in Patient Reported Outcomes - Depression|Change in Disease Biomarkers - Cellular|Change in Disease Biomarkers - Serum","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00061632","April 27, 2017","April 30, 2018","October 25, 2018","May 31, 2017",,"May 2, 2019","Emory University, Atlanta, Georgia, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03171194"
84,"NCT03042572","Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs","SAIL","Unknown status","No Results Available","Peripheral Arterial Disease|Cardiovascular Diseases|Vascular Diseases","Drug: Allogeneic Mesenchymal Stromal Cell|Other: Placebo","Therapy Success|Major amputation|Minor amputation|Mortality|Ulcer healing|Changes in pain|Pain-free walking distance|Ankle-brachial index (ABI)|Toe-brachial index (TBI)|Quality of life based on EuroQol 5D (EQ5D) questionnaire scores|Quality of life based on Short Form 36 (SF36) questionnaire scores|Clinical status according to Fontaine classification|Clinical status according to Rutherford classification","Martin Teraa, MD, PhD|ZonMw: The Netherlands Organisation for Health Research and Development|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NL59038.000.16","December 2018","December 2020","July 2021","February 3, 2017",,"May 3, 2018","University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03042572"
85,"NCT01216865","Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot",,"Unknown status","No Results Available","Diabetic Foot|Critical Limb Ischemia|Mesenchymal Stem Cells|Umbilical Cord","Biological: umbilical cord mesenchymal stem cells|Drug: Standard Therapy","Angiographic evaluation of angiogenesis at ischemic limb|Pain|Ankle-Brachial pressure index|Wound healing (wound size, wound stage)|Walking distance|Rate and extent of amputations","Qingdao University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCDF001","January 2011","December 2012","July 2013","October 7, 2010",,"October 13, 2010","Stem Cell Research Center of Medical School Hospital of Qingdao University, Qingdao, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01216865"
86,"NCT03106662","Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies",,"Completed","No Results Available","Hematopoietic Stem Cell Transplantation","Biological: mesenchymal stem cells|Drug: cyclophosphamide administration","Effect of mesenchymal stem cells on overall survival in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft versus host disease incidence in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft failure incidence in haploidentical stem cell transplantation","Ankara University|The Scientific and Technological Research Council of Turkey","All","18 Years and older   (Adult, Older Adult)","Phase 3","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","213S196","October 2014","July 2017","October 2017","April 10, 2017",,"January 10, 2018","Ankara University School of Medicine Department of Hematology, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT03106662"
87,"NCT02239393","Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study","MESCAMS","Completed","No Results Available","Multiple Sclerosis","Biological: Mesenchymal Stem Cells","Safety|Efficacy","Ottawa Hospital Research Institute","All","18 Years to 50 Years   (Adult)","Phase 2","31","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140368","June 2015","December 2019","December 2019","September 12, 2014",,"March 4, 2020","Health Sciences Centre, Winnipeg, Manitoba, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02239393"
88,"NCT02641860","Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis","Biological: Mesenchymal progenitor cells","Safety, recording of Adverse Events and Serious Adverse Events|WOMAC Score|VAS Score|SF-36|The volume of articular cartilage|WORMS Score","Cellular Biomedicine Group Ltd.|RenJi Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","22","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBMG-Allo-KOA-1.1","December 2015","March 2018","March 2018","December 30, 2015",,"September 13, 2018","Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02641860"
89,"NCT01360164","Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia",,"Unknown status","No Results Available","Hereditary Ataxia","Biological: human umbilical cord mesenchymal stem cells","scores of International Cooperative Ataxia Rating Scale （ICARS） scale and Berg Scale|the volume of Cerebellum of Brain Magnetic Resonance Imaging （MRI） Scan|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of Participants with Serious Adverse Events as a Measure of Safety and Tolerability","Shenzhen Beike Bio-Technology Co., Ltd.|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The Affiliated Nanjing Brain Hospital of Nanjing University Medical School|Nanjing University Medical College Affiliated Wuxi Second Hospital|Xuzhou Medical University|The Second Hospital of Nanjing Medical University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BKCR-HA-1.0(2010)","January 2010","December 2012","December 2013","May 25, 2011",,"November 28, 2012","Nanjing University Medical College Affiliated Drum Tower Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01360164"
90,"NCT02866721","Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis","CEASE-CF","Completed","No Results Available","Cystic Fibrosis","Biological: Mesenchymal Stem Cells","Dose limiting toxicity (DLT), triggered by occurrence in the first 24 hours after hMSC infusion of grade ≥3 infusion-related allergic toxicities|Incidence and severity of adverse events|Number of pulmonary exacerbations|Diary reports (Cystic Fibrosis Respiratory Symptom Diary (CFRSD))|Changes in subject reported symptoms as captured by the Respiratory Signs and Symptoms Questionnaire (RSSQ) from Baseline (Visit 2) Day 1 to Baseline (Visit 2) Day 2, Visits 3, 4, 5, 6 and 7 and at times when a pulmonary exacerbation is being considered|Changes in physical examination|Changes in vital signs including oxygen saturation checked throughout infusion|Changes in spirometry (FEV1 %, FEV1 (Liters), FEF25-75) determined 30 minutes, 4 hours, and 24 hours after completion of infusion and from Baseline (Visit 2) Day 1 to Visits 3, 4, 5, 6 and 7|Change in sputum quantitative microbiology (bacterial colony forming units between Baseline to Day 7 and Day 28)|Changes in hematology, comprehensive chemistry, ESR, hs-CRP, and urinalysis results|Change in blood inflammatory biomarkers from Baseline to Day 7 and Day 28|Change in sputum inflammatory biomarkers from Baseline to Day 7 and Day 28","Erica Roesch|Case Western Reserve University|Cystic Fibrosis Foundation|University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Protocol CF-MSC-01|DASENB15A0","August 2016","August 2020","August 2020","August 15, 2016",,"December 22, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02866721"
91,"NCT02165904","Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI",,"Completed","Has Results","Spinal Cord Injury","Biological: Adult Autologous Mesenchymal Bone Marrow Cell","Efficacy-Sensivity Improvement Using the ASIA Score|Efficacy- Changes in Functional Independence Measure Scale|Efficacy-Change in Barthel Score|Efficacy-IANC-SCIFRS Scale|Efficacy-Changes in PENN Score.|Changes in ASHWORTH Score|Efficacy-Changes in EVA Score|Efficacy- Changes in Geffner Score|Efficacy- Changes in NBD Score|Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)|Efficacy-Urodynammic in Terms of Detrusor Pressure|Efficacy-Urodynamic Studies Bladder Compliance|Efficacy-Urodynamic Studies Maximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)|Number of Adverse Events .|Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples","Puerta de Hierro University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM2|2011-005684-24","May 2014","May 2016","May 2016","June 18, 2014","July 19, 2019","July 19, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02165904"
92,"NCT03505034","Intrathecal Transplantation of UC-MSC in Patients With Late Stage of Chronic Spinal Cord Injury",,"Recruiting","No Results Available","Spinal Cord Injuries","Drug: Umbilical Cord Mesenchymal Stem Cells","Changes in American Spinal Injury Association (ASIA) Score Scale|Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS)|Changes in electromyogram test|Changes in residual urine","Third Affiliated Hospital, Sun Yat-Sen University|West China Hospital|Shanghai East Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","43","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IT-UCMSC-LCSCI","September 1, 2019","December 31, 2021","December 31, 2021","April 23, 2018",,"May 1, 2019","The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03505034"
93,"NCT02181712","Mesenchymal Stem Cell Therapy for Lung Rejection",,"Completed","No Results Available","Lung Transplant Reject|Bronchiolitis Obliterans","Biological: Mesenchymal stem cell 0.5|Biological: Mesenchymal stem cell 1.0","Number of Participants with serious and non-serious adverse events|Changes in pulmonary function tests","Mayo Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-000025","July 2014","August 12, 2021","August 12, 2021","July 4, 2014",,"October 7, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02181712"
94,"NCT01504464","The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis",,"Completed","No Results Available","Osteoarthritis","Biological: mesenchymal stem cell|Biological: Placebo","physical function improvement|change in pain density|joint swelling|joint erythema|deterioration of joint function|Allergic reactions","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royan-Bone-010","October 2012","September 2015","October 2015","January 5, 2012",,"May 17, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01504464"
95,"NCT02249676","Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders",,"Completed","No Results Available","Devic's Syndrome|Devic's Neuromyelitis Optica|Devic Syndrome|Devic's Disease|Devic Disease","Biological: Autologous mesenchymal stem cells","EDSS|Annual relapse rate|Lesion load|Retinal nerve fiber layer (RNFL)|Cognition|Immunological assessments|cerebral volume","Tianjin Medical University General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB2013-055-02","January 2013","December 31, 2014","December 31, 2014","September 25, 2014",,"October 17, 2018","Tianjin Medical University General Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02249676"
96,"NCT03383081","The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis, Knee","Biological: Low dose mesenchymal stem cells|Biological: High dose mesenchymal stem cells|Procedure: Intraarticular injection","Kellgren-Lawrence Grading Scale|Assessment of Preoperative Cartilage Defect Severity (AMADEUS)|Lysholm scoring|The international knee documentation committee (IKDC) knee evaluation form|Visual Analogue Scale/Score（VAS）","Sclnow Biotechnology Co., Ltd.","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLnow-XY-02","October 1, 2018","June 2022","December 2022","December 26, 2017",,"September 23, 2021","Xiangya Hospital Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03383081"
97,"NCT02266394","Hypoxia and Inflammatory Injury in Human Renovascular Hypertension",,"Completed","No Results Available","Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Disease|Chronic Kidney Disease","Drug: Mesenchymal stem cell|Procedure: Mesenchymal stem cell delivery with stent placement","Change in Kidney function|Safety of Mesenchymal stem cell infusion|Decrease in Kidney inflammation","Mayo Clinic|University of Mississippi Medical Center|University of Alabama at Birmingham","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-002799","October 21, 2014","September 25, 2020","September 25, 2020","October 17, 2014",,"January 27, 2021","University of Alabama, Birmingham, Alabama, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT02266394"
98,"NCT04104412","The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Lumbar Discogenic Pain",,"Recruiting","No Results Available","Lumbar Discogenic Pain","Biological: human umbilical cord mesenchymal stem cell","Validity evaluation by detection the change of the VAS pain score relief rate for Lumbar disc pain of participants in different time point and compare with the VAS pain score before treatment|Observe treatment|Safety evaluation by detecting adverse events and serious adverse events|Safety evaluation by detecting Activated partial thromboplastin time (APTT)|Safety evaluation by detecting Prothrombin time (PT)|Safety evaluation by detecting Fibrinogen|Safety evaluation by detecting Thrombin time (TT)","Sclnow Biotechnology Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLnow-XW-01","August 15, 2019","November 1, 2021","July 31, 2024","September 26, 2019",,"October 27, 2020","Xuanwu Hospital Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04104412"
99,"NCT01649700","Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells",,"Completed","No Results Available","The Sequelae Caused by Severe Brain Injury","Biological: autologous adipose-derived mesenchymal stem cells","Safety evaluation|Positron emission tomography|Magnetic Resonance Imaging|Electroencephalogram|Neuropsychological assessment|Electrodiagnostic Testing|Assessment of language and swallowing functions|Measure of the severity of disability|Assessment of spasticity and strength|Assessment of brain motor control","National Yang Ming University","All","20 Years to 40 Years   (Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-VGH-201101","October 2011","May 2013","May 2013","July 25, 2012",,"September 12, 2014","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01649700"
100,"NCT01649687","Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells",,"Completed","No Results Available","Cerebellar Ataxia","Biological: Allogeneic adult adipose-derived mesenchymal stem cells","Safety evaluation|Alterations in SARA score|Positron emission tomography|Magnetic resonance spectroscopy|Assessment of language and swallowing functions|Evaluation of syncope|Balance test","National Yang Ming University","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-VGH-201001","May 2012","January 2014","January 2014","July 25, 2012",,"September 12, 2014","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01649687"
101,"NCT04318600","Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis",,"Completed","No Results Available","Lupus Nephritis|Mesenchymal Stem Cells","Drug: human amniotic mesenchymal stem cell","Incidence of Adverse Events|Changes in 24h urine protein quantification before and after treatment；|Changes in eGFR before and after treatment;|Changes in SLEDAI score before and after treatment；","Yan'an Affiliated Hospital of Kunming Medical University|The First People's Hospital of Yunnan","All","14 Years to 60 Years   (Child, Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2014001","January 1, 2014","March 1, 2017","January 1, 2019","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04318600"
102,"NCT04776239","Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)","ACESO-IHD","Recruiting","No Results Available","Diabetes Mellitus|Ischemic Heart Disease","Drug: 100 million Allogeneic Mesenchymal Human Stem Cells|Other: Placebo","Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR|Post-PCI coronary artery endothelial function as assessed via FFR|Target lesion lumen loss|Flow Mediated Diameter Percentage (FMD%)|EPC-CFUs levels|Circulating angiogenic factors marker levels|Circulating inflammatory markers|Seattle Angina Questionnaire (SAQ) Angina Frequency|EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire|EQ-5D Quality of life Questionnaire Overall Health Status Question|Short Form (SF) 36 Questionnaire Quality of Life Questionnaire|International Index of Erectile Function (IIEF) Questionnaire|Sexual Quality of Life - Females (SQOL-F) Questionnaire|Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE)|Incidence of Major Adverse Cardiac Events (MACE)|Rates of Adverse Events|Number of participants with abnormal lab values|Number of participants with Target Vessel Failure","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20200874|1R01HL134558-01","August 16, 2021","July 16, 2024","July 16, 2024","March 1, 2021",,"August 18, 2021","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04776239"
103,"NCT01090817","An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease",,"Completed","No Results Available","Crohn Disease","Drug: Mesenchymal stromal cells (MSC) for infusion","Clinical response to MSC: Reduction of Crohn's disease Activity score by 100 points or more at six weeks post start of therapy|Incidence of infusional toxicity|Induction of remission|Improved quality of life|Endoscopic improvement.","R.P.Herrmann|The Queen Elizabeth Hospital|Concord Hospital|Sir Charles Gairdner Hospital|The Alfred|Royal Perth Hospital","All","18 Years to 55 Years   (Adult)","Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC2009/123|CTN2010/0098","January 2010","June 2014","June 2015","March 23, 2010",,"June 9, 2015","Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01090817"
104,"NCT04499105","Effectiveness and Safety of Mesenchymal Stem Cell (MSC) Implantation on Degenerative Discus Disease Patients","MSC","Recruiting","No Results Available","Degenerative Disc Disease|Low Back Pain|Disc Degeneration","Drug: Mesenchymal Stem Cell + NaCl 0,9% 2ml","Improvement of Low Back Pain|Tissue Improvement","Ahmad Jabir Rahyussalim|Indonesia University","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-02-0143","July 24, 2017","December 2020","December 2020","August 5, 2020",,"August 6, 2020","Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04499105"
105,"NCT03209986","Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Procedure: mesenchymal stem cell transplantation via peripheral vein|Other: mesenchymal stem cell","Efficacy: Change of liver functions as assessed by MELD score|Safety: Adverse events as assessed according to CTCAE 4.03|Survival Benefit: Survival Rate at different time points|Histological change of the liver: Histological scores assessed by liver biopsy|Clinical benefit: Incidences of cirrhosis-related complications such as GI bleeding, ascites, hepatorenal syndrome, hepatoencephalopathy","Xijing Hospital of Digestive Diseases","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XJMSC0001","November 8, 2017","June 30, 2019","December 31, 2019","July 6, 2017",,"September 11, 2018","Xijing Hospital of Digestive Disease, Xijing Hospital, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03209986"
106,"NCT01788059","The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital",,"Completed","No Results Available","Nonunion Fracture","Other: injection the mesenchymal stem cell in non union site","clinical and radiological union at 1 month to 6 months|•Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects.|Incidence of adverse events in patients (e.g infection , malignancy , ...) Adverse events will be continuously monitored","Emdadi Kamyab Hospital","All","18 Years to 60 Years   (Adult)","Phase 2","19","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","900939","January 2013","October 2013","November 2013","February 11, 2013",,"December 30, 2013","Emdai Kamyab Hospital, Mashhad, Khorasan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01788059"
107,"NCT04939077","Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC)",,"Recruiting","No Results Available","Myocardial Ischemia|Ventricular Dysfunction, Left","Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells","Left ventricular ejection fraction|Left ventricular end diastolic volume|Left ventricular end systolic volume|Stroke volume|Left ventricular apex four-chamber end systolic diameter|6 minutes walking distance|THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF","Shanghai East Hospital","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MR-31-20-000323","November 27, 2019","July 31, 2022","November 30, 2022","June 25, 2021",,"June 25, 2021","Shanghai East Hospital, Shanghai Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04939077"
108,"NCT03357575","The Comparison of Efficacy and Safety of the Mesenchymal Stem Cells From Adipose and Hyaluronic Acid",,"Unknown status","No Results Available","Knee Osteoarthritis","Biological: Mesenchymal Stem Cells from adipose|Biological: Hyaluronic Acid","Unexplained local and systemic symptoms or death|VAS score|WOMAC score","Peking University People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUPH20170912","January 1, 2018","June 1, 2020","December 1, 2020","November 30, 2017",,"November 30, 2017",,,"https://ClinicalTrials.gov/show/NCT03357575"
109,"NCT02235844","Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)",,"Completed","No Results Available","Duchenne's Muscular Dystrophy","Biological: Umbilical Cord Mesenchymal Stem Cells","Adverse Events|Change from baseline of weight|Change of muscle diameter (circumferential measurements) from baseline|Change from baseline of Pulmonary Maximum Expiratory Pressure|Change from baseline of Pulmonary Forced Vital Capacity|Maximum Change from baseline of Predicted Inspiratory Pressure %|Change from baseline of Predicted Maximum Expiratory Pressure %|Change from baseline of Predicted Forced Vital Capacity %","Allergy and Asthma Consultants, Wichita, Kansas|Aidan Foundation|Neil H. Riordan PhD","Male","28 Years to 31 Years   (Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IND 16026 DMD Single Patient","September 2014","September 30, 2017","September 30, 2017","September 10, 2014",,"September 16, 2019","Asthma and Allergy Consultants, Wichita, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02235844"
110,"NCT00734396","Mesenchymal Stem Cells and Subclinical Rejection","Measure","Completed","No Results Available","Organ Transplantation","Procedure: Mesenchymal stem cell infusion","Primary 1 Safety: rate of (serious) adverse events in the study population 2 Feasibility: determination of the number of expanded MSCs in relation to the amount of BM collected, number of passages required and time to reach study target doses|Secondary endpoints: 1 Presence of late acute rejection (in the 6 month biopsy compared with the 4 week biopsy). 2 Sirius red staining for renal cortical matrix accumulation. 3 Immunologic response before and after MSC infusion.","Leiden University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P08.119|NL21298.000.08","February 2009","March 2012","December 2012","August 14, 2008",,"January 7, 2013","Leiden Universitary Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT00734396"
111,"NCT01765634","Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease",,"Unknown status","No Results Available","Acute Graft-versus-host Disease","Biological: Mesenchymal stem cells|Biological: Non-mesenchymal stem cells","The efficacy of treatment for refractory aGVHD|acute and late toxic side effects of MSCs treatment","Nanfang Hospital of Southern Medical University|Sun Yat-sen University|Peking University People's Hospital|Guangdong Provincial People's Hospital|Guangzhou General Hospital of Guangzhou Military Command|Southern Medical University, China|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People's Hospital|Zhongshan People's Hospital, Guangdong, China","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-MSCs-aGVHD-2013","January 2013","December 2015","December 2016","January 10, 2013",,"January 10, 2013","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01765634"
112,"NCT03550183","Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease",,"Enrolling by invitation","No Results Available","Parkinson's Disease","Biological: mesenchymal stem cells","Changes of the Unified Parkinson's Disease Rating Scale (UPDRS)|Changes of in the Hoehn and Yahr staging|Changes of the Mini-Mental State Examination (MMSE)|Changes of the Hamilton depression scales 24 (HAMD 24)|Changes of the Hamilton Anxiety Scale 14 (HAMA-14)|Adverse reaction","Hebei Newtherapy BIo-Pharma technology Co., Ltd.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18967728D","January 10, 2018","October 10, 2021","December 30, 2022","June 8, 2018",,"August 26, 2021","Hebei Newtherapy BIo-Pharma Technology Co., Ltd, Shijiazhuang, Hebei, China",,"https://ClinicalTrials.gov/show/NCT03550183"
113,"NCT02804945","Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies",,"Completed","No Results Available","Blood And Marrow Transplantation|Adult Respiratory Distress Syndrome","Biological: Mesenchymal Stem Cells (MSCs)","Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)","M.D. Anderson Cancer Center|Katz Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0327|NCI-2016-01184","February 24, 2017","June 13, 2019","June 13, 2019","June 17, 2016",,"April 10, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02804945"
114,"NCT01586312","Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells","MSV_allo","Completed","Has Results","Osteoarthritis, Knee|Arthritis of Knee|Knee Osteoarthritis","Other: Allogenic mesenchymal stromal cells injection|Drug: Hyaluronic Acid","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)|Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)","Red de Terapia Celular|University of Valladolid|Sanidad de Castilla y León|Centro Medico Teknon","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","TerCel004|2011-005321-51|EC11-309|MSV_allo","April 2012","December 2013","June 2014","April 26, 2012","November 6, 2014","October 16, 2015","Centro Medico Teknon, Barcelona, Spain|Hospital Clinico Universitario, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01586312"
115,"NCT04749667","Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis","SMART-MS","Recruiting","No Results Available","Multiple Sclerosis|Progressive Multiple Sclerosis","Other: MSCs|Drug: Saline","Neurophysiological parameters - Combined evoked potentials|Neurophysiological parameters - Somatosensoric evoked potantials|Neurophysiological parameters - Motor evoked potentials|Neurophysiological parameters - Visual evoked potentials|MRI-Lesion volumes|MR- Brain volumes|Expanded disability status scale|Patient reported outcomes (PROs)|Nine-Hole-Peg Test (9-HPT)|Timed 25 Foot Walk (T25FW)|Visual function|Optical coherence tomography (OCT)|Rate and nature of adverse- and serious adverse events","Haukeland University Hospital|University of Bergen|University Hospital Ulm|University Hospital, Akershus|St. Olavs Hospital|University Hospital of North Norway","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","159326","August 9, 2021","October 4, 2024","January 4, 2025","February 11, 2021",,"September 8, 2021","University hospital of North Norway, Tromsø, Troms Og Finnmark, Norway|St.Olav university hospital, Trondheim, Trøndelag, Norway|Haukeland University Hospital, Bergen, Vestland, Norway|Akershus university hospital, Lørenskog, Viken, Norway",,"https://ClinicalTrials.gov/show/NCT04749667"
116,"NCT01765660","Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease",,"Unknown status","No Results Available","Chronic Graft-versus-host Disease","Biological: Mesenchymal stem cells|Biological: Non-mesenchymal stem cells","The efficacy of treatment for refractory cGVHD|acute and late toxic side effects of MSCs treatment","Nanfang Hospital of Southern Medical University|Sun Yat-sen University|Peking University People's Hospital|Guangdong Provincial People's Hospital|Guangzhou General Hospital of Guangzhou Military Command|Southern Medical University, China|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People's Hospital|Zhongshan People's Hospital, Guangdong, China","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-MSCs-cGVHD-2013","January 2013","December 2015","December 2016","January 10, 2013",,"January 10, 2013","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01765660"
117,"NCT02574572","Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury",,"Unknown status","No Results Available","Spinal Cord Injury","Biological: Autologous mesenchymal cells transplantation","Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging|Functional improvement in ASIA (American Spinal Injury Association) grade|Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)|Improvements in sensorial mapping and neuropathic pain","Hospital Sao Rafael","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-003","September 6, 2017","December 31, 2019","June 30, 2020","October 14, 2015",,"November 28, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT02574572"
118,"NCT03343782","Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes","ASD2","Completed","No Results Available","Type 2 Diabetes Mellitus","Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell","Insulin dose|Adverse events|Hemoglobin A1c (HbA1c) level","Vinmec Research Institute of Stem Cell and Gene Technology","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VinmecRISCGT70","November 1, 2017","August 1, 2019","August 1, 2019","November 17, 2017",,"June 18, 2021","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03343782"
119,"NCT04416139","Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19","COVID-19","Recruiting","No Results Available","Covid 19","Biological: Infusion IV of Mesenchymal Stem cells","Functional Respiratory changes: PaO2 / FiO2 ratio|Clinical cardiac changes: Heart rate per minute|Clinical Respiratory Changes: Respiratory rate per minute|Changes in body temperature|General biochemical changes in Leukocytes|General biochemical changes on lymphocytes|General biochemical changes on platelets|General biochemical changes on fibrinogen|General biochemical changes on pocalcitonin|General biochemical changes on ferritin|General biochemical changes on D-dimer|Changes on inflammatory C-reactive protein|Cahnges on Inflammatory cytokine TNFa|Changes on Inflammatory cytokine IL10|Changes on Inflammatory cytokine IL1|Changes on Inflammatory cytokine IL6|Changes on Inflammatory cytokine IL 17|Changes on VEGF|Radiological Changes|Immunological changes on T cell|Immunological changes on Dendritic cells|Immunological changes on CD4+ T|Immunological changes on CD8+ T|Immunological changes on NK cell|Adverse events|RNA detection by SARS-Cov2 PCR","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-3354-20-21-1","May 1, 2020","April 30, 2021","May 1, 2021","June 4, 2020",,"June 4, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04416139"
120,"NCT03683953","The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells",,"Unknown status","No Results Available","Safety Issues|Effect of Drugs","Other: mesenchymal stem cells therapy|Drug: 0.9% sodium chloride","number of patients with BPD after instillation mesenchymal stem cells","Guangdong Women and Children Hospital","All","28 Weeks to 37 Weeks   (Child)","Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong W CH","September 29, 2018","August 1, 2019","July 1, 2020","September 25, 2018",,"September 25, 2018",,,"https://ClinicalTrials.gov/show/NCT03683953"
121,"NCT04345601","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)",,"Recruiting","No Results Available","Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19","Biological: Mesenchymal Stromal Cells|Other: Supportive Care","Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-47561 MSC for COVID-19","February 12, 2021","October 2022","October 2022","April 14, 2020",,"October 6, 2021","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04345601"
122,"NCT01741090","The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis",,"Unknown status","No Results Available","Alcoholic Liver Cirrhosis","Biological: mesenchymal stem cell injection","The improvement of Liver Histologic grade|The evaluation of hepatic dendritic cells activity by immunohistochemistry|Liver fibrosis quantitative analysis using Hydroxyproline contents in liver tissue|Real-Time Polymerase Chain Reaction for relative mRNA expression of TGF-beta, collagen, procollagen, MMP2 or 9|Hepatic venous pressure gradient(HVPG)|Hepatic vein arrival time using microbubble contrast enhanced ultrasonography|Liver stiffness measurement with transient elastography|Child-Pugh score|MELD score","Yonsei University","All","20 Years to 60 Years   (Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR109021","September 2009","June 2013","August 2013","December 4, 2012",,"December 10, 2012","Yonsei University Wonju College of Medicine Wonju Christian Hospital, Wonju, Kangwon-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01741090"
123,"NCT00659620","Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy",,"Unknown status","No Results Available","Kidney Transplant|Chronic Allograft Nephropathy","Biological: mesenchymal stem cell","Creatinine and creatinine clearance rate|Patient and graft survival [ Time Frame: At 1 years post-transplant ].|The proportion of renal biopsy after 12 months|The incidence of infectious complications|Incidence of adverse events associated with MSC and immunosuppression","Fuzhou General Hospital|Organ Transplant Institute, China","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","fuzhough0712","May 2008","May 2008","May 2010","April 16, 2008",,"April 16, 2008","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT00659620"
124,"NCT01377870","Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: intravenous injection of mesenchymal stem cells|Biological: injection of cell free media","MRI metrics changes|Brain atrophy|number of sever relapses|EDSS|MSFC|quality of life|RAO Test|intravenous cell transplantation","Royan Institute","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royn-nerve-001","December 2011","March 2014","April 2014","June 21, 2011",,"March 7, 2018","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01377870"
125,"NCT02012153","Mesenchymal Stromal Cells in Kidney Transplant Recipients",,"Recruiting","No Results Available","Kidney Transplant Rejection","Biological: Mesenchymal Stromal Cells","Circulating naïve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).|T-cell function by ELISPOT assay in mixed lymphocyte reaction.|Number of adverse events.|Circulating regulatory T cell count.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.","Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-Tx tolerance|2013-003221-29","December 2013","December 2022","March 2023","December 16, 2013",,"November 5, 2020","U.O. Nefrologia e Dialisi, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT02012153"
126,"NCT02945462","Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)",,"Completed","No Results Available","Erectile Dysfunction","Biological: autologous mesenchymal stem cells","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire|Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test.","University of Jordan","Male","25 Years to 65 Years   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDUJCTC","September 2013","November 2015","October 2016","October 26, 2016",,"November 16, 2016",,,"https://ClinicalTrials.gov/show/NCT02945462"
127,"NCT03299413","Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease",,"Unknown status","No Results Available","Inflammatory Bowel Diseases","Biological: Wharton Jelly Mesenchymal stem cells","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Evaluation of the efficacy of the injected cells (Change from Baseline in partial mayo score)","Hanan Jafar|Scientific Research Support fund|University of Jordan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBDUJCTC","June 5, 2017","November 2019","January 2020","October 3, 2017",,"April 10, 2019","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03299413"
128,"NCT01775774","Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome","START","Completed","Has Results","Acute Respiratory Distress Syndrome","Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells","Incidence of Pre-specified Infusion Associated Adverse Events|Incidence of Severe Adverse Events (SAEs)|Ventilator Free Days at Study Day 28|Duration of Vasopressor Use (Days)|ICU Free Days to Day 28|Hospital Survival to Day 60|Mortality at Hospital Discharge","Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARDS MSC 001|1U01HL108713-01","July 2013","February 2014","February 2015","January 25, 2013","August 14, 2017","August 14, 2017","University of California San Francisco Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01775774"
129,"NCT01522716","Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease",,"Terminated","No Results Available","Graft-Versus-Host Disease","Biological: Mesenchymal stromal cells","Change in disease activity according to National Institute of Health criteria|Change in disease activity as measured by histological examination|Change in self-assessed disease activity and quality of life|Safety (Adverse events, infections and relapse)|Freedom from steroids at 1 year after MSC treatment","Karolinska Institutet|Region Stockholm","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-cGVH","August 2011","March 2016","March 2017","February 1, 2012",,"November 25, 2020","Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01522716"
130,"NCT02065167","Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip","ORTHO-2","Completed","No Results Available","Avascular Necrosis of the Femoral Head","Biological: Cultured autologous Mesenchymal Cells","Complication rate|complication rate|Progression of disease to the next stage|Amount of necrotic bone in the femoral head in MRI|Pain (VAS)|serum levels of bone turnover markers","Universidad Autonoma de Madrid","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ORTHO -2|2012-002010-39","February 2014","June 2016","December 2017","February 17, 2014",,"October 14, 2021","Department of Orthopaedic Surgery, Hôpital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHU Tours, Tours, France|University Children's Hospital, Tübingen, Germany|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, Bologna, Italy|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02065167"
131,"NCT02150551","Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease",,"Completed","No Results Available","Inflammatory Bowel Diseases","Biological: Allogeneic bone marrow-derived mesenchymal stromal cells","Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Proportion of patients with clinical response|Number of subjects demonstrating an improvement of laboratory tests reflecting systemic inflammation.|Number of subjects with endoscopic healing after treatment.","Catherine Bollard|Children's National Research Institute","All","12 Years to 22 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STOMP","September 2015","September 27, 2019","September 27, 2019","May 30, 2014",,"July 14, 2020","Children's National Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02150551"
132,"NCT03356821","Perinatal Arterial Stroke Treated With Stromal Cells Intranasally","PASSIoN","Completed","No Results Available","Perinatal Arterial Ischemic Stroke|Neonatal Stroke","Biological: Mesenchymal Stem Cells","Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the acute setting.|Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the subacute/long-term setting","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development|M.D. Anderson Cancer Center|The University of Texas Health Science Center at San Antonio","All","up to 10 Days   (Child)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL59265.000.16","February 11, 2020","July 27, 2021","July 27, 2021","November 29, 2017",,"October 7, 2021","Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03356821"
133,"NCT01764100","Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)","MSC-GvHD","Unknown status","No Results Available","Graft vs Host Disease","Genetic: Mesenchymal stromal cells","Any toxic effect reported during MSCs infusion or in the subsequent 10 days by clinical monitoring|Feasibility as the possibility of producing adequate lots of patient dedicated MSCs for any patients presenting with steroid resistant GVHD|Number of patients with GvHD resolution|Determination of recurrence of GvHD|Relapse of haematological disease|Survival","Ettore Biagi, MD|Azienda Ospedaliera San Gerardo di Monza","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-MSC|2008-007869-23","September 2009","May 2013","September 2013","January 9, 2013",,"January 9, 2013","U.O. Ematologia - Ospedali Riuniti di Bergamo, Bergamo, BG, Italy|Clinica Pediatrica CTMO - Azienda Ospedaliera San Gerardo, Monza, MB, Italy|U.O. Ematologia CTMO - Azienda Ospedaliera San Gerardo, Monza, MB, Italy",,"https://ClinicalTrials.gov/show/NCT01764100"
134,"NCT04713878","Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia",,"Completed","No Results Available","Coronavirus Disease 2019 (COVID-19) Pneumonia","Other: Mesenchymal stem cells","Change of clinical symptoms as respiratory distress or need for oxygen support|Change of cytokine storm parameters|Change of pulmonary functions|Change of clinical symptoms","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020.05.20","May 8, 2020","June 30, 2020","July 15, 2020","January 19, 2021",,"January 20, 2021","University of Health Sciences, Istanbul, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04713878/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04713878"
135,"NCT01446614","Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease",,"Unknown status","No Results Available","Parkinson's Disease","Biological: bone marrow derived mesenchymal stem cells","Number of participants with adverse events|Effect assessment","Guangzhou General Hospital of Guangzhou Military Command","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-2011-10","October 2011","June 2013","June 2014","October 5, 2011",,"October 5, 2011","Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01446614"
136,"NCT02770430","Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease",,"Unknown status","No Results Available","Graft vs Host Disease","Biological: mesenchymal stem cells|Drug: conventional treatment","Complete response: disappearance of all symptoms|Partial response: with a decrease at least of one degree of GVHD|VGPR: decrease to the stage I of GVHD|Stable disease: when there is a stability of the disease (by Clinical evaluation)|Number of infection (by Clinical and laboratory evaluation)|Type of infection (by Clinical and laboratory evaluation)","Hospital de Clinicas de Porto Alegre","All","Child, Adult, Older Adult","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-0407","September 2015","September 2017","December 2018","May 12, 2016",,"May 12, 2016","Centro Terapia e Tecnologia Celular, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT02770430"
137,"NCT01446640","Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury","MSC","Unknown status","No Results Available","Spinal Cord Injury","Biological: bone marrow derived mesenchymal stem cells","Number of participants with adverse events|Electromyogram and Electroneurophysiologic test|Muscle strength assessment|Motor and sensory assessment","Guangzhou General Hospital of Guangzhou Military Command","All","16 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-2011-09","October 2011","June 2013","June 2014","October 5, 2011",,"October 5, 2011","Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01446640"
138,"NCT02814864","Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy","PRISME","Recruiting","No Results Available","Pelvic Radiation Therapy|Radiation-induced Hemorrhagic Cystitis","Drug: Mesenchymal Stromal Cell (MSC) injections","Decrease of one grade on the LENT SOMA|The effect of treatment on analgesic drug consumption (analgesic, opiates).|The effect of treatment on quality of life with SF36 questionnaire|The effect of treatment on quality of life with HADS questionnaire|The effect of treatment on pain|Frequency of diarrhea","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P130935|2014-001462-99","April 14, 2021","April 2022","April 2022","June 28, 2016",,"August 3, 2021","Hématologie et thérapie cellulaire, Hôpital Saint Antoine, Paris, France",,"https://ClinicalTrials.gov/show/NCT02814864"
139,"NCT04519684","Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease","IPAAF","Recruiting","No Results Available","Ileal Pouch|Crohn Disease","Drug: Mesenchymal stem cells|Other: Placebo","Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease","Amy Lightner|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CCF-Stem Cells IBD-002","October 28, 2020","October 2022","October 2022","August 20, 2020",,"March 19, 2021","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04519684"
140,"NCT04444271","Mesenchymal Stem Cell Infusion for COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Mesenchymal stem cells|Other: Placebo","Overall survival|Clinical improvement|Time of COVID19 PCR negativity|Radiological improvement (day 15 and day 30 assessment)|days required to discharge from hospital","Dr. Zaineb Akram|National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","All","10 Years and older   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIBMT-MSc-COVID-2020","May 1, 2020","August 30, 2020","September 30, 2020","June 23, 2020",,"June 30, 2020","NIBMT, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04444271"
141,"NCT01676441","Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury",,"Terminated","No Results Available","Spinal Cord Injury","Drug: cellgram-spine","Compared change of Motor Score of the American Spinal Injury Association (ASIA) scale|Sensory score of the American Spinal Injury Association (ASIA) scale|Electrophysiological change (Motor Evoked Potentials-MEP, Somatosensory Evoked Potentials-SSEP)|MRI and Diffusion Tensor Imaging of spinal cord","Pharmicell Co., Ltd.","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cerecellgram-spine","August 2008","March 4, 2021","March 4, 2021","August 31, 2012",,"March 23, 2021","Asan medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01676441"
142,"NCT02097641","Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)","START","Completed","Has Results","Respiratory Distress Syndrome, Adult","Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Biological: Plasma-Lyte A","Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion|Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion|Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)|PaO2:FiO2 Change From Baseline to Day 3|Lung Injury Score From Baseline to Day 3|Oxygenation Index Change From Baseline to Day 2|SOFA Score Change From Baseline to Day 3|Number of Patients Death to Day 28|Mortality to Day 60|Number of Ventilator-free Days to Day 28|Non-pulmonary Organ-failure-free Days to Day 28|Angiopoietin 2 Change From Baseline to 6 h|Angiopoietin 2 Change From Baseline to 24 h|Interleukin 6 Change From Baseline to 6 h|Interleukin 6 Change From Baseline to 24 h|Interleukin 8 Change From Baseline to 6 h|Interleukin 8 Change From Baseline to 24 h|RAGE Change From Baseline to 6 h|RAGE Change From Baseline to 24 h","Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota|Ohio State University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCSF-hMSC-ARDS-P2|1U01HL108713-01","March 15, 2014","March 9, 2017","February 9, 2018","March 27, 2014","April 10, 2019","April 10, 2019","University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Saint Paul, Minnesota, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02097641/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02097641"
143,"NCT04434794","Treatment of Gingival Recession Using Mesenchymal Stem Cells",,"Completed","No Results Available","Gingival Recession","Biological: mesenchymal stem cells|Other: standard treatment","number of patients cured","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(GR2)","January 1, 2018","December 31, 2019","December 31, 2019","June 17, 2020",,"June 17, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04434794"
144,"NCT01305694","Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.","MSC","Unknown status","No Results Available","Aplastic Anemia","Biological: bone marrow derived mesenchymal stem cells","Number of participants with adverse events|Hematologic response|Relapse|Clonal evolution to PNH, myelodysplasia or acute leukemia|Survival","Guangzhou General Hospital of Guangzhou Military Command|Guangzhou Municipal Twelfth People's Hospital|Guangdong Prevention and Treatment Center for Occupational Diseases","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-2010-16","February 2011","June 2012","December 2012","March 1, 2011",,"March 1, 2011","Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01305694"
145,"NCT02481440","Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI",,"Completed","Has Results","Spinal Cord Injuries","Biological: human umbilical cord mesenchymal stem cells (hUC-MSCs)","American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up|American Spinal Injury Association (ASIA) Total Score|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score|International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score|Penn Scale|Modified Ashworth Scale|Geffner Scale|Neurogenic Bowel Dysfunction (NBD) Scale|Residual Urine Volume","Limin Rong|Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","102","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","hUC-MSC-SCI","March 30, 2018","March 31, 2020","March 31, 2020","June 25, 2015","June 30, 2020","June 30, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02481440/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02481440"
146,"NCT02987413","Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients",,"Completed","No Results Available","Motor Neuron Disease","Biological: Autologous Mesenchymal stem cells (MSCs)","Serious Adverse Events related to the treatment|Revised ALS Functional Rating Scale (ALSFRS-R)","Hospital e Maternidade Dr. Christóvão da Gama|IEP São Lucas - Instituto de Ensino e Pesquisa|Clinica Jordy Sinapse|TECHLIFE - Centro de Tecnologia Celular","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HospitalMCG|IEPSaoLucas","April 28, 2015","March 2016","April 5, 2017","December 9, 2016",,"August 7, 2017","Hospital e Maternidade Dr Christovao da Gama, Santo Andre, Sao Paulo, Brazil|Instituto de Ensino e Pesquisas - IEP-São Lucas, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02987413"
147,"NCT02304562","Umbilical Cord Blood-derived Mesenchymal Stem Cells in Regeneration of Sweat Glands and Body Repair",,"Unknown status","No Results Available","Sweat Gland Diseases","Biological: UCB Mesenchymal Stem Cells treatment","Frequency of Adverse Events|Active and inactive lesion count","Chinese PLA General Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHIN-PLAGH-ST-004","January 2013","December 2017","December 2017","December 2, 2014",,"December 2, 2014","Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02304562"
148,"NCT03818854","Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome","STAT","Recruiting","No Results Available","Respiratory Distress Syndrome, Adult","Biological: Human Mesenchymal Stromal Cells|Biological: Cell Reconstitution Media","Change in oxygenation index (OI)|Acute Lung Injury Score (LIS)|Pulmonary Dead Space Fraction|Chest radiograph assessment of pulmonary edema (RALE score)|Ventilator free-days|Duration of assisted ventilation over 28 days|Percentage of patients achieving pressure support ventilation for 2 hours|Occurrence of Infection|Sequential Organ Failure Assessment (SOFA) over 7 days|All-cause hospital mortality|Glasgow Outcome Score (GCS)|Percentage of patients occurred any thromboembolic events|Plasma angiopoietin-2|Plasma Receptor for Advanced Glycation Endproducts (RAGE)|Plasma interleukin-6|Plasma interleukin-8|Plasma Soluble tumor necrosis factor 1 (sTNF-1)|Plasma protein C|Plasma lipoxin A4|Plasma Resolvin D1|Plasma angiopoietin-1|Plasma keratinocyte growth factor (KGF)|Urine microalbumin|Total protein in min-bronchoalveolar lavage (mBAL)|Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events","Michael A. Matthay|United States Department of Defense|Harborview Injury Prevention and Research Center|Oregon Health and Science University|Vanderbilt University Medical Center|The University of Texas Health Science Center, Houston|University of Minnesota|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCSF-hMSC-ARDS-P1P2-12","November 26, 2019","July 1, 2023","July 1, 2024","January 28, 2019",,"August 24, 2021","University of California Davis Medical Center, Sacramento, California, United States|Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03818854"
149,"NCT04823000","Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis","MSC-pMS","Completed","No Results Available","Multiple Sclerosis","Biological: Mesenchymal Stem Cells (MSC)","Appearance of adverse events|The changes in Expanded Disability Status Scale (EDSS) score 0-10 scale, higher scores show worsening of disability)|Changes in the percentage of CD4/CD25/FoxP3 triple positive stained cells (T regulatory cells), following MSC-treatment|Changes in the percentage of CD3+CD69+ cells (activated lymphocytes), following MSC-treatment|Changes in the percentage of CD11c+/CD86+/Lin- cells (dendritic cells and antigen-presenting macrophages), following MSC-treatment|Changes in the proliferation ability of mononuclear cells to PHA, following MSC-treatment","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-MS-001","January 1, 2013","December 1, 2016","April 1, 2020","March 30, 2021",,"March 30, 2021",,,"https://ClinicalTrials.gov/show/NCT04823000"
150,"NCT03357770","The Maximum Tolerated Dose of Mesenchymal Stem Cells From Umbilical Cord",,"Unknown status","No Results Available","Knee Osteoarthritis|Umbilical Cord Bleeding","Drug: mesenchymal stem cells","Unexplained local and systemic symptoms or death","Peking University People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUPH20170910","January 1, 2018","December 1, 2020","June 1, 2021","November 30, 2017",,"November 30, 2017",,,"https://ClinicalTrials.gov/show/NCT03357770"
151,"NCT01573923","Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis","LC","Unknown status","No Results Available","Liver Cirrhosis","Biological: mesenchymal stem cells|Biological: Conventional therapy","survival time|Serum markers regarding liver and kidney function|Serum markers regarding lipid and sugar profile|Serum markers regarding cytokine profile|Serum levels of Hepatitis B and C|tolerance and the adverse events|Changes of any clinical symptoms","Alliancells Bioscience Corporation Limited","All","30 Years to 60 Years   (Adult)","Phase 1|Phase 2","320","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Alliancells-2012-1","July 2014","July 2015","October 2015","April 10, 2012",,"April 14, 2015","The 302 Hospital of Chinese People's Liberation Army, Beijing, Beijing, China|the First Affiliated Hospital of Lanzhou University, Lanzhou, Gansu, China|Hainan BOAO Life infinity international anti-aging medical center, Qionghai, Hainan, China|The first people's hospital of Lianyungang, Lianyungang, Jiangsu, China|Tongji Hospital of Tongji University, Shanghai, Shanghai, China|The 323 Hospital of Chinese People's Liberation Army, Xi'an, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT01573923"
152,"NCT03878628","Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease","MESADDE","Active, not recruiting","No Results Available","Dry Eye|Kerato Conjunctivitis Sicca|Aqueous Tear Deficiency","Drug: Adipose tissue-derived mesenchymal stem cells","Pain at injection site: grade|Infection at injection site|Bleeding at injection site|Eyelid function disorder|Periorbital edema|Ocular discomfort|Flu-like symptoms|Fever|OSDI questionnaire|Schirmer's I test|Tear osmolarity|Ocular SICCA Grading Score|HLA anti-bodies","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","001-2018","October 16, 2019","June 30, 2020","June 30, 2022","March 18, 2019",,"October 8, 2020","Rigshospitalet, Copenhagen, DK, Denmark",,"https://ClinicalTrials.gov/show/NCT03878628"
153,"NCT01854957","MEsenchymal StEm Cells for Multiple Sclerosis","MESEMS","Unknown status","No Results Available","Multiple Sclerosis","Biological: Autologous Mesenchymal Stem Cells","Safety|efficacy|Efficacy","Antonio Uccelli|Azienda Ospedaliera Universitaria Integrata Verona|Ospedale San Raffaele|University of Genova","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MESEMS|2011-001295-19","July 2012","July 2014","September 2014","May 16, 2013",,"May 16, 2013","University of Genova, Genova, Italy",,"https://ClinicalTrials.gov/show/NCT01854957"
154,"NCT01183728","Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells","KDD&MSV","Completed","Has Results","Osteoarthritis, Knee|Knee Degenerative Disease|Knee Osteoarthritis","Other: Autologous bone marrow mesenchymal stem cells (MSV)","Feasibility and Safety of the Implementation of MSV in the Treatment of Osteoarthritis of the Knee.|Indication of Efficacy","Red de Terapia Celular|Fundacion Teknon, Centro Medico Teknon, Barcelona|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Institut de Terapia Regenerativa Tissular|EGARSAT Suma Intermutual, Barcelona, Spain|Cetir Sant Jordi, S.a..","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TerCel001|Eudra-CT 2009-017405-11|Protocol Code","May 2010","August 2014","September 2014","August 18, 2010","January 15, 2015","January 15, 2015","Teknon Medical Center, ITRT, Barcelona, Spain|Instituto de Biologia y Genetica Molecular (IBGM), University of Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01183728"
155,"NCT04078308","Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients","MSCTXT1DM","Unknown status","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 1|Diabetes Mellitus, Insulin-Dependent","Biological: Intravenous Injection of autologous mesenchymal stem cells|Other: Intravenous injection of placebo","Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change from baseline number of hypoglycemic Unawareness episodes at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Fasting Blood Sugar (FBS) at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline C-peptide at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline HbA1C at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline 2-hour postprandial blood glucose at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline daily dose of exogenous insulin injected by patients (IU/kg/day) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from baseline Lability Index (LI) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline SF-36 Quality of life (QOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Diabetes Specific Quality of life (DQOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline Autoantibodies levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline serum cytokines levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells","Royan Institute|Tehran University of Medical Sciences|Iranian Stem Cell Council","All","8 Years to 40 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","RI-SCBT-94000019|IRCT2016070428786N1|94000019|REP-441","July 6, 2015","September 26, 2019","April 1, 2020","September 6, 2019",,"September 6, 2019","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04078308"
156,"NCT02574585","Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury",,"Not yet recruiting","No Results Available","Spinal Cord Injury","Biological: Autologous mesenchymal cells transplantation","Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging spinal cord injury|Functional improvement in ASIA (American Spinal Injury Association) grade|Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)|Improvements in sensorial mapping and neuropathic pain","Hospital Sao Rafael","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-005","December 2019","December 2021","January 2022","October 14, 2015",,"November 28, 2017",,,"https://ClinicalTrials.gov/show/NCT02574585"
157,"NCT02731586","Effect on Allogenic Mesenchymal Stem Cells on Osseointegration of Dental Implants","MSC&IMPLANTS","Unknown status","No Results Available","Edentulous Alveolar Ridge","Drug: Allogenic Mesenchymal stem cells","Determination of Implant Stability with RFA","Sri Sai College of Dental Surgery and Research Centre","All","18 Years to 64 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","SSCDS-IMP-201601","January 2016","December 2017","March 2018","April 7, 2016",,"October 6, 2017","Sri Sai College Of Dental Surgery and Research Centre, Vikarabad, Telangana State, India",,"https://ClinicalTrials.gov/show/NCT02731586"
158,"NCT01759784","Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS",,"Withdrawn","No Results Available","Amyotrophic Lateral Sclerosis","Biological: Intraventricular injection","fever|unconsciousness|brain hematoma|vomiting|ALS-FRS|EMG-NCV","Royan Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Nerve-004","March 2014","March 2017",,"January 3, 2013",,"January 1, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01759784"
159,"NCT02287831","Umbilical Cord Mesenchymal Stem Cells Injection for Diabetes Secondary Peripheral Arterial Disease",,"Unknown status","No Results Available","Diabetes|Peripheral Arterial Disease","Biological: umbilical cord mesenchymal stem cells","Angiographic evaluation of angiogenesis at ischemic limb|Ankle-Brachial pressure index|Walking distance|Pain|Laser Doppler evaluation of blood perfusion at ischemic limb","Institute of Hematology & Blood Diseases Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13ZCZDSY02200","February 2014","June 2016",,"November 11, 2014",,"February 25, 2016",,,"https://ClinicalTrials.gov/show/NCT02287831"
160,"NCT01228266","Mesenchymal Stem Cell Transplantation in MS","CMM-EM","Terminated","No Results Available","Multiple Sclerosis","Biological: autologous mesenchymal stem cells","To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study|To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales","Albert Saiz|Instituto de Salud Carlos III|Hospital Clinic of Barcelona","All","18 Years to 50 Years   (Adult)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMM-EM","December 2010","June 2013","December 2013","October 26, 2010",,"February 13, 2014","Neurology Service, Hospital Clinic de barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01228266"
161,"NCT02323789","Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa","ADSTEM","Unknown status","No Results Available","Recessive Dystrophic Epidermolysis Bullosa","Drug: Mesenchymal stromal cells","Lack of serious and severe adverse events (SAEs) related to the administration of the investigational medicinal product.|Presence of new type VII collagen at the dermal-epidermal junction post treatment.|Change in general markers of inflammation|Changes in specific markers of inflammation|Change in the clinical changes in the skin assessed with clinical photographs|Differences in quality of life data|Change in BEBSS and EBDASI scores|Change in Pain scores|Change in pruritus score using the Leuven Itch Scale (LIS)|Quantification of total blister numbers over the entire body surface area|10. Increase in the skin strength measured by time to blister formation after negative pressure skin suction test|Qualitative analyses based on a series of interview questions","King's College London","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ADSTEM001","June 2015","July 2017","July 2017","December 23, 2014",,"March 3, 2017","Guys and St Thomas' hospital NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02323789"
162,"NCT04457037","Treatment of Patients With Trophic Ulcers Using Mesenchymal Stem Cells",,"Completed","No Results Available","Trophic Ulcer","Biological: Autologous adipose-derived mesenchymal stem cells","Number of patients with tropic ulcers cured|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(TrophicUlcer)","October 1, 2009","December 31, 2013","December 31, 2013","July 7, 2020",,"July 7, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04457037"
163,"NCT02705742","Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis",,"Unknown status","No Results Available","Liver Cirrhosis","Biological: Mesenchymal Stem Cells","All cause mortality","Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMMA-HCV-MSC-1","January 2016","July 2017","December 2017","March 10, 2016",,"June 7, 2016","Gulhane Military Medical Academy, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT02705742"
164,"NCT04821479","Repeated Mesenchymal Stem Cell Injections in ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: Mesenchymal stem cells (MSC)","Safety of multiple intrathecal MSC administration. Incidence of adverse events following multiple intrathecal MSC injections during 2 years follow-up period|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of ALSFRSr|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of respiratory forced vital capacity FVC","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0208-16-HMO","January 1, 2016","June 30, 2020","December 31, 2020","March 29, 2021",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04821479"
165,"NCT01499459","Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Genetic: autologous mesenchymal stem cell transplantation","clinical improvement|liver regeneration","Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11111111|1111111","June 2008","July 2012","August 2012","December 26, 2011",,"March 22, 2012","Gulhane Military Medical Academy Department of Gastroenterology, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT01499459"
166,"NCT02057211","Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study",,"Terminated","No Results Available","Type 1 Diabetes Mellitus","Biological: autologous mesenchymal stem cell transplantation|Procedure: sham transplantation of mesenchymal stem cells","∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.","Uppsala University Hospital","All","18 Years to 40 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","AS Dnr2013/195","April 2014","November 2017","November 2017","February 7, 2014",,"November 6, 2020","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT02057211"
167,"NCT04445454","Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection",,"Recruiting","No Results Available","Coronavirus Infection","Biological: Mesenchymal stromal cells","To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)","University of Liege","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJT2012","June 12, 2020","September 30, 2022","September 30, 2022","June 24, 2020",,"September 1, 2021","CHU de Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT04445454"
168,"NCT01860417","Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)","Disc_allo","Completed","No Results Available","Degenerative Disc Disease|Intervertebral Disc Disease|Low Back Pain","Biological: Allogenic Mesenchymal Stromal Cells|Drug: Mepivacaine","Safety and tolerability|Pain and disability evolution|Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)|Llife quality evolution (Short Form (SF)-12 questionnaire)","Red de Terapia Celular|Citospin|University of Valladolid","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","TerCel005|2012-004444-30|Disc_allo_MSV","April 2013","April 2017","April 2017","May 22, 2013",,"April 26, 2017","Hospital Clinico Universitario, Valladolid, Spain|Instituto de Biologia y Genetica Molecular, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01860417"
169,"NCT01730547","Mesenchymal Stem Cells for Multiple Sclerosis",,"Unknown status","No Results Available","Multiple Sclerosis","Biological: Autologous mesenchymal stem cells","To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients.|To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).","Karolinska Institutet","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-MS","February 2013","December 2015","December 2015","November 21, 2012",,"January 15, 2015","Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01730547"
170,"NCT05008588","Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Sub-Acute Stroke Infarct",,"Not yet recruiting","No Results Available","Ischemic Stroke","Biological: Conditioned Medium|Biological: Umbilical Cord Mesenchymal Stem Cells|Procedure: Neurologic and Neutrophic Drugs","Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation|Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation|Change baseline Magnetic Resonance Imaging at 6 month after transplantation|The National Institute of Health Stroke Scale (NIHSS) Scoring|modified Rankin Scale (mRS)","PT. Prodia Stem Cell Indonesia","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/STROKE/PSI/2021","September 2021","December 2021","January 2022","August 17, 2021",,"August 17, 2021","Gatot Soebroto Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|PT Prodia StemCell Indonesia, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT05008588"
171,"NCT02484950","Mesenchymal Stem Cell Augmentation in Patients Undergoing Arthroscopic Rotator Cuff Repair",,"Recruiting","No Results Available","Full Thickness Rotator Cuff Tear","Biological: Mesenchymal stem cell augmentation in rotator cuff repair|Procedure: Standard arthroscopic rotator cuff repair","American Shoulder and Elbow Surgeons (ASES) Score|Magnetic Resonance Imaging (MRI) Scan|Functional Outcomes - Shoulder Exam|Patient Centered Outcomes - Shoulder Survey","Rush University Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15042702","November 2015","June 2022","November 2022","June 30, 2015",,"May 19, 2021","Rush University Medical Center, Chicago, Illinois, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02484950/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02484950"
172,"NCT04456361","Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19",,"Active, not recruiting","No Results Available","ARDS, Human|Covid-19","Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords","Oxygen saturation|Oxygen pressure in inspiration|ground-glass opacity|Pneumonia infiltration|Lactate dehydrogenase|C-reactive protein|D-dimer|Ferritine","Instituto de Medicina Regenerativa","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-ARDS-001","April 16, 2020","October 15, 2020","December 15, 2020","July 2, 2020",,"August 4, 2020","Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico",,"https://ClinicalTrials.gov/show/NCT04456361"
173,"NCT05039411","Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease",,"Not yet recruiting","No Results Available","Perianal Fistula Due to Crohn's Disease|Fistula in Ano","Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs)","Incidence of any treatment-emergent adverse events (TE-AEs)|Clinical healing","CryoCord Sdn Bhd|University of Malaya","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCSB-CT-PF-01-2021 (Ver_01)","January 1, 2022","December 31, 2023","December 31, 2023","September 9, 2021",,"September 9, 2021","University of Malaya Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT05039411"
174,"NCT04661644","Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients With Critical Limb Ischemia",,"Recruiting","No Results Available","Critical Limb Ischemia","Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)","Changes in ischemic pain|Changes in pain-free walking distance|Changes in TBI (Toe Brachial Index)|Changes in ABI (Ankle Brachial Index)|Change in size of the Ulcer|Determination of maximum tolerable dose according to DLT occurrence|Incidence of abnormal laboratory tests results|Incidence of abnormal blood pressure|Incidence of abnormal temperature|Incidence of abnormal physical condition","S.Biomedics Co., Ltd.|Dt&Sanomedics","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-AC-001","November 4, 2020","June 2022","June 2022","December 10, 2020",,"August 27, 2021","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04661644"
175,"NCT03522545","Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression",,"Recruiting","No Results Available","Treatment-resistant Bipolar Depression","Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Biological: Placebo","Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)|Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of mania subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of depression subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity overall subscale|Change in neurocognition as assessed by the California Verbal Learning Test|Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)|Number of participants with inflammatory markers as assessed by multiplex biomarker analysis|Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)|Number of participants who withdrawal due to Adverse Events (AEs)|Number of participants with suicidal ideation based on clinical assessment|Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment","The University of Texas Health Science Center, Houston","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0657","June 1, 2021","July 1, 2022","July 1, 2022","May 11, 2018",,"September 27, 2021","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03522545"
176,"NCT04650568","Biologic Augmentation With Mesenchymal Stem Cells in Patients Undergoing Anterior Cruciate Ligament Reconstruction","BMAC","Enrolling by invitation","No Results Available","Anterior Cruciate Ligament Injury|Anterior Cruciate Ligament Rupture","Device: Autologous Bone Marrow Derived Mesenchymal Stem Cells|Other: Sham incision","Signal to Noise Quotient|Side to side difference in anterior tibial translation|Patient reported outcomes- Tegner Score|Patient reported outcomes- Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr)|Patient reported outcomes- International Knee Documentation Committee (IKDC) Score","Rush University Medical Center","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","17082504","November 3, 2017","December 3, 2021","December 3, 2021","December 2, 2020",,"February 5, 2021","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04650568"
177,"NCT04184258","Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells",,"Completed","No Results Available","Systemic Lupus Erythematosus","Biological: Pooled mesenchymal stem cell|Other: Standard treatment according to the Clinical protocols","Efficacy evaluation|Safety eveluation","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC1(SLE)","July 1, 2019","December 31, 2020","December 31, 2020","December 3, 2019",,"January 22, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04184258"
178,"NCT05075811","Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease",,"Not yet recruiting","No Results Available","Pouch, Ileal|Fistula","Drug: Ossium vBM-MSC|Other: Placebo","Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease","Amy Lightner|Ossium Health, Inc.|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CSP-5007","November 15, 2021","November 15, 2024","November 15, 2024","October 13, 2021",,"October 13, 2021","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05075811"
179,"NCT00659217","Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis",,"Unknown status","No Results Available","Lupus Nephritis","Biological: mesenchymal stem cell","the proportion of participants who achieve and maintain remission|Patient survival|Creatinine and proteinuria.|SLE disease activity index|Serology (ANA, dsDNA)|ComplementC3 and C4","Organ Transplant Institute, China","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","fuzhough0713","May 2008","May 2010","May 2010","April 16, 2008",,"April 16, 2008","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT00659217"
180,"NCT01322789","Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients",,"Unknown status","No Results Available","Diabetes Mellitus, Insulin-Dependent","Biological: Intravenous Mesenchymal stem cell infusion","AUC C-peptide levels during mixed meal tolerance test|Safety|Daily insulin use|Hemoglobin A1C|Anti-GAD titres|Immunologic reconstitution parameters","University of Sao Paulo","All","12 Years to 35 Years   (Child, Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCFMRPUSP 2|CNPQ 552266/2005-1","September 2008","November 2015","December 2015","March 25, 2011",,"March 25, 2011","Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01322789"
181,"NCT03164083","The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis",,"Withdrawn","No Results Available","Osteoarthritis","Biological: Mesenchymal stem cell|Biological: Placebo","physical function improvement|Change in pain density|Joint swelling|Joint erythema|Deterioration of joint function|Allergic reactions","SCARM Institute, Tabriz, Iran","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SCARM-Osteoarthritis-001","November 10, 2019","August 21, 2020","December 5, 2020","May 23, 2017",,"March 18, 2020","SCARM Institute, Tabriz, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03164083"
182,"NCT01429012","Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting",,"Withdrawn","No Results Available","Nonunion Fracture","Biological: Mesenchymal Stem Cells|Other: Culture medium without MSC.","Safety of Mesenchymal Stem Cells injection in nonunion fractures.|Proportion of patients receiving Mesenchymal Stem Cells that develop a partial or complete callus at 6 and 12 months, compared to patients receiving placebo.|Proportion of patients receiving Mensechymal Stem Cells that develop a partial or complete callus at 2, 3, 4, 8 and 10 months, compared to patients receiving placebo|Timing of development of a partial or complete callus in the 2 groups.|Patient evaluation of pain and global satisfaction.|Proportion of patients achieving different degrees of functional success.|Incidence of adverse events and severe adverse events in the 2 groups.|Evaluation of early homing of Mesenchymal Stem Cells.|Value of [18F]-NaF PET scans for early prediction of the onset of the bone healing process.","University of Liege","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TJT1101","November 2012","November 2016","November 2016","September 5, 2011",,"May 12, 2021","Liège University Hospital, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT01429012"
183,"NCT04565665","Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","COVID-19 Infection|COVID-19-Associated Acute Respiratory Distress Syndrome|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed","Other: Best Practice|Biological: Mesenchymal Stem Cell","Incidence of composite serious adverse events (Phase I)|Patients alive without grade 3, 4 infusional toxicity (Phase II)|Patients alive with grade 3 or 4 infusional toxicity (Phase II)|Patients not alive (Phase II)|Proportion of successfully extubated patients who present intubated on ventilator support (Phase I)|Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Overall survival rate (Phase I)|Survival rate in patients who present intubated on ventilator support (Phase I)|Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Clinical parameters (Phase I)|Oxygenation parameters (Phase I)|Respiratory parameters (Phase I)|Laboratory markers (Phase I)|Hospitalization stay (Phase I)|Intensive care unit stay (Phase I)|Incidence of infusion-related adverse events (Phase I)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0365|NCI-2020-06741","July 29, 2020","April 30, 2023","April 30, 2023","September 25, 2020",,"October 26, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04565665"
184,"NCT04357600","Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B",,"Recruiting","No Results Available","Liver Cirrhoses","Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell","Child Pugh Score|Examination of liver function|MELD Score","PT. Prodia Stem Cell Indonesia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/LC/01/2018","May 17, 2018","December 20, 2020","December 20, 2020","April 22, 2020",,"June 4, 2020","Cipto Mangunkusumo hospital, Jakarta, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04357600"
185,"NCT01056471","Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis",,"Completed","No Results Available","Autoimmune Diseases|Immune System Diseases|Demyelinating Diseases|Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System","Other: Autologous mesenchymal stem cells from adipose tissue.","To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells|To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Carlos III Health Institute|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMM/EM/2008","January 2010","June 2012","June 2015","January 26, 2010",,"August 7, 2015","Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01056471"
186,"NCT04522869","Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia","UCMSCBA","Recruiting","No Results Available","Primary Biliary Cirrhosis","Biological: Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation","The change of PELD scores during study|The change of albumin (Liver function)|The change of total bilirubin (Liver function)|The change of prothrombin time|The change of liver biopsy|The number of Adverse Events (AE) and Serious Adverse Events (SAE)","Vinmec Research Institute of Stem Cell and Gene Technology|Children's Hospital Number 2, Ho Chi Minh City, Vietnam","All","5 Months to 2 Years   (Child)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISC.19.10","August 10, 2019","September 25, 2021","October 25, 2021","August 21, 2020",,"September 1, 2020","Vinmec International Hospital Times City, Hà Nội, Hanoi, Vietnam|Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04522869"
187,"NCT04390152","Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.","BioXcellerator|Clinical Somer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BIOXSOMCOV001","January 13, 2020","December 2021","April 2022","May 15, 2020",,"January 15, 2021","BioXcellerator, Medellin, Antioquia-CO, Colombia|Clinical Somer, Rionegro, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT04390152"
188,"NCT01392105","Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction","SEED-MSC","Completed","No Results Available","Acute Myocardial Infarction","Drug: Mesenchymal stem cell|Drug: Control group","Absolute changes in global LVEF by SPECT|Changes in left ventricular end-diastolic volume (LVEDV)|Changes in left ventricular end-systolic volume (LVESV)|Changes in regional wall motion score index (WMSI) by Echocardiography|Major adverse cardiac event (MACE)","Yonsei University|FCB-Pharmicell Co Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC2-Version 6.0","March 2007","May 2010","May 2010","July 12, 2011",,"July 12, 2011","Yonsei University Wonju College of Medicine, Wonju Christian Hospital, Wonju, Gangwon-do, Korea, Republic of|Inha University Hospital, Inchon, Korea, Republic of|Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01392105"
189,"NCT03288571","Use of Wharton Jelly in Diabetic Nephropathy",,"Unknown status","No Results Available","Diabetic Nephropathies","Biological: Wharton Jelly Mesenchymal stem cells","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Evaluation of the preliminary efficacy of the injection on kidney's Estimated Glomerular filtration rate|Evaluation of the preliminary efficacy of the injection on kidney's protein to creatinine ratio","Sophia Al-Adwan|Jordan University of Science and Technology|An-Najah National University|University of Jordan","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DNJUCTC","November 2019","December 2020","January 2021","September 20, 2017",,"July 24, 2019",,,"https://ClinicalTrials.gov/show/NCT03288571"
190,"NCT01157650","Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue",,"Completed","No Results Available","Crohn Disease","Other: Autologous mesenchymal stem cells","Security and tolerance|therapeutic effect","Clinica Universidad de Navarra, Universidad de Navarra","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/CROH|2009-009880-71","June 2010","September 2013","September 2013","July 7, 2010",,"November 8, 2016","Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Provincial de Navarra, Pamplona, Spain|Hospital Virgen del Camino, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT01157650"
191,"NCT04426643","Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells",,"Completed","No Results Available","Urinary Incontinence","Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|The state institution N. N. Alexandrov National Cancer Centre of Belarus","Male","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(UIM)","August 1, 2020","February 20, 2021","March 31, 2021","June 11, 2020",,"May 25, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04426643"
192,"NCT03478215","Mesenchymal Stromal Cells in Living Donor Kidney Transplantation",,"Recruiting","No Results Available","Renal Transplantation|Mesenchymal Stem Cells","Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion|Other: Normal Saline (Placebo) Infusion","Number of participants without any infusional toxicity, occurring within 24 hours of infusion.|Number of participants without any acute rejection, graft loss, or death at 6 months post transplant.","The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Pro00012858|U1111-1169-2289","February 2016","July 2021","July 2021","March 27, 2018",,"December 14, 2020","Houston Methodist Hospital System, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03478215"
193,"NCT02192749","Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism",,"Completed","No Results Available","Autism","Biological: Umbilical cord mesenchymal stem cells","Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC)","Translational Biosciences","All","6 Years to 16 Years   (Child)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBS-UCMSC-ASD001","July 2014","August 2017","August 2017","July 17, 2014",,"October 13, 2017","Stem Cell Institute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02192749"
194,"NCT01257776","Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients",,"Completed","No Results Available","Critical Limb Ischemia (CLI)|Diabetes","Drug: Autologous adipose derived mesenchymal stem cells","Angiographic assessment of neovasculogenesis (angiogenesis plus arteriogenesis)|Major adverse event (death, target limb amputation)|Ankle Brachial Index|University of Texas Classification at target limb","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CeTMAd/ICPD/2008","December 2010","February 2013","July 2015","December 10, 2010",,"August 5, 2015","University Hospital Virgen Macarena, Seville, Spain|CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine), Seville, Spain",,"https://ClinicalTrials.gov/show/NCT01257776"
195,"NCT03562065","Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord","MSC-SLE","Recruiting","No Results Available","Lupus Erythematosus|Stem Cell Transplant","Biological: mesenchymal stem cells","Toxicity of allogeneic MSC injection according to CTCAE|Toxicity of allogeneic MSC injection according to CTCAE Month 1|Toxicity of allogeneic MSC injection according to CTCAE Month 3|Toxicity of allogeneic MSC injection according to CTCAE Month 6|Toxicity of allogeneic MSC injection according to CTCAE Month 12|Proportion of subjects with Clinical Response Month 3|Proportion of subjects with Clinical Response Month 6|Proportion of subjects with Clinical Response Month 9|Proportion of subjects with Clinical Response Month 12|Disease activity measured by the BILAG index Month 3|Disease activity measured by SELENA-SLEDAI Month 3|Disease activity measured by SELENA-SLEDAI Month 6|Disease activity measured by the BILAG index Month 6|Disease activity measured by the BILAG index Month 9|Disease activity measured by SELENA-SLEDAI Month 9|Disease activity measured by the BILAG index Month 12|Disease activity measured by SELENA-SLEDAI Month 12|SRI Month 3|SRI Month 6|SRI Month 9|SRI Month 12|comorbidities Month 3|comorbidities Month 6|comorbidities Month 9|comorbidities Month 12|Quality of life Month SF-36 Month 3|Quality of life EQ-5D Month 3|Quality of life Month SF-36 Month 6|Quality of life EQ-5D Month 6|Quality of life Month SF-36 Month 9|Quality of life EQ-5D Month 9|Quality of life Month SF-36 Month 12|Quality of life EQ-5D Month 12|Steroids Month 3|Steroids Month 6|Steroids Month 9|Steroids Month 12","Assistance Publique - Hôpitaux de Paris","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150302","September 11, 2019","June 1, 2023","June 1, 2024","June 19, 2018",,"July 8, 2021","Saint-Louis Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03562065"
196,"NCT04441658","Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Type 2 Diabetes|Mesenchymal Stem Cells","Biological: Umbilical Cord Mesenchymal Stem Cells|Biological: saline","The changes in HbA1C level|Reduction of insulin requirement|The changes in blood glucose level","Shanghai East Hospital","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DFSC-2020(CR)-02","April 10, 2020","July 2022","December 2022","June 22, 2020",,"June 22, 2020","Shanghai East Hospital, Shanghai Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04441658"
197,"NCT04382547","Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells",,"Completed","No Results Available","COVID|Covid-19|Coronavirus|Pneumonia|Pneumonia, Viral|Pneumonia, Interstitial|Sars-CoV2","Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC2(Covid)","May 11, 2020","June 30, 2021","June 30, 2021","May 11, 2020",,"August 23, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04382547"
198,"NCT02152657","Evaluation of Autologous Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury: a Pilot Study",,"Completed","No Results Available","Spinal Cord Injury","Other: Mesenchymal stem cell transplantation","Magnetic resonance imaging|Sensitivity and motor strength on the inferior limbs|Improvement in urological function|Improvements in sensorial mapping and neuropathic pain","Hospital Sao Rafael","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-002","January 2015","December 2015","December 2016","June 2, 2014",,"April 26, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT02152657"
199,"NCT03876197","Mesenchymal Stem Cells for Radiation-induced Xerostomia",,"Enrolling by invitation","No Results Available","Radiation Toxicity|Xerostomia Due to Radiotherapy|Dry Mouth|Hyposalivation|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Long Term Adverse Effects","Biological: Autologous adipose-derived mesenchymal stem/stromal cells|Other: Placebo","Safety: Serious Adverse Events (SAEs) and new chronic diseases|Overall survival|Relapse of oropharyngeal cancer|New malignancies|Zoonotic Diseases|Patient-reported outcome measures-Health-related quality of life (HRQoL","Rigshospitalet, Denmark","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","CVB2019-1|2014-004349-29","August 1, 2020","December 1, 2022","December 1, 2023","March 15, 2019",,"October 22, 2020","Department of Otolaryngology, University Hospital of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03876197"
200,"NCT02443961","Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies",,"Active, not recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: Mesenchymal Stem Cell (MSC) therapy","Feasibility and security of MSC therapy in very low birth weight preterm babies at risk of developing bronchopulmonary dysplasia (Number of participants with adverse events)|Biomarker analysis (IL-1beta, IL-6, IP-10, INF-gamma, TGF beta, NLRP3, RAGE, HMGB1, VEGFA, GREMLIN1, sVEGFR1, IGF, ENDOTHELIN-1, SMPD-1, SP-D, SMPD3.|Changes in the echocardiographic parameters related with PH and preterm birth, in patients treated with MSC (Number of participants with echocardiographic adverse events)|Incidence of BPD and PH in very low birth weight babies treated with MSC","Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Instituto de Salud Carlos III|Fundación de Ayuda a la Investigación sobre la Hipertensión pulmonar","All","1 Month to 28 Weeks   (Child)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PULMESCEL-1","April 2, 2019","April 2, 2020","April 2025","May 14, 2015",,"February 3, 2021","Hospital Universitario A Coruña, A Coruña, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02443961"
201,"NCT02283879","Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela",,"Unknown status","No Results Available","Cerebral Hemorrhage","Biological: Human umbilical cord mesenchymal stem cells","Safety evaluation through vital signs, the results of clinical lab tests and adverse events (AEs)|Improvement of infarct size measured by brain MRI|Modified Barthel index|National Institutes of Health stroke scale(NIHSS) score","Shenzhen Hornetcorn Bio-technology Company, LTD|The Fifth Affiliated Hospital of Guangzhou Medical University","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYK-Cerebral hemorrhage","March 2015","December 2016","April 2017","November 5, 2014",,"May 24, 2016","The Fifth Affiliated Hospital Immunotherapy center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02283879"
202,"NCT01985464","Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis",,"Unknown status","No Results Available","Rheumatoid Arthritis","Biological: Umbilical cord mesenchymal stem cells","Number of participants with adverse events|Number of participants with a change in disease activity index as measured by 28-DAS Score|Number of participants with a change in current disease activity as measured by EULAR Response Criteria|Change from baseline quality of life measure (based on Stanford HAQ)|Change from baseline C-reactive protein|Change from baseline erythrocyte sedimentation rate (ESR)|Change from baseline anti-citrulline antibody measure|Change from baseline rheumatoid factor (RF)","Translational Biosciences","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBS-UCMSCRA-001","October 2013","December 2019","June 2020","November 15, 2013",,"June 20, 2019","Stem Cell Institute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT01985464"
203,"NCT02034188","Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: Umbilical cord mesenchymal stem cells","Number of participants with adverse events|Number of participants with a change in disability as measured by Expanded Disability Status Scale (EDSS)|Number of participants with a change in neurological impairment as measured by Scripps Neurological Rating Scale|Number of participants with a change in cognitive function as measured by the • Paced Auditory Serial Addition Test (PASAT)|Number of participants with a change in upper extremity function as measured by the Nine Hole Peg Test|Number of participants with a change in mobility and leg function as measured by the 25 foot walking test|Number of participants with a change in quality of life as measured by the Short form 36 (SF-36) quality of life questionnaire|Number of participants experiencing pulmonary edema as measured by 12-lead electrocardiogram (ECG)|Number of participants with a change in brain or spinal cord lesions as measured by gadolinium-enhanced magnetic resonance imaging (MRI)","Translational Biosciences","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBS-UCMSC-001","January 2014","March 2016","March 2016","January 13, 2014",,"August 10, 2017","Stem Cell Institute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02034188"
204,"NCT04326985","RCT Mesenchymal Stem Cells Versus Hyaluronic Acid in OA Knee):","MSC","Completed","No Results Available","Osteoarthritis, Knee","Biological: Autologous Mesenchymal Stem Cells Treatment (MSCs)|Drug: Hyaluronic acid (HA)","Knee Society Score|Knee Society Function Score|Magnetic resonance image (MRI) and X-ray assessment|Health related quality of life score (HRQoL) - SF36|Western Ontario and McMaster Osteoarthritis Index (WOMAC)|Visual Analogic Scale (VAS) pain evaluation","Chinese University of Hong Kong","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OA MSC Study protocol v 1.4","January 31, 2015","January 30, 2019","February 28, 2019","March 30, 2020",,"May 18, 2020","Department of Orthopaedics & Traumatology, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04326985"
205,"NCT02032446","Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease","PTC-UC-MSC","Unknown status","No Results Available","Hematologic Malignancies","Biological: UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)","vital parameters|assessed of acute graft versus host disease (GvHD)","A.O. Ospedale Papa Giovanni XXIII|Associazione Italiana per la Ricerca sul Cancro","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT 2012-000582-21","September 2013","September 2016","September 2019","January 10, 2014",,"January 18, 2019","A O Papa Giovanni XXIII, Bergamo, Italy|Ao S Croce E Carle, Cuneo, Italy|AO Careggi, Firenze, Italy|IRCCS G Gaslini, Genova, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|Clinica Pediatrica San Gerardo, Monza, Italy|Azienda Ospedaliero-Universitaria Di Udine, Udine, Italy|Ospedale San Bortolo, Vicenza, Italy",,"https://ClinicalTrials.gov/show/NCT02032446"
206,"NCT04216849","Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy",,"Recruiting","No Results Available","Type 2 Diabetes With Renal Manifestations","Biological: human umbilical cord mesenchymal stem cells|Other: saline","UACR|HbA1c|insulin/C peptide|insulin dosage|eGFR","Shanghai East Hospital|Chinese PLA General Hospital","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DFSC-2019(CR)-06","July 1, 2020","February 1, 2022","July 1, 2022","January 3, 2020",,"December 17, 2020","Shanghai East Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04216849"
207,"NCT01459640","Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis",,"Unknown status","No Results Available","Osteoarthritis","Drug: Hyaluronic Acid|Biological: Autologous bone marrow-derived mesenchymal stem cells","Change from baseline in cartilage thickness at 12 months by MRI|Visual Analog Score|IKDC Subjective Knee Evaluation Form (2000)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)","National University of Malaysia|Cytopeutics Pte. Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FF-114-2011","March 2011","March 2014","March 2014","October 25, 2011",,"October 25, 2011","UKM Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01459640"
208,"NCT04992832","Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）","PRIME-HFrEF","Recruiting","No Results Available","Heart Failure, Systolic","Biological: human umbilical cord mesenchymal stem cells|Other: human serum albumin","Left ventricular ejection fraction|Mortality|NT-proBNP|Left ventricular end diastolic diameter|6 minutes walking distance|Minnesota Living with Heart Failure Questionnaire（MLHFQ）|PET/CMR","Shanghai East Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DFSC-2018(CR)-08","July 28, 2021","October 31, 2023","December 31, 2023","August 5, 2021",,"November 18, 2021","Heart Failure Department, East Hospital Affiliated to Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04992832"
209,"NCT00850187","Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Bone marrow derived mesenchymal stem cells","Knee cartilage defects|pain","Royan Institute|Tehran University of Medical Sciences","All","45 Years to 60 Years   (Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan - Bone - 001","August 2008","July 2010","December 2010","February 24, 2009",,"January 5, 2012","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00850187"
210,"NCT02291926","Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect",,"Completed","No Results Available","Cartilage Diseases|Osteoarthritis","Biological: Human umbilical cord mesenchymal stem cells","Severity of adverse events|Magnetic resonance imaging (MRI) of the knee|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)","Shenzhen Hornetcorn Bio-technology Company, LTD|The Fifth Affiliated Hospital of Guangzhou Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYK-Articular Cartilage Defect","December 2014","July 2016","December 2016","November 17, 2014",,"May 10, 2017","The Fifth Affiliated Hospital Immunotherapy center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02291926"
211,"NCT03461458","Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease",,"Active, not recruiting","No Results Available","Degenerative Disc Disease","Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells","Number of patients who experience adverse events (AEs)|Change in low back pain and function following injection of AD-MSCs|Changes from Baseline in disc height index as measured by X-ray at 12 months and 24 months|Changes from Baseline in T2 weighted signal intensity of the Nucleus Pulposus (NP) as measured by MRI without contrast","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-002136","October 17, 2018","September 30, 2021","September 30, 2021","March 12, 2018",,"December 29, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03461458"
212,"NCT04538885","Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision",,"Not yet recruiting","No Results Available","MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision","Biological: The pleiotropic factor derived from mesenchymal stem cells","Wound healing time and healing rate","Chinese PLA General Hospital|Gansu Provincial Maternity and Child-Care Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CHIN-PLAGH-MP-04","September 10, 2020","March 31, 2021","May 30, 2021","September 4, 2020",,"September 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04538885"
213,"NCT01771679","Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging",,"Suspended","No Results Available","Chronic Effect of Ultraviolet Radiation on Photoaged Skin|Dermatologic Disorders","Biological: Allogeneic Mesenchymal Bone Marrow Cells","MSC Safety and Tolerability|MSC Efficacy","Stemedica Cell Technologies, Inc.","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","29","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STEM 102-M","July 2015","April 2022","December 2022","January 18, 2013",,"November 2, 2020","eStudy Site, La Mesa, California, United States|Naval Medical Center San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01771679"
214,"NCT03184935","Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)",,"Suspended","No Results Available","Myelodysplastic Syndromes","Biological: Allogeneic umbilical cord mesenchymal stem cells|Drug: Decitabine","Treatment related-adverse events counting|Improvement in clinical function","Sclnow Biotechnology Co., Ltd.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SCLnow-IMIMH-03","October 2021","June 2022","December 2022","June 14, 2017",,"September 23, 2021","Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China",,"https://ClinicalTrials.gov/show/NCT03184935"
215,"NCT01902082","Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome",,"Unknown status","No Results Available","ARDS","Drug: Mesenchymal stem cells|Drug: Placebo","Compare the adverse events between mesenchymal stem cell treatment and placebo groups|Hospital indices by treatment group","Shaoxing Second Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MSCs in ARDS","November 2012","June 2014","June 2014","July 18, 2013",,"July 18, 2013","Shaoxing Second Hospital, Shaoxing, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01902082"
216,"NCT04996966","Effect of Human Umbilical Cord-derived Mesenchymal Stem Cells on Non-cardiac Surgery-induced Lung Injury",,"Recruiting","No Results Available","Ischemic Heart Disease|Lung Injury|Non-cardiac Surgery","Biological: human umbilical cord-derived mesenchymal stem cells|Other: saline","oxygenation index|The value of arterial blood cLAC|The content of IL-1β|The content of IL-6|The content of TGF-α|The content of HMGB1|The content of IL-10|The content of B-type natriuretic peptide (BNP)|electrocardiogram|The average length of stay in hospital|The visual analog scale（VAS）score|The hospital for special surgery (HSS) Knee Score|The New York Heart Association (NYHA) Functional Classification|The 36-Item Short Form Survey (SF-36)|The Hamilton Anxiety Scale|The incidence of allergic reaction|The body temperature|The pulse rate|The respiration rate|The blood pressure|The content of C-reactive protein (CRP)","Shanghai East Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFDA-001","August 2021","April 2022","June 2022","August 9, 2021",,"August 9, 2021","Shanghai East Hospital, Shanghai Tongji University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04996966"
217,"NCT00927784","Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD",,"Terminated","Has Results","Heart Failure","Biological: Mesenchymal Precursor cells (RevascorTM)|Drug: Cryoprotective media alone","Incidence of Infectious Myocarditis|Incidence of Myocardial Rupture|Incidence of Neoplasm|Incidence of Hypersensitivity Reaction|Incidence of Immune Sensitization|Assessment of LVAD Wean|Incidence of Study Intervention-related Adverse Events|Incidence of All Serious Adverse Events|Number of Patients Who Experienced Donor-specific HLA Sensitization|Incidence of Myocardial Neovascularization at Time of Explant|Incidence of Cardiomyocyte Regeneration at Explant|Incidence of Cell Engraftment and Fate at Explant|Incidence of Survival to Cardiac Transplantation","Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI)|Angioblast Systems","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GCO 08-1093|P50HL077096","August 2009","May 2010","February 2011","June 25, 2009","March 5, 2019","March 5, 2019","Sharp Memorial Hospital, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Jewish Hospital, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Intermountain Medical Center, Salt Lake City, Utah, United States|Sacred Heart Medical Center, Spokane, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00927784"
218,"NCT01985633","Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee","MSCPRPOAK","Unknown status","No Results Available","Osteoarthritis, Knee","Biological: Mesenchymal stem cell suspension|Biological: PRP","Pain relief|Functional Outcome","Aditya K Aggarwal|Postgraduate Institute of Medical Education and Research","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Adi_MSC_PRP_OA_2013","January 2013","June 2014","June 2014","November 15, 2013",,"November 18, 2013","Department of Orthopaedics Postgraduate Institute of Medical Education & Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01985633"
219,"NCT02213705","Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells","MSC","Active, not recruiting","No Results Available","SYSTEMIC SCLERODERMA|ALLOGENEIC MESENCHYMAL STEM CELLS|ADULT","Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS","toxicity|survival|progression free survival|Rodnan score|Clinical response","Assistance Publique - Hôpitaux de Paris","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC Severe Systemic Sclerosis","May 6, 2014","February 9, 2020","January 27, 2022","August 11, 2014",,"October 19, 2020","Saint-Louis Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02213705"
220,"NCT01873625","Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: mesenchymal cell transplantation|Biological: placebo","pain|physical activity|walking distance|Imaging","Royan Institute","All","10 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-RA-001","October 2009","March 2011","December 2011","June 10, 2013",,"June 10, 2013","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01873625"
221,"NCT02215811","Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells",,"Unknown status","No Results Available","Acute Respiratory Distress Syndrome, Adult","Biological: Mesenchymal stromal cells","In-hospital mortality|Pulmonary compliance|Pulmonary tidal volume|Adverse events|All-cause mortality|Recovery of organ functions","Karolinska University Hospital|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-ARDS","March 2014","December 2015",,"August 13, 2014",,"August 13, 2014","Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT02215811"
222,"NCT02790762","Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis",,"Unknown status","No Results Available","Pneumoconiosis","Biological: Human umbilical cord mesenchymal stem cells","Severity of adverse events|Immunological Indicator in serum|The level of ceruloplasmin in serum|The level of type Ⅲ procollagen peptide in serum|Lung function as assessed by spirometry|Chest high kilovolt X-ray examination","Shenzhen Hornetcorn Bio-technology Company, LTD|The Second Affiliated Hospital of University of South China","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYK-pneumoconiosis","June 2016","June 2017","October 2017","June 6, 2016",,"June 6, 2016","The second Affiliated Hospital of University of Soth China, Hengyang, Hunan, China",,"https://ClinicalTrials.gov/show/NCT02790762"
223,"NCT03176498","Human Umbilical Cord Mesenchymal Stem Cell Therapy for Cerebral Infarction Patients in Convalescent Period.",,"Suspended","No Results Available","Cerebral Infarction","Biological: Allogeneic umbilical cord mesenchymal stem cell|Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium","Motor function analysis|Neurological deficits analysis|Limb motor function analysis|Barthel Index analysis","Sclnow Biotechnology Co., Ltd.","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SCLnow-IMIMH-01","October 2021","June 2022","December 2022","June 5, 2017",,"September 23, 2021","Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China",,"https://ClinicalTrials.gov/show/NCT03176498"
224,"NCT01849887","Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke",,"Withdrawn","No Results Available","Ischemic Stroke","Biological: bone marrow-derived mesenchymal stem cells|Drug: Placebo","Number of Adverse Events","University of California, Irvine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DR3-07521","January 2016","January 2016","January 2016","May 9, 2013",,"January 22, 2016","University of California Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT01849887"
225,"NCT04130100","Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Low Dose of Mesenchymal stem cell|Biological: High Dose of Mesenchymal stem cell|Drug: Sodium Hyaluronate","Kellgren and Lawrence's rating|WOMAC score|Volume of femoral surface of knee joint on MRI|relaxation time of femoral surface of knee joint on MRI","CAR-T (Shanghai) Biotechnology Co., Ltd.","All","40 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KT005SH002","April 4, 2019","September 30, 2021","December 30, 2021","October 17, 2019",,"October 17, 2019","Changhai hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04130100"
226,"NCT03180450","The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)",,"Suspended","No Results Available","Heart Failure","Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Drug: conventional treatment","Heart color ultrasound evaluation|Single therapy effectiveness evaluation","Sclnow Biotechnology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLnow-IMIMH-04","October 2021","June 2022","December 2022","June 8, 2017",,"September 23, 2021","Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China",,"https://ClinicalTrials.gov/show/NCT03180450"
227,"NCT02751125","Reconstruction of Jaw Bone Using Mesenchymal Stem Cells",,"Completed","No Results Available","Bone Atrophy","Drug: BCP with autologous mesenchymal stem cells (MSC).","Amount of newly formed bone induced by MSCs and the bone substitute. These measurements are based on radiological assessments.|Implant stability|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","University of Bergen|University of Ulm|Haukeland University Hospital|Université de Nantes","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-003139-50","June 2014","March 1, 2019","March 1, 2020","April 26, 2016",,"March 3, 2020","Institute of Clinical Dentistry, University of Bergen, Bergen, Hordaland, Norway",,"https://ClinicalTrials.gov/show/NCT02751125"
228,"NCT01364246","Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica",,"Unknown status","No Results Available","Progressive Multiple Sclerosis|Neuromyelitis Optica.","Biological: human umbilical cord mesenchymal stem cells","Score of Expanded Disability Status Scale (EDSS)|Visual Evoked Potential (VEP)|Brainstem Auditory Evoked Potential (BAEP)|Somatosensory Evoked Potential(SEP)|Brain Magnetic Resonance Imaging （MRI） Scan","Shenzhen Beike Bio-Technology Co., Ltd.|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The Affiliated Nanjing Brain Hospital of Nanjing University Medical School|Nanjing University Medical College Affiliated Wuxi Second Hospital|Xuzhou Medical University|The Second Hospital of Nanjing Medical University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BKCR-MS-1.0(2010)","January 2010","March 2013","December 2014","June 2, 2011",,"November 28, 2012","Nanjing University Medical College Affiliated Drum Tower Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01364246"
229,"NCT01297972","Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia",,"Completed","No Results Available","Aplastic Anemia","Biological: Intravenous bone marrow mesenchymal stem cells infusion","Number of Participants with Adverse Events as a Measure of Safety and Tolerability of intravenous allogeneic unrelated mesenchymal stem cells infusion in patients with severe acquired aplastic anemia.|Level of cytopenias|Transfusional requirements|Incidence of infections and febrile neutropenia","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONEP 16119","February 2011","November 2013","November 2013","February 17, 2011",,"February 4, 2014","Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01297972"
230,"NCT03362424","Mesenchymal Stem Cells in Rotator Cuff Repair",,"Recruiting","No Results Available","Rotator Cuff Tear|Tendon Injuries|Mesenchymal Stem Cell","Biological: Mesenchymal stem cell|Procedure: Rotator cuff repair","MRI integrity|American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES)|University at California at Los Angeles Shouder Rating Scale (UCLA)|Visual Analog Scale for Pain (VAS)","University of Sao Paulo","All","35 Years and older   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2.335.243","November 1, 2020","December 1, 2023","December 1, 2023","December 5, 2017",,"April 29, 2021","Universidade de São Paulo, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03362424"
231,"NCT03180463","The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells",,"Suspended","No Results Available","Osteonecrosis of Femoral Head","Drug: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Procedure: core decompression","MRI imageological examination|Harris Hip Score","Sclnow Biotechnology Co., Ltd.","All","Child, Adult, Older Adult","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SCLnow-IMIMH-05","October 2021","June 2022","December 2022","June 8, 2017",,"September 23, 2021","Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China",,"https://ClinicalTrials.gov/show/NCT03180463"
232,"NCT03673748","Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells","MSV_LE","Not yet recruiting","No Results Available","Lupus Nephritis|Lupus Erythematosus","Drug: Mesenchymal stromal cells (MSC)|Drug: Placebo","Frequency of severe adverse events|Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)|Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)|Change in prednisone dose measured as percent of the baseline value|Cellular markers of inflammation and autoimmunity|Serum markers of inflammation and autoimmunity","Red de Terapia Celular|Hospital del Río Hortega|Hospital Clínico Universitario de Valladolid|University of Valladolid","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","36","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_006|2017-000391-28","March 2022","March 2023","December 2023","September 17, 2018",,"September 23, 2021","University Hospital Río Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT03673748"
233,"NCT02652351","Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis",,"Unknown status","No Results Available","Hepatic Cirrhosis","Biological: Human umbilical cord mesenchymal stem cells","Severity of adverse events|Hepatic function|Liver fibrosis index","Shenzhen Hornetcorn Bio-technology Company, LTD|The Second Affiliated Hospital of University of South China","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYK-hepatic cirrhosis","March 2016","May 2016","October 2016","January 11, 2016",,"May 23, 2016","The second Affiliated Hospital of University of Soth China, Hengyang, Hunan, China",,"https://ClinicalTrials.gov/show/NCT02652351"
234,"NCT01856140","Treatment of Tendon Injury Using Mesenchymal Stem Cells","ALLO-ASC","Unknown status","No Results Available","Lateral Epicondylitis","Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection","Change from baseline in Visual analog scale (VAS) at 6 and 12 weeks","Seoul National University Hospital","All","19 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNUH-RM-SGChung-ASC-01","May 2013","January 2014","April 2014","May 17, 2013",,"November 26, 2013","Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01856140"
235,"NCT04348461","BAttLe Against COVID-19 Using MesenchYmal Stromal Cells",,"Suspended","No Results Available","COVID|Respiratory Distress Syndrome","Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Instituto de Investigación Sanitaria y Biomédica de Alicante|Hospital General Universitario Gregorio Marañon|Clinica Universidad de Navarra, Universidad de Navarra|University of Salamanca|Hospital General Universitario de Alicante|Hospital Clínico Universitario Virgen de la Arrixaca","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BALMYS-19","May 6, 2020","September 15, 2020","September 30, 2021","April 16, 2020",,"March 17, 2021","Fundacion Jimenez Diaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04348461"
236,"NCT01436058","Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoartritis",,"Completed","No Results Available","Osteoarthritis","Biological: mesenchymal stem cell","safety|pain|physical function|defect","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-007","September 2010","September 2011","September 2011","September 19, 2011",,"September 19, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01436058"
237,"NCT03186456","The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction",,"Suspended","No Results Available","Cerebral Infarction","Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Drug: Aspirin Tablet","Treatment related-adverse events counting|Modified Rankin Scale|Barthel activities of daily living (ADL) Index|NIH stroke scale (NIHSS)","Sclnow Biotechnology Co., Ltd.","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SCLnow-IMIMH-02","October 2021","June 2022","December 2022","June 14, 2017",,"September 23, 2021","Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China",,"https://ClinicalTrials.gov/show/NCT03186456"
238,"NCT03239535","Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy",,"Unknown status","No Results Available","Critical Limb Ischemia","Biological: Mesenchymal stem cells|Biological: Normal saline","Adverse events|Amputation-free survival|Limb salvage from major amputation|Relief of the rest pain|Improvement in healing trophic disorders|Improvement in perfusion by the ankle-brachial index|Improvement in perfusion by radioisotope scintigraphy|Improvement in total walking distance (TWD) using a standard treadmill test","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSC-CLI/FMBA/001","October 1, 2013","August 1, 2018","November 1, 2018","August 4, 2017",,"August 4, 2017","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03239535"
239,"NCT04432545","Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement",,"Available","No Results Available","Systemic Sclerosis Pulmonary|Pulmonary Hypertension|Pulmonary Fibrosis","Biological: Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly",,"Universidad de la Sabana|Fundación Neumologica Colombiana|Stem Medicina Regenerativa|CryoHoldco LATAM","All","18 Years to 65 Years   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"2019-10",,,,"June 16, 2020",,"June 16, 2020","Universidad de la Sabana, Chía, Chia, Colombia",,"https://ClinicalTrials.gov/show/NCT04432545"
240,"NCT02687646","Clinical Trial With MSC for Graft Versus Host Disease Treatment",,"Active, not recruiting","No Results Available","Acute Graft Versus Host Disease","Drug: Adult Allogeneic Mesenchymal cells from adipose tissue.","Safety measured by incidence of serious adverse events|Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Andalusian Initiative for Advanced Therapies|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-EICH-2014|2014-005533-32","May 2016","June 2022","June 2022","February 22, 2016",,"December 2, 2020","Clinica Universitaria de Navarra, Av Pio XII ,36, Pamplona, Navarra, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital clinico universitario de salamanca, Salamanca, Spain|Virgen del Rocio University Hospital, av. Manuel Siurot s/n, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02687646"
241,"NCT01909154","Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia","CME-LEM1","Completed","Has Results","Spinal Cord Injury","Biological: Mesenchymal stromal cell therapy","Safety-Number of Adverse Events|Efficacy-Sensitivity Recovery Using ASIA Scale|Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)|Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)|Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)","Puerta de Hierro University Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM1|2010-023285-46","March 2013","April 2014","March 2015","July 26, 2013","March 29, 2019","March 29, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01909154"
242,"NCT02633163","Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)",,"Recruiting","No Results Available","Systemic Lupus Erythematosus","Drug: Low Dose Mesenchymal Stem Cells (MSCs)|Drug: High Dose Mesenchymal Stem Cells (MSCs)|Drug: Placebo Infusion","Clinical response at Week 24 as defined by the SLE Responder Index (SRI):|Change in SLEDAI score between groups|Renal and non-renal organ system flares|Changes in SLICC-DI|Changes in HR-QOL|Changes in Fatigue|Changes in Pain|Changes in Depression|Changes in patient-reported lupus-specific disease status|Steroid-sparing effect|Cumulative systemic steroid dose|Changes in the presence of serum and urine biomarkers of SLE activity:","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MUSC-UCMSC-001","October 26, 2018","December 2022","June 2023","December 17, 2015",,"September 28, 2021","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|The Feinstein Institute for Medical Research, Manhasset, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02633163"
243,"NCT01157403","Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes",,"Unknown status","No Results Available","Evidence of Liver Transplantation","Biological: Autologous transplantation","C peptide release test","Lu Debin|Third Military Medical University","All","10 Years to 40 Years   (Child, Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ldb201001","July 2010","July 2014","August 2014","July 7, 2010",,"June 18, 2013","Endocrine Department, the south west Hospital of the Third Military Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT01157403"
244,"NCT02949414","A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells",,"Suspended","No Results Available","Tracheomalacia|Tracheal Stenosis","Procedure: Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells","Number of treatment related SAE's as assessed by CTCAE grades as defined in version 4.0|Efficacy: Post Implant Stent free period|Efficacy: Post Implant Tracheostomy free period|Efficacy: Mean Airway Diameter evaluations as captured by CT scans|Efficacy: Changes in lung function results using a combination of FEV1, FEF50 and PEFR results|Number of treatment related AEs as assessed by CTCAE grading version 4.0","Cell Therapy Catapult|University College, London|Videregen","All","18 Years and older   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D-00173-CT2013002","September 2016","September 2019","September 2024","October 31, 2016",,"March 29, 2018","Royal Nose Throat and Ear Institute, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02949414"
245,"NCT03873506","Follow-Up Study of Mesenchymal Stem Cells for Bronchopulmonary Dysplasia",,"Unknown status","No Results Available","Bronchopulmonary Dysplasia","Drug: transplantation of hUC-MSCs","Readmission rate|Duration of the hospital stay due to respiratory infection|Rate of Survival|Incidence of Tumorigenicity|Growth measured by Z-score|Number of neurological developmental delay|Number of blindness and deafness","Children's Hospital of Chongqing Medical University","All","1 Month to 5 Years   (Child)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","yunqiu xia","July 1, 2018","July 1, 2020","December 31, 2020","March 13, 2019",,"March 14, 2019","Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03873506"
246,"NCT04467047","Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19","COVID19","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: Mesenchymal Stromal Cells infusion","Overall survival|Changes on inflammatory C-reactive protein|Hospital stay|Oxygenation index (PaO2/FiO2)|Improvement in Liao's score (2020)|Radiological improvement|Time of COVID19 PCR negativity","Hospital de Clinicas de Porto Alegre","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200148","July 25, 2020","October 30, 2020","December 30, 2020","July 10, 2020",,"July 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04467047"
247,"NCT01297413","A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke",,"Completed","No Results Available","Ischemic Stroke","Biological: Allogeneic adult mesenchymal bone marrow stem cells","The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.|National Institutes of Health Stroke Scale Score.|Mini Mental Status Exam score.|Barthel Index Score.|The Geriatric Depression Scale Score.","Stemedica Cell Technologies, Inc.|University of California, San Diego|Mercy Gilbert Medical Center at AZ|Chandler Regional Medical Center at Chandler AZ|UCI Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STEM 101-M","February 2011","September 2017","November 15, 2018","February 16, 2011",,"December 3, 2018","Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States|University of California Irvine Department of Neurology, Orange, California, United States|University of California San Diego Division of Neurological Surgery, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01297413"
248,"NCT02981576","Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.",,"Completed","No Results Available","Spinal Cord Injuries","Biological: Autologous Mesenchymal Stem Cells","Comparing the number of side effects and the improvement on ASIA Impairment score between SCI patients receiving autologous AT-MSC vs BM-MSC.|Investigating the number of side effects in SCI patients receiving autologous BM-MSC.|Investigating the effectiveness of autologous BM-MSC in treating SCI patients.|Investigating the number of side effects in SCI patients receiving autologous AT-MSC.|Investigating the effectiveness of autologous AT-MSC in treating SCI patients.","University of Jordan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCIUJCTC","November 2016","May 5, 2018","January 20, 2019","December 5, 2016",,"September 24, 2019","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02981576"
249,"NCT00294112","Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease",,"Completed","No Results Available","Crohn's Disease","Drug: Prochymal™ adult human mesenchymal stem cells|Drug: adult human mesenchymal stem cells","Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 Points|Number of Participants with Reduction in CDAI of at Least 70 points|Improvement as Assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)|Time to Improvement in IBDQ|Number of Participants with Reduction of at Least 50% in Fistulas in Participants with Fistulas Draining Under Moderate Compression|Number of Participants with Induction of Remission as Defined by Reduction of CDAI to Below 150|Time to Reduction in CDAI of at Least 100 Points|Time to Reduction in CDAI of at Least 70 Points|Time to Induction of Remission as Defined by Reduction of CDAI to Below 150.|Number of Participants with Adverse Events","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSIRIS-601-602","March 13, 2006","July 21, 2006","July 21, 2006","February 20, 2006",,"April 2, 2020","Osiris Clinical Site, Baton Rouge, Louisiana, United States|Osiris Clinical Site, Charlotte, North Carolina, United States|Osiris Clinical Site, Pittsburgh, Pennsylvania, United States|Osiris Clinical Site, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00294112"
250,"NCT00953485","Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)",,"Unknown status","No Results Available","Sjogren's Syndrome|Mesenchymal Stem Cells","Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)","Sjögren's syndrome disease activity index|pSS Serology (ANA, dsDNA, SS-A, SS-B)|Improvement of salivary gland function (measured as stimulated saliva flow rate)","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","15 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NJGLYY002","June 2009","December 2010","December 2011","August 6, 2009",,"August 20, 2009","the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT00953485"
251,"NCT04889963","Regeneration of Posterior Cruciate Ligament Injury Using Hypoxic Conditioned Allogenic Adipose Mesenchymal Stem Cell and Condition Medium",,"Recruiting","No Results Available","Adypose Mesenchimal Stem Cell|Ligament Rupture|Ligament Derived Conditined Medium","Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium","tensile strength of posterior cruciate ligament|Thrombosite of Growth Factor - beta 1|basic fibroblast of growth factor","Gadjah Mada University","Male","2 Months to 12 Months   (Child)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STEMCELL-LIGAMENTREGENERATION","January 1, 2021","June 30, 2021","June 30, 2021","May 17, 2021",,"May 17, 2021","Sholahuddin Rhatomy, Sleman, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04889963"
252,"NCT04047810","Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)",,"Active, not recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Biological: Mesenchymal Stem Cells","Adverse Events","Mayo Clinic","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-007748","January 6, 2020","December 31, 2021","December 31, 2021","August 7, 2019",,"September 16, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04047810"
253,"NCT03745417","Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis","UCMSCs","Not yet recruiting","No Results Available","Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity","Biological: Umbilical cord mesenchymal stem cells","PASI score improvement rate|Psoriasis Area and Severity Index(PASI)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|the Body Surface Area (BSA%)|the Dermatology Life Quality Index（DLQI）","Guangdong Provincial Hospital of Traditional Chinese Medicine|Peking Union Medical College Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2018-11","August 31, 2021","August 28, 2022","December 31, 2022","November 19, 2018",,"February 9, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03745417"
254,"NCT00972660","Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease",,"Unknown status","No Results Available","Graft Versus Host Disease","Biological: Mesenchymal stem cell (MSC)|Drug: Prednisone and cyclosporine or primary therapies","The total Response rate defined as patients with complete and partial response.|Overall Survival|Events Free Survival|The percentage of patients who can taper or discontinue the immunosuppressive agents|Serum cytokine levels and lymphocyte subsets in patients with chronic GVHD","Guangdong Provincial People's Hospital|Sun Yat-sen University","All","Child, Adult, Older Adult","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GDREC.[2009]008","September 2009","December 2015","December 2017","September 7, 2009",,"August 26, 2014","Guangdong General Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT00972660"
255,"NCT03378414","Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia",,"Not yet recruiting","No Results Available","Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia Type 3|Spinocerebellar Ataxia Type 6","Procedure: Intravenous infusion|Procedure: Intrathecal injection|Biological: umbilical cord mesenchymal stem cell","Scale for the assessment anf rating of ataxia (SARA)|Image examinations|Inventory of Non-Ataxia Symptoms (INAS) score|Cerebrospinal fluid (csf) routine","Sclnow Biotechnology Co., Ltd.","All","16 Years to 60 Years   (Child, Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLnow-XY-03","October 2021","June 2022","December 2022","December 19, 2017",,"October 27, 2020",,,"https://ClinicalTrials.gov/show/NCT03378414"
256,"NCT04194671","Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury",,"Not yet recruiting","No Results Available","Acute Kidney Injury|Mesenchymal Stem Cells","Biological: Mesenchymal stem cells|Other: Saline","The difference in the renal function between the two groups (MSC treatment group vs placebo control group) within 28 days after receiving MSC/ placebo treatment|Overall survival within 28 days after receiving MSC/ placebo treatment|Overall survival within 3 months after receiving MSC/ placebo treatment|Renal replacement therapy (RRT) dependent within 3 months after receiving MSC/ placebo treatment|Complete renal recovery within 3 months after receiving MSC/ placebo treatment|Partial renal recovery within 3 months after receiving MSC/ placebo treatment|ICU and hospitalization duration of stay among all AKI patients within 3 months after receiving MSC/ placebo treatment|Adverse events within 3 months after receiving MSC/ placebo treatment","Chinese PLA General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSC-001","December 31, 2021","October 31, 2022","December 31, 2022","December 11, 2019",,"October 25, 2021","Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04194671"
257,"NCT01745744","Application of Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue in Critical Chronic Ischemic Syndrome of Lower Limbs (CLI) in Nondiabetic Patients.",,"Completed","No Results Available","Critical Limb Ischemia","Other: Mesenchymal stem cells from adipose tissue","Number of adverse events and serious adverse events|Evolution of chronic critical ischemia","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CeTMAd/ICC/2009|2009-013554-32","February 2011","July 2018","July 2018","December 10, 2012",,"July 9, 2018","Hospital San Lazaro, Sevilla, Spain|University Hospital Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01745744"
258,"NCT00883870","Mesenchymal Stem Cells in Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia","Drug: mesenchymal stem cells|Drug: Plasmalyte A","AE and symptomatic relief|Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler","Stempeutics Research Pvt Ltd","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SRPL/CLI/07-08/001","April 2009","February 2010","August 2012","April 20, 2009",,"March 5, 2013","M.S.Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Sri Ganga Ram Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00883870"
259,"NCT01061099","Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta","STOD3","Completed","No Results Available","Osteogenesis Imperfecta Type II|Osteogenesis Imperfecta Type III","Biological: Mesenchymal Stromal Cells","To determine the safety or repeated infusions of donor-derived and MSCs in subjects with severe osteogenesis imperfecta > 5years after an allogeneic bone marrow transplant and no prior bone marrow transplant.|To determine if MSCs elicit an immune response after repeated infusions.|To determine the change in clinical course (growth, bone mineral content, fracture rate, development/activities) of subjects after experimental MSC intervention therapy as compared with each subject's own pre-MSC intervention therapy.","Nationwide Children's Hospital","All","up to 19 Years   (Child, Adult)","Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-4-5947","February 2010","March 2013","February 2014","February 2, 2010",,"April 24, 2015","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01061099"
260,"NCT03529136","Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis",,"Unknown status","No Results Available","Decompensated Liver Cirrhosis","Biological: UC-MSC","overall survival","Shandong Qilu Stem Cells Engineering Co., Ltd.|Shanghai Public Health Clinical Center|First Affiliated Hospital of Fujian Medical University|Yantai Hospital for Infectious Diseases|The Second Affiliated Hospital of Chongqing Medical University|Jinan Hospital for Infectious Diseases","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","252","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTR1800015304","June 1, 2018","December 31, 2019","April 30, 2020","May 18, 2018",,"May 18, 2018",,,"https://ClinicalTrials.gov/show/NCT03529136"
261,"NCT05127122","Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Acute Respiratory Distress Syndrome: A Phase I/II Clinical Trial","EXIT-ARDS","Not yet recruiting","No Results Available","ARDS, Human","Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline","The incidence of serious adverse events.|All-Cause Mortality at 28 days|Ventilator-free days at 28days|Improvement in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DB-EF-EXITARDS-0003","December 2021","August 2022","August 2022","November 19, 2021",,"November 19, 2021",,,"https://ClinicalTrials.gov/show/NCT05127122"
262,"NCT01932164","Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients",,"Completed","Has Results","Cleft Lip and Palate","Procedure: maxillary alveolar graft by tissue engineering|Procedure: Bone tissue engineering using mesenchymal stem cells","Amount of New Bone Mass Formed|Quality of Bone Regeneration","Hospital Sirio-Libanes|Hospital Infantil Universitario Niño Jesús, Madrid, Spain","All","7 Years to 12 Years   (Child)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSL 2013-04","May 2013","December 16, 2015","December 16, 2015","August 30, 2013","March 30, 2015","May 28, 2020","Hospital Sírio Libanês, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01932164"
263,"NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",,"Recruiting","No Results Available","KRAS NP_004976.2:p.G12D|Metastatic Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8","Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA","Maximum Tolerated Dose Determined by Dose Limiting Toxicity|Minimal residual disease rate in high-risk patients|Overall survival (OS)|Progression-free survival (PFS)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0126|NCI-2018-01441","January 27, 2021","March 31, 2022","March 31, 2022","August 1, 2018",,"April 29, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03608631"
264,"NCT04898088","A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients","REPAIR","Completed","No Results Available","COVID-19 Pneumonia","Biological: Mesenchymal Stem Cells Transplantation","Expression of PARP1 gene as indicator of base excision repair|Expression of genes ATM, RAD51, RAD52 and WRN as indicator of Recombinational repair|Expression of genes RAD23B and ERCC1 as indicator of Nucleotide excision repair|Expression of genes MLH1, MSH2 and MSH6as indicator of Mismatch repair","SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi|Istinye University|Liv Hospital (Ulus)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8860/9193","January 1, 2020","August 30, 2020","September 30, 2020","May 24, 2021",,"May 24, 2021","Istinye University, Istanbul, Turkey|SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04898088"
265,"NCT00603330","Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function",,"Recruiting","No Results Available","Graft-versus-host Disease|Poor Graft Function|Low Donor T-cell Chimerism","Biological: Mesenchymal stem cells","Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.|Arm 2. Efficacy of MSC infusion as treatment for poor graft function|Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT|Toxicity of MSC infusion","University of Liege|KU Leuven|Maastricht University Medical Center|Ziekenhuis Netwerk Antwerpen (ZNA)|University Hospital, Antwerp|University Hospital, Ghent|AZ-VUB|AZ Sint-Jan AV|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|University Hospital of Mont-Godinne|Jolimont Hospital Haine Saint Paul|Queen Fabiola Children's University Hospital","All","Child, Adult, Older Adult","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJB0703P1","January 2008","November 1, 2021","November 2021","January 29, 2008",,"April 28, 2021","UZA, Edeghem, Antwerpen, Belgium|Hôpital des enfants Reine Fabiola, Brussels, Brabant, Belgium|AZ VUB Jette, Brussels, Brabant, Belgium|Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Brussels, Brabant, Belgium|AZ Gasthuisberg Leuven, Leuven, Flamish Brabant, Belgium|UZ Gent, Gent, Flanders Ost, Belgium|Hôpital de Jolimont, Haine St Paul, Hainaut, Belgium|Cliniques Universitaires Mont-Godinne, Yvoir, Namur, Belgium|AZ St Jan, Brugge, West Flanders, Belgium|Hôpital Stuyvenberg, Antwerpen, Belgium|CHU Sart Tilman, Liege, Belgium|University Hospital Maastricht, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT00603330"
266,"NCT01609283","A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: autologous mesenchymal stem cells","Number of patients with dose-limiting toxicities|Number of patients with adverse events|Change in serum sedimentation rate|Change in C-reactive protein levels|Change in complete blood counts|Change in total nucleated cell count in cerebrospinal fluid (CSF)|Change in protein level in cerebrospinal fluid (CSF)|Number of patients with presence of cancer cells in their cerebrospinal fluid (CSF)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-008415","May 2012","January 31, 2019","January 31, 2019","May 31, 2012",,"September 3, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01609283"
267,"NCT00644410","Autologous Mesenchymal Stromal Cell Therapy in Heart Failure",,"Completed","No Results Available","Congestive Heart Failure","Biological: Mesenchymal stromal cell|Biological: Saline","Improvements in left ventricular function|Clinical improvements","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC heart failure","September 2008","March 2015","March 2015","March 26, 2008",,"March 17, 2015","The Heart Centre, Rigshospitalet University Hospital Copenhagen,, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00644410"
268,"NCT01659762","A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.","EPIC/MSC/IBD","Completed","No Results Available","Crohn's Disease","Biological: autologous mesenchymal stromal cell","Number of adverse events|Crohn's disease activity Index (CDAI)","Emory University|Atlanta Clinical and Translational Science Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00051454|EPIC001","July 2012","July 2015",,"August 8, 2012",,"October 17, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01659762"
269,"NCT03743155","Clinical Trial to Evaluate the Effect and Safety of MSV in Xerostomy",,"Unknown status","No Results Available","Xerostomia Due to Radiotherapy","Biological: mesenchymal cells","Changes in the characteristics and degree of discomfort of xerostomia trough OHIP questionnaire|Changes in the characteristics and degree of discomfort of xerostomia.|Sialometry results|Restoration of the glandular structure.|Measurement of submaxillary gland functionalism changes based on Gammagraphy|AEs and SAEs","Institut de Terapia Regenerativa Tissular","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XRS-ITRT-2018","December 15, 2018","May 30, 2019","May 30, 2021","November 16, 2018",,"November 16, 2018","Institut de Terapia Regenerativa Tissular, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03743155"
270,"NCT03901235","MSC Intratissular Injection in Crohn Disease Patients","MSC","Recruiting","No Results Available","Efficacy and Safety","Biological: Mesenchymal Stromal Cells","Proportion of patients with deep ulcer healing|Proportion of patients with stricture healing|Proportion of patients with complex perianal fistula healing|Safety assessed by the incidence of treatment-emergent adverse events during the study period|Evolution of clinical disease activity index|Evolution of Short health scale (quality of life)|Evolution of the Lemann Index (measuring cumulated intestinal damage in Crohn's disease)|Evolution of the "" Group of Therapeutic Study of Inflammatory Disorders of the Digestive Tube"" obstructive score for Crohn Disease strictures","University of Liege|Centre Hospitalier Universitaire de Liege","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJT1707P1","January 15, 2018","December 31, 2021","December 31, 2022","April 3, 2019",,"February 17, 2021","CHU de Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT03901235"
271,"NCT03580291","Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)",,"Unknown status","No Results Available","Lupus Nephritis","Other: Mesenchymal stem cells|Drug: Mycophenolate Mofetil|Other: Placebo of Mesenchymal stem cells|Drug: Placebo of Mycophenolate Mofetil","Total remission rate|The time for subjects of the two groups to achieve PR and CR|Levels of 24-hour urinary protein|Ratio of Urinary Protein / Creatinine|Levels of serum albumin|Levels of serum creatinine|The estimated glomerular filtration rate ( eGFR )|Levels of Complement component 3 (C3)|Levels of Complement component 4 (C4)|The antinuclear antibody (ANA) levels|The anti-double stranded DNA antibody (dsDNA) levels|Patient Health Assessment Questionnaire (HAQ) score|Physician Global Assessment (PhGA) score|The (Systemic lupus Erythematosis Disease Activity index) SLEDAI score|The (British Isles lupus assessment group ) BILAG score|The SLE reaction index|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Lingyun Sun|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years to 60 Years   (Adult)","Phase 2","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2017001","August 1, 2018","June 1, 2021","June 1, 2021","July 9, 2018",,"July 10, 2018","The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03580291"
272,"NCT00813267","Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head",,"Unknown status","No Results Available","Osteochondritis of the Femoral Head","Biological: mesenchymal stem cell infusion|Biological: bone marrow mononuclear cell infusion","The femoral head blood-supply artery angiographies and the areas of femoral head necrosis|Coxa joint paining|Walking distance|Joint functions|Life","Jianming Tan|Fuzhou General Hospital","All","12 Years to 60 Years   (Child, Adult)","Early Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","fuzhough1221","December 2009","August 2011","August 2015","December 23, 2008",,"October 10, 2012","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT00813267"
273,"NCT01983709","Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer","MSC","Terminated","No Results Available","Prostate Cancer","Biological: Allogeneic Human Mesenchymal Stem Cells","Amount of systemically infused (MSC) DNA relative to recipient DNA at sites of prostate cancer in men with localized adenocarcinoma of the prostate that are scheduled to undergo a prostatectomy|Feasibility of infusing MSCs into men with localized prostate cancer who plan to undergo a prostatectomy.|Determine the proportion of MSC to recipient DNA in the peripheral blood|Determine the proportion of MSC to recipient DNA within the seminal vesicle.|Changes in the Sexual Health Inventory for Men (SHIM) survey post-prostatectomy.|Change in urinary function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in bowel habits as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in sexual function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in hormonal function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in overall satisfaction as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Safety as assessed by number of participants experiencing adverse events|Safety as assessed by number of participants experiencing serious adverse events|Safety as assessed by number of participants experiencing treatment-related adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","Male","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1348|NA_00083720","October 2013","June 2017","June 2017","November 14, 2013",,"July 16, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01983709"
274,"NCT04055415","Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension",,"Unknown status","No Results Available","Pulmonary Hypertension","Biological: adipose derived mesenchymal stem cells|Drug: Conventional drug therapy（expectorant，bronchodilator）","Change in Pulmonary Vascular Resistance from Baseline|Change from Baseline in Participant Quality of Life Using the SF-36|Change in Plasma NT-pro-BNP levels|Change in the IL-1β, IL-6, PGE-2, TGF-β, TNF-α and IGF-1 (ng/ul)|Incidence of Treatment Adverse|Change in Six Minute Walk distance","Liaocheng People's Hospital","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","mashengjun2","August 1, 2019","August 1, 2020","February 1, 2021","August 13, 2019",,"August 13, 2019","Liaocheng city people's hospital, Liaocheng, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04055415"
275,"NCT01306513","Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema",,"Completed","No Results Available","Emphysema","Biological: autologous bone marrow derived mesenchymal stromal cells","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Leiden University Medical Center","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL28562.000.09","October 2010","June 2012","November 2012","March 2, 2011",,"November 19, 2012","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01306513"
276,"NCT00646724","Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: cotransplantation of islet and mesenchymal stem cell","Exogenous insulin requirement|Hemoglobin A1c|Glucose and C-peptide levels|liver function|kidney function|Portal vein Ultrasound|autoantibodies|Complete Blood Count","Fuzhou General Hospital","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","fuzhough0712","January 2008","January 2012","January 2014","March 28, 2008",,"June 16, 2011","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT00646724"
277,"NCT03521323","Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury",,"Recruiting","No Results Available","Spinal Cord Injuries","Drug: Umbilical Cord Mesenchymal Stem Cells|Drug: Placebos","Changes in American Spinal Injury Association (ASIA) Score Scale|Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS)|Changes in electromyogram test|Changes in residual urine","Third Affiliated Hospital, Sun Yat-Sen University|West China Hospital|Shanghai East Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IT-UCMSC-ECSCI","September 1, 2019","December 31, 2021","December 31, 2021","May 11, 2018",,"May 1, 2019","The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03521323"
278,"NCT02384018","Mesenchymal Stem Cell and Islet Co-transplantation",,"Active, not recruiting","No Results Available","Chronic Pancreatitis|Diabetes","Biological: autologous mesenchymal stromal cell","C-peptide level after mixed meal tolerance test|Liver function, kidney function|The absence of severe hypoglycemic episodes","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCT-BMMSC15-001|5R21DK099696","December 2014","December 2026","December 2026","March 10, 2015",,"December 16, 2020","GI Surgery, Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02384018"
279,"NCT03521336","Intrathecal Transplantation of UC-MSC in Patients With Sub-Acute Spinal Cord Injury",,"Recruiting","No Results Available","Spinal Cord Injury","Drug: Umbilical Cord Mesenchymal Stem Cells|Drug: Placebo","Changes in American Spinal Injury Association (ASIA) Score Scale|Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS)|Changes in electromyogram test|Changes in residual urine","Third Affiliated Hospital, Sun Yat-Sen University|West China Hospital|Shanghai East Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IT-UCMSC-SASCI","September 1, 2019","December 31, 2021","December 31, 2021","May 11, 2018",,"May 1, 2019","Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03521336"
280,"NCT01824069","Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy","HULPVAS","Completed","No Results Available","Nonrevascularizable Critical Ischemia of the Lower Limbs","Other: Intramuscular injection of a suspension of adult mesenchymal stem cells derived","Safety of inject mesenchymal stem cells in MMII|Quality of life of patients after treatment","Instituto de Investigación Hospital Universitario La Paz|Hospital Universitario La Paz","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HULPVAS-2011-01|2012-000290-23","April 2013","April 2014","September 2015","April 4, 2013",,"June 15, 2016","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01824069"
281,"NCT04520022","Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB",,"Completed","No Results Available","Recessive Dystrophic Epidermolysis Bullosa","Drug: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells","Adverse events related to the intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell|Change in type VII collagen and anchoring fibril expression at dermoepidermal junction|Change in Birmingham Epidermolysis Bullosa Severity Score (BEBSS)|Change in Global severity score|Change in total body surface area affected by RDEB|Change in Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire|Change in blister count|Change in pruritus visual analogue scale (VAS)|Change in pain visual analogue scale (VAS)","Gangnam Severance Hospital|Daewoong Pharmaceutical Co. LTD.","All","10 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","5","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3-2015-0285","October 13, 2016","January 10, 2020","January 10, 2020","August 20, 2020",,"August 20, 2020","GangnamSeverance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04520022"
282,"NCT04919135","Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty",,"Not yet recruiting","No Results Available","Frailty","Biological: Umbilical Cord Mesenchymal Stem Cells transplantation|Drug: standard frailty treatment and supplementary medication","Adverse events and serious adverse events|Reduced activities|Slowing of mobility|reduction of handgrip strength|exhaustion|the level of pain in the knee|respiratory function|Quality of Life|patients' inflammation|patients' immune|immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells|Cellular senescence|metabolic profiles of CD3+ cells","Vinmec Research Institute of Stem Cell and Gene Technology","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VinmecISC2111","July 1, 2021","November 30, 2021","November 30, 2022","June 9, 2021",,"June 9, 2021",,,"https://ClinicalTrials.gov/show/NCT04919135"
283,"NCT01610440","Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy",,"Unknown status","No Results Available","Duchenne Muscular Dystrophy","Biological: human umbilical cord mesenchymal stem cells","Activities of Daily Living(ADL)scale|Incidences of Adverse Event and Serious Adverse Event|Change from baseline in CK|Change from baseline in LDH|Change from baseline in ALT|Change from baseline in AST|Change from baseline to manual muscle test(MMT)|Change from baseline in electromyography(EMG)","Shenzhen Beike Bio-Technology Co., Ltd.|The Second Affiliated Hospital of Kunming Medical University","All","5 Years to 12 Years   (Child)","Phase 1|Phase 2","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BKCR-DMD-1(Ⅰ)","October 2011","March 2013","October 2013","June 4, 2012",,"November 30, 2012","The Second Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT01610440"
284,"NCT05122234","Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19",,"Completed","No Results Available","COVID-19","Biological: Injection of secretome - mesenchymal stem cell|Other: Placebo|Drug: Standard treatment of Covid-19","Assessment of inflamation marker levels|Assessment of clinical outcome|Assessment of laboratory routine|Assessment of photo thorax|Assessment of RT-PCR conversion|Mortality rate","Indonesia University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","54/FI/P-KCOVID-19.2B3/IX/2020","August 10, 2020","July 30, 2021","November 14, 2021","November 16, 2021",,"November 16, 2021","RSUPN Dr. Cipto Mangunkusumo, Jakarta Pusat, DKI Jakarta, Indonesia|RSUP Fatmawati, Jakarta, DKI Jakarta, Indonesia|RSUP Persahabatan, Jakarta, DKI Jakarta, Indonesia|Rumah Sakit Universitas Indonesia, Depok, Jawa Barat, Indonesia",,"https://ClinicalTrials.gov/show/NCT05122234"
285,"NCT03570333","Progenitor Potential of Mesenchymal Stem Cells in Palatal Tissue Harvested From Molar and Premolar Sites",,"Active, not recruiting","No Results Available","Gingival Recession|Lack of Keratinized Gingiva (Disorder)","Diagnostic Test: progenitor potential of Gingival Mesenchymal cells","Osteogenic potential|Adipogenic potential|Genotype assay","University of Alabama at Birmingham","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GMC:18","September 17, 2018","December 30, 2019","December 30, 2021","June 26, 2018",,"April 28, 2021","UAB School of Dentistry Department of Periodontology, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03570333"
286,"NCT01716481","The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study","STARTING-2","Unknown status","No Results Available","Stroke, Ischemic","Other: Mesenchymal stem cell","Categorical shift in modified Rankin scale (mRS)|Change of National Institutes of Health stroke scale (NIHSS)|Early improvement of National Institutes of Health stroke scale (NIHSS)|Dichotomized modified Rankin scale (mRS)|Change of modified Rankin scale (mRS)|Dichotomized modified Barthel index (mBI)|Change of modified Barthel index (mBI)|Change of gross motor function|Change of Fine motor function|Change of Mobility|Change of mini-mental status exam (MMSE)|Change of quality of life|Safety outcome","Samsung Medical Center|Pharmicell Co., Ltd.","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-10-047","November 2012","December 2017","December 2017","October 29, 2012",,"April 26, 2017","Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01716481"
287,"NCT02162693","Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Mesenchymal progenitor cells|Biological: Sodium Hyaluronate","WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Recording of Adverse Events and Serious Adverse Events","Cellular Biomedicine Group Ltd.|RenJi Hospital|General Hospital of Chinese Armed Police Force","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","53","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CBMG-KOA-Ⅱb","November 2013","May 2016","November 2016","June 13, 2014",,"November 17, 2017","General Hospital of Chinese Armed Police Force, Beijing, China|Shanghai Renji Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02162693"
288,"NCT04651855","The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS","ALSTEM","Recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Drug: Mesenchymal stem cells isolated from Wharton's jelly","The number of (S)AESI [(Serious) Adverse Event of Special Interest]|Disease progression|Pulmonary function decline|Muscle strength decline|Upper motor neuron function|Cognitive function|Quality of life changes|The change of defined cytokines, chemokines, growth factors, cystatin C and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)|The change of defined cytokines, chemokines and cystatin C level in blood|The change of creatinine and p75ECD level in urine|Muscle function changes|The change of the brain visualization|SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI|Survival period to disease progression|Mortality rate","Polski Bank Komorek Macierzystych JSC (PBKM)|National Center for Research and Development, Poland","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALSTEM","December 2, 2020","October 2021","February 2023","December 3, 2020",,"December 3, 2020","JST sp. z o.o., Częstochowa, Poland",,"https://ClinicalTrials.gov/show/NCT04651855"
289,"NCT03028428","Intra-articular Injection of MSCs in Treatment of Knee OA",,"Unknown status","No Results Available","Osteoarthritis|Stem Cells|MSC","Biological: Placenta Derived Mesenchymal Stem Cell|Drug: Sodium Hyaluronate","adverse events|radiographic evidence|WOMAC assessment|VAS|SF-36","Affiliated Hospital of Jiangsu University","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHJiangsuU-FSK-MSC-OA","December 2016","December 2018","December 2019","January 23, 2017",,"January 30, 2018",,,"https://ClinicalTrials.gov/show/NCT03028428"
290,"NCT03979898","Safety and Effectiveness of Autologous Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With CP","CP","Completed","No Results Available","Cerebral Palsy","Biological: ASTROSTEM","Kaufman Assessment Battery for Children (K-ABC)|Blood concentration test|Gross Motor Function Measurement (GMFM)|Box and Block Test|Modified Ashworth Scale (MAS)|SF-36|Verification of ASTROSTEM's effect on the brain through fMRI & MRS (Magnetic Resonance Spectroscopy) scan","R-Bio|Kyung Hee University Hospital at Gangdong","All","36 Months to 12 Years   (Child)","Early Phase 1","1","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","biostar-CP","June 15, 2017","April 23, 2019","May 13, 2019","June 7, 2019",,"June 7, 2019","KyungHee University Gandong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03979898"
291,"NCT04466098","Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)",,"Active, not recruiting","No Results Available","Acute Respiratory Distress Syndrome|ARDS (Moderate or Severe)|COVID-19 Pneumonia","Biological: Mesenchymal stromal cells|Other: Placebo","Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen","Masonic Cancer Center, University of Minnesota","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2020LS075|MT2020-12","July 30, 2020","December 1, 2021","December 1, 2021","July 10, 2020",,"March 23, 2021","University of Minnesota, Minneapolis, Minnesota, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04466098"
292,"NCT02192736","Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma",,"Unknown status","No Results Available","Asthma","Biological: Trophic factors from umbilical cord mesenchymal stem cells","Number of patients with adverse events|Number of patients with a change in pulmonary function from baseline as measured by Forced Expiratory Volume (FEV1) following American Thoracic Society (ATS) guidelines|Number of patients with a change in pulmonary function from baseline as measured by Forced Vital Capacity (FVC) following American Thoracic Society (ATS) guidelines|Number of patients with a change in quality of life from baseline as measured by the University of Pittsburgh Medical Center (UPMC) Asthma Questionnaire","Translational Biosciences","All","21 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBS-MTFAS-001","July 2014","April 2020","October 2020","July 17, 2014",,"June 26, 2018","Punta Pacifica Hospital, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02192736"
293,"NCT02857010","Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure","Liveradvance","Unknown status","No Results Available","Acute on Chronic Hepatic Failure","Biological: Allogenic mesenchymal stem cells|Other: Placebo","Change in organ function: chronic liver failure-sequential organ failure assessment (CLIF-SOFA)|Child-Pugh score as a marker of liver function|Model for End-stage Liver Disease (MELD) score as a marker of liver function|serum bile acids as a surrogate marker of liver function|ammonia levels as a surrogate marker of liver function|Lactate levels as a surrogate marker of liver function|Hepatic portal venous gradient (HPVG)|Endothelial function measured by nitric oxide levels|Endothelial function measured by von Willebrand factor levels|Renal function measured by serum creatinine|Renal function measured by Blood urea nitrogen (BUN)|urine neutrophil gelatinase-associated lipocalin (NGAL) as a surrogate marker of renal function|Inflammatory response|Transcriptome analysis|Number of participants alive|Number of participants with treatment-related adverse events as assessed by World Health Organization (WHO) classification for acute and subacute toxicity|Change in chronic liver failure C acute on chronic liver failure score (clif C ACLF)","Pere Gines|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinic of Barcelona","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2012-003900-11","February 2016","February 2018","February 2020","August 5, 2016",,"August 5, 2016","Hospital Clinic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02857010"
294,"NCT02237846","Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis",,"Withdrawn","No Results Available","Osteoarthritis of the Knee","Biological: Human umbilical cord tissue-derived mesenchymal stem cells","Number of participants with adverse events|Number of participants with a change in joint function from baseline WOMAC assessment|Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system","Translational Biosciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNEI-2014-TBS-UCMSCOA-001","September 2014","November 2018","August 2019","September 11, 2014",,"August 10, 2017","Stem Cell Instsitute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02237846"
295,"NCT02003131","Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis",,"Withdrawn","No Results Available","Osteoarthritis of the Knee","Biological: Trophic factors from umbilical cord mesenchymal stem cells","Number of participants with adverse events|Number of participants with a change in joint function from baseline WOMAC assessment at 12 months|Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system at 12 months","Translational Biosciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBS-MTFOA-001","December 2013","December 2018","June 2019","December 6, 2013",,"August 10, 2017","Stem Cell Institute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02003131"
296,"NCT01895413","Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair",,"Completed","No Results Available","Osteoarthritis","Procedure: Bone marrow aspiration","Change in WOMAC (Western Ontario and McMaster Universities)score|Change from baseline in cartilage thickness at 6 months by MRI|Knee pain relief (WOMAC and Lequesne scores)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)","Alexandra Cristina Senegaglia|Pontifícia Universidade Católica do Paraná|Consultório Médico Dr. Alcy Vilas Boas Jr., Paraná, Brasil|Hospital Marcelino Champagnat, Paraná, Brasil|Fundação Araucária","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTM_LESÃO ARTICULAR-461/2010","September 2012","July 2013","January 2016","July 10, 2013",,"December 13, 2017","Centro de Tecnologia Celular, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil",,"https://ClinicalTrials.gov/show/NCT01895413"
297,"NCT02940418","Use of Stem Cells in Diabetes Mellitus Type 1",,"Unknown status","No Results Available","Diabetes Mellitus Type 1","Biological: Adipose mesenchymal cells with bone marrow mononuclear cells","Safety of using allogenic ASC assessed by any adverse events","Sophia Al-Adwan|University of Jordan","All","18 Years to 35 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T1DM.UJCTC","February 19, 2017","November 2019","January 2020","October 20, 2016",,"July 24, 2019","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02940418"
298,"NCT05018871","Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intravenous Infusion for CP",,"Suspended","No Results Available","Cerebral Palsy","Biological: autologous adipose derived mesenchymal stem cells","Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-GR-8-04","December 2021","December 2025","December 2025","August 24, 2021",,"October 15, 2021","Mitera Hospital Athens Greece, Marousi, Greece",,"https://ClinicalTrials.gov/show/NCT05018871"
299,"NCT05018793","Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intrathecal Injection for SCI",,"Suspended","No Results Available","Spinal Cord Injuries","Biological: autologous adipose derived mesenchymal stem cells","Safety (adverse events)|Efficacy: American Spinal Injury Association Impairment Scale (ASIA)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-GR-10-02","December 2021","December 2025","December 2025","August 24, 2021",,"October 15, 2021","Mitera Hospital Athens Greece, Marousi, Greece",,"https://ClinicalTrials.gov/show/NCT05018793"
300,"NCT01456819","Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia",,"Unknown status","No Results Available","Critical Limb Ischemia","Biological: Mononuclear and mesenchymal stem cells|Biological: Mononuclear cells","Change in angiogenesis|Change in ulcer size|Visual Analog Score|Exercise Treadmill Test|Improvement in vascularity and blood supply","National University of Malaysia|Cytopeutics Sdn. Bhd.","All","20 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FF-113-2011|NMRR-11-904-9763","March 2011","December 2015","February 2016","October 21, 2011",,"April 10, 2015","UKM Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01456819"
301,"NCT02302599","Mesenchymal Stem Cells to Treat Type 2 Diabetes","UC-MSCs","Completed","No Results Available","Type 2 Diabetes|Mesenchymal Stem Cells","Biological: Umbilical cord mesenchymal stem cells|Biological: Controlled suspension liquid","The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D|Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D|safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D","Chinese PLA General Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","103","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHIN-PLAGH-ST-003","January 2013","December 2020","December 2020","November 27, 2014",,"February 3, 2021","Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02302599"
302,"NCT02260375","MSC Therapy in Liver Transplantation",,"Recruiting","No Results Available","Liver Transplant Rejection","Biological: Mesenchymal Stromal Cells","Number of adverse events|Liver tissue mRNA level of Transferrin receptor CD71 (TFRC) and Hepcidin antimicrobial peptide (HAMP) genes|Circulating naive and memory T cell conts (CD45RA/CD45RO)(flow cytometry analysis)|T-cell function in mixed lymphocyte reaction","Monia Lorini|Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC liver transplant tolerance|2014-001531-37","October 2014","October 2024","October 2025","October 9, 2014",,"April 6, 2018","U.S.C Nefrologia e Dialisi, Bergamo, Italy|USC Chirurgia Generale III, Bergamo, Italy|USC Ematologia, Bergamo, Italy|USC Gastroenterologia, Bergamo, Italy|Servizio di Immunoematologia e Medicina Trasfusionale, Bologna, Italy|Unità Chirurgia Generale e Trapianti, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT02260375"
303,"NCT02421484","Cellular Immunotherapy for Septic Shock: A Phase I Trial","CISS","Completed","No Results Available","Septic Shock","Biological: Allogeneic mesenchymal stromal cells","Number of adverse events as a measure of safety and tolerability","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014809","May 2015","June 2016","October 30, 2018","April 20, 2015",,"October 31, 2018","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02421484"
304,"NCT04433104","Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease",,"Recruiting","No Results Available","COPD","Biological: Umbilical Cord Mesenchymal Stem Cells transplantation|Drug: drug therapy according to Vietnamese MOHS procedure","Adverse events and serious adverse events|Quality of Life using Georges Respiratory Questionnaire|Chest CT|arterial blood gas analysis (pH)|arterial blood gas analysis (PaO2)|arterial blood gas analysis (PaCO2)|arterial blood gas analysis (BE)|arterial blood gas analysis (HCO3-)|Respiratory functions (FEV1)|Respiratory functions (FEV1/FVC)|Respiratory functions (VC)|Respiratory functions (TLC)|Respiratory functions (RV)|Respiratory functions (DLCO)|Respiratory functions (DLNO/DLCO)|inflammatory response (CRP)|inflammatory response (Pro-BNP)|inflammatory response (Troponin-T)|cytokine analysis from patients' plasma|modified medical research council","Vinmec Research Institute of Stem Cell and Gene Technology","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VinmecISC1916","June 9, 2020","July 30, 2021","December 25, 2021","June 16, 2020",,"April 21, 2021","Vinmec International Hospital Times City, Hà Nội, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04433104"
305,"NCT02957552","Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation","MYSTEP1","Recruiting","No Results Available","Pediatric Liver Transplantation","Biological: Mesenchymal Stem Cells","Number of participants with MYSTEP-score grade 3 and grade 2 (toxicity of MSC infusion)|Number of participants with occurrence of any severe adverse events (SAE)|Graft function after liver transplantation - Number of participants with abnormal liver tests|Individual need for immunosuppressive medication|Time to first biopsy-proven acute rejection (BPAR)|Immune monitoring: donor-specific antibodies (DSA)|Patient and graft survival at 1 and 2 years after liver transplantation","University Hospital Tuebingen","All","8 Weeks to 18 Years   (Child, Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MYSTEP1|2014-003561-15","March 10, 2017","December 2019","December 2021","November 6, 2016",,"November 14, 2018","University Children's Hospital, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT02957552"
306,"NCT04282928","Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells for the Treatment of Severe Viral Pneumonian",,"Not yet recruiting","No Results Available","Severe Pneumonia","Biological: Human umbilical cord mesenchymal stem cells|Procedure: Routine treatment","mortality|average length of stay|Changes of inflammatory index - the number of leukocyte or lymphocyte|Changes of inflammatory index - the percentage of lymphocytes|Changes of inflammatory index - cytokines|Changes of oxygenation index|Throat swab/blood viral load|Chest imaging outcome","Shanghai East Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EC.D（BG）.013.02.0","February 2020","January 2021","March 2021","February 25, 2020",,"February 25, 2020","Shanghai East Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04282928"
307,"NCT04876326","Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy",,"Recruiting","No Results Available","Multiple System Atrophy|Parkinsonism|Multiple System Atrophy, Parkinson Variant","Biological: Autologous Adipose Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation","Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation|Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation","Indonesia University","All","Child, Adult, Older Adult","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TGHISMMSCMSA","October 5, 2020","October 5, 2021","October 5, 2021","May 6, 2021",,"May 6, 2021","Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04876326"
308,"NCT03925324","Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device","STEM-VAD","Active, not recruiting","No Results Available","Ischemic Heart Disease|Non-ischemic Cardiomyopathy","Biological: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Other: Placebo","Temperature|Uncontrolled systemic infection|All-cause mortality|NK cell depletion|Change in the following cardiac biomarker|Change in RV systolic function|Hospitalizations due to right heart failure|6 minute walk distance changes|Gout flares","Medstar Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STEMVAD-001","May 3, 2019","May 2021","June 2021","April 24, 2019",,"December 17, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT03925324"
309,"NCT03487731","Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain","VALIANT","Withdrawn","No Results Available","Facetogenic Back Pain|Back Pain","Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Drug: Placebo","Incidence of any treatment-emergent serious adverse events|Difference in subject quality of life assessment - SF-12|Difference in subject quality of life assessment - Oswestry Low Back Pain|Death from any cause.|Change in pain using the Numeric rating scale","Joshua M Hare|University of Miami","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20180018","December 1, 2020","December 1, 2025","December 1, 2025","April 4, 2018",,"October 20, 2020","ISCI / University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03487731"
310,"NCT04255147","Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia",,"Not yet recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells","Occurrence and rate of dose limiting toxicity|Rate of Death|Occurrence of Other Severe Complications of Prematurity|FiO2 and Oxygen Index|Need for Ventilatory Support|Need for Postnatal Steroids|Incidence and Severity of BPD|Rate of Survival Without (moderate or severe) BPD|Changes in Pulmonary Hemodynamics|Biological Measure of Clinical Improvement|Biological Measure of Lung Improvement|Feasibility: Cell Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Bayley Scale of Infant and Toddler Development|Long-term Safety Follow-Up|Animated Information Video","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)|Ontario Institute of Regenerative Medicine (OIRM)|Stem Cell Network","All","up to 21 Days   (Child)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HULC-1","January 2022","June 2023","December 2035","February 5, 2020",,"March 9, 2021","The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04255147"
311,"NCT02410239","MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)",,"Withdrawn","No Results Available","Cerebral Adrenoleukodystrophy","Biological: Mesenchymal Stem Cells","Maximum Tolerated Dose|Radiographic Response","Masonic Cancer Center, University of Minnesota","All","4 Years and older   (Child, Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014LS018","June 2015","July 2017","July 2022","April 7, 2015",,"December 2, 2017",,,"https://ClinicalTrials.gov/show/NCT02410239"
312,"NCT05127369","Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression",,"Not yet recruiting","No Results Available","Depression","Drug: Dental pulp mesenchymal cell injection|Drug: Dental pulp mesenchymal cell vehicle|Drug: fluoxetine hydrochloride capsule","The total score of Montgomery Asperger Depression Scale (MADRS) decreased from baseline after 8 weeks of treatment|Effective rate of treatment (effective: the total score of MADRS decreased by ≥ 50% compared with baseline)|Remission rate of treatment (remission: MADRS total score ≤ 11 points)","CAR-T (Shanghai) Biotechnology Co., Ltd.","All","18 Years to 60 Years   (Adult)","Not Applicable","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","KT013HAN001","January 1, 2022","December 30, 2023","June 30, 2024","November 19, 2021",,"November 19, 2021",,,"https://ClinicalTrials.gov/show/NCT05127369"
313,"NCT04234750","Mesenchymal Stem Cell-derived Pleiotropic Factor in the Treatment of Donor Sites",,"Recruiting","No Results Available","Evaluate the Safety and Effectiveness of Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Donor Sites","Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor","wound healing rate|Vancouver score","Chinese PLA General Hospital","All","6 Years to 60 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MP-02","October 17, 2019","December 30, 2020","June 30, 2021","January 21, 2020",,"May 12, 2020","People's Liberation Army Central Air Force Hospital, Datong, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT04234750"
314,"NCT04594850","Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously","Cellgram-ED","Recruiting","No Results Available","Erectile Dysfunction","Biological: Cellgram-ED","The amount of change in EF score in the International Erectile Function Questionnaire (IIEF) at administration of the clinical trial drug compared to the baseline value|Changes in SEP Q 2 and Q 3 evaluation after administration of investigational drug compared to baseline|Global Assessment Question (GAQ) evaluation after administration of investigational drugs|Changes in Penile Doppler Sonography(PDS) level after administration of clinical trial drug compared to baseline","Pharmicell Co., Ltd.","Male","19 Years to 79 Years   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PMC-P-10","October 19, 2020","October 31, 2023","October 31, 2023","October 20, 2020",,"October 26, 2020","Asan medical center, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|Seoul ST. Mary's hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04594850"
315,"NCT04388761","Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)",,"Recruiting","No Results Available","Ischemia Reperfusion Injury","Drug: Allogeneic adipose derived mesenchymal stem cells","Serious Adverse Events (SAEs)","Tambi Jarmi|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-000264","September 28, 2020","February 1, 2024","February 1, 2024","May 14, 2020",,"October 14, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04388761"
316,"NCT01461720","Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct",,"Unknown status","No Results Available","Middle Cerebral Artery Infarction","Other: Standard medical care|Biological: Autologous bone marrow-derived mesenchymal stem cells","Change in NIH Stroke Scale|Change in Barthel Index|Change in modified Rankin Scale|Change in size of infarct based on brain MRI stroke sequences|Change in Stroke Specific Quality of Life Scale|Change in Stroke Impact Scale","National University of Malaysia|Cytopeutics Sdn. Bhd.","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FF-115-2011","March 2012","December 2015","March 2016","October 28, 2011",,"April 1, 2015","UKM Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01461720"
317,"NCT04811651","Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke","UMSIS","Recruiting","No Results Available","Ischemic Stroke","Biological: Umbilical Cord-derived Mesenchymal Stem Cells|Drug: Placebo","Proportion of modified Rankin Scale (mRS) 0-2|changes in Fugl-Meyer scale|changes in Purdue hand function test|changes in box and block test|Proportion of modified Rankin Scale (mRS) 0-1|changes in the national institutes of health stroke scale (NIHSS)|changes in Mini-mental State Examination (MMSE) score|changes in Montreal Cognitive Assessment (MoCA) score|The changes of head images|changes in some serum biomarkers","General Hospital of Shenyang Military Region","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","k（2019）46","March 15, 2021","February 1, 2023","October 1, 2023","March 23, 2021",,"March 23, 2021","Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China",,"https://ClinicalTrials.gov/show/NCT04811651"
318,"NCT02580019","Umbilical Cord Derived Mesenchymal Stem Cells Treatment in Ischemic Stroke","Recruiting","Unknown status","No Results Available","Stroke","Biological: Human umbilical cord mesenchymal stem cells","Number of treatment related-adverse events during the study period.|Comparison of National Institutes of Health stroke scale (NIHSS).|Comparison of modified Rankin scale (mRS).|Distinguish of EuroQol 5d (EQ-5D) between pre- and post-treatment 180 days.|Comparison of infarct size measured by brain MRI.","Affiliated Hospital to Academy of Military Medical Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Hospital307","February 2016","December 2016","December 2017","October 20, 2015",,"December 2, 2015","Department of Neurosurgery,Affiliated Hospital of Academy of Military Medical Sciences(307 Hospital), Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02580019"
319,"NCT02292628","Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence",,"Completed","No Results Available","Faecal Incontinence","Drug: Infusion of mesenchymal stem cells from adipose tissue|Other: Infusion of placebo","Number of Serious Adverse Events|Changes in the faecal incontinence diary|Anorectal manometry|Jorge-Wexner Score|Faecal Incontinence Quality of Life","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CMMAd/InFe/2011","October 2013","September 2017","September 2017","November 17, 2014",,"April 17, 2018","H. Juan Ramón Jiménez, Huelva, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Regional U de Málaga, Málaga, Spain|Hospital U Virgen del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02292628"
320,"NCT04224207","Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells","WJ-MSC","Completed","No Results Available","Retinitis Pigmentosa|Inherited Retinal Dystrophy","Biological: Wharton's jelly derived mesenchymal stem cell","ETDRS visual acuity|Outer retinal thickness","Ankara Universitesi Teknokent","All","18 Years to 60 Years   (Adult)","Phase 3","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01.11.2018/01","April 1, 2019","October 30, 2019","January 1, 2020","January 13, 2020",,"January 13, 2020","Ankara University Biotechnology Institute, Ankara, Türkiye, Turkey|Umut Arslan, Ankara, Türkiye, Turkey",,"https://ClinicalTrials.gov/show/NCT04224207"
321,"NCT04549285","Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome","MISTIC","Withdrawn","No Results Available","Multisystem Inflammatory Syndrome in Children","Biological: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)","Safety of the Investigational Product, hCT-MSCs, infusion reactions|Safety of the Investigational Product, hCT-MSCs, related adverse events|Safety of the Investigational Product, hCT-MSCs, anti-HLA antibodies|Survival|Inotrope support|Hospital Discharge|Duration of ICU stay|cardiac abnormalities","Joanne Kurtzberg, MD|Duke University","All","18 Years to 20 Years   (Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00106044","March 12, 2021","February 1, 2022","February 1, 2022","September 16, 2020",,"September 14, 2021","Emory University School of Medicine, Atlanta, Georgia, United States|New York Medical College, Westchester Medical Center (WMC), Westchester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04549285"
322,"NCT04520373","Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients",,"Recruiting","No Results Available","Spinal Cord Injuries|Paralysis","Other: Best Medical Management: Occupational and Physical Therapy|Biological: Autologous, Adipose Derived Mesenchymal Stem Cells","•Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|change in Neurogenic Bladder Symptom Score (NBSS)|change in Neurogenic Bowel Symptom Score|Incidence of abnormal CSF composition|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Correlation of adverse events to study drug","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-011706","June 25, 2020","June 2022","June 2024","August 20, 2020",,"September 5, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04520373"
323,"NCT02580695","A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis","Biological: umbilical-cord mesenchymal stromal cells|Drug: Hyaluronic Acid","Proportion of patients who experience an adverse event|Physical function improvement measured by WOMAC OA index|Change in pain density measured by Visual analogue scale (VAS)|QoL improvement measured by SF-36|Changes in WORMS scale measured by knee MRI","Francisco Espinoza, MD|Universidad de los Andes, Chile","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C4COA01","December 2015","January 2017","April 2017","October 20, 2015",,"December 26, 2018","Clinica Universidad de los Andes, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT02580695"
324,"NCT01843387","Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy",,"Completed","No Results Available","Diabetic Nephropathy|Type 2 Diabetes","Biological: Mesenchymal Precursor Cells (MPCs)","The primary objective of the study is to assess the safety and tolerability of MPC therapy|Exploratory assessment of the efficacy of MPC therapy","Mesoblast, Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSB-DN001","July 2013","September 2014","September 2015","April 30, 2013",,"October 14, 2016","Monash Universtiy, Clayton, Australia|Melbourne Renal Research Group, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01843387"
325,"NCT02805855","Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis, Knee","Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells","Number of subjects experiencing adverse events.","Jacob L. Sellon, M.D.|Mayo Clinic","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-008179","October 26, 2016","April 26, 2023","April 26, 2023","June 20, 2016",,"January 6, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02805855"
326,"NCT04392206","AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses",,"Recruiting","No Results Available","End Stage Renal Disease","Drug: Adipose Derived Mesenchymal Stem Cells","Number of participants with treatment-related adverse events","Albert Hakaim|Mayo Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-007203","May 15, 2020","June 1, 2025","June 1, 2026","May 18, 2020",,"July 12, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04392206"
327,"NCT01526850","Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease","MSCsTcGVHD","Unknown status","No Results Available","Chronic Graft Versus Host Disease","Biological: Biological: mesenchymal stem cell|Drug: Cyclosporine and Glucocorticoid","The total Response rate defined as patients with complete and partial response|one-year survival rate|disease relapse|quality of life","Chinese Academy of Medical Sciences|Zhejiang University|Chinese PLA General Hospital|307 Hospital of PLA|Peking Union Medical College","All","2 Years to 60 Years   (Child, Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D07050701350701","February 2012","December 2013","June 2014","February 6, 2012",,"August 3, 2012","Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01526850"
328,"NCT04328714","Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease",,"Recruiting","No Results Available","Acute Leukemia|Myelodysplastic Syndromes","Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells","Number of successful preparations and deliveries of investigational product|Number of adverse events attributed to the investigational product|Maximal Tolerated Dose|Primary graft failure|Secondary graft failure|Platelet engraftment|Non-relapse mortality (NRM)|Change in Acute graft-versus-host disease (aGvHD) Incidence|Change in Chronic graft-versus-host disease (cGvHD) Incidence|Disease-free survival (DFS)|Primary cause of death|Relapse|Early discontinuation|Viral activation","Edwin Horwitz|Emory University","All","1 Year and older   (Child, Adult, Older Adult)","Phase 1","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00105305","December 2021","August 2023","August 2023","March 31, 2020",,"November 5, 2021","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04328714"
329,"NCT01440309","Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis","MSCsTreatPBC","Unknown status","No Results Available","Primary Biliary Cirrhosis","Biological: Biological: mesenchymal stem cell|Drug: ursodeoxycholic acid","serum level of alkaline phosphatase|histological changes in liver biopsies|Serum levels of TNF-alpha|changes in fatigue|The occurrence of cirrhosis and its complications|Serum levels of Interleukin|changes in pruritus severity","Robert Chunhua Zhao, MD, PhD|Peking Union Medical College Hospital|Chinese Academy of Medical Sciences","All","18 Years to 60 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008BAI59B03/2011AA020119","November 2011","November 2013","December 2013","September 26, 2011",,"August 3, 2012","Peking Union Medical College Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01440309"
330,"NCT03929120","Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)",,"Recruiting","No Results Available","Interstitial Lung Disease|Connective Tissue Diseases","Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)","Adverse Events","Mayo Clinic","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-007216","November 5, 2019","October 2021","December 2021","April 26, 2019",,"June 7, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03929120"
331,"NCT02883803","Treatment of Severe Infections With Mesenchymal Stem Cells","CHOCMSC","Not yet recruiting","No Results Available","Septic Shock","Biological: Injection of mesenchymal stem cells|Biological: Injection of albumin alone","SOFA score|Number of living days without catecholamines|Number of living days without mechanical ventilation|Number of living days without dialysis|Duration of residence time in recovery unit|Mortality, across all causes|Administration safety (i.e. side effects)","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PHRCI 2012/CHOCMSC-GIBOT/SKJ","December 2019","November 2021","November 2022","August 30, 2016",,"October 25, 2019","Service de Réanimation Médicale, Hôpital Bocage, Dijon, France|Service de Réanimation Médicale, Hôpital Central, Nancy, France|Hôpital Hautepierre, Service de réanimation médicale, Strasbourg, France|UTCT, Hôpital Brabois, Vandoeuvre-les-Nancy, France",,"https://ClinicalTrials.gov/show/NCT02883803"
332,"NCT01854125","Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites",,"Unknown status","No Results Available","Immune Function in Blood|Liver Function in Blood|Variation of Ascites|Characters of Quality of Life|Child-Pugh Score","Biological: autologous bone marrow mesenchymal stem cells transplantation|Biological: autologous bone marrow msenchymal stem cells transplantation","change in immune function,liver function in blood","Nanjing PLA General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NanjingPLAGH1|Jinling 01","May 2013","January 2014",,"May 15, 2013",,"May 15, 2013","Jinling Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01854125"
333,"NCT02477540","A Safety and Efficacy Study of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia",,"Withdrawn","No Results Available","Critical Limb Ischemia","Drug: Cellgram-CLI","Ankle Brachial Pressure Index, ABPI|Collateral vessel formation on digital subtraction angiography (DSA)|Difference of Wound size|Improved transcutaneous oxygen pressure (TCPO2)|Pain on the Visual Analogue Scale(VAS)|Reduced limb amputation|Temperature change on thermography|Dose about using analgesic medicine|Change in Rutherford classification|Frequency about using analgesic medicine","Pharmicell Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellgram-CLI","December 2019","June 2020","June 2020","June 22, 2015",,"March 22, 2019",,,"https://ClinicalTrials.gov/show/NCT02477540"
334,"NCT05011474","Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration","MANT3_ASC","Enrolling by invitation","No Results Available","Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc","Biological: administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3","1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection|Confirmation of the degree of pain improvement in VAS|Confirmation of the degree of improvement in disability (ODI)|Confirmation of increase in water content in the nucleus using MRI","Inbo Han|CHA University","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-10-013","April 23, 2021","January 20, 2022","December 31, 2022","August 18, 2021",,"August 25, 2021","CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05011474"
335,"NCT04366323","Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19",,"Active, not recruiting","No Results Available","Sars-CoV2","Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate","Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AdiQure/COVID-19","April 27, 2020","October 2021","October 2021","April 28, 2020",,"November 30, 2020","Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Unversitario Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04366323"
336,"NCT02338271","Autologous Adipose Derived Stem Cell Therapy for Intervertebral Disc Degeneration",,"Unknown status","No Results Available","Low Back Pain","Other: autologous adipose derived mesenchymal stem cell","Evaluation of Safety and Tolerability (Adverse events)|Change in the T2 MRI signal intensity of the nucleus pulposus|Overall improvement in the Disc Height Index|improvement in Visual Analogue Scale (VAS)|improvement in Oswestry Disability Index (ODI)|improvement in Short Form-36","Inbo Han|CHA University|Bundang CHA Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADMSC-DD-Han","January 2015","December 2017","December 2017","January 14, 2015",,"January 14, 2015","CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02338271"
337,"NCT02886884","Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects","ACESO","Active, not recruiting","No Results Available","Diabetes Mellitus","Drug: 20 million Allogeneic Mesenchymal Human Stem Cells|Drug: 100 million Allogeneic Mesenchymal Human Stem Cells","Incidence of Treatment Related Serious Adverse Events (TE-SAEs)|EPC-CFU levels|CRP Marker Levels|Circulating Angiogenic Factor Levels|Flow Mediated Diameter Percentage (FMD%)|Circulating Inflammatory Marker Levels","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160686|1R01HL134558-01","October 20, 2017","September 2023","September 2024","September 1, 2016",,"February 2, 2021","University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02886884"
338,"NCT04314011","Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty",,"Recruiting","No Results Available","Aging Frailty","Biological: Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Biological: Placebo","Safety of HUC-MSCs infusion|Difference in rate of decline of Frailty|Difference in subject quality of life assessments|Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts|Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts","Shanghai East Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EC.D (BG).020.02.0","June 1, 2020","August 1, 2021","December 1, 2022","March 18, 2020",,"March 5, 2021","Shanghai East Hospital, Shanghai Tongji University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04314011"
339,"NCT03211793","Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis","MANUS","Unknown status","No Results Available","Systemic Sclerosis|Digital Ulcer","Drug: Mesenchymal stromal cells|Other: Placebo","Toxicity of the treatment|Serious adverse events|Change in perceived pain based on the Numerical Rating Scale|Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)|Change in perceived pain based on the pain VAS ( part of the S-HAQ)|Change in perceived pain based on the use of analgesics.|Quality of life - SF-36|Quality of life - Euroqol|Disability|Hand function|Number (and change in number) of digital ulcers|Healing of digital ulcers|Ulcer size|Time to healing of digital ulcers|Need to alter medication regime|Modified Rodnan Skin Score|Severity of Raynaud's symptoms|Changes in capillary morphology and architecture|Changes in laboratory parameters|Changes in circulating cell populations","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MANUS|2015-000168-32","November 2018","November 1, 2020","November 1, 2020","July 7, 2017",,"June 7, 2018","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03211793"
340,"NCT05035862","Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma",,"Recruiting","No Results Available","Asthma","Drug: Albuterol Sulfate|Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)|Drug: Prednisone","Change in number of adverse events and severe adverse events post-intervention|Number of grade ≥3 adverse reaction attributable to the γMSC product|Change in lung function test|In- vivo trafficking of MSCs after intravenous infusion|Upper airway inflammation of MSC treatment|Circulating inflammatory cells of MSC treatment|Biophysical characteristics of the cell products and correlation with clinical outcome","Emory University|The Marcus Foundation","All","18 Years to 30 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00002655|2709","October 2021","February 2023","February 2023","September 5, 2021",,"October 8, 2021","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05035862"
341,"NCT00366145","Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease",,"Completed","No Results Available","Graft Versus Host Disease","Biological: Mesenchymal Stem Cells|Biological: placebo|Drug: Standard of Care for GVHD","Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration|Overall Survival at 180 days Post First Infusion","Mesoblast, Inc.|Mesoblast, Ltd.","All","6 Months to 70 Years   (Child, Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","280","August 17, 2006","December 26, 2008","May 28, 2009","August 21, 2006",,"April 6, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Cancer Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Univeristy of California San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Emory University, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northwestern Center for Clinical Research, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois - Chicago, Chicago, Illinois, United States|Indiana Blood and Bone Marrow Transplant Center, Beech Grove, Indiana, United States|Univeristy of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Louisiana State University, Shreveport, Louisiana, United States|University of Maryland/Greenbaum, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos/Wayne State University, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Univeristy of Mississippi Medical Center, Jackson, Mississippi, United States|University of Nebraska, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park, Buffalo, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University/New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest Univeristy School of Medicine, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Baylor University, Dallas, Texas, United States|Univeristy of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Research Center, San Antonio, Texas, United States|Virginia Commonwealth/Massey Cancer Center, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Wisconsin Madison, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Brisbane Hospital, Herston, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Co-Medica Research Network, Calgary, Alberta, Canada|British Columbia's Children's Hospital, Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|London Health Sciences Centre- Westminster Campus, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Hopital Enfant-Jesus, Quebec, Canada|Hopital du Saint-Sacrement, Quebec, Canada|Universia degli Studi di Pesaro, Pesaro, PU, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Kantonsspital Basel, Basel, Switzerland|Barts & London School of Medicine, London, England, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom|Bristol Royal Hospital for Children, Bristol, UK, United Kingdom|Glasgow Royal Infirmary, Glasgow, UK, United Kingdom|Leeds General Infirmary, Leeds, UK, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00366145"
342,"NCT03608592","Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS","ARDS","Unknown status","No Results Available","Acute Respiratory Distress Syndrome","Biological: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Biological: normal saline","Infusion associated events|Mortality|Ventilation free days(VFDs)|Oxygenation index(OI) changes|Lung injury score(LIS)|Positive end expiratory pressure(PEEP)|Plateau pressure(Pplat)|Driving pressure|Static compliance","Sun Yat-sen University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QHJH201804","June 1, 2018","August 1, 2020","December 1, 2020","August 1, 2018",,"September 4, 2019","Huimin Yi, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03608592"
343,"NCT02403947","MEsenchymal StEm Cells for Multiple Sclerosis","MESEMS","Terminated","No Results Available","Multiple Sclerosis","Drug: Mesenchymal stem cells|Drug: Suspension media","Safety of MSCs infusion, number, timeframe of occurrence and severity of Adverse Events|efficacy: number of contrast-enhancing lesions (GEL) at MRI scan|Efficacy of the experimental treatment in term of combined MRI activity|Efficacy assessed by combined unique MRI activity, volume of GEL, and volume of BH|Efficacy assessed by combined unique MRI activity, volume of GEL and volume of BH|Efficacy: Number of relapses|Efficacy: Time to sustained progression of disability","University Hospital, Toulouse","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12 394 03","February 2015","December 2017","December 2017","March 31, 2015",,"December 3, 2018","Purpan Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02403947"
344,"NCT04312113","Angiographic Delivery of AD-MSC for Ulcerative Colitis",,"Recruiting","No Results Available","Ulcerative Colitis","Drug: Adipose derived, autologous mesenchymal stem cells","Number of participants with treatment-related adverse events|Number of participants with mucosal healing|Number of participants with clinical symptom response|Number of participants with improved healing on pathology","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-000826","November 16, 2020","December 31, 2022","December 31, 2022","March 18, 2020",,"September 30, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04312113"
345,"NCT04325594","The Application of the Umbilical Cord Mesenchymal Stem Cells in the Complex Treatment of Chronic Heart Failure of Non-ischemic Etiology","RegenHeart","Enrolling by invitation","No Results Available","Chronic Heart Failure|Non-ischemic Cardiomyopathy|Non-ischemic Dilated Cardiomyopathy","Procedure: Cardiac catheterization|Biological: Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells","change in the contractile function of the heart|change in the size of the heart|change in the volumes of the heart|change in the clinical condition evaluated by the Scale for Heart failure to Optimize Clinical Status|change in the markers of myocardial dysfunction|change in the in the 6-minute walk test|change in the functional status|change in the quality of life evaluated by the questionnaire Short Form 12 Healthy Survey|change in the quality of life evaluated by the Kansas City Cardiomyopathy Questionnaire|change in the quality of life evaluated by the Minnesota Living with Heart Failure Questionnaire","The Research-Clinical Center for Cardiac Surgery and Transplantology LLP|State-Financed Health Facility ""Samara Regional Medical Center Dinasty""","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCCCT 02-02-2020","March 1, 2020","October 31, 2020","December 31, 2020","March 27, 2020",,"March 27, 2020","The Research-Clinical Center for Cardiac Surgery and Transplantology LLP, Taraz, Zhambyl, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT04325594"
346,"NCT02277145","A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells",,"Completed","No Results Available","Post-radiotherapy Pulmonary Fibrosis","Biological: clinical grade umbilical cord mesenchymal stem cells","Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF-β1 content|Safety Evaluation|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in pulmonary function analysis|Clinical Indicator 3: 6-minute walk test distance|Clinical Indicator 4: change in MRC chronic dyspnea scale|Clinical Indicator 5: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum 1: T lymphocyte counts in peripheral blood|Immunological Indicator in serum 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in serum 3: concent of immunoglobulin|Immunological Indicator in serum 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in serum 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in serum 6: expression levels of IL-12, IL-10|Immunological Indicator in lavage fluid 1: T lymphocyte counts in peripheral blood|Immunological Indicator in lavage fluid 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in lavage fluid 3: concent of immunoglobulin|Immunological Indicator in lavage fluid 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in lavage fluid 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in lavage fluid 6: expression levels of IL-12, IL-10|Inflammatory Indicators: measured by routine blood test including C-reactive protein (CRP)|Fibrosis Indicators in serum 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in serum 2: content of hydroxyproline|Fibrosis Indicators in serum 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)|Fibrosis Indicators in lavage fluid 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in lavage fluid 2: content of hydroxyproline|Fibrosis Indicators in lavage fluid 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)","Jianwu Dai|Southwest Hospital, China|Chinese Academy of Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAS-XDA001-SH/IGDB","October 2014","December 2018","December 2018","October 28, 2014",,"July 24, 2019","First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital), Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT02277145"
347,"NCT03602872","Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis",,"Withdrawn","No Results Available","Knee Osteoarthritis","Biological: Human allogeneic mesenchymal bone marrow derived stem cells","Safety evaluation of all AE/SAEs|Procedure tolerance (procedure pain/discomfort incidence)|WOMAC questionnaire|OAKHQOL questionnaire","Clinica Santa Clarita, Mexico","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO-OAR-BW-001","August 2019","April 2020","April 2020","July 27, 2018",,"July 15, 2020","Clinica Santa Clarita, Tijuana, Baja California, Mexico",,"https://ClinicalTrials.gov/show/NCT03602872"
348,"NCT02330978","Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.",,"Completed","Has Results","Retinal Degeneration|Primary Open-angle Glaucoma","Procedure: Intravitreal transplantation of mesenchymal stem cell|Biological: Culture and isolation of autologous bone-marrow mesenchymal stem cells","Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR)|Changes in Visual Acuity|Changes in Visual Field|Changes in Optical Coherence Tomography Parameters Related to Glaucoma|Changes in Retinal Ganglion Cells Function by ERG","University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCRP 14151/2010","January 2014","September 2016","September 2016","January 5, 2015","July 8, 2019","July 8, 2019","Ribeirão Preto Medical School, Ribeirao Preto, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02330978"
349,"NCT02672267","A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction",,"Completed","No Results Available","Myocardial Infarction","Biological: Stem cells|Other: Placebo","The safety and tolerability of aMBMC intravenous administration during the six month study period as determined by major adverse events MACE endpoint|The change from baseline on physical exam conducted at 1, 3 and 6 months post-administration|LV end diastolic volume|LV end systolic volume|Infarct size measured by MRI, with contrast|Global Left Ventricular Ejection Fraction","Altaco XXI, LLP|Duke University","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","CARDIO 1/2","July 2014","April 2016","April 2016","February 3, 2016",,"October 6, 2016","National Research Medical Center, Astana, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT02672267"
350,"NCT02677350","AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)","GALENE","Withdrawn","No Results Available","Crohn's Disease|Fistulizing Crohn's Disease|Stem Cells","Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)","Evaluation of treatment emergent adverse events from the bone marrow-derived allogeneic mesenchymal stem cells implant|Clinically: to assess changes in the Crohn's Disease Activity Index (CDAI), the Perianal Disease Activity Index (PDAI).|Endoscopic assessment of rectum using a limited simplified endoscopic activity score for Crohn's disease (SES-CD) to evaluate extent and severity of ulcers.|Radiologic assessment using MRI|Evaluate symptomatic patients.|Evaluate the effect of local treatment with allogeneic bmMSCs using the short Inflammatory Bowel Disease Questionnaire (sIBDQ)|Evaluate the effect of local treatment with allogeneic bmMSCs using the Short Form (SF)-36 score|C-reactive protein (CRP)|Major Adverse Events","Joshua M Hare|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150965","December 1, 2019","December 2025","December 2026","February 9, 2016",,"June 24, 2019","Univeristy of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02677350"
351,"NCT01739777","Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy","RIMECARD","Completed","No Results Available","Dilated Cardiomyopathy","Biological: ucMSC|Other: Controls","• Change in global left ventricular ejection fraction|• Change in functional capacity measured in O2 consumption|• Occurrence of major adverse cardiac event|• Change in high sensitivity C-reactive protein (hs CRP)|• Reduction in level of B-type natriuretic peptide (BNP)","Universidad de los Andes, Chile","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","UANDES-C4C|CORFO-11IEI-9766","December 2012","June 2015","June 2015","December 3, 2012",,"June 4, 2015","Universidad de los Andes, Santiago de Chile, Chile",,"https://ClinicalTrials.gov/show/NCT01739777"
352,"NCT01275612","Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers","CIS/MSC08","Withdrawn","No Results Available","Solid Tumors|Acute Kidney Injury","Biological: Mesenchymal stromal cell infusion","Serum creatinine concentration.|Neutrophil gelatinase-associated lipocalin (NGAL)|N-acetyl-p- D glucosaminidase enzyme (NAG)","Mario Negri Institute for Pharmacological Research","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIS/MSC 08|2008-007485-35","November 2010","March 19, 2018","March 19, 2018","January 12, 2011",,"March 21, 2018","Unit of Oncology - Ospedali Riuniti of Bergamo, Bergamo, BG, Italy",,"https://ClinicalTrials.gov/show/NCT01275612"
353,"NCT01781390","Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction","AMICI","Active, not recruiting","No Results Available","Acute Myocardial Infarction","Biological: 12.5 M Mesenchymal Precursor Cells (MPC)|Other: Placebo|Biological: 25M Mesenchymal Precursor Cells (MPC)","The primary efficacy endpoint is the change in left ventricular (LV) end-systolic volume (LVESV) as assessed by cardiac MRI from baseline to 6 months post investigational agent infusion","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANG.AMI-IC001","December 2012","July 17, 2018","April 2021","February 1, 2013",,"July 28, 2020",,,"https://ClinicalTrials.gov/show/NCT01781390"
354,"NCT02495766","Autologous Mesenchymal Stromal Cells for Multiple Sclerosis","EMMES","Completed","No Results Available","Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis","Drug: XCEL-MC-ALPHA|Drug: Placebo","Adverse events|Cumulative number of MRI Gd-enhancing lesions|Multiple Sclerosis Outbreaks|Expanded Disability Status Scale (EDDS) score|Cumulative number of lesions visualized on T2 sequence","Banc de Sang i Teixits|Vall d'Hebron Research Institute (VHIR)","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XCEL-MS-02","May 11, 2015","November 27, 2017","November 15, 2018","July 13, 2015",,"January 21, 2020","Hospital Vall Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02495766"
355,"NCT02565459","MSC and Kidney Transplant Tolerance (Phase A)",,"Recruiting","No Results Available","Chronic Renal Failure","Biological: Mesenchymal Stromal Cells","Number of adverse events|Circulating naive and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis)|Circulating regulatory T cell count.|T-cell function in mixed lymphocyte reaction.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR","Monia Lorini|Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Third-party MSC-Tx tolerance A|2015-002186-27","September 2015","September 2021","December 2021","October 1, 2015",,"April 6, 2018","U.O. Nefrologia e Dialisi, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT02565459"
356,"NCT01849237","Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia",,"Unknown status","No Results Available","Septic Shock|Nonchemotherapy Drug-induced Neutropenia|Neutropenia After Chemotherapy in Oncohematological Patients|Neutropenia in Patients With Aplastic Anemia","Genetic: Mesenchymal stromal cells|Drug: Standard therapy of septic shock","mortality|Evaluation of MSC therapy effects on organ dysfunction|Evaluation of MSC therapy effects on systemic inflammatory parameters|Evaluation of MSC therapy effects on septic shock reversal","National Research Center for Hematology, Russia","All","17 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RuMCeSS","December 2012","April 2013","May 2015","May 8, 2013",,"May 10, 2013","National Research Center for Hematology, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01849237"
357,"NCT01222039","Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.","CMM/EICH/2008","Completed","No Results Available","Graft Versus Host Disease|Chronic and Expanded Graft Versus Host Disease|Immune System Diseases","Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.","Number of adverse events|Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment|Overall survival and disease-free survival.|Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT: 2008-004014-27","June 2010","June 2014","June 2014","October 18, 2010",,"November 18, 2016","Hospital de Jerez de la Frontera., Jerez de la Frontera, Cádiz., Spain|Hospital Universitario Virgen de las Nieves, Granada., Spain|Hospital Universitario Virgen del Rocío de Sevilla, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01222039"
358,"NCT01919827","Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis","CMM/FPI","Completed","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: Endobronchial infusion of adult mesenchymal stem cells|Biological: Autologous mesenchymal stem cells derived from bone marrow","Number of participants with adverse side effects.|Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF","Clinica Universidad de Navarra, Universidad de Navarra","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMM/FPI","March 2013","May 1, 2018","May 1, 2018","August 9, 2013",,"May 3, 2018","Servicio de Neumología, Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Servicio de Neumología. Hospital Universitario de Salamanaca, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT01919827"
359,"NCT03259217","Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers",,"Unknown status","No Results Available","Stem Cell Transplant","Drug: Stem Cell Product","complete healing|Rate of healing|rate of ulcer recurrence","Assiut University","All","Child, Adult, Older Adult","Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","stem cell in DFU","October 2017","July 2018","January 2019","August 23, 2017",,"August 23, 2017",,,"https://ClinicalTrials.gov/show/NCT03259217"
360,"NCT03333681","Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: Autologous mesenchymal stem cells","Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells","Mashhad University of Medical Sciences","Female","35 Years to 60 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","931523|122","June 20, 2016","August 15, 2018","September 15, 2018","November 7, 2017",,"March 13, 2019",,,"https://ClinicalTrials.gov/show/NCT03333681"
361,"NCT02668068","A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells",,"Completed","No Results Available","Pneumoconiosis","Procedure: large volume whole-lung lavage (WLL)|Biological: clinical grade umbilical cord mesenchymal stem cells","Incidence of Treatment-Emergent Adverse Events (Safety Evaluation)|Imaging indicator: Quantitative analysis of CT density histograms|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in MRC chronic dyspnea scale|Clinical Indicator 3: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in lavage fluid : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in serum : expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Immunological Indicator in lavage fluid: expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Fibrosis Indicators in serum: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|Fibrosis Indicators in lavage fluid: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|self-evaluation","Jianwu Dai|Southwest Hospital, China|Nanjing Chest Hospital|Chinese Academy of Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CAS-XDA-SH/NCH/IGDB","January 2016","March 2019","March 2019","January 29, 2016",,"July 24, 2019","First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital), Chongqing, Chongqing, China|Nanjing Chest Hosptial, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02668068"
362,"NCT04466007","Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia",,"Recruiting","No Results Available","Limb Ischemia|Diabetic Foot","Drug: High dose allogeneic mesenchymal stromal cells|Drug: Low dose allogeneic mesenchymal stromal cells|Drug: Placebos","Complication rate after treatment administration|Evaluation of vascularization though RMN|Rutherford-Becker scale|Wifi scale|Ankle arm index|Temperature|Twin perimeter|Neuropathic symptoms (altered sensitivity)|% amputations","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario La Paz|Gregorio Marañón Hospital|Hospital Clínico Universitario de Valladolid|Hospital Universitario Virgen de la Arrixaca|University of Salamanca|Hospital General Universitario de Alicante|Hospital Universitario La Fe|Hospital Victoria Eugenia Cruz Roja Española","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NOMA (No More Amputations)","January 11, 2021","June 2022","June 2022","July 10, 2020",,"May 26, 2021","Hospital General de Alicante, Alicante, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|La Paz University Hospital, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Victoria Eugenia Cruz Roja Española, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04466007"
363,"NCT02530047","Mesenchymal Stem Cells (MSC) for Ovarian Cancer",,"Completed","No Results Available","Ovarian Cancer","Genetic: MSC-INFβ|Behavioral: Questionnaires","Maximum Tolerated Dose (MTD) of Mesenchymal Stem Cells-Interferon-β (MSC-IFNβ)|Correlation Between the Number of MSC-IFNβ Infused and the Production of Interferon-β and the Number of MSC-IFNβ Detected at the Tumor Sites Via Tumor Biopsy Pre- and Post-Treatment","M.D. Anderson Cancer Center","Female","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0032|CA 136411|NCI-2015-01504","May 16, 2016","June 13, 2019","June 13, 2019","August 20, 2015",,"July 18, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02530047"
364,"NCT01745783","Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis",,"Active, not recruiting","No Results Available","Multiple Sclerosis","Other: Bone marrow mesenchymal stem cells autologous|Other: Placebo comparator","Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image|Differences the results obtained in the two groups of patients due to determined parameters.","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CeTMMo/EM/2010|2010-023368-42","January 2013","June 2021","February 2022","December 10, 2012",,"July 22, 2021","University Hospital Reina Sofia, Córdoba, Spain|University Regional Hospital Carlos Haya, Málaga, Spain|University Hospital Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01745783"
365,"NCT01914887","Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis","ALOASCU","Unknown status","No Results Available","Ulcerative Colitis","Drug: Allogeneic adipose tissue-derived mesenchymal stem cells","Safety|Efficacy: Change from Baseline in Modified Truelove-Witts score|Efficacy: Change from Baseline in Quality of Life index, Inflammatory Bowel Disease Questionnaire (IBDQ-32)|Efficacy: Change from baseline in Mayo endoscopic index.|Change from Baseline in C Reactive Protein|Change from Baseline in fecal calprotectin","Instituto de Investigación Hospital Universitario La Paz|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|Ministry of Health, Spain","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HLPDIG-2010-01|2010-023798-20","June 2013","December 2013","December 2013","August 2, 2013",,"August 2, 2013","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01914887"
366,"NCT04615455","Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome","AMASS","Recruiting","No Results Available","Keratoconjunctivitis Sicca, in Sjogren's Syndrome","Drug: ASCs|Drug: Cryostor CS10","Ocular Surface Disease Index (OSDI)|Non-invasive keratography tear break-up time (NIKBUT)|Tear meniscus height (TMH)|Schirmer's I test|Tear osmolarity|Oxford scale|HLA anti-bodies","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2020-002804-38","November 3, 2020","August 1, 2022","September 1, 2022","November 4, 2020",,"September 16, 2021","Rigshospitalet, Copenhagen, DK, Denmark",,"https://ClinicalTrials.gov/show/NCT04615455"
367,"NCT03386708","hUC Mesenchymal Stem Cells (19#iSCLife®-CSD) Therapy for Patients With Healing Poor After Uterus Injury",,"Completed","No Results Available","Uterus; Injury","Procedure: intrauterine injection|Procedure: intravenous injection|Biological: umbilical cord mesenchymal stem cell|Drug: Normal saline (NS)","Intrauterine adhesion patients efficacy evaluation|Incision lacuna and incision diverticulum patients efficacy evaluation|Ultrasound of uterus evaluation|Hysteroscopy evaluation|Pain score","Sclnow Biotechnology Co., Ltd.","Female","18 Years to 50 Years   (Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLnow-XY-01","October 1, 2018","June 1, 2021","September 21, 2021","December 29, 2017",,"September 27, 2021","Xiangya Hospital Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03386708"
368,"NCT02045745","Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells","CSM/FAP/2012","Unknown status","No Results Available","Postoperative Air Leaks in Risk Patients","Biological: Implantation of autologous mesenchymal stem cells (CSM) expanded ""in vitro"" and administered directly into the lung suture line","Safety of the procedure|Analyze the efficacy of the procedure","Red de Terapia Celular|Castilla y León Hematology and hemotherapy Foundation|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/FAP/2012|2013-000535-27","December 2013","December 2017","December 2017","January 27, 2014",,"March 30, 2017","University Clinical Hospital of Salamanca, Salamanca, Salamanca/Castilla León, Spain",,"https://ClinicalTrials.gov/show/NCT02045745"
369,"NCT04429763","Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia","CELMA","Not yet recruiting","No Results Available","COVID-19","Biological: Umbilical cord derived mesenchymal stem cells|Biological: Placebo","Clinical deterioration or death","Trustem|Fundación Universitaria de Ciencias de la Salud|Hospital de San Jose|Hospital Infantil Universitario de San Jose","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","202001","July 2020","September 2020","November 2020","June 12, 2020",,"June 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04429763"
370,"NCT04493918","Effectivity of Mesenchymal Stem Cell on Vertebral Bone Defect Due to Mycobaterium Tuberculosis Infection",,"Recruiting","No Results Available","Spinal Tuberculosis|Mesenchymal Stem Cell","Combination Product: Mesenchymal Stem cell + Nacl 0.9%|Combination Product: NaCl 0.9%","Vertebral bony fusion","Ahmad Jabir Rahyussalim|Indonesia University","All","15 Years to 64 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-04-0389","May 21, 2017","December 30, 2020","December 30, 2020","July 30, 2020",,"August 3, 2020","Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04493918"
371,"NCT02855112","Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients",,"Unknown status","No Results Available","Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]","Biological: Adipose derived mesenchymal stem cell","Changes in action potential of muscles on ElectroMyoGram (EMG) test|Changes in Motility on Modified Barthel Index Score","Tehran University of Medical Sciences","All","5 Months to 12 Months   (Child)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","94-01-87-28524","June 2015","December 2016","July 2017","August 4, 2016",,"August 4, 2016","Children's Medical Center, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02855112"
372,"NCT04314661","Comparative Effectiveness of Arthroscopy and Non-Arthroscopy Using Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium for Osteoartrithis","OA","Recruiting","No Results Available","Osteoarthritis, Knee","Biological: Mesenchymal Stem Cells with Arthoscopy|Biological: Mesenchymal Stem Cells without Arthoscopy|Biological: Conditioned Medium without Arthoscopy","Visual Analog Scale (VAS)|Western Ontario and McMaster Universities Osteoarthritis Index|Laboratory Asessment|Magnetic Resonance Imaging (MRI) T2 mapping","PT. Prodia Stem Cell Indonesia","All","55 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/OA/01/2020","August 3, 2020","September 8, 2020","December 8, 2020","March 19, 2020",,"July 15, 2020","Gatot Soebroto Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04314661"
373,"NCT02685098","A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation","CHAMP","Recruiting","No Results Available","Ischemia|Peripheral Arterial Disease|Peripheral Vascular Disease|Vascular Disease|Arterial Occlusive Disease|Arteriosclerosis|Atherosclerosis|Cardiovascular Disease|Pathologic Processes|Orthopedic Procedures|Amputation","Biological: Allogeneic bone marrow derived mesenchymal stem cells","Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the MeDRA scale.|Gene and protein arrays, IHC staining, and multiparametric flow cytometry will measure the time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation.|Recruitment of proangiogenic hematopoietic cells into sites of ischemia will be measured and reported as assessed by the role of MSCs injected in human skeletal muscle at the time of amputation.","Indiana University","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1505714405","January 2017","September 2021","September 2025","February 18, 2016",,"February 12, 2020","Indiana University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02685098"
374,"NCT04714801","Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation",,"Recruiting","No Results Available","Lung Transplant Rejection","Drug: adipose derived mesenchymal stromal cells|Drug: Saline","Pulmonary graft dysfunction (PDG)|Kidney glomerular Filtration Rate|Inflammatory markers","Rigshospitalet, Denmark","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASC Lungtransplantation","October 1, 2020","November 30, 2023","November 30, 2024","January 19, 2021",,"July 16, 2021","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04714801"
375,"NCT00314483","Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease",,"Unknown status","No Results Available","Graft vs Host Disease","Drug: Mesenchymal Stem Cell Infusion","Control of GVHD|Infusional toxicity|Risk of relapse","Christian Medical College, Vellore, India","All","2 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMCMSC_GVHD012006","June 2007",,"June 2008","April 14, 2006",,"July 6, 2007","Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT00314483"
376,"NCT01895439","Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: Autologous Mesenchymal Stem Cells","The number of patients with any relevant side effects observed|Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.","University of Jordan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSUJCTC","October 2012","February 2016","February 2016","July 10, 2013",,"May 2, 2017","Cell Therapy Center, Jordan University Hospital, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT01895439"
377,"NCT01540292","Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders",,"Terminated","No Results Available","Crohn's Disease","Biological: Mesenchymal Stem Cells (MSC)","Clinical Response Rate|Clinical Response|Remission|Crohn's Disease Activity Index Level|C-reactive Protein levels|Fecal calprotectin levels|Immune modulation investigation|Incidence of infections","University of Liege","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJT1123","February 1, 2013","December 31, 2015","December 31, 2015","February 28, 2012",,"May 12, 2021","University Hospital Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT01540292"
378,"NCT01720888","Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy",,"Unknown status","No Results Available","Ischemic Dilated Cardiomyopathy","Other: BM-MSCs","Change in LV ejection fraction as measured by echocardiogram and cardiac MRI after implantation|Changes in functional status|Improvement in other LV parameters as assessed by echocardiogram and cardiovascular magnetic resonance(CMR).|Resolution of scar tissue volume/area on cardiac MRI|Change in serum N Terminal-pro B type natriuretic peptide(NT-proBNP)level|Freedom from major adverse cardiac events as defined by myocardial infarction, hospitalization for angina, myocardial infarction or heart failure, or death (all cause of mortality).","National University of Malaysia|Cytopeutics Sdn. Bhd.","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ERGS/1/2011/SKK/UKM/02/72","July 2012","December 2015","December 2015","November 2, 2012",,"April 16, 2015","UKM Medical Centre, Cheras, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01720888"
379,"NCT00813969","Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS",,"Completed","No Results Available","Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis","Biological: Autologous mesenchymal stem cell transplantation","To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS|To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions|To evaluate safety and tolerability of autologous MSC transplantation over 6 months","The Cleveland Clinic|University Hospitals Cleveland Medical Center","All","18 Years to 55 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS-MSC-001","March 2011","January 2014","May 2014","December 23, 2008",,"March 30, 2016","Cleveland Clinic Mellen Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00813969"
380,"NCT02032004","Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.","DREAM HF-1","Completed","No Results Available","Chronic Heart Failure","Biological: Allogeneic Mesenchymal Precursor Cells (MPC)|Other: Sham Comparator","Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).|Time-to-first terminal cardiac event (TCE)|Time-to-hospital admissions for non-fatal decompensated HF events|Time-to-urgent care outpatient HF visits|Time-to-successfully resuscitated cardiac death (RCD) events|Total length of in-hospital stay in intensive care unit for non-fatal decompensated HF events|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, and successfully RCD events)|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, successfully RCD events or TCE)|Time-to-cardiac death|Time-to-all-cause death|Time-to-first non-fatal MI (myocardial infarction), non-fatal CVA (cerebrovascular attack) or coronary artery revascularization|Left Ventricular (LV) remodeling in LVESV determined by 2-D echocardiography|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and clinical outcomes|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and change in Month 6 to baseline LVESV and clinical outcomes|LV remodeling in LVEDV determined by 2-D echocardiography|Overall Left Ventricular systolic performance as assessed by LVEF (RVG or echocardiogram)|Functional exercise capacity as assessed by 6 Minute Walk Test|Functional status by New York Heart Association (NYHA) class|Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire|Quality of Life Measure - EuroQoL 5-dimensional (EQ-5D) questionnaire|Safety as assessed by occurrence of adverse events related to the index cardiac catheterization on Day 0|Safety as assessed by occurrence of treatment-emergent adverse events|Safety as assessed by clinical laboratory tests (serum chemistry - ALT, AST, alkaline phosphate, GGT, LDH, BUN, creatinine, uric acid, total bilirubin - and hematology - hematocrit, hemoglobin, WBC, eosinophils, ANC, platelet count)|Safety as assessed by urinalysis (blood, glucose, ketones, total protein)|Safety as assessed by vital signs (pulse, systolic BP, diastolic BP)|Safety as assessed by 12-lead electrocardiogram (ECG) findings - QTcF, QTcB, QT, QRS complex, HR and T waves.|Safety as assessed by telemetry monitoring findings (clinically significant arrhythmias)|Safety as assessed by rhythm analysis (specifically, ventricular arrhythmias) by interrogation of any implanted device capable of defibrillation|Safety as assessed by 24-hr Holter monitoring (HR, rate & duration of arrhythmias, a-fib average rate, supra- & ventricular ectopy singles/couplets/runs/totals, sustained & non-sustained ventricular tachycardia, longest pauses RR duration, total pauses)|Safety as assessed by physical examination findings judged as clinically significant changes from baseline by the investigator or newly occurring abnormalities (including weight)|Safety as assessed by important cardiovascular events from adjudicated data","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","566","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSB-MPC-CHF001","February 14, 2014","May 29, 2020","May 29, 2020","January 9, 2014",,"May 25, 2021","Mesoblast Investigational Site 10757 - Cardiology, P.C., Birmingham, Alabama, United States|Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa, Mesa, Arizona, United States|Mesoblast Investigational Site 10756 - Mayo Clinic, Phoenix, Arizona, United States|Mesoblast Investigational Site 13023 - University of Arizona Medical Center, Tucson, Arizona, United States|Mesoblast Investigational Site 10754 - University of California, San Diego, La Jolla, California, United States|Mesoblast Investigational Site 10759 - Scripps Clinic, La Jolla, California, United States|Mesoblast Investigational Site 13265 - University of California, Los Angeles, Los Angeles, California, United States|Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation, Los Angeles, California, United States|Mesoblast Investigational Site 10778 - Orange County Cardiology, Orange, California, United States|Mesoblast Investigational Site 13031 - St. John's Regional Medical Center, Oxnard, California, United States|Mesoblast Investigational Site 13275 - Stanford University Hospital, Stanford, California, United States|Mesoblast Investigational Site 13267 - Bethesda Heart Hospital, Boynton Beach, Florida, United States|Mesoblast Investigational Site 10780 - Morton Plant Hospital, Clearwater, Florida, United States|Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida, Gainesville, Florida, United States|Mesoblast Investigational Site 13273 - University of Florida Health, Jacksonville, Florida, United States|Mesoblast Investigational Site 10768 - University of Miami, Miami, Florida, United States|Mesoblast Investigational Site 13280, Orlando, Florida, United States|Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute, Tampa, Florida, United States|Mesoblast Investigational Site 13027 - Emory University School of Medicine, Atlanta, Georgia, United States|Mesoblast Investigational Site 10765 - Georgia Regents University, Augusta, Georgia, United States|Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center, Chicago, Illinois, United States|Mesoblast Investigational Site 13030 - University of Iowa, Iowa City, Iowa, United States|Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky, Lexington, Kentucky, United States|Mesoblast Investigational Site 13022 - University of Louisville, Louisville, Kentucky, United States|Mesoblast Investigational Site 13266, New Orleans, Louisiana, United States|Mesoblast Investigational Site 10782, Boston, Massachusetts, United States|Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Mesoblast Investigational Site 10762 - Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Mesoblast Investigational Site 10761 - Mayo Clinic, Rochester, Minnesota, United States|Mesoblast Investigational Site 13281, Las Vegas, Nevada, United States|Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center, Newark, New Jersey, United States|Mesoblast Investigational Site 10776 - Columbia University Medical Center, New York, New York, United States|Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System, Charlotte, North Carolina, United States|Mesoblast Investigational Site 10781 - Duke University, Durham, North Carolina, United States|Mesoblast Investigational Site 10758 - The Christ Hospital, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10770 - University of Cincinnati, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10773, Cleveland, Ohio, United States|Mesoblast Investigational Site 13278 - OhioHealth Research Institute, Columbus, Ohio, United States|Mesoblast Investigational Site 10785 - Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Mesoblast Investigational Site 13261 - University of Pennsylvania, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10767 - Temple University Hospital, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 13277, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10774 - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Mesoblast Investigational Site 10777 - Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Mesoblast Investigational Site 13024 - Austin Heart, PLLC, Austin, Texas, United States|Mesoblast Investigational Site 13274 - Soltero CV Research Center, Baylor Scott & White Research Institute, Dallas, Texas, United States|Mesoblast Investigational Site 10755 - Texas Heart Institute, Houston, Texas, United States|Mesoblast Investigational Site 13268 - Houston Methodist Hospital, Houston, Texas, United States|Mesoblast Investigational Site 10763 - University Hospital, Salt Lake City, Utah, United States|Mesoblast Investigational Site 10771 - Heart & Vascular Research, Swedish Medical Center, Seattle, Washington, United States|Mesoblast Investigational Site 10764 - University of Wisconsin, Madison, Wisconsin, United States|Mesoblast Investigational Site 10769 - Aurora Healthcare, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 13279, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 10789 - Aspirus Research Institute, Wausau, Wisconsin, United States|Mesoblast Investigational Site 11027, Edmonton, Alberta, Canada|Mesoblast Investigational Site 11024 - Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|Mesoblast Investigational Site 11025 - St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02032004"
381,"NCT02375568","Large-scale Expansion and Characterization of Mesenchymal Stem Cells for Clinical Application",,"Unknown status","No Results Available","Knee Injuries","Other: 103024-F","Cell viability ratio of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage|Doubling time of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage|Percentage expression of cluster differentiation 90,105, 34, 45 surface markers of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage|Alcian blue staining of synovial membrane MSC and infrapatellar fat pad MSC|Tyep II collagen and aggrecan gene expression of synovial membrane MSC and infrapatellar fat pad MSC","Chin-Hung Chang|EMO Biomedicine Corporation|Far Eastern Memorial Hospital","All","Child, Adult, Older Adult",,"6","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","201405EMO","May 2014","August 2015","August 2015","March 2, 2015",,"March 2, 2015","Far Eastern Memorial Hospital, Pan-Ciao, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02375568"
382,"NCT03609905","Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis","AMSC_UC","Recruiting","No Results Available","Ulcerative Colitis (UC)","Biological: Adipose-cord mesenchymal stromal cells (A-MSCs)|Other: Conventional drugs","Change From Baseline in Endoscopic Score (as Measured by Ulcerative Colitis Endoscopic Index of Severity)|Change from Baseline in clinical response (CDAI points)|To evaluate the quality of life index, Short Inflammatory Bowel Disease Questionnaire (SIBDQ)|Histologic Evaluation of Ulcerative Colitis|Immune response in ulcerative colitis.|Incidence of Treatment Adverse.","Liaocheng People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","lcsrmyy-yp1","July 1, 2018","June 1, 2021","December 1, 2021","August 1, 2018",,"September 2, 2020","Liaocheng city people's hospital, Liaocheng, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03609905"
383,"NCT01076920","Mesenchymal Stem Cells and Myocardial Ischemia","MESAMI","Completed","No Results Available","Chronic Myocardial Ischemia|Left Ventricular Dysfunction","Genetic: Mesenchymal stem cells","Evaluate safety and feasibility of transendocardial injection using the NogaStar XP Mapping Catheter with the MyostarTM Left Ventricular Injection Catheter of autologous MSC in subjects with chronic myocardial ischemia and left ventricular dysfunction|Change from baseline in SF-36, VO2max, 6 min walk test, and the NYHA, CCS Classifications Effect related to cardiac function","University Hospital, Toulouse|French Blood Establishment|Nantes University Hospital|Ministry of Health, France","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0505008","October 2009","February 2014","September 2014","February 26, 2010",,"September 19, 2014","University Hospital (Rangueil), Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01076920"
384,"NCT02497443","Safety of Autologous MSC Infusion to Treat Epilepsy","AMSCDRSE","Completed","No Results Available","Epilepsy","Biological: Autologous mesenchymal stem cells","Safety of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy|Efficacy of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy","Ministry of Public Health, Republic of Belarus","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Minsk-MH001","April 2011","December 2017","December 2019","July 14, 2015",,"December 29, 2020",,,"https://ClinicalTrials.gov/show/NCT02497443"
385,"NCT04361942","Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)","COVID_MSV","Recruiting","No Results Available","COVID-19 Pneumonia","Biological: Mesenchymal Stromal Cells|Other: Placebo","Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses","Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_007|2020-001682-36","May 1, 2020","November 30, 2021","December 31, 2021","April 24, 2020",,"March 10, 2021","Hospital Universitario Rio Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04361942"
386,"NCT01840540","MSC for Occlusive Disease of the Kidney",,"Completed","No Results Available","Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension","Drug: Arterial infusion of autologous mesenchymal stem cells","Renal blood flow and function in the treated kidneys.|Level of kidney function.","Mayo Clinic","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009298","April 2013","March 2014","April 2017","April 25, 2013",,"August 7, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01840540"
387,"NCT03477942","Impact of Mesenchymal Stem Cells in Knee Osteoarthritis",,"Recruiting","No Results Available","Musculoskeletal Pain|Knee Osteoarthritis|Cartilage Injury|Cartilage Degeneration","Biological: Autologous Mesenchymal Stem Cells","Primary Endpoint: Incidence of treatment emergent major adverse events directly related to MSC injection|Secondary Endpoint: Development of Pain following injection based on Visual Analog Scale scoring.|Secondary Endpoint: Clinical Evaluation of Injection based on functional outcomes scoring using KOOS, IKDC and Lysholm scoring scales.|Secondary Endpoint: Reparative potential of intra-articular MSCs based on improvement in cartilage quality using MRI.","University Hospitals Cleveland Medical Center|Case Western Reserve University","All","18 Years to 60 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","JV 1.1","October 1, 2018","June 2022","July 2022","March 27, 2018",,"September 10, 2021","University Hospital Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03477942"
388,"NCT00476060","Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis",,"Unknown status","No Results Available","Cirrhosis","Procedure: Autologous mesenchymal stem cell transplantation","MELD score, quality of life, liver volume, histological improvement (In a subset of patients with evidences of clinical and biochemical improvement, follow up liver biopsy will be performed at the end of follow up).|All cause mortality, tracking the infused cells in the patients' bodies.","University of Tehran","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DDRC85-13","January 2007","August 2011","August 2011","May 21, 2007",,"January 11, 2011","Digestive Disease Research Center, Shariati Hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00476060"
389,"NCT05131412","Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation","MSCTPHSCT","Completed","No Results Available","Pneumonia|Hematopoietic Stem Cell Transplantation",,"overall cure rate|time to cure","Guangzhou Women and Children's Medical Center","All","1 Year to 17 Years   (Child)",,"107","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GWCMC_HJ_XY_001","August 8, 2018","January 1, 2021","October 31, 2021","November 23, 2021",,"November 23, 2021","Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05131412"
390,"NCT02985346","Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis",,"Unknown status","No Results Available","Idiopathic Pulmonary Hemosiderosis","Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis","Complete remission","Sun Yat-sen University","All","1 Month to 18 Years   (Child, Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WTan","January 2017","December 2020",,"December 7, 2016",,"December 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02985346"
391,"NCT03166865","Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis",,"Unknown status","No Results Available","Osteoarthritis of the Knee","Biological: Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Other: Hyaluronic acid","Change From Baseline in visual analogue scale (VAS)|Change From Baseline in western Ontario and McMaster Universities Osteoarthritis Index score|Change From Baseline in knee society score (KSS)|Change From Baseline in MOS item short from health survey(SF-36)|The number of cartilage defects, thickness of cartilage evaluated by X-ray and MRI|The IL-1β, IL-6, PGE-2, TGF-β, TNF-α and IGF-1 of articular cavity fluid","Liaocheng People's Hospital","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","lcsrmyygk","October 1, 2018","June 1, 2020","October 1, 2020","May 25, 2017",,"June 4, 2018","Liaocheng city people's hospital, Liaocheng, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03166865"
392,"NCT01429038","Mesenchymal Stem Cells After Renal or Liver Transplantation",,"Active, not recruiting","No Results Available","Liver Failure|Kidney Failure","Biological: Mesenchymal Stem Cells","Infusional toxicity|Incidence of infections (bacterial, viral, fungal, parasitic) and cancers|Patient and graft survivals|Effects of MSC on graft function|Biopsy-proven (Banff classification) rejection rates|Feasibility and safety of weaning or decreasing immunosuppression|Recipient's immune function|Anti-MSC donor HLA antibodies.","University of Liege","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJT1106P1","February 2012","December 2021","December 2021","September 5, 2011",,"May 12, 2021","University Hospital Liege, Liege, Belgium",,"https://ClinicalTrials.gov/show/NCT01429038"
393,"NCT04615429","Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19 Pneumonia","Biological: Mesenchymal stromal cells|Other: Placebo","Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration|All-cause mortality|Time to PaO2/FiO2 ratio greater than 200 mmHg|Clinical status on the World Health Organization ordinal scale|PaO2/FiO2 ratio|SOFA score|Oxygen therapy-free days|Duration of hospitalization|Duration of ICU admission|Incidence of non-invasive ventilation|Incidence of invasive mechanical ventilation|Duration of non-invasive ventilation|Duration of invasive mechanical ventilation|Mechanical ventilation-free days|Survival rate|Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest.","Cristina Avendaño Solá|Puerta de Hierro University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","COVID-AT|2020-002193-27","September 15, 2020","January 2022","February 2022","November 4, 2020",,"November 10, 2021","Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04615429"
394,"NCT02166021","Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis (MS)","Biological: Mesenchymal stem cells","Safety Assessment|Neurological efficacy|EDSS score|Ambulation score|Functional scores|Single injection vs. repeated MSCs injection|Relapse rate|T2-weighted flair lesions load in MRI|Total brain volume in MRI|Gadolinium enhancing lesions in MRI|Functional MRI|25-feet timed walking|9-hole peg test|Paced Auditory Serial Addition Test (PASAT)|Cognitive function: Controlled Oral Word Association Test (COWAT)|Optical coherence tomography (OCT)|Immunology","Dimitrios Karussis|Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MSC-MS-001-IL","January 29, 2015","June 15, 2018","December 24, 2018","June 18, 2014",,"August 1, 2019","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT02166021"
395,"NCT03265808","Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.","Alaunus","Recruiting","No Results Available","Major Depressive Disorder|Alcohol Use Disorder","Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)|Drug: Placebo","Incident of treatment emergent-serious adverse events|Change in serum concentrations of high sensitivity C-reactive protein.|Change in serum concentrations of inflammatory biomarkers|Change in depressive symptoms as assessed by MADRS|Change in Depressive symptoms as assessed by CGI|Change in quantity of alcohol use as assessed by TLFB|Change in frequency of alcohol use as assessed by TLFB|Change in Anhedonia as measured by SHAPS|Change in cravings as assessed by AUQ|Change in cravings as assessed by OCDS|Change in cognition as assessed by BAC-A|Change in functioning as assessed by UPSA-B|Change in functioning as assessed by GAF|Change in quality of life as assessed by QOLI","Joshua M Hare|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Miami","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20170674|1R01AA024933-01A1","March 18, 2018","October 23, 2022","April 2025","August 29, 2017",,"June 30, 2021","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03265808"
396,"NCT02304588","Stem Cell Therapy for Patients With Vascular Occlusive Diseases Such as Diabetic Foot",,"Unknown status","No Results Available","Diabetic Foot|Lower Limb Ischemia","Biological: Mesenchymal stem cells","Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 6 Week","Chinese PLA General Hospital","All","30 Years to 78 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHIN-PLAGH-ST-001","January 2013","December 2015","December 2017","December 2, 2014",,"December 2, 2014","Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02304588"
397,"NCT00962923","Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)",,"Unknown status","No Results Available","Systemic Sclerosis|Mesenchymal Stem Cells","Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)","mRSS score,HRQOL score, SF-36 score for SSc patients|Remission for organ function, VC, DLCO, PAP, serum albumin, serum creatitin, weight loss, 24h proteinuria|SSc Serology(ATA,ACA,ANA,anti-ssDNA,anti-dsDNA,IgM,IgG,and IgA,complement C3 and C4|Change of peripheral blood B and T cells","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NJGLYY003","August 2009","December 2010","December 2011","August 20, 2009",,"August 20, 2009","the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT00962923"
398,"NCT03795974","Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral Palsy",,"Unknown status","No Results Available","Cerebral Palsy, Spastic","Biological: MNC|Biological: MSC|Procedure: Control","Change from baseline Gross Motor Function Classification System (GMFCS)|Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)|Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)|Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)|Change from baseline Modified Ashworth scale|Change from baseline acquired Brain Magnetic Resonance Imaging (MRI) findings|Change from baseline Brain Magnetic Resonance Spectroscopy (MRS)|Change from baseline Diffuse Tensor Imaging (DTI) fiber count of periventricular white matter","Tehran University of Medical Sciences|Hormozgan University of Medical Sciences","All","4 Years to 14 Years   (Child)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRCT201706176907N13","July 23, 2017","October 2019","December 2019","January 8, 2019",,"January 8, 2019","Tehran University of Medical Sciences , Growth and Development Research Center- Children's Medical Center, Tehran, Iran, Islamic Republic of|Tehran University of Medical Sciences Chidren's Medical Center Radiology Department, Tehran, Iran, Islamic Republic of|Tehran University of Medical Sciences, Department of Pediatric Neurology , Children's Medical Center, Tehran, Iran, Islamic Republic of|ROYAN Stem Cell Technology Co, Tehran, Iran, Islamic Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03795974/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03795974"
399,"NCT03265613","Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis","ADMSP","Active, not recruiting","No Results Available","Mesenchymal Stromal Cells|Psoriasis|Drug Toxicity|Drug Effect","Biological: adipose-derived multipotent mesenchymal stem cells","Incidence of adverse events (AEs) related to intervention|Incidence of serious adverse events (SAEs) related to intervention|Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）","Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2017-01","September 24, 2017","August 20, 2019","December 28, 2021","August 29, 2017",,"March 1, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03265613"
400,"NCT04855955","Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease",,"Available","No Results Available","Alzheimer Disease","Drug: Adipose-Derived Mesenchymal Stem Cells",,"Celltex Therapeutics Corporation",,"Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"CTXSP0001",,,,"April 22, 2021",,"April 22, 2021",,,"https://ClinicalTrials.gov/show/NCT04855955"
401,"NCT00911365","Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy",,"Completed","No Results Available","Multiple System Atrophy","Biological: autologous mesenchymal stem cells|Biological: normal saline","Scores on unified MSA rating scale","Yonsei University","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","4-2008-0137","May 2008","June 2011","June 2011","June 1, 2009",,"August 4, 2011","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00911365"
402,"NCT05016011","Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury",,"Recruiting","No Results Available","Osteoarthritis, Knee","Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Procedure: Marrow cellution","Recording of Adverse Events and Serious Adverse Events|International Knee Documentation Committee (IKDC) score|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Visual Analog Score (VAS)|Magnetic resonance imaging (MRI)|Immunohistochemistry (IHC)","Cytopeutics Sdn. Bhd.|Universiti Kebangsaan Malaysia Medical Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POD0032/CP/R","July 1, 2020","June 1, 2022","June 1, 2023","August 23, 2021",,"August 23, 2021","Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM-UKM), Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT05016011"
403,"NCT02035514","Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis",,"Completed","No Results Available","Relapsing Remitting Multiple Sclerosis (RRMS)","Biological: Bone marrow autologous mesenchymal stem cells transplantation","Change from baseline in safety|Change from baseline in effectiveness by MRI|Feasibility|Change in clinical efficacy|Change in Quality of life|Immunology|Axonal effect","Germans Trias i Pujol Hospital|Ministerio de Sanidad, Servicios Sociales e Igualdad","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CELLTRiMS|2010-024081-21","December 2013","July 2016","July 2016","January 14, 2014",,"December 15, 2016","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02035514"
404,"NCT01759797","Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: intra venous injection of stem cell","Fever|Unconsciousness|vomiting|ALS-FRS|FVC|EMG-NCV","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Nerve-005","January 2013","January 2014","March 2014","January 3, 2013",,"July 6, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01759797"
405,"NCT03810521","Dose-escalation of Cellistem-OA in Patients With Knee Osteoarthritis","CLT-OA1","Unknown status","No Results Available","Osteoarthritis, Knee","Biological: umbilical cord derived-mesenchymal stromal cells","Incidence of adverse events|Change in WOMAC score|Change in VAS score|Changes in structural joint assessment by MRI","Universidad de los Andes, Chile","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLT-OA1","March 1, 2019","October 30, 2019","December 30, 2019","January 18, 2019",,"January 18, 2019","Clínica Universidad de los Andes, Santiago, Xiii, Chile",,"https://ClinicalTrials.gov/show/NCT03810521"
406,"NCT03308565","Adipose Stem Cells for Traumatic Spinal Cord Injury","CELLTOP","Active, not recruiting","No Results Available","Spinal Cord Injuries|Paralysis","Biological: Autologous, Adipose derived Mesenchymal Stem Cells","Incidence of acute adverse events|Incidence of delayed adverse events|Severity of adverse events|Relationship of adverse events to study drug|Incidence of serious adverse events (SAE)|Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by motor evoked potentials (MEP)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide","Allan Dietz, Ph.D.|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-004621","December 5, 2017","November 2022","November 2023","October 12, 2017",,"November 17, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03308565"
407,"NCT01771640","Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: intrathecal injection","Fever|Unconscious|Vomiting|ALS-FRS|FVC","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Nerve-006","August 2013","October 2014","December 2014","January 18, 2013",,"March 7, 2018","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01771640"
408,"NCT02544802","Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee",,"Unknown status","No Results Available","Osteoarthritis Knee","Drug: Adipose-Derived Mesenchymal Stem Cells","Safety of intra-articular injection of autologous ADMSCs by incidence of adverse events and alterations in vital signs, blood chemistry profiles, complete blood count, urinalysis, and also the physical examination of the knees.|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of Short Form 36 questionnaire (SF-36)|Clinical assessment of Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Clinical assessment of Hospital for Special Surgery (HSS) Knee Score|Clinical imaging assessment of knee X-ray|Clinical imaging assessment of MRI of the knee","Steminent Biotherapeutics Inc.","All","50 Years to 70 Years   (Adult, Older Adult)","Phase 1","4","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-VGH-201102","June 2015","February 2017","July 2017","September 9, 2015",,"April 20, 2016","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02544802"
409,"NCT02675556","Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression","ANU","Terminated","No Results Available","Treatment Resistant Depression","Drug: Allo-hMSCs|Drug: Placebo","Incidence of any treatment-emergent serious adverse events (TE-SAEs)|Reduction of Inflammation","Joshua M Hare|University of Miami","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20140917","October 31, 2017","March 26, 2019","March 26, 2019","February 5, 2016",,"April 1, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02675556"
410,"NCT01207193","Treatment Of Bone Cyst With Bone Marrow Mesenchymal Cell Transplantation",,"Completed","No Results Available","Bone Cyst","Biological: cell injection","fulfill bone cyst defect|effect of mesenchymal cell transplantation","Royan Institute","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-005","October 2009","October 2011","December 2011","September 22, 2010",,"December 14, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01207193"
411,"NCT04356287","Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis","CARE-SSc","Not yet recruiting","No Results Available","Sclerosis, Systemic|Mesenchymal Stem Cells","Biological: UCMSC|Other: Placebo","Measure of safety one month after first infusion (adverse events)|Measure of safety one month after second infusion (adverse events)|Change in modified Rodnan skin score (mRss) between Month 0 and Month 12","Marie Hudson, MD|Assistance Publique - Hôpitaux de Paris|University Paris 7 - Denis Diderot|Université de Montréal|Medical University of South Carolina|Centre hospitalier de l'Université de Montréal (CHUM)|McGill University Health Centre/Research Institute of the McGill University Health Centre|Sir Mortimer B. Davis - Jewish General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-05-2020-2251","December 2021","December 2022","December 2023","April 22, 2020",,"September 10, 2021",,,"https://ClinicalTrials.gov/show/NCT04356287"
412,"NCT04235296","Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Residual Burn Wound",,"Recruiting","No Results Available","Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Residual Burn Wound","Biological: epidermal growth factor|Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor","wound healing rate","Chinese PLA General Hospital","All","6 Years to 60 Years   (Child, Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHIN-PLAGH-MP-03","November 17, 2019","December 30, 2020","June 30, 2021","January 21, 2020",,"May 12, 2020","PLA Central Theater Air Force Hospital, Datong, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT04235296"
413,"NCT00891501","The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects",,"Unknown status","No Results Available","Degenerative Arthritis|Chondral Defects|Osteochondral Defects","Procedure: Bone Marrow Aspiration|Procedure: Bone marrow mesenchymal stem cell implantation","Improvement in Clinical Scores and Radiological images","Cairo University","All","15 Years to 55 Years   (Child, Adult)","Phase 2|Phase 3","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Amgad","November 2006","December 2014","December 2014","May 1, 2009",,"May 1, 2009","Deaprtment of Orthopedic Surgery and Tissue Culture Unit of the Department of Medical Biochemistry - Cairo University School of Medicne - Kasr Al Ainy Hospitals -Al-Saray Street, El Manial, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT00891501"
414,"NCT01389661","Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)","BIOMAX","Completed","No Results Available","Maxillary Cyst|Bone Loss of Substance","Biological: MSV treatment","To evaluate the feasibility and safety of the implementation of MSV in the treatment of maxillary cysts|Indication of efficacy","Red de Terapia Celular|Sanidad de Castilla y León|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Citospin","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","11","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TerCel0002|2010-024246-30|EC10-255|BIOMAX-VA-2010","April 2011","April 25, 2016","April 25, 2016","July 8, 2011",,"April 27, 2017","Río Hortega University Hospital, Valladolid, Valladid, Spain|Bionand, Parque Tecnológico de Andalucía, Universidad de Málaga, Malaga, Spain|Instituto de Biologia y Genetica Molecular, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01389661"
415,"NCT04062136","Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia",,"Unknown status","No Results Available","Bronchopulmonary Dysplasia","Combination Product: stem cell transplantation","Adverse events and serious adverse events|The proportion of patients win from oxygen|The lung fibrosis","Vinmec Research Institute of Stem Cell and Gene Technology","All","1 Month to 6 Months   (Child)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VinmecISC1915","March 1, 2019","November 30, 2020","November 30, 2020","August 20, 2019",,"August 20, 2019","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam|Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04062136"
416,"NCT01849159","Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema",,"Withdrawn","No Results Available","Pulmonary Emphysema","Biological: Mesenchymal stem cells|Other: Reference therapy: 400 mL of 0.9% NaCl solution","Safety compared with placebo|Change from baseline in the lung tissue density measured by CT-densitometry at6, 12, 24 months|DLCO change from baseline at 6, 12, 24 months|Change from baseline in the functional parameters (FEV1, TLC, RV, FEV1/FVC) at 6,12,18,24 months|Dynamics of the physical capacity (by the 6-min test results)|Dynamics of the blood gas composition (PaO2, PaCO2)|Dynamics of serum level IL-6, TNF-α, Leptin|Quality of life indices by the questionnaire (SF-36)|Number and frequency of exacerbations|Body mass index","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-HYP-01|FMBA-FRCC-MSC-01","March 2014","December 2016","June 2017","May 8, 2013",,"January 9, 2018","Federal Research Clinical Center of Federal Medical and Biological Agency of Russia, Moscow, Moscow Region, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01849159"
417,"NCT01142856","Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: autologous mesenchymal stem cells","Safety|Neurologic disability score","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-001995","June 2010","April 2011","April 2011","June 11, 2010",,"May 3, 2012","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01142856"
418,"NCT02808208","Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure",,"Enrolling by invitation","No Results Available","End Stage Renal Disease (ESRD)|Vascular Access Complication","Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|Drug: Placebo|Biological: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)","Hemodialysis outflow vein diameter|Hemodialysis AVF Blood flow","Mayo Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","15-009053","June 7, 2017","December 2021","December 2021","June 21, 2016",,"July 26, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02808208"
419,"NCT04153630","Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa",,"Unknown status","No Results Available","Epidermolysis Bullosa Dystrophica, Recessive","Biological: mesenchymal stem cells derived from bone marrow (BM-MSCs)","Safety evaluation: Incidence of Treatment-Emergent Adverse Events as assessed by protocol.|Cutaneous mechanical resistance|Skin surface affected|Number of blisters|Non-specific general markers of systemic inflammation: white blood cell count|Non-specific general markers of systemic inflammation: Negative acute phase reactant (albumin)|Non-specific general markers of systemic inflammation: Negative acute phase reactants (pre-albumin, transferrin and retinol-binding protein)|Non-specific general markers of systemic inflammation: Positive acute phase reactants (c-reactive protein and fibrinogen)|Non-specific general markers of systemic inflammation: Positive acute phase reactants (ferritin)|Severity index according to ""The Birmingham Epidermolysis Bullosa Severity Score"" before and after treatment|Severity index according to ""The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) before and after treatment|Expression of Collagen VII (C7) in skin biopsy|Analysis of anchoring fibrils|Variation of pain respect to baseline status: Visual Analog Scale|Modification in itching perceived|Change in quality of life of patient: European Quality of Life-5 Dimensions-5 level (EUROQL-5D)|Evaluation of circulating anti-C7 antibodies|Change in general condition of the patient","Instituto de Investigación Hospital Universitario La Paz|Universidad Carlos III Madrid (TERMeG)|St John's Institute of Dermatology Kings College London|Instituto de Salud Carlos III|DEBRA|CIBER Enfermedades raras","All","12 Months to 18 Years   (Child, Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MesenSistem-EB","May 17, 2018","March 2021","March 2021","November 6, 2019",,"November 8, 2019","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04153630"
420,"NCT00447460","Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell",,"Unknown status","No Results Available","Graft-vs-Host Disease (GVHD)","Procedure: Mesenchymal stem cell (MSC)","Determine the safety/efficacy of expanded in-vitro allogenic mesenchymal stem cell infusion in patients developing a GVHD refractory to the usual therapeutic measures after undergoing an allogeneic hematopoietic stem cell transplant.|Efficacy will be evaluated in terms of GVHD response.|Safety will be evaluated in terms of incidence of adverse events and toxicities related to the administration of MSC.|Evaluation of infectious complications after MSC infusion.|Analyse the influence of MSC infusion on the posttransplant relapse risk of the base disease.|Study the influence of MSC infusion on DFS and OS.|Determine MSC grafted into the bone marrow (or in other organs).","University of Salamanca|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/EICH2005|EudraCT Number: 2005-003674-14","January 2007",,"August 2009","March 14, 2007",,"March 22, 2007","University Clinic of Navarra, Navarra, Pamplona, Spain|Santa Creu i Sant Pau Hospital, Barcelona, Spain|Clinic i Provincial Hospital, Barcelona, Spain|University Hospital of Salamanca, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT00447460"
421,"NCT01547091","Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis","RA","Unknown status","No Results Available","Rheumatoid Arthritis","Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|Biological: UC-MSC+DMARDS","Safety of MSC treatment.|RA Serology|Disease Activity Score (DAS 28) Index Mean Change From Baseline|Patient's assessment of pain.","Alliancells Bioscience Corporation Limited","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Alliancells-1","April 2013","October 2014","December 2014","March 7, 2012",,"June 27, 2013","The 323 Hospital of Chinese People's Liberation Army, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT01547091"
422,"NCT04421274","Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction","Bmmsct","Completed","No Results Available","Myocardial Infarction","Biological: Bone marrow mesenchymal stem cells transfer|Drug: Best medical treatment|Procedure: Percutaneous coronary intervention","changes in myocardial metabolic activity|Changes in left ventricular ejection fraction (LVEF)|incidence of cardiovascular events|overall mortality|adverse events at 12 months after transplantation of autologous BM-MSCs","Afﬁliated Hospital of North Sichuan Medical College|Chinese PLA General Hospital|Peking Union Medical College Hospital|Beijing Tongren Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ScPHFPC-100306","May 1, 2008","July 10, 2010","July 15, 2011","June 9, 2020",,"June 9, 2020","The Third Hospital of Mianyang, Mianyang, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04421274"
423,"NCT02467387","A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure",,"Completed","Has Results","Non-Ischemic Heart Failure","Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Drug: Lactated Ringer's Solution","Safety Will be Evaluated by Number of AE|Change in LVEF From Baseline to Day 90 Post-initial Infusion.","CardioCell LLC|Stemedica Cell Technologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STEM-104-M-CHF","June 1, 2014","May 11, 2017","May 11, 2017","June 10, 2015","January 7, 2020","January 7, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Centers for Heart Failure Therapy, Chicago, Illinois, United States|Stony Brook Heart Institute, Stony Brook, New York, United States|Hospital of the University of Pennsylvania, Heart Failure and Transplant Program, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02467387/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02467387"
424,"NCT03173638","Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy","NEUROSTEM","Active, not recruiting","No Results Available","Non Arteritic Ischemic Optic Neuropathy","Procedure: intravitreal injection of MSV","Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale|Adverse events procedure-related (intravitreal injection)","Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA|University of Valladolid","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IOBA01-2016|2016-003029-40","March 23, 2018","April 2022","December 2022","June 2, 2017",,"April 6, 2021","IOBA - Applied Ophthalmobiology Institute, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT03173638"
425,"NCT00420134","Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial",,"Completed","No Results Available","Liver Failure|Cirrhosis","Procedure: injection of progenitor of hepatocyte drived from Mesenchymal stem cell","Liver function test|MELD score|Cirrhosis mortality after 6 months","Shahid Beheshti University of Medical Sciences|Tarbiat Modarres University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","348","February 2006","May 2009","June 2009","January 9, 2007",,"September 17, 2009","Research Center for Gastroenterology and Liver Diseases, Tehran, Iran, Islamic Republic of|Research center of Gastroenterology and Liver Disease, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00420134"
426,"NCT03378063","Stem Cells for Bronchopulmonary Dysplasia",,"Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: transplantation of mesenchymal stem cell|Drug: no transplantation of mesenchymal stem cell","death|Bayley Scales of Infant Development","Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Children's Hospital of Chongqing Medical University|Chongqing Maternal and Child Health Hospital","All","1 Month to 3 Months   (Child)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","stem cell for BPD","November 1, 2017","December 30, 2022","December 30, 2022","December 19, 2017",,"February 16, 2021","Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03378063"
427,"NCT03798353","Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue","PERISCOPE","Active, not recruiting","No Results Available","Myocardial Infarction","Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|Procedure: Surgery by sternotomy","Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation.|Death rate or rehospitalization due to cardiovascular causes|Rate of relevant arrhythmias in Holter of 24 hours|Relevant changes in N-terminal B-type natriuretic peptide (NT-proBNP) and High sensitivity troponin I (hsTnI) levels|Changes in the necrotic myocardial mass ratio|Changes of regional contractility|Changes in ejection fraction of the left ventricle|changes in left and right ventricular geometric remodeling|Changes in the score on the quality of life test Short Form 36 Healthy Survey (SF-36).|Changes in the score on the quality of life Kansas City Cardiomyopathy Questionnaire (KCCQ) test in cases of participants with heart failure will be used.","Fundació Institut Germans Trias i Pujol|Germans Trias i Pujol Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ICOR-2016-02|2018-001964-49","May 13, 2019","September 2022","September 2022","January 9, 2019",,"October 5, 2021","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03798353"
428,"NCT03800810","Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord Blood for Osteoarthritis Management",,"Unknown status","No Results Available","Osteoarthritis, Knee","Drug: Hyaluronic Acid|Biological: Umbilical Cord Mesenchymal Stem Cell|Biological: Recombinant Human Somatropin","Cartilage T2 map score|IKDC score|WOMAC score|VAS score","Indonesia University","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISMMSCOA","May 2015","May 2019","May 2019","January 11, 2019",,"January 23, 2019","Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT03800810"
429,"NCT04315025","Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa","RP","Completed","No Results Available","Retinitis Pigmentosa","Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Biological: Conditioned Medium (CM)","Visual Acuity Test|Visual Field Test|Funduscopy|Electrorectinography|Optical Coherence Tomography (OCT)|Angiography","PT. Prodia Stem Cell Indonesia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CT/RP/02/2018","October 7, 2018","June 20, 2019","September 20, 2019","March 19, 2020",,"June 4, 2020","Jakarta Eye Center Hospital, Jakarta, DKI Jakarta, Indonesia|Sardjito Hospital, Yogyakarta, Special Region, Indonesia",,"https://ClinicalTrials.gov/show/NCT04315025"
430,"NCT04056819","Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction",,"Recruiting","No Results Available","Acute Myocardial Infarction","Biological: Allogeneic umbilical cord mesenchymal stem cells","Incidence of Treatment emergent adverse event (TEAE) as presented by MedDRA coding system|Incidence of Serious adverse event (SAE) as presented by MedDRA coding system|Incidence of Suspected and unexpected serious adverse reaction (SUSAR) as presented by MedDRA coding system|New York Heart Association (NYHA) Classification|Incidence of major adverse cardiovascular events (MACE)|Serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)|Pulmonary function test|12-lead ECG Test|Cardiac MRI (cMRI) for baseline and efficacy evaluation","Ever Supreme Bio Technology Co., Ltd.","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ES-CMSC01-A1101","May 29, 2020","June 2022","December 2022","August 14, 2019",,"February 3, 2021","China Medical University Hospital, Taichung, Non-US, Taiwan",,"https://ClinicalTrials.gov/show/NCT04056819"
431,"NCT02408432","Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines",,"Active, not recruiting","No Results Available","Cardiomyopathy|Heart Failure","Biological: Mesenchymal Stem Cell Transplantation|Drug: Standard of Care for Heart Failure","Adverse Events of Allogeneic Human Mesenchymal Stem Cells (hMSCs) Determined by CTCAE version 4|Change in Left Ventricular Ejection Fraction (LVEF)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0519|NCI-2015-00969|P30CA016672","January 11, 2016","January 31, 2023","January 31, 2023","April 3, 2015",,"November 22, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02408432"
432,"NCT04522986","An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection","COVID-19","Completed","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Biological: Mesenchymal stem cell","Safety: Adverse Event","Rohto Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADR-001-1919","August 21, 2020","February 2, 2021","February 2, 2021","August 21, 2020",,"March 18, 2021","Osaka University Hospital, Suita, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT04522986"
433,"NCT02688049","NeuroRegen Scaffold™ Combined With Stem Cells for Chronic Spinal Cord Injury Repair",,"Enrolling by invitation","No Results Available","Spinal Cord Injury","Biological: NeuroRegen scaffold/mesenchymal stem cells transplantation|Biological: NeuroRegen scaffold/neural stem cells transplantation","Improvements in ASIA (American Spinal Injury Association) Impairment Scale|Improvements in Somatosensory Evoked Potentials (SSEP)|Improvements in Motor Evoked Potentials (MEP)|Improvements in Independence Measures|Changes at the transplantation site in spinal cord by Magnetic Resonance Imaging (MRI)|Improvements in Urinary and Bowel Function|Safety and Tolerability assessed by Adverse Events","Chinese Academy of Sciences|Affiliated Hospital of Logistics University of CAPF","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-MNSCI/IGDB","January 2016","December 2021","December 2021","February 23, 2016",,"December 23, 2020","Affiliated Hospital of Logistics Universtiy of CAPF, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02688049"
434,"NCT01302015","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease",,"Completed","No Results Available","Buerger's Disease","Biological: RNL-Vascostem®","Treadmill Walking Distance|VAS(Visual Analog Scale)|Toe-Brachial Pressure Index, TBPI|Transcutaneous oxygen pressure, TcPO2|Arterial Brachial Pressure Index, ABPI|Pain Free Walking Distance, PFWD|Angiography|Laser Doppler|dose and frequency in use of a analgesic medicine|Safety Evaluation","R-Bio","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vascostem","December 2007","December 2013","December 2013","February 23, 2011",,"June 5, 2019","Seoul St. Mary's Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01302015"
435,"NCT00957931","Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs",,"Completed","Has Results","Sickle Cell Disease|Thalassemia|Diamond-Blackfan Anemia","Procedure: Bone marrow transplantation|Biological: Mesenchymal Stromal Cells","Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)|Overall Survival 6 Months Following HCT|Overall Survival 1 Year Following HCT|Count of Participants With Disease-free Survival 6 Months Following HCT|Count of Participants With Disease-free Survival 1 Year Following HCT","Stanford University|University of Minnesota|University of Alabama at Birmingham","All","1 Year to 25 Years   (Child, Adult)","Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC01","March 2009","August 2013","August 2013","August 13, 2009","August 6, 2018","August 6, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00957931"
436,"NCT04657458","Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS",,"Available","No Results Available","Covid19|ARDS|Hypoxia|Cytokine Storm","Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment",,"Direct Biologics, LLC","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"DB-EAP-001",,,,"December 8, 2020",,"July 12, 2021",,,"https://ClinicalTrials.gov/show/NCT04657458"
437,"NCT03945487","Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis",,"Recruiting","No Results Available","Decompensated Liver Cirrhosis","Biological: umbilical cord-derived mesenchymal stem cell|Other: Comprehensive treatment","Liver function|The incidence of serious complications|The incidence of adverse events|Disease-free survival time|Incidence of hepatocellular carcinoma (HCC) events","Beijing 302 Hospital","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Beijing302-011","May 20, 2019","December 30, 2021","December 30, 2023","May 10, 2019",,"May 10, 2019","Beijing 302 Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03945487"
438,"NCT04093336","Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients",,"Recruiting","No Results Available","Infarction, Middle Cerebral Artery|Infarction, Anterior Cerebral Artery|Cerebral Infarction|Stroke, Ischemic|Acute Stroke|Brain Infarction|Infarction, PCA|Infarction, Posterior Circulation, Brain","Biological: human umbilical cord mesenchymal stem cells|Biological: Placebo|Other: standardized treatment","adverse events|the National Institutes of Health Stroke Scale (NIHSS) of 3 months|the Barthel index (BI) of 3 months","Shanghai East Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018-DFSC-002（V3）","January 13, 2019","April 30, 2024","August 31, 2024","September 18, 2019",,"October 28, 2021","Gang Li, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04093336"
439,"NCT01549665","Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease","GVHD-MSC","Unknown status","No Results Available","Graft-Versus-Host Disease|GVHD|Allogeneic Hematopoietic Transplant|Disorder Related to Transplantation","Biological: Human umbilical cord blood-derived mesenchymal stem cells","Safety of UCB-MSC in SR-GVHD|Complete, Partial Response Rate at 28 and 180 Days in participants with SR-GVHD treated with UCB-MSC","Samsung Medical Center|Medipost Co Ltd.","All","up to 30 Years   (Child, Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CR-008","January 2012","December 2012","December 2012","March 9, 2012",,"March 16, 2012","Department of Pediatrics, Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01549665"
440,"NCT01606215","Stem Cells in Rapidly Evolving Active Multiple Sclerosis","STREAMS","Completed","No Results Available","Multiple Sclerosis","Drug: Mesenchymal stem cells|Drug: Placebo","Frequency, Timing and Severity of Adverse events in MSC and placebo groups as Assessed by CTCAE v4.0|Total number of GELs at weeks 4, 12 and 24 after MSC therapy|contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.|Comparison of contrast enhancing lesions between treatment periods|Combined unique MRI activity|Relapses|Progression of disability|Disease free patients|MSFC score|peripheral immune responses|Type 4 hypersensitivity reaction","Imperial College London","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRO1959|13HH0228","January 2013","August 2019","August 2019","May 25, 2012",,"August 9, 2019","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01606215"
441,"NCT04014166","Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia",,"Recruiting","No Results Available","Thrombocytopenia|Mesenchymal Stem Cells","Other: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)","Changes of the platelet counts after hUC-MSCs infusion|Incidence of adverse events after hUC-MSCs infusion|Changes in virus safety indicators after hUC-MSCs infusion|Changes of concentration of hUC-MSCs in peripheral blood|Changes of antibody production of hUC-MSCs in peripheral blood|Changes of immune function in refractory ITP patients after hUC-MSCs infusion","Institute of Hematology & Blood Diseases Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC2019002-EC-1","November 21, 2019","December 31, 2021","December 31, 2022","July 10, 2019",,"July 1, 2021","Yunfei Chen, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04014166"
442,"NCT04592640","Stem Cells for Uremic Calciphylaxis Patients",,"Active, not recruiting","No Results Available","Chronic Kidney Diseases|Calciphylaxis|Calcific Uremic Arteriolopathy|Treatment","Other: Human amniotic mesenchymal stem cells","Wound Healing|Wound Pain|Measured Quality of Life|Systemic Infection|Survival State","Ningning Wang|The First Affiliated Hospital with Nanjing Medical University","All","18 Years to 60 Years   (Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Stem cell","September 17, 2018","September 17, 2022","September 17, 2022","October 19, 2020",,"December 11, 2020","The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04592640"
443,"NCT02334878","Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence",,"Completed","No Results Available","Urinary Incontinence, Stress","Biological: Stem Cells,Mesenchymal|Procedure: surgery (TVT)","change in cough test & urodynamic study as a measure of efficacy of treatment|Quality of life as measured by the Incontinence Quality of Life (I-QOL) Instrument Score","Ain Shams Maternity Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU 3098/2014","October 1, 2015","October 30, 2016","December 1, 2016","January 8, 2015",,"September 11, 2017","Maternity hospital, Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02334878"
444,"NCT01374854","Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: Umbilical mesenchymal stem cell (UC-MSCs) infusion|Drug: traditional therapy","c-peptide area under the curve during OGTT|The incidence and severity of adverse events related to the stem cell infusion procedure|The reduction in fasting blood glucose (FBG)|The increase in basal C-peptide|The reduction in exogenous insulin requirements|Decrease in HbA1c|insulin area under the curve during OGTT","Fuzhou General Hospital","All","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-T1DM","January 2009","December 2010","December 2014","June 16, 2011",,"November 20, 2012","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT01374854"
445,"NCT02065245","AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery","CRATUS","Completed","Has Results","Frailty","Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Biological: Placebo|Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)","Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)|Change in Frailty as Assessed by CHAMPS Questionnaire|Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test|Change in Slowing of Mobility as Measured by SPPB|Change in Weight|Change in Diminished Hand Grip Strength|Change in Exhaustion as Measured by the MFI Questionnaire|Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire|Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.|Change in Sense of Smell as Measured by UPSIT|Death|Change in Ejection Fraction (EF)|Change in Inflammatory Markers Levels|Change in Inflammatory Markers|Change in Inflammatory Marker D-dimer Levels","Longeveron Inc.|The Emmes Company, LLC","All","60 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20130646","March 3, 2014","October 2, 2019","October 2, 2020","February 17, 2014","April 27, 2021","July 14, 2021","ISCI/University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02065245/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02065245"
446,"NCT04061746","Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: Mesenchymal Stem Cells (MSCs)|Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)","12 month Change in C-peptide area under the curve after a 2-hour MMTT|6 Month Change in C-Peptide area under the curve after a 2-hour MMTT|6 Month peak C-peptide after a 2-hour MMTT|1 year peak C-peptide after a 2-hour MMTT|Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","12 Years to 30 Years   (Child, Adult)","Phase 1","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00085542|R01DK118529-01A1","February 13, 2020","July 1, 2023","July 1, 2023","August 20, 2019",,"March 8, 2021","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04061746"
447,"NCT02646007","Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation(BM-MSC) for Kienbock's Disease",,"Unknown status","No Results Available","Kienböck's Disease","Biological: BM-MSC transplantation","Pain|Bone density|Quality of life evaluated by Visual Analogue Score (VAS)|Infection: Presence of any sign or symptoms of infection|Cyst formation: Presence of any cyst or mass formation","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-014","November 2015","November 2018","December 2018","January 5, 2016",,"July 20, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02646007"
448,"NCT03361631","Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes","MESERIC","Unknown status","No Results Available","Erectile Dysfunction|Stem Cells|Diabetes Mellitus, Type 1","Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells","To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the clinical score IIEF-5 (International Index of Erectile Function-5)|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the EHS score|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of arterial insufficiency|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of venous insufficiency (venous leakage)|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the number of bone marrow extraction|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the bone marrow samples|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the cell culture of the marrow of diabetic patients|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the cell transport delay (between preparation and injection)|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the patient recruitment rate calculated by the ratio between the number of participants and the number of eligible patients|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved","Central Hospital, Nancy, France","Male","18 Years to 50 Years   (Adult)","Phase 1","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRCI2016/MESERIC-EL OSTA/NK","June 30, 2018","July 30, 2018","December 31, 2019","December 5, 2017",,"December 5, 2017",,,"https://ClinicalTrials.gov/show/NCT03361631"
449,"NCT02218437","Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）","MSC-SAA","Unknown status","No Results Available","Complications of Organ Transplant Stem Cells Umbilical Cord","Drug: MSC+ATG","The response and complete remission rate with different doses of Umbilical Cord Derived MSC to treat child with SAA|The relapse rate with different doses of MSC to treat child with SAA","Chinese Academy of Medical Sciences","All","1 Month to 18 Years   (Child, Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-2014-SAA-1|H0806-MSC-2014","October 2013","October 2015","October 2015","August 18, 2014",,"August 18, 2014","Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02218437"
450,"NCT03869229","Adipose-derived Mesenchymal Stem Cells in Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis|Hip Osteoarthritis|Glenohumeral Osteoarthritis|Osteoarthritis","Biological: Intra-articular injection of ADMSC","HIP DISABILITY AND OSTEOARTHRITIS OUTCOME SCORE (HOOS)|Harris Hip Score|Knee injury and Osteoarthritis Outcome Score (KOOS)|modified Harris Hip Score for knee|The International Knee Documentation Committee (IKDC Questionnaire)|WOMAC (for hip and knee)|Disability of Arm, Shoulder and Hand [DASH]|The Constant-Murley score (CMS)|Visual Analog Scale (VAS)|Nature, incidence and severity of adverse events (AEs)|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Inflammation monitoring","Medical University of Warsaw","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002/LIFE/2019","April 5, 2019","March 1, 2020","March 20, 2022","March 11, 2019",,"April 9, 2019","Life Clinic, Warsaw, Mazovian, Poland",,"https://ClinicalTrials.gov/show/NCT03869229"
451,"NCT02068794","MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer",,"Recruiting","No Results Available","Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Malignant Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma","Other: Laboratory Biomarker Analysis|Procedure: Mesenchymal Stem Cell Transplantation|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter","Maximum tolerated dose (MTD) (Phase I)|Number and severity of adverse events (Phase I)|Overall toxicity incidence (Phase I)|Toxicity profiles by dose level and patient (Phase I)|Proportion of patients alive at 12 months (Phase II)|Tumor response (Phase II)|Rate of progression free survival (Phase II)|Overall survival (Phase II)|Progression free survival (Phase II)|Maximum grade for each type of toxicity (Phase II)","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","57","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1266|NCI-2014-00016|P30CA015083|P50CA136393|P50CA083639","March 31, 2014","March 1, 2022","March 1, 2022","February 21, 2014",,"April 8, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02068794"
452,"NCT01484574","A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease",,"Completed","No Results Available","Critical Limb Ischemia|Buerger's Disease","Biological: Allogeneic Mesenchymal Stem Cells","Relief of the rest pain|Healing of ulcerations or reduction of ulcer area in the target limb|Pain free walking distance|Major amputation free survival|Ankle brachial pressure index (ABPI) - measured by Doppler|Increase in transcutaneous partial oxygen pressure (TcPO2)|Quality of life by King's College VascuQOL questionnaire|Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)|The type of adverse events AE(s), number of AE(s) and proportion of patients with AE(s).|Assessment of clinical laboratory parameters|Physical examination findings and assessment of vital signs|Assessment of electrocardiogram (ECG) parameters","Stempeutics Research Pvt Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRPL/CLI/10-11/001","January 2012","February 2014","March 2016","December 2, 2011",,"September 13, 2016","Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, Delhi, India|Division of Peripheral Vascular and Endovascular Sciences, Medanta - The Medicity, Gurgaon, Haryana, India|Department of Vascular and Endovascular Surgery, M. S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India|Peripheral Vascular Surgery, Sri Jayadeva Institute of Cardiovascular Sciences & Research, Bangalore, Karnataka, India|Department of Surgery, KMC, Mangalore, Mangalore, Karnataka, India|Department of Vascular Surgery, Madras Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, Sri Ramchandra Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, Stanley Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, AMRI Hospital, Kolkata, West Bengal, India|Nightingale Hospital, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT01484574"
453,"NCT01378182","Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis",,"Completed","No Results Available","Wilson's Disease","Genetic: allogeneic mesenchymal stem cell transplantation","differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies","Murat Kantarcioglu|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110S153","April 2011","March 2013","December 2014","June 22, 2011",,"December 31, 2014","Department of Gastroenterology; Gulhane Military Medical Academy, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT01378182"
454,"NCT02643823","Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis",,"Unknown status","No Results Available","Rheumatoid Arthritis","Biological: hUC-MSC + DMARDs|Drug: DMARDs","Severity of adverse events|RA Serology|Disease Activity Score (DAS 28) Index","Shenzhen Hornetcorn Bio-technology Company, LTD|Futian People's Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYK-Rheumatoid Arthritis","January 2016","January 2017","June 2017","December 31, 2015",,"May 24, 2016","The Fourth People's Hospital of Shenzhen, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02643823"
455,"NCT03014219","Phase 1 Crohn's Pediatric Sub-study of MSC AFP",,"Withdrawn","No Results Available","Perianal Fistula","Drug: Only 1 arm: treatment with MSC-AFP","Number of Subjects with any Adverse Events that are related to study drug|Number of Subjects with healing in response to the study drug treatment","William A. Faubion, M.D.|Mayo Clinic","All","12 Years to 17 Years   (Child)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-005574","July 2017","July 2019","July 2020","January 9, 2017",,"July 6, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03014219"
456,"NCT02943889","Stem Cell Transplantation in Cirrhotic Patients",,"Unknown status","No Results Available","Liver Cirrhosis","Biological: Mesenchymal stem cell transplantation","Improvement of liver function in form of improvement in child score|Postpone or to overcome liver transplantation complications","Assiut University","All","Child, Adult, Older Adult","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCT-LC","October 2016","June 2017","August 2017","October 25, 2016",,"October 25, 2016",,,"https://ClinicalTrials.gov/show/NCT02943889"
457,"NCT02625246","Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis","CELEB","Completed","No Results Available","Bronchiectasis","Biological: hMSCs","Number of Participant with treatment emergent serious adverse events|Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum|rate of decline of lung function|frequency of acute exacerbations|reported dyspnea and quality of life assessment|death from any cause","Marilyn Glassberg|University of Miami","All","30 Years to 87 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150627","February 4, 2016","May 15, 2019","May 15, 2019","December 9, 2015",,"August 28, 2019","University of Miami Hospitals & Clinics, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02625246"
458,"NCT00823316","Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation",,"Completed","No Results Available","Acute Leukemia","Biological: Human umbilical cord blood-derived mesenchymal stem cells","- Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate|- AGVHD grade","Medipost Co Ltd.","All","2 Years to 19 Years   (Child, Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CR-MSC003","August 2008","February 2010","February 2010","January 15, 2009",,"April 23, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00823316"
459,"NCT04314687","Stem Cell and Conditioned Medium for Cerebral Palsy",,"Recruiting","No Results Available","Cerebral Palsy","Biological: Umbilical Cord Mesenchymal Stem Cells|Biological: Conditioned Medium|Other: Standard Therapy","Gross Motor Function|Cognitive Function|Chemical Marker","PT. Prodia Stem Cell Indonesia","All","6 Months to 3 Years   (Child)","Phase 1|Phase 2","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CT/CP/02/2020","June 25, 2020","September 25, 2020","December 25, 2020","March 19, 2020",,"June 4, 2020","Indonesian National Brain Center, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04314687"
460,"NCT00250302","Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures",,"Completed","No Results Available","Tibial Fracture","Procedure: autologous mesenchymal stem cells implantation","Safety|Number of patients reaching clinical union of fracture","Hadassah Medical Organization|Teva Branded Pharmaceutical Products R&D, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-01-HMO-CTIL","April 2009","April 2011","April 2011","November 8, 2005",,"April 28, 2011","Hadassah Medical Organizaton, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00250302"
461,"NCT03726255","Stem Cell Therapy: a Compassionate Use Program in Perianal Fistula","RESCeCUF","Completed","No Results Available","Perianal Fistula","Procedure: Mesenchymal Stem Cell injection","Number of patients with fistula healed|Number of adversus events","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","24 Years to 70 Years   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EO166-18_FJD","April 1, 2014","January 26, 2018","July 26, 2018","October 31, 2018",,"November 13, 2018","Instituto Investigación Sanitario Fundación Jiménez Díaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03726255"
462,"NCT01700920","PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells","CSM/ON/2011","Completed","No Results Available","Osteonecrosis of the Femoral Head","Procedure: bone marrow aspirate",,"Red de Terapia Celular|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","3","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/ON/2011","July 2012","December 2015","December 2015","October 4, 2012",,"March 30, 2017","University Hospital of Salamanca, Salamanca, Castilla y León, Spain",,"https://ClinicalTrials.gov/show/NCT01700920"
463,"NCT04315987","NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","HOPE","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: NestaCell®|Biological: Placebo","Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 / FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles;","Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HOPE","June 2020","August 2020","August 2020","March 20, 2020",,"June 9, 2020","Hospital Vera Cruz, Campinas, São Paulo, Brazil|Hospital de Barueri, São Paulo, Brazil|IncCOR, São Paulo, Brazil|UNIFESP, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04315987"
464,"NCT02462330","Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)","MESAMI2","Recruiting","No Results Available","Chronic Myocardial Ischemia","Drug: Autologous MSC from bone marrow|Drug: Placebo comparator","Change in VO2max|Left ventricular viability|NYHA/CCS class|Quality of life (Minnesota questionnaire)|VO2 max|6'walking-test|Echocardiography|Myocardial perfusion imaging|BNP blood test","University Hospital, Toulouse","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10 142 01","February 19, 2016","December 2022","December 2022","June 4, 2015",,"October 28, 2021","University hospital of Henri Mondor, Créteil, France|University hospital of Grenoble, Grenoble, France|University hospital of Lille, Lille, France|University hospital of Nantes, Nantes, France|University hospital of Pitié-Salpêtrière, Paris, France|Cardiology Department of Rangueil Hospital - Rangueil Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02462330"
465,"NCT03751735","Efficacy of Wharton Jelly in Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction Associated With Type 2 Diabetes Mellitus","Biological: Wharton Jelly Mesenchymal stem cells","Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography.|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires","Sophia Al-Adwan|University of Jordan","Male","25 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WJEF.EDUJCTC","January 27, 2017","January 13, 2019","February 26, 2019","November 23, 2018",,"April 10, 2019","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03751735"
466,"NCT00752479","Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance",,"Terminated","No Results Available","Kidney Transplant","Biological: Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|Drug: Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil","Assessing the percentage of inhibition of memory T cell response and/or naive T cell response, the induction of donor-reactive T cell anergy and the appearance in the peripheral blood of regulatory T cells.|Safety parameters related to MSC infusion, graft function, graft rejection","Mario Negri Institute for Pharmacological Research","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","MSC TX|2009-012350-20","May 2008","July 2013","December 2013","September 15, 2008",,"April 9, 2015","Nephrology Unit, Bergamo, BG, Italy",,"https://ClinicalTrials.gov/show/NCT00752479"
467,"NCT03437759","MSC-Exos Promote Healing of MHs","MSCs","Active, not recruiting","No Results Available","Macular Holes","Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)","Macular holes closure|Best corrected visual acuity(BCVA)","Tianjin Medical University","All","up to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2015KY-05","March 1, 2017","May 30, 2018","December 30, 2021","February 19, 2018",,"April 6, 2021","Tianjin Medical University Hospital, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT03437759"
468,"NCT04326959","Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid","Keloid","Not yet recruiting","No Results Available","Keloid","Biological: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Biological: Conditioned Medium|Biological: Triamcinolone Acetonide","Alfa SMA-1|Collagen type 1|Core Biopsy/Histopathology|Ultrasonography","PT. Prodia Stem Cell Indonesia","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/KLD/03/2020","September 1, 2020","September 8, 2020","December 1, 2020","March 30, 2020",,"July 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04326959"
469,"NCT04340609","Stem Cell in Acute Myocardial Infarction","AMI","Recruiting","No Results Available","Acute Myocardial Infarction","Biological: Mesenchymal Stem Cells","Major adverse cardiac events (MACE) endpoints of mortality|Re-infarction|Target vessel revascularization (TVR)|Heart failure hospitalization|Cardiac MRI|Echocardiography|Electrocardiography (ECG)|Wellness Parameter|Laboratory Assessment","PT. Prodia Stem Cell Indonesia","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/AMI/01/2019","March 11, 2019","October 11, 2020","March 11, 2021","April 9, 2020",,"June 4, 2020","PT Prodia StemCell Indonesia, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04340609"
470,"NCT04064879","The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine",,"Suspended","No Results Available","Chronic Migraine, Headache","Other: AD-SVF","Adverse Event Reporting|Headache Diary|Headache Impact Test (HIT-6)","Neurological Associates of West Los Angeles|Cell Surgical Network Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICSS-2018-014","August 16, 2018","August 15, 2022","August 16, 2023","August 22, 2019",,"March 4, 2021","Neurological Associates of West Los Angeles, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04064879"
471,"NCT00587990","Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)","PROMETHEUS","Terminated","Has Results","Stem Cell Transplantation|Ventricular Dysfunction, Left","Biological: Lower dose mesenchymal stem cell (MSC) injection|Genetic: Placebo|Biological: Higher dose MSC injection","Number of Patients With Serious Adverse Events|Change in Infarct Scar Size (ISS) Over 18 Month Period|Left Ventricular Function (LVF) in Region of MSC Injection|Regional Left Ventricular Wall Thickening|Left Ventricular End Diastolic Wall Thickness|Change in Left Ventricular End Diastolic and Systolic Volume|Change in Left Ventricular Ejection Fraction|Change in Peak Volume Oxygen|Change in Six Minute Walk Test|Change in NYHA Functional Class|Minnesota Living With Heart Failure Questionnaire Scores|Incidence of Major Adverse Cardiac Events (MACE)|Number of Participants With Abnormal 48-Hour Ambulatory ECG Recordings|Change in Pulmonary Function|Serial Troponin Values (ng/mL)|Creatinine Kinase - Muscle/Brain (MB) (ng/mL)|Number of Clinically Significant Laboratory Values|Rate of Treatment Emergent Adverse Events|Number of Abnormal Echocardiogram Readings 2 Days Post CABG.","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|Johns Hopkins University Specialized Center for Cell Based Therapy|The Emmes Company, LLC|University of Miami","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20070598|U54HL081028","November 2007","June 2011","June 2011","January 8, 2008","April 2, 2015","September 10, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00587990"
472,"NCT03169231","Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty",,"Active, not recruiting","No Results Available","Aging Frailty","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo","Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo|Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo|Change in TNF-alpha compared to placebo","Longeveron Inc.","All","70 Years to 85 Years   (Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","001-03","July 6, 2017","April 30, 2021","September 2021","May 30, 2017",,"August 16, 2021","Soffer Health Institute, Aventura, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami VA Healthcare System, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Advanced Research for Health Improvement, LLC, Naples, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03169231"
473,"NCT04869761","Stem Cell Therapy for Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Diseases|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Diabetes Mellitus|Diabetic Nephropathies","Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions","Adverse events and/or serious adverse events","LaTonya J. Hickson|Mayo Clinic","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-008380","October 7, 2021","December 2026","May 2027","May 3, 2021",,"November 4, 2021","Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04869761"
474,"NCT02513238","Mesenchymal Stemcells for Radiation Induced Xerostomia","MESRIX","Completed","No Results Available","Xerostomia","Drug: Mesenchymal stem cell|Drug: Isotonic NaCl","Number of Participants with Adverse Events as a Measure of Safety|Change in whole saliva production|Subjective complaints of xerostomia|Change in volume and vascularisation - MRI of glands - composite|MRI - Change in fibrosis|histological sections - gland tissue - composite|histological sections - fibrosus|histological sections - vascularisation","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1406653","August 8, 2015","April 6, 2017","April 6, 2017","July 31, 2015",,"August 21, 2017",,,"https://ClinicalTrials.gov/show/NCT02513238"
475,"NCT00875654","Intravenous Stem Cells After Ischemic Stroke","ISIS","Completed","No Results Available","Ischemia|Stroke","Genetic: Autologous mesenchymal stem cells","feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Clinical and functional effects of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Determination of the most effective dose of stem cells|To define the best criteria for a future trial (phase III)|To define the best target population for a future study","University Hospital, Grenoble|Commissariat A L'energie Atomique|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCIC 06 25","August 2010","October 20, 2017","October 20, 2017","April 3, 2009",,"November 1, 2017","Neuroradiology/MRI, University Hospital of Grenoble, Grenoble, France|Stroke Unit, University Hospital of Grenoble, Grenoble, France|Tissular and cell therapy unit, UniversityHospitalof Grenoble, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT00875654"
476,"NCT02223897","Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary Lesions",,"Unknown status","No Results Available","Ischemic-type Biliary Lesions","Drug: huc-MSCs|Drug: Placebo","The incidence of ITBLs|Changes in biliary enzymology|Biliary blood supply","Yang Yang|Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2014006","July 2014","June 2017","June 2018","August 22, 2014",,"August 22, 2014","Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02223897"
477,"NCT04506073","Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD",,"Active, not recruiting","No Results Available","Parkinson's Disease","Drug: MSC+placebo|Drug: MSC|Drug: Placebo","Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale|Safety and tolerability as measured by serious adverse reactions.|Safety and tolerability as measured by immunologic responses.|Motor function as measured by the Timed-Up-and-Go (TUG) scale|Global measurement of disability as measured by the change in the screening ""Off"" modified Hoehn and Yahr (H&Y)|Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)|Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)|Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)|Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).|Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)|Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)|Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)|Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)|Measurement of putative paracrine mechanism of MSCs using neuroimaging|Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors|Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid","The University of Texas Health Science Center, Houston|Michael J. Fox Foundation for Parkinson's Research","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HSC-MS-20-0150","November 9, 2020","May 1, 2023","May 1, 2023","August 10, 2020",,"November 5, 2021","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04506073"
478,"NCT01678534","Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial","AMASCIS-01","Completed","No Results Available","Ischemic Stroke","Drug: Allogenic mesenchymal stem cells from adipose tissue|Drug: Placebo","Number of participants with Adverse events, complications.|Efficacy","Instituto de Investigación Hospital Universitario La Paz","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMASCIS-01/2011|2011-003551-18","September 2014","December 2017","December 2017","September 5, 2012",,"February 28, 2018","University Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01678534"
479,"NCT02108132","Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia",,"Unknown status","No Results Available","Hemophilia","Biological: Cellular therapy|Biological: cellular therapy","Assessment of Safety / Efficacy|Assessment of Coagulation Profile","Cairo University|Affiliated Hospital to Academy of Military Medical Sciences","All","6 Years to 40 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-HEM","August 2014","August 2015","February 2016","April 9, 2014",,"April 9, 2014","Military Medical Academy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02108132"
480,"NCT03321942","Treatment of Chronic Renal Failure With Adipose Tissue-derived Mesenchymal Stem Cells",,"Unknown status","No Results Available","Mesenchymal Stem Cells|Chronic Kidney Diseases|Renal Interstitial Fibrosis","Drug: Treatment group|Drug: Control group","serum creatinine|glomerular filtration rate|apparent relaxation rate","The Affiliated Hospital of Xuzhou Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XYFY2016-KL031-01","January 1, 2017","December 31, 2018","December 31, 2018","October 26, 2017",,"October 26, 2017","The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03321942"
481,"NCT04236479","Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)",,"Recruiting","No Results Available","Congenital Heart Disease (CHD)","Biological: BM-MSC","Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery.","Catherine Bollard|Children's National Research Institute","All","up to 6 Months   (Child)","Phase 1","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00011914","July 29, 2020","April 2022","April 2023","January 22, 2020",,"April 5, 2021","Children's National Health System, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04236479"
482,"NCT02706132","Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation",,"Unknown status","No Results Available","Liver Transplantation","Biological: Mesenchymal Stem Cells(MSCs)","Efficacy: one year graft survival rate|the rate of acute rejection|the rate of ischemic-type biliary lesions|safety: rate of (serious) adverse events in the study population","Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015-08","February 2014","December 2016","March 2017","March 11, 2016",,"March 11, 2016","The Third Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02706132"
483,"NCT01725698","The Combined Effect of Mesenchymal Stem Cell, HA-CaSO4,BMP-2, and Implant in Inducing The Healing of Critical-Sized Bone Defect",,"Unknown status","No Results Available","Union","Drug: Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant","RADIOGRAPHIC UNION SCALE (RUST Score) as a measure of bone union|Visual analog scale as the measure of clinical union","Indonesia University","All","17 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SCNONUNION12","November 2012","December 2014","December 2014","November 14, 2012",,"November 14, 2012","University of Indonesia, National University of Singapore, Jakarta, Singapore, Indonesia, Singapore, Indonesia",,"https://ClinicalTrials.gov/show/NCT01725698"
484,"NCT03840343","Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease",,"Recruiting","No Results Available","Diabetic Kidney Disease|Diabetic Nephropathies|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Chronic Kidney Disease|Diabetic Nephropathy Type 2|Kidney Failure|Kidney Insufficiency","Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose","Adverse Events|Kidney Function","Mayo Clinic|Regenerative Medicine Minnesota","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-002423|RMM 091718 CT 001","October 23, 2019","December 2024","December 2025","February 15, 2019",,"February 26, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03840343"
485,"NCT02564328","Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke",,"Unknown status","No Results Available","Stroke","Genetic: Intravenous stem cell transplantation","Change from baseline in Fugl-Meyer Scale at 12 months|Change from baseline in NIH Stroke Scale at 12 months|Change from baseline in Barthel Index at 12 months|Change from baseline in SSS at 12 months|Change from baseline in mRS at 12 months|Improvement of vision measured by brain visual examination","Southern Medical University, China|Second Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201400000003-2","November 2014","November 2016","November 2017","September 30, 2015",,"September 30, 2015","Xiaodan Jiang, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02564328"
486,"NCT04228666","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer Disease","Biological: HB-adMSCs","Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|Tumor necrosis factor-alpha|Interleukin-1|Interleukin-6|C-reactive protein|Amyloid beta 40|Amyloid beta 42|Volumetric changes in hippocampus, ventriculus, and whole brain|Mini Mental Status Exam|Alzheimer's disease Cooperative Study Activities of Daily Living|Quality of Life Enjoyment and Satisfaction Questionnaire|Altoida Neuro Motor Index|Clinical Dementia Rating Questionnaire","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBALZ01","March 1, 2020","February 1, 2022","February 1, 2022","January 14, 2020",,"July 7, 2021","Clinical Trial Network, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04228666"
487,"NCT02490020","A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death",,"Unknown status","No Results Available","Disorder Related to Renal Transplantation|Renal Transplant Rejection","Biological: mesenchymal stem cell","Numbers of participants enrolled into the MSC group and control group|Incident rates of BPAR and DGF after renal transplantation with MSC prevention before operation","Qipeng Sun|Zhujiang Hospital|The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine|Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 60 Years   (Adult)","Phase 1","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","zssy20150624","January 2016","December 2016","December 2018","July 3, 2015",,"July 3, 2015",,,"https://ClinicalTrials.gov/show/NCT02490020"
488,"NCT02064062","Autologous Stem Cells in Achilles Tendinopathy","ASCAT","Unknown status","No Results Available","Achilles Tendinitis, Right Leg|Achilles Tendinitis|Achilles Degeneration|Achilles Tendon Thickening|Tendinopathy|Achilles Tendinitis, Left Leg","Biological: Autologous Mesenchymal Stem Cells","The primary safety outcome will be the incidence rate of Serious Adverse Reaction (SAR).|Incidence of success|Conventional ultrasound changes from baseline|Ultrasound Tissue Characterisation (UTC) changes from baseline|Inter-observer reliability of UTC against conventional US","University College, London","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12/0419|2013-000966-12","January 2015","December 2018",,"February 17, 2014",,"May 12, 2016","Royal National Orthopaedic Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02064062"
489,"NCT02945449","Safety of Wharton Jelly in Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction Associated With Type 2 Diabetes Mellitus","Biological: Wharton Jelly Mesenchymal stem cells","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire","Sophia Al-Adwan|University of Jordan","Male","25 Years to 70 Years   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WJ.EDUJCTC","January 4, 2017","October 15, 2018","November 2018","October 26, 2016",,"November 15, 2018","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02945449"
490,"NCT03187431","Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis",,"Unknown status","No Results Available","Stem Cell Transplant Complications","Biological: autologous bone marrow mesenchymal stem cells","number of participants with treatment related side effects as infection, allergic reaction, disease acute exacerbation, and ectopic tissue formation|Post therapy diffusing capacity of CO% (DLCO)predicted|post therapy forced vital capacity (FVC)% predicted.","Assiut University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AssiutU4","December 11, 2017","October 1, 2018","December 1, 2018","June 15, 2017",,"June 15, 2017",,,"https://ClinicalTrials.gov/show/NCT03187431"
491,"NCT02776943","UCMSC Transplantation in the Treatment of Cartilage Damage",,"Unknown status","No Results Available","Cartilage Damage|Degenerative Osteoarthritis","Biological: umbilical cord mesenchymal stem cells|Device: Hyaluronic acid","Knee Function Change and Improvement|Severity of adverse events","South China Research Center for Stem Cell and Regenerative Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCMSC-4","June 2016","December 2018","June 2019","May 18, 2016",,"May 18, 2016",,,"https://ClinicalTrials.gov/show/NCT02776943"
492,"NCT04018729","Cell Therapy Associated With Endobronchial Valve","CEL&VAL","Unknown status","No Results Available","Chronic Obstructive Pulmonary Disease Severe","Device: Zephyr Endobronchial Valve|Biological: Marrow-derived mesenchymal stromal cell","All-cause death|Number of participants with worsening of dyspnea|Number of participants with respiratory functional worsening|Impairment of exercise capacity|Increased oxygen use","Hospital de Clinicas de Porto Alegre|Pontifícia Universidade Católica do Paraná|Universidade Federal do Rio de Janeiro","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2018-0327","November 4, 2019","November 30, 2019","February 28, 2021","July 12, 2019",,"October 17, 2019",,,"https://ClinicalTrials.gov/show/NCT04018729"
493,"NCT04219657","Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application",,"Completed","No Results Available","Accidental Wound|Heel Injury|Stem Cell Transplant","Biological: mesenchymal stem cell application","Ranges of Movement of ankle joint|duration of hospital stay|Weight bearing capacity of patients","King Edward Medical University","All","8 Years to 12 Years   (Child)","Phase 1","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Sushil_Rijal","October 29, 2016","December 20, 2019","December 22, 2019","January 7, 2020",,"February 17, 2020","Pediatric Surgery Department, King Edward Medical University, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04219657"
494,"NCT05094011","Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease",,"Not yet recruiting","No Results Available","Idiopathic Parkinson's Disease","Biological: Aadipose-Derived Mesenchymal Stem Cells","Grading of Adverse Events|Routine physical examinations|Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell]|Changes in vital signs: blood pressure [Safety of Mitocell]|Changes in vital signs: pulse rate [Safety of Mitocell]|Changes in vital signs: body temperature [Safety of Mitocell]|Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell]|Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell]|Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell]|Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell]|Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell]|Electrocardiogram (ECG)|Magnetic Resonance Imaging (MRI)|MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale)|Modified Hoehn & Yahr staging|18F-DOPA PET|levodopa equivalent daily dose (LEDD)|PDQ-39 (Parkinson's Disease Questionnaire)|Beck Depression Inventory (BDI-II) scores|Hamilton Depression Rating Scale (HAM-D-17) scores|Mini Mental State Examination (MMSE) Scores","Taiwan Mitochondrion Applied Technology Co., Ltd.","All","45 Years to 70 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MITOCELL-01","February 1, 2022","September 30, 2022","July 31, 2024","October 26, 2021",,"November 23, 2021",,,"https://ClinicalTrials.gov/show/NCT05094011"
495,"NCT03955497","Effectiveness of Autologous Adipose-derived Stem Cells in the Treatment of Knee Cartilage Injury",,"Recruiting","No Results Available","Knee Osteoarthritis|Cartilage Degeneration","Other: Autologous Adipose-derived Mesenchymal Stem Cell Gel|Drug: Sodium Hyaluronate|Procedure: Extraction of abdominal fat","Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Hospital for special surgery knee score postoperative 12 month|Hospital for special surgery knee score postoperative 24 month|Hospital for special surgery knee score postoperative 36 month|Visual Analogue Scale Postoperative Day 1|Visual Analogue Scale Postoperative Day 2|Visual Analogue Scale Postoperative Day 3|Visual Analogue Scale Postoperative Day 7|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Visual Analogue Scale Postoperative 12 month|Visual Analogue Scale Postoperative Day One|Visual Analogue Scale Postoperative 24 month|Visual Analogue Scale Postoperative 36 month|Evaluation of cartilage repair under MRI postoperative 12 month|Evaluation of cartilage repair under MRI postoperative 24 month|Evaluation of cartilage repair under MRI postoperative 36 month|Degree of meniscus injury under MRI postoperative 12 month|Degree of meniscus injury under MRI postoperative 24 month|Degree of meniscus injury under MRI postoperative 36 month|Evaluation of cartilage repair under arthroscope postoperative 12 month|Degree of meniscus injury under arthroscope postoperative 12 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Squatting to Standing Time postoperative 12 month|Squatting to Standing Time postoperative 24 month|Squatting to Standing Time postoperative 36 month","Qilu Hospital of Shandong University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2018023","October 1, 2018","October 1, 2022","December 1, 2022","May 20, 2019",,"September 16, 2020","Qilu hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03955497"
496,"NCT05095532","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT",,"Not yet recruiting","No Results Available","Chronic Pancreatitis|Mesenchymal Stem Cells","Biological: Bone marrow-derived mesenchymal stem cells|Other: Placebo","Change in Islet Cell Function|Change in HbA1C levels from baseline to 12 months.|Proportion of insulin-independent patients following IAT|Average daily insulin requirement|Beta cell function as assessed by beta-score","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pro00099487|R01DK126454","December 1, 2021","June 30, 2026","June 30, 2026","October 27, 2021",,"November 23, 2021",,,"https://ClinicalTrials.gov/show/NCT05095532"
497,"NCT01513694","Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease",,"Completed","No Results Available","Intervertebral Disc Disease","Procedure: Instrumented posterolateral arthrodesis",,"Red de Terapia Celular|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/Fusión/2009","January 2010","May 4, 2017","May 4, 2017","January 20, 2012",,"June 2, 2017","Trauma Service. Hospital Universitario de Salamanca, Salamanca, Castilla-León, Spain",,"https://ClinicalTrials.gov/show/NCT01513694"
498,"NCT02327832","Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs",,"Unknown status","No Results Available","Liver Regeneration","Procedure: Autologous BMSCs|Drug: bone marrow-derived mesenchymal stem cells","The incidence of adverse events|Child-Pugh score|Serum albumin levels|Serum fibrosis markers|Improvement or disappearance of lower extremity edema|Subjective symptom scores (SF-36)","Yamaguchi University Hospital","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICHINAI-BMSC1","December 2014","March 2017",,"December 30, 2014",,"December 30, 2014","Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT02327832"
499,"NCT02501811","Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure","CONCERT-HF","Completed","Has Results","Ischemic Cardiomyopathy","Biological: Mesenchymal Stem Cells (MSC)|Biological: c-kit+ cells|Biological: Placebo (Plasmalyte A)","Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Scar Size Percent (DEMRI)|Change From Baseline in Scar Tissue Mass (DEMRI)|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Scar Size Percent (DEMRI)-Trajectory|Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Participants With Major Adverse Cardiac Events (MACE)|Participants Experiencing Other Significant Clinical Events|Cumulative Days Alive and Out of Hospital for Heart Failure","The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 2","125","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-SPH-15-0413|5UM1HL087318","October 2015","June 25, 2020","July 22, 2020","July 17, 2015","April 26, 2021","April 26, 2021","Stanford University School of Medicine (Falk Cardiovascular Research Center), Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdisciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02501811"
500,"NCT01851070","A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Allogeneic Mesenchymal Precursor Cells|Drug: Normal Saline","Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion|Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA|Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA","Mesoblast, Ltd.|PPD","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSB-RA001","July 2013","May 2016","March 2017","May 10, 2013",,"June 26, 2020","Pinnacle Research Group, Anniston, Alabama, United States|Arthrocare Arthritis Care and Research PC, Gilbert, Arizona, United States|Triwest Research Associates, El Cajon, California, United States|UCLA, Los Angeles, California, United States|Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Arthritis Center, Palm Harbor, Florida, United States|Sarasota Arthritis Research Center, Sarasota, Florida, United States|McIlwain Medical Group, Tampa, Florida, United States|JHU Arthritis Center Baltimore, Baltimore, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Office of Ramesh C. Gupta, MD, Fair Lawn, New Jersey, United States|DJL Clinical Research, Charlotte, North Carolina, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Accurate Clinical Research, Houston, Texas, United States|Texas Arthritis Research Center, San Antonio, Texas, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Southern Clinical Research Pty Ltd, Hobart, Tasmania, Australia|Emeritus Research, Malvern, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01851070"
501,"NCT04371601","Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019",,"Active, not recruiting","No Results Available","COVID-19 Pneumonia","Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells","Changes of oxygenation index (PaO2/FiO2) ,blood gas test|Detection of TNF-α levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin","Fuzhou General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-CoViD-2020","March 1, 2020","December 31, 2021","December 31, 2022","May 1, 2020",,"May 1, 2020","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04371601"
502,"NCT03371329","Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage",,"Completed","No Results Available","Hemorrhagic Stroke|Intracerebral Hemorrhage","Biological: MSC","Occurrence of adverse events|Changes in neurological function test","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-003524","December 12, 2017","October 9, 2020","October 9, 2020","December 13, 2017",,"December 21, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03371329"
503,"NCT02362646","Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients",,"Completed","Has Results","Heart Failure|Cardiomyopathy|Ventricular Dysfunction","Biological: MPC Intramyocardial Injection|Drug: Control Solution","Number of Temporary Weans From LVAD Support Tolerated|Number of Participants With Adverse Events|Physiologic Assessments|Histopathological Assessments of Myocardial Tissue|Overall Survival|Change in Quality of Life (QoL)|Hopkins Verbal Learning Test|Trailmaking Tests A and B|MCG Complex Figures|Digit Span|Digit Symbol Substitution Test|Controlled Oral Word Association|Length of Stay|Hospitalizations|Hospital Costs|Functional Status","Annetine Gelijns|National Heart, Lung, and Blood Institute (NHLBI)|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 2","159","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 08-1078-0008|2U01HL088942-07","July 2015","August 10, 2018","August 23, 2019","February 13, 2015","November 26, 2019","November 26, 2019","University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Stanford, California, United States|University of Maryland, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Montefiore Einstein Heart Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor Research Institute, Plano, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Institut Universitaire de Cardiologie de Quebec (Hopital Laval), Québec City, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02362646/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02362646"
504,"NCT03724617","Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Collagen Scaffold in the Treatment of Thin Endometrium",,"Completed","No Results Available","Thin Endometrium|Intrauterine Adhesion","Drug: umbilical cord mesenchymal stem cells combined with collagen scaffold","the change of endometrial thickness|pregnancy rate|live birth rate|abortion rate","Sir Run Run Shaw Hospital","Female","20 Years to 40 Years   (Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRRSHRMC20180924","October 29, 2018","June 30, 2020","December 31, 2020","October 30, 2018",,"April 13, 2021","Sir Run Run Shaw hopital,School of medicine,Zhejiang University, Hangzhou, China",,"https://ClinicalTrials.gov/show/NCT03724617"
505,"NCT03237442","Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn",,"Unknown status","No Results Available","Ocular Corneal Burn","Biological: human umbilical cord mesenchymal stem cells|Biological: placebo","the percent of cornea perforation","Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SSCST-MSC-OCB-01","January 1, 2018","December 30, 2018","June 30, 2019","August 2, 2017",,"August 2, 2017","The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03237442"
506,"NCT04626583","Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells",,"Recruiting","No Results Available","Mesenchymal Stromal Cells|Cornea|Safety|Corneal Defect","Biological: Allogeneic MSC","Primary Safety Outcome: Incidence of treatment emergent adverse events (TEAE) assessed at 28 days.|Primary Efficacy Outcome: Proportion of participants with improvement in epithelial defect or barrier integrity relative to baseline (based on fluorescein staining)|Secondary Efficacy Outcomes: Visual Acuity|Secondary Efficacy Outcomes: Time to Completion of Corneal Epithelialization|Secondary Efficacy Outcomes: Durability of the Corneal Epithelialization and Healing|Secondary Efficacy Outcomes: Corneal stromal haze|Secondary Efficacy Outcomes: Corneal epithelial thickness","University of Illinois at Chicago|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0334|W81XWH-18-1-0661","March 5, 2021","November 30, 2021","December 30, 2023","November 12, 2020",,"July 28, 2021","University of Illinois, Department of Ophthalmology and Visual Sciences, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04626583"
507,"NCT04692376","MSC for Treatment of cGVHD After Allo-HSCT",,"Recruiting","No Results Available","Chronic Graft-versus-host Disease","Biological: Mesenchymal stem cells|Drug: Glucocorticoids|Drug: cyclosporine","ORR|OS|DFS|Response rate|EBV DNA-emia|CMV DNA-emia|PGF","Nanfang Hospital of Southern Medical University|Sun Yat-sen University|Xinqiao Hospital, Army Medical University|Peking University People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-cGVHD-2020","January 10, 2021","December 31, 2022","June 30, 2023","December 31, 2020",,"December 31, 2020","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04692376"
508,"NCT02833792","Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Dementia","Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Other: Placebo","Safety of aMBMC administration|Efficacy of aMBMC administration","Stemedica Cell Technologies, Inc.|Stemedica International SA","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STEM105-M-AD","June 2016","December 2022","June 2023","July 14, 2016",,"October 29, 2020","John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT02833792"
509,"NCT01576328","Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Drug: Mesenchymal Precursor Cells (MPCs)","Primary objective of the study is to assess the safety and tolerability of MPC therapy","Mesoblast, Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSB-DM003","April 2012","October 2013","October 2015","April 12, 2012",,"June 2, 2020","SC Clinical Research, Garden Grove, California, United States|Diabetes Research Institute, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Big Sky Clinical Research, Butte, Montana, United States|Desert Endocrinology Clinical Research Center-Henderson, Henderson, Nevada, United States|Alliance Against Diabetes/AAD Clinical Research, Las Vegas, Nevada, United States|Active Practices and Research, Newington, New Hampshire, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|Providence Health Partners - Center for Clinical Reseach, Dayton, Ohio, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|West Houston Clinical Research Services, Houston, Texas, United States|Paragon Research Center, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|National Clinical Research - Norfolk, Inc, Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Capital Clinical Research Center, Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01576328"
510,"NCT01758055","Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells (MSCs) in Emphysema Patients",,"Unknown status","No Results Available","Emphysema","Biological: Autologous MSCs transplantation","forced vital capacity( FVC), forced expiratory volume(FEV1), FEV1/FVC|six minute walk test","Arda Kiani|Royan Institute|Masih Daneshvari Hospital","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","f-91-135","December 2012","December 2013","January 2014","December 31, 2012",,"December 31, 2012","Masih-Daneshvari Hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01758055"
511,"NCT04064957","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Spinal Cord Injury",,"No longer available","No Results Available","Spinal Cord Injuries","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access:Individual Patients",,"HBSCI02",,,,"August 22, 2019",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04064957"
512,"NCT00395200","Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)","MSCIMS","Completed","No Results Available","Multiple Sclerosis","Procedure: MSC Treatment","Adverse events|Visual function (acuity and colour)|Visual evoked potential latency|Optic nerve Magnetisation Transfer Ratio|Retinal nerve fibre layer thickness (by optical coherence tomography)|Brain lesion Magnetisation Transfer Ratio|MRI brain T1 hypointensity load|Multiple Sclerosis Functional Composite Score|Expanded Kurtzke Disability Status Score","University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|Medical Research Council","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRCRG44871|REC Reference: 07/Q0108/104","July 2008","December 2010","December 2010","November 2, 2006",,"October 25, 2011","University of Cambridge Dept of Clinical Neurosciences, Cambridge, Cambridgeshire, United Kingdom|University College London Institute of Neurology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00395200"
513,"NCT03279796","Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","Rotator Cuff Tear|Lateral Epicondylitis","Biological: Autologous adipose-derived MSCs|Drug: Compound betamethasone","Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeks|Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|The Disabilities of the Arm, Shoulder and Hand(DASH) Score|Adverse events","Second Affiliated Hospital, School of Medicine, Zhejiang University|Zhejiang Xingyue Biotechnology Co., Ltd.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2017.No.55","October 1, 2018","December 31, 2019","December 31, 2021","September 12, 2017",,"April 26, 2018","Weiliang Shen, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03279796"
514,"NCT02594839","Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease",,"Completed","No Results Available","Idiopathic Interstitial Pneumonia|Interstitial Lung Disease|Idiopathic Pulmonary Fibrosis","Drug: Bone marrow mesenchymal stem cells|Drug: Placebo","Safety: Number of serious adverse events|DLCO changes from baseline|FVC changes from baseline|exercise capacity changes","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILD-01","February 2013","January 2018","January 2018","November 3, 2015",,"January 9, 2018","Federal Research Clinical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02594839"
515,"NCT04400032","Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome","CIRCA-19","Completed","No Results Available","Acute Respiratory Distress Syndrome|Covid19","Biological: Mesenchymal Stromal Cells","Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28","Ottawa Hospital Research Institute|Stem Cell Network|Ontario Research Fund","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200243-01H","May 15, 2020","April 22, 2021","April 22, 2021","May 22, 2020",,"April 26, 2021","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04400032"
516,"NCT02587715","A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS",,"Unknown status","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Other: Liberation therapy","Proportion of patients with clinical improvement in EDSS score compared to baseline|Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI|Proportion of patients with reduction in T2 lesion volume on brain MRI|Proportion of patients with reduction in brain volume on MRI|Proportion of patients with clinical improvement in MSIS score compared to baseline|Proportion of patients with clinical improvement in MSFC score compared to baseline|Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test|Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test|Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)|Proportion of patients with reduced number of relapses or freedom from progression of disease","Novo Cellular Medicine Institute LLP","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","69","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRT/NOVO/2015/001","February 2015","February 2017","February 2017","October 27, 2015",,"October 28, 2015","Novo Cellular Medicine Institute, San Fernando, Trinidad, Trinidad and Tobago",,"https://ClinicalTrials.gov/show/NCT02587715"
517,"NCT04352803","Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease",,"Not yet recruiting","No Results Available","Covid-19 Pneumonia|Cyotokine Storm","Biological: Autologous Adipose MSC's","Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate","Regeneris Medical","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-MSCIV","April 2020","April 2024","April 2026","April 20, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04352803"
518,"NCT02893306","MSC Administration for the Management of Type 1 Diabetic Patients","DMT1-MSC","Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: MSCs","Changes in insulin pancreatic reserve|Changes in insulin requirement","Universidad del Desarrollo|Clinica Alemana de Santiago","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DMT1-MSC","March 2012","March 2017","March 2017","September 8, 2016",,"September 8, 2016","Clinica Alemana de Santiago, Santiago, Region Metropolitana, Chile",,"https://ClinicalTrials.gov/show/NCT02893306"
519,"NCT02418325","A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS",,"Terminated","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Other: Liberation therapy","Proportion of patients with clinical improvement in EDSS score compared to baseline|Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI|Proportion of patients with reduction in T2 lesion volume on brain MRI|Proportion of patients with reduction in brain volume on MRI|Proportion of patients with clinical improvement in MSIS score compared to baseline|Proportion of patients with clinical improvement in MSFC score compared to baseline|Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test|Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test|Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)|Proportion of patients with reduced number of relapses or freedom from progression of disease","Genesis Limited","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","69","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRT/GENESIS/2015/001","February 2015","February 2017","February 2017","April 16, 2015",,"November 4, 2015","Genesis Institute of Cellular Medicine, Genesis (Trinidad and Tobago) Private Limited, San Fernando, Trinidad, Trinidad and Tobago",,"https://ClinicalTrials.gov/show/NCT02418325"
520,"NCT01714167","Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Stroke",,"Unknown status","No Results Available","Stroke","Genetic: intracerebral stem cell transplantation","Change from baseline in NIH Stroke Scale at 12 months|Improvement of infarct size measured by brain MRI","Wenzhou Medical University|University of North Texas Health Science Center","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WZMC-2011-8","June 2012","October 2015","December 2015","October 25, 2012",,"June 8, 2015","The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01714167"
521,"NCT04489732","MSCs for Radiation-induced Xerostomia",,"Not yet recruiting","No Results Available","Xerostomia Following Radiotherapy","Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells","Percentage of subjects experiencing dose limiting toxicity (DLT)|Change in Saliva production rate|Saliva composition analysis: Change in salivary pH|Saliva composition analysis: Change in total protein concentration in saliva|Saliva composition analysis: Change in amylase concentration in saliva|Saliva composition analysis: Change in mucin concentration in saliva|Change in The University of Michigan Xerostomia Related Quality of Life (XeQOL) score|Change in The MD Anderson Dysphagia Index (MDADI) score|Change in Visual Analogue Scale (VAS) xerostomia score|Change in salivary gland size","University of Wisconsin, Madison|University of Wisconsin Carbone Cancer Center (UWCCC)|National Institute of Dental and Craniofacial Research (NIDCR)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-1290|A533300|SMPH/HUMAN ONCOLOGY/HUMAN ONCO|UW20025|NCI-2021-00070|1UG3DE030431-01","November 2021","June 2023","May 2024","July 28, 2020",,"August 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04489732"
522,"NCT04625738","Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome","MSC-COVID19","Completed","No Results Available","COVID19 ARDS","Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|Biological: Placebo","PaO2 / FiO2 ratio|respiratory function evolution|respiratory assistance|organ failures 1|organ failures 2|organ failures 3|duration of intensive care|Cause of death|respiratory morbidity (TDM, functional respiratory measures)|viral load|Anti-HLA antibody rate|immediate hypersensitivity reactions|thromboembolic adverse events 1|thromboembolic adverse events 2|infectious adverse events","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-002772-12","November 6, 2020","May 14, 2021","September 1, 2021","November 12, 2020",,"November 5, 2021","Nancy University Hospital, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04625738"
523,"NCT04822922","Safety of UC-MSC Transfusion for ACLF Patients",,"Not yet recruiting","No Results Available","Acute-On-Chronic Liver Failure","Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)","Safety of treatment|Short-time efficacy of treatment","Hai Li|Shanghai Jiao Tong University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-ACLF-1","September 30, 2021","July 31, 2022","July 21, 2024","March 30, 2021",,"July 21, 2021","Ren Ji Hospital, School of Medicine, Shanghai Jiao TongUniversity,, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04822922"
524,"NCT04551456","WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease","WANICHD","Not yet recruiting","No Results Available","Coronary Artery Disease","Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS","The primary end point was checking incidence of adverse events (AEs) within 12 months,|The secondary end point was measuring low attenuation plaque volume LAPV|The secondary end point was efficacy 2","Navy General Hospital, Beijing|Chinese PLA General Hospital|Peking University Third Hospital|Peking Union Medical College Hospital|Xijing Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NavyGHB-007","November 30, 2020","December 30, 2021","December 30, 2022","September 16, 2020",,"September 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04551456"
525,"NCT04464213","Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Other: Single dose experiments|Other: Multi-dose experiments","Rate of adverse event|Rate of serious adverse event|Rate of cure rate","Beijing Tongren Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","43","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HS201901","November 1, 2020","August 1, 2021","December 31, 2021","July 9, 2020",,"December 11, 2020","National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, Beiijng, China",,"https://ClinicalTrials.gov/show/NCT04464213"
526,"NCT02359929","BMT Autologous MSCs for GvHD",,"Completed","No Results Available","Graft Versus Host Disease|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease","Biological: Autologous mesenchymal stromal cells (MSCs)","Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs)|Overall Response Rate for acute GVHD subjects|Overall Response Rate for chronic GVHD subjects|Transplant-related mortality|Incidence of Relapse|Disease-free survival|Overall-survival","Emory University|CURE Foundation","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00076372","January 2015","June 15, 2020","January 11, 2021","February 10, 2015",,"March 4, 2021","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02359929"
527,"NCT03392311","Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis",,"Enrolling by invitation","No Results Available","Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity","Drug: Calcipotriol ointment|Biological: adipose-derived multipotent mesenchymal stem cells","Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）","Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2016-04-02","August 17, 2019","December 15, 2019","April 30, 2021","January 5, 2018",,"March 4, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03392311"
528,"NCT03369275","Cellular Immunotherapy for Septic Shock","CISS2","Unknown status","No Results Available","Septic Shock|Sepsis|Pathologic Processes|Shock|Infection|Systemic Inflammatory Response Syndrome|Inflammation","Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Other: Placebo","The reduction in days on mechanical ventilation, or renal replacement therapy, or vasopressors.|Incidence of treatment-emergent adverse events (Safety and tolerability)|Biological endpoints as markers of vascular permeability|Mortality|Organ Failure Scores|Organ Support Measures|Length of ICU Stay (in days)|Length of Hospital Stay (in days)|Hospital Re-Admissions|Patient Reported Outcomes-FIM|Patient Reported Outcomes-SF 36","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)|Ontario Institute for Regenerative Medicine (OIRM)|Stem Cell Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201706","March 2018","February 2020","October 2020","December 11, 2017",,"December 11, 2017",,,"https://ClinicalTrials.gov/show/NCT03369275"
529,"NCT01274975","Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.","MSC","Completed","No Results Available","Spinal Cord Injury","Other: Autologous Adipose Derived Mesenchymal Stem Cells","safety evaluation","R-Bio","Male","19 Years to 60 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Astrostem","July 2009","November 2009","February 2010","January 12, 2011",,"March 26, 2014",,,"https://ClinicalTrials.gov/show/NCT01274975"
530,"NCT04785027","Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis",,"Recruiting","No Results Available","Traditional Chinese Medicine|Drug Effect|Drug Safety|Psoriasis|Mesenchymal Stromal Cells","Drug: PSORI-CM01 formula|Drug: Gu Ben Hua Yu formula|Biological: adipose-derived multipotent mesenchymal stem cells","PASI score improvement rate|PASI (Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI (Dermatology Life Quality Index)","Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2020-01-01","March 17, 2021","September 30, 2022","September 30, 2022","March 5, 2021",,"May 25, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04785027"
531,"NCT03826433","hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis",,"Recruiting","No Results Available","Hepatitis B","Biological: Peripheral iv","Validity evaluation by detection of the Model for end-stage Liver Disease score of participants|Safety evaluation by detecting Blood routine|Validity evaluation by detection of the child-pugh of participants","Sclnow Biotechnology Co., Ltd.","All","18 Years to 60 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCLnow-XY-04","October 1, 2018","June 2022","December 2022","February 1, 2019",,"September 23, 2021","Xiangya Hospital Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03826433"
532,"NCT01624779","Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Drug: autologous adipose tissue derived mesenchymal stem cells","Significant MRI Change before and after intervention|Significant neurologic funtion Change before and after intervention|Significant Electrophysiological Change before and after intervention|Adverse event","Bukwang Pharmaceutical","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KOR-01","April 2012","May 2014","May 2014","June 21, 2012",,"February 13, 2015","Korea University Anam Hospital, Seoul, Seongbukgu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01624779"
533,"NCT04484402","Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells",,"Completed","No Results Available","Corneal Ulcer|Corneal Disease|Corneal Dystrophy","Biological: mesenchymal stem cells|Biological: limbal stem cells|Other: standard treatment","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_LSC","October 3, 2016","December 30, 2019","December 30, 2019","July 23, 2020",,"July 30, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04484402"
534,"NCT02398370","Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED","PMD-MSC-ED-01","Completed","No Results Available","Erectile Dysfunction","Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)","Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s)","Melissa Marchand|Z Urology","Male","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMD-MSC-ED-01","July 2013","December 2014","March 2015","March 25, 2015",,"April 27, 2015","Z Urology, Coral Springs, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02398370"
535,"NCT02395029","Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD","PMD-MSC-PD-01","Completed","No Results Available","Peyronie's Disease","Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)","Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s)","Melissa Marchand|Z Urology","Male","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMD-MSC-PD-01","August 2013","December 2014","March 2015","March 20, 2015",,"March 20, 2015","Z Urology, Coral Springs, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02395029"
536,"NCT02298023","Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)",,"Completed","Has Results","Rotator Cuff Tear","Biological: allogenic adipose stem cell injection|Biological: fibrin glue/normal saline injection|Biological: normal saline injection","Change of Pain During Activity From Baseline to 3 Months After Intervention|Pain During Rest|Pain During Activity|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|Disability of Arm, Shoulder and Hand (DASH) Score|University of California, Los Angeles(UCLA) Shoulder Score|Tear Size at 3 Months After Injection|Tear Size at 12 Months After Injection","Seoul National University Hospital","All","19 Years to 90 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALLO-ASC_TR","September 2014","July 19, 2016","April 10, 2018","November 21, 2014","June 30, 2021","October 19, 2021","Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02298023"
537,"NCT02208713","Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)",,"Unknown status","No Results Available","Dystrophy","Biological: Intramuscular injection","Myalsia|Mass formation|Hematoma|Muscle bulk|CPK","Royan Institute","All","18 Years to 50 Years   (Adult)","Phase 1","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Nerve-007","May 2014","November 2017","December 2017","August 5, 2014",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02208713"
538,"NCT01162915","Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury",,"Suspended","No Results Available","Spinal Cord Injury","Biological: Autologous bone marrow-derived mesenchymal stem cells.","Safety","TCA Cellular Therapy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-SCI-I","July 2010","May 2014","May 2014","July 15, 2010",,"May 9, 2014","TCA Cellular Therapy, LLC, Covington, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01162915"
539,"NCT05061030","A Double-blinded, Randomized, Parallel, Placebo-controlled Trial of Wharton's Jelly-derived Allogeneic Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents",,"Not yet recruiting","No Results Available","Type1diabetes","Biological: the ATMP Protrans","Safety at one year evaluated as adverse events|Safety at five years evaluated as adverse events|Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.|Insulin independency|Low insulin needs|Insulin needs|HbA1c|Time in target|Time in range|C-peptide|Change in peak C-peptide","Uppsala University Hospital","All","7 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WJMSC-P01","October 2021","September 2028","December 2028","September 29, 2021",,"September 29, 2021",,,"https://ClinicalTrials.gov/show/NCT05061030"
540,"NCT04815213","The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans",,"Recruiting","No Results Available","Premature Ovarian Failure","Biological: expanded autologous bone marrow derived MSC","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes|Number of patients with positive ovarian changes|Number of patients with increased endometrial thickness","University of Jordan","Female","18 Years to 38 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","POF.UJCTC","January 1, 2020","January 31, 2022","January 31, 2022","March 24, 2021",,"March 24, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04815213"
541,"NCT04034316","Reduce Immunosuppression With Atmp in NS ChildrEn","RACE","Enrolling by invitation","No Results Available","Nephrotic Syndrome in Children|Steroid-Dependent Nephrotic Syndrome|Idiopathic Nephrotic Syndrome","Other: Cord-blood mesenchymal stromal cells","The percentage of patients without nephrotic syndrome recurrence after complete withdrawal of immunosuppressive treatment for at least 6 months|The percentage of adverse events|The time to recurrence of nephrotic syndrome|The percentage of participants achieving a reduction in the immunosuppressive therapy|The dose of immunosuppressive therapy to prevent further NS relapses|Reported Quality of Life","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|Laboratorio Sperimentale di Immunologia e Trapianti, Oncoematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia","All","3 Years to 18 Years   (Child, Adult)","Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIFA-2016-02364896|2018-001162-42","November 2, 2018","June 30, 2022","December 2022","July 26, 2019",,"August 26, 2021","Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, MI, Italy",,"https://ClinicalTrials.gov/show/NCT04034316"
542,"NCT02812121","UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure",,"Unknown status","No Results Available","Liver Failure","Drug: umbilical cord blood mesenchymal stem cells","The incidence of adverse reactions after umbilical cord blood derived mesenchymal stem cells (UC-MSC) infusions.|The survival time of patients after UC-MSC infusions.|The influence on levels of ALT (U/L) and AST (U/L) after UC-MSC infusions|The influence on levels of ALB(g/L) after UC-MSC infusions|The influence on levels of TBil (umol/L) after UC-MSC infusions|The influence on levels of INR after UC-MSC infusions|The influence on levels of MELD score, SOFA score and CTP score after UC-MSC infusions|The incidence of fatal complications after UC-MSC infusions.|Comparison of levels of NKG2A among the groups after UC-MSC infusions|Comparison of levels of NKG2D among the groups after UC-MSC infusions|Comparison of levels of NKP46 among the groups after UC-MSC infusions|Comparison of levels of KIR2DL1 among the groups after UC-MSC infusions|Comparison of levels of KIR2DL3 among the groups after UC-MSC infusions|Comparison of levels of KIR3DL1 among the groups after UC-MSC infusions|Comparison of levels of perforin among the groups after UC-MSC infusions|Comparison of levels of FasL among the groups after UC-MSC infusions|Comparison of levels of gramzymeB among the groups after UC-MSC infusions","Sun Yat-sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","261","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCBMSC|LBingliang","June 2016","June 2017","June 2018","June 24, 2016",,"June 24, 2016",,,"https://ClinicalTrials.gov/show/NCT02812121"
543,"NCT01753440","Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy",,"Completed","No Results Available","Coronary Artery Disease|Ischemic Cardiomyopathy","Procedure: Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).","iMP-related adverse events|Hypersensitivity|Scar reduction|LVEF|Change in quality of life","AHEPA University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHEPA_CTL_01","November 2012","September 2014","December 2014","December 20, 2012",,"May 7, 2019","AHEPA University Hospital, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT01753440"
544,"NCT04675359","Adipose-derived MSCs After Enzymatic Digestion vs. Mechanically Fragmented Fat Transfer in Knee Osteoarthritis Treatment",,"Not yet recruiting","No Results Available","Knee Osteoarthritis|Chondropathy","Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint","Changes in patients reported outcome measures - Knee Injury and Osteoarthritis Outcome Score (KOOS)|Changes in flexibility of the knee joint|Changes in X-ray imaging of the knee joint in a standing position (AP view)|Changes in MRI with T-2 Mapping of the knee cartilage","Medical University of Warsaw","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MSC","July 1, 2021","June 30, 2023","December 1, 2023","December 19, 2020",,"January 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04675359"
545,"NCT00136903","Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)",,"Completed","No Results Available","Graft Vs Host Disease","Drug: Prochymal - 2 million cells|Drug: Prochymal - 8 million cells","Protocol 260 - Response by Day 28, also called Overall Response. Overall response. includes complete response (CR) and partial response (PR)|Protocol 261- Patients were followed for 2 years for safety. The incidence rate of different adverse events among subjects treated with either dose of Prochymal® in the preceding study (Protocol No. 260).|Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,|Protocol 260 - Time to best response of GVHD|Protocol 260 - Time to improvement of GVHD in one or more organs|Protocol 261 - Survival through study day 90","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","260-261","April 27, 2005","July 28, 2006","July 14, 2008","August 29, 2005",,"March 9, 2020","St. Francis Hospital, Indianapolis, Indiana, United States|Kansas City Cancer Centers - BMT, Kansas City, Missouri, United States|The Cancer Center at Hackensack University, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, FEC, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00136903"
546,"NCT01591200","Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis",,"Completed","No Results Available","Alcoholic Liver Cirrhosis","Biological: Allogeneic Mesenchymal Stem Cells","Safety|Liver function tests.|CT scan of abdomen.|Change in MELD score|Improvement in quality of life as assessed by SF 36 questionnaire|Histological evaluation of liver biopsy by immunohistochemical staining for AFP, PCNA, SMA|Change in Child-Pugh score","Stempeutics Research Pvt Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRPL/LC/09-10/001","June 2012","April 2016","April 2016","May 3, 2012",,"September 15, 2016","Centre for Liver Research & Diagnostics, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Manipal Hospital, Bangalore, Karnataka, India|KMC Hospital, Mangalore, Karnataka, India|Institute of liver disease, HPB surgery and transplant Global Hospitals, Mumbai, Maharashtra, India|Bombay Hospital & Medical Research Center, Mumbai, Maharashtra, India|Ruby Hall clinic, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|SMS Medical college and Hospital, Jaipur, Rajasthan, India|SGPGI Lucknow, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01591200"
547,"NCT02881489","Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis","UwmBmmscALS","Unknown status","No Results Available","Amyotrophic Lateral Sclerosis","Other: Biological: Cell-based therapy","Changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) between patients before and after stem cell transplantation.","University of Warmia and Mazury","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UWM/ALS-MSC.2015/002","November 2015","April 2018","December 2018","August 29, 2016",,"August 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02881489"
548,"NCT04089579","hCT-MSC in Children With Autism Spectrum Disorder","IMPACT","Recruiting","No Results Available","Autism|Autism Spectrum Disorder","Biological: Cord Tissue Mesenchymal Stromal Cells|Other: Placebo Infusion","Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","4 Years to 11 Years   (Child)","Phase 2","164","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00102894","October 12, 2020","October 1, 2022","May 1, 2023","September 13, 2019",,"March 18, 2021","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04089579"
549,"NCT02855073","Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects",,"Unknown status","No Results Available","Defect of Articular Cartilage|Knee Osteoarthritis","Biological: ReJoinTM|Drug: Sodium Hyaluronate","WOMAC scores|VAS scores|SF-36 scores|Outbridge scoring|CRP|Cartilage defect size|Cartilage volume","Cellular Biomedicine Group Ltd.|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","28","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CBMG-ReJoinTM-CL-1.0","July 2014","December 2019","December 2019","August 4, 2016",,"December 17, 2018","Shanghai ninth people's hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02855073"
550,"NCT01045382","MSC and HSC Coinfusion in Mismatched Minitransplants",,"Terminated","No Results Available","Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute|Leukemia, Myelocytic, Chronic|Myeloproliferative Disorders|Myelodysplastic Syndromes|Multiple Myeloma|Leukemia, Lymphocytic, Chronic|Hodgkin's Disease|Lymphoma, Non-Hodgkin","Biological: Mesenchymal stem cells|Other: Isotonic solution","One-year overall survival in the 2 arms.|Incidence of grade II-IV and grade III-IV acute GVDH|Number of absolute donor T cells after HCT in each arm|Cumulative incidence of non-relapse mortality|Incidence of extensive chronic GVHD in each arm|Incidence of graft rejection in each arm.|Quality and timing of immunologic reconstitution in each arm.|Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC|Proportion of patients with measurable disease at HCT who achieve a complete response in each arm.|Cumulative incidence of relapse|Incidence of progression-free survival|Incidence of infections","University of Liege|AZ Sint-Jan AV|Ziekenhuis Netwerk Antwerpen (ZNA)|Jules Bordet Institute|Universiteit Antwerpen|AZ-VUB|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|University Hospital, Ghent","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","TJB0909","July 2010","August 2021","August 2021","January 11, 2010",,"September 8, 2021","UZA, Edeghem, Antwerpen, Belgium|St-Luc UCL, Brussels, Brabant, Belgium|AZ Gasthuisberg Leuven, Leuven, Flamish Brabant, Belgium|UZ Gent, Gent, Flanders Ost, Belgium|AZ St-Jan, Brugge, Flanders West, Belgium|Cliniques Universitaires Mont-Godinne, Yvoir, Namur, Belgium|Hôpital Stuyvenberg, Antwerpen, Belgium|Bordet Institute, Brussels, Belgium|Vrije Universiteit Brussel, Brussels, Belgium|CHU-ULg, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT01045382"
551,"NCT02854579","Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy",,"Unknown status","No Results Available","Hypoxic-Ischemic Encephalopathy","Biological: neural progenitor cell|Biological: Paracrine factors|Biological: progenitor cell and paracrine factors","Neonatal Behavioral Neurological Assessment|number of adverse events|Bayley score|Peabody development measure scale|Number of death|Number of participants with treatment-related central nervous tumor as assessed by Magnetic Resonance Imaging or CT","Navy General Hospital, Beijing|Bethune International Peace Hospital|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Hunan Children's Hospital|Shangluo Central Hospital|252 Military Hospital","All","up to 14 Days   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NavyGHB-P-01","January 2013","July 2017","December 2017","August 3, 2016",,"August 3, 2016","Navy General Hospital, Beijing, Beijing, China|Navy General Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02854579"
552,"NCT03254758","A Study of ADR-001 in Patients With Liver Cirrhosis",,"Recruiting","No Results Available","Decompensated Liver Cirrhosis","Biological: Mesenchymal stem cell","Safety profile of ADR-001 including the incidence of adverse events (Phase 1)|Improvement rate of Child-Pugh score (Phase 2)|Change of liver function evaluated by Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh grade (Phase 1)|Change of liver function evaluated by Child-Pugh score (Phase 2)|Improvement rate of Child-Pugh grade (Phase 2)|Safety profile of ADR-001 including the incidence of adverse events (Phase 2)","Rohto Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","27","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADR-001-01","July 20, 2017","December 2021","December 2021","August 18, 2017",,"September 16, 2021","Niigata University Medical & Dental Hospital, Niigata, Japan|Nihon University Itabashi Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03254758"
553,"NCT01210950","Distraction Osteogenesis in Limb-length Discrepancy With Mesenchymal Cell Transplantation",,"Completed","No Results Available","Leg Length Inequality","Biological: cell and RPR injection","effect of mesenchymal cell transplantation to decrease limb inequal|improve life quality","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-006","September 2009","December 2013","December 2013","September 29, 2010",,"April 28, 2014","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01210950"
554,"NCT03525418","Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)","ELPIS","Active, not recruiting","No Results Available","HLHS","Biological: Longeveron Mesenchymal Stem Cells","Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.|Efficacy: Change from baseline in right ventricular ejection fraction (%).|Efficacy: Change from baseline in right ventricular end-systolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic diameter.|Efficacy: Change from baseline tricuspid regurgitation.|Efficacy: Change in weight (in kilograms).|Efficacy: Change in height (in centimeters).|Efficacy: Change in head circumference (in centimeters).|Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial.","Longeveron Inc.","All","up to 1 Year   (Child)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-0000-05","February 21, 2018","December 15, 2020","September 2021","May 15, 2018",,"September 30, 2021","Emory University/Childen's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University Hospital, Baltimore, Maryland, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Utah/Heart Center-Primary Children's Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03525418"
555,"NCT04971161","Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)",,"Recruiting","No Results Available","Skin Ulcer Venous Stasis Chronic","Biological: allo-APZ2-CVU|Drug: Placebo","Complete wound closure at Week 18 already persisting for at least two weeks|Assessment of adverse event (AE) occurrence|Wound size change in percent at each post-baseline follow-up visit|Time to complete wound closure|Complete wound closures at each post-baseline follow-up visit|Duration of wound closure|Recurrence of the wound|Quality of wound healing (wound exudate) at each post-baseline follow-up visit|Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit|Quality of wound healing (scar formation) at each post-baseline follow-up visit|Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14|Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit|Physical examination and vital signs at V14","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","allo-APZ2-CVU-IIb","August 18, 2021","August 2023","August 2023","July 21, 2021",,"November 17, 2021","Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd, Augsburg, Germany|Fachklinik Bad Bentheim, Dermatologische Ambulanz, Bad Bentheim, Germany|Franziskus-Krankenhaus Berlin, Klinik für Innere Medizin, Angiologie und Diabetologie, Berlin, Germany|Hautärzte Braunschweig am Altstadtmarkt, Hautärztliche Gemeinschaftspraxis, Braunschweig, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Medizinische Klinik und Poliklinik III Angiologie und Gefäßzentrum, Dresden, Germany|Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Klinik für Dermatologie, Düsseldorf, Germany|Universitätsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie, Erlangen, Germany|Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie, Freiburg, Germany|Marienhospital Gelsenkirchen GmbH, Klinik für Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gefäß- und Endovaskuläre Chirurgie und Kinderchirurgie), Gelsenkirchen, Germany|SRH Wald-Klinikum Gera GmbH, Zentrum für Klinische Studien, Gera, Germany|Praxis Dr. med. Abdou Zarzour, Halle, Germany|Universitätsklinikum Hamburg- Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Hamburg, Germany|MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH, Hanau, Germany|SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplinäres Gefäßzentrum Innere Medizin, Karlsbad, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH, Kiel, Germany|Helios Klinikum Krefeld, Klinik für Dermatologie und Venerologie, Krefeld, Germany|Hautarztpraxis Langenau, Studienzentrum, Langenau, Germany|medamed GmbH, Studienambulanz Leipzig, Leipzig, Germany|Beldio Research GmbH, Memmingen, Germany|Dermazentrum München, Standort Neuhausen, Studienzentrum, München, Germany|Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie, Münster, Germany|Klinikum Nürnberg Nord, Klinik für Dermatologie, Nürnberg, Germany|Hautarztpraxis Prof. Dr. med. Khusru Asadullah, Potsdam, Germany|Caritas-Krankenhaus St. Josef, Klinik für Plastische und Ästhetische, Hand- und Wiederherstellungschirurgie, Regensburg, Germany|Universitätsmedizin Rostock, Klinik und Poliklinik für Dermatologie und Venerologie, Rostock, Germany|Helios Kliniken Schwerin, Plastische, Rekonstruktive und Ästhetische Chirurgie, Schwerin, Germany|Hautärztliche Gemeinschaftspraxis Dr. Leitz und Kollegen, Stuttgart, Germany|Universitätsklinikum Tübingen, Universitäts-Hautklinik Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie, Ulm, Germany|Helios Universitätsklinikum Wuppertal, Zentrums für Dermatologie, Allergologie und Dermatochirurgie, Wuppertal, Germany|Universitätsklinikum Würzburg, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT04971161"
556,"NCT02966717","Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)","CKD","Unknown status","No Results Available","Renal Insufficiency, Chronic|Nephrotic Syndrome","Drug: Rituximab|Drug: conventional therapy|Drug: Mesenchymal stem cells","The change of serum creatinine elevation|The percentage of end-stage renal disease or death.","Zhujiang Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Tangxun8022","August 2016","October 2016","October 2021","November 17, 2016",,"November 22, 2016","Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02966717"
557,"NCT03816852","The Safety and Efficiency Study of Mesenchymal Stem Cell in Premature Ovarian Insufficiency",,"Suspended","No Results Available","Premature Ovarian Failure","Biological: hucMSCs","Menstrual changes|Kupperman score|hormone level|Follicular development","Sclnow Biotechnology Co., Ltd.","Female","19 Years to 40 Years   (Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SCLnow-HNRM-01","October 1, 2018","October 2021","October 2022","January 25, 2019",,"September 23, 2021","Henan Provincial People's Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT03816852"
558,"NCT02315027","Mesenchymal Stem Cell Therapy in Multiple System Atrophy",,"Active, not recruiting","No Results Available","MSA","Biological: Autologous Mesenchymal Stem Cells","Adverse event frequency (by severity, type, attribution, and intervention dose).|Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort).|Rate of change from baseline to 12 months (or last available date) in UMSARS II score.|Rate of change from baseline to 12 months (or last available date) in UMSARS total score.|Rate of change in COMPASS-select score from baseline to 12 months.|Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months.|MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months.|Change in CSF biomarkers from baseline to 2 months.","Mayo Clinic|Food and Drug Administration (FDA)|National Institute of Neurological Disorders and Stroke (NINDS)","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|U.S. Fed|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-005950|R01FD004789|R01NS092625","October 2012","March 2024","March 2024","December 11, 2014",,"September 14, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02315027"
559,"NCT03691909","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis","HB-adMSCs","Completed","No Results Available","Rheumatoid Arthritis","Biological: HB-adMSCs","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|The effect of single inject of HB-adMSCs on TNF-a in patients with acute RA|The effect of single inject of HB-adMSCs on IL-6 in patients with acute RA|The effect of single inject of HB-adMSCs on CRP in patients with acute RA|The effect of single inject of HB-adMSCs on ESR in patients with acute RA|The effect of single inject of HB-adMSCs on joint count in patients with acute RA.","Hope Biosciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBRA01","September 25, 2018","August 17, 2020","September 28, 2020","October 2, 2018",,"July 6, 2021","Accurate Clinical Research, Pasadena, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03691909"
560,"NCT03766217","Bone Tissue Engineering With Dental Pulp Stem Cells for Alveolar Cleft Repair","CLOSE","Completed","No Results Available","Cleft Lip and Palate","Combination Product: Mesenchymal stem cells associated with biomaterials|Combination Product: Iliac crest autogenous bone graft","Alveolar bone filling rate|Serious adverse events|Non serious adverse events|Bone Tissue Engineering With Dental Pulp Stem Cells for Alveolar Cleft Repair|Position of the canine tooth and formation of dental root|Patient-reported outcome (PRO, including appearance, fuction and quality of life)","Hospital Sirio-Libanes|Ministry of Health, Brazil","All","7 Years to 12 Years   (Child)","Phase 3","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CAAE47719215.5.0000.5461","April 5, 2019","December 6, 2019","December 15, 2019","December 6, 2018",,"May 13, 2020","Hospital Sírio-Libanes, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03766217"
561,"NCT01449032","MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)","MyStromalCell","Completed","No Results Available","Chronic Ischemic Heart Disease","Biological: MSC|Biological: Saline","Exercise test|Clinical evaluation","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MyStromalCell","April 2010","January 2014","January 2014","October 7, 2011",,"June 10, 2014","Rigshospitalet University Hospital Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT01449032"
562,"NCT03181087","Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars",,"Recruiting","No Results Available","Uterine Scar","Other: Umbilical cord MSCs","Safety evaluation through vital signs, the results of clinical lab tests and adverse events|Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence","Maternal and Child Health Hospital of Foshan","Female","21 Years to 35 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCHHFoshan-1701","December 11, 2021","October 31, 2022","May 30, 2023","June 8, 2017",,"June 9, 2021","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03181087"
563,"NCT01499056","Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint",,"Completed","No Results Available","Hip Osteoarthritis","Biological: stem cell injection","swelling of hip joint|deterioration of joint function|skin allergic reaction|Respiratory reaction|Quantitative changes in pain intensity|physical function improvement|subchondral bone edema|cartilage thickness","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-008","June 2010","February 2011","March 2011","December 26, 2011",,"December 26, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01499056"
564,"NCT02336646","Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease",,"Completed","No Results Available","Critical Limb Ischemia","Drug: Allogenic MSC|Drug: Normal saline","Adverse events|Efficacy-The Wong Baker FACES® pain rating scale|Efficacy-Transcutaneous oxygen pressure(TcPO2)|Efficacy-walking distance (TWD)|Efficacy-Ankle Brachial Pressure Index (ABPI)","Taiwan Bio Therapeutics Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2012-02-070B","May 1, 2015","April 27, 2018","December 20, 2018","January 13, 2015",,"August 25, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02336646"
565,"NCT03608579","Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA",,"Recruiting","No Results Available","Osteoarthritis, Hip","Drug: Autologous Adipose Derived Mesenchymal Stromal Cells","Nature, incidence and severity of adverse events (AEs)|Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles|Change in Tegner activity scale in the target hip following completion of treatment cycles|Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles|Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles|Change in radiographic joint morphology|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Change periarticular soft-tissues|Change in synovial fluid biomarkers within the target hip","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000015","November 5, 2018","December 31, 2021","December 31, 2021","August 1, 2018",,"December 24, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03608579"
566,"NCT02034786","Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid","LipAge","Unknown status","No Results Available","Lipodystrophies|Aesthetics Procedure","Procedure: Adipose tissue collection|Biological: Transdermal injection|Procedure: Transdermal injection","Adverse Events Analysis|Efficacy Analysis","Cryopraxis Criobiologia Ltda.|Hospital Federal de Bonsucesso","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cryo 394.191|394.191","March 2015","May 2016","June 2016","January 13, 2014",,"February 4, 2015","Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT02034786"
567,"NCT03414697","Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes",,"Unknown status","No Results Available","Cerebral Palsy","Other: Control group|Procedure: UC-MSCs","The Gross Motor Function Measure (GMFM)-88 item score|Fine Motor Function Measure scale (FMFM) score|The Modified Ashworth scale (MAS) score|Gesell Development Schedule score|Incidence of adverse reactions","The First Affiliated Hospital of Dalian Medical University","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FirstHospitalDalianMU004","April 2018","September 2020","December 2020","January 30, 2018",,"January 30, 2018","The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China",,"https://ClinicalTrials.gov/show/NCT03414697"
568,"NCT01643681","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration",,"Withdrawn","No Results Available","Lumbar Intervertebral Disc Degeneration","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Magnetic Resonance Imaging|Changes of Neurological Functions|Safety evaluation","R-Bio|Korea University Anam Hospital","All","19 Years to 70 Years   (Adult, Older Adult)","Not Applicable","0","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-LIDD","July 2012","March 2014","December 2015","July 18, 2012",,"June 5, 2019","Korea University Anam Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01643681"
569,"NCT05017298","Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells","AdMSCs","Not yet recruiting","No Results Available","Corona Virus Infection|Covid19","Biological: Autologous adipose-derived stem cells","Safety of AdMSC injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study based on the rate of all AdMSC-associated adverse events (AEs) in all subjects.|Safety for AdMSCs based upon incidence of all AEs|Compare the mortality rate|Recognized immune measurements evaluating patients' symptom changes and overall function|Organ functional tests including blood specific enzymes and proteins|Duration (days) of weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agent's usage|Duration of hospitalization (days)|Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens (oropharyngeal swabs) using CDC standard method|Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method|Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-004","November 1, 2021","November 1, 2022","November 15, 2024","August 23, 2021",,"August 23, 2021",,,"https://ClinicalTrials.gov/show/NCT05017298"
570,"NCT04174898","MSC Infusion for Anti-aging and Regenerative Therapy","REGEN","Not yet recruiting","No Results Available","Aging Well|Regenerative Medicine","Biological: human Mesenchymal Stem Cell (MSC) infusion therapy","To evaluate number of Participants with Treatment-Related Adverse Events|Improvement in General Well-Being, as assessed by our 'Quality of Life' Questionnaire, adapted from SF36.|Change in inflammatory marker levels|Change in medication dosage (if any)","Landmark Medical Centre Sdn Bhd|CytoMed Therapeutics Pte Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Protocol LMC-101","April 15, 2020","April 14, 2021","April 14, 2022","November 22, 2019",,"November 22, 2019","Landmark Medical Centre Sdn Bhd, Johor Bahru, Johor Darul Takzim, Malaysia",,"https://ClinicalTrials.gov/show/NCT04174898"
571,"NCT01770613","A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)",,"Withdrawn","No Results Available","ST Segment Elevation Myocardial Infarction (STEMI)|Allogeneic Mesenchymal Bone Marrow Cells","Biological: Stem cells","The safety and tolerability of aMBMC intravenous administration during the twelve month study period as determined by major adverse events MACE endpoint.|The change from baseline on physical exam conducted at day 14 and at 1, 3, 6 and 12 months post-administration, as available:|• LV end diastolic volume|• LV end systolic volume|• Infarct size measured by MRI, with and without contrast (only for patients eligible for MRI)|• Global Left Ventricular Ejection Fraction (measured by echocardiography)|• SF-36 Health Assessment|• Incidence of Ventricular Arrhythmias requiring intervention at 1 and 3 months post-administration","Stemedica Cell Technologies, Inc.|CardioCell LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STEM 103-M-STEMI","February 2013","May 2016","May 2017","January 18, 2013",,"April 27, 2017","Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States|Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01770613"
572,"NCT02290041","Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response",,"Completed","No Results Available","Discordant Immunological Response in HIV Infected Subjects","Drug: Infusion of MSC|Drug: Infusion of placebo","Incidence of adverse reactions|Incidence of opportunist diseases|Changes in CD4+ cell count and CD4+/CD8+ ratio|T CD4 +/µl count evolution and CD4 +/CD8 + ratio throughout 48 weeks","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CeTMAd-VIH-2014","February 8, 2017","July 30, 2019","July 30, 2019","November 13, 2014",,"March 4, 2020","Virgen del Rocío University Hospital, Seville, Spain",,"https://ClinicalTrials.gov/show/NCT02290041"
573,"NCT01742260","Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials",,"Unknown status","No Results Available","Surgically-Created Resection Cavity","Procedure: Repair of cranial defects by tissue engineering","Failure of cranioplasty implant|Quantitative bone density of the tissue engineered construct and adjacent bone from CT scan at 12 months.|Assessment of cosmesis by photography","R.P.Herrmann|Royal Perth Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012/047|2012/022238","July 2013","December 2016","December 2017","December 5, 2012",,"June 9, 2015","Royal Perth Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01742260"
574,"NCT02923375","A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease",,"Completed","No Results Available","Graft vs Host Disease","Biological: Mesenchymoangioblast-derived mesenchymal stem cells","Incidence and severity of treatment emergent adverse events [safety and tolerability]|Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]|Complete Response by Day 28|Partial Response by Day 28|Overall Survival at Day 28|Complete Response by Day 100|Partial Response by Day 100|Overall Survival at Day 100","Cynata Therapeutics Limited","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYP-GvHD-P1-01|2016-000070-38","March 1, 2017","August 28, 2018","June 30, 2020","October 4, 2016",,"August 11, 2020","Sydney Local Health District, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|NHS Foundation Trust, Bristol, United Kingdom|NHS Trust, Leeds, United Kingdom|NHS Foundation Trust, Liverpool, United Kingdom|NHS Foundation Trust, Manchester, United Kingdom|NHS Foundation Trust, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02923375"
575,"NCT01092026","Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells",,"Unknown status","No Results Available","Allogeneic Stem Cell Transplantation","Other: cord blood transplantation","treatment-related mortality|Hematopoietic recovery","Universitair Ziekenhuis Brussel","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHS-UCB2009","November 2010","December 2017","December 2017","March 24, 2010",,"June 6, 2016","UZ Brussel, Brussel, Belgium",,"https://ClinicalTrials.gov/show/NCT01092026"
576,"NCT02603744","Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)",,"Unknown status","No Results Available","Premature Ovarian Failure","Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)","ovary mass|ovary abcess|Follicle Stimulating Hormone (FSH) serum level|Anti-Mullerian Hormone (AMH) serum level|Number of antral follicle|Antral follicle volume|Menstruation recurrence rate|Pregnancy rate","Royan Institute","Female","20 Years to 39 Years   (Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rep-Bio-Royan-001","June 2015","June 2018","November 2018","November 13, 2015",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02603744"
577,"NCT05086939","Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis (ARTROCELL)","ARTROCELL","Active, not recruiting","No Results Available","Knee Osteoarthritis","Drug: Autologous MSCs|Drug: Allogenic MSCs|Drug: Hyaluronic Acid","Range of motion.|Pain self-assessment.|Knee Osteoarthritis.|Functional response.|X-ray changes of osteoarthritis.|Radiological response using nuclear magnetic resonance imaging.|Perceived general well-being.|Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units|Evaluation of presence of adverse events related with investigational medical product (IMP).","Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Spanish Clinical Research Network - SCReN|Hospital Universitari de Bellvitge|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Instituto de Investigación Biomédica de Salamanca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARTROCELL|2019-002446-21","May 26, 2021","December 2025","December 2025","October 21, 2021",,"October 28, 2021","Centro Médico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Fundación Jiménez Díaz, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT05086939"
578,"NCT02888704","Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: ADSTEM Inj. (Adult human mesenchymal stem cells)","The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03|The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value|The variation of SCORAD index as contrasted with baseline value|The variation of each index score of SCORAD index as contrasted with baseline value|The variation of the degrees of disease as contrasted with baseline value|The variation of investigator's global assessment (IGA) as contrasted with baseline value|The variation of eczema area and severity index (EASI) total score as contrasted with baseline value|The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value|The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value|The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value|The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value|The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value","EHL Bio Co., Ltd.","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AD-CP-15-1|30902","July 2016","December 2017","December 2017","September 5, 2016",,"December 22, 2017","Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02888704"
579,"NCT03449069","Pediatric MSC-AFP Sub-study for Crohn's Fistula",,"Recruiting","No Results Available","Fistula in Ano|Crohn Disease","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity)|Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.|Number of participants with radiographic response to the treatment regarding the treated fistula.","Mayo Clinic","All","12 Years to 17 Years   (Child)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-010539","July 23, 2018","February 28, 2022","February 28, 2022","February 28, 2018",,"April 1, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03449069"
580,"NCT03209700","Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas","MSC-AFP","Completed","No Results Available","Perianal Fistula|Cryptoglandular Perianal Fistula|Crohn's Perianal Fistula","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","William A. Faubion, M.D.|Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-004503","July 20, 2017","December 10, 2019","December 10, 2019","July 6, 2017",,"January 3, 2020","Mayo Clinic in Minnesota, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03209700"
581,"NCT01552707","Safety Study of Mesenchymal Stem Cells and Spinal Fusion",,"Completed","No Results Available","Lumbar Spondylolisthesis Involving L4-L5, and/or|Degenerative Discopathy Involving L4-L5","Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment","safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Feasibility of XCEL-MT-OSTEO-ALPHA (composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Efficacy spinal fusion by imaging procedures (X-Ray).|Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)|Clinical outcomes (VAS)|Clinical outcomes (SF-36)|Clinical outcome (Oswestry Disability Index)","Banc de Sang i Teixits|TFS Trial Form Support|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","69","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-MT-10-02","July 19, 2012","May 3, 2018","October 21, 2019","March 13, 2012",,"January 21, 2020","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Parc de Salut Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Universitari Dexeus (ICATME), Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01552707"
582,"NCT02807389","Stem Cell Fistula Plug in Post Surgical Leak Fistulas",,"Completed","No Results Available","Surgical Leak Fistula","Drug: MSC Fistula Plug","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Fistula Closure","Mayo Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-004326","March 14, 2017","April 2, 2019","April 2, 2019","June 21, 2016",,"April 23, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02807389"
583,"NCT01922908","Mesenchymal Stromal Cells for Ischemic Stroke","SAMCIS","Withdrawn","No Results Available","Ischemic Stroke","Biological: MSC Infusion|Biological: Placebo Comparator","maximum tolerated dose (MTD) of IV MSCs|Improved functional outcome","Sean Savitz|The University of Texas Health Science Center, Houston","All","18 Years to 83 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SAMCIS","December 2016","December 2018","December 2018","August 14, 2013",,"April 18, 2018",,,"https://ClinicalTrials.gov/show/NCT01922908"
584,"NCT04525378","MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","Covid19|ARDS, Human","Other: Mesenchymal stromal cell-based therapy","Intrahospital mortality|Length of stay in the ICU and Hospital|Days without mechanical ventilation in 28 days|PaO2 / FiO2 ratio|Incidence of secondary infections|Incidence of adverse events|Quantification of inflammatory response markers","D'Or Institute for Research and Education","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCL02/2020","July 1, 2020","September 30, 2020","October 31, 2020","August 25, 2020",,"August 26, 2020","Hospital São Rafael, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT04525378"
585,"NCT01687777","Mensenchymal Stem Cell (MSC) Included in OrthADAPT Membrane for Rotator Cuff Tears Repair","msctendonrep","Unknown status","No Results Available","Chronic Disease","Biological: Mesenchymal Stem Cells (MSCs)|Biological: OrthADAPT","Constant Shoulder Score|Nuclear Magnetic Resonance (RMN)","Hospital San Carlos, Madrid|Hospital General Universitario Gregorio Marañon","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EC07/90208|2007-007630-19","May 2010","June 2013","December 2013","September 19, 2012",,"September 19, 2012","Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01687777"
586,"NCT02589119","Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)",,"Completed","No Results Available","Perianal Fistula|Cryptoglandular Perianal Fistula","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-003200","January 2016","September 2019","September 2019","October 28, 2015",,"December 6, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02589119"
587,"NCT01175655","A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation","MSC in OB","Completed","No Results Available","Bronchiolitis Obliterans|Lung Transplantation","Other: MSC","To establish the safety of infusions of MSC from related or unrelated HLA identical or HLA mismatched donors in the management of bronchiolitis obliterans syndrome after lung transplantation.|To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC|To document survival post MSC infusion","The Prince Charles Hospital|Cell & Tissue Therapies Western Australia","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC 28105","February 2010","July 2015","July 2016","August 5, 2010",,"September 27, 2021","TPCH, Brisbane, Queensland, Australia|RPH, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01175655"
588,"NCT03220243","Stem Cell Coated Fistula Plug in Patients With Crohn's RVF",,"Completed","No Results Available","Fistula Vagina|Crohn Disease","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","Mayo Clinic","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-002892","October 19, 2017","September 20, 2020","September 20, 2020","July 18, 2017",,"October 30, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03220243"
589,"NCT02270307","MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis","MSC-CY","Unknown status","No Results Available","Leukemia|Multiple Myeloma","Drug: Cyclophosphamide|Biological: Mesenchymal stromal cells","Overall survival","National Research Center for Hematology, Russia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MSC-CY-Russia","January 2014","January 2016","January 2016","October 21, 2014",,"October 21, 2014","BMT department, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02270307"
590,"NCT01872624","Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema",,"Completed","No Results Available","Pulmonary Emphysema","Procedure: Bronchoscopy","Absence of lung deficits during the procedure and/or in the 4 months follow-up|Quality of Life|Pulmonary function|Inflammation","Hospital de Clinicas de Porto Alegre|Ministry of Health, Brazil|National Research Council, Brazil|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Rio de Janeiro State Research Supporting Foundation (FAPERJ)|Universidade Federal do Rio de Janeiro|Pontifícia Universidade Católica do Paraná","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-0150","May 2013","December 2014","March 2015","June 7, 2013",,"March 25, 2015","Pontificia Universidade Catolica do Parana, Curitiba, PR, Brazil|Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT01872624"
591,"NCT03631420","Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants",,"Active, not recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells","The incidence and frequency of adverse events related to administration of UMC119-01.|The percentage of subjects who died from any cause during the study.|Changes of the oxygen saturation.|Changes of chest x-ray findings in participants before and after administration.|Changes of inflammatory markers (pg/ml) before and after administration.|Comparison of the incidence and severity of preterm children's complications in participants before and after administration.|The number of days of intubation, or where ventilator or oxygen therapy.|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).","Meridigen Biotech Co., Ltd.","All","up to 51 Days   (Child)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UMC119-01-001","October 26, 2018","December 31, 2022","July 31, 2025","August 15, 2018",,"April 26, 2021","National Chen-Kung University Hospital, Tainan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03631420"
592,"NCT01207869","Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia",,"Unknown status","No Results Available","Bronchopulmonary Dysplasia|Extremely Premature Infants|Severe BPD That Conventional Therapies Has Failed|No Severe Congenital Anomalies|no Severe IVH Neither Cystic PVL","Biological: ucMSCs|Other: Normal saline","The relations between the cytokine concentrations in the BAL fluid and PAP.|The severity score of BPD ranging from 0 to 6 on the serial chest radiographs","China Medical University Hospital","All","up to 6 Months   (Child)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","DMR99-104","July 2010","June 2012","July 2012","September 23, 2010",,"September 23, 2010","China Medical University Hospital, Taichung,, Taiwan",,"https://ClinicalTrials.gov/show/NCT01207869"
593,"NCT01142050","Stem Cell Therapy for Type 2 Diabetes Mellitus",,"Unknown status","No Results Available","Type 2 Diabetes Mellitus","Biological: mesenchymal stem cells","ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;|Serious adverse event frequency and severity","Cellonis Biotechnology Co. Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellonis-CR-2.3","August 2010","August 2011","December 2011","June 11, 2010",,"June 11, 2010","Armed Police General Hospital, P.R. China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01142050"
594,"NCT01958502","Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold",,"Unknown status","No Results Available","Nonunion of Fracture","Genetic: surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold","clinical and radiological union at 1 month to 6 months|Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects(infection,malignancy,local or systemic allergic reaction)","Emdadi Kamyab Hospital|National Taiwan University of Science and Technology","All","18 Years to 60 Years   (Adult)","Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","910359","July 2013","July 2014","November 2014","October 9, 2013",,"October 9, 2013","Emdai Kamyab Hospital, Mashhad, Khorasan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01958502"
595,"NCT02230514","Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones",,"Completed","No Results Available","Atrophic Nonunion of Fracture","Drug: XCEL-MT-OSTEO-ALPHA|Other: autologous iliac crest|Procedure: Surgery","Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures|Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures|Efficacy assessment by quality of life test","Banc de Sang i Teixits|Hospital ASEPEYO Sant Cugat","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-PSART-01|2013-005025-23","November 20, 2014","March 5, 2019","December 20, 2019","September 3, 2014",,"April 12, 2021","Hospital ASEPEYO Sant Cugat, Sant Cugat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02230514"
596,"NCT03917797","Mesenchymal Stromal Cells (MSC´s) in Renal Lupus","MSC-ROLE","Recruiting","No Results Available","Lupus Erythematosus, Systemic|Lupus Glomerulonephritis","Biological: MSC treatment|Drug: Standard of Care|Drug: Placebo","Achievement of Global Renal Response (GR) at Study Endpoint|Achievement of Complete Renal Response (CR) at Study Endpoint|Achievement of Partial Renal Response (PR) at Study Endpoint|Treatment Failure|Response of SLE Responder Index (SRI).|Selena Sledai|BILAG score|Disease Flares|Biomarker Response","Universidad de los Andes, Chile","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Phase II Lupus MSC","April 2, 2019","December 2022","December 2022","April 17, 2019",,"November 16, 2020","Clínica Universidad de los Andes, Santiago de Chile, Región Metropolitana, Chile|Hospital Barros Luco Trudeau, Santiago de Chile, Región Metropolitana, Chile",,"https://ClinicalTrials.gov/show/NCT03917797"
597,"NCT02307435","Allogenic Mesenchymal Stem Cell for Bone Defect or Non Union Fracture","AMSC","Unknown status","No Results Available","Non Union Fracture|Metaphyseal Fibrous Defect","Biological: MSC","cell viability|lower extremity functional score|disabilities of arm shoulder and hand","Indonesia University","All","19 Years to 30 Years   (Adult)","Early Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISMMSC001","August 2014","December 2017","December 2017","December 4, 2014",,"December 4, 2014","University of Indonesia, Jakarta Pusat, Jakarta, Indonesia|Faculty of Medicine, University of Indonesia, Propinsi DKI Jakarta, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT02307435"
598,"NCT01443689","Allogenic Stem Cell Therapy in Patients With Acute Burn",,"Unknown status","No Results Available","Burns","Biological: human umbilical cord mesenchymal stem cells|Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Drug: Conventional therapy","The ratio of wound contraction and re-epithelialisation|Complete healing time for investigated burn area|Vancouver Scar Scale|Incidence of infections and bleedings in burn wounds|Engraftment assessment: Vitality of the graft|McGill pain Questionnaire|Incidence of Adverse Events and Serious Adverse Events","Shenzhen Beike Bio-Technology Co., Ltd.|The Second Affiliated Hospital of Kunming Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BKCR-BURN-1.0(2011)","July 2011","March 2013","July 2013","September 30, 2011",,"November 28, 2012","The Second Affiliated Hospital of Kunmming Medical College, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT01443689"
599,"NCT03692221","Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease",,"Not yet recruiting","No Results Available","Disc Degeneration","Drug: MSC Treatment group 1 (low dose)|Drug: MSC Treatment group 2 (high dose)|Other: Healthy Control (no treatment)","Rate of treatment related adverse events|Changes in Pain -Visual Analogue Scale (VAS) for back pain|Changes in Pain - Oswestry Disability Index (ODI) scores over time|changes in Quality of life - Short form Health Survey 36 (SF-36)|changes in MRI monitoring of transplant site","Salim M Hayek|University Hospitals Cleveland Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","014924/0012/A002","June 2019","September 30, 2021","September 30, 2022","October 2, 2018",,"April 4, 2019","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03692221"
600,"NCT02398604","Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome","ELPIS","Terminated","No Results Available","Hypoplastic Left Heart Syndrome","Drug: Allo-hMSCs|Drug: Placebo","Monitor major adverse cardiac events|Composite Change from baseline in right ventricular function, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular end-systolic diameter and tricuspid regurgitation|Number of participants with incidence of mortality or need for transplantation after the BDCPA operation|Composite Changes in somatic growth velocity over time (weight, height, head circumference) from the BDCPA operation|Assessment of Co-morbidity","Longeveron Inc.","All","up to 30 Days   (Child)","Phase 1","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140718","April 2015","March 2019","March 2019","March 25, 2015",,"July 19, 2021","University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02398604"
601,"NCT03458156","Umbilical Cord Mesenchymal Stem Cell Transplantation for Lupus Nephritis",,"Unknown status","No Results Available","Lupus Nephritis","Biological: SLE group|Biological: LN group|Other: the control group","SLEDAI-2000 score|BILAG-2004 score|Health Assessment Questionnaire (HAQ) score","The First Affiliated Hospital of Dalian Medical University","All","18 Years to 60 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DalianMU_JL_002","January 2017","September 2019","January 2020","March 8, 2018",,"March 12, 2018",,,"https://ClinicalTrials.gov/show/NCT03458156"
602,"NCT02013674","The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)","Trident","Completed","Has Results","Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction","Biological: Allogeneic hMSCs","Number of Participants With Treatment-emergent Serious Adverse Events (SAE).|Infarct Scar Size (ISS)|Number of Participant With Reported Tissue Perfusion|Peak Oxygen Consumption (VO2)|Six-minute Walk Test.|Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.|Number of Incidents of Major Adverse Cardiac Events (MACE).|Number of Participants With Treatment Emergent Adverse Event (AE)|Minnesota Living With Heart Failure (MLHF) Questionnaire Scores|Echocardiographic-derived Measures of Left Ventricular Function|Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)|Difference Between the Regional Left Ventricular Wall Thickening|Difference Between Left Ventricular End Diastolic Wall Thickness|Difference Between the Left Ventricular Ejection Fraction (LVEF)|Difference in LVEF|Difference in Left Ventricular Volume|Difference in Left Ventricular Regional Myocardial Perfusion|Number of Participants With Abnormal Electrocardiogram (ECG) Reads.|Number of Clinically Significant of Abnormal Lab Values.|Serial Troponin I|Number of Participants With Abnormal ECHO Reading|Creatinine Kinase Muscle/Brain (CK-MB)","Joshua M Hare|The Emmes Company, LLC|University of Miami","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120660","February 13, 2014","March 2, 2017","September 18, 2017","December 17, 2013","February 5, 2020","February 11, 2020","ISCI / University of Miami, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02013674/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02013674"
603,"NCT04213248","Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD",,"Recruiting","No Results Available","Dry Eye","Drug: Umbilical Mesenchymal Stem Cells derived Exosomes","Changes in Ocular Surface Disease Index (OSDI) Score|Changes in tear secretion amount by Schirmer's Test|Changes in Tear break time|Changes in Ocular Surface Staining|Changes in best corrected visual acuity (BCVA).|Changes in conjunctiva redness score|Changes in tear meniscus height","Zhongshan Ophthalmic Center, Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019KYPJ048","February 18, 2020","May 2020","May 2020","December 30, 2019",,"February 21, 2020","Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04213248"
604,"NCT02611167","Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)","Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy|Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score|Change in motor function as assessed by the UPDRS Motor score|Change in motor function as assessed by Timed-Up-and-Go (TUG)|Change in disability as measured by the Modified Hoehn and Yahr Scale|functional connectivity between substantia nigra and dorsal striatum as assessed by resting state functional magnetic resonance imaging (fMRI)|perfusion as assessed by arterial spin-labeled (ASL) perfusion MRI|structural connectivity as assessed by diffusion-weighted MRI for diffusion tensor image (DTI) analysis|volume of subcortical structures as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|cortical thickness as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in gross brain structure as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in brain activity as assessed by task state fMRI|Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score|Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)|Change in cognitive function as assessed by the Montreal Cognitive Assessment (MoCA)|Change in immunologic response as assessed by plasma concentrations of cytokines|Change in suicidal ideation or behaviors as assessed by and Columbia Suicide Severity Rating Scale (CSSRS)","The University of Texas Health Science Center, Houston","All","45 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-Schiess MSC PD","November 1, 2017","September 18, 2019","September 18, 2019","November 20, 2015",,"September 7, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02611167"
605,"NCT04888949","A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)",,"Recruiting","No Results Available","SARS-CoV-2 Infection( COVID-19 )","Biological: Mesenchymal stem cell|Biological: Placebo","Ventilator Free Days","Rohto Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADR-001-1921","June 15, 2021","September 30, 2022","September 30, 2022","May 17, 2021",,"September 10, 2021","Osaka University Hospital, Suita, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT04888949"
606,"NCT03874572","Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth","MESRIX-SAFETY","Active, not recruiting","No Results Available","Xerostomia Due to Radiotherapy|Hyposalivation|Xerostomia|Oropharynx Cancer|Salivary Gland Diseases|Dry Mouth|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Stem Cells","Biological: Allogeneic adipose derived stem/stromal cells","Safety: Number of patients with serious adverse events|Immune reponse :Development of donor specific antibodies|Efficacy: Change in Unstimulated Whole Salivary flow rate|Efficacy: Change in Stimulated Whole Salivary flow rate|Efficacy: Change in quality of life|Efficacy: Salivary gland function|Efficacy: Change in Saliva composition|Efficacy: Change in Saliva Proteomics|Efficacy: Change in RNA in Saliva|Immune reponse","Rigshospitalet, Denmark","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVB2018-2|2018-003856-19","March 18, 2019","June 22, 2020","December 1, 2025","March 14, 2019",,"January 29, 2021","Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark|Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03874572"
607,"NCT02962661","Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines",,"Recruiting","No Results Available","Cardiomyopathy|Heart Failure","Other: Best Practice|Other: Laboratory Biomarker Analysis|Biological: Mesenchymal Stem Cell Transplantation","Incidence of adverse events|Change in left ventricular ejection fraction (LVEF)|Change in improvement of left ventricular (LV) systolic function as assessed by LVEF|LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography|Cardiac death|Re-hospitalization after heart failure|Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing|Nonfatal myocardial infarction|Revascularization","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0835|NCI-2016-01921|P30CA016672","July 18, 2020","July 30, 2023","July 30, 2023","November 11, 2016",,"October 8, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02962661"
608,"NCT04602104","A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: low dose hMSC-Exos|Biological: medium dose hMSC-Exos|Biological: high dose hMSC-Exos|Biological: Dosage 1of hMSC-Exos|Biological: Dosage 2 of hMSC-Exos|Biological: No hMSC-derived exosomes","Incidence of adverse reaction|TTCI|28-day mortality|Murray lung injury score|PaO2/FiO2|SOFA score|ApachⅡ score|The number of days the survivor was in ICU","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","169","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEXARDS","November 30, 2020","June 2022","September 2022","October 26, 2020",,"November 2, 2021","Ruijin Hospital, Medical School of Shanghai Jiaotong University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04602104"
609,"NCT02698813","Safety Study of Filler Agent Composed of Umbilical Cord Mesenchymal Stem Cells and Hyaluronic Acid",,"Unknown status","No Results Available","Senescence Wrinkles, Acne, Pitting Scar","Biological: umbilical cord mesenchymal stem cells and hyaluronic acid|Drug: hyaluronic acid","Proportion of patients with non-serious and serious adverse events|Wrinkle Severity Rating Scale (WSRS) Evaluation|Global Aesthetic Improvement Scale (GAIS) Evaluation","South China Research Center for Stem Cell and Regenerative Medicine","All","18 Years to 60 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","UCMSC-HA-1","December 2016","December 2018",,"March 4, 2016",,"March 4, 2016",,,"https://ClinicalTrials.gov/show/NCT02698813"
610,"NCT03325504","A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union","ORTHOUNION","Active, not recruiting","No Results Available","Non Union Fracture","Biological: Cultured Mesenchymal Stem Cells|Procedure: Autologous iliac crest graft","Bone consolidation|Radiological Bone consolidation|Level of Pain|Complications|Health status","Universidad Autonoma de Madrid","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ORTHOUNION|2015-000431-32|EUCTR2015-000431-32-ES","September 5, 2017","June 30, 2021","June 30, 2022","October 30, 2017",,"October 6, 2021","CHU Clermont-Ferrand, Clermont-Ferrand, France|Department of Orthopaedic Surgery, Hospital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHU Nantes, Nantes, France|Department of Orthopaedic Surgery Toulouse University Hospital, Toulouse, France|Department of Orthopaedic Surgery, CHU Tours, Tours, France|Universitätsklinikum Frankfurt, Department of Trauma, Hand and Reconstructive Surgery, Frankfurt, Germany|Universitätsklinikum Freiburg, Klinik für Orthopädie und Unfallchirurgie, Freiburg, Germany|Universitätsklinikum München, Munich, Germany|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, SSD Fisiopatologia Ortopedica e Medicina Rigenerativa, Bologna, Italy|Arienda Spedali Civili di Brescia II Ortopedia e Traumatologia, Brescia, Italy|Istituto Ortopedico Galeazzi, Chirugia dell´Anca l, Milano, Italy|Azienda Ospedaliero- Universitaria di Modena, Reparto di Ortopedia e Traumatologia, Modena, Italy|Azienda Universitaria Ospedaliera di Pisa- II, Clinica di Ortopedia e Traumatologia, Pisa, Italy|Hospital U. Puerta de Hierro-Majadahonda, Servicio de Cirugía Ortopédica y Traumatología, Majadahonda, Madrid, Spain|Hospital Clínica San Carlos, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. 12 de Octubre, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. Gregorio Marañon, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. La Princesa, Servicio de CirugíaOrtopédica y Traumatología, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03325504"
611,"NCT03070275","Dental Implant Placement in Adjunction With Autologous Alveolar Bone-Marrow Derived Mesenchymal Stem Cells (aBM-MSCs)","Implant_bone","Completed","No Results Available","Implant Therapy","Biological: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Procedure: Two-stage surgical implant placement","A reduction in the marginal bone levels|Radiographic changes in the marginal bone levels|Reduction in the thickness of the buccal/lingual bone|Changes in the alveolar mucosa|Changes in the width of keratised mucosa","Aristotle University Of Thessaloniki","All","20 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ELKE_91480","February 2015","June 2017","December 2017","March 3, 2017",,"November 1, 2018",,,"https://ClinicalTrials.gov/show/NCT03070275"
612,"NCT03847844","UCMSCs as Front-line Approach of Treatment for Patients With aGVHD","GVHD Cyto-MSC","Recruiting","No Results Available","Acute-graft-versus-host Disease","Biological: Umbilical cord derived mesenchymal stem cell|Other: Placebo","Rate of Complete Response (CR) at Day 28|Rate of Partial Response (PR) at Day 28|Rate of PR and CR at Day 14|Percentage of patient requiring MMF rescue during treatment|Rate of long term complication incidence|Rate of chronic clinical response incidence|Overall survival (OS) rate at 3 months|Correlation between response to Cyto-MSC at Day 14 and Day 28 to survival at 90 days|Relapse-free survival at 3 months|Disease relapse at 3 months|Incidence of infection|Incidence of CMV reactivation|Measurement quality of life of cancer patients by using EORTC QLQ-C30 questionnaire|Measurement quality of life in bone marrow transplantation by using FACT-BMT questionnaire|Measurement of health-related quality of life in children and young people by using PEDsQL questionnaire (patients age less than 18 years old)|Measurement of generic health status among patients by using EQ-5D questionnaire","Cytopeutics Sdn. Bhd.|Universiti Tunku Abdul Rahman|Ministry of Science, Technology and Innovation, Malaysia","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","POD0030/CP/R","February 1, 2019","October 31, 2021","December 31, 2021","February 20, 2019",,"July 15, 2020","Hospital Ampang, Ampang, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT03847844"
613,"NCT04834609","Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas",,"Completed","No Results Available","Perianal Fistula|Adipose Tissue|Tissue Transplantation","Procedure: Injection of autologous adipose tissue in anal fistula","Investigation of cell proliferation of AT-MSCs|Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte|Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast|Measurement of gene expression profile of AT-MSCs|Healing of anal fistula after treatment|Evaluation of fistula healing after treatment|Functional gastroenterological outcome after treatment|Defecation disorder evaluation after treatment|Functional urological outcome after treatment","University of Aarhus|University of Southern Denmark|UiT The Arctic University of Norway","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT-MSCs_Anal fistulas","January 2015","October 2017","February 2021","April 8, 2021",,"April 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04834609"
614,"NCT03137199","Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma","ASTEC","Terminated","No Results Available","Asthma","Biological: hMSCs","Number of Participant with treatment emergent serious adverse events|Difference in lung function|Decrease in peripheral eosinophilia|Difference in subject reported dyspnea and quality of life assessments|Death from any cause","Marilyn Glassberg|The Marcus Foundation|University of Miami","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160350","June 22, 2017","March 3, 2020","April 29, 2020","May 2, 2017",,"May 21, 2020","University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03137199"
615,"NCT04654286","Human Amniotic Membrane and Mesenchymal Stem Cells Composite","BPI+MSC","Recruiting","No Results Available","Brachial Plexus Neuropathies","Procedure: Nerve transfer procedure|Procedure: Nerve transfer with HAM-AdMSC composite wrapping","Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Functional motor power outcome pre-surgery|Functional motor power outcome at 12 months follow-up|Initial elbow flexion MRC grade 1 (in months)|Initial elbow flexion MRC grade 3 (in months)|Pain outcome pre-surgery|Pain outcome at 12 months follow-up|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at 12 months follow-up|Short Form-36 (SF-36) score pre-surgery|Short Form-36 (SF-36) score at 12 months follow-up","Dr. Soetomo General Hospital","All","15 Years to 55 Years   (Child, Adult)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","647 / Panke.KKE/ XI / 2016","November 17, 2016","July 30, 2021","July 30, 2022","December 4, 2020",,"December 7, 2020","Cell and Tissue Bank - Regenerative Medicine, Dr. Soetomo General Academic Hospital/ Faculty of Medicine Universitas Airlangga, Surabaya, East Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04654286"
616,"NCT05116761","ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome",,"Not yet recruiting","No Results Available","Covid19|Postviral Syndrome|Dyspnea","Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline","Increased distance on Six Minute Walk Test (6MWT)|Incidence of Serious Adverse Events (SAEs)|EuroQol-5D (EQ-5D)|Medical Research Council (MRC) Dyspnea Scale","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DB-EF-POSTCOVID-0002","December 2021","August 2022","August 2022","November 11, 2021",,"November 11, 2021",,,"https://ClinicalTrials.gov/show/NCT05116761"
617,"NCT01442129","The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation",,"Completed","Has Results","Heart Failure|Cardiomyopathy|Ventricular Dysfunction","Biological: MPC Intramyocardial injection|Biological: Control Solution","Intervention Related Adverse Events|Functional Status and Ventricular Function","Deborah Ascheim|National Heart, Lung, and Blood Institute (NHLBI)|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 08-1078-00006|U01HL088942|U01HL088942-04|711","April 2012","March 2013","August 2013","September 28, 2011","October 13, 2014","May 1, 2015","University of Florida, Gainsville, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Montefiore Einstein Heart Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States|Texas Heart Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01442129"
618,"NCT03044119","The Effect of Platelet Rich Fibrin Matrix With and Without Peripheral Blood Mesenchymal Stem Cells on Implant Stability",,"Unknown status","No Results Available","Dental Implants","Biological: Dental Implant with PRFM|Biological: Dental Implant with PRFM and PBMSCs","Insertion torque values at the time of placement of dental implant|Implant stability quotient (ISQ) using Resonance frequency analysis (RFA).","KLE Society's Institute of Dental Sciences","All","25 Years to 50 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KLESInstitute","March 15, 2018","July 20, 2019","October 20, 2019","February 6, 2017",,"January 16, 2019","Kle Society'S Institute of Dental Sciences, Bengaluru, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT03044119"
619,"NCT04011059","Randomized Study of Coronary Revascularization Surgery With Injection of WJ-MSCs and Placement of an Epicardial Extracellular Matrix","scorem-cells","Not yet recruiting","No Results Available","Cardiovascular Diseases|Heart Failure|Coronary Artery Disease|Mesenchymal Stem Cell Transplantation|Regenerative Medicine","Biological: Wharton's jelly-derived mesenchymal cells","Left ventricular ejection fraction (LVEF)|Final diastolic and systolic volumes|Left ventricule viability|Ventricular arrhythmias|Estimated functional status|Change in the median score of Quality of life|Delayed enhancement of the left ventricle|Improvement in the 6-minute walk test|Mortality at 3 and 12 months due to cardiovascular causes|Mortality at 3 and 12 months due to all causes","Hospital San Vicente Fundación|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)|IPS Universitaria Servicios de Salud Universidad de Antioquia|Hospital San Vicente Fundación - Rionegro","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","001","July 2, 2019","January 30, 2022","June 30, 2023","July 8, 2019",,"July 9, 2019","Hospital San Vicente Fundación, Medellín, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT04011059"
620,"NCT02384499","Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study",,"Completed","No Results Available","Fecal Incontinence","Biological: ALLO-ASC injection|Drug: Placebo","Clinically measured abnormality of laboratory tests and adverse events|Satisfaction as measured by Wexner Score","Yonsei University","All","19 Years and older   (Adult, Older Adult)","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","3-2014-0271","December 2014","June 30, 2017","June 30, 2017","March 10, 2015",,"August 13, 2018","Section of Colon and Rectal Surger, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02384499"
621,"NCT03994666","Cell Therapy in Critical Limb Ischemia","CLI","Not yet recruiting","No Results Available","Critical Limb Ischemia","Biological: allogeneic umbilical cord-derived mesenchymal stem cells|Biological: Placebo (NaCl)","Incidence of treatment - emergent adverse events|Transcutaneous oxygen pressure","CHU de Reims","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PO19059","September 2019","December 2020","December 2021","June 21, 2019",,"June 21, 2019","Damien JOLLY, Reims, France",,"https://ClinicalTrials.gov/show/NCT03994666"
622,"NCT01038596","Mesenchymal Stromal Cells and Osteoarthritis",,"Completed","No Results Available","Osteoarthritis",,"Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donors|Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation","Technische Universität Dresden|German Federal Ministry of Education and Research","All","50 Years to 90 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HipMSC-Osteoarthritis","January 2009","June 2016","December 2016","December 24, 2009",,"April 14, 2017","University Hospital Dresden, Orthopaedic Department, Dresden, Germany",,"https://ClinicalTrials.gov/show/NCT01038596"
623,"NCT01724398","Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Plasma Exchange for Patients With Liver Failure",,"Unknown status","No Results Available","Liver Failure","Other: Conventional plus UC-MSC treatment|Other: Conventional plus PE treatment|Other: Conventional plus UC-MSC and PE therapy|Other: Conventional treatment","Survival rate and time|Improve biochemical indexes [alanine aminotransferase (ALT), albumin (ALB), total bilirubin (TBIL), prothrombin time (PT), INR and so on]|The clinical symptom improvement [including appetite, debilitation, abdominal distension, edema of lower limbs, et al]|Liver function evaluation using Child-Pugh score and MELD score|Immune function improvement [including Th1/Th2]|The occurrence of complications [including body temperature, tetter and allergy]|Incidence of hepatocellular carcinoma","Third Affiliated Hospital, Sun Yat-Sen University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-PE","November 2012","March 2015","March 2015","November 9, 2012",,"February 28, 2013","Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01724398"
624,"NCT04544215","A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection",,"Recruiting","No Results Available","Drug-resistant","Biological: Dosage 1 of MPCs-derived exosomes|Biological: Dosage 2 of MPCs-derived exosomes|Biological: No MPCs-derived exosomes","Primary Outcome Measures:|1.Bacterial clearance rate on the 8th d;|2.Mortality on the 28th and 90th d;|3.Recurrence rate after cure within 28 d;|4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;|5.Duration of mechanical ventilation within 28 d;|6.Length of ICU stay (d) within 28 d;|7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEXDR","July 1, 2020","May 2023","July 2023","September 10, 2020",,"September 10, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04544215"
625,"NCT03552848","Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection",,"Unknown status","No Results Available","Multiple Organ Dysfunction Syndrome","Biological: MSC","survival after intervention|adverse events|sequential organ failure assessment score(SOFA)|interleukin-6|the effects on kidney function|the effects on liver function|the effects on lung function|the effects on coagulation function|the effects on central nervous system","Fujian Medical University","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2018005","July 1, 2018","December 1, 2019","December 1, 2019","June 12, 2018",,"June 18, 2019","Department of Cardiovascular Surgery, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT03552848"
626,"NCT02104440","Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro",,"Completed","No Results Available","Cytopenia","Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded ""in vitro""","Adverse effects at the time of infusion and infections after infusion of MSC|Mesenchymal cell efficiency in recovering cytopenia","Red de Terapia Celular|University of Navarrra Hospital (Clinica Universitaria)|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Hospitales Universitarios Virgen del Rocío|Spanish National Health System","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/CIT|2013-000534-35","October 2013","March 2017","March 2017","April 4, 2014",,"March 30, 2017","University Clinical Hospital of Salamanca, Salamanca, Salamanca/Castilla León, Spain",,"https://ClinicalTrials.gov/show/NCT02104440"
627,"NCT03174587","Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis",,"Completed","No Results Available","Lupus Nephritis","Biological: allogenic bone marrow derived mesenchymal stem cells","Safety assessment(evaluation)","Corestem, Inc.|Hanyang University","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","7","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS20AT04-LN101","May 30, 2017","March 12, 2019","August 19, 2019","June 2, 2017",,"November 20, 2019","Hanyang university hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03174587"
628,"NCT00698191","Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)",,"Unknown status","No Results Available","Refractory Systemic Lupus Erythematosus","Biological: Allogeneic MSC (AlloMSC)","Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)|Lupus serology (ANA, dsDNA, C3, C4)|Renal function (GFR, BUN, urinalysis)|Percentage of systemic T regulatory population","Nanjing Medical University|National Natural Science Foundation of China","All","15 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSFC30772014","March 2007","December 2011","December 2012","June 17, 2008",,"June 17, 2008","Department of Rheumatology and Immunology, Nanjing University Medical College Affiliated Drum Tower Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT00698191"
629,"NCT04744051","ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion",,"Recruiting","No Results Available","Post-Concussion Syndrome","Drug: 50 Adipose Derived Stem Cell Infusion|Drug: 150 Adipose Derived Stem Cell Infusion|Drug: 300 Adipose Derived Stem Cell Infusion|Drug: Placebo Infusion","Health Status using the 36 item Short Form Health Survey (SF-36)|Assessment of Visual Attention and Task Switching|Assessment of Contextual Verbal Learning|Assessment of Verbal Fluency|Assessment of Attention and Executive functions|Assessment of Unstructured Verbal Learning and Memory|Assessment of Visuospatial Learning and Memory|Assessment of Symptoms of Anxiety over Time|Assessment of Pain|Assessment of Sleep Quality|Assessment of Treatment by Participant|Assessment of Depression by Participant","American CryoStem Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRYO_PCS_ADSC_001|FDA File No. 019089","February 2021","September 2021","November 2021","February 8, 2021",,"February 9, 2021","BioSolutions Clinical Research Center, La Mesa, California, United States",,"https://ClinicalTrials.gov/show/NCT04744051"
630,"NCT05043610","MSCs for Prevention of MI-induced HF","PREVENT-TAHA","Recruiting","No Results Available","Myocardial Infarction, Acute|Myocardial Infarction First|Myocardial Infarction, Anterior Wall|Cardiac Remodeling, Ventricular|STEMI|Regenerative Medicine|Heart Failure","Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|Other: Conventional Treatment","Incidence of Heart Failure|Change in Left Ventricular Function from base line|Cardiovascular Death|Composite outcome of cardiovascular death and heart failure incidence","Shiraz University of Medical Sciences|National Institute of Medical Research Development (NIMAD), Iran|Cell Tech Pharmed Company, Iran","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IR.SUMS.REC.1400.409","January 1, 2021","November 1, 2025","November 1, 2025","September 14, 2021",,"September 14, 2021","Al-Zahra Heart Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of|Faghihi Hospital, Shiraz, Fars, Iran, Islamic Republic of|Namazee Hospital, Shiraz, Fars, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05043610"
631,"NCT04399889","hCT-MSCs for COVID19 ARDS",,"Recruiting","No Results Available","COVID|Corona Virus Infection|COVID19","Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Other: Placebo","Safety of the Investigational Product- Infusion Reactions|Safety of the Investigational Product- delayed reactions|Safety of the Investigational Product- formation of anti-HLA antibodies|Time to recovery|Increase in PaO2/FiO2 ratio|Days to hospital discharge to home|The number of ventilator free days|Number of days requiring oxygen support|Percent of screened patients who are enrolled and randomized","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00105410","June 18, 2020","April 1, 2022","July 31, 2022","May 22, 2020",,"October 25, 2021","Boca Raton Regional Hospital, Boca Raton, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|University of Miami Hospital, Miami, Florida, United States|New York Medical College, Valhalla, New York, United States|Duke Hospital, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04399889"
632,"NCT03326505","Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment",,"Completed","No Results Available","Multiple Sclerosis","Biological: Umbilical cord derived Mesenchymal Stem Cells|Other: Supervised physical therapy","Isolation and Expansion of Mesenchymal Stem Cells|Safety and Efficacy Assessment Pre and Post Treatment|Motor Functions Assessments|Measuring Non-motor outcomes to assess treatment efficacy.|Biological Assessments","University of Jordan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","ALLOMSUJCTC","September 25, 2017","January 25, 2020","February 20, 2020","October 31, 2017",,"March 4, 2020","Cell Therapy Center, University of Jordan, Amman, Jordan|Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03326505"
633,"NCT04457609","Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients",,"Recruiting","No Results Available","COVID|Pulmonary Infection|Sars-CoV2","Drug: Oseltamivir|Drug: Azithromycin|Biological: Umbilical Cord Mesenchymal Stem Cells","Clinical improvement: Presence of dyspnea|Clinical improvement: presence of sputum|Clinical improvement: fever|Clinical improvement: ventilation status|Clinical improvement: blood pressure|Clinical improvement: heart rate|Clinical improvement: respiratory rate|Clinical improvement: oxygen saturation|General laboratory outcome from leukocyte level|General laboratory outcome from lymphocytes level|General laboratory outcome from blood pH|General laboratory outcome from blood level of CO2|General laboratory outcome from blood base excess level|General laboratory outcome from blood oxygen partial pressure|General laboratory outcome from blood level of HCO3|General laboratory outcome from blood level of O2 saturation|General laboratory outcome from level of CRP|General laboratory outcome from level of SGOT/SGPT (AST/ALT)|General laboratory outcome from the level of ureum/creatinine level|General laboratory outcome from the level of eGFR|General laboratory outcome from the level of sodium|General laboratory outcome from the level of potassium|General laboratory outcome from the level of chloride|Changes in procalcitonin level|General laboratory outcome from albumin level|General laboratory outcome from total bilirubin level|Changes in D-Dimer level|Changes in fibrinogen level|Cardiac changes from troponin level|Cardiac changes from NT proBNP level|Changes in Leukemia Inhibiting Factor|Changes in level of IL-6|Changes in level of IL-10|Changes in level of vascular endothelial growth factor (VEGF)|Changes in level of ferritin|Changes in level of CXCR3|Changes in level of CD4|Changes in level of CD8|Changes in level of CD56|Radiologic Improvement from Chest X-Ray/CT Scan","Indonesia University","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISMMSCCOVID19","July 2020","August 2020","September 2020","July 7, 2020",,"July 7, 2020","Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|Persahabatan General Hospital, Jakarta, DKI Jakarta, Indonesia|Sulianti Saroso Center for Infectious Disease, Jakarta, DKI Jakarta, Indonesia|Universitas Indonesia Hospital, Depok, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04457609"
634,"NCT03102879","Encapsulated Mesenchymal Stem Cells for Dental Pulp Regeneration.","RanoKure","Completed","Has Results","Periapical Periodontitis","Procedure: Regenerative Endodontic Procedure|Procedure: Conventional Root Canal Treatment","Number of Participats Showing Efficacy (Functionality)|Change in Pulpal Response|Change in Apical Lesion Size|Pain to Percussion|Numbers of Participants With Adverse Event|Pulp Regeneration","Universidad de los Andes, Chile|Cells for Cells, Chile","All","16 Years to 58 Years   (Child, Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPD-8-16","September 23, 2016","September 30, 2018","September 30, 2018","April 6, 2017","January 21, 2020","January 21, 2020","Universidad de los Andes, Santiago, Chile","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03102879/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03102879"
635,"NCT02195323","Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Chronic Kidney Disease","Biological: Intravenous injection","mass formation|Creatinin|GFR","Royan Institute","All","25 Years to 60 Years   (Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Kidney-004","April 2014","December 2015","January 2016","July 21, 2014",,"January 5, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02195323"
636,"NCT03973827","Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes",,"Recruiting","No Results Available","Type1diabetes","Drug: ProTrans","The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions|Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.|Number of patients insulin independent (ADA criteria) at day 372.|Number of patients with daily insulin needs <0.25U/kg at day 372.|HbA1c at day 372|Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372|Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.","NextCell Pharma Ab","Male","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ProTrans-Repeat|2018-004158-11","May 17, 2019","October 17, 2020","October 17, 2024","June 4, 2019",,"June 5, 2019","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT03973827"
637,"NCT01668576","Properties of Mesenchymal Stem Cells in Lung Transplant",,"Terminated","No Results Available","Lung Transplantation",,"Intrinsic variability of MSCs measured by time to third passage of confluent MSC|2-3 IDO production measured as ug/mL of passage 3 MSCs|Percent specific inhibition of CD4 and CD8 T cell proliferation toward donor target cells in one way mixed-lymphocyte reactions","Emory University","All","18 Years to 70 Years   (Adult, Older Adult)",,"4","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB00053075","August 2012","September 2014","September 2014","August 20, 2012",,"January 14, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01668576"
638,"NCT01322906","Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV)",,"Unknown status","No Results Available","Liver Failure","Other: Group 1|Other: Group 2|Other: Group 3","Liver Function|Immune state","Sun Yat-sen University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABMS-LF","March 2011","November 2011","July 2012","March 25, 2011",,"April 11, 2011",,,"https://ClinicalTrials.gov/show/NCT01322906"
639,"NCT01213953","Isolation and Authentication of Mesenchymal Stem Cell-like Progenitor Cells From the Degenerated Intervertebral Disc of Lumbar Spine",,"Unknown status","No Results Available","Lower Back Pain|Disc Degeneration",,,"Taipei Medical University WanFang Hospital","All","20 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","98025","September 2010","October 2011","December 2011","October 4, 2010",,"October 19, 2010","Taipei Medical University - WanFang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01213953"
640,"NCT04366830","Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection",,"No longer available","No Results Available","Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19","Drug: Remestemcel-L",,"Mesoblast International Sàrl|Mesoblast, Ltd.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"MSB-MSC-ARDS001",,,,"April 29, 2020",,"February 18, 2021","Mount Sinai Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04366830"
641,"NCT02484560","Efficacy of Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2",,"Unknown status","No Results Available","Duchenne Muscular Dystrophy","Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell","Degree of improvement in patients with Duchenne Muscular Dystrophy after stem cell therapy treatment administered using Northstar Ambulatory Assessment, Magnetic Resonance Imaging & Spectroscopy, muscle strength assessment equipment, and a questionnaire.","University of Gaziantep|Istınye University, Cukurova University, Yıldırım Beyazıt University, Gaziantep Deva Hospital, Gaziantep Public Hospital","Male","8 Years to 14 Years   (Child)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","56733164/203","June 2015","December 2015","December 2015","June 29, 2015",,"July 1, 2015","Gaziantep University Hospital, Gaziantep, Turkey",,"https://ClinicalTrials.gov/show/NCT02484560"
642,"NCT03137979","Gingiva Mesenchymal Stem Cells Treatment of Chronic Periodontitis",,"Unknown status","No Results Available","Periodontitis","Biological: GMSCs and collagen scaffolds|Biological: Collagen scaffolds|Procedure: Open flap debridement","The evaluation of alveolar bone regeneration|Probing pocket depth (PPD)|Attachment level (AL)|Gingival index (GI)|Tooth mobility degree (TMD)","Hebei Medical University","All","35 Years to 60 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","17277787D-PD","January 2017","December 2018","December 2019","May 3, 2017",,"May 3, 2017","the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China",,"https://ClinicalTrials.gov/show/NCT03137979"
643,"NCT04497805","Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-SHEET","Proportions of subjects who achieved complete wound closure.|Time to initial complete wound closure between the 2 groups.|Changes in wound size compared to baseline between the 2 groups.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.|Durability of complete wound closure for the additional 24 weeks.","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALLO-ASC-SHEET","August 1, 2020","June 2022","December 2022","August 4, 2020",,"January 22, 2021","University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04497805"
644,"NCT04971980","Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis",,"Recruiting","No Results Available","Rheumatoid Arthritis","Drug: hUC-MSC infusion (BC-U001)","Number and frequency of adverse events (AEs)|Changes of vital signs from 1 hour after infusion to day 28±3|Changes of complete blood count (CBC) from day 1 to day 28±3|Changes of blood biochemical from day 1 to day 28±3|Changes of coagulation function from day 1 to day 28±3|Routine urine analysis|Urine pregnancy test (female only)|Cardiac rate measured by twelve-lead electrocardiogram|Percentage of participants achieving ACR20|Percentage of participants achieving ACR50|Percentage of participants achieving ACR70|Change from baseline of the disease activity score based on DAS28-CRP|Change from baseline of the disease activity score based on DAS28-ESR|EULAR response|Change from baseline of the health assessment questionnaire(HAQ) score|Change from baseline of the simplified disease activity index (SDAI) score|Change from baseline of the clinical disease activity index (CDAI) score|Change from baseline of TNF-α level|Change from baseline of IL-6 level","Beijing Baylx Biotech Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BC-U001-RA2019","April 12, 2021","April 2022","December 2022","July 22, 2021",,"July 26, 2021","Peking Union Medical College Hospital (Dongdan campus), Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04971980"
645,"NCT01652209","To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.",,"Recruiting","No Results Available","Acute Myocardial Infarction","Biological: Hearticellgram-AMI","LVEF amount of change|Infarct size amount of change|Left ventricle end systolic size change|Left ventricular end-diastolic size change|Incidence of critical heart events|Heart rate variability change amount|Left ventricular local wall movement disorder index change|N-terminal pro-brain natriuretic peptide (NT-proBNP) change","Pharmicell Co., Ltd.","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-BD-CT-P-003","September 1, 2013","August 31, 2022","December 31, 2023","July 27, 2012",,"October 22, 2021","Kangwon National University Hospital, Chuncheon, Korea, Republic of|Chungnam National University Hospital, Chungnam, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Yongin Severance Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Catholic University of Korea, Seoul ST. Mary's Hospital., Seoul, Korea, Republic of|Korea University Medicine, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wŏnju, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01652209"
646,"NCT02033525","Mesenchymal Stromal Cells for Degenerative Meniscus Injury",,"Completed","No Results Available","Chronic Meniscal Injury","Drug: XCEL-M-ALPHA and standard rehabilitation|Other: Rehabilitation","VAS for pain|Safety|Efficacy by MRI|Efficacy by clinical questionnaires","Banc de Sang i Teixits|Hospital Universitari Quirón Dexeus|Ministerio de Sanidad, Servicios Sociales e Igualdad","All","40 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-MEN-01|2011-006270-13","January 31, 2014","May 2, 2017","May 2, 2017","January 10, 2014",,"January 9, 2018","ICATME-Hospital Quiron Dexeus, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02033525"
647,"NCT00482092","Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease",,"Completed","No Results Available","Crohn's Disease","Drug: adult human mesenchymal stem cells|Drug: Placebo","Disease remission (CDAI at or below 150)|Disease improvement (Reduction by at least 100 points in CDAI)|Improvement in quality of life (IBDQ)|Reduction in number of draining fistulas","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRD 603","September 17, 2007","September 15, 2014","September 15, 2014","June 4, 2007",,"March 10, 2020","University of Southern California University Hospital, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Western States Clinical Research, Wheat Ridge, Colorado, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Carle Clinic Association, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Gulf Coast Research, Baton Rouge, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|National Institutes of Health, Bethesda, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Center for Clinical Studies, Dearborn, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|St Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Rochester Institute for Digestive Diseases, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University Hospital and Medical Center, Stony Brook, New York, United States|Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States|Options Health Research, Tulsa, Oklahoma, United States|Allegheney Center for Digestive Health, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Gastroenterology Center of the Midsouth, Germantown, Tennessee, United States|Nashville GI Specialists, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire Research Institute, Richmond, Virginia, United States|Seattle Gastroenterology Associates, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Health Science Centre, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|University of Otago, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand",,"https://ClinicalTrials.gov/show/NCT00482092"
648,"NCT00260338","Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia",,"Completed","No Results Available","Myocardial Ischemia|Coronary Heart Disease","Biological: stem cell","Improvement in myocardial perfusion measured by SPECT|Safety|Improvement in myocardial perfusion and function measured by PET and MR|Exercise time|Clinical angina status","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Jens Kastrup","December 2005","July 2009","July 2009","December 1, 2005",,"May 31, 2013","Cardiovascular Lab. 2014, The Heart Centre, Rigshospitalet, Blegdamcvej 9, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00260338"
649,"NCT01913886","Mesenchymal Stem Cells to Treat Ischemic Cardiomyopathy",,"Completed","No Results Available","Ischemic Cardiomyopathy","Procedure: MSCs injection","Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiogram.|Change in quality of life|Changes in exercise capacity|Changes in plasma inflammatory markers","Alexandra Cristina Senegaglia|Santa Casa de Misericórdia de Curitiba, Brazil|Fundação Araucária|Pontifícia Universidade Católica do Paraná","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC_Isquemica","January 2010","September 2013","March 2016","August 1, 2013",,"December 13, 2017","Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil",,"https://ClinicalTrials.gov/show/NCT01913886"
650,"NCT05093725","CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage",,"Not yet recruiting","No Results Available","Umbilical Cord of Normal Labor","Device: flow cytomery","evaluation the best passage of MSC culture by CD49 surface marker","Sohag University","All","Child, Adult, Older Adult",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Soh-med-21-10-01","November 2021","June 2022","June 2022","October 26, 2021",,"October 26, 2021","Sohag University Hospital, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT05093725"
651,"NCT05121870","Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis",,"Recruiting","No Results Available","Decompensated Cirrhosis","Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）","Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week|Change in MELD score from baseline to 48 weeks|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin activity (PA)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|ChronicLiver Disease Questionnaire (CLDQ)|Incidence of liver cancer|Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events","Beijing 302 Hospital|Shanghai Changzheng Hospital|LanZhou University|Renmin Hospital of Wuhan University|Chinese PLA General Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCRC-ID202105","September 1, 2021","June 30, 2023","December 31, 2023","November 16, 2021",,"November 16, 2021","The First Hospital of Lanzhou University, Lanzhou, Gansu, China|Hainan hospital of Chinese PLA General Hospital, Sanya, Hainan, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Beijing 302 Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05121870"
652,"NCT04346368","Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)",,"Not yet recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)","Biological: BM-MSCs|Biological: Placebo","Changes of oxygenation index (PaO2/FiO2)|Side effects in the BM-MSCs treatment group|Clinical outcome|Hospital stay|CT Scan|Changes in viral load|Changes of CD4+, CD8+ cells count and concentration of cytokines|Rate of mortality within 28-days|Changes of C-reactive protein","Guangzhou Institute of Respiratory Disease|Guangzhou Eighth People's Hospital|Tongji Hospital|Guangzhou Cellgenes Biotechnology Co.,Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SC-2020-01","April 2020","December 2020","December 2020","April 15, 2020",,"April 15, 2020","Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04346368"
653,"NCT01696591","The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD",,"Unknown status","No Results Available","Alzheimer Disease|Dementia|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Tauopathies|Neurodegenerative Diseases|Delirium, Dementia, Amnestic, Cognitive Disorders|Mental Disorders","Biological: NEUROSTEM®-AD","Safety|Efficacy","Duk Lyul Na|Medipost Co Ltd.|Samsung Medical Center","All","50 Years to 75 Years   (Adult, Older Adult)",,"14","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MP-CR-007-F/U","March 2012","September 2013","September 2013","October 1, 2012",,"October 1, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01696591"
654,"NCT03384433","Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke",,"Recruiting","No Results Available","Cerebrovascular Disorders","Biological: exosome","Incidence of Treatment-Emergent Adverse Events|measurement of Modified Ranking Scale","Isfahan University of Medical Sciences|Tarbiat Modarres University","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","med shahid beheshti university","April 17, 2019","June 17, 2021","December 17, 2021","December 27, 2017",,"January 25, 2021","Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03384433"
655,"NCT03449082","Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)",,"Active, not recruiting","No Results Available","Lateral Epicondylitis","Biological: High concentration of Allo-ASC|Biological: Low concentration of Allo-ASC|Drug: Fibrin glue|Drug: Normal saline","Change of pain visual analogue scale (VAS) during activity|Change of pain visual analogue scale (VAS) at rest|Change of Mayo elbow performance index (MEPI)|Ultrasonographic assessment|Shear wave elastography|Magnetic resonance image (MRI) assessment","Seoul National University Hospital|Korea Health Industry Development Institute","All","19 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNUH-RM-SGChung-ASC-02","May 4, 2018","April 3, 2019","December 30, 2021","February 28, 2018",,"March 26, 2021","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03449082"
656,"NCT03484741","Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: MSC and PRP","Fasting blood glucose|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose|C-peptide|Blood insulin level","Van Hanh General Hospital|University of Science Ho Chi Minh City","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIME 1001","April 1, 2017","November 2018","November 2018","April 2, 2018",,"April 4, 2018","Van Hanh Geral Hospital, Ho Chi Minh City, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03484741"
657,"NCT04288102","Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)",,"Completed","No Results Available","Corona Virus Disease 2019(COVID-19)","Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）","Change in lesion proportion (%) of full lung volume from baseline to day 28.|Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) × voxel volume (in voxel)|Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|Time to clinical improvement in 28 days.|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Blood oxygen saturation|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)|mMRC (Modified Medical Research Council) dyspnea scale|Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|Changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.|Adverse events|Serious adverse events|All-cause mortality","Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|The General Hospital of Central Theater Command|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-013-D","March 5, 2020","May 12, 2020","July 9, 2020","February 28, 2020",,"August 19, 2020","General Hospital of Central Theater Command, Wuhan, Hubei, China|Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04288102"
658,"NCT01143168","Stem Cell Therapy for Type 1 Diabetes Mellitus",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells","Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.|Serious adverse event frequency and severity","Cellonis Biotechnology Co. Ltd.","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellonis-CR-1.3","August 2010","August 2011","December 2011","June 14, 2010",,"June 14, 2010","Armed Police General Hospital, P. R. China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01143168"
659,"NCT05018858","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus",,"Recruiting","No Results Available","Lupus","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-4","October 2021","October 2025","October 2025","August 24, 2021",,"August 24, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018858"
660,"NCT01385644","A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis","MSC in IPF","Completed","Has Results","Idiopathic Pulmonary Fibrosis","Other: Placental MSC","Number of Participants Who Demonstrated Acute Adverse Events Following Infusion|Percentage Change in Lung Function as Assessed by FVC Compared to Baseline|Percentage Change in 6 Minute Walk Distance Compared to Baseline|Percentage Change in Lung Function as Assessed by DLCO Compared to Baseline","The Prince Charles Hospital|Mater Medical Research Institute","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HREC/09/QPCH/105","October 2010","May 2013","May 2013","June 30, 2011","December 29, 2015","December 29, 2015","The Prince Charles Hospital, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT01385644"
661,"NCT01297218","The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease",,"Completed","No Results Available","Dementia of the Alzheimer's Type","Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells","Number of participants with Adverse event|Changes from the baseline in ADAS-cog at 12 weeks post-dose","Medipost Co Ltd.","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CR-007","February 2011","September 2011","December 2011","February 16, 2011",,"April 23, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01297218"
662,"NCT05003960","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism",,"Recruiting","No Results Available","Autism","Biological: AlloRx","Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-8-02","September 2021","September 2025","September 2025","August 13, 2021",,"August 13, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003960"
663,"NCT05018819","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP",,"Recruiting","No Results Available","Cerebral Palsy","Biological: AlloRx","Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-11-ATG-11-02","November 2021","November 2025","November 2025","August 24, 2021",,"August 24, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018819"
664,"NCT05003908","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes",,"Recruiting","No Results Available","Diabetes","Biological: AlloRx","Safety (adverse events)|Efficacy: the level of A1C|Efficacy: the level of C-Peptide|Efficacy: Insulin dose reduction","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-11-01","November 2021","November 2025","November 2025","August 13, 2021",,"August 13, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003908"
665,"NCT05003388","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS",,"Recruiting","No Results Available","Multiple Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: Kurtzke Expanded Disability Status Scale (EDSS)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-9-03","October 2021","October 2025","October 2025","August 12, 2021",,"August 12, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003388"
666,"NCT05003934","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA",,"Recruiting","No Results Available","Rheumatoid Arthritis","Biological: AlloRx","Safety (adverse events)|Efficacy: the 28-joint disease activity score (DAS 28)|Efficacy: visual analog scale (VAS)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-10-03","September 2021","September 2025","September 2025","August 13, 2021",,"August 13, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003934"
667,"NCT05018832","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI",,"Recruiting","No Results Available","Traumatic Brain Injury","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-12-4","November 2021","November 2025","November 2025","August 24, 2021",,"August 24, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018832"
668,"NCT05018845","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD",,"Recruiting","No Results Available","Chronic Kidney Diseases","Biological: AlloRx","Safety (adverse events)|Efficacy: creatinine levels|Efficacy: changes in eGFR","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-22","November 2021","November 2025","November 2025","August 24, 2021",,"August 24, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018845"
669,"NCT05003947","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD",,"Recruiting","No Results Available","Inflammatory Bowel Diseases","Biological: AlloRx","Safety (adverse events)|Efficacy: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-11-04","October 2021","October 2025","October 2025","August 13, 2021",,"August 13, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003947"
670,"NCT05016804","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis",,"Recruiting","No Results Available","Systemic Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: skin score|Efficacy: Forced vital capacity (FVC)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-12-04","November 2021","November 2025","November 2025","August 23, 2021",,"August 23, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05016804"
671,"NCT05018767","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty",,"Recruiting","No Results Available","Frailty","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-11-ATG-12-01","November 2021","November 2025","November 2025","August 24, 2021",,"August 24, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018767"
672,"NCT05016817","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF",,"Recruiting","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: AlloRx","Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Oxygen saturation test","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-13-08","September 2021","September 2025","September 2025","August 23, 2021",,"August 23, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05016817"
673,"NCT04909892","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise",,"Withdrawn","No Results Available","Covid19","Biological: COVI-MSC","Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Change in Pulmonary Function Tests (PFTs)|Change in oxygenation|Change in biomarker levels","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-PLH-201","August 2021","January 2022","January 2022","June 2, 2021",,"September 16, 2021",,,"https://ClinicalTrials.gov/show/NCT04909892"
674,"NCT05003921","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS",,"Recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: revised ALS functional rating scale (ALSFRS-R)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-7-ATG-7-01","September 2021","September 2025","September 2025","August 13, 2021",,"August 13, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003921"
675,"NCT00114452","Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction",,"Completed","No Results Available","Myocardial Infarction","Biological: Provacel|Biological: Placebo","Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups.","Mesoblast, Inc.|Mesoblast, Ltd.","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","401-402","March 22, 2005","October 4, 2006","April 24, 2008","June 15, 2005",,"March 10, 2020","Arizona Heart Institute, Phoenix, Arizona, United States|University of California - San Diego; Thornton, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|Rush University Medical Center, Chicago, Illinois, United States|The Care Group, Indianapolis, Indiana, United States|Jewish Hospital, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington Adventist, Takoma Park, Maryland, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Columbia Presbyterian Hospital, New York, New York, United States|University of Rochester - Strong Memorial, Rochester, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Austin Heart Institute, Austin, Texas, United States|Texas Medical School, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00114452"
676,"NCT03828123","Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis","AMSC-ALS-001","Completed","No Results Available","Motor Neuron Disease, Amyotrophic Lateral Sclerosis","Biological: Suspension of human autologous MSC 3P in 1.5 ml","Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events|Efficacy: Inhibition of the disease progression - ALS functional rating scale|Efficacy: Inhibition of the disease progression - Norris scale|Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC)","Bioinova, s.r.o.|Department of Neurology, University Hospital Motol, Prague, Czech Republic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-ALS-001","January 2012","August 18, 2017","August 18, 2017","February 4, 2019",,"February 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03828123"
677,"NCT04104451","PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Drug: Corlicyte","SAE|Antibodies to HLA Class I - number and percent|Antibodies to HLA Class I - Time To Development|Increase Ulcer Size|Adverse Reaction|Suspected Adverse Reaction|Suspected Serious Adverse Reaction|Change in A1c","University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-1113","November 12, 2019","June 2022","September 2022","September 26, 2019",,"October 27, 2021","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04104451"
678,"NCT00955669","Comparison of Autologous Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer",,"Completed","No Results Available","Autologous Transplantation|Diabetic Foot","Biological: Symptoms and Objective Examination","Magnetic resonance angiography","Third Military Medical University","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ldb2008101","August 2009","August 2010","August 2010","August 10, 2009",,"December 1, 2010","the southwest Hospital, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT00955669"
679,"NCT05042206","Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Disease Stage 3B|Chronic Kidney Disease stage4","Biological: Cellgram-CKD","Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)|Changes in eGFR|Changes in BUN|Changes in Creatinine","Pharmicell Co., Ltd.","All","19 Years to 79 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-P-12","October 2021","April 2023","April 2023","September 13, 2021",,"October 21, 2021","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05042206"
680,"NCT02381366","Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study",,"Completed","No Results Available","Bronchopulmonary Dysplasia","Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells","Number of participants with adverse reactions for 84 days after treatment|Number of participants with adverse reactions between 84 days after treatment and 20 months of corrected age|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)|Hospital Re-admission between 84 days after treatment until 20 months of corrected age|Bayley Scales of Infant and Toddler Development between 84 days after treatment until 20 months of corrected age","Medipost America Inc.|Medipost Co Ltd.","All","up to 14 Days   (Child)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MD-BPD-US001","March 2015","September 2016","May 2018","March 6, 2015",,"August 16, 2018","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02381366"
681,"NCT01605383","Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head",,"Completed","No Results Available","Avascular Necrosis of Femur Head","Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment","Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Bone regeneration by measuring the necrotic angle using the modified Kerboul method|Dynamic changes of signal intensity|Clinical outcomes (pain) by Visual Analogue Scale (VAS)|Clinical outcomes (SF-36)|Clinical outcome (WOMAC)","Banc de Sang i Teixits|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain|European Regional Development Fund","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-MT-10-01|2010-023998-18","May 5, 2015","April 11, 2018","June 27, 2019","May 24, 2012",,"January 21, 2020","Hospital Universitari Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01605383"
682,"NCT01728727","Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis|End Stage Liver Disease","Other: UC-MSC transplantation|Other: conventional treatment","one year survival rate|MELD score|Child Pugh Score|alpha fetoprotein|renal function","Air Force Military Medical University, China|The Second Affiliated Hospital of Chongqing Medical University|Eastern Hepatobiliary Surgery Hospital|Chinese Academy of Medical Sciences|Fudan University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120912-3","September 2012","September 2014","September 2015","November 20, 2012",,"November 20, 2012","Xijing Hospital of Digestive Disease, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT01728727"
683,"NCT02013700","Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)","AETHER","Terminated","No Results Available","Idiopathic Pulmonary Fibrosis (IPF)","Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|Biological: matched placebo","To determine the safety and tolerability of intravenous allo hMSCs in patients with Idiopathic Pulmonary Fibrosis (IPF).|- To explore effects of allo hMSCs on lung function: forced vital capacity (FVC).|To explore effects of allogenic human mesenchymal stem cells on symptom related quality of life.|Difference in frequency of acute exacerbations of Idiopathic Pulmonary Fibrosis (IPF)|Death from any cause.|To explore effects of allogenic human mesenchymal stem cells on lung function: Diffusing Capacity (DLCO)","Joshua M Hare|The Lester And Sue Smith Foundation|The Emmes Company, LLC|University of Miami","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120946","November 13, 2013","December 11, 2015","November 24, 2016","December 17, 2013",,"March 9, 2021","Interdisciplinary Stem Cell Institute / University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02013700"
684,"NCT02449005","Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects","PerioRegen","Completed","No Results Available","Chronic Periodontitis","Biological: BM-MSCs/fibrin glue/collagen fleece|Other: Fibrin glue/collagen fleece|Procedure: Open flap debridement","A reduction in the distance in mm from the bottom of the periodontal pocket to the cementoenamel junction using a manual probe (Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) with 20-25g of pressure by a single calibrated examiner.|A reduction in the distance in mm between the gingival margin and the bottom of the defect using a manual periodontal probe (Hu-Friedy XP-23/QW) by a single calibrated examiner.","Aristotle University Of Thessaloniki|University of Glasgow","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELKE-90467","March 2014","September 2016","December 2016","May 20, 2015",,"November 1, 2018","Dental School, Aristotle University, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT02449005"
685,"NCT04064983","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease",,"No longer available","No Results Available","Parkinson Disease","Biological: HB-adMSCs",,"Hope Biosciences","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"HBPD01",,,,"August 22, 2019",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04064983"
686,"NCT00658073","Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts",,"Completed","No Results Available","Renal Transplant Rejection","Procedure: Kidney transplantation with MSCs infusion|Procedure: kidney transplantation without MSC infusion","Incidence rate of biopsy-proven acute rejection and early renal function recovery|Patient and graft survival and prevalence of adverse events","Fuzhou General Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-K-2","March 2008","September 2010","October 2010","April 14, 2008",,"March 8, 2011","Stem cell therapy center,Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT00658073"
687,"NCT04448106","Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis","AdMSCs","Not yet recruiting","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip|Osteoarthritis Shoulder","Biological: Celltex- AdMSCs","the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects.|Any organ damage or safety concerns determined by SMAC 20 blood test.|Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|changes in joint images (X-ray or MRI) from the baseline","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-002","August 1, 2021","August 1, 2022","August 15, 2024","June 25, 2020",,"July 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04448106"
688,"NCT01769872","Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","ASIA (American Spinal Injury Association) scale|Magnetic Resonance Imaging|MEP/SSEP|ADL (activities of daily living)|SF-36|ODI (Oswestry Disability Questionnaire)|Frequency of Adverse Events","R-Bio|Korea University Anam Hospital","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-SPI","January 2013","January 2016",,"January 17, 2013",,"August 2, 2016","Korea University Anam Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01769872"
689,"NCT05116540","Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis","HBMS01","Recruiting","No Results Available","Multiple Sclerosis","Biological: HB-adMSCs|Drug: Placebo","To investigate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by improvements in the Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Expanded Disability Status Scale (EDSS)|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Barthel Index|To determine the efficacy of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in 9-Hole Peg Test|To identify the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in Patient Health Questionnaire (PHQ-9)|To assess the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by the incidence of adverse events or serious adverse events","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBMS01","November 22, 2021","November 22, 2023","November 22, 2023","November 11, 2021",,"November 11, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05116540"
690,"NCT00836732","Mesenchymal Stem Cells: Alterations in Genome","MESSAGE","Completed","No Results Available","Pened Chest Surgery for Programmes Coronary Bypass","Procedure: harvest of a small bone marrow sample","Presence of small genetic alteration in mesenchymal stem cells","Nantes University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","BRD 08/9-S","November 2008","March 2012","March 2012","February 4, 2009",,"September 30, 2013","nantes University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT00836732"
691,"NCT01342250","Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis",,"Completed","No Results Available","Liver Cirrhosis","Biological: conventional therapy plus low dose hUC-MSCs treatment|Biological: conventional therapy plus medium dose hUC-MSCs treatment|Biological: conventional therapy plus high dose hUC-MSCs treatment","Overall Survival (OS)|Liver function improvement|The size of liver and the width of portal venous|Incidence of hepatocellular carcinoma within 1 year|Child-Pugh score, MELD score,SF36-quality of life (SF36-QOL)|The clinical symptom improvement(including appetite, debilitation, abdominal distension, edema of lower limbs, et al )","Shenzhen Beike Bio-Technology Co., Ltd.|No.85 Hospital, Changning, Shanghai, China","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BKCR-LD-1.0(2010)","October 2010","July 2011","October 2011","April 27, 2011",,"October 14, 2011","Shanghai Liver Disease Research Center, the Nanjing Military Command (Shanghai 85 Hospital), Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01342250"
692,"NCT02666391","Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)",,"Unknown status","No Results Available","Acute Myocardial Infarction|Myocardial Infarction|Ischemic Cardiomyopathy","Biological: umbilical cord mesenchymal stem cells","Change in global left ventricular ejection fraction (LVEF)measured by echocardiography.|Change in infarct size and myocardial viability within the infarcted region measured by emission computed tomography (ECT).|Pump failure Killip classification|New York Heart Association(NYHA) classification|Occurrence of major adverse event","South China Research Center for Stem Cell and Regenerative Medicine|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-2","May 2016","December 2017","December 2017","January 28, 2016",,"January 28, 2016",,,"https://ClinicalTrials.gov/show/NCT02666391"
693,"NCT04087889","Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer",,"No longer available","No Results Available","Pancreatic Cancer","Biological: HB-adMSCs",,"Hope Biosciences","Male","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"HBPC01",,,,"September 12, 2019",,"July 6, 2021","Hope Biosciences, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04087889"
694,"NCT03564808","Long Term Effects on Skin Hyper Pigmentation With and Without Mesenchymal Stem Cell Enriched Adipose Tissue Grafting for ""Contour Deformities With Pigmentary Changes on Face""","MSCs","Unknown status","No Results Available","Skin Pigmentation Over Contour Deformities of Face|Trauma, Rhomberg Disease","Drug: MSC","Pigmentary change","King Edward Medical University","All","Child, Adult, Older Adult","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCs","June 27, 2018","May 25, 2019","May 25, 2019","June 21, 2018",,"July 6, 2018","Plastic surgery department king Edward Medical University Lahore, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT03564808"
695,"NCT01206179","Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell",,"Completed","No Results Available","Nonunion Fractures","Biological: cell injection","Radiological progression of bone fusion|Reduction of pain using VAS|Cost analysis based on length of hospital stay","Royan Institute","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-004","March 2009","March 2011","May 2011","September 21, 2010",,"December 14, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01206179"
696,"NCT01751282","Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds",,"Terminated","No Results Available","Non Healing Wounds","Genetic: Stem Cell","Wound closure|Overall rate of wound healing reduction","Roger Williams Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RO1AR06034201A1","June 2010","June 2015","June 2015","December 17, 2012",,"October 4, 2016","Roger Williams Medical Center, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01751282"
697,"NCT02709343","Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction","ASSIST-CLAD","Recruiting","No Results Available","Chronic Lung Allograft Dysfunction (CLAD)","Drug: Bone-marrow derived MSCs|Drug: Placebo","Progression-free survival|Time to fall in FEV1 > 10%|Freedom from Bronchiolitis Obliterans Syndrome (BOS) grade 3|All cause mortality|CLAD-specific mortality|Freedom from acute rejection|Freedom from the development of new donor specific anti-HLA antibodies|Freedom from CLAD progression|Rate of FEV1 decline|Rate of FVC decline|Change in 6-minute walk distance (6MWD)|Change in St George's Respiratory Questionnaire (SGRQ) Score|Inpatient bed-days","The University of Queensland|Isopogen|Cell and Tissue Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 2","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ASSIST-CLAD","April 21, 2017","June 2022","June 2022","March 16, 2016",,"March 31, 2020","St Vincents Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT02709343"
698,"NCT03969680","Mesenchymal Stem Cell Transplantation for Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Auotologous BMSCs plus autologous PRP|Biological: Auotologous PRP","Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS)","Yantai Yuhuangding Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2019-002","July 8, 2019","June 30, 2020","December 31, 2020","May 31, 2019",,"January 22, 2020","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03969680"
699,"NCT04063215","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy",,"Recruiting","No Results Available","Traumatic Brain Injury","Biological: HB-adMSCs","Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basos|Absolute Neutrophils|Absolute Lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature Granulocytes|Absolute Immature Granulocytes|Platelets|Prothrombin Time|INR|Urine Pregnancy|Whole brain MRI|PET/DT-MRI|Glasgow Outcome Score|Galveston Orientation and Amnesia Test|Rivermead Post-Concussion Symptoms Questionnaire|Automated Neuropsychological Assessment Metrics|Verbal Selective Reminding Test|Verbal Fluency Test|Stroop|Interleukin 1-alpha|Interleukin 4|Tumor necrosis factor alpha|Interleukin 6|Interleukin 10","Hope Biosciences|The University of Texas Health Science Center, Houston","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBTBI01","January 1, 2020","August 29, 2021","August 29, 2021","August 21, 2019",,"July 6, 2021","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04063215"
700,"NCT04689152","Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis","Cellgram-LC","Recruiting","No Results Available","Alcoholic Cirrhosis","Biological: Cellgram-LC","Transplant free survival (TFS)|Survival rate|Change amount of Child-Pugh score|Change amount of MELD score|Change amount of Liver function test|Change amount of Fibrosis-4|Change amount of FibroScanⓇ|Change amount of EQ-5D|Change amount of EQ-VAS","Pharmicell Co., Ltd.","All","20 Years to 71 Years   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-P-07","March 2, 2021","March 2, 2026","March 2, 2026","December 30, 2020",,"August 24, 2021","Soonchunhyang University Hospital, Bucheon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Gangwon National University Hospital, ChunCheon, Korea, Republic of|Hallym Univ. Medical Center, ChunCheon, Korea, Republic of|Gangneung Asan Hospital, Gangneung-si, Korea, Republic of|Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Soonchunhyang University Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of|Yongin Severance Hospital, Yongin, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04689152"
701,"NCT02237547","Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury",,"Withdrawn","No Results Available","Spinal Cord Injury","Biological: Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells","Number of patients with adverse events|Number of subjects with a change in American Spinal Injury Association (ASIA) score from baseline|Number of subjects with a change in Frankel Scale score from baseline","Translational Biosciences","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNEI-2014-TBS-UCMSC-SCI001","September 2014","January 2019","October 2019","September 11, 2014",,"August 10, 2017","Stem Cell Institute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02237547"
702,"NCT01531348","Intravitreal Injection of MSCs in Retinitis Pigmentosa",,"Completed","No Results Available","Retinitis Pigmentosa","Other: BM-MSC","Change from baseline in laser flare and cell measurements|Change from baseline in visual function tests","Mahidol University|Ministry of Health, Thailand","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RP-001","April 2012","July 2020","July 2020","February 10, 2012",,"September 8, 2021","Siriraj Hospital Mahidol University, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01531348"
703,"NCT03933995","Follow up Study(Phase 1) to Evaluate Safety of Autologous Bone Marrow Derived MSCs in Erectile Dysfunction",,"Recruiting","No Results Available","Erectile Dysfunction","Other: no Intervention","Safety Evaluation assessed by Tumor Marker Test.|Safety Evaluation assessed by Serious Adverse Events, cancer incidence and recurrence of prostate cancer.|Safety Evaluation assessed by Vital Signs.","Pharmicell Co., Ltd.","Male","20 Years and older   (Adult, Older Adult)",,"10","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","PMC-P-09","March 11, 2019","February 28, 2022","November 30, 2022","May 1, 2019",,"October 22, 2020","Asan medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03933995"
704,"NCT04385056","Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia",,"Recruiting","No Results Available","Bradykinesia","Biological: MSCTC-0010","Incidence of Serious Adverse Events and Adverse Events","IMAC Holdings, Inc.","All","55 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMAC-001","December 15, 2020","July 1, 2022","July 1, 2022","May 12, 2020",,"January 6, 2021","IMAC Regeneration Center, Paducah, Kentucky, United States|Ozzie Smith IMAC Regeneration Center, Chesterfield, Missouri, United States|David Price IMAC Regeneration Center, Brentwood, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04385056"
705,"NCT02025413","Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method","CTC-EMT","Completed","No Results Available","Metastatic Progressive Castration-resistant Prostate Cancer|Metastatic Progressive Breast Cancer","Device: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)","Feasibility as measured by successfully detecting at least one CTC in at least 2 out of 10 subjects, comparing the non-detection rate over time.|Comparison of the proportion of patients with no detectable CTCs between capture methods over time|Changes in CTCs (using each method) over time during systemic therapy|Change in correlation of CTC enumeration using each method with baseline clinical and pathologic disease characteristics (for example, clinical stage, site of metastatic disease, Gleason sum for CRPC, PSA for CRPC, previous therapies)|Median number of CTCs detected by each method over time","Duke University|Prostate Cancer Foundation|United States Department of Defense|Janssen Diagnostics, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Other|U.S. Fed|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","Pro00032772","November 2011","December 2015","December 2015","January 1, 2014",,"December 20, 2018","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02025413"
706,"NCT04342325","The Clinical Trial of ADR-001 for IgA Nephropathy",,"Active, not recruiting","No Results Available","Glomerulonephritis , IGA","Biological: infusion of ADR-001 (Mesenchymal stem cell)","Incidence of adverse events|Clinical remission (proteinuria, hematuria)|Proteinuria|Hematuria|Estimated glomerular filtration rate (eGFR)","Nagoya University|Rohto Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAMCR013|jRCT2043200002","June 15, 2020","January 31, 2022","March 31, 2023","April 13, 2020",,"November 12, 2021","Kasugai Municipal Hospital, Kasugai, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan",,"https://ClinicalTrials.gov/show/NCT04342325"
707,"NCT04313647","A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers",,"Completed","Has Results","Healthy","Biological: 1X level of MSCs-Exo|Biological: 2X level of MSCs-Exo|Biological: 4X level of MSCs-Exo|Biological: 6X level of MSCs-Exo|Biological: 8X level of MSCs-Exo","Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE)","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXVT","March 12, 2020","April 30, 2020","July 31, 2020","March 18, 2020","August 4, 2021","August 4, 2021","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04313647"
708,"NCT03298399","Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease",,"Withdrawn","No Results Available","Sickle Cell Disease","Biological: Autologous MSCs","Safety and tolerability of EPIC2016-MSC003 based upon dose limiting toxicities (DLTs)|Primary graft rejection|Late graft rejection|Time to neutrophil engraftment|Time to platelet engraftment|Lineage specific donor chimerism|Immune reconstitution|Acute GVHD|Chronic GVHD|Transplant-related mortality (TRM)|Event-free survival (EFS)|Overall survival (OS)","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","12 Years to 40 Years   (Child, Adult)","Phase 1","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00090514|1K23HL133446","December 21, 2017","October 25, 2018","October 25, 2018","October 2, 2017",,"November 7, 2018",,,"https://ClinicalTrials.gov/show/NCT03298399"
709,"NCT00690066","PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)",,"Completed","No Results Available","Type 1 Diabetes Mellitus|Type 1 Diabetes|Diabetes Mellitus, Insulin-Dependent|Juvenile Diabetes","Drug: PROCHYMAL®|Drug: Placebo","C-peptide area under the concentration curve (AUC) response (MMTT)|Peak C-peptide response (MMTT)|Basal C-peptide response|Total daily insulin dose (units/kg)|Glycosylated hemoglobin (HbA1c) levels|Number of severe and documented hypoglycemic events|Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies","Mesoblast, Inc.|Juvenile Diabetes Research Foundation|Mesoblast, Ltd.","All","12 Years to 35 Years   (Child, Adult)","Phase 2","63","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","901","June 11, 2008","December 12, 2010","December 19, 2011","June 4, 2008",,"March 10, 2020","University of Alabama, Division of Endocrinology & Metabolism, Birmingham, Alabama, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|Stanford University, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Diabetes Research Institute, Miami, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University of Minnesota, Minneapolis, Minnesota, United States|Desert Endocrinology CRC, Henderson, Nevada, United States|Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States|University of North Carolina Diabetes Care Center, Chapel Hill, North Carolina, United States|American Health Research, Inc., Charlotte, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Providence Health Partners - Center for Clinical Research, Dayton, Ohio, United States|Cumberland Valley Endocrinology, Carlisle, Pennsylvania, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|The Strelitz Diabetes Center, Eastern VA Medical School, Norfolk, Virginia, United States|University of Wisconsin Health- West Clinic, Madison, Wisconsin, United States|Clinical and Transitional Science Institute, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00690066"
710,"NCT02941666","Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip",,"Recruiting","No Results Available","Osteonecrosis",,"The quantity of mesenchymal stem cells present in the synovial fluid of patients with precollapse ON of the femoral head and postcollapse ON of the femoral head compared to patients without intraarticular hip pathology.","Mayo Clinic","All","18 Years to 90 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","16-002241","September 2016","November 2021","November 2021","October 21, 2016",,"February 23, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02941666"
711,"NCT00683722","PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","No Results Available","Pulmonary Disease, Chronic Obstructive|Pulmonary Emphysema|Chronic Bronchitis","Drug: PROCHYMAL™|Drug: Placebo","Number of Participants with Adverse Events (AEs)|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume to Forced Vital Capacity Ratio (FEV1/FVC) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) %predicted at Year 1 and Year 2|Change from Baseline in Alveolar Volume (VA) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide to Alveolar Volume ratio (DLCO/VA)at Year 1 and Year 2|Change from Baseline in Functional residual capacity (FRC) at Month 6|Change from Baseline in Total Lung Capacity (TLC) at Month 6|Change from Baseline in Residual Volume (RV) at Month 6|Change from Baseline in Airway Resistance (RAW) at Month 6|Change from Baseline in 6-Minute Walk Test at Year 1 and Year 2|Change from Baseline in Borg Dyspnea Scale at Year 2|Change from Baseline in Health-related quality of life: St George's Respiratory Questionnaire (SGRQ) at Year 1 and Year 2|Change from Baseline in Physician Global Assessment Scale at Year 1 and Year 2|Time to COPD Exacerbation|Number of COPD Exacerbations|Change from Baseline in Pulmonary Hypertension at Month 6|Change from Baseline in Systemic Inflammation at Year 1 and Year 2","Mesoblast, Inc.|Mesoblast, Ltd.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","801","May 20, 2008","March 9, 2009","August 24, 2010","May 23, 2008",,"March 10, 2020","David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, United States|American Health Research, Charlotte, North Carolina, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Vermont Lung Center, University of Vermont, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00683722"
712,"NCT01291329","Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)","WJ-MSC-AMI","Completed","No Results Available","ST-Elevation Myocardial Infarction","Genetic: intracoronary human umbilical WJ-MSC transfer","Quantify myocardium metabolic and perfusion measured by F-18-fluorodeoxyglucose (F-18-FDG) postremission tomography (PET) and 99 mTctetrofosmine single-photon (SPET), as well as global left ventricular ejection fraction measured by echocardiography.|Secondary endpoints: safety will be determined by the assessment of major adverse coronary events (MACE).","Navy General Hospital, Beijing|Chinese PLA General Hospital|General Hospital of Chinese Armed Police Forces|First People's Hospital of Foshan","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006AA02Z469","February 2011","February 2012","July 2012","February 8, 2011",,"February 13, 2015","Fu Cheng Lu 6, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01291329"
713,"NCT02585622","NEPHSTROM for Diabetic Kidney Disease","NEPHSTROM","Recruiting","No Results Available","Diabetic Kidney Disease","Biological: Mesenchymal Stromal Cells|Other: Placebo","Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.|Glomerular filtration rate (GFR)|Urinary Albumin/Creatinine Ratio (ACR)|Urinary albumin excretion (UAE).|Fasting blood glucose (target <126mg/dL)|HbA1c (target <75mmol/mol or <9%)|Total cholesterol (target <200 mg/dl)|LDL cholesterol (target <100 mg/dl)|Triglycerides (target <170 mg/dl)|Arterial blood pressure (the target value <130/80 mmHg)|Quality of life|Anti-HLA antibody development|Inflammation and fibrosis related soluble mediators|Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.|Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.|Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.|Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells|Cost-effectiveness of cell therapy","Mario Negri Institute for Pharmacological Research|Leiden University Medical Center|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy|Belfast Health and Social Care Trust|National University of Ireland, Galway, Ireland|University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK|NHS Blood and Transplant","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","NEPHSTROM|2016-000661-23","December 11, 2017","December 2021","July 2022","October 23, 2015",,"July 14, 2021","National University of ireland - Galway University Hospital -Regenerative Medicine Institute, Galway, Ireland|ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Bergamo, BG, Italy|Belfast Health and Social Care Trust - Belfast City Hospital, Belfast, United Kingdom|University Hospital Birmingham NHS Foundation Trust - Queen Elizabeth Medical Centre, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02585622"
714,"NCT04951882","Application of hUC-MSCs in Treating Acute Lung Injury: a Single Center Prospective Clinical Research",,"Recruiting","No Results Available","Acute Lung Injury","Biological: human derived umbilical cord derived mesenchymal stem cells","PaO2/FiO2|the days of ventialtion and hospital stay","Second Affiliated Hospital, School of Medicine, Zhejiang University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-592","June 9, 2021","December 31, 2022","December 31, 2022","July 7, 2021",,"July 7, 2021","SAHZU, Hanzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04951882"
715,"NCT01643655","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head",,"Completed","No Results Available","Avascular Necrosis of the Femoral Head","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Magnetic Resonance Imaging|SPECT/CT|Hip X-ray|HHS (Harris Hip Score)|WOMAC (Western Ontario and McMaster Universities) Index|UCLA (University of California Los Angeles) hip questionnaire|Safety evaluation","R-Bio|SMG-SNU Boramae Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-AVN","May 2012","December 2014","March 2015","July 18, 2012",,"August 31, 2017","SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01643655"
716,"NCT03058068","Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis","HAPI","Withdrawn","No Results Available","Cystic Fibrosis","Biological: Allo-hMSCs|Biological: Placebo","Incidence of any treatment-emergent serious adverse event (TE-SAE)|Change in Symptoms for pulmonary function test|Change in Symptoms 6-minute walk test|Change in Symptoms of body mass index|Change in Rate of pulmonary exacerbations|Change in Local and Systemic Inflammation in inflammatory markers|Change in Local and Systemic Inflammation for sputum inflammatory markers|Change in Local and Systemic Inflammation related to quality of life|Change in Local and Systemic Inflammation via the short form-36|Change in Local and Systemic Inflammation via the PHQ-9 Questionnaire|Change in Local and Systemic Inflammation via the CFQ-R Questionnaire|Change in Local and Systemic Inflammation via the GAD-7 Questionnaire","Joshua M Hare|University of Miami","All","20 Years to 45 Years   (Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20160140","December 2020","September 2027","September 2028","February 20, 2017",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT03058068"
717,"NCT00827398","Treatment of Steroid Resistant GVHD by Infusion MSC","MSCforGVHD","Completed","No Results Available","Graft-versus-host-disease","Biological: MSC (hPPL)","number of adverse events after infusion of MSC (hPPL)|Number of severe infections after MSC infusion|Response of acute GVHD|Determination of incidence of chronic GVHD|Survival","N.M. Wulffraat|UMC Utrecht","All","1 Month to 68 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL13729.000.07","January 2009","July 2013","July 2013","January 22, 2009",,"November 6, 2014","UMC Utrecht, department of pediatrics, Utrecht, Netherlands|UMCU department of Haematology, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00827398"
718,"NCT04954534","Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM®",,"Not yet recruiting","No Results Available","Alzheimer's Disease","Biological: human umbilical cord blood derived mesenchymal stem cells","Change from the baseline in ADAS-Cog|Change in CDR-SOB|Change from the baseline in K-MMSE(korean version)|Change from the baseline in CGA-NPI|Change from the baseline in SIB|ADAS-Cog Response Rate|Change in CIBIC-plus|Change from the baseline in CSF biomarkers","Samsung Medical Center|Medipost Co Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","9","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARC-CR-01","July 12, 2021","January 31, 2022","June 30, 2022","July 8, 2021",,"July 14, 2021","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04954534"
719,"NCT01300598","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Degenerative Arthritis",,"Completed","No Results Available","Degenerative Arthritis","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Safety evaluation|WOMAC(Western Ontario and McMaster Universities) Index|Magnetic Resonance Imaging|KSCRS(Knee Society Clinical rating System)|VAS(11-point box visual analogue scale)|Histological evaluates","R-Bio","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Jointstem","December 2008","September 2011","March 2012","February 21, 2011",,"June 5, 2019","SMG-SNU Boramae Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01300598"
720,"NCT01759212","Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.",,"Active, not recruiting","No Results Available","Heart Failure|Ischemic Cardiomyopathy","Biological: Allogeneic stem cells implantation","Improvement in myocardial perfusion/viability|Morbidity|Change in left ventricular function","AHEPA University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHEPA_CTL_02","October 2012","December 2023","December 2025","January 3, 2013",,"January 12, 2021","AHEPA University Hospital, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT01759212"
721,"NCT04535856","Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients","DW-MSC","Completed","No Results Available","Covid19|Corona Virus Infection|SAR","Drug: allogeneic mesenchymal stem cell|Other: Placebo","Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change","Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Daewoong Pharmaceutical Co. LTD.","All","19 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DW_DWP710101|U1111-1263-1723","November 14, 2020","January 14, 2021","January 14, 2021","September 2, 2020",,"January 27, 2021","Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia",,"https://ClinicalTrials.gov/show/NCT04535856"
722,"NCT04905836","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress",,"Not yet recruiting","No Results Available","Covid19","Biological: COVI-MSC|Drug: Placebo","All-cause mortality rate at Day 28|Incidence of all adverse events (AEs) (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of severe adverse events (safety)|Incidence of infusion-related adverse events (safety)|All-cause mortality rate at Day 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-COV-202","October 2021","December 2021","March 2022","May 28, 2021",,"October 19, 2021",,,"https://ClinicalTrials.gov/show/NCT04905836"
723,"NCT04992247","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise","BR","Not yet recruiting","No Results Available","Covid19","Biological: COVI-MSC|Biological: Placebo","Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Relief of symptoms on Day 30 and Day 60|Change in Pulmonary Function|Change in oxygenation|Change in biomarker levels","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-PLH-203BR","October 2021","April 2022","June 2022","August 5, 2021",,"August 5, 2021",,,"https://ClinicalTrials.gov/show/NCT04992247"
724,"NCT03967275","Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn","SyMbOL","Recruiting","No Results Available","Bone Marrow Donor","Other: bone marrow harvest","The number of donors needed to obtain 3 BM harvest.","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)",,"3","Other","Observational","Observational Model: Other|Time Perspective: Prospective","EGN_2018_11","September 9, 2020","September 2021","September 2030","May 30, 2019",,"April 9, 2021","Saint Louis Hospital, APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT03967275"
725,"NCT04909879","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome",,"Withdrawn","No Results Available","Acute Respiratory Distress Syndrome|Ards","Biological: COVI-MSC|Drug: Placebo","All-cause mortality rate at Day 28|All-cause mortality rate at Days 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Clinical status at Day 28|Change in oxygenation","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-ARDS-201","September 2021","February 2022","April 2022","June 2, 2021",,"September 24, 2021",,,"https://ClinicalTrials.gov/show/NCT04909879"
726,"NCT04611256","Mesenchymal Stem Cells in Patients Diagnosed With COVID-19",,"Recruiting","No Results Available","Covid19","Biological: MSC|Drug: Control","Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 25 days|Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes|Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10|Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE.","Hospital Reg. Lic. Adolfo Lopez Mateos|Instituto de Terapia Celular: ITC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","060I.2020","August 1, 2020","November 30, 2020","December 30, 2020","November 2, 2020",,"November 12, 2020","Hospital Regional Lic Adolfo Lopez Mateos, Mexico City, Ciudad De Mexico CDMX (Mexico City), Mexico",,"https://ClinicalTrials.gov/show/NCT04611256"
727,"NCT04548583","Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis",,"Recruiting","No Results Available","Crohn Colitis","Drug: Remestemcel-L|Other: Placebo","Treatment related adverse events|Complete clinical healing|Clinical response|Partial clinical response|Lack of response|Crohn's disease activity index|Inflammatory bowel disease questionnaire|EuroQol 5 Dimensions survey|Inflammatory bowel disease patient reported treatment impact survey|Short Form 36 health survey","The Cleveland Clinic|Mesoblast, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CCF-Stem Cells IBD-004","November 4, 2020","October 2023","October 2023","September 14, 2020",,"February 10, 2021","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04548583"
728,"NCT01394432","""ESTIMATION Study"" for Endocardial Mesenchymal Stem Cells Implantation in Patients After Acute Myocardial Infarction","ESTIMATION","Unknown status","No Results Available","Acute Myocardial Infarction|Heart Failure","Procedure: PCI and Stem Cells or Placebo injections","Reduction in left ventricle systolic volume on 15% mesured by MRI|All-cause death|number of patients with thromboembolic events|number of heart failure hospitalizations|Distance during 6-minute walking test|number of patients with life-threatening arrhythmias|BNP level|SPECT and Echo data","Meshalkin Research Institute of Pathology of Circulation","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RBI-1749|RU8HM86-54N","July 2011","November 2012","November 2016","July 14, 2011",,"September 23, 2015","State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01394432"
729,"NCT02968459","Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars",,"Recruiting","No Results Available","Uterine Scar","Other: Umbilical cord MSCs|Other: 0.9% Saline","Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence","Maternal and Child Health Hospital of Foshan","Female","21 Years to 35 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCHHFoshan-1603","October 2021","December 2021","April 2022","November 18, 2016",,"June 9, 2021","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02968459"
730,"NCT04728698","Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress",,"Withdrawn","No Results Available","Covid19|ARDS","Drug: COVI-MSC|Drug: Placebo","Mortality at Day 28|Mortality at Days 60 and 90|Number of ventilator-free days|Improvement in oxygenation|SOFA score at Day 28","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MSC-COV-201","March 2021","September 2021","September 2021","January 28, 2021",,"September 16, 2021","Fresno Community Hospital, Fresno, California, United States",,"https://ClinicalTrials.gov/show/NCT04728698"
731,"NCT04780685","A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19",,"Recruiting","No Results Available","Covid19","Biological: hMSC","Survival|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0","Stemedica Cell Technologies, Inc.|bioRASI, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STEM-107-COVID-19","March 20, 2021","August 31, 2021","December 31, 2021","March 3, 2021",,"August 3, 2021","Providence Medical Foundation, Fullerton, California, United States|Providence Saint John's Health Center - Saint John's Cancer Institute, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04780685"
732,"NCT04453111","Efficacy of Bone-marrow-derived and Placenta-derived Multipotent Mesenchymal Stem / Stromal Cells for Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Placenta-derived MMSCs|Biological: Bone marrow-derived MMSCs|Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe","Number of participants with adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Physical function improvement measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC).|Radiographic evidence. Whole-Organ Magnetic Resonance Imaging Score (WORMS)|Quality of Life (QOL) assessment|The Visual Analog Scale (VAS) assessment","Institute of Cell Therapy|The Institute of Traumatology and Orthopedics of NAMS of Ukraine|Kyiv City Clinical Hospital № 6","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#7/09.26.2018","January 2, 2020","August 2021","October 2021","July 1, 2020",,"July 7, 2020","Institute of Cell Therapy, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04453111"
733,"NCT04543994","Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)","UC","Recruiting","No Results Available","Ulcerative Colitis","Drug: Remestemcel-L|Other: Placebo","Treatment related adverse events|Clinical and endoscopic remission|Clinical and endoscopic response|Partial clinical and endoscopic response|Lack of response|Mayo clinic score","The Cleveland Clinic|Mesoblast, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CCF-Stem Cells IBD-005","November 10, 2020","November 2023","November 2023","September 10, 2020",,"February 10, 2021","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04543994"
734,"NCT04212728","Treatment of Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Auotologous AMSCs plus autologous PRP|Biological: Auotologous PRP","Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS)","Yantai Yuhuangding Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2019-003","December 2019","December 2020","December 2021","December 27, 2019",,"December 27, 2019","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04212728"
735,"NCT01483248","Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis|Fibrosis|Liver Disease|Digestive System Disease","Biological: conventional therapy plus MenSC transplantation|Drug: Conventional therapy plus placebo treatment","Overall Survival|Liver function improvement|Complications|The improvement of ascites after 12-week treatment|Child-Pugh score|MELD score|SF36-quality of life","S-Evans Biosciences Co., Ltd.|Zhejiang University|Zhejiang General Hospital of Armed Police|Zhenjiang First People's Hospital|Wuhan General Hospital of Guangzhou Military Command","Female","20 Years to 50 Years   (Adult)","Phase 1|Phase 2","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SEB-1115-LC","October 2010","October 2013","October 2015","December 1, 2011",,"June 7, 2012","the First Affiliated Hospital of Zhejiang University-IRB, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01483248"
736,"NCT02943486","Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2","MSCDTDFU","Unknown status","No Results Available","Foot Ulcer, Diabetic","Other: dac-MSCs|Other: MSCs|Drug: Fitostimoline","Wound size change|Granulation tissue percentage|Pigmentation change|Presence of Exudate","Universidad Autónoma de Bucaramanga|Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","124174455522","January 2017","June 2018","January 2019","October 24, 2016",,"October 24, 2016",,,"https://ClinicalTrials.gov/show/NCT02943486"
737,"NCT02853942","Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm",,"Unknown status","No Results Available","Injury of Facial Nerve, Unspecified Side, Initial Encounter","Biological: Autologous adipose stem cell therapy|Drug: Mecobalamin","House-Brackmann facial nerve grading scale","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XH-16-012","October 2016","October 2017","December 2017","August 3, 2016",,"August 9, 2016",,,"https://ClinicalTrials.gov/show/NCT02853942"
738,"NCT01233102","Mesenchymal Stem Cells Treat Liver Cirrhosis",,"Suspended","No Results Available","Liver Cirrhosis","Drug: Conserved Therapy|Procedure: Hepatic artery infusion or Intravenous infusion","The level of serum alanine aminotransferase (ALT）|The level of serum total bilirubin (TB)|The level of serum prothrombin time (PT)|The level of serum prealbumin(PA)|The level of serum albumin (ALB)|Overall survival|liver biopsy","Yufang Shi|Soochow University|Chinese Academy of Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SIBS-IHS-20101010|2010CB945600","October 2009","December 2017","December 2019","November 3, 2010",,"February 22, 2016","First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01233102"
739,"NCT02890953","Efficacy and Safety of Pneumostem® for IVH in Premature Infants (Phase 2a)",,"Recruiting","No Results Available","Cell Transplantation","Drug: Pneumostem|Drug: Normal saline","Death or shunt operation|ventricular dilatation|Death","Samsung Medical Center","All","up to 28 Days   (Child)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-06-005","March 28, 2017","December 2020","December 2021","September 7, 2016",,"April 11, 2019","Samsung Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02890953"
740,"NCT03115749","Intestinal Mesenchymal Stem Stells and Inflammatory Bowel Diseases","COSMIC","Unknown status","No Results Available","Inflammatory Bowel Diseases","Other: Intestinal biopsies during colonoscopy|Other: Biopsies taken on surgical specimen","Proliferation and differentiation of intestinal MSCs in IBD patients.|Comparison of MSCs between IBD patients and control patients","University Hospital, Montpellier","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","9755","September 2018","February 2021","February 2021","April 14, 2017",,"May 21, 2018",,,"https://ClinicalTrials.gov/show/NCT03115749"
741,"NCT03877471","Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency","MSCLCTWPOI","Active, not recruiting","No Results Available","Primary Ovarian Insufficiency","Genetic: Cell therapy","Temperature|Pulse|Breaths per minute|Blood pressure|Number of antral follicle|Follicle-stimulating hormone (FSH) serum level|Estradiol (E2) serum level|Anti-Mullerian hormone (AMH) serum level|Ovarian volume","Chinese Academy of Sciences|The First Affiliated Hospital of Zhengzhou University|National Natural Science Foundation of China","Female","up to 40 Years   (Child, Adult)","Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IOZ ChineseAS POI-2","April 3, 2019","July 1, 2020","December 31, 2021","March 15, 2019",,"August 5, 2021","The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT03877471"
742,"NCT01690247","Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance",,"Unknown status","No Results Available","Evidence of Liver Transplantation","Drug: Conventional plus UC-MSC|Drug: Conventional plus placebo","Incidence rate of acute rejection and early liver function recovery|Patient and graft survival, and prevalence of adverse events","Beijing 302 Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Beijing302-008","February 2012","February 2014","February 2015","September 21, 2012",,"May 31, 2013","Beijing 302 Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01690247"
743,"NCT01875081","REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)",,"Completed","No Results Available","Alcoholic Liver Cirrhosis","Biological: Livercellgram","Histopathological evaluation (Fibrosis Grade - Laennec Scoring System)|Histopathological evaluation score (Ratio of 1-time injection group to 2-time injection group comparison)|MELD Score|Child-Pugh grade|Liver Function Test (ALT, AST, ALP, Albumin, billirubin, r-GT)|Visual Inspection (Liver volume, Fibroscan)","Pharmicell Co., Ltd.","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-BD-CT-P-002","November 2012","March 2016","March 2016","June 11, 2013",,"March 17, 2016","Pharmicell Co., Ltd., Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01875081"
744,"NCT04961658","Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients","AMETHYST","Recruiting","No Results Available","Septic Shock","Biological: GEM00220","The safety of GEM00220 will be assessed by monitoring adverse events|Maximum Feasible Tolerated Dose","Northern Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-GEM-001","August 11, 2021","December 2021","November 2022","July 14, 2021",,"September 28, 2021","Lakeridge Health, Oshawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04961658"
745,"NCT03003364","Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury, Chronic","Drug: XCEL-UMC-BETA|Drug: Placebo","Incidence of treatment-emergent adverse events|Extent and severity of a patient's spinal cord injury|Motor electrophysiology assessment|Somatosensory electrophysiology assessment|Electrical nerve stimulation on pain perception|Mictional dysfunction|Anal sphincter integrity|Neuropathic pain|Spasticity|Functionality|Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)|Urinary disorder|Size injury|Presence of allogeneic cells|Immunology","Banc de Sang i Teixits|Hospital de Neurorehabilitació Institut Guttmann|Recerca Clínica S.L.|Syntax for Science, S.L","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XCEL-SCI-01","December 27, 2016","July 25, 2019","February 11, 2020","December 28, 2016",,"February 17, 2020","Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03003364"
746,"NCT00555828","Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction",,"Unknown status","No Results Available","Myocardial Infarction","Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs)|Procedure: Standard-of-care treatment with NOGA® mapping and staged injections.","Evaluate the safety and feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping Catheter with the Biosense MyostarTM Left Ventricular Injection Catheter of allogeneic mesenchymal precursor cells (MPCs) in subjects with AMI.|Explore efficacy for subsequent study design and dose related tolerance: •Effect related to cardiac function.•Change from baseline in SF-36, KCCQ, SAQ, and the NYHA Classification.•Follow-up safety through Day 360 • Dose selection for future stu","Angioblast Systems","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","EMT-AB001","March 2008","December 2013","December 2013","November 9, 2007",,"February 17, 2010","University of Minnesota/Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Texas Heart Institute/St. Luke's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00555828"
747,"NCT02338375","Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product","Cartistem","Unknown status","No Results Available","Osteochondral Lesion of Talus","Biological: Cartistem","evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE|evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by 100-mm VAS(Visual Analogue Scale)","Samsung Medical Center","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2012-10-078","December 2012","August 2015","December 2015","January 14, 2015",,"January 14, 2015","Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02338375"
748,"NCT04349631","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,"Completed","No Results Available","COVID-19","Biological: HB-adMSCs","Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","Child, Adult, Older Adult","Phase 2","56","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HBCOV01","April 22, 2020","November 24, 2020","May 1, 2021","April 16, 2020",,"July 7, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04349631"
749,"NCT00721045","A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure",,"Completed","No Results Available","Heart Failure","Biological: Mesenchymal Precursor Cells (MPCs)|Procedure: standard-of-care treatment with mock mapping and injection procedures.","The primary objective of this study is to evaluate the feasibility and safety of transendocardial injection using mapping Catheter with the Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic MPCs in subjects with heart failure.|The secondary objectives are to explore functional efficacy for subsequent study design.","Mesoblast, Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HF-AB002","August 2008","June 2011","July 2013","July 23, 2008",,"March 11, 2020","Mercy Gilbert Medical Center, Gilbert, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Minneapolis Heart Institute 920 East 28th St, Suite 300, Minneapolis, Minnesota, United States|UPMC, Pittsburgh, Pennsylvania, United States|Texas Heart Institue, Houston, Texas, United States|Swedish Heart and Vascular Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00721045"
750,"NCT00993941","Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein",,"Unknown status","No Results Available","Liver Cirrhosis","Procedure: Autologous BMSCs transplantation|Drug: Conserved therapy","The levels of serum alanine aminotransferase (ALT), total bilirubin (TB),prothrombin time (PT), albumin (ALB), prealbumin(PA), precollagenⅢ(PCⅢ), collagenⅣ(Ⅳ-C), laminin(LN), hyaluronidase(HN), liver histological improvement.","Sun Yat-sen University","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1-Bingliang","October 2009","October 2010","April 2011","October 14, 2009",,"December 6, 2010","Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT00993941"
751,"NCT02672306","Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease","SEESUPAD","Unknown status","No Results Available","Alzheimer's Disease","Biological: UCMSCs|Biological: Placebo","Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score|Change in Mini-Mental State Examination (MMSE) Score|Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score|Change in Neuropsychiatric Inventory (NPI) Score|Changes in AD Biomarkers","South China Research Center for Stem Cell and Regenerative Medicine|Guangzhou General Hospital of Guangzhou Military Command of PLA|Third Affiliated Hospital, Sun Yat-Sen University","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","UCMSC-1","October 20, 2017","October 2018","October 2019","February 3, 2016",,"April 26, 2018","South China Research Center for Stem Cell and Regenerative Medicine,South China Institute of Biomedicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02672306"
752,"NCT03638154","Regenerative Potential of Cultured Gingival Fibroblast- Mesenchymal Stem Cells in Treatment of Periodontitis",,"Completed","No Results Available","Periodontal Intrabony Defect","Procedure: GF+GMSCs carried on β TCP|Procedure: β TCP bone substitute only","bone gain in periodontal defects(by mm)|the regenerative power of the defect was evaluated by growth factor concentration in GCF.","Ain Shams University","All","32 Years to 50 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","PER 16-P1","March 15, 2016","April 15, 2016","February 22, 2018","August 20, 2018",,"August 20, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03638154/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03638154"
753,"NCT04753476","Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia",,"Recruiting","No Results Available","Covid-19|Cytokine Storm","Biological: Injection of Secretome-MSCs|Drug: Standard treatment of Covid-19","Change in patients clinical manifestation|Need for a ventilator|Duration of using a ventilator|Length of stay|Routine blood profile|CRP|D-dimer|Blood Gas Analisis (BGA)|Photo thorax|Survival","Stem Cell and Cancer Research Indonesia|Provincial Government of Central Java, Indonesia","All","Child, Adult, Older Adult","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCCR_Secretome","June 8, 2020","February 1, 2022","March 1, 2022","February 15, 2021",,"May 24, 2021","RSUD Bantul, Bantul, Central Java, Indonesia|RS PKU Muhammadiyah Gamping, Yogyakarta, Central Java, Indonesia|RS Primaya Bekasi Timur, Bekasi, Jakarta, Indonesia|Bhayangkara Hospital, Makassar, South Celebes, Indonesia|Gatot Soebroto Army Hospital, Jakarta, Indonesia|Dr. Esnawan Antariksa Air Force Hospital, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04753476"
754,"NCT00749164","Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment","MSCGVHD","Unknown status","No Results Available","Graft-Versus-Host Disease","Procedure: MSC transplantation","GVHD re-staging and/or GVHD mortality ,side effects","Hadassah Medical Organization","All","Child, Adult, Older Adult","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBR-0137-08-HMO-CTIL","September 2009","February 2012","August 2012","September 9, 2008",,"August 11, 2009","Hadassah University Hospital, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00749164"
755,"NCT02635464","Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy",,"Completed","No Results Available","Chronic Ischemic Cardiomyopathy","Biological: hUC-MSCs+Injectable collagen scaffold+CABG|Biological: hUC-MSCs+CABG|Procedure: CABG","Incidence of treatment-emergent adverse events|Myocardial blood flow|Left ventricle ejection fraction (LVEF)|Infarct size|New York Heart Association (NYHA) Functional Classification|Canadian Cardiovascular Society (CCS) Angina Grading Scale","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-CIC/IGDB","October 2015","August 2019","August 2019","December 18, 2015",,"December 23, 2020","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02635464"
756,"NCT02491658","Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris",,"Unknown status","No Results Available","Psoriasis Vulgaris","Biological: UC-MSCs","Change from Baseline in Psoriasis Area and Severity Index (PASI) score at 8 weeks|Change from Baseline in Dermatology Life Quality Index (DLQI) score at 8 weeks|body temperature will be monitored for any possible infusion-related toxicities.|blood pressure will be monitored for any possible infusion-related toxicities.|Psoriasis Area and Severity Index (PASI) score|Dermatology Life Quality Index (DLQI) score","Affiliated Hospital to Academy of Military Medical Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307-PV-MSC","April 2015","December 2016","December 2016","July 8, 2015",,"July 8, 2015","Affiliated Hospital to Academy of Military Medical Sciences, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02491658"
757,"NCT01954147","Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus",,"Unknown status","No Results Available","Type 2 Diabetes","Drug: GLP-1|Biological: SC|Other: Standard Medical Treatment","HbA1C|Fasting Blood Glucose","Diabetes Care Center of Nanjing Military Command","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC/GLP-1","October 2013","October 2014","October 2015","October 1, 2013",,"February 20, 2014","Diabetes Care Center of Nanjing Military Command, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT01954147"
758,"NCT03866330","Wharton's Jelly-derived Mesenchymal Stem Cells in Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis|Hip Osteoarthritis|Knee Osteoarthritis|Glenohumeral Osteoarthritis","Biological: Intraarticular injection of WJMSC","HIP DISABILITY AND OSTEOARTHRITIS OUTCOME SCORE (HOOS)|Harris Hip Score|Knee injury and Osteoarthritis Outcome Score (KOOS)|modified Harris Hip Score for knee|The International Knee Documentation Committee (IKDC Questionnaire)|WOMAC (for hip and knee)|Disability of Arm, Shoulder and Hand [DASH]|The Constant-Murley score (CMS)|Visual Analog Scale (VAS)|1. Nature, incidence and severity of adverse events (AEs)|2. Change in radiographic/magnetic resonance joint morphology|3. Change in cartilage thickness|4. Change in cartilage volume|5. Change in cartilage morphology|6. Change in subchondral bone morphology|8. Inflammation monitoring","Medical University of Warsaw","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","001/LIFE/2019","March 1, 2019","December 2019","March 1, 2022","March 7, 2019",,"March 8, 2019","Life Clinic, Warsaw, Mazovian, Poland",,"https://ClinicalTrials.gov/show/NCT03866330"
759,"NCT03336996","Assessement the Reconstruction of Motor Circuits in Nerve Fiber Injuries After the Treatment of Umbilical Cord Mesenchymal Stem Cells With Blood Oxygen Level-dependent Drived Diffusion Tensor Imaging",,"Unknown status","No Results Available","Characterize and Evaluate Functional After Transplantation|Determine the Therapeutic Efficiency|Correlate the Imaging Results","Biological: stem cell transplantation|Procedure: BOLD-fMRI drived DTI scanning","BOLD-fMRI drived DTI scanning|FIM|NIHSS|Motor evoked potential","General Hospital of Ningxia Medical University","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Xhechun4","March 2018","March 2020","March 2021","November 8, 2017",,"November 8, 2017","General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China",,"https://ClinicalTrials.gov/show/NCT03336996"
760,"NCT01844063","Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure",,"Unknown status","No Results Available","Liver Failure","Genetic: Conventional plus BM-MSC treatment|Genetic: Conventional plus UC-MSC treatment|Drug: Conventional treatment","survival rate|Liver function|Marker of liver cancer|The degree of hepatic necrosis|The improvement of symptoms|The score for Model for End-Stage Liver Disease|The improvement of immune function|complications|The incidence of hepatocellular carcinoma","Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","The Third Affiliated Hospital","July 2013","January 2016","January 2019","May 1, 2013",,"July 8, 2013","Qi Zhang, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01844063"
761,"NCT03454737","Treatment of Refractory Patellar Tendinopathy With Mesenquimal Trunk Cells. Comparative Study With PRP.","TENDO","Unknown status","No Results Available","Patellar Tendinopathy","Procedure: mesenchymal stem cells|Procedure: Pure platelet-rich plasma","Improvement in the tendon ecotexture|Presence of patellar tendon regeneration by the peritendinous and intratendinous infusion of MSV patellar tendinopathy compared to the P-PRP group|the strength of the extensor muscle group|subjective clinical evolution of the patient|strength of the extensor muscle group","Institut de Terapia Regenerativa Tissular","Male","18 Years to 48 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MSC-TENDO-2015|2016-001262-28","December 13, 2017","June 20, 2019","December 14, 2020","March 6, 2018",,"December 19, 2018","Institut de Terapia Regenerativa Tissular, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03454737"
762,"NCT04869397","Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","ProTrans19+","Recruiting","No Results Available","Covid19","Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Other: Placebo","Composite endpoint|Clinical status evaluation assessed by the 9-point ordinal scale|Survival|Time to clinical improvement assessed by the 9-point ordinal scale|Duration of hospitalization and ICU stay","McGill University Health Centre/Research Institute of the McGill University Health Centre","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2021-6954","June 14, 2021","June 30, 2022","July 30, 2022","May 3, 2021",,"June 15, 2021","McGill University Health Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04869397"
763,"NCT03166189","Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures",,"Completed","No Results Available","Infertility, Female|Infertility of Uterine Origin|Asherman Syndrome","Biological: bone marrow-derived MSC and HRT|Other: hormonal replacement therapy","Assessment of endometrial receptivity|Clinical pregnancy rate|Treatment-Emergent Adverse Events","D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology","Female","21 Years to 44 Years   (Adult)","Phase 2","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-001","December 20, 2017","March 16, 2019","December 28, 2019","May 25, 2017",,"January 2, 2020","D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03166189"
764,"NCT04652908","Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial","CuRe","Recruiting","No Results Available","Myelomeningocele","Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|Other: Untreated contemporaneous cohort","Safety of the placenta-derived mesenchymal stem cell (PMSC-ECM) Product|Efficacy of the PMSC-ECM Product","Diana Lee Farmer|California Institute for Regenerative Medicine (CIRM)|University of California, Davis","All","19 Weeks to 25 Weeks   (Child)","Phase 1|Phase 2","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1617774","June 21, 2021","March 2024","March 2024","December 3, 2020",,"August 25, 2021","UC Davis Health, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04652908"
765,"NCT03905824","The Effectiveness of Adding Allogenic Stem Cells After Traditional Treatment of Osteochondral Lesions of the Talus","OLT","Recruiting","No Results Available","Osteochondral Fracture of Talus","Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord|Procedure: Debridement and microfracture","Change on tissue reparation quality|Change over time of general health status|Change over time of functional limitations of foot and ankle.|Change over time of functionality of musculoskeletal ankle and foot pathology|Change on declared pain|Surgical time|Complication rate|Cost-effective comparative analysis","University of Chile","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","OLT Protocol","January 15, 2019","December 31, 2020","December 31, 2024","April 5, 2019",,"April 9, 2019","Universidad de Chile Clinical Hospital, Santiago, Independencia, Chile",,"https://ClinicalTrials.gov/show/NCT03905824"
766,"NCT01453738","Allogeneic Mesenchymal Stem Cells in Osteoarthritis",,"Completed","No Results Available","Osteoarthritis of Knee","Biological: Ex- vivo cultured adult allogeneic MSCs|Biological: Plasmalyte-A","Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score (Whole-Organ Magnetic Resonance Imaging Score) of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline","Stempeutics Research Pvt Ltd","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SRPL/OA/09-10/001","November 2011","November 2014","November 2014","October 18, 2011",,"May 12, 2016","Department of Orthopedics, M. S. Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Department of Orthopedics, Kasturba Medical College, Manipal, Karnataka, India|Seth G. S. Medical College and KEM Hospital, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Department of Immunology Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01453738"
767,"NCT04355728","Use of UC-MSCs for COVID-19 Patients",,"Completed","No Results Available","Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19","Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care","Incidence of pre-specified infusion associated adverse events|Incidence of Severe Adverse Events|Survival rate after 90 days post first infusion|Ventilator-Free Days|Change in Oxygenation Index (OI)|Plat-PEEP|Sequential Organ Failure Assessment (SOFA) Scores|Small Identification Test (SIT) scores|Troponin I levels|C-Reactive Protein levels|Arachidonic Acid (AA)/Eicosapentaenoic Acid (EPA) Ratio|D-dimer levels|25-Hydroxy Vitamin D levels|Alloantibodies levels|Blood white cell count|Platelets count","Camillo Ricordi|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20200671|20200370","April 25, 2020","October 31, 2020","October 31, 2020","April 21, 2020",,"March 1, 2021","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04355728"
768,"NCT04146519","Parkinson's Disease Therapy Using Cell Technology",,"Recruiting","No Results Available","Transplantation:Mesenchymal Stem Cell Transplantation","Biological: Autologous mesenchymal stem cells|Other: Placebo","motor symptoms change|non-motor symptoms change|sleep quality change|daytime sleepiness change|signs of depression change","Belarusian Medical Academy of Post-Graduate Education","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20171292","July 1, 2017","December 1, 2021","December 31, 2021","October 31, 2019",,"March 3, 2021","the Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04146519"
769,"NCT04252118","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: MSCs","Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase","Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Huoshenshan Hospital|Tianjin Haihe Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020003D","January 27, 2020","December 2020","December 2021","February 5, 2020",,"April 15, 2020","Beijing 302 Military Hospital of China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04252118"
770,"NCT03684122","Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).",,"Active, not recruiting","No Results Available","Parkinson Disease","Biological: Injection of Umbilical cord derived MSCs","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection|Drug Reduction Rate test|Tractography|Blood-based biomarkers|Cerebrospinal Fluid (CSF) based biomarkers","University of Jordan","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PKUJCTC","June 1, 2018","July 30, 2020","September 20, 2021","September 25, 2018",,"August 25, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03684122"
771,"NCT03233074","Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors","COSMOS","Recruiting","No Results Available","Myelodysplastic Syndromes|Acute Myeloid Leukemia|Cardio-vascular Surgery","Other: Bone marrow analyses","Changes in cellular properties of mesenchymal stromal cells|Number of differential biomarkers in mesenchymal stromal cells","Institut de Cancérologie de la Loire|Centre Hospitalier Universitaire de Saint Etienne","All","50 Years to 80 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2017-0701|2017-A02088-45","November 17, 2017","September 30, 2021","September 30, 2021","July 28, 2017",,"January 25, 2021","CHU de Saint-Etienne, Saint-Priest-en-Jarez, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France",,"https://ClinicalTrials.gov/show/NCT03233074"
772,"NCT04711200","LYell SYndrome MEsenchymal Stromal Cells Treatment","LYSYME","Not yet recruiting","No Results Available","Epidermal Necrolysis|Lyell Syndrome|Toxic Epidermal Necrolysis|Overlap Syndrome|Mesenchymal Stromal Cells|Adipose Derived Stromal Cells","Drug: Adipose derived stromal cells intravenously injected","Safety : Observation of at least one adverse effect|Efficacy : Rate of complete or almost complete reepithelialisation|Rate of observed and predicted death by the SCORTEN|Duration of hospitalisation according to our historical cohort related to BSA involved|Duration of hospitalisation according to our historical cohort related to onset of the disease|Duration of hospitalisation according to our historical cohort related to SCORTEN|Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes)|Rate of sepsis|Rate of intensive care transfer|Rate of sequelae|Th1/Th2 immune response in the peripheral blood of the patients|Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood|Epidermal chimerism study on healed skin biopsy|Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed.","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150941J","January 2022","January 2025","January 2025","January 15, 2021",,"September 28, 2021",,,"https://ClinicalTrials.gov/show/NCT04711200"
773,"NCT04476901","Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","DCMII","Recruiting","No Results Available","Non-ischemic Dilated Cardiomyopathy","Biological: allogeneic human mesenchymal stem cells (hMSCs)|Other: Placebo","Change in LVEF|Change in global ventricular strain|Change in left regional strain|Left ventricular function concordance|Change in LVEDVI|Change in LVESVI|Change in Maximal oxygen consumption (peak VO2)|Change in Exercise tolerance|Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score|Change in New York Heart Association (NYHA) Class|Percent change in flow mediated diameter|Change in EPC-CFU|Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change in cytokines|Incidence of MACE|Incidence of TE-SAEs","Joshua M Hare|United States Department of Defense|The University of Texas Health Science Center, Houston|University of Miami","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","136","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200566|CDMRP-PR191597|20-02-134","May 7, 2021","December 2024","December 2024","July 20, 2020",,"September 17, 2021","Stanford University, Stanford, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Texas Heart Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04476901"
774,"NCT03626090","Mesenchymal Stem Cell Therapy for Liver Cirrhosis",,"Recruiting","No Results Available","Liver Cirrhosis","Biological: Autologous BM MSC","Clinical Examination|MR Elastography|The level of serum alanine aminotransferase (ALT)|The level of glomerular filtration rate (GFR)|The level of serum prothrombin time (PT)|The level of serum total bilirubin (TB)|The level of serum albumin (ALB)|MELD Score","Stem Med Pte. Ltd.|Parkway Cancer Centre|Asian American Liver Centre|Desmond Wai Liver & Gastrointestinal Diseases Centre","All","21 Years to 69 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-SM-L0001","August 18, 2018","October 22, 2021","October 22, 2021","August 10, 2018",,"March 17, 2021","Asian American Liver Centre - Gleneagles Hospital (Annexe Block), Singapore, Singapore|Parkway Cancer Centre - Gleneagles Hospital, Singapore, Singapore|Desmond Wai Liver & Gastrointestinal Disease Centre - Mount Elizabeth Novena Specialist Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03626090"
775,"NCT02083718","Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function",,"Unknown status","No Results Available","Stem Cell Transplantation, Hematopoietic|Poor Graft Function|Hematological Diseases","Biological: PBSC|Biological: MSCs","Percentage of Participants with Hematopoietic Recovery|Number of Participants with Serious and Non-Serious Adverse Events","Nanfang Hospital of Southern Medical University|Academy Military Medical Science, China|Peking University People's Hospital|Sun Yat-sen University|Guangdong Provincial People's Hospital|Guangzhou General Hospital of Guangzhou Military Command|Third Affiliated Hospital, Sun Yat-Sen University|Shanghai Zhongshan Hospital","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-PBSC-MSC-2014","January 2014","January 2016","January 2017","March 11, 2014",,"March 11, 2014","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02083718"
776,"NCT02379442","Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids",,"Terminated","Has Results","Graft-Versus-Host Disease","Biological: MSC","Proportion of Subjects Without a Treatment Related Severe Adverse Event","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 99 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","1","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150088|15-H-0088","February 23, 2015","December 13, 2017","December 13, 2017","March 5, 2015","May 1, 2019","May 1, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02379442/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02379442"
777,"NCT01957826","Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy",,"Unknown status","No Results Available","Primary Idiopathic Dilated Cardiomyopathy","Other: bone marrow-derived MSCs injection|Other: placebo intervention","Major adverse cardiac adverse events. SAEs and AEs.|NYHA functional class.|Incidence of complications with the use of NOGA XPTM catheters.|Laboratory parameters including C-reactive protein an brain natriuretic peptide|NYHA Functional Class|Max.oxygen consumption(MVO2),functional capacity.|Quality of life questionnaires|Extension. of perfusion defects(MRI/SPECT).|LVEF, ventricular vol.,wall motion score index(echocard./MRI/SPECT|LVEF(left ventriculogram, electromech. mapping parameters(NOGA XPTM))","Hospital General Universitario Gregorio Marañon|Ministerio de Sanidad, Servicios Sociales e Igualdad","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FIBHGM-ECNC017-2010|2010-024406-35|MIYOCYTE","March 2013","March 2018","March 2018","October 8, 2013",,"November 18, 2016","Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01957826"
778,"NCT00885729","Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects",,"Unknown status","No Results Available","Defect of Articular Cartilage","Procedure: stem cells|Procedure: Chondrocytes|Other: Rehabilitation program","Lysholm score|Radiographics","University Hospital, Akershus","All","18 Years to 50 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","S-0738c 2009","April 2009","July 2011","July 2018","April 22, 2009",,"October 15, 2015","Oslo UniversityHospital-Ullevaal, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT00885729"
779,"NCT03059355","Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.","CERES","Active, not recruiting","No Results Available","Endothelial Dysfunction|Metabolic Syndrome|Chronic Inflammation","Biological: UCMSCs|Biological: BMMSCs|Other: Placebo","Incidence of any treatment-emergent serious adverse events (TE-SAEs)|Change of inflammatory markers|Effect on Frailty Phenotype Score|Effect on Physical Performance through Quality of Life questionnaires|Change of Pro-inflammatory cytokines in laboratory analysis|Determine if there is an improvement in symptoms between subjects receiving umbilical cord cells versus bone marrow cells|Number of study participants experiencing safety events (difference between dose and placebo subjects)","Joshua M Hare|University of Miami","All","21 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170095","April 12, 2018","June 2025","June 2026","February 23, 2017",,"October 28, 2020","ISCI / University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03059355"
780,"NCT02561767","Effect of BM-MSCs in DCD Kidney Transplantation",,"Unknown status","No Results Available","Kidney Transplantation|Acute Kidney Tubular Necrosis","Other: bone marrow-derived mesenchymal stem cells|Other: Saline|Drug: Induction therapy (ATG or Basiliximab)|Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)","Estimated glomerular filtration rate|Incidence of slow graft function|Incidence of delayed graft function|Proportion of normal renal function recovery|Time to renal function recovery|Patient survival|Renal graft survival|Incidence of acute rejection|Severe adverse events","First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital of Guangzhou Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSCs-KTx-DCD-150924","October 2015","October 2016","October 2017","September 28, 2015",,"September 28, 2015","The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02561767"
781,"NCT04333368","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","STROMA-CoV2","Active, not recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","APHP200395|2020-001287-28","April 6, 2020","November 2, 2020","November 1, 2021","April 3, 2020",,"September 10, 2021","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04333368"
782,"NCT00826046","Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)",,"No longer available","No Results Available","Graft-Versus-Host Disease","Drug: Prochymal®",,"Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)",,,"Industry","Expanded Access",,"276",,,,"January 21, 2009",,"March 9, 2020","Indiana BMT, Beech Grove, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00826046"
783,"NCT01297205","Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia",,"Completed","No Results Available","Bronchopulmonary Dysplasia","Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells","Number of participant with adverse reaction|Incidence of BPD at 36 Week's postmenstrual age","Medipost Co Ltd.","All","up to 14 Days   (Child)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CR-006","December 2010","September 2011","December 2011","February 16, 2011",,"April 7, 2014","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01297205"
784,"NCT02107118","Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men",,"Withdrawn","No Results Available","Erectile Dysfunction|Cardiac Disease","Biological: ARM 1: AdMSC: adipose stem cells|Other: ARM 2: Placebo","Improvements in IIEF scores of greater than 2|Improvements in RHI (reactive hyperemic index) scores of greater than 0.3","Baylor College of Medicine","Male","40 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-34570 No.11-13-40-07","May 2015","March 2020","February 2022","April 8, 2014",,"May 25, 2015","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02107118"
785,"NCT01532076","Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts","ROBUST","Terminated","No Results Available","Osteoporotic Fractures","Procedure: Cellularized composite graft augmentation|Procedure: Acellular composite graft augmentation","Development of secondary dislocation within 12 months postoperative|Functional outcome 6 weeks, 6 and 12 months after fixation|Safety|bone mineral density|Histology|Dose-response","University Hospital, Basel, Switzerland","All","50 Years and older   (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","348/10","June 2012","September 2014","September 2014","February 13, 2012",,"September 17, 2014","University Hospital Basel, Basel, Basel-Stadt, Switzerland",,"https://ClinicalTrials.gov/show/NCT01532076"
786,"NCT02961725","Stem Cells for Treatment of Bronchopleural Fistula",,"Unknown status","No Results Available","Bronchopleural Fistula","Biological: UCMSC","closure of the fistula|complication","The Second Affiliated Hospital of Fujian Medical University|Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-BF","April 2016","April 2017","April 2019","November 11, 2016",,"November 11, 2016","The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT02961725"
787,"NCT04501341","BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients",,"Recruiting","No Results Available","T2D","Biological: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Biological: Intravenous Infusion of UC-MSC","Decreasing total daily dose of insulin (>= 30%)|Increasing of C-peptide level|Decreasing of insulin resistance level|Immunology/inflammatory markers|Adverse events|HbA1c","Indonesia University|Dr Cipto Mangunkusumo General Hospital","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","132/PT02.FK25/U.Eu113/METEND/V","March 14, 2016","December 1, 2021","December 1, 2021","August 6, 2020",,"August 6, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04501341"
788,"NCT04276987","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia",,"Completed","No Results Available","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXCOVID","February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"September 7, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04276987"
789,"NCT01981330","Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring",,"Completed","No Results Available","Improved Healing of Scarred Vocal Folds|Improved Vocal Fold Status|Improved Vocal Fold Function","Biological: aMSC|Biological: aMSC+hyaluronan gel","Improved healing of scarred vocal folds","Karolinska University Hospital|The Swedish Research Council|Laryngfonden|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010/1650 and 2014-51432","January 2012","February 24, 2020","February 24, 2020","November 11, 2013",,"February 25, 2020","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01981330"
790,"NCT03355365","Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis",,"Active, not recruiting","No Results Available","Multiple Sclerosis","Biological: Intrathecal MSC-NP injection|Other: Intrathecal saline injection","Expanded Disability Status Scale (EDSS) Plus|Multiple sclerosis functional composite (MSFC)|Bladder function","Tisch Multiple Sclerosis Research Center of New York","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TISCHMS-MSCNP-002","September 21, 2018","May 2022","November 2023","November 28, 2017",,"October 6, 2021","Tisch MS Research Center of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03355365"
791,"NCT04670302","Mesenchymal Stem Cells and Amniotic Membrane Composite for Supraspinatus Tendon Repair Augmentation",,"Recruiting","No Results Available","Supraspinatus Tear","Procedure: Tendon repair procedure|Procedure: Tendon repair augmented with AAdMSC-HAM composite","Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Pain pre-surgery|Pain at follow-up 12 months|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at follow-up 12 months|Constant-Murley Score (CS) pre-surgery|Constant-Murley Score (CS) at follow-up 12 months|Tear recurrence (re-tear)","Dr. Soetomo General Hospital","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","1208/KEPK/V/2019","October 17, 2019","December 31, 2021","December 31, 2022","December 17, 2020",,"December 17, 2020","Dr. Soetomo General Academic Hospital/ Department Orthopaedic & Traumatology Faculty of Medicine Universitas Airlangga, Surabaya, East Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04670302"
792,"NCT03822858","Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis",,"Available","No Results Available","Multiple Sclerosis","Drug: Intrathecal MSC-NP injection",,"Tisch Multiple Sclerosis Research Center of New York","All","18 Years to 70 Years   (Adult, Older Adult)",,,"Other","Expanded Access:Treatment IND/Protocol",,"TISCHMS-MSCNP-003",,,,"January 30, 2019",,"October 13, 2021","Tisch MS Research Center of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03822858"
793,"NCT03504241","Tolerance by Engaging Antigen During Cellular Homeostasis","TEACH","Recruiting","No Results Available","Kidney Transplantation|Renal Transplantation|Renal Transplant Recipient","Biological: Donor-derived Mesenchymal Stromal Cells|Drug: alemtuzumab|Drug: belatacept|Drug: sirolimus|Drug: mycophenolate mofetil|Drug: mycophenolate acid|Drug: prednisone","Proportion of Participants who Achieve Operational Tolerance|Proportion of Participants who Remain Off Immunosuppression|Proportion of Participants who Return to Immunosuppression|Proportion of Participants who Achieve Belatacept Monotherapy|Proportion of Participants who Die|Time from Transplant to the First Episode of Rejection|Incidence of Participants who Develop Donor Specific Antibody (DSA)|Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration|Frequency of Select Adverse Events (AEs)|Incidence of Post-Transplant Diabetes|Frequency of Antibody-Mediated Acute Cellular Rejection|Frequency of Antibody-Mediated Chronic Rejection","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc.","All","19 Years and older   (Adult, Older Adult)","Phase 1","6","NIH|Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ITN062ST|UM1AI109565|NIAID CRMS ID#: 20676","July 30, 2018","April 2025","April 2027","April 20, 2018",,"May 6, 2021","Duke University Health System, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03504241"
794,"NCT04573270","Mesenchymal Stem Cells for the Treatment of COVID-19",,"Completed","No Results Available","Covid19|Prophylaxis","Biological: PrimePro|Other: Placebo","Survival Rates|Contraction Rates","Thomas Advanced Medical LLC|HeartStem Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00043080","April 24, 2020","August 20, 2020","September 1, 2020","October 5, 2020",,"October 5, 2020","Southern California Hospital at Culver City / Southern California Hospital at Hollywood, Culver City, California, United States",,"https://ClinicalTrials.gov/show/NCT04573270"
795,"NCT02509156","Stem Cell Injection in Cancer Survivors","SENECA","Completed","Has Results","Cardiomyopathy Due to Anthracyclines","Biological: Allo-MSCs|Biological: Placebo","Proportion of Major Adverse Cardiac Events (MACE)|Proportion of Other Significant Clinical Events|Subjects With Events Precluding Their Receipt of Product|Subjects Who Receive Less Than 20 Injections During SPI|Subjects Who Did Not Receive the Study Product (Either 100 Million Cells or Placebo)|Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable|Subjects Who Fail to Complete Follow-up|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Area of Injury|Change From Baseline in Area of Injury-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Cumulative Days Alive and Out of Hospital for Heart Failure","The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-SPH-15-0443|5UM1HL087318","August 2016","November 2019","April 20, 2020","July 27, 2015","November 5, 2020","November 5, 2020","Stanford University School of Medicine, Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdiciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02509156"
796,"NCT04520945","Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis",,"Not yet recruiting","No Results Available","Osteoarthritis, Knee","Biological: Chondrogen|Biological: Placebo","VAS score|WOMAC score|IKDC score|KOOS score|PROMIS29 score|Kellegren-Lawrence grading|Interleukins","Meluha Life Sciences SDN BHD","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Chondrogen","October 31, 2020","September 30, 2021","September 30, 2022","August 20, 2020",,"August 20, 2020","Department of Orthopedic & Traumatology, Faculty of Medicine, Hospital Canselor Tuanku Mukhriz, UKM Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur., Cheras, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT04520945"
797,"NCT04825730","Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy",,"Not yet recruiting","No Results Available","Degenerative Arthritis|Knee Arthritis","Drug: JOINTSTEM","Adverse Events|Adverse Events (Special Attention Target)","R-Bio","All","20 Years and older   (Adult, Older Adult)","Not Applicable","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BS-JS-IIT1-FU","December 1, 2021","December 1, 2027","December 31, 2028","April 1, 2021",,"April 1, 2021",,,"https://ClinicalTrials.gov/show/NCT04825730"
798,"NCT03799718","Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS",,"Completed","No Results Available","Multiple Sclerosis, Chronic Progressive","Biological: NurOwn (MSC-NTF cells)","Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation","Brainstorm-Cell Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCT-101-US","March 13, 2019","March 11, 2021","March 30, 2021","January 10, 2019",,"September 1, 2021","University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Redwood City, California, United States|The Mount Sinai Hospital, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03799718"
799,"NCT03472742","An Follow-Up Study of Liver Cirrhosis",,"Recruiting","No Results Available","Decompensated Liver Cirrhosis","Drug: Mesenchymal Stem Cell","Number of patients with adverse events (AEs) and serious AEs (SAEs)|Change of liver function evaluated by Child-Pugh Score|Improvement rate of Child-Pugh score|Improvement rate of Child-Pugh grade|Number of patients with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) findings|Number of patients with abnormal pulse rate findings|Number of patients with abnormal body temperature findings|Number of patients with abnormal electrocardiogram (ECG) findings|Number of patients with abnormal clinical chemistry parameters|Number of patients with abnormal clinical hematology parameters|Number of patients with abnormal urinalysis parameters","Rohto Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Older Adult)",,"21","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADR-001-02","March 7, 2018","December 31, 2021","June 30, 2022","March 21, 2018",,"March 11, 2021","Niigata University Medical & Dental Hospital, Niigata, Japan",,"https://ClinicalTrials.gov/show/NCT03472742"
800,"NCT01218464","Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure",,"Unknown status","No Results Available","Liver Failure|Mesenchymal Stem Cells","Drug: Conventional plus MSC treatment|Drug: Conventional plus pacebo treatment","The levels of serum Total Protein and Albumin|The levels of serum Total Bilirubin and Direct Bilirubin|The levels of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Cholinesterase (CHE)|The level of alpha-fetoprotein (AFP)|The content of ascites|Survival rate and time|Body temperature, tetter and allergy|The levels of Prothrombin Activity (PA) and Prothrombin Time (PT)|The score for Model for End-Stage Liver Disease","Beijing 302 Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Beijing302-003","March 2009","March 2014","March 2014","October 11, 2010",,"May 31, 2013","Beijing 302 Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01218464"
801,"NCT04527224","Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","Covid19 Pneumonia","Drug: AstroStem-V","Treatment related adverse events|Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values|Oxygenation index (PaO2 / FiO2 ratio)|Mortality rate|Ventilator treatment status|Improvement of pneumonia|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test","Nature Cell Co. Ltd.","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASVP1N2A-US","December 1, 2021","October 1, 2022","April 1, 2023","August 26, 2020",,"April 1, 2021",,,"https://ClinicalTrials.gov/show/NCT04527224"
802,"NCT05080465","Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis",,"Active, not recruiting","No Results Available","Liver Cirrhosis","Biological: Autologous BM MSC","MR Elastography|The level of serum alanine aminotransferase (ALT)|Clinical Examination|The level of glomerular filtration rate (GFR)|The level of serum albumin (ALB)|The level of serum total bilirubin (TB)","Ukraine Association of Biobank","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 3","700","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","UAB00240818-1","December 2, 2018","October 7, 2021","February 2, 2022","October 15, 2021",,"October 15, 2021","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,"https://ClinicalTrials.gov/show/NCT05080465"
803,"NCT01933802","Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: intrathecal administration of autologous MSC-NP","Number of participants with adverse events|Number of participants with adverse events .|Preliminary evaluation of efficacy","Tisch Multiple Sclerosis Research Center of New York","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TISCHMS-MSCNP-001|IND 13889","April 2014","December 2016","March 2017","September 2, 2013",,"March 19, 2018","Tisch MS Research Center of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01933802"
804,"NCT02529566","Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine",,"Unknown status","No Results Available","Lumbar Degenerative Disc Disease|Lower Back Pain|Chronic Lower Back Pain",,"Numeric Pain Rating Scale (NPRS)|Oswestry Disability Index (ODI)|SF-12 Health Survey|EQ-5D Quality Adjusted Life Years","The Foundation for Spinal Research, Education and Humanitarian Care, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HSC-2013","July 2013","July 2018","July 2018","August 20, 2015",,"February 15, 2017","Trinity Stem Cell Institution, Odessa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02529566"
805,"NCT00543374","Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease",,"Completed","No Results Available","Crohn's Disease","Drug: Placebo|Drug: PROCHYMAL adult human mesenchymal stem cells","Duration of clinical benefit (Crohn's disease activity index)|Re-induction of clinical benefit (Crohn's disease activity index)|Improvement in quality of life (Inflammatory Bowel Disease Questionnaire [IBDQ] instrument)","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRD 610","September 17, 2007","July 2009","April 28, 2011","October 15, 2007",,"April 8, 2020","Advanced Clinical Research Institute, Anaheim, California, United States|Veteran's Administration Medical Center (does not require vet status), Long Beach, California, United States|University of Southern California University Hospital, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Western States Clinical Research, Wheat Ridge, Colorado, United States|Gastroenterology Center of Connecticut, Hamden, Connecticut, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Venture Research Institute, Miami, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Carle Clinic Association, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Gulf Coast Research, Baton Rouge, Louisiana, United States|National Institutes of Health, Bethesda, Maryland, United States|Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Center for Clinical Studies, Dearborn, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|St Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Gastroenterology Research Associates, Cedar Knolls, New Jersey, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Rochester Institute for Digestive Diseases, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University Hospital and Medical Center, Stony Brook, New York, United States|Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Dayton Science Institute, Dayton, Ohio, United States|Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States|Options Health Research, Tulsa, Oklahoma, United States|Allegheney Center for Digestive Health, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Gastroenterology Center of the Midsouth, Germantown, Tennessee, United States|Nashville GI Specialists, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Memorial Hermann Hospital, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire Research Institute, Richmond, Virginia, United States|Seattle Gastroenterology Associates, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00543374"
806,"NCT01879046","Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells","ARTHROSTEM","Completed","No Results Available","Knee Osteoarthritis","Procedure: arthroplasty","Increased expression of chondrogenic markers|Increasing secretion of anti-inflammatory molecules in vitro","Nantes University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RC12_0394","October 2015","December 2016","December 2016","June 17, 2013",,"February 17, 2017","Nantes University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT01879046"
807,"NCT01777646","Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF","Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","14","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-002-HMO-CTIL","December 2012","September 2014","September 2015","January 29, 2013",,"March 8, 2018","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01777646"
808,"NCT04953572","Treatment of Cartilage Defects With Peripheral Blood Stem Cells",,"Not yet recruiting","No Results Available","Cartilage Injury","Genetic: autologous peripheral blood mesenchymal stem cell|Procedure: Microfracture|Combination Product: Microfracture + collagen membrane|Procedure: Autologous osteochondral transplantation","Magnetic Resonance Imaging in the 6th month after surgery|Magnetic Resonance Imaging in the 12th month after surgery|Magnetic Resonance Imaging in the 24th month after surgery|The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index|International knee documentation committee (IKDC) Knee Joint Score Sheet","Peking University Third Hospital|Inner Mongolia People's Hospital|Hebei Medical University Third Hospital|Tianjin Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PekingUTH001","August 1, 2021","December 31, 2023","December 31, 2023","July 8, 2021",,"July 8, 2021","Institute of Sports Medicine, Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04953572"
809,"NCT01733186","Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects",,"Completed","Has Results","Degeneration Articular Cartilage Knee","Biological: CARTISTEM®","IKDC Score|VAS|Lysholm Score|KOOS Score","Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-0201-01","January 7, 2013","June 2, 2017","August 29, 2017","November 26, 2012","July 30, 2021","July 30, 2021","Cartilage Restoration Center; RUSH University Medical Center, Chicago, Illinois, United States|Cartilage Repair Center; Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01733186/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01733186"
810,"NCT02368587","Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy","WJ-ICMP Tria","Not yet recruiting","No Results Available","Ischemic Cardiomyopathy","Biological: WJMSCs Vs. placebo|Biological: Placebo","The primary end point was safety in incidence of adverse events (AEs) within 12 months|The secondary end point was efficacy in absolute change of the global LV ejection fraction (LVEF) from baseline to 12 months by MRI","Navy General Hospital, Beijing|First People's Hospital of Foshan|General Hospital of Armed Police, Beijing|PLA General Hospital, Beijing","All","17 Years to 90 Years   (Child, Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NavyGHB","January 1, 2020","January 1, 2021","July 2021","February 23, 2015",,"December 5, 2019",,,"https://ClinicalTrials.gov/show/NCT02368587"
811,"NCT00768066","The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)","TAC-HFT","Completed","Has Results","Stem Cell Transplantation|Ventricular Dysfunction, Left","Biological: Autologous human mesenchymal cells (hMSCs)|Biological: Autologous human bone marrow cells (hBMCs)|Biological: Placebo","Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|Serial Troponin Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Serial Creatine Kinase Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Incidence of the Major Adverse Cardiac Events (MACE) Endpoint, Defined as the Composite Incidence of (1) Death, (2) Hospitalization for Heart Failure, or (3) Non-fatal Recurrent MI.|Ectopic Tissue Formation.|Number of Deaths|Change From Baseline in Distance Walked in Six-minutes (Six-minute Walk Test).|Change From Baseline in the Minnesota Living With Heart Failure (MLHF) Questionnaire Total Score.|Percent Change From Baseline in Scar Mass as a Fraction of Left Ventricle Mass by Cardiac MRI or CT.","University of Miami|The Emmes Company, LLC","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20070443","August 2008","August 2012","September 2013","October 7, 2008","December 14, 2015","December 14, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00768066"
812,"NCT01144962","Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease",,"Completed","No Results Available","Crohn's Disease|Fistula","Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.","Safety and efficacy (fistula closure)|Clinical scores|Endoscopic scores|Quality of life|C-reactive protein (CRP)|Safety","Leiden University Medical Center|DigestScience","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P10.102","June 2010","September 2014","December 2014","June 16, 2010",,"December 30, 2014","Leiden University Medical Center (LUMC), Leiden, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01144962"
813,"NCT04896853","Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTrans®",,"Recruiting","No Results Available","COVID-19 Acute Respiratory Distress Syndrome","Biological: ProTrans®","Safety and tolerance of a single infusion of ProTrans®|Effect of ProTrans® -MSC on patient clinical status, including mortality|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 7|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 15|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 30|Time to clinical improvement after ProTrans® - MSC infusion|Effect of of ProTrans® -MSC on lung damage|Duration of hospitalization and Intensive Care Unit (ICU) stay|Kinetics of COVID-19 viral load after ProTrans® -MSC infusion","NextCell Pharma Ab|Karolinska Trial Alliance","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO TRANS 19+|2020-002078-29","May 18, 2021","September 30, 2024","December 31, 2024","May 21, 2021",,"May 21, 2021","Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT04896853"
814,"NCT02439541","Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy","UCMSC-Heart","Unknown status","No Results Available","Chronic Ischemic Heart Disease|Heart Failure|Angina","Biological: UCMSC group","Number and nature of adverse events|Incidence of major adverse coronary events (MACE)|Exercise Time and Level|Quantify myocardium perfusion measured by SPECT|Assessment of heart function by left ventricular ejection fraction|Clinical Improvement in NYHA Classification","Affiliated Hospital to Academy of Military Medical Sciences|Ivy Institute of Stem Cells Co. Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307-IVY-SC-001","May 2015","December 2017","December 2018","May 8, 2015",,"March 16, 2016","Department of cardiology,Affiliated Hospital to Academy of Military Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02439541"
815,"NCT00498316","Cord Blood Expansion on Mesenchymal Stem Cells",,"Completed","No Results Available","Myelodysplastic Syndrome|Leukemia","Procedure: Cord Blood Infusion|Drug: Busulfan|Drug: Fludarabine|Drug: Rituximab|Other: ATG|Drug: Cyclophosphamide|Drug: Clofarabine|Radiation: Total Body Irradiation (TBI)|Drug: Melphalan|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: G-CSF","Engraftment and Time to Engraftment","M.D. Anderson Cancer Center|ViaCell|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","1 Year to 80 Years   (Child, Adult, Older Adult)","Phase 1","98","Other|Industry|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0781|NCI-2011-02823|RP100469 02|1P01CA148600-01A1|5R01CA061508-20","July 3, 2007","October 2016","October 2016","July 10, 2007",,"February 28, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00498316"
816,"NCT02442037","Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis","UCMSC-UC","Unknown status","No Results Available","Ulcerative Colitis","Biological: UCMSC group|Other: Control group(Normal saline)","Safety will be determined by the assessment of major adverse events.|Clinical response (CDAI points)|Endoscopic improvement is assessed by UCEIS.|Level of C-reactive protein","Affiliated Hospital to Academy of Military Medical Sciences|Ivy Institute of Stem Cells Co. Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","307-IVY-SC-002","May 2015","May 2017","December 2017","May 13, 2015",,"May 15, 2015","Department of gastroenterology,Affiliated Hospital to Academy of Military Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02442037"
817,"NCT03047772","Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients","TEAM-AMI","Unknown status","No Results Available","Myocardial Infarction|Stem Cell Transplantation|Angioplasty, Transluminal, Percutaneous Coronary","Drug: Atorvastatin|Drug: Intensive Atorvastatin|Drug: Low dose BMMSC|Drug: Middle dose BMMSC|Drug: High dose BMMSC|Drug: Transplantation","Changes in left ventricular ejection fraction from baseline to 12 months'","Yuejin Yang|Peking Union Medical College Hospital|The First Hospital of Hebei Medical University|Zunyi Medical College|Chinese Academy of Medical Sciences, Fuwai Hospital","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","124","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2016-807-10.1","March 6, 2018","December 31, 2018","December 31, 2018","February 9, 2017",,"January 25, 2018",,,"https://ClinicalTrials.gov/show/NCT03047772"
818,"NCT04435249","ENgineered Tissue Repair of BronchopleUral fiSTula","ENTRUST","Not yet recruiting","No Results Available","Bronchopleural Fistula","Other: BPF-001","Safety: Emergent or worsening Serious Adverse Events (SAEs) related to the BPF implant during the 3 months post-defect repair|Efficacy: Bronchopleural Fistula (BPF) closure at 3 months assessed by visual appearance and no clinical signs of leaks.|Change from Baseline in Physiological and Quality of Life scores at 3, 6, 9, 12 months, Evaluation Questionnaire 5D (EQ-5D), 6-minute walking test (6MWT), ambulatory oxygen (O2).|Safety and tolerability: - Adverse Events (AEs) including pre-defined postoperative AEs of special interest up to 30± 3 days post implantation- Related AEs reported after 3, 6, 9, 12, 24 and 36 months|Viability and the integrity of the repair area (closure) visually via bronchoscope. Integrity assessed by visual appearance of no visible leaks- Structural closure of the defect and visual health of the defect area and surrounding tissue|Absence of other surgical interventions at 6, 9, 12, 24 and 36 months","Cell Therapy Catapult|Videregen Therapeutics|Papworth Hospital NHS Foundation Trust|Royal Free Hospital NHS Foundation Trust","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UK-2019-004939-24","January 4, 2022","September 2023","November 2024","June 17, 2020",,"October 20, 2021",,,"https://ClinicalTrials.gov/show/NCT04435249"
819,"NCT02881476","Therapeutic Treatment of Amyotrophic Lateral Sclerosis","UwmWjmscAls","Unknown status","No Results Available","Amyotrophic Lateral Sclerosis","Other: Biological: Cell-based therapy","Changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) between patients before and after stem cell transplantation.","University of Warmia and Mazury","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UWM/ALS-MSC.2015/001","November 2015","April 2018","December 2018","August 29, 2016",,"August 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02881476"
820,"NCT02444858","Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury","UCMSC-PQLI","Unknown status","No Results Available","Paraquat Poisoning|Lung Injury","Biological: UCMSC group|Other: Control group(Normal saline)","Safety will be determined by the assessment of major adverse events.|The efficacy of UC-MSC treatment was measured clinical evaluation.|The efficacy of UC-MSC treatment was measured by chest computerized tomography.|The efficacy of UC-MSC treatment was monitored by pulmonary function.|The efficacy of UC-MSC treatment was measured by lab Indicators.","Affiliated Hospital to Academy of Military Medical Sciences|Ivy Institute of Stem Cells Co. Ltd","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","307-IVY-SC-004","May 2015","May 2017","December 2017","May 15, 2015",,"May 15, 2015","Department of poisoning and treatment,Affiliated Hospital to Academy of Military Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02444858"
821,"NCT03069209","Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)",,"Active, not recruiting","No Results Available","Premature Ovarian Failure","Biological: Stem Cells","Return of menstrual cycle|Pregnancy|FSH levels|Follicular function|Endometrium thickness","Stem Cells Arabia","Female","19 Years to 39 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA-POF1","January 2015","June 2021","January 2022","March 3, 2017",,"May 17, 2018","Stem Cells Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03069209"
822,"NCT03078621","Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy",,"Active, not recruiting","No Results Available","Cerebral Palsy","Biological: Stem Cell Therapy","Changes in Motor Performance.|Motor function studies|Specific white matter tract analysis using MRI","Stem Cells Arabia","All","2 Years to 12 Years   (Child)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA-CP1","September 2016","October 2020","January 2021","March 13, 2017",,"March 17, 2020",,,"https://ClinicalTrials.gov/show/NCT03078621"
823,"NCT02997878","A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH","Merlin","Recruiting","No Results Available","Cholangitis, Sclerosing|Hepatitis, Autoimmune","Biological: Orbcel-C","Stage 1- Dose finding and Incidence of treatment emergent adverse events (safety and tolerability) PSC and AiH Patients|Stage 2: Incidence of treatment emergent adverse events (safety and tolerability) - Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AiH) patients|Stage 2: Activity: change in Alkaline Phosphatase (ALP) value : ( absolute % change /duration of change between baseline and day 56) - PSC|Stage 2: Activity: change in Alanine transaminase ( absolute % change /duration of change between baseline and day 56) - Autoimmune Hepatitits|Autoimmune Hepatitis secondary outcomes 1|Autoimmune Hepatitis secondary outcomes 2|AIH secondary outcomes 3|AIH secondary outcomes 4|PSC secondary outcomes 1|PSC secondary outcomes 2|PSC secondary outcomes 3","University of Birmingham|European Union|NHS Blood and Transplant","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG-13-124","December 7, 2018","December 2021","December 2021","December 20, 2016",,"February 8, 2019","University hospitals Birmingham NHS foundation Trust, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02997878"
824,"NCT02444455","Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury","UCMSC-ALI","Unknown status","No Results Available","Acute Lung Injury|Acute Respiratory Distress Syndrome","Biological: UCMSC group","Safety will be determined by the assessment of major adverse events|Quantify pulmonary respiratory function measured by chest computerized tomography|The efficacy of UC-MSC treatment was measured by arterial blood gas analysis|The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation，IL-6|The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation，IL-8","Affiliated Hospital to Academy of Military Medical Sciences|Ivy Institute of Stem Cells Co. Ltd","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307-IVY-SC-003","May 2015","March 2017","December 2017","May 14, 2015",,"May 14, 2015","Department of Respiration,Affiliated Hospital to Academy of Military Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02444455"
825,"NCT01399749","Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects","ASCROD","Unknown status","No Results Available","Articular Cartilage Lesion of the Femoral Condyle","Other: Implantation of autologous cells","Hyaline cartilage production for chondral knee lesions repair|Efficacy: Clinical evolution|Efficacy: Functional evolution|Efficacy: Histological evaluation|Efficacy: Radiological evaluation|Safety: Adverse events|Safety: Acute inflammatory events","Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HLPTRA-2009-01|2009-016628-29","September 2011","June 2012","June 2012","July 22, 2011",,"July 22, 2011","La Paz University Hospital. Orthopedic Surgery and Traumatology Department, Knee Unit; Cell Therapy Laboratory., Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01399749"
826,"NCT02351011","Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA",,"Completed","No Results Available","Osteoarthritis of Knee","Biological: 1 x 10^6 MSCs|Biological: 10 x 10^6 MSCs|Biological: 50 x 10^6 MSCs","Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Marx Activity Scale (Patient-reported activity)|Short-Form 36 (Health-related quality of life)|Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)|Cartilage oligomeric matrix protein (COMP)|Hyaluronic acid (HA)|C-terminal telopeptide of type II collagen (CTXII)|Types I and II collagen cleavage (C1,2C)|Type II collagen cleavage (C2C)|IL-6/TNFα/IL-15","Jas Chahal|University Health Network, Toronto","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MSC-001","February 2015","December 2018","December 2018","January 30, 2015",,"September 27, 2019","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02351011"
827,"NCT04456439","Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)",,"Available","No Results Available","Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","Biological: Remestemcel-L|Drug: Hydrocortisone|Drug: Diphenhydramine",,"Mesoblast International Sàrl|Mesoblast, Ltd.","All","2 Months to 17 Years   (Child)",,,"Industry","Expanded Access:Intermediate-size Population",,"MSB-MSC-MISC001",,,,"July 2, 2020",,"February 18, 2021",,,"https://ClinicalTrials.gov/show/NCT04456439"
828,"NCT02619877","Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers",,"Completed","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Other: Standard therapy","Proportion of re-epithelialization|Time to re-epithelialization|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ALLO-ASC-DFU-201","October 2015","September 2016","October 2016","December 2, 2015",,"September 1, 2017","Korea University Guro Hospital, Guro-gu, Seoul, Korea, Republic of|Eulji General Hospital, Nowon-Gu, Seoul, Korea, Republic of|Severance Hospital, Seodaemun-Gu, Seoul, Korea, Republic of|Asan medical center, Songpa-Gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02619877"
829,"NCT02619851","A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects",,"Active, not recruiting","No Results Available","Burn Injury","Biological: ALLO-ASC-DFU|Device: Conventional Therapy","Time of re-epithelialization|Safety (laboratory tests and adverse events)|Burn Scar Index|healing status of the wound evidenced by photography","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALLO-ASC-BI-201","December 2015","December 2022","June 2023","December 2, 2015",,"July 21, 2021","Hallym university Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02619851"
830,"NCT02796079","A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications",,"Unknown status","No Results Available","Peripheral Vascular Disease|Ischemia|Diabetic Foot","Biological: mesenchymal stem cells|Biological: saline","Area of diabetic foot ulcers|Improvement of transcutaneous oxygen partial pressure (TcPO2)|Improvement of microvascular cutaneous reactivity by laser Doppler perfusion monitoring (LDPM)|Pain (Visual-Analog Scale)|Walking distance (treadmill) if possible","Jie Shen|Nanfang Hospital of Southern Medical University|Academy Military Medical Science, China|The Fifth Affiliated Hospital of Southern Medical University|Southern Medical University, China|The Third Affiliated Hospital of Southern Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ThirdSouthernMedical","January 2015","December 2017","December 2018","June 10, 2016",,"April 6, 2017","the Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02796079"
831,"NCT01844661","Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.",,"Completed","No Results Available","Children|Solid Tumors|Metastases","Biological: CELYVIR","Adverse effects after intravenous infusions|Clinical outcome","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Instituto de Salud Carlos III","All","6 Months to 75 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT2008-000364-16","January 2013","December 2014","January 2016","May 1, 2013",,"February 19, 2016","Hospital Universitario Niño Jesús, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01844661"
832,"NCT04366063","Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","Covid-19","Biological: Cell therapy protocol 1|Biological: Cell therapy protocol 2","Adverse events assessment|Blood oxygen saturation|Intensive care unit-free days|Clinical symptoms|Respiratory efficacy|Biomarkers concentrations in plasma","Royan Institute|Tehran University of Medical Sciences|Shahid Beheshti University of Medical Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","991919|IRCT20200217046526N2","April 5, 2020","June 6, 2020","December 10, 2020","April 28, 2020",,"April 30, 2020","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04366063"
833,"NCT00815945","Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors",,"Completed","No Results Available","Mesenchymal Tumor|Carcinosarcoma|Leiomyosarcoma","Drug: PegLiposomal Doxorubicin|Drug: Carboplatin","Anticancer activity in terms of progression-free survival time (PFS)|Tolerability, i.e. type, frequency, severity and duration of adverse reactions (CTCAE,Version 3.0)|Anticancer activity in patients with measurable or evaluable disease in terms of response rates (CR, PR, SD, PD) according to RECIST criteria|Overall survival|Correlation of tumor marker CA-125 with imaging methods","AGO Study Group|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","41","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGO-GYN 7","June 2008","November 2011","January 2012","December 31, 2008",,"February 14, 2017","Charité, Campus Virchow Klinikum, Frauenklinik, Berlin, Germany|Malteser Krankenhaus, Gynäkologie und Geburtshilfe, Bonn, Germany|Klinikum Bremen-Mitte gGmbH, Frauenklinik, Bremen, Germany|Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Germany|Evangelisches Krankenhaus Düsseldorf, Frauenklinik, Duesseldorf, Germany|Universitätsklinikum Essen, Frauenklinik, Essen, Germany|Klinikum der J. W. Goethe-Universität, Klinik für Gynäkologie und Geburtshilfe, Frankfurt, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|Gynäkologisch-onkologische Praxis, Hannover, Germany|St. Vincentius Kliniken AG, Frauenklinik, Karlsruhe, Germany|Universitätsklinikum Giessen und Marburg GmbH, Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Marburg, Germany|Klinikum Großhadern, Frauenklinik, München, Germany|Universitätsklinikum Tübingen, Frauenklinik, Tübingen, Germany|Universitätsklinikum Ulm, Universitätsfrauenklinik, Ulm, Germany|Dr. Horst Schmidt Kliniken GmbH, Klinik für Gynäkologie und gynäkologische Onkologie, Wiesbaden, Germany",,"https://ClinicalTrials.gov/show/NCT00815945"
834,"NCT01051882","Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC-NTF cells transplantation (IM)|Biological: MSC-NTF cells transplantation (IT)","Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-001-HMO-CTIL","June 2011","December 2012","March 2013","January 20, 2010",,"January 10, 2019","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01051882"
835,"NCT03291366","Mesenchymal Stem Cells in Central Nervous System injury2017",,"Active, not recruiting","No Results Available","Central Nervous System Injury","Drug: UCMSCC|Drug: conventional treatment","life quality score|adverse events","Fuzhou General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-CNS2017","January 2017","January 2020","January 2022","September 25, 2017",,"September 25, 2017",,,"https://ClinicalTrials.gov/show/NCT03291366"
836,"NCT04235868","Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Non-healing Wounds",,"Recruiting","No Results Available","Mesenchymal Stem Cell-derived Bioactivator for Treating Chronic Wounds","Biological: Stem cell-derived derived pleiotropic factor|Biological: fibroblast growth factor","wound healing rate","Chinese PLA General Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MP-01","October 20, 2019","August 30, 2020","October 30, 2020","January 22, 2020",,"May 12, 2020","Chinese PLA General Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04235868"
837,"NCT02442817","Linagliptin and Mesenchymal Stem Cells: A Pilot Study",,"Completed","No Results Available","Schizophrenia","Drug: Linagliptin","SDF1-α (stromal cell-derived factor alpha) Concentration|DPP-4 (Dipeptidyl peptidase-4) Activity|Monocyte State|Absolute/Differential leukocyte count|CD271+ cells","University of Nevada, Reno|Augusta University","All","18 Years to 45 Years   (Adult)","Phase 4","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LING-1","March 2, 2015","March 2, 2018","March 2, 2018","May 13, 2015",,"November 9, 2020","University of Nevada School of Medicine, Reno, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT02442817"
838,"NCT04289194","Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Drug: HCR040 (Phase 1)|Drug: Placebo (Phase 2)|Drug: HCR040 (Phase 2)","Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection|Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040|Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040|Mechanical ventilation-free days 28 days after the administration of HCR040|Percent mortality 28 days after the administration of HCR040|Daily pulmonary mechanics values (Ppl, DP, CRS)|Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040|Vasopressor-free days 28 days after the administration of HCR040|ICU-free days 28 days after the administration of HCR040","Histocell, S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALICELL-CT-01|2019-002688-89","December 10, 2019","August 15, 2021","April 16, 2022","February 28, 2020",,"May 14, 2021","Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain|Fundación Jiménez Díaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04289194"
839,"NCT05047276","Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma","PULSE-UM","Not yet recruiting","No Results Available","Uveal Melanoma, Metastatic","Biological: AloCelyvir","Overall response rate|Progression Free Survival (PFS)|Overall Survival (OS)|Evaluate Safety","José María Piulats Rodríguez|Instituto de Salud Carlos III|Institut d'Investigació Biomèdica de Bellvitge","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PULSE-UM","October 1, 2021","June 30, 2023","December 31, 2024","September 17, 2021",,"September 17, 2021","ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05047276"
840,"NCT03920397","Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation","Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation","Universidade Federal do Rio de Janeiro","All","16 Years to 35 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nutro_MesenchymalStemCells_DM1","March 1, 2015","March 1, 2021","May 1, 2021","April 18, 2019",,"May 26, 2021","Clementino Fraga Filho University Hospital of Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03920397"
841,"NCT04998058","Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting",,"Not yet recruiting","No Results Available","Bone Loss, Osteoclastic|Bone Loss, Alveolar|Alveolar Bone Loss|Alveolar Bone Atrophy|Grafting Bone","Procedure: Maxillary sinus floor elevation grafting with synthetic bone substitute.","Assessment of changes in bone density and quantity|Assessment of bone quantity|Presence of bone formation markers","Pontificia Universidade Católica do Rio Grande do Sul|ITI International Team for Implantology, Switzerland|KU Leuven|Rio Grande do Sul Brain Institute (InsCer)","All","35 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Bone Graft-Exosomes Project","September 30, 2021","August 30, 2022","September 30, 2023","August 10, 2021",,"August 10, 2021","Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT04998058"
842,"NCT02900014","Validation of a Production Method of Stem Cell Isolated From the Nasal Cavity for an Innovative Cell Therapy of Cleft Palate",,"Unknown status","No Results Available","Cleft Palate","Procedure: sampling mesenchymal stem cells","number of nasal mesenchymental stem cells","Assistance Publique Hopitaux De Marseille","All","up to 6 Months   (Child)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2015-12|2015-A00984-45","August 2015","December 2016","December 2017","September 14, 2016",,"September 14, 2016","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT02900014"
843,"NCT04339504","Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: SMUP-IA-01(low-dose)|Biological: SMUP-IA-01(mid-dose)|Biological: SMUP-IA-01(high-dose)","Change of total score in WOMAC (Western Ontario and McMaster University)|Change of score in WOMAC three subscales (Pain, stiffness, physical function)|Change of score in 100 mm VAS (Visual Analogue Scale)|Change of score in IKDC(International Knee Documentation Committee)|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score)|Change in K&L(Kellgren-Lawrence) grade|Change in joint space width|Change in mechanical axis, anatomical axis|Rate of surgery to treat application site after treatment of SMUP-IA-01|Changes in biomarker","Medipost Co Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-SMUP-IA-P01-F/U","April 14, 2020","December 2025","December 2025","April 9, 2020",,"April 24, 2020","Seoul national University Hospital, Seoul, Jongno-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04339504"
844,"NCT03585855","Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)",,"Terminated","No Results Available","Interventional","Other: MSC transplantation","Safety of MSC transplantation as assessed by adverse events according to CTCAE Version 5Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR)|Graft survival rate","University Medical Centre Ljubljana|Slovenian Research Agency","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P3-0323","January 1, 2019","July 23, 2019","July 23, 2019","July 13, 2018",,"July 25, 2019","University Medical Centre Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT03585855"
845,"NCT02494752","Role of Mesenchymal Stem Cells in Fat Grafting",,"Unknown status","No Results Available","Romberg's Disease|Craniofacial Microsomia|Lipodystrophy|Mixed Connective Tissue Disease","Procedure: Fat graft enriched with ex vivo expanded stem cells|Procedure: Fat graft not enriched with ex vivo expanded stem cells","Change from baseline in thickness of subcutaneous tissue|Change from base line in post operative appearance","King Edward Medical University","All","16 Years to 60 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","229/RC/KEMU","August 2015","February 2016","February 2016","July 10, 2015",,"July 10, 2015",,,"https://ClinicalTrials.gov/show/NCT02494752"
846,"NCT02557724","Mobilization of Mesenchymal Stem Cells During Liver Transplantation",,"Completed","No Results Available","Liver Failure|Liver Neoplasm","Procedure: blood samples","post operative liver injury|Total Bilirubin level|(INR) International Normalized Ratio|(ALT) Alanine Aminotransferase|(AST) Aspartate Aminotransferase","Rutgers, The State University of New Jersey","All","18 Years to 80 Years   (Adult, Older Adult)",,"35","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20140000266","September 2015","July 2017","July 2017","September 23, 2015",,"October 16, 2018","University Hospital, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02557724"
847,"NCT03732872","Epithelial Mesenchymal Transition Markers in OSMF",,"Completed","No Results Available","Oral Submucous Fibrosis","Diagnostic Test: Biopsy tissue analysis|Diagnostic Test: Saliva analysis","Change in Expression of E-cadherin levels in all the groups in IHC|Change in Expression of vimentin levels in all the groups in IHC|Change in Expression of collagen IV levels in all the groups in IHC|Change in Expression of miRNA 21 in all three groups using Real Time-PCR|CHange in E cadherin levels in PCR|Change in vimentin levels in PCR|Change in e-cadherin expression with respect to disease category clinically in OSMF patients with habits|Change in e-cadherin expression with respect to disease category histologically in OSMF patients with habits|Change in vimentin expression with respect to disease category clinically in OSMF patients with habits|Change in vimentin expression with respect to disease category histologically in OSMF patients with habits|Change in collagen IV expression with respect to disease category clinically in OSMF patients with habits|Change in collagen IV expression with respect to disease category hstologically in OSMF patients with habits|Change in mi RNA 21 expression with respect to disease category clinically in OSMF patients with habits|Change in mi RNA 21 expression with respect to disease category histologically in OSMF patients with habits","The Oxford Dental College, Hospital and Research Center, Bangalore, India|Credora Life Sciences, India","All","18 Years and older   (Adult, Older Adult)",,"185","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Oxford DC","January 15, 2015","December 28, 2017","March 20, 2018","November 7, 2018",,"November 7, 2018",,,"https://ClinicalTrials.gov/show/NCT03732872"
848,"NCT02241018","MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD",,"Unknown status","No Results Available","Acute Graft-versus-host Disease","Drug: CD25 monoclonal antibody|Drug: calcineurin inhibitors|Biological: MSCs","The efficacy of treatment for steroid-resistant aGVHD|Incidence of infections|Incidence of primary underlying disease relapse|Incidence of chronic GVHD","Nanfang Hospital of Southern Medical University|Guangdong Provincial People's Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Guangzhou General Hospital of Guangzhou Military Command|Guangzhou First People's Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Southern Medical University, China|Peking University People's Hospital|Huazhong University of Science and Technology|Sun Yat-sen University|Academy Military Medical Science, China","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-MSC-aGVHD-2014","September 2014","September 2018","December 2018","September 16, 2014",,"September 16, 2014","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02241018"
849,"NCT02054208","Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL","Number of subjects with adverse events|Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change in CIBIC-plus|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers","Medipost Co Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-CR-010","March 2014","December 2019","December 2019","February 4, 2014",,"August 28, 2020","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02054208"
850,"NCT00099762","Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia",,"Completed","No Results Available","Osteomalacia|Neoplasms",,,"National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","All","8 Years to 100 Years   (Child, Adult, Older Adult)",,"45","NIH","Observational",,"050050|05-D-0050","December 15, 2004","September 2, 2009",,"December 20, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00099762"
851,"NCT04612465","Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula",,"Recruiting","No Results Available","Crohn's Fistula","Biological: ASC|Drug: Fibringlue","Proportion of subjects who are completely blocked fistula|Proportion of subjects who are more than 50% blocked fistula|Score of evaluation about Investigator satisfaction using questionnaire|Proportion of subjects who are confirmed maintenance of fistula blockage by radiology test|Visual improvement effect of perianal fistula wound through photography of it","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ANTG-ASC-301","January 9, 2020","December 31, 2021","December 31, 2021","November 3, 2020",,"January 22, 2021","Seoul Natinoal Univetsity Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04612465"
852,"NCT02448849","Autologous BM-MSC Transplantation in Combination With Platelet Lysate (PL) for Nonunion Treatment",,"Unknown status","No Results Available","Bone Fracture","Biological: Percutaneous injection|Other: Percutaneous injection","clinical union|Radiological healing|Pain|Quality of life|Walking distance","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royan-Bone-013","June 2015","April 2017","August 2017","May 20, 2015",,"October 30, 2015","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02448849"
853,"NCT02062931","Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure",,"Unknown status","No Results Available","Premature Ovarian Failure","Biological: Stem Cell Preparation and Injection","Improvement of Cases","Sayed Bakry|Cairo University|Affiliated Hospital to Academy of Military Medical Sciences|Al-Azhar University","Female","20 Years to 40 Years   (Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AzharU223101547","March 2012","May 2015","November 2016","February 14, 2014",,"May 13, 2014","Al-Azhar University hospitals and Al Azhar Regenerative Medicine International Center (ARMIC), Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02062931"
854,"NCT03123458","Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders",,"Unknown status","No Results Available","Immune Related Disorder|Tissue Damage","Biological: clonal fetal MSCs","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Number of participants with reduced symptoms or stabilized conditions after treatment","Shenzhen Geno-Immune Medical Institute","All","1 Year to 80 Years   (Child, Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-17001","January 1, 2016","December 31, 2019","December 31, 2020","April 21, 2017",,"February 26, 2018","Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China|Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Aerospace Center Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03123458"
855,"NCT04835883","Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients",,"Recruiting","No Results Available","Systemic Lupus Erythematosus","Biological: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)","Reduction of corticosteroid dose to ≤ 7.5 mg/day of prednisone or equivalent|Hematologic improvement without ongoing SLE treatment|Renal response improvement|Proportion of subjects who achieve a prednisone dose of ≤ 7.5mg/day or equivalent|Proportion of subjects achieving Low Level Disease Activity State|Proportion of subjects with ≥ 4 point reduction from baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 4 having SLE responder index 4 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 5 having SLE responder index 5 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 6 having SLE responder index 6 (SRI6)|Time to first severe modified SLE Flare Index (SFI) flare|Change from baseline of hematologic parameters|Time to first hematologic flare|Change in baseline of renal function parameters|Time to event for each of the individual components of treatment failure|Time to complete remission|Time to first renal flare","Hanyang University Seoul Hospital|Corestem, Inc.|Ministry of Health & Welfare, Korea","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS20AT04-SLE101","September 26, 2019","November 5, 2021","January 20, 2026","April 8, 2021",,"April 8, 2021","Hanyang University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04835883"
856,"NCT01290367","Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain",,"Completed","No Results Available","Degenerative Disc Disease","Biological: Single Dose MPCs Injection|Procedure: Single injection of saline solution|Procedure: Single injection of hyaluronic acid","To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).|To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs.|To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS).","Mesoblast, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MSB-DR001","August 2011","July 2013","July 2015","February 7, 2011",,"June 26, 2020","Arizona Pain Specialists, Scottsdale, Arizona, United States|UC Davis Spine Center, Sacramento, California, United States|The Spine Institute, Santa Monica, California, United States|IPM Medical Group, Inc., Walnut Creek, California, United States|Denver Spine, Denver, Colorado, United States|Rocky Mountain Associates in Orthopedic Medicine, P.C., Loveland, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina, United States|Central Texas Spine Institute, Austin, Texas, United States|Richmond Bone and Joint Clinic, Memorial Hermann Medical Group, Richmond, Texas, United States|Virginia Spine Research Institute, Inc., Richmond, Virginia, United States|Washington Center for Pain Management, Edmonds, Washington, United States|The Center for Pain Relief, Inc., Charleston, West Virginia, United States|Monash Medical Center, Clayton, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01290367"
857,"NCT02445547","Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease",,"Completed","No Results Available","Crohn Disease","Other: UC-MSCs by peripheral intravenous infusion|Drug: received hormone maintenance therapy","Crohn's disease activity index|Harvey-Bradshaw index|Corticosteroid dosage","Fuzhou General Hospital|Shaanxi Provincial People's Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-CD","June 2012","June 2015",,"May 15, 2015",,"January 18, 2017","Shaanxi Provincial People's Hospital, Xi Ail, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT02445547"
858,"NCT03774537","Human Mesenchymal Stem Cells For Infants At High Risk For Bronchopulmonary Dysplasia",,"Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: Transplantation of hUC-MSCs|Drug: No transplantation of hUC-MSCs","Number of participants with adverse reactions related to infusion after treatment|The incidence and severity of BPD defined by the National Institutes of Child Health and Human Development (NICHD) workshop.|Changes of high-resolution chest CT in participants|Changes of temperature in participants|Changes of blood pressure in participants|Changes of respiratory rate in participants|Changes of oxygen saturation in participants","Children's Hospital of Chongqing Medical University","All","up to 14 Days   (Child)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XiaYQ","March 1, 2019","December 1, 2020","December 31, 2021","December 13, 2018",,"March 6, 2019","Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03774537"
859,"NCT03014037","Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration",,"Active, not recruiting","No Results Available","Osteoarthritis","Procedure: Unilateral Bone Marrow Procurement|Procedure: Bilateral Bone Marrow Procurement","Change Quality of Life assessed by the Emory Quality of Life (EQOL) Survey Score|Change in the Knee Injury and Osteoarthritis Outcome Score (KOOS)|Capacity of Isolated Cells to Differentiate Down Cell Lineages","Emory University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00093044","September 7, 2017","May 2021","May 2021","January 9, 2017",,"May 12, 2020","The Emory Clinic, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03014037"
860,"NCT03509025","Follow-up Study for Participants Jointstem Clinical Trial",,"Completed","No Results Available","Knee Osteoarthritis","Drug: Jointstem","Adverse Events|WOMAC score|WOMAC 3 subscale score|X-ray","R-Bio","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JM2b-FU","February 8, 2017","December 9, 2020","December 9, 2020","April 26, 2018",,"January 29, 2021","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|GangNam Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03509025"
861,"NCT03516006","Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis",,"Active, not recruiting","No Results Available","Primary Sclerosing Cholangitis","Drug: UCMSC|Drug: UDCA","adverse effects regarding UCMSC infusion|Pathological score of liver inflammation|Changes of biliary lesions in magnetic resonance image|alanine aminotransferase","Fuzhou General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-PSC","January 2017","January 2019","January 2024","May 4, 2018",,"May 4, 2018",,,"https://ClinicalTrials.gov/show/NCT03516006"
862,"NCT03370874","Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.",,"Active, not recruiting","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Procedure: Vehicle sheet","Proportions of subjects who achieved complete wound closure|Time taken to complete wound closure between the two groups|Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups|Change rates in wound size and depth compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations","Anterogen Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALLO-ASC-DFU-301","July 4, 2018","June 30, 2021","June 30, 2021","December 13, 2017",,"January 22, 2021","Korea University Kuro Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03370874"
863,"NCT05106972","Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis",,"Recruiting","No Results Available","Liver Cirrhosis","Drug: UC-MSC infusion","Number of Participants with abnormal Total bilirubin|Number of Participants with abnormal albumin|Ishak Inflammation Rating System|Ishak Fibrosis Score|Overall survival (OS)|HBV-DNA|incidence of liver cancer|Number of Participants with abnormal immunoglobulin|portal vein flow rate|portal vein width|abdominal volume|Number of Participants with abnormal coagulation function","Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.","All","20 Years to 60 Years   (Adult)","Not Applicable","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCT20181032","December 1, 2021","December 31, 2024","December 31, 2025","November 4, 2021",,"November 4, 2021","Haikou People's Hospital, Haikou, China",,"https://ClinicalTrials.gov/show/NCT05106972"
864,"NCT04305548","Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma","ISG-MCS","Active, not recruiting","No Results Available","Mesenchymal Chondrosarcoma","Drug: Trabectedin","Overall tumour Response Rate, according to RECIST v 1.|Choi criteria response rate|Overall Survival|Progression Free Survival (PFS)|Clinical Benefit Rate|Duration of response|Adverse events related to the treatment","Italian Sarcoma Group|PharmaMar","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISG-MCS","September 14, 2021","September 1, 2024","December 31, 2024","March 12, 2020",,"November 5, 2021","Nuovo Ospedale di Prato, Prato, Firenze, Italy|Policlinico Universitario Campus Biomedico, Roma, RM, Italy|Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy|Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, Italy|Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy|Ospedale Giaccone, Palermo, Italy",,"https://ClinicalTrials.gov/show/NCT04305548"
865,"NCT04313322","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells",,"Recruiting","No Results Available","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Clinical outcome|CT Scan|RT-PCR results","Stem Cells Arabia","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19","March 16, 2020","June 30, 2020","September 30, 2020","March 18, 2020",,"March 18, 2020","Stem Cells Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04313322"
866,"NCT04339660","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19","Biological: UC-MSCs|Other: Placebo","The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time","Puren Hospital Affiliated to Wuhan University of Science and Technology|Shanghai University|Qingdao Co-orient Watson Biotechnology group co. LTD|Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pr20200402","February 1, 2020","June 30, 2020","June 30, 2020","April 9, 2020",,"April 9, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04339660"
867,"NCT05078385","Safety of Mesenchymal Stem Cell Extracellular Vesicles (BM-MSC-EVs) for the Treatment of Burn Wounds",,"Not yet recruiting","No Results Available","Burns","Drug: AGLE-102","Primary Objective|Secondary Objective","Aegle Therapeutics|Congressionally Directed Medical Research Programs","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGLE-102-102","July 2022","April 2024","July 2024","October 14, 2021",,"October 14, 2021",,,"https://ClinicalTrials.gov/show/NCT05078385"
868,"NCT05125562","Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial",,"Recruiting","No Results Available","COVID-19","Drug: ExoFlo","Change in SARS-CoV-2 log viral load from baseline to Day=7|Change in viral load area under the curve (AUC) from baseline to Day=29|Proportion of patients showing symptom improvement or resolution Day=7, 11, 15|- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-EF-EMOTECOVID-0006","May 7, 2021","August 7, 2022","August 7, 2022","November 18, 2021",,"November 18, 2021","Helen Keller Hospital, Sheffield, Alabama, United States|St. Joseph Hospital Heritage, Fullerton, California, United States|Donald Guthrie Foundation/ Robert Packer Hospital, Sayre, Pennsylvania, United States|Direct Biologics, Austin, Texas, United States|Covenant Health, Lubbock, Texas, United States|PRX Research, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05125562"
869,"NCT03754465","Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Procedure: Hydrogel SHEET(Vehicle control)","Proportions of subjects who achieved complete wound closure|Time to initial complete wound closure between the two groups|Changes in wound size compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups|Durability of complete wound closure","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALLO-ASC-SHEET-102","January 2, 2019","December 30, 2021","December 30, 2021","November 27, 2018",,"January 22, 2021","University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03754465"
870,"NCT04356300","Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection",,"Not yet recruiting","No Results Available","Multiple Organ Failure","Biological: Exosome of MSC","survival after intervention|sequential organ failure assessment score|interleukin-6|The number of allergic reactions|The number of people who get cancer|the effects on kidney function|the effects on liver function|the effects on lung function|the effects on coagulation function|the effects on central nervous system","Fujian Medical University","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020005","September 1, 2020","September 1, 2021","September 1, 2030","April 22, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04356300"
871,"NCT02958267","Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee",,"Completed","Has Results","Knee Osteoarthritis","Biological: BMAC injection|Biological: PRP injection|Device: Gel-One® hyaluronate injection","Knee Injury and Osteoarthritis Outcome Score|Numeric Pain Rating Scale|Patient Reported Outcome Measurement Information System Global Health Scores","OhioHealth","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OH1-16-00672","December 2016","August 2018","August 2018","November 8, 2016","September 24, 2019","September 24, 2019","McConnell Spine, Sport, and Joint Physicians, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02958267/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02958267"
872,"NCT04428801","Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: autologous adipose-derived stem cells","Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-003","September 2021","September 2022","September 2024","June 11, 2020",,"July 23, 2021",,,"https://ClinicalTrials.gov/show/NCT04428801"
873,"NCT04273646","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia|COVID-19","Biological: UC-MSCs|Drug: Placebo","Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio","Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202001","April 20, 2020","June 30, 2020","February 15, 2022","February 18, 2020",,"April 14, 2020","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04273646"
874,"NCT03183726","A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial",,"Completed","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Wound size and depth measurement","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)",,"4","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALLO-ASC-DFU-102","January 11, 2016","June 30, 2017","July 31, 2017","June 12, 2017",,"January 10, 2018",,,"https://ClinicalTrials.gov/show/NCT03183726"
875,"NCT00851162","Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions",,"Withdrawn","No Results Available","Bone Neoplasms","Biological: Trinity multipotent stem cells|Biological: Demineralized bone matrix(DBM)","Time to fill bony defect|Adverse reaction from bone graft","Emory University","All","11 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00009762","March 2009","March 2010","March 2010","February 25, 2009",,"November 28, 2012","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00851162"
876,"NCT03827096","Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease","AMSC-DSD-001","Terminated","No Results Available","Degenerative Disc Disease","Drug: Suspension of human autologous MSC 3P in 1.5 ml","Safety: To demonstrate absence of complications at the site of spinal fusion|Efficacy: To assess the quality of life determined by Oswestry Questionnaire.|Efficacy: To assess the quality of spinal fusion by X-ray imaging|Efficacy: To assess the quality of spinal fusion measured by computed tomography (CT).","Bioinova, s.r.o.|Department of Spine Surgery, University Hospital Motol, Prague, Czech Republilc","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-DSD-001","August 27, 2013","December 14, 2016","December 14, 2016","February 1, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT03827096"
877,"NCT03183661","A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial",,"Unknown status","No Results Available","Crohn Disease","Biological: ALLO-ASC-CD","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Anterogen Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)",,"9","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALLO-ASC-CD-102","November 16, 2016","March 31, 2021","April 30, 2021","June 12, 2017",,"June 12, 2017",,,"https://ClinicalTrials.gov/show/NCT03183661"
878,"NCT04341610","ASC Therapy for Patients With Severe Respiratory COVID-19","ASC COVID-19","Withdrawn","No Results Available","Respiratory Tract Diseases","Drug: Stem Cell Product","Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization","Rigshospitalet, Denmark","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EudraCT number: 2020-001330-36","April 20, 2020","January 30, 2021","April 30, 2021","April 10, 2020",,"May 27, 2020","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04341610"
879,"NCT00187018","Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study",,"Completed","No Results Available","Osteogenesis Imperfecta","Biological: Bone marrow transplant","To find out the effects (good and bad) of bone marrow cell infusions using donor bone marrow that has had CD3+ cells removed|To find out if there is any effect on the growth rate of children with osteogenesis imperfecta who receive donor bone marrow which has had CD3+ cells removed|To find out if there is any effect on the total bone mineral content of children with OI|who receive donor bone marrow which has had CD3+ cells removed|To find out the effect of the CD3 washed-out marrow cell therapy on the growth rate of the children","St. Jude Children's Research Hospital","All","Child, Adult, Older Adult","Not Applicable","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STOD2","March 2004","August 2007","August 2007","September 16, 2005",,"March 4, 2015","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00187018"
880,"NCT05018637","Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture",,"Enrolling by invitation","No Results Available","Vertebral Compression Fracture|Osteoporotic Fractures","Drug: WJ-MSC|Drug: Teriparatide","improvement in Visual Analogue Scale|improvement in Oswestry Disability Index|Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry|Presence of new vertebral fracture|Change in the bone mineral density (computed tomography) of fractured vertebrae","Inbo Han|CHA University","Female","40 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-11-010","September 1, 2020","December 31, 2022","December 31, 2022","August 24, 2021",,"August 24, 2021","CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05018637"
881,"NCT03460223","Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis",,"Unknown status","No Results Available","Renal Cirrhosis","Biological: MSC","BUN|Cr|eGFR|Cystatin C|Urine protein|Hb|Hct|Ca|P|ALT|PTH|VitD|ALB|TC|TG","Nanjing Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NJLT006","April 1, 2018","March 1, 2020","September 1, 2020","March 9, 2018",,"March 9, 2018",,,"https://ClinicalTrials.gov/show/NCT03460223"
882,"NCT03736564","Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia",,"Recruiting","No Results Available","Osteomalacia","Combination Product: 68Ga-DOTATATE PET/CT","68Ga-DOTATATE PET Positive Maximum Intensity Projection","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-008120","January 31, 2019","June 1, 2024","December 1, 2025","November 9, 2018",,"June 22, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03736564"
883,"NCT03033277","Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI)",,"Unknown status","No Results Available","Primary Ovarian Insufficiency","Biological: Placebo transplantation|Biological: HUC-MSCs transplantation","Number of mature follicle|Follicle-stimulating hormone (FSH) serum level|Estradiol (E2) serum level|Anti-Mullerian hormone (AMH) serum level|Number of antral follicle development|Ovarian volume|Pregnancy rate","Chinese Academy of Sciences|The Third Affiliated Hospital of Guangzhou Medical University","Female","20 Years to 40 Years   (Adult)","Phase 1|Phase 2","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Multi-cited POI Recovery","February 2016","April 2017","July 2018","January 26, 2017",,"January 26, 2017","Institute of Zoology, Chinese Academy of Sciences., Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03033277"
884,"NCT04629105","Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)","RECOVER","Recruiting","No Results Available","ARDS, Human|Covid19","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo","Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography","Longeveron Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-006","July 24, 2020","August 2023","July 2025","November 16, 2020",,"September 30, 2021","Miami VA Healthcare System, Miami, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04629105"
885,"NCT04610359","Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis",,"Recruiting","No Results Available","Interstitial Cystitis|Stem Cell Transplant|Mesenchymal Stem Cell","Drug: MR-MC-01","Incidence of Treatment-Emergent Adverse Events (TEAEs)|Incidence of Treatment-Emergent Adverse Events|Changes of pain after stem cell injection|Changes of PUF (Pelvic Pain and Urgency/Frequency) scores after stem cell injection|Changes of ICQ (O'Leary-Sant interstitial cystitis symptom index/problem index) scores after stem cell injection|Changes of voiding profiles after stem cell injection|Changes of Hunner lesion after stem cell injection","Asan Medical Center|MIRAE CELL BIO","Female","20 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-1451","October 20, 2020","October 2022","December 2022","October 30, 2020",,"October 30, 2020","Department of Urology, Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04610359"
886,"NCT01087996","The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)",,"Completed","Has Results","Stem Cell Transplantation","Biological: Auto-hMSCs|Biological: Allo-hMSCs","Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months","University of Miami|National Heart, Lung, and Blood Institute (NHLBI)|The Emmes Company, LLC","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090352|R01HL110737|R01HL107110|R01HL084275|P20HL101443|R01HL094849","March 2010","April 2011","October 2012","March 16, 2010","May 27, 2015","May 27, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01087996"
887,"NCT01448434","Allogeneic Mesenchymal Stem Cells for Osteoarthritis",,"Completed","No Results Available","Osteoarthritis of Knee Joint","Biological: Ex- vivo cultured adult allogeneic MSCs|Biological: Plasmalyte-A","Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline","Stempeutics Research Pvt Ltd|Stempeutics Research Malaysia SDN BHD","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 2","72","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SRM/OA/10-11/001","September 2011","September 2013","September 2013","October 7, 2011",,"May 12, 2016","Pantai Cheras Medical Centre, Kuala Lumpur, Federal territory, Malaysia|Serdang Hospital, Kuala Lumpur, Selangor, Malaysia|KPJ Ampang Puteri Specialist Hospital, Kuala Lumpur, Selangor, Malaysia|Selayang Hospital, Kuala Lumpur, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT01448434"
888,"NCT04972890","The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction",,"Recruiting","No Results Available","Urologic Diseases|Erectile Dysfunction With Diabetes Mellitus","Biological: stem cells|Other: placebo","Changes in IIEF-5 Score after stem cells injection|Changes in Peak Systolic Velocity (PSV) after stem cells injection|Changes in End Diastolic Velocity after stem cells injection|Changes in Resistive Index after stem cells injection|Changes in Pulsatility Index after stem cells injection|Changes in E-selectin expression after stem cells injection|Changes in Vascular Endothelial Growth Factor (VEGF) expression after stem cells injection|Changes in Bcl-2 expression after stem cells injection|Changes in microRNA 16 expression after stem cells injection|Changes in microRNA 126 expression after stem cells injection|Changes in Hba1c after stem cells injection|Changes in Fasting Blood Glucose after stem cells injection|Changes in total cholesterol after stem cells injection|Changes in low-density lipoprotein (LDL) after stem cells injection|Changes in high-density lipoprotein (HDL) after stem cells injection|Changes in Triglycerides (TG) level after stem cells injection|Number of participants with side effects after intracavernosal injection","Indonesia University","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","19-04-0516","October 27, 2020","December 31, 2021","July 31, 2022","July 22, 2021",,"July 22, 2021","Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04972890"
889,"NCT00976430","Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease",,"Terminated","No Results Available","Parkinson's Disease","Procedure: Autologous Bone marrow derived stem cells transplant","Improvement in clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests.","Jaslok Hospital and Research Centre","All","35 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JHC525","July 2009","November 30, 2011","April 30, 2012","September 14, 2009",,"August 14, 2018","Jaslok Hospital And Research Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00976430"
890,"NCT04137406","Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis",,"Unknown status","No Results Available","Breast Cancer|Lymph Node Metastases",,"Protein expression difference|survival","Peking University People's Hospital","Female","Child, Adult, Older Adult",,"160","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Luminal A sirt1","January 1, 2019","December 30, 2020","December 30, 2020","October 24, 2019",,"October 24, 2019","Peking university people's hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04137406"
891,"NCT03389919","Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT",,"Recruiting","No Results Available","Mesenchymal Stem Cell Transplantation","Biological: MSC administration (intraosseal)","Engraftment","National Research Center for Hematology, Russia","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BM-MSC-01","January 1, 2017","December 31, 2020","December 31, 2022","January 4, 2018",,"January 4, 2018","BMT department, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03389919"
892,"NCT03798028","The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis",,"Unknown status","No Results Available","Rheumatoid Arthritis","Biological: UC-MSCs","Improvement rate of blood routine hemoglobin (HGB) compared to baseline.|Improvement rate of forced vital capacity (FVC) and/or carbon monoxide diffusing capacity (DLCO) compared to baseline.|The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70.|White blood cell count and platelet count improved compared to the baseline.|Improvement rate of forced vital capacity (FVC) and/or carbon monoxide|Image improvement of lung on high resolution CT.|Improvement of 6-minute walking distance compared to baseline.","Xijing Hospital|Changhai Hospital|Southwest Hospital, China","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2014ZX09508002","December 26, 2017","December 31, 2019","June 30, 2020","January 9, 2019",,"January 9, 2019","Xijing Hospital, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03798028"
893,"NCT04850469","Study of MSC-Exo on the Therapy for Intensively Ill Children",,"Not yet recruiting","No Results Available","Sepsis|Critical Illness",,"The death rate of children|Marshall Multiple Organ Dysfunction Score|the age, PaO2/FlO2, and plateau pressure score (APPS)|length of stay in PICU","Children's Hospital of Fudan University","All","up to 18 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","fdpicu-13","January 1, 2022","December 31, 2023","December 31, 2024","April 20, 2021",,"April 20, 2021","Children's Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04850469"
894,"NCT03648463","Use of MRI Labeling Technique to Track Mesenchymal Stem Cell Survival in Orthopaedic Conditions",,"Unknown status","No Results Available","Cartilage Degeneration|Rotator Cuff Tear|Osteoarthritis, Knee","Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection","Integration of the mesenchymal stem cells.|Knee Injury and Osteoarthritis Outcome Score (pain subscale)","Stanford University","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","IRB-46711","October 1, 2019","December 31, 2020","December 31, 2020","August 27, 2018",,"March 28, 2019",,,"https://ClinicalTrials.gov/show/NCT03648463"
895,"NCT03007576","Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)",,"Completed","No Results Available","Osteoarthritis,Knee","Biological: RegStem","Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Clinical assessment of International Knee Documentation Committee (IKDC) score|Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of knee X-ray|Clinical assessment of knee MRI","EMO Biomedicine Corporation|Far Eastern Memorial Hospital","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMOCT01","August 1, 2017","August 31, 2019","August 31, 2019","January 2, 2017",,"November 13, 2019","Far Eastern Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03007576"
896,"NCT04537351","The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause","MEND","Recruiting","No Results Available","Covid19|Acute Respiratory Distress Syndrome","Biological: CYP-001","Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups|Incidence and severity of treatment-emergent adverse events|Change in C-reactive protein (CRP) levels|Proportional differences between groups on the Clinical Improvement Scale|Changes in P/F ratio|Changes in respiratory rate|Changes in oxygenation index|Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)|Changes in positive end-expiratory pressure|Ventilator-free days|Proportional differences between groups on the SF-36|Proportional differences between groups on the mini mental state examination","Cynata Therapeutics Limited|Cerebral Palsy Alliance","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYP-COVID-19-01","August 24, 2020","December 31, 2021","December 31, 2021","September 3, 2020",,"May 20, 2021","Nepean Hospital, Kingswood, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Footscray Hospital, Footscray, Victoria, Australia|Sunshine Hospital, Saint Albans, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04537351"
897,"NCT04434768","Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke",,"Recruiting","No Results Available","Acute Stroke","Biological: UMSC01","SAE incidences over the study period|SUSAR incidences over the study period|TEAE incidences over the study period|Changes of Glasgow Coma Scale (GCS; Score range: Max.15, Min. 3) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in National Institute of Health Stroke Scale (NIHSS; Score Range: 0~42; the higher score the worsen outcome) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in mRS from Baseline Visit (Visit 1) to subsequent scheduled visits.|Changes in FMT from Baseline Visit (Visit 1) to subsequent schedules visits|Changes in BI from Baseline Visit (Visit 1) to subsequent schedules visits|Change and ratios of MRI image from baseline to subsequent scheduled visits|Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits","Ever Supreme Bio Technology Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ES-CMSC01-B1101","May 5, 2020","July 30, 2022","September 30, 2022","June 17, 2020",,"August 18, 2021","China Medical University Hospital, Taichung, Non-US, Taiwan",,"https://ClinicalTrials.gov/show/NCT04434768"
898,"NCT02474342","Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease",,"Completed","No Results Available","Rotator Cuff Disease","Biological: Autologous Adipose Tissue Derived MSCs Transplantation","SPADI(Shoulder pain and disability index)Score|Constant-Murley score|Visual Analog Scale_pain in motion|Changes in the size of rotator cuff tears determined by MRI|Changes in the size of rotator cuff tears determined by arthroscopy|Adverse event","Seoul National University Hospital","All","19 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRM-15-01","July 7, 2015","November 2016","November 7, 2016","June 17, 2015",,"March 7, 2017","Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02474342"
899,"NCT01562002","Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome",,"Completed","No Results Available","Limbus Corneae Insufficiency Syndrome","Procedure: Stem Cell with Amniotic Membrane Transplant","Viability and safety of mesenchymal stem cell transplant|Absence of complications in pre and peri surgical implantation|Improvement of 2 lines in Best Corrected Visual Acuity","Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Red de Terapia Celular","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","27","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IOBA-05-2010","March 2012","December 2014","December 2014","March 23, 2012",,"January 8, 2015","IOBA, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01562002"
900,"NCT03186417","Mesenchymal Stem Cells in Early Rheumatoid Arthritis",,"Recruiting","No Results Available","Rheumatoid Arthritis","Biological: 2 million hMSC/kg|Biological: 4 million hMSC/kg|Biological: 6 million hMSC/kg|Biological: placebo","Safety assessed by dose limiting toxicity (DLT)|Safety assessed by dose limiting toxicity|Safety assessed by change in spirometry|Safety assessed by all adverse events|Change in patient reported outcomes|DAS28-CRP","MetroHealth Medical Center|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB16-00587|R21AR069226","December 15, 2017","March 31, 2022","May 31, 2022","June 14, 2017",,"February 2, 2021","UH Hospitals Cleveland, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03186417"
901,"NCT04280003","Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke","AMASCIS-02","Recruiting","No Results Available","Ischemic Stroke|Adipose Tissue-derived Stem Cell|Functional Status","Other: Alogenic adipose tissue-derived stem cells|Drug: Placebo solution","Safety of administration of adipose tissue-derived mesenchymal stem cells measured as reported adverse events|Safety of administration of adipose tissue-derived mesenchymal stem cells measured as neurological o systemic complications|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the Modified Rankin Scale|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the NIHSS|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measuring blood brain repair biomarkers","Instituto de Investigación Hospital Universitario La Paz","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMASCIS - 02","January 20, 2021","July 15, 2023","July 15, 2023","February 21, 2020",,"July 22, 2021","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04280003"
902,"NCT04336254","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo)","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020K-G005|hDPSC-CoVID-2019-02-2020","May 6, 2020","November 30, 2021","December 31, 2021","April 7, 2020",,"March 10, 2021","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04336254"
903,"NCT04232592","Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions",,"Not yet recruiting","No Results Available","Intrauterine Adhesion","Biological: Inject a solution of stem cell preparation|Biological: Inject stem cells","Incidence of different Adverse Events of transplantation of mesenchymal cells from human embryonic stem cells|Normal recovery rate of endometrial thickness|recurrence rate of intrauterine adhesions|Intrauterine adhesions score|The endometrial biopsies for CD31|Menstrual volume change|Clinical pregnancy rate|The endometrial biopsies for estrogen|The endometrial biopsies for Ki67","Qi Zhou|Tongji Hospital|Chinese Academy of Sciences","Female","18 Years to 38 Years   (Adult)","Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chinese ASZQ-005","January 2020","January 2022","January 2022","January 18, 2020",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04232592"
904,"NCT00877903","Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)",,"Completed","No Results Available","Myocardial Infarction","Drug: Prochymal®|Drug: Placebo","Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3|Left Ventricular End Systolic Volume|Infarct Size|Left Ventricular Ejection Fraction|Left Ventricular End Diastolic Volume|Number of Participants with Ventricular Arrhythmias|Duke Activity Status Index (DASI) Assessment|New York Heart Association (NYHA) Congestive Heart Failure Classification Status|Maximal Symptom-limited Exercise Test (Treadmill)|Number of Participants with Major Adverse Cardiac Events (MACE)|Overall Survival|Number of Participants with Adverse Events","Mesoblast, Inc.|Mesoblast, Ltd.","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","403","March 30, 2009","May 18, 2011","March 14, 2016","April 8, 2009",,"April 2, 2020","Mercy Gilbert Medical Center / Catholic Health Care West, Gilbert, Arizona, United States|University of Arizona, Tucson, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|University of California - San Diego (UCSD), San Diego, California, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The Care Group, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Maryland Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University at Buffalo - Buffalo General Hospital, Buffalo, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Lindner Research Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State University - Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|The Stern Cardiovascular Center, Germantown, Tennessee, United States|Austin Heart P.A., Austin, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Wisconsin School of Medicine, Madison, Wisconsin, United States|McGill University Health Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00877903"
905,"NCT04029896","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy",,"No longer available","No Results Available","Cerebral Palsy","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","Male","3 Years and older   (Child, Adult, Older Adult)",,,"Other|Industry","Expanded Access:Individual Patients",,"HBCP01",,,,"July 23, 2019",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04029896"
906,"NCT02325843","the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn",,"Completed","No Results Available","Chemical Burns","Other: human bone marrow MSC","Incidence of adverse events by subconjunctival injection of BMMSCs|Incidence of corneal perforation rate after subconjunctival injection of BMMSCs|Time of corneal epithelialization|Visual acuity","Sun Yat-sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014MEKY059","July 2015","December 2017","December 2017","December 25, 2014",,"April 11, 2019",,,"https://ClinicalTrials.gov/show/NCT02325843"
907,"NCT02123368","Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells",,"Completed","No Results Available","Osteoarthritis","Drug: Hyaluronic acid|Biological: 10 million Bone marrow mesenchimal stem cells|Biological: 100 million Bone marrow mesenchimal stem cells","Baseline Visual analogue scale (VAS)|Baseline value of knee injury and osteoarthritis outcome score (Koos).|Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).|Baseline SF-36 value|Baseline euroquol 5D value|Baseline Lequesne index|Baseline femorotibial distance|Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events|Visual analogue scale (VAS) at on month|Visual analogue scale (VAS) at 3 months|Visual analogue scale (VAS) at 6 months|Visual analogue scale (VAS) at 12 months|Value of knee injury and osteoarthritis outcome score (Koos) at 1 month|Value of knee injury and osteoarthritis outcome score (Koos) at 3 month|Value of knee injury and osteoarthritis outcome score (Koos) at 6 month|Value of knee injury and osteoarthritis outcome score (Koos) at 12 months|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months|SF-36 value at 1 month|SF 36 value at 3 months|SF 36 value at 6 months|SF 36 value at 12 months|Euroquol 5D value at 1 month|Euroquol 5D value at 3 months|Euroquol 5D value at 6 months|Euroquol 5D value at 12 months|Lequesne index at 1 month|Lequesne index at 3 months|Lequesne index at 6 months|Lequesne index at 12 months|Femorotibial distance at 6 months|Femorotibial distance at 12 months|Baseline MRI WORMS protocol|MRI WORMS protocol score at 6 months|MRI WORMS protocol score at 12 months","Clinica Universidad de Navarra, Universidad de Navarra","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMM/ART|2009-017624-72","May 2012","November 2014","February 2015","April 25, 2014",,"October 24, 2017","Traumatology department. Complejo Hospitalario de Salamanca, Salamanca, Castilla y León, Spain|Orthopaedic and traumatology department. Clínica Universidad de Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT02123368"
908,"NCT03406585","Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes",,"Unknown status","No Results Available","Type1 Diabetes Mellitus","Drug: ProTrans: Allogeneic transplantation with WJMSCs|Drug: Placebos","Safety; measured through set safety parameters|Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment|Number of patients insulin independent (ADA criteria) at days 187 and 372|Number of patients with daily insulin needs <0.25U/kg at days 187 and 372|Insulin requirement/kg BW at days 187 and 372|HbA1c at days 187 and 372.|Glucose variability at day 372|Delta change of levels of fasting C-peptide at day 372|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372","NextCell Pharma Ab","All","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ProTrans-T1D|2017-002766-50","November 28, 2017","June 1, 2020","June 1, 2020","January 23, 2018",,"June 5, 2019","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03406585"
909,"NCT02256241","The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin","RING UB LIGASE","Unknown status","No Results Available","Group 1: Trauma Operation for Otherwise Healthy Patients|Group 2: Primary Tumors of Mesenchymal Origin",,"Protein and mRNA levels of RING ubiquitin ligases during osteogenesis|Protein and mRNA levels of RING ubiquitin ligases in musculoskeletal tumors and its correlation to staging and grading","Rambam Health Care Campus|Technion, Israel Institute of Technology","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort","0180-14-RMB","October 2014","July 2019","July 2019","October 3, 2014",,"February 24, 2015","Rambam MC, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT02256241"
910,"NCT02579460","Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition",,"Enrolling by invitation","No Results Available","Barrett's Esophagus|Gastroesophageal Reflux Disease","Other: Cessation of Acid Suppressing Medications","Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days|change in p38 pathway from baseline to 14 days|change in phosoho-p38 from baseline to 14 days|Show oxidative DNA damage associated with p38 activation|change in VEGF from baseline to 14 days|change in APE-1 from baseline to 14 days|change in NPM1 from baseline to 14 days|change in phospho-NPM1 from baseline to 14 days","Dallas VA Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","53","U.S. Fed|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15-022|1R01DK103598-01A1","November 2015","October 2022","October 2022","October 19, 2015",,"August 18, 2021","Dallas VA Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02579460"
911,"NCT02566655","Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis","CSM/OP/2011","Completed","No Results Available","Osteoporosis|Spinal Fractures","Biological: Fucosylated MSC for Osteoporosis","Rate of serious and non-serious adverse events related to the procedure.|Number of new fractures|Pain, measured by Visual Analog Scale|Functionality, measured by Oswestry Disability Questionnaire|Quality of Life, measured by EuroQoL-5D test|Bone resorption, measured by biochemical index|Bone formation, measured by biochemical index|Bone metabolism, measured by biochemical index|Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)|Bone structure, measured by histomorphometric evaluation|Trabecular bone density measured by quantitative computed tomography of the radius","Red de Terapia Celular|Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Hospital Universitario Virgen de la Arrixaca|Spanish National Health System|Public Health Service, Murcia|BIONAND, Universidad de Málaga, IBIMA, Ciber-bbn|Grupo de Tecnología Sanitaria CIBER-BBN, Inst. Biomecánica de Valencia","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/OP/2011|2012-005814-20","September 2015","December 2016","May 2018","October 2, 2015",,"October 8, 2020","Hospital Clínico Virgen de la Arrixaca, El Palmar, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT02566655"
912,"NCT02600130","Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Biological: Longeveron Mesenchymal Stem Cells|Biological: Placebo","To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.","Longeveron Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00-0000-01","October 10, 2016","September 2020","September 2021","November 9, 2015",,"September 30, 2021","Brain Matters Research, Delray Beach, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Miami Jewish Health, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02600130"
913,"NCT00361049","Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant",,"Completed","No Results Available","Cancer","Biological: graft versus host disease prophylaxis/therapy|Genetic: fluorescence in situ hybridization|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: in vitro-treated bone marrow transplantation|Procedure: management of therapy complications","Safety|Complete and partial resolution of graft-vs-host disease (GVHD)|Cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute GVHD","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","49","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWRU3Y03|P30CA043703|CASE-CWRU-3Y03","September 2004","June 2009","November 2010","August 7, 2006",,"November 5, 2010","Geauga Regional Hospital, Cleveland, Ohio, United States|Lake/University Ireland Cancer Center, Cleveland, Ohio, United States|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University Suburban Health Center, Cleveland, Ohio, United States|UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States|Southwest General Health Center, Cleveland, Ohio, United States|UHHS Westlake Medical Center, Cleveland, Ohio, United States|Mercy Cancer Center at Mercy Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00361049"
914,"NCT04290182","A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring",,"Recruiting","No Results Available","Hoarseness|Dysphonia|Aphonia|Vocal Fold; Scar","Biological: MSC-KI-PL-204","Safety and tolerability of treatment|Assessment of VF function|Assessment of subjective voice ratings|Assessment of tissue metabolism and healing","Karolinska University Hospital|Swedish Foundation for Strategic Research","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-06160 and 5.1-2019-92069","March 2020","June 2022","June 2023","February 28, 2020",,"February 28, 2020","Karolinska Trial Alliance, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04290182"
915,"NCT04243681","Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis",,"Completed","No Results Available","Cirrhosis, Liver","Combination Product: CD 34 and MSC infusion|Drug: Standard of care for Cirrhosis management","To assess the safety of combination of hematopoetic and mesenchymal stem cell in patients of liver cirrhosis.|Change in MELD (Model for End stage Liver disease) score.|Change in Child Pugh score.|Change in the percentage of CD 34 cells in liver.","Asian Institute of Gastroenterology, India","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 4","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECR/346/Inst/AP/2013","July 1, 2019","August 1, 2020","September 1, 2020","January 28, 2020",,"October 22, 2020","Asian Institute Of Gastroenterology, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT04243681"
916,"NCT02331966","Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia",,"Unknown status","No Results Available","Tumor Induced Oncogenic Osteomalacia",,"Differential expression of Molecular pathways in tumors inducing oncogenic osteomalacia","AHEPA University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","51741","September 2014","December 2016","March 2017","January 6, 2015",,"January 6, 2015","1st Department of Internal Medicine AHEPA University Hospital, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT02331966"
917,"NCT04776538","Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients","MESRIX-III","Recruiting","No Results Available","Xerostomia Following Radiotherapy","Biological: Stem cells|Biological: Placebo","Salivary gland function|Incidence of treatment-emergent adverse events|Patient-Reported Outcome of xerostomia|Salivary composition","Rigshospitalet, Denmark|Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet|The Cell Therapy Facility, The Blood bank, Dept. of Clinical Immunology, 2034, Rigshospitalet, Denmark|Department of Oncology, 3994, Rigshospitalet, Denmark|Department of Oncology Herlev Hospital, Denmark|Department of Dentistry and Oral Health, Aarhus, Denmark","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CVB2018-1","February 9, 2021","October 1, 2023","October 1, 2023","March 1, 2021",,"March 1, 2021","Christian von Buchwald, MD, DMSc, Professor, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04776538"
918,"NCT03460795","Safety and Efficacy Study of Co-transfering of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease",,"Not yet recruiting","No Results Available","Liver Cirrhosis","Biological: MSC and Tregs","Albumin (ALB)|Alanine aminotransferase (ALT)|Prealbumin (PA)|Total bilirubin (TB)|Direct bilirubin (DB)|Blood urea nitrogen (BUN)|Uric acid (UA)|Serum creatinine (Scr)|Child-Pugh|Model for end-stage liver disease (MELD)|Quality of life (QOL)","Nanjing Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NJLT005","June 1, 2020","March 1, 2025","September 1, 2025","March 9, 2018",,"March 4, 2020","Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03460795"
919,"NCT02587572","Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial","SIRONA","Not yet recruiting","No Results Available","Metabolic Disease|Endothelial Dysfunction","Biological: Peripheral Intravenous (IV) infusion of LMSCs","Endothelial function: Changes in endothelial function as assessed by the following:|Difference in rate of change in the metabolic syndrome as defined by the following:","Longeveron Inc.","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00-0000-02","December 2021","December 2022","December 2022","October 27, 2015",,"August 16, 2021",,,"https://ClinicalTrials.gov/show/NCT02587572"
920,"NCT02407470","Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia",,"Unknown status","No Results Available","Severe Aplastic Anemia","Drug: Rabbit antithymoglobulin (ATG)|Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs)|Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs)","Engraftment at 42 days post AD-HSC transplantation for patients with severe aplastic anemia.|To estimate the overall survival (OS) at 1 year following AD-HSC transplantation for Patients with Severe Aplastic Anemia|Relapse|Incidence of chronic graft-versus-host disease|Evaluation of the occurrence of secondary malignancies|Hematology labs|Number of participants with adverse events as a measure of safety and tolerability of intravenous AD-HSC infusion in patients with severe aplastic anemia|Transfusional requirements|To assess treatment related mortality","Navy General Hospital, Beijing|Peking Union Medical College Hospital|General Hospital of Beijing PLA Military Region|Chinese Academy of Medical Sciences","All","14 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ginkgocell-ADHSC-AA-001","January 2015","January 2017","July 2017","April 3, 2015",,"April 3, 2015","Navy General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02407470"
921,"NCT02022904","Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology",,"Withdrawn","No Results Available","Prostate Cancer","Device: Near infrared (NIR) emissive nanotechnology","Change in Non-detection rate of CTC's in men with CRPC|Median number of CTC's detected by each capture method|Change in median number of CTC's for each method|Correlation of CTC enumeration with presenting clinical stage|Correlation of CTC enumeration with sites of metastatic disease|Correlation of CTC enumeration with Gleason sum|Correlation of CTC enumeration with PSA kinetics|Correlation of CTC enumeration with therapies|Correlation of CTC enumeration with overall survival|Correlation of CTC enumeration with progression-free survival|Correlation of CTC enumeration with response to therapy","Duke University|United States Department of Defense","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","Pro00037349","May 2012","June 2015","June 2015","December 30, 2013",,"July 30, 2015",,,"https://ClinicalTrials.gov/show/NCT02022904"
922,"NCT04744116","Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease",,"Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Steroid Refractory Graft Versus Host Disease","Other: Cellular Therapy|Drug: Ruxolitinib","Death from any cause|Response|Incidence of adverse events|Graft versus host disease status|Proportion of response|Time to complete response|Time to very good partial response|Time to partial response|Incidence of complete response for each organ|Incidence of very good partial response for each organ|Incidence of partial response for each organ|Durability of organ response|Cumulative incidence of non-relapse mortality (NRM)|Cumulative incidence of relapse/progression of the primary disease|Overall survival|Disease-free survival|Graft versus host disease-free survival|Incidence of chronic graft versus host disease|Incidence of systemic infections|Incidence of toxicities|Incidence of any grade cytokine release|Incidence of any infusional toxicity","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-1122|NCI-2020-13889|P01CA148600","February 17, 2021","November 30, 2021","November 30, 2021","February 8, 2021",,"November 19, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04744116"
923,"NCT01741857","Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus",,"Unknown status","No Results Available","Systemic Lupus Erythematosus","Biological: human umbilical cord derived MSC transplantation for SLE","British Isles Lupus Assessment Group score (BILAG)|Lupus serology (Alb, ANA, dsDNA, C3, C4)|Renal function (GFR, Blood Urea Nitrogen, urinalysis)","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NJGLYY005","January 2012","December 2013","December 2013","December 5, 2012",,"November 5, 2013","The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01741857"
924,"NCT01233960","Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease",,"Completed","No Results Available","Crohn's Disease","Drug: adult human mesenchymal stem cells","Disease remission|Disease Improvement|Improvement in Quality of Life (IBDQ)|Number of Adverse events as a measure of safety|Infusional toxicity as a measure of safety and tolerability","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","73","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRD 611","November 29, 2010","September 15, 2014","September 15, 2014","November 3, 2010",,"March 10, 2020","University of California, San Francisco, San Francisco, California, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|University of Chicago, Chicago, Illinois, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Saint Louis Center for Clinical Research, Saint Louis, Missouri, United States|St. Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth HItchcock Medical Center, Lebanon, New Hampshire, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Gastroenterology Center of the Midsouth, PC, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|McGuire Research Institute, Richmond, Virginia, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|University of Otago, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand",,"https://ClinicalTrials.gov/show/NCT01233960"
925,"NCT00976287","Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Procedure: Hepatic artery infusion|Procedure: Conserved Therapy","The levels of serum alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT), albumin (ALB)","Sun Yat-sen University|Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","zssy","January 2008","December 2009","June 2010","September 14, 2009",,"September 15, 2009",,,"https://ClinicalTrials.gov/show/NCT00976287"
926,"NCT02331134","Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer",,"Recruiting","No Results Available","Malignant Melanoma|Head and Neck Cancer","Drug: Filgrastim","Tissue and Hematopoietic Stem Cell Collection|Identify pharmacodynamic markers","University of Colorado, Denver|Karsh Family Research Fund","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14-0842.cc","May 13, 2015","February 2022","March 2022","January 6, 2015",,"March 22, 2021","University of Colorado Cancer Center, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02331134"
927,"NCT01325103","Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Procedure: Stem Cell Transplantation","Feasibility and safety of bone marrow stem cell transplantation in patients with spinal cord injury|Functional improvement in muscle strength|Improvement of sphincters control.","Hospital Sao Rafael|Oswaldo Cruz Foundation|Irep Sociedade de Ensino Superior Médio e Fundamental Limitada|Hospital Espanhol","All","18 Years to 50 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-001","July 2010","December 2012","December 2012","March 29, 2011",,"November 28, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT01325103"
928,"NCT04629833","Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy","IDUNN","Recruiting","No Results Available","Steroid-refractory Acute Graft-versus-host Disease","Biological: MC0518|Biological: BAT","Overall Response (OR)|Freedom from Treatment Failure (FFTF)|Overall Survival|Acute Graft-versus-host Disease (aGvHD) Response|Change from Baseline in aGvHD Grades|Time to Response|Duration of Response|Best Overall Response (OR)|Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight|Number of Participants with Chronic Graft-versus-host Disease (cGvHD)|Time to Chronic Graft-versus-host Disease (cGvHD)|Number of Participants with Graft Failure (GF)|Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease|Time to Relapse or Progression in Participants with Underlying Malignant Disease|Event-free survival (EFS)|Non-relapse Mortality (NRM)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity|Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)|Change from Baseline in Performance score based on Lansky Scale|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)|Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score","medac GmbH","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC-MSC.1/aGvHD","August 16, 2021","January 28, 2024","December 31, 2025","November 16, 2020",,"September 9, 2021","Grenoble Cedex, Grenoble, France|Lille, Lille, France|Nice, Nice, France|Pierre Benite Cedex, Pierre Benite Cedex, France|Rennes, Rennes, France|Vandoeuvre les Nancy, Vandoeuvre les Nancy, France|Tuebingen, Baden-Wuerttemberg, Tuebingen, Baden-Wuerttemberg, Germany|Munich, Bavaria, Munich, Bavaria, Germany|Wuerzburg, Würzburg, Bavaria, Germany|Frankfurt am Main, Hessen, Frankfurt am Main, Hessen, Germany|Hannover, Niedersachsen, Hannover, Niedersachsen, Germany|Muenster, Nordrhein-Westfalen, Münster, Nordrhein-Westfalen, Germany|Essen, North Rhine-Westphalia, Essen, North Rhine-Westphalia, Germany|Koeln, North Rhine-Westphalia, Koeln, North Rhine-Westphalia, Germany|Dresden, Dresden, Sachsen, Germany|Leipzig, Saxony, Leipzig, Saxony, Germany|Jena, Thüringen, Jena, Thüringen, Germany|Jena, Thüringen, Jena, Thüringen, Germany|Berlin, Berlin, Berlin, Germany|Bonn, Bonn, Germany|Frankfurt, Frankfurt, Germany|Freiburg, Freiburg, Germany|Mainz, Mainz, Germany|Mannheim, Mannheim, Germany|Tuebingen, Tuebingen, Germany|Wroclaw, Wrocław, Dolnoslaskie, Poland|Barcelona, Barcelona, Spain|Barcelona, Barcelona, Spain|Barcelona, Barcelona, Spain|Barcelona, Barcelona, Spain|Barcelona, Barcelona, Spain|Madrid, Madrid, Spain|Madrid, Madrid, Spain|Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04629833"
929,"NCT01494480","The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis",,"Unknown status","No Results Available","Amyotrophic Lateral Sclerosis","Procedure: stem cell transplantation","Nerve functional evaluation|Forced vital capacity|Blood test|Urinal test|Electrophysiology examination","General Hospital of Chinese Armed Police Forces","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20111207ALS","March 2012","January 2013","April 2015","December 19, 2011",,"June 20, 2012","Yihua An, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01494480"
930,"NCT01454336","Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone",,"Completed","No Results Available","Liver Fibrosis","Biological: Cell injection","ALT|AST|Serum Albumin|Liver Fibrosis|Progression of fibrosis","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-liver-003","June 2010","July 2013","July 2013","October 19, 2011",,"May 13, 2014","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01454336"
931,"NCT01420432","Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis (AS)",,"Unknown status","No Results Available","Ankylosing Spondylitis","Biological: Human umbilical cord-derived MSCs","The Assessment of Spondyloarthritis International Society (ASAS)20 response|erythrocyte sedimentation rate (ESR)|imageology|C-reactive protein (CRP)|Percentage of systemic T regulatory cell population|Side effects","Shandong University","All","18 Years to 60 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Zhangni","January 2011","December 2013","December 2013","August 19, 2011",,"August 19, 2011","Department of Hematology of the 2nd Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01420432"
932,"NCT03592849","The Efficacy and Safety of Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchymal Stem Cells in Infertile Women With Thin Endometrium or Endometrial Scarring",,"Enrolling by invitation","No Results Available","Infertility, Female|Endometrium","Procedure: UC-MSCs therapy","endometrial thickness|ongoing pregnancy rate|live birth rate|endometrial blood flow","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","Female","20 Years to 42 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC201700101","September 10, 2018","January 31, 2021","December 2021","July 19, 2018",,"September 1, 2021","Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03592849"
933,"NCT04758533","Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy","AloCELYVIR","Recruiting","No Results Available","Diffuse Intrinsic Pontine Glioma|Medulloblastoma, Childhood, Recurrent","Biological: AloCELYVIR","Dose-Limiting Toxicities rate (DLTs)|Objective response rate|Feasibility of the combination/monotherapy|Incidence of treatment-Emergent Adverse Event|Progression-free survival (PFS)|Overall Survival (OS)|Antiadenoviral humoral immune response in patients|Antiadenoviral tumoral immune response in patients|Replication kinetics of Icovir-5","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIBHNJ-2020-01","April 19, 2021","October 2024","October 2024","February 17, 2021",,"August 26, 2021","Hospital Infantil Universitario Niño Jesús, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04758533"
934,"NCT05130983","A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease",,"Not yet recruiting","No Results Available","Crohn Disease|IBS - Irritable Bowel Syndrome","Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate","• To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|monoclonal antibodies. • To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.|• To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers.","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-CROHNS-0004","January 1, 2022","January 1, 2024","March 1, 2024","November 23, 2021",,"November 23, 2021",,,"https://ClinicalTrials.gov/show/NCT05130983"
935,"NCT04490486","Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19","COVID-19","Not yet recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Corona Virus Infection","Biological: UCMSCs|Other: Placebo","Percent of participants with treatment related Serious Adverse Events (SAE)|Change in inflammatory marker levels|Change in systemic inflammatory marker levels|COVID-19 Viral Load|Change in SOFA score|Change in electrolytes levels|Change in LDH levels|Number of subjects discharged from the ICU|Percentage of participants with less requirement for vasoactive agents|Rate of Mortality|Percentage of participants with changes in immune marker expression|Percentage of participants with changes in radiologic findings|Percentage of participants with less pneumonia symptoms","Joshua M Hare|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20200575","March 1, 2022","June 1, 2024","June 1, 2024","July 29, 2020",,"August 20, 2021","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04490486"
936,"NCT01323894","Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling",,"Completed","No Results Available","Primary Disease",,"Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons between Non-viral and Viral administration in Tissue Engineered Bone Regeneration","China Medical University Hospital","All","10 Years to 80 Years   (Child, Adult, Older Adult)",,"3","Other","Observational",,"DMR-99-IRB-122","August 2011","August 2012","July 2013","March 28, 2011",,"June 17, 2016","China Medical Universty Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01323894"
937,"NCT01182662","Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia",,"Unknown status","No Results Available","Aplastic Anemia","Other: Human umbilical cord-derived MSCs and cyclosporin A|Other: cyclosporin A","SAA clinical symptoms|The number of blood cells|Bone borrow hemocytology|Percentage of systemic T regulatory cell population and T lymphocyte subsets","Shandong University|National Natural Science Foundation of China","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","kongdx|No. 30670903","August 2010","August 2013","August 2013","August 17, 2010",,"August 31, 2010","Department of Hematology of the 2nd Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01182662"
938,"NCT02801890","Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)",,"Completed","No Results Available","Ultra Filtration Failure","Biological: Intravenous injection","Systemic infection|Hepatic failure|Renal failure|Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).|Ratio of 4-hour dialysate/plasma urea (D/P urea )|Ratio of dialysate glucose concentrations (D/D glucose )|peritoneal membrane transport function|Glomerular filtration rate (GFR):","Royan Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-kidney-006","August 2015","February 2017","March 2017","June 16, 2016",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02801890"
939,"NCT03397095","Sequential Treatment of Extra-Corporeal Shock Wave Combined With aUtologous Bone marRow Mesenchymal Stem Cells on Patients With ischEmic Heart Disease : the S-CURE Study","S-CURE","Recruiting","No Results Available","Ischemic Heart Disease","Combination Product: CSWT+BMMSCs|Device: CSWT+Sham operation","Change from baseline to 6 months follow-up in LVEF.|Change from baseline to 6 months follow-up in infarct size.|Change from baseline to 6 months follow-up in exercise distance increment|Change from baseline to 6 months follow-up in quality of life measured by MLHFQ|Change from baseline to 6 months follow-up in NYHA Classification.|Percent of patients with adverse events.|Change from baseline to 6 months follow-up in exercise time increment.|Change from baseline to 6 months follow-up in quality of life measured by KCCQ","Shanghai 10th People's Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S-CURE","April 3, 2018","December 1, 2019","April 1, 2022","January 11, 2018",,"August 28, 2019","Shanghai Tenth People's Hospital, Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03397095"
940,"NCT02982915","Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty","HERA","Active, not recruiting","No Results Available","Aging Frailty","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Biological: Fluzone High Dose Vaccine","The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:|Prevention of the illness caused by any influenza viral type/subtype in association with influenza like symptoms:|Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:|Differences in rate of decline from Aging Frailty|Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment|PROMIS Short Form 20a questionnaire|PROMIS Mobility questionnaire|PROMIS Upper Extremity questionnaire|Short Form 36 questionnaire|IIEF questionnaire|SQOL-F questionnaire|Death from any cause","Longeveron Inc.","All","65 Years to 90 Years   (Older Adult)","Phase 1|Phase 2","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-0000-03","November 2016","April 2021","December 2021","December 6, 2016",,"September 30, 2021","Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|University of Miami, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Optimal Research LLC, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02982915"
941,"NCT01489267","A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation","SCA","Unknown status","No Results Available","Hereditary Cerebellar Ataxia.","Other: stem cell transplantation","blood test|Nerve functional evaluation|Urinal test|Electrophysiology examination","General Hospital of Chinese Armed Police Forces","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20111031SCA|20111031limin","December 2011","July 2013","July 2014","December 9, 2011",,"June 20, 2012","Yihua An, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01489267"
942,"NCT01129739","Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes",,"Unknown status","No Results Available","Myelodysplastic Syndromes","Other: Human umbilical cord-derived MSCs|Other: cyclosporine A (CsA)","MDS clinical symptoms (mainly anemia symptoms)|A routine blood test|Bone borrow cytomorphologic examination|Percentage of T regulatory cell population in peripheral blood","Shandong University|National Natural Science Foundation of China","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CZheng|No. 30670903","May 2010","May 2013","May 2013","May 25, 2010",,"May 25, 2010","Department of Hematology of the 2nd Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01129739"
943,"NCT01539902","Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis","hUC-MSC-SLE","Unknown status","No Results Available","Lupus Nephritis","Biological: Human Umbilical Cord derived MSCs|Drug: Cyclophosphamide","Efficacy and Safety","CytoMed & Beike","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CT 11-03","February 2012","March 2013","May 2013","February 28, 2012",,"March 6, 2012","Second Affiliated Hospital & SLE Research Centre, Kunming Medical University, Kunming China, Kunming, Yunan, China",,"https://ClinicalTrials.gov/show/NCT01539902"
944,"NCT02210624","Safety and Efficacy Assessment of Autologous Bone-marrow Derived Adult Mesenchymal Stem Cell Therapy in Patients With Anoxic(or Hypoxic) Brain Injury Pilot Trial",,"Unknown status","No Results Available","Anoxic Brain Injury","Biological: HYNR-CS inj.","safety assessment|Glasgow Coma Scale(GCS)|FOUR score|Functional Independence Measure(FIM)|Disability Rating Scale(DRS)|Cerebral Performance Category(CPC)scale","Hyun Young Kim|Hanyang University Seoul Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYNR_CS_ABI001","March 2013","December 2018","December 2018","August 7, 2014",,"August 10, 2017","Hanyang University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02210624"
945,"NCT01413035","Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes",,"Unknown status","No Results Available","Type 2 Diabetes","Biological: MSC","To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus|To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus","Shandong University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","diabetes","July 2011","December 2013","July 2014","August 9, 2011",,"August 9, 2011","Department of Hematology of the 2nd Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01413035"
946,"NCT04877067","Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation","Magnovision","Completed","No Results Available","Methanol Poisoning|Toxic Optic Neuropathy|Stem Cell Tyrosine Kinase 1 Y842X|Magnetic Field Exposure","Biological: Wharton jelly derived mesenchymal stem cell|Device: Repetitive electromagnetic stimulation","ETDRS visual acuity:|Visual field sensitivity: Fundus perimetry deviation index (FPDI, %)|Ganglion cell complex thickness (GCC thickness, µm):|Pattern visual evoked potential (pVEP)","Ankara Universitesi Teknokent|International Olympic Committee","All","18 Years and older   (Adult, Older Adult)","Phase 3","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","56733164/203 E.1925","April 1, 2019","April 30, 2021","April 30, 2021","May 7, 2021",,"May 10, 2021","Ankara University Biotechnology Institute, Ankara, Türkiye, Turkey|Umut Arslan, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04877067"
947,"NCT04003857","Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial",,"Recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: PNEUMOSTEM®|Biological: normal saline","Respiratory outcome: Number of hospitalizations|Mortality|Growth measured by Z-score|Neurological developmental status: Korean Developmental Screening Test for infants and children(K-DST)|Deafness or Blindness|Bayley Scales of Infant and Toddler Development (Third Edition)|Gross Motor Function Classification System for Cerebral Palsy|Number of adverse events|Number of admissions to Emergency Room (ER)|Medical treatment records","Medipost Co Ltd.","All","6 Months to 60 Months   (Child)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-CR-012-F/U","July 5, 2019","June 30, 2027","June 30, 2027","July 1, 2019",,"August 28, 2020","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04003857"
948,"NCT02286128","Effect of NF-кB Dependent Proinflammation on Osteogenic Differentiation of the Mesenchymal Stem Cells in Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes",,"Correlation between NF-кB dependent-proinflammation markers and osteoblast-specific gene expression in the MSC to measure the effects of NF-кB dependent-proinflammation on differentiation potential toward osteoblast in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and apoptotic marker expression in the MSC to measure effects of NF-кB dependent-proinflammation on cellular apoptosis in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and the expression of RAGE and its downstream signals in the MSC to measure effects of NF-кB dependent-proinflammation on cellular RAGE activation in type 2 diabetes.","Chiang Mai University","All","18 Years and older   (Adult, Older Adult)",,"75","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","ChiangMaiU","November 2014","May 3, 2018","May 3, 2018","November 7, 2014",,"July 12, 2018","Mattabhorn Phornputkul, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT02286128"
949,"NCT00759018","Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD",,"No longer available","No Results Available","Graft vs Host Disease|Graft-Versus-Host Disease","Biological: remestemcel-L",,"Mesoblast, Inc.|Mesoblast, Ltd.","All","2 Months to 17 Years   (Child)",,,"Industry","Expanded Access",,"275",,,,"September 25, 2008",,"March 9, 2020","Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF, San Francisco, California, United States|Children's National, Washington, District of Columbia, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Childrens Memorial, Chicago, Illinois, United States|James Witcomb Riley Hosptial for Children, Indianapolis, Indiana, United States|LSU Health Science Center/Children's Hospital, New Orleans, Louisiana, United States|Wayne State University/Childrens' Hospital, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Doernbecher Children's Hospital (OHSU), Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|Texas Childrens Hospital, Houston, Texas, United States|Methodist Childrens Hospital of South Texas, San Antonio, Texas, United States|Massey Cancer Center, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|Montreal Children's Hospital, Montreal, Quebec, Canada|CHU Sainte-Justine, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00759018"
950,"NCT03337243","Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis|Knee Pain Chronic|Joint Disease|Arthritis|Osteo Arthritis Knee|Musculoskeletal Disease","Procedure: HAM and HUMCWJ Injections","Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months|Change in pain during sit-to-stand over 3 months|Change in pain during supine to upright over 3 months|Change in pain during ascent/decent stairs over 3 months","Sport and Spine Rehab Clinical Research Foundation","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","StemCell","November 9, 2017","April 26, 2019","April 26, 2019","November 8, 2017",,"May 6, 2020","Scott Medical Health Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03337243"
951,"NCT02838069","A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis","ADIPOA-2","Recruiting","No Results Available","Osteoarthritis","Biological: Injection (2x106 ASC/5ml).|Biological: Injection (10x106 ASC/5ml).|Other: Placebo","Improvement of pain or physical function|Disability (WOMAC)|Disability (KOOS)|Disability (SAS)|Change in Quality of life|painkillers consumption|Structural changes (X-Ray)|Structural changes (MRI)","University Hospital, Montpellier|University Hospital, Toulouse|Assistance Publique - Hôpitaux de Paris|NATIONAL UNIVERSITY OF IRELAND, GALWAY (NUIG)|ISTITUTO ORTOPEDICO RIZZOLI (IOR)|Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France|ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)|HUMAN MED AG (HM)|Stichting Katholieke Universiteit|SPORTS SURGERY CLINIC LIMITED|UNIVERSITA DEGLI STUDI DI PADOVA (UNIPD)|EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS GGMBH (EWK)|PINTAIL LTD (PT)|Centre National de la Recherche Scientifique, France|UNIVERSITAET ULM (UULM)|Cambridge University Hospitals NHS Foundation Trust|Aries srl (ARIES)","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 2","153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UF 9494","September 2016","January 2022","June 2023","July 20, 2016",,"April 13, 2020","UH Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02838069"
952,"NCT05027581","Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)",,"Recruiting","No Results Available","Osteoarthritis, Knee","Drug: Bone marrow mesenchymal stem cells|Drug: hyaluronic acid","Efficacy-Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) assessment|Efficacy-Visual Analogue Scale (VAS) assessment|Efficacy-SF-36 Quality of Life (QoL) health survey questionnaire|Efficacy-Whole-Organ Magnetic Resonance Imaging Score (WORMS)|Efficacy-knee joint space width (JSW)|Efficacy-synovial fluid|Efficacy-rescue medication|Safety-AE/SAE based on NCI-CTCAE v5.0|Safety-vital signs|Safety-laboratory examination|Safety-physical examination","Taiwan Bio Therapeutics Co., Ltd.|A2 Healthcare Taiwan Corporation","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Chondrochymal-01","September 15, 2021","September 10, 2023","September 10, 2024","August 30, 2021",,"September 24, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05027581"
953,"NCT04368806","A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis, Knee","Drug: JointStem|Other: Placebo Control","Western Ontario and McMaster Universities Arthritis Index (WOMAC) function Score|Visual Analog Scale (VAS) score|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Function)|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Pain)|Total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score|International Knee Documentation Committee (IKDC) score|36-Item Short Form health survey questionnaires (SF-36) score|Structural changes in knee joint|Kellgren-Lawrence grade|Number and amount of rescue medication use","Nature Cell Co. Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JS-OAP3-US01","May 26, 2021","June 30, 2022","December 30, 2022","April 30, 2020",,"July 19, 2021","TriWest Research Associates, El Cajon, California, United States|BioSolutions Clinical Research Center, La Mesa, California, United States|Source Healthcare, Santa Monica, California, United States|International Spine Pain, and Performance Center, Washington, District of Columbia, United States|Rothman Orthopaedic Institute, Egg Harbor Township, New Jersey, United States|Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04368806"
954,"NCT02336230","A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD",,"Completed","No Results Available","Grade B aGVHD|Grade C aGVHD|Grade D aGVHD","Drug: remestemcel-L","Rate of overall response (OR) in the study population at Day 28 post initiation of therapy (Day 0) with remestemcel-L (MSC)|Overall survival at Day 100 post initiation of remestemcel-L therapy|Rate of very good partial response (VGPR) at Day 28 post initiation of remestemcel-L therapy|Rate of OR at Day 100 post initiation of remestemcel-L therapy|Rate of VGPR at Day 100 post initiation of remestemcel-L therapy|Rate of OR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by organ involvement|Rate of VGPR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by organ involvement|Rate of OR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by individual subject organ involvement|Rate of VGPR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by individual subject organ involvement|Rate of OR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by baseline aGVHD grade|Rate of VGPR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by baseline aGVHD grade|Overall survival at Day 100 post initiation of remestemcel-L therapy, stratified by baseline aGVHD grade and organ involvement|Rate of aGVHD progression requiring additional aGVHD medications/therapy through Day 100 post initiation of remestemcel-L therapy|Effect of additional remestemcel-L therapy after Day 28 on rate of OR at Days 56 and 100 post initiation of remestemcel-L therapy|Effect of additional remestemcel-L therapy after Day 28 on rate of VGPR at Days 56 and 100 post initiation of remestemcel-L therapy","Mesoblast, Inc.|Quintiles, Inc.|Mesoblast, Ltd.","All","2 Months to 17 Years   (Child)","Phase 3","55","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSB-GVHD001","June 4, 2015","January 18, 2018","April 9, 2018","January 12, 2015",,"March 11, 2020","Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Nemours Children's Specialty Care, Jacksonville, Florida, United States|Miami Children's Research Institute, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Albert Einstein College of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02336230"
955,"NCT00557635","Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow",,"Suspended","No Results Available","Tibia or Femur Pseudo-arthrosis","Procedure: Chirurgical procedure","Evaluate osseous setting at 3-months follow-up and compare our results with past studies|Feasibility and tolerance of this therapeutic strategy","University Hospital, Clermont-Ferrand","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0026","January 2008","November 2011","December 2011","November 14, 2007",,"September 23, 2009",,,"https://ClinicalTrials.gov/show/NCT00557635"
956,"NCT00225095","A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy",,"Completed","No Results Available","Recovery Following Partial Medial Meniscectomy","Drug: Mesenchymal Stem Cells|Drug: Hyaluronan","Meniscal Volume|Quality of Life Questionnaire|Visual Analog Scale (VAS)|Lysholm Knee Scale|Safety Assessment Adverse Event|Safety Assessment Immunological|Safety Assessment Laboratory|Safety Assessment Physical Exam|Safety Assessment Magnetic Resonance Imaging (MRI)","Mesoblast International Sàrl|University of Southern California|Midwest Orthopedics at Rush - Chicago, IL|Unlimited Research - San Antonio, TX|Triangle Orthopaedic Associates, P.A.|Orthopedic Center of Vero Beach - Vero Beach, FL|OrthoIndy|TRIA Orthopaedic Center|Greater Chesapeake Orthopaedic Associates, LLC|Mesoblast, Ltd.","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Osiris 550","September 2005","April 2008","April 2008","September 23, 2005",,"October 26, 2020","University of Southern California, Los Angeles, California, United States|Orthopedic Center of Vero Beach, Vero Beach, Florida, United States|Midwest Orthopaedics at Rush, Chicago, Illinois, United States|Ortholndy, Indianapolis, Indiana, United States|Greater Chesapeake Associates, Baltimore, Maryland, United States|TRIA Orthopaedic Center, Bloomington, Minnesota, United States|Triangle Orthopaedics Associates, P.A., Durham, North Carolina, United States|Unlimited Research, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00225095"
957,"NCT01159899","Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee",,"Unknown status","No Results Available","Osteoarthritis|Knee Osteoarthritis|Osteochondritis Dissecans|Osteonecrosis","Procedure: Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis","IKS, International Knee Score|KOOS, Knee Injury and Osteoarthritis Outcome Score","Michel Assor, MD|University of Marseille","All","30 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC- AS3","July 2010","December 2014","December 2014","July 12, 2010",,"January 8, 2013","Knee and Lower Limb Institute, Dr Michel Assor, Marseille, France",,"https://ClinicalTrials.gov/show/NCT01159899"
958,"NCT02365142","Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma","CMM-PRGF/ART","Unknown status","No Results Available","Knee Osteoarthritis","Biological: 100 million Bone marrow mesenchimal stem cells|Biological: Platelet Rich plasma (PRGF)","Baseline Visual analogue scale (VAS) Baseline Visual analogue scale (VAS)|Baseline value of knee injury and osteoarthritis outcome score (Koos).|Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).|Baseline SF-36 value|Baseline euroquol 5D value|Baseline Lequesne index|Baseline femorotibial distance|Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events|Visual analogue scale (VAS) at 1 month|Visual analogue scale (VAS) at 3 months|Visual analogue scale (VAS) at 6 months|Visual analogue scale (VAS) at 12 months|Value of knee injury and osteoarthritis outcome score (Koos) at 1 month|Value of knee injury and osteoarthritis outcome score (Koos) at 3 month|Value of knee injury and osteoarthritis outcome score (Koos) at 6 month|Value of knee injury and osteoarthritis outcome score (Koos) at 12 months","Clinica Universidad de Navarra, Universidad de Navarra","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CMM-PRGF/ART|2011-006036-23","June 2014","June 2018","June 2018","February 18, 2015",,"October 24, 2017","Hospital Universitario de Salamanca, Salamanca, Castilla-León, Spain|Departamento Cirugía Ortopédica y Traumatología. Clinica Universidad de Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT02365142"
959,"NCT02328612","Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers","CELLULA","Completed","No Results Available","Sepsis","Other: Intravenous infusion of cells","Inflammatory response as measured by laboratory measurements and functional assays of innate immunology","Tigenix S.A.U.|Cellerix","Male","18 Years to 35 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cx611-0102","October 2014","March 2015","March 2015","December 31, 2014",,"April 3, 2015","Academic Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02328612"
960,"NCT01897987","Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial",,"Completed","No Results Available","Bronchopulmonary Dysplasia","Biological: Pneumostem®|Biological: normal saline","Respiratory outcome: readmission rate and duration of the hospital stay due to respiratory infection|Whether the subject is receiving medical treatments and if so, duration of the treatment (use of oxygen, steroid, or brochodilator)|Number of admissions to Emergency Room|Survival|Growth measured by Z-score|Neurological developmental status on K-ASQ, Bayley Scale, Gross Motor Function Classification System (GMFCS) for Cerebral Palsy|Deafness or Blindness|Number of adverse events|Significant changes in vital signs|Significant changes in physical exam","Medipost Co Ltd.","All","7 Months to 7 Months   (Child)","Not Applicable","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","MP-CR-009-FU","January 2014","March 2020","March 2020","July 12, 2013",,"August 7, 2020","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01897987"
961,"NCT01828957","Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants",,"Completed","No Results Available","Bronchopulmonary Dysplasia","Biological: Pneumostem®|Other: Normal Saline","Incidence of BPD (moderate to severe) or mortality at 36 weeks PMA|Intubation duration|Incidence of BPD|Survival rate|Duration of ventilator dependence|Duration of CPAP treatment|Postnatal steroid use (%) for the purpose of ventilator weaning|Cumulative duration of oxygen use|Incidence of Retinopathy of Prematurity (ROP) of Grade III or more|Retinopathy of Prematurity (ROP) that require treatment with avastin or laser|Growth velocity (Z-score)|Length of stay prior to the first discharge from the hospital|Incidence of adverse events|Clinically significant laboratory findings|Incidence of pneumothorax that require intubation|Incidence of moderate to severe pulmonary hemorrhage|Incidence of intraventricular hemorrhage of grade 3 or more","Medipost Co Ltd.","All","up to 14 Days   (Child)","Phase 2","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-CR-009","April 2013","May 2015","August 2015","April 11, 2013",,"September 6, 2019","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01828957"
962,"NCT03857841","A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD",,"Terminated","Has Results","Bronchopulmonary Dysplasia","Biological: UNEX-42|Biological: Phosphate-buffered saline","Number of Subjects With Treatment-emergent Adverse Events During the Post-treatment Phase (Safety and Tolerability)","United Therapeutics","All","up to 14 Days   (Child)","Phase 1","3","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNX-BP-101","October 9, 2019","May 20, 2021","May 20, 2021","February 28, 2019","October 12, 2021","October 12, 2021","University of Colorado Hospital, Aurora, Colorado, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03857841/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03857841/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03857841"
963,"NCT04275024","Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients",,"Enrolling by invitation","No Results Available","Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity","Drug: Calcipotriol ointment|Drug: PSORI-CM01 Granule|Biological: adipose-derived multipotent mesenchymal stem cells","PASI score improvement rate|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI(Dermatology Life Quality Index)","Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2016-05-02","April 1, 2020","July 24, 2020","December 24, 2021","February 19, 2020",,"March 4, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04275024"
964,"NCT01993368","Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis","PAG","Terminated","No Results Available","Aggressive Periodontitis|Chronic Periodontitis","Other: flow cytometry","proportion of lymphocytes, myeloid and mesenchymal populations in the samples","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-PP-07","November 2013","December 2017","December 2017","November 25, 2013",,"February 7, 2018","Odontology Department, Nice Unversity Hospital, Nice, France",,"https://ClinicalTrials.gov/show/NCT01993368"
965,"NCT02181478","Intra-Osseous Co-Transplant of UCB and hMSC",,"Completed","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Myelofibrosis|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Lymphoid Malignancies|Chronic Myelogenous Leukemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Procedure: mesenchymal stem cell transplantation","Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","6","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1Z14|NCI-2014-01316|P30CA043703","July 22, 2015","December 19, 2019","February 7, 2020","July 4, 2014",,"December 4, 2020","Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02181478"
966,"NCT01759823","Bone Marrow Derived Stem Cell Transplantation in T2DM",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Biological: mesenchymal stem cell transplantation|Other: control|Biological: MNC's TRANSPLANTATION","Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function","Postgraduate Institute of Medical Education and Research","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","stem cell therapy in T2DM","December 2012","December 2014","October 2015","January 3, 2013",,"October 27, 2015","Postgraduate Institute of Medical Education and Research, Chandigarh, UT, India",,"https://ClinicalTrials.gov/show/NCT01759823"
967,"NCT04711811","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Musculoskeletal Pain","CMP","No longer available","No Results Available","Chronic Pain","Biological: HB-adMSC",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences",,"18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access:Individual Patients",,"HBCMP01",,,,"January 15, 2021",,"July 7, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04711811"
968,"NCT01079143","Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients","CERTITEM","Completed","Has Results","Renal Interstitial Fibrosis","Drug: Certican®|Drug: Neoral|Drug: Myfortic|Drug: Simulect®|Drug: Corticosteroids","Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population|Interstitial Fibrosis/Tabular Atrophy (IF/TA)|Change in Interstitial Fibrosis/Tabular Atrophy (IF/TA) Grade|Risk Factors of IF/TA Progression|Change in Percentage of Interstitial Fibrosis (IF) by Numerical Quantification|Number of Participants With Progression of Renal Fibrosis Using Numerical Quantification|Number of Participants With Epithelial-mesenchymal Transition (EMT) Status|Number of Participants With Epithelial-mesenchymal Transition (EMT) Score|Change in EMT Score|Incidence (Number) of Subclinical Rejections and Borderline Lesions|Change From Baseline (M3) in Estimated Glomerular Filtration Rate (eGFR)|Change in Estimated Glomerular Filtration Rate (eGFR) at M12 From Baseline (M3) - ANCOVA Model|Change in Urine Protein/Creatinine Ratio (Without Imputation)|Treatment Failures|Type of Biopsy Proven Acute Rejection (BPAR)|Severity of BPAR|Incidence (Number) of BPAR|Incidence (Number) of Participants With Graft Losses","Novartis Pharmaceuticals|Novartis","All","19 Years to 75 Years   (Adult, Older Adult)","Phase 3","194","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRAD001AFR10|2009-011473-33","September 2009","June 2012","June 2012","March 2, 2010","March 18, 2014","March 18, 2014","Novartis Investigative Site, Caen, Cedex, France|Novartis Investigative Site, Amiens cedex1, France|Novartis Investigative Site, Angers, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Nice Cedex 1, France|Novartis Investigative Site, Paris cedex 15, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, St Priest en Jarez Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Suresnes, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Tours Cedex, France|Novartis Investigative Site, Vandoeuvre Les Nancys, France",,"https://ClinicalTrials.gov/show/NCT01079143"
969,"NCT03172117","Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.",,"Recruiting","No Results Available","Alzheimer's Disease","Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL","Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in CIBIC-plus|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers","Medipost Co Ltd.","All","50 Years to 86 Years   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-CR-010-F/U","May 19, 2017","December 31, 2021","December 31, 2021","June 1, 2017",,"August 28, 2020","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03172117"
970,"NCT03015623","A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy",,"Active, not recruiting","No Results Available","Acute Kidney Injury","Biological: SBI-101|Device: Sham","Safety and tolerability as measured by incidence of IP-related serious adverse events","Sentien Biotechnologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBI-101-01","June 20, 2017","December 2021","December 2021","January 10, 2017",,"March 16, 2021","Lehigh Valley Hospital, Allentown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03015623"
971,"NCT03943940","BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients","T2DM","Unknown status","No Results Available","Type 2 Diabetes Mellitus","Biological: BM-MNC and UC-MSC|Other: Control","The level of C-peptid and HOMA-β|The level of HOMA-IR and cytokines TNF-α, IL-1β|Blood glucose level|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose and drug dosage","Van Hanh General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TNLS012019-TBG","April 24, 2019","December 30, 2019","August 30, 2020","May 9, 2019",,"May 10, 2019","Van Hanh General Hospital, Ho Chi Minh City, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03943940"
972,"NCT01742533","Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure",,"Unknown status","No Results Available","Premature Ovarian Failure，","Biological: human umbilical cord mesenchymal stem cells|Biological: hUCMSCs and hCBMNCs|Biological: human cord blood mononuclear cells|Drug: Hormone Replacement Therapy","Serum Level of follicle-stimulating hormone|Uterine and Ovary characteristics of B ultrasound， including Uterine/Ovarian size and Blood Flow|Modified Kupperman Score|Incidence of Adverse Events and Serious Adverse Events","Shenzhen Beike Bio-Technology Co., Ltd.","Female","18 Years to 39 Years   (Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BKCR-POF-1(Ⅰ)","March 2012","June 2013","March 2014","December 5, 2012",,"December 5, 2012","Shenzhen People's Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01742533"
973,"NCT01842477","Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing","OrthoCT1","Completed","No Results Available","Delayed Union After Fracture of Humerus, Tibial or Femur","Procedure: Implantation of bone substitute plus autologous cultured mesenchymal cells","Complication rate as percentage of patients with local complications regarding the non-union treatment in the follow-up|Number of patients with proven bone healing|Amount of radiological callus|Clinical consolidation|No reoperation done or scheduled|Changes in serum levels of bone turnover markers","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C11-12|2011-005441-13","May 2013","February 5, 2016","February 5, 2016","April 29, 2013",,"December 2, 2017","Depatment of Orthopaedic Surgery, Hôpital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHRU Tours, Tours, France|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01842477"
974,"NCT00186914","Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation",,"Completed","No Results Available","Osteodysplasia","Biological: Marrow stromal cell infusion","To evaluate the safety of the stromal cell infusion","St. Jude Children's Research Hospital|Drexel University|Wayne State University","All","Child, Adult, Older Adult","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STOD","July 1999","November 2001","January 2008","September 16, 2005",,"March 4, 2015","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00186914"
975,"NCT04348435","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,"Completed","No Results Available","COVID-19","Biological: HB-adMSCs|Other: Placebos","Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","Child, Adult, Older Adult","Phase 2","55","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HBCOV02","May 14, 2020","July 9, 2021","July 30, 2021","April 16, 2020",,"August 20, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04348435"
976,"NCT04914403","Mesenchymal Stem Cells for The Treatment of Frailty Syndrome",,"Not yet recruiting","No Results Available","Frailty Syndrome","Biological: UMC119-06-05","The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes in exercise performance using 6-min walk test (6MWT).|Changes in grip strength.|Changes in quality of life measured by change in SF12 (12-Item Short Form).|Changes in physical activity using International Physical Activity Questionnaire (IPAQ) questionnaire|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in Clinical Frailty Scale.","Meridigen Biotech Co., Ltd.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-05-FS-01","July 2021","December 2022","July 2023","June 4, 2021",,"June 9, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04914403"
977,"NCT04240873","Clinical Study of Intra Articular Injection of Catholic MASTER Cell (Bone Marrow Derived Mesenchymal Stem Cell) in Knee Osteoarthritis","MSC-OA","Recruiting","No Results Available","Osteoarthritis, Knee","Biological: Catholic MASTER cell|Other: Saline","adverse event according to CTCAE 5.0, clinically meaningful abnormalites in laboratory tests (blood)|Western Ontario and McMaster Universities Arthritis Index (WOMAC) score|Knee injury and Osteoarthritis Outcome Score (KOOS)|International knee documentation committee (IKDC)|Cartilage damage evaluation through knee MRI|SF-36 questionnaire|Serum inflammatory cytokine, acute phase reactant, bone turnover marker|Cartilage damage evaluation through knee x-ray","Seoul St. Mary's Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KC19CNSI0469","November 15, 2019","March 31, 2021","March 31, 2022","January 27, 2020",,"January 27, 2020","Catholic University of Korea, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04240873"
978,"NCT00609661","Adult Stem Cell Response to Burn Injury",,"Withdrawn","No Results Available","Wound Healing|Burn",,,"Ohio State University","All","16 Years and older   (Child, Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2006H00286","February 2008","February 2010","June 2010","February 7, 2008",,"October 8, 2012",,,"https://ClinicalTrials.gov/show/NCT00609661"
979,"NCT04037345","Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: SMUP-IA-01(low-dose)|Biological: SMUP-IA-01(mid-dose)|Biological: SMUP-IA-01(high-dose)","Change of total score in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) compared to baseline at 6 months after treatment|Change of score in WOMAC three subscales (Pain, stiffness, physical function)compared to baseline at 6 months after treatment|Change of score in 100 mm VAS (Visual Analogue Scale) compared to baseline|Change of score in IKDC(International Knee Documentation Committee)compared to baseline|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score) compared to baseline at 6 months after treatment|Change in K&L(Kellgren-Lawrence) grade compared to the baseline at 3 months and 6 months after treatment|Change in joint space width compared to the baseline at 3 months and 6 months after treatment|Change in mechanical axis, anatomical axis compared to the baseline at 3 months and 6 months after treatment","Medipost Co Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-SMUP-IA-01-P01","October 7, 2019","November 12, 2020","November 12, 2020","July 30, 2019",,"February 24, 2021","Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04037345"
980,"NCT04097652","Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke",,"Recruiting","No Results Available","Acute Ischemic Stroke","Biological: UMC119-06","The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Modified Rankin Score (mRS)|Changes in National Institute of Health Stroke Scale (NIHSS)|Changes in Barthel Index (BI)|Changes in Brain MRI","Meridigen Biotech Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-01","December 5, 2019","December 2022","December 2023","September 20, 2019",,"April 23, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04097652"
981,"NCT04739930","Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation",,"Recruiting","No Results Available","Cartilage Injury","Procedure: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Procedure: Control group incision","Synovial Fluid Cytokine Measurement","Rush University Medical Center|Joint Restoration Foundation (JRF)","All","18 Years to 50 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17121805","March 2, 2018","December 31, 2021","March 31, 2022","February 5, 2021",,"February 5, 2021","Rush University Medical Center, Chicago, Illinois, United States","""Informed Consent Form: HIPAA Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/Prot_001.pdf|""Informed Consent Form: Main Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT04739930"
982,"NCT04657315","Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients","MSC11FCD-GBM","Enrolling by invitation","No Results Available","Glioblastoma|Adult Gliosarcoma|Neoplasms, Brain|Neoplasms, Germ Cell and Embryonal|Recurrent Glioblastoma","Drug: MSC11FCD","Maximum tolerated dose (MTD)|Number Of Adverse Events related to the treatment|Overall Survival improvement (OS)|Progression Free Survival (PFS)|Tumor assessment in regard to the investigational drug based on the RANO criteria|Clinical efficacy assessment","CHA University|Ajou University School of Medicine","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHAMC 2019-08-022","June 24, 2020","December 31, 2021","December 31, 2022","December 8, 2020",,"March 29, 2021","Bundang CHA Medical Center, Seongnam, Kyunggido, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04657315"
983,"NCT04206007","Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease",,"Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease Moderate","Biological: UMC119-06","The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Forced Vital Capacity (FVC).|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).|Changes in exercise performance using 6-min walk test (6MWT).|Changes in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).|Changes in modified medical research council (mMRC) -dyspnea scale.","Meridigen Biotech Co., Ltd.","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-COPD-01","June 11, 2020","March 31, 2022","December 31, 2023","December 20, 2019",,"April 23, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04206007"
984,"NCT04347967","Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)",,"Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: UMC119-06","The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in mortality status|Ventilator Free Days (VFD)|Change in Oxygenation Index (OI)|Change in Lung Injury Score (LIS)|Change in positive end-expiratory pressure (PEEP)|Change in Lung Static Compliance|Change in acute physiology and chronic health evaluation score (APACHE II)","Meridigen Biotech Co., Ltd.","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-ARDS-01","September 2021","December 2022","December 2023","April 15, 2020",,"May 18, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04347967"
985,"NCT01343511","Safety and Efficacy of Stem Cell Therapy in Patients With Autism",,"Completed","No Results Available","Autism","Biological: human cord blood mononuclear cells|Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells","Childhood Autism Rating Scale，CARS|Clinical Global Impression Scale，CGI|Aberrant Behavior Checklist，ABC|Adverse Event and Serious Adverse Event","Shenzhen Beike Bio-Technology Co., Ltd.|Shandong Jiaotong Hospital|Association for the Handicapped Of Jinan","All","3 Years to 12 Years   (Child)","Phase 1|Phase 2","37","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BKCR-AUTISM-1.0(2009)","March 2009","June 2010","May 2011","April 28, 2011",,"October 14, 2011","Shandong Jiaotong Hospital, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01343511"
986,"NCT03639506","Clinical Application of Autologous Mitochondria Transplantation for Improving Oocyte Quality.",,"Unknown status","No Results Available","Repetition Failure","Procedure: autologous mitochondria transplantation|Combination Product: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|Drug: intracytoplasmic sperm injection (ICSI)","live birth rate|clinical pregnancy rate|number of oocytes retrieved|fertility rate|normal fertility rate|good quality embryo rate","Sun Yat-sen University","Female","20 Years to 43 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","newivf20180817","September 2018","December 2020","September 2021","August 21, 2018",,"August 21, 2018",,,"https://ClinicalTrials.gov/show/NCT03639506"
987,"NCT02023788","Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study",,"Completed","No Results Available","Bronchopulmonary Dysplasia|Respiratory Tract Infections|Premature Birth of Newborn","Biological: PNEUMOSTEM","Number of subjects with adverse drug reactions|Respiratory outcomes|Survival|Z-score|Potential neurological development test outcomes","Medipost Co Ltd.","All","45 Months to 63 Months   (Child)",,"8","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MP-CR-006-F/U-5y","April 2014","October 2016","October 2016","December 30, 2013",,"September 4, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02023788"
988,"NCT04706312","Transplantation of hAMSCs for Woman With DOR",,"Not yet recruiting","No Results Available","Diminished Ovarian Response","Other: stem cells","Safety and tolerability after hAMSCs injection.|The ratio of transplantable embryo in DOR patients after hAMSCs injection.|Ovarian function in DOR patients after hAMSCs injection.|Outcomes of IVF in DOR patients after hAMSCs injection.","The First Affiliated Hospital with Nanjing Medical University","Female","35 Years to 45 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-SCR-03","April 2021","January 2022","April 2024","January 12, 2021",,"February 9, 2021","Clinical Center of Reproductive Medicine at the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04706312"
989,"NCT03562715","microRNAs Role in Pre-eclampsia Diagnosis",,"Completed","No Results Available","Preeclampsia",,"The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media","Cairo University","Female","23 Years to 35 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","BC (1870)","November 28, 2016","June 15, 2017","December 25, 2017","June 19, 2018",,"June 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03562715"
990,"NCT04863183","Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis",,"Not yet recruiting","No Results Available","Mesenchymal Stem Cells|Knee Osteoarthritis|Cell Therapy","Biological: CELLISTEM-OA|Drug: Triamcinolone acetonide","Decrease in joint pain|Increased joint functionality|Improvement in the quality of life|Imaging improvement of articular cartilage","Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle|Cells for Cells","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","OA-01","June 1, 2021","December 31, 2021","June 30, 2022","April 28, 2021",,"April 28, 2021",,,"https://ClinicalTrials.gov/show/NCT04863183"
991,"NCT02630836","Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture",,"Withdrawn","No Results Available","Femoral Neck Fracture","Drug: XCEL-MT-OSTEO-BETA|Procedure: Surgical treatment","safety of XCEL-MT-OSTEO-BETA in proximal femur fractures by Adverse events, physical exam, laboratory tests.|efficacy through CT scan|efficacy through xRay|efficacy by clinical assessment|efficacy by quality of life questionnaire","Banc de Sang i Teixits|Fundacion Clinic per a la Recerca Biomédica","All","70 Years to 85 Years   (Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-MT-10-03|2010-024041-78","December 2015","December 2017","December 2018","December 15, 2015",,"March 17, 2017",,,"https://ClinicalTrials.gov/show/NCT02630836"
992,"NCT05132972","Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients","UCMSC","Recruiting","No Results Available","Covid 19","Biological: Normoxic Allogenic UCMSC|Other: Normal saline solution","Duration of hospital stay|Post-administration clinical and radiological improvement|Adverse Event and Serious Adverse Event Evaluation","Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia|Dr. Moewardi General Hospital, Surakarta, Indonesia|Dr. Sardjito General Hospital, Yogyakarta, Indonesia|Dr. Hasan Sadikin General Hospital, Bandung, Indonesia|PT Bifarma Adiluhung","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BRIN20211118a","January 17, 2021","November 2021","November 2021","November 24, 2021",,"November 24, 2021","Dr. Moewardi General Hospital, Surakarta, Central Java, Indonesia|Dr. Hasan Sadikin, Bandung, West Java, Indonesia|Dr. Sardjito General Hospital, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT05132972"
993,"NCT04893174","Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).",,"Not yet recruiting","No Results Available","Osteoarthritis, Knee","Biological: UMC119-06-05|Device: Hyaluronic acid","The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes of total score in the Western Ontario and McMaster (WOMAC) assessment on the target knee.|Changes of arthritis pain on target knee using the 100-mm visual-analogue scale (VAS).|Whole Organ Magnetic Resonance Imaging Score (WORMS).|Changes in Kellgren-Lawrence (K-L) grading and joint space on target knee.|Amount of rescue medications required.","Meridigen Biotech Co., Ltd.","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-05-KOA-01","January 2022","September 2022","June 2023","May 19, 2021",,"May 28, 2021","Taipei Medical University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04893174"
994,"NCT04377334","Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)",,"Not yet recruiting","No Results Available","ARDS|COVID-19","Biological: MSC","lung injury score|D-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|Survival|extubation|lymphocyte subpopulations|SARS-CoV-2-specific antibody titers|complement molecules (C5-C9)","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RESCOVID","September 2021","March 2022","June 2022","May 6, 2020",,"June 7, 2021","University Hospital Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT04377334"
995,"NCT04759105","Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD","ACTIVE","Recruiting","No Results Available","Intervertebral Disc Degeneration|Chronic Low-back Pain","Drug: Autologous BM-MSC|Other: Sham Procedure","Pain clinical relief|Functional disability index improvement|Work ability improvement|Measure pain relief of the patient|Measure functional disability index of the patient|Evaluate disability and quality of life evolution of the patient|Disability and quality of life evolution|Assess rescue painkillers medication|Structural assessment|Evaluation of cost|Incidence of Adverse Events (AE)|Assessment of vital signs|Evaluation of blood and urine analysis|Analysis of chemical biomarkers for tissue degeneration","Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ACTIVE trial_(BRIC2018-ID03)|2019-004476-19","November 17, 2020","July 31, 2021","June 30, 2022","February 18, 2021",,"February 18, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04759105"
996,"NCT05066334","Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD","DREAM","Recruiting","No Results Available","Intervertebral Disc Degeneration|Chronic Low-back Pain","Drug: Autologous BM-MSC|Procedure: Sham","Pain Change|Functional disability index evaluation|Disability evolution|Quality of life evolution|Drug consumption of rescue painkillers medication|Measurement of pain|Employment and work status assessment|Structural assessment|Evaluation of costs|Body Mass Index evaluation|Haematological evaluation: safety parameter|Coagulation status: safety parameter|Metabolic functions: safety parameter|Inflammation: safety parameter|Urinalysis|Spine examination|Specific Adverse Events Evaluation","Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","DREAM (GR - 2018-12367168)|2019-002749-40","March 22, 2021","May 31, 2022","June 9, 2023","October 4, 2021",,"October 4, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT05066334"
997,"NCT04445220","A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy",,"Recruiting","No Results Available","COVID-19|Acute Kidney Injury|Sepsis","Biological: SBI-101","Safety and tolerability as measured by incidence of IP-related serious adverse events","Sentien Biotechnologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBI-101-02","November 19, 2020","March 2022","September 2022","June 24, 2020",,"September 8, 2021","University of New Mexico School of Medicine, Albuquerque, New Mexico, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04445220"
998,"NCT02503280","The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.","TAC-HFT-II","Withdrawn","No Results Available","Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction","Drug: Autologous hMSCs|Drug: Autologous Human C-Kit CSCs II|Drug: Placebo|Device: Biosense Webster MyoStar NOGA Injection Catheter System","Incidence of any treatment emergent serious adverse events (TE-SAEs)|Treatment Emergent adverse event rates|Ectopic tissue formation|48-hour ambulatory electrocardiogram (ECG) recordings.|Hematology value changes post-catheterization|Urinalysis results changes post-catheterization|Clinical chemistry values post-catheterization|Pulmonary function|Serial troponin I values|Creatine kinase-MB (CK-MB) value changes post-catheterization|Post-cardiac catheterization echocardiogram.|Magnetic resonance imaging (MRI) measures of infarct scar size (ISS)|Echocardiographic measures of infarct scar size (ISS)|Magnetic resonance imaging (MRI) of Left Regional Ventricular Function|Echocardiographic measures of Left Regional Ventricular Function|Magnetic resonance imaging (MRI) of Global Ventricular Function|Echocardiographic measures of Global Ventricular Function|Tissue perfusion measured by MRI.|Peak oxygen consumption (Peak VO2) (by treadmill determination).|Six-minute walk test.|New York Heart Association (NYHA) functional class.|Minnesota Living with Heart Failure (MLHF) questionnaire.|Incidence of Major Adverse Cardiac Events (MACE)","Joshua M Hare|University of Miami","All","21 Years to 89 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20120203","March 1, 2025","March 2030","March 2032","July 20, 2015",,"October 22, 2020","ISCI / University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02503280"
999,"NCT01318330","Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD)","Homeo-GH","Completed","No Results Available","Graft-vs-Host Disease","Drug: Homeo-GH","To evaluate number of paticipants with adverse events|GVHD clinical response","HomeoTherapy Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","Homeo-GH","November 2010","December 2011","June 2012","March 18, 2011",,"July 19, 2012","Inha University Hospital, In Cheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01318330"
1000,"NCT02080650","Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)",,"Completed","No Results Available","Prostate Cancer|Renal Cell Carcinoma|Bladder Cancer|Colorectal Cancer|Gastric Cancer|Pancreatic Cancer|Non-small Cell Lung Cancer|Advanced MET Amplified Solid Tumor","Device: Mesenchymal-marker based ferrofluid (c-MET)|Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid","Feasibility|Difference in the median number of CTCs|Association of the number of detectable CTCs with baseline clinical and pathologic disease characteristics.|Kinetics of CTCs over time during treatment with c-MET targeted therapies","Duke University|Prostate Cancer Foundation|Janssen Diagnostics, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","62","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","Pro00052149","March 2014","May 19, 2016","July 19, 2016","March 6, 2014",,"August 1, 2017","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02080650"
1001,"NCT03631589","MSC for Severe aGVHD",,"Recruiting","No Results Available","Steroid-resistant Severe aGVHD","Biological: MSCs","complete and partial response rate|Adverse events that are related to treatment","Fujian Medical University","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-SCT-01","December 1, 2017","December 1, 2019","December 1, 2021","August 15, 2018",,"August 15, 2018","Fujian Medical University Union Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT03631589"
1002,"NCT04918706","Allogeneic MSC Treatment for Pulmonary Emphysema",,"Recruiting","No Results Available","Pulmonary Emphysema|Mesenchymal Stromal Cells","Genetic: Allogeneic MSC|Drug: Placebo","Difference in expression of CD31|The difference between MSC and placebo treatment in change in CO diffusion capacity|The differences in expression of Surfactant Protein-C expression by alveolar type II cells in lung tissue obtained from study patients treated with placebo or MSC.|The difference in immunostaining of various leukocytes in resected lung tissue, including T lymphocytes, B lymphocytes, macrophages and neutrophils obtained from study patients treated with placebo or MSC.|The difference in shear stress responses, expressed as % elongation of 100 cells, of isolated pMVECs ex vivo obtained from study patients treated with placebo or MSC.|The difference in endothelial microparticles concentration and concentration of immunological markers in blood samples from study patients treated with placebo or MSC.|The correlation between arterial pO2 or gas transfer value TLCO (measured as standard of care) and the outcome of the primary objective of the study for patients treated with MSC or placebo.","Leiden University Medical Center|Erasmus Medical Center|VU University Medical Center","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEP study","June 25, 2019","September 1, 2021","June 1, 2022","June 9, 2021",,"June 9, 2021","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT04918706"
1003,"NCT03529877","Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa",,"Active, not recruiting","No Results Available","Recessive Dystrophic Epidermolysis Bullosa","Biological: allo-APZ2-EB","Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing|Assessment of adverse event (AE) occurrence|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)|Inflammation (measured by panel of inflammation markers)|Pain assessment as per NRS|Itch assessment as per NRS|Differences in patient's quality of life in EB|Physical examination until Week 12;|Vital signs: Body temperature until Week 12;|Vital signs: Blood pressure until Week 12;|Vital signs: Heart rate until Week 12;|Overall survival at month 24","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Granzer Regulatory Consulting & Services|Ticeba GmbH","All","up to 55 Years   (Child, Adult)","Phase 1|Phase 2","16","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","allo-APZ2-EB-II-01","January 16, 2019","December 2021","December 2021","May 18, 2018",,"October 14, 2020","University of Minnesota, Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States|EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU), Salzburg, Austria|Hôpital Saint-Louis; Département de dermatologie, Paris, France|Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany|King's College London; St John's Institute of Dermatology;, London, United Kingdom|Great Ormond Street Hospital; Dermatology Department, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03529877"
1004,"NCT03860155","Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure",,"Terminated","No Results Available","Acute-On-Chronic Liver Failure","Biological: allo-APZ2-ACLF","Change of Model for End-Stage Liver Disease (MELD) score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.|Assessment of adverse event (AE) occurrence|Change of MELD score at Weeks 3, 4, 8, 12, 16 and 20|Change of Child-Pugh-Score at Weeks 3, 4, 8, 12, 16, 20 and 24|Change of CLIF-C ACLF score at Weeks 3, 4, 8, 12, 16, 20 and 24|Overall survival time until Week 24|Complications of ACLF (hepatorenal syndrome [HRS], variceal bleeding, ascites, hepatic encephalopathy [HE], spontaneous bacterial peritonitis [SBP])|Transient elastography assessment at Weeks 4, 12 and 24|Infections (proven infection necessitating systemic use of antibiotics)|Change of levels of C-reactive protein in serum at Weeks 3, 4, 8, 12, 16, 20 and 24|Liver Function Test (ALT, AST, AP, Albumin, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24|Changes in the profile of 80 different immunomodulatory cytokines at Weeks 3, 4, 8, 12, 16, 20 and 24|Changes in dialytic treatment until Week 24|Time to respiratory failure after first IMP administration until Week 24|Duration of the initial hospital stay|Duration of initial intensive care stay|Optional: Evaluation of liver biopsy (necrosis quantification)|Physical examination at Week 24|Vital signs at Week 24: Body temperature|Vital signs at Week 24: Blood pressure|Vital signs at Week 24: Heart rate|Vital signs at Week 24: Respiratory rate|Hematological laboratory parameters at Week 24|Clinical chemistry parameters at Week 24|Coagulation parameter ""factor V"" at Week 24|Coagulation parameter ""INR"" at Week 24|Overall survival at Week 24 and at Month 24","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","allo-APZ2-ACLF-II-01","March 22, 2019","March 26, 2021","March 26, 2021","March 1, 2019",,"November 17, 2021","Universitätsklinikum Carl-Gustav-Carus an der TU Dresden, Medizinische Klinik I, Dresden, Germany|Universitätsklinikum Essen, Klinik für Gastroenterologie und Hepatologie, Medizinisches Forschungszentrum, Essen, Germany|Universitätsklinikum Frankfurt, Medizinische Klinik 1, Sektion Translationale Hepatologie, Frankfurt, Germany|Universitätsklinikum Magdeburg A.ö.R., Medizinische Fakultät der Otto-von-Guericke-Universität, Magdeburg, Germany|Medizinische Fakultät Mannheim der Universität Heidelberg, II. Medizinische Klinik, Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT03860155"
1005,"NCT01663376","Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Major Adverse Events Analysis (MAEs)|Ankle-Brachial Index (ABI)|Digital subtraction angiography (DSA)|Thermography|Wong-Baker FACES Pain Rating Score|Treadmill test","R-Bio|Pusan National University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-CLI","January 2009","March 2010","April 2011","August 13, 2012",,"June 5, 2019","Pusan National University Hospital, Pusan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01663376"
1006,"NCT03158896","Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease",,"Recruiting","No Results Available","Acute Graft Versus Host Disease","Biological: MSCTC-0010 Dose Escalation","proportion of participants who have a TRSAE after infusion of MSCTC 0010|Proportion of participants who achieve a complete response (CR) of aGVHD by study day 42|Proportion of participants with improvement of GVHD in 1 or more organs involved with GVHD by day 42|Occurrence of addition of escalated immunosuppressive therapy by day 90|Occurrence of Formation of ectopic tissue foci at day 90","University of Kansas Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT-2016-aGvHD-MSCTC-0010","July 9, 2018","August 2022","August 2023","May 18, 2017",,"April 19, 2021","Kansas University Cancer Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03158896"
1007,"NCT04939337","A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.",,"Enrolling by invitation","No Results Available","Crohn's Disease","Drug: TH-SC01","Percentage of Participants who Achieve Combined Remission|Percentage of Participants who Achieve Clinical Remission|Percentage of Participants who Achieve Clinical Response|Percentage of Participants who decrease in PDAI|Percentage of Participants who decrease in IBDQ|Percentage of Participants who decrease in VAS scale|Percentage of Participants who decrease in Wexner incontinence score","Jinling Hospital, China|Jiangsu Topcel-KH Pharmaceutical Co., Ltd","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20181231","November 12, 2020","January 2024","August 2024","June 25, 2021",,"June 25, 2021","Jinling hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04939337"
1008,"NCT04928287","Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)","PD","Active, not recruiting","No Results Available","Parkinson Disease","Biological: HB-adMSCs|Other: Placebo","Changes in MDS-UPDRS Part II.|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities|AEs of special interest (serious or non-serious) - infections|AEs of special interest (serious or non-serious) - hypersensitivities.|Laboratory values. CBC|Laboratory values. CMP|Laboratory values. Coagulation Panel|Vital signs. - Respiratory Rate (breaths per minute)|Vital signs. - Heart Rate (beats per minute)|Vital signs. - Body Temperature (Fahrenheit )|Vital signs. - Blood Pressure (mmHg)|Weight in lb.|Physical examination results. General|Physical examination results. Body Systems.|Changes in MDS-UPDS total score.|Changes in MDS-UPDRS Part I.|Changes in MDS-UPDRS Part III.|Changes in MDS-UPDRS Part IV.|Changes in Neuro-QOL. - Communication|Changes in Neuro-QOL. - Social Roles and Activities|Changes in Neuro-QOL. - Anxiety|Changes in Neuro-QOL. - Depression|Changes in Neuro-QOL. - Dyscontrol|Changes in Neuro-QOL. - Fatigue|Changes in Neuro-QOL. - Mobility|Changes in Neuro-QOL. - Well-Being|Changes in Neuro-QOL. - Sleep|Changes in Neuro-QOL. - Fine Motor|Changes in Neuro-QOL. - Stigma|Changes in Neuro-QOL. - Social Roles|Changes in Neuro-QOL. - Cognition|Changes in Parkinson's disease fatigue scale (PFS-16).|Changes in Parkinson's disease Questionnaire (PDQ-39).|Changes in Visual Analog Scale for Pain.|Changes in Dosage of medications taken to treat Parkinson's disease.|Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).|Incidence and risk of AEs of special interest (serious or non-serious),|Clinically significant changes in laboratory values. - CBC|Changes in Visual Analog Scale for muscle spasms.|Clinically significant changes in vital signs. - Respiratory Rate|Clinically significant changes in vital signs. - Heart Rate|Clinically significant changes in vital signs. - Body Temperature.|Clinically significant changes in vital signs. - Blood Pressure.|Clinically significant changes in vital signs. - Oxygen Saturation.|Clinically significant changes in physical examination results.|Clinically significant changes in weight in lb.|Clinically significant changes in laboratory values. - CMP|Clinically significant changes in laboratory values. - Coagulation Panel","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBPD03","June 28, 2021","May 28, 2023","May 28, 2023","June 16, 2021",,"October 29, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04928287"
1009,"NCT03183804","A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-201 Clinical Trial",,"Unknown status","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Other: Standard therapy","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)",,"54","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALLO-ASC-DFU-202","April 24, 2016","August 17, 2018","August 31, 2018","June 12, 2017",,"June 12, 2017","Eulji General Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan medical center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03183804"
1010,"NCT02755376","Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell",,"Completed","No Results Available","Deficiency of Anterior Cruciate Ligament","Biological: Cartistem(TM)|Biological: hyaluronic acid|Procedure: ACL reconstruction only","Bone formation on interface between bone tunnel and graft|Arthroscopic grading of graft|Telos stress X-ray|KT-2000|clinical knee scoring|Instability assessing with physical examination|Tunnel enlargement after anterior cruciate ligament reconstruction","Samsung Medical Center","All","20 Years to 50 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SMC 2013-07-117-002","January 1, 2014","April 28, 2016","December 1, 2018","April 28, 2016",,"April 10, 2019","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02755376"
1011,"NCT00883727","Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI",,"Completed","No Results Available","Myocardial Infarction","Drug: Stem cell|Drug: Plasmalyte A","AE and ECG parameters|Regional myocardial perfusion and infarct size","Stempeutics Research Pvt Ltd","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SRPL/AMI/07-08/001","April 2009","May 2010","August 2012","April 20, 2009",,"March 5, 2013","Care Hospital, Hyderabad, Andhra Pradesh, India|SAL Hospital and Medical Institute, Ahmedabad, Gujarat, India|MS Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT00883727"
1012,"NCT02917681","Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis",,"Unknown status","No Results Available","AMYOTROPHIC LATERAL SCLEROSIS","Other: Two intrathecal MSC injections","Safety|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)|Change in Handheld dynamometry|Change in Electrical Impedance Myography|Change in Forced Vital Capacity (FVC)|Change in Isometric Strength|Changes in morphometric parameters of MRI of encephalon and spinal cord","University of Sao Paulo General Hospital|Pontifícia Universidade Católica do Paraná","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","401922/2014-6","September 2016","February 2019","August 2019","September 28, 2016",,"September 28, 2016","University of Sao Paulo School of Medicine Clinics Hospital, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02917681"
1013,"NCT03079401","Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle",,"Recruiting","No Results Available","Hypoplastic Left Heart Syndrome|Atrioventricular Canal","Biological: MPC; rexlemestrocel-L","Safety- Incidence of severe adverse events|Safety- Absence of PRA status change or local inflammation|Efficacy- rate of biventricular conversion|Efficacy- improvement of LV end diastolic pressure|Efficacy- improvement of LV mass/volume ratio","Boston Children's Hospital","All","up to 5 Years   (Child)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB-P00020575","November 27, 2017","January 2022","January 2024","March 14, 2017",,"October 5, 2021","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03079401"
1014,"NCT04390139","Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19","COVIDMES","Recruiting","No Results Available","COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome","Drug: XCEL-UMC-BETA|Other: Placebo","All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin","Banc de Sang i Teixits","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BST-COVID-01","May 13, 2020","October 2021","December 2021","May 15, 2020",,"April 8, 2021","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04390139"
1015,"NCT02145923","Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis",,"Unknown status","No Results Available","Neutropenic Enterocolitis|Myeloablative Chemotherapy Induced Bone Marrow Aplasia","Procedure: Peripheral blood stem cell mobilisation and collection|Drug: High-dose chemotherapy|Drug: Bone marrow derived allogeneic MMSCs infusion|Procedure: Autologous peripheral blood stem cells infusion","Number of serious adverse events (SAEs) and serious adverse reactions (SARs)|Time of hematopoietic recovery|Neutropenic enterocolitis|Infectious complications|Transfusion needs","Burnasyan Federal Medical Biophysical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RU-FMBC-05-01-14","May 2014","June 2016","December 2016","May 23, 2014",,"June 10, 2015","State Research Center Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02145923"
1016,"NCT03589287","Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Chondrochymal®","Number of participants with adverse events as measure of safety and tolerability|Efficacy - Radiographic evidence|Efficacy - WOMAC assessment|Efficacy - Visual Analogue Scale(VAS) assessment|Efficacy - Lequesne Index assessment|Efficacy - Keen Society Score(KSS) assessment|Efficacy - QOL assessment","Taipei Veterans General Hospital, Taiwan|Virginia Contract Research Organization Co., Ltd. Taiwan","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-11-006C","May 2, 2018","May 3, 2019","April 30, 2020","July 17, 2018",,"August 19, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03589287"
1017,"NCT01632475","Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia",,"Active, not recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: Pneumostem®","Number of subjects with Adverse Drug Reaction|Neurological development test outcome from the subjects who were treated with Pneumostem®, compared with the patients who suffered from the same conditions but not treated with Pneumostem®|Growth","Samsung Medical Center|Medipost Co Ltd.","All","4 Months to 2 Years   (Child)",,"9","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MP-CR-006-F/U","September 2011","September 2025","September 2026","July 3, 2012",,"April 9, 2019","Samsung Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01632475"
1018,"NCT04170426","Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis","Biological: autologous adipose derived stem cells","Adverse Events and Sever Adverse Events|Efficacy of Celltex AdMSCs","Celltex Therapeutics Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTX0019-001","December 2021","December 2022","December 2024","November 20, 2019",,"July 23, 2021",,,"https://ClinicalTrials.gov/show/NCT04170426"
1019,"NCT03633565","Comparative Study of Strategies for Management of Duchenne Myopathy (DM)",,"Unknown status","No Results Available","Myopathy","Drug: Sildenafil (Phosphodiesterase inhibitors)|Drug: Prednisolone (Steroids)|Procedure: Mesenchymal stem cell transplantation","6 Minute Walk Distance (6MWD)","Assiut University","Male","5 Years to 15 Years   (Child)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","smdmauch","September 2018","September 2021","November 2021","August 16, 2018",,"August 16, 2018",,,"https://ClinicalTrials.gov/show/NCT03633565"
1020,"NCT03818737","Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)","MILES","Active, not recruiting","No Results Available","Osteoarthritis","Biological: Autologous Bone Marrow Concentrate (BMAC)|Biological: Adipose-derived Stromal Vascular Fraction (SVF)|Biological: Umbilical Cord Tissue (UCT)|Drug: Depomedrol and Normal saline (Corticosteroid injection)","Change in Visual Analog Pain Scale (VAS-pain) scores|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)|Change in EuroQuality of Life (EQ5D-3L) scores|Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) scores","Emory University|The Marcus Foundation","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00108046","March 28, 2019","December 31, 2021","December 31, 2021","January 28, 2019",,"May 11, 2021","Andrews Institute, Gulf Breeze, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Duke University, Durham, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT03818737"
1021,"NCT04982224","Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer",,"Recruiting","No Results Available","Advanced NSCLC","Drug: REGN5093-M114","Dose limiting toxicities (DLTs)|Treatment-emergent adverse events (TEAEs)|Serious adverse events (SAEs)|Deaths|Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])|Concentrations of REGN5093-M114 in serum|Total monoclonal antibodies (REGN5093- M114 plus unconjugated antibody) in serum|Concentrations of M24 in plasma|Objective response rate (ORR)|ORR|TEAEs|SAEs|Laboratory abnormalities (grade 3 or higher per CTCAE)|Duration of response (DOR)|Disease control rate (DCR)|Time to tumor response (TTR)|Progression free survival (PFS)|Overall survival (OS)|Immunogenicity as measured by anti-drug antibody (ADA) to REGN5093-M114","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","83","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5093-M114-ONC-1864|2020-005065-14","October 18, 2021","September 20, 2026","September 20, 2026","July 29, 2021",,"October 13, 2021","Regeneron Research Facility, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04982224"
1022,"NCT04642911","Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy","AUB001","Active, not recruiting","No Results Available","Diabete Type 2|Mesenchymal Stem Cell","Other: Long term follow up","Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study","Ukraine Association of Biobank","All","Child, Adult, Older Adult",,"91","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UAB00171120-1","October 15, 2020","September 1, 2021","October 10, 2030","November 24, 2020",,"October 15, 2021","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,"https://ClinicalTrials.gov/show/NCT04642911"
1023,"NCT04623606","Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones","BOOST2B","Recruiting","No Results Available","Osteogenesis Imperfecta","Biological: BOOST cells","Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)|Number of fractures [ Time Frame: From baseline to 16 months follow-up ]|Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.|Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)|Growth (cm). [ Time Frame: From baseline to16 months follow up]|Weight (kg). [ Time Frame: From baseline to 16 months follow up]|Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]|Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)|Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (μg/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples.","Christian Medical College, Vellore, India|Ministry of Science and Technology, India|Vinnova|Karolinska Institutet","All","1 Year to 8 Years   (Child)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMCB2B0X","May 20, 2019","November 2021","December 2021","November 10, 2020",,"November 10, 2020","Christian Medical College, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT04623606"
1024,"NCT02672280","Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects","SEESCMMSCTSD","Unknown status","No Results Available","Wounds|Diabetic Foot Ulcers|Burns","Device: Medical Collagen Membrane with MSC|Device: Medical Collagen Membrane","Incidence of adverse events that are related to study treatment and associated with the grafting site|Percentage of wound closure as determined|Scar outcome assessment|Incidence of contracture release or revision surgeries|Incidence of increased temperature sensitivity|Incidence of paresthesias, pain, dulling of sensation assessed|Incidence and severity of infections at grafting sites|Incidence of all adverse events|Percentage area of re-grafting as determined","South China Research Center for Stem Cell and Regenerative Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-3","May 2016","December 2017","December 2017","February 3, 2016",,"February 3, 2016",,,"https://ClinicalTrials.gov/show/NCT02672280"
1025,"NCT02579148","Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes",,"Withdrawn","No Results Available","Erectile Dysfunction|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus","Biological: HUCMSC injection|Biological: collagen scaffolds/HUCMSC injection","Improvements in IIEF scores|Penile colour Doppler ultrasonography combined with prostaglandin-E1 injection|Safety and Tolerability assessed by Adverse Events","Leilei Zhu|Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","Male","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","DTH-922-DYT","September 2015","December 2016","April 2017","October 19, 2015",,"April 8, 2016","Drum Tower Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02579148"
1026,"NCT04294290","Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder","TACT","Recruiting","No Results Available","Autism Spectrum Disorder","Biological: hCT-MSC infusion","Safety of hCT-MSC infusion as measured by incidence of infusion reactions|Safety of hCT-MSC infusion as measured by severity of infusion reactions|Safety of hCT-MSC infusion as measured by incidence of product-related infections|Safety of hCT-MSC infusion as measured by severity of product-related infections|Safety of hCT-MSC infusion as measured by evidence of alloimmunization via anit-HLA antibodies|Safety of hCT-MSC infusion as measured by incidence of graft vs. host disease|Safety of hCT-MSC infusion as measured by severity of graft vs. host disease|Safety of hCT-MSC infusion as measured by incidence of unexpected adverse events|Safety of hCT-MSC infusion as measured by severity of unexpected adverse events|Change in PDD Behavior Inventory Autism Composite Score (PDDBI)|Change in mean of the Socialization Subscale and Communication Subscale standard scores on the Vineland Adaptive Behavior Scales (VABS-3)|Change in Clinical Global Impression Scale (CGI)|Change in Communicative Development Inventories (CDI-2)|Change in attention abilities as assess via eye-tracking|Change in brain activity as measured by EEG","Duke University|The Marcus Foundation","All","18 Months to 48 Months   (Child)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00104460","February 24, 2021","December 1, 2022","December 1, 2022","March 4, 2020",,"March 19, 2021","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04294290"
1027,"NCT04371393","MSCs in COVID-19 ARDS",,"Active, not recruiting","No Results Available","Mesenchymal Stromal Cells|Remestemcel-L|Acute Respiratory Distress Syndrome|COVID","Biological: Remestemcel-L|Drug: Placebo","Number of all-cause mortality|Number of days alive off mechanical ventilatory support|Number of adverse events|Number of participants alive at day 7|Number of participants alive at day 14|Number of participants alive at day 60|Number of participants alive at day 90|Number of participants alive at 12 Months|Number of participants with resolution and/or improvement of ARDS|Severity of ARDS|Length of stay|Readmissions|Length of Stay in Intensive Care Unit|Clinical Improvement Scale|Change in plasma hs-CRP concentration|Change in serum hs-CRP concentration|Change in IL-6 inflammatory marker level|Change in IL-8 inflammatory marker level|Change in TNF-alpha inflammatory marker level|Pulmonary symptoms","Icahn School of Medicine at Mount Sinai|Mesoblast, Inc.|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","223","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 08-1078-0014","April 30, 2020","January 14, 2021","February 2022","May 1, 2020",,"April 5, 2021","Dignity Health, Gilbert, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Emory University, Atlanta, Georgia, United States|Lutheran Hospital, Fort Wayne, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|New York University Langone Health, New York, New York, United States|Mount Sinai Health, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor, Smith & White, Plano, Texas, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04371393"
1028,"NCT03056742","A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease",,"Withdrawn","No Results Available","Critical Limb Ischemia Due to Buerger's Disease","Biological: Stempeucel(R)","Relief of the rest pain|Reduction of ulcer area in the target limb|Total walking distance|Major amputation free survival|Ankle brachial pressure index (ABPI) - measured by Doppler|Quality of life (QOL) by King's College VascuQOL questionnaire|Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)","Stempeutics Research Pvt Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRPL/CLI/10-11/001 Version 4","February 20, 2017","April 2018","October 2019","February 17, 2017",,"April 7, 2017","Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, Delhi, India|Department of Vascular and Endovascular Surgery, M. S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India|Department of Vascular Surgery, Madras Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, Sri Ramchandra Medical College, Chennai, Tamil Nadu, India|Saveetha Medical College & Hospital, Chennai, Tamil Nadu, India|SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India|Health Point Hospital, Kolkata, West Bengal, India|Nightingale Hospital, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03056742"
1029,"NCT04995081","Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate) (PD)","HBPD04","Recruiting","No Results Available","Parkinson Disease","Biological: Biological/Vaccine: Allogeneic HB-adMSCs|Other: Placebo","1. Changes in the total score MDS-UPDRS Part II.|2. Incidence of treatment-emergent Adverse Event (TEAEs).|3. Incidence of treatment-emergent Serious Adverse Events (SAEs).|4. AEs of special interest (serious or non-serious) - thromboembolic events.|5. AEs of special interest (serious or non-serious) - thromboembolism of the extremities|6. AEs of special interest (serious or non-serious) - infections|7. AEs of special interest (serious or non-serious) - hypersensitivities.|8. Laboratory value Complete Blood Count (CBC)|9. Laboratory values Chemistry Metabolic Panel (CMP)|10. Laboratory values Coagulation Panel; Prothrombin time, Partial Prothrombin time, and INtern|11. Vital signs. - Respiratory Rate (breaths per minute)|12. Vital signs. - Heart Rate (beats per minute)|13. Vital signs. - Body Temperature (Fahrenheit )|14. Vital signs. - Blood Pressure (mmHg)|15. Weight in lb.|16. Physical examination results. General|17. Physical examination results. Body Systems.|18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.|19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.|20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.|21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.|22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).|23. Changes in Parkinson's disease fatigue scale (PFS-16)|24. Changes in Parkinson's disease Questionnaire (PDQ-39).|25. Changes in Visual Analog Scale for Pain.|26. Changes in Visual Analog Scale for Muscle spasms.|27. Changes in Dosage of medications taken to treat Parkinson's disease.","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","45 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBPD04","July 16, 2021","July 20, 2023","July 20, 2023","August 6, 2021",,"August 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04995081"
1030,"NCT02579369","Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa",,"Unknown status","No Results Available","Dystrophic Epidermolysis Bullosa","Other: Allogeneic mesenchymal stem cells|Device: Polyurethene Film","Area of re-epithelization|Percentage of a target wound's re-epithelialization|Time taken to re-epithelization|Safety assessed by clinically measured abnormality of laboratory tests and adverse events","Anterogen Co., Ltd.","All","10 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALLO-ASC-EB-101","October 2015","June 2017","December 2017","October 19, 2015",,"January 4, 2017","Gangnam Severence Hospital, Gangnam Gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02579369"
1031,"NCT04210440","The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression","NEC15","Completed","No Results Available","Hip Necrosis|Hip Injuries","Procedure: Core decompression procedure","Avoiding arthroplasty|Harris Hip Score","Dante Dallari, MD|Istituto Ortopedico Rizzoli","All","18 Years to 50 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0029170","March 1, 2003","March 1, 2011","March 1, 2012","December 24, 2019",,"December 24, 2019","Istituto Ortopedico Rizzli, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT04210440"
1032,"NCT03298763","Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer","TACTICAL","Recruiting","No Results Available","Adenocarcinoma of Lung","Genetic: MSCTRAIL|Drug: Placebo","Determination of recommended Phase II dose (RP2D) of MSCTRAIL in combination of cisplatin and pemetrexed treatment (Phase 1)|Tumour response rate (Phase 2)|Frequency of adverse events (Phase 1 & 2)|Best Overall response (Phase 1&2)|Progression free survival (Phase 1 & 2)|Overall survival (Phase 2)","University College, London","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UCL/14/0453","March 5, 2019","September 1, 2023","September 1, 2025","October 2, 2017",,"April 28, 2021","University College London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03298763"
1033,"NCT03706482","Boost Brittle Bones Before Birth","BOOSTB4","Recruiting","No Results Available","Osteogenesis Imperfecta","Biological: BOOST cells","Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events.|Number of fractures.|Time (days) to first fracture after each stem cell administration.|Numbers of fractures at birth.|Change in bone-marrow density (g/cm2).|Growth (cm).|Growth (kg).|Change in clinical status of OI.|Assessment of biochemical bone turnover by analysis of the markers P-Calcium, P-Phosphate, P-Albumin, S-ALP, fP-PTH, S-25-OH Vitamin D, Bone specific S-ALP, S-CTx, S-Osteocalcin and U-DPD/Krea and U-NTx/Krea in blood and urine samples.","Karolinska Institutet|Karolinska University Hospital|Great Ormond Street Hospital for Children NHS Foundation Trust|University College, London|Universitätsklinikum Köln|UMC Utrecht|Leiden University Medical Center|Lund University","All","up to 18 Months   (Child)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KIBB01","August 12, 2019","August 12, 2023","August 12, 2033","October 16, 2018",,"October 14, 2021","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03706482"
1034,"NCT04219241","Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.","ADORE-EXT","Active, not recruiting","No Results Available","Huntington Disease","Biological: Cellavita-HD","Maintenance of effectiveness on clinical progression of the disease|Clinical neurological worsening over the treatment by UHDRS|BMI assessment|Risk of suicidal ideation and/or behavior by C-SSRS|Risk of suicidal ideation and/or behavior by HDS|CNS assessment by MRI (Magnetic Ressonance Imaging)","Azidus Brasil|Cellavita Pesquisa Científica Ltda","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","35","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADORE-EXT|23917319.0.0000.5412","February 10, 2020","January 2022","April 2022","January 7, 2020",,"June 23, 2021","Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04219241"
1035,"NCT01548092","Stromal Vascular Fraction (SVF) for Treatment of Recto-vaginal Fistula","HULPCIR","Unknown status","No Results Available","Recto-vaginal Fistula","Drug: Adipose-derived stem cells without expanded","Safety of treatment of treated recto-vaginal fistulae. Percentage of treated enterocutaneous fistulae and percentage of subjects with closed fistulae|Quality of life assessment using the SF-12 Questionnaire|Adverse events","Instituto de Investigación Hospital Universitario La Paz","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC10-343|2010-024330-35","December 2011","July 2012","December 2013","March 8, 2012",,"March 8, 2012","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01548092"
1036,"NCT02696876","Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair","AURA","Recruiting","No Results Available","Defect of Articular Cartilage|Cartilage Injury|Osteoarthritis, Knee","Device: Arthroscopic synovial brushing|Procedure: Microfracture","The mean change in the number of MSCs present in the knee pre- and post- microfracture/microfracture plus arthroscopic synovial brushing.|Number of patients whose clinical effusion scores improve at 3, 6 and 12 months|Number of patients whose semi-quantitative MRI cartilage scores improve at 6 and 12 months|Median KOOS scores at 3, 6 and 12 months (pain; other symptoms; function in daily living; function in sport; knee-related QoL; average score)|Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Visual Analogue Scale (VAS)","University of Leeds|The Leeds Teaching Hospitals NHS Trust","All","16 Years to 55 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RR15/173","January 2017","December 2021","December 2021","March 2, 2016",,"April 28, 2021","Chapel Allerton Orthopaedic Centre, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02696876"
1037,"NCT02083731","MSC for Treatment of CMV Infection",,"Unknown status","No Results Available","Stem Cell Transplantation, Hematopoietic|CMV Infection|Hematological Diseases","Biological: MSCs","Percentage of Participants achieved complete remission of CMV infection|Number of Participants with Serious and Non-Serious Adverse Events","Nanfang Hospital of Southern Medical University|Academy Military Medical Science, China|Peking University People's Hospital|Sun Yat-sen University|Guangdong Provincial People's Hospital|Guangzhou General Hospital of Guangzhou Military Command|Third Affiliated Hospital, Sun Yat-Sen University|Shanghai Zhongshan Hospital","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-MSC-CMV-2014","January 2014","January 2016","January 2017","March 11, 2014",,"January 7, 2015","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02083731"
1038,"NCT02352077","NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair",,"Enrolling by invitation","No Results Available","Spinal Cord Injury","Biological: NeuroRegen scaffold with BMMCs or MSCs transplantation","Safety Evaluation Number of patients with adverse events|Improvements in Neurophysiological Measures omatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP) monitoring will be assessed|Improvements in ASIA Impairment Scale|Improvements in Independence Measures and Quality of Life|Improvements in Pain assessed based on Visual analog scale (VAS)|Improvements in Urinary and Bowel Function assessed based on bladder pressure monitory before and after transplantation|Changes at the Transplantation Site in Spinal Cord by Magnetic Resonance Imaging (MRI)","Chinese Academy of Sciences|Affiliated Hospital of Logistics University of CAPF|The First Affiliated Hospital of Soochow University|First Hospitals affiliated to the China PLA General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAS-XDA-SCI/IGDB","January 2015","December 2021","December 2021","February 2, 2015",,"December 23, 2020","First Hospitals affiliated to the China PLA General Hospital, Beijing, China|The First Affiliated Hospital of Soochow University, Suzhou, China|Affiliated Hospital of Logistics Universtiy of CAPF, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02352077"
1039,"NCT00284986","Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients",,"Completed","No Results Available","Graft Versus Host Disease","Drug: Prochymal (TM)","Response by Day 28|Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at day 1|Best stage of each involved organ by Day 28|Time to improvement or resolution of GVHD in one or more organs|Adverse events|Infusional toxicity|Overall relapse of underlying disease|Overall survival|Formation of ectopic tissue foci|Incidence of infection","Mesoblast, Inc.|Mesoblast, Ltd.","All","6 Months to 70 Years   (Child, Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Osiris 270-271","November 18, 2005","April 25, 2006","February 8, 2007","February 1, 2006",,"March 10, 2020","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00284986"
1040,"NCT01795950","Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: PLX-PAD","Incidence of treatment-emergent AEs (frequency and severity at each dose level)|Incidence of SAEs|Change in Six Minute Walk distance|Change in Dyspnea Score|Change in WHO Functional Classification|Change in Plasma NT-pro-BNP levels|Change from Baseline in echocardiography parameters|Change in cardiopulmonary hemodynamics","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLX-PH-101","April 2013","December 2015","January 2016","February 21, 2013",,"February 17, 2016","The Prince Charles Hospital, Brisbane, Queensland, Australia|The Alfred Hospital, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01795950"
1041,"NCT02809781","A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis",,"Unknown status","No Results Available","Spondylitis|Spondylitis, Ankylosing|Ankylosis|Arthritis|Spondylarthritis|Spondylarthropathies|Spinal Diseases|Musculoskeletal Diseases|Bone Diseases","Biological: Intravenous infusion of MSCs|Drug: Etanercept","The Assessment of Spondyloarthritis International Society (ASAS)20 response|BASDAI score comparing to baseline|BASFI score comparing to baseline|Imageology|C-reactive protein (CRP)|Erythrocyte sedimentation rate (ESR)|Tumor necrosis factor alpha (TNF-α)|Interleukin 6 (IL-6)|Interleukin 17 (IL-17)","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Nanfang Hospital of Southern Medical University|Second Affiliated Hospital of Guangzhou Medical University","All","18 Years to 45 Years   (Adult)","Phase 2|Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SYSU-81332612","June 2016","August 2018","December 2018","June 22, 2016",,"June 24, 2016","Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02809781"
1042,"NCT01824121","Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism",,"Unknown status","No Results Available","Progressive Supranuclear Palsy","Biological: stem cell therapy","incidence of adverse events|changes in brain images","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","032011|2011-004051-39","December 2012","December 2014","December 2014","April 4, 2013",,"April 4, 2013","ICP Parkinson Institute, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01824121"
1043,"NCT01719640","MSC and BMMNC in Type 2 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: infusion of BMMSCs|Drug: infusion BMMNCs|Drug: insulin","HbA1c|exogenous insulin requirements|fasting hemoglucose|fasting c-peptide|The incidence and severity of adverse events related to the stem cell infusion procedure","Fuzhou General Hospital","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-BMMNC-DM","January 2011","January 2014","January 2015","November 1, 2012",,"April 25, 2018","Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT01719640"
1044,"NCT01662973","Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis",,"Unknown status","No Results Available","Primary Biliary Cirrhosis","Other: conventional plus UC-MSC treatment|Other: Conventional plus placebo treatment","Serum alkaline phosphatase (ALP)|Histological changes in liver biopsies|Serum Bilirubin|Serum AST|Mayo risk score|Number of patients with Portal Hypertension after 12 weeks treatment|MELD score|Number of participants with improvement of clinical symptoms","Beijing 302 Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Beijing302-005","October 2011","October 2013","October 2013","August 13, 2012",,"May 31, 2013","Beijing 302 Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01662973"
1045,"NCT01220492","Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis",,"Completed","No Results Available","Liver Cirrhosis","Drug: conventional plus MSC treatment|Drug: conventional plus placebo treatment","survival time|incidence of HCC events|The levels of serum albumin|The levels of serum total bilirubin|The levels of serum prothrombin activity|the levels of serum cholinesterase|complications","Beijing 302 Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","266","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","beijing302-002","May 2009","April 2016","April 2016","October 14, 2010",,"August 8, 2018","Beijing 302 Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01220492"
1046,"NCT04675970","Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy","UB-OVF","Active, not recruiting","No Results Available","Primary Ovarian Insufficiency|Premature Ovarian Failure","Other: Observational","Antral follicular count (AFC) serum levels|anti-Müllerian hormone (AMH) serum levels|Regular menstruation and/or pregnancy","Ukraine Association of Biobank","Female","18 Years to 40 Years   (Adult)",,"86","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UAB1220-2","September 1, 2020","September 15, 2022","September 15, 2022","December 19, 2020",,"October 15, 2021","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,"https://ClinicalTrials.gov/show/NCT04675970"
1047,"NCT02728115","Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease","SAVE-DH","Active, not recruiting","No Results Available","Huntington Disease","Biological: Cellavita HD Lower Dose|Biological: Cellavita HD Higher dose","Safety of Cellavita HD by periodic monitoring changes at adverse events, vital signs, laboratory tests, ECG and incidence of benign and malignant neoplasms|Preliminary efficacy of Cellavita HD by UHDRS improvement and global clinical response (CIBIS)|Preliminary efficacy of Cellavita HD by comparison of the inflammatory markers|Immunological Response of Cellavita HD|Preliminary efficacy of Cellavita HD by comparison of the CNS assessment|Risk of suicidal ideation by Hamilton Depression Rating Scale (HDRS)","Azidus Brasil|Cellavita Pesquisa Científica Ltda|Azidus Brasil Scientific Research and Development Ltda","Male","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","SAVE-DH|51005115.9.0000.5412","October 16, 2017","October 2022","December 2023","April 5, 2016",,"June 23, 2021","Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02728115"
1048,"NCT01754454","Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease",,"Unknown status","No Results Available","Acute GVH Disease","Biological: Human Umbilical Cord Derived MSC","Safety of UC-MSC in patients with acute graft-versus-host disease|Efficacy of UC-MSC in patients with acute graft-versus-host disease","Affiliated Hospital to Academy of Military Medical Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307-CTC-MSC-002","December 2012","December 2016","December 2016","December 21, 2012",,"April 8, 2016","Department of Hematopoietic Stem Cell Transplantation, Beijing, China|Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01754454"
1049,"NCT04551443","WJMSCs Anti-inflammatory Therapy in Acute Myocardial Infarction","WAIAMI","Not yet recruiting","No Results Available","Acute Myocardial Infarction","Biological: Intravenous infusion placebo|Biological: Intravenous infusion WJMSCs","Any composite of major adverse cardiovascular events|Checking patient LVEF|Checking patient infarct size|checking patient perfusion defect.|Coronary disease|Coronary congestive heart failure|Coronary changes in hsCRP","Navy General Hospital, Beijing|Peking University Third Hospital|Peking Union Medical College Hospital|Xijing Hospital|Chinese PLA General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PLAG6C","November 1, 2020","December 30, 2021","December 30, 2022","September 16, 2020",,"September 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04551443"
1050,"NCT01602328","A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects","ACT-AKI","Terminated","No Results Available","Acute Kidney Injury","Biological: AC607|Biological: Vehicle Only","Time to Kidney Recovery defined as a post-operative serum creatinine return to pre-operative baseline values.|All-Cause Mortality or Dialysis (composite endpoint).","AlloCure Inc.","All","21 Years and older   (Adult, Older Adult)","Phase 2","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AC 6071103","June 2012","June 2014","August 2014","May 21, 2012",,"August 6, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, San Diego, San Diego, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|Maine Medical Center, Portland, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|UTHealth, The University of Texas Health Science Center at Houston, Houston, Texas, United States|Fletcher Allen Health Care - Renal Services, Burlington, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|CAMC Clinical Trials Center, Charleston, West Virginia, United States|Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|University of Manitoba - St. Boniface Hospital, Winnipeg, Manitoba, Canada|CDHA Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|McMaster - Hamilton General Hospital / TAARI, Hamilton, Ontario, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01602328"
1051,"NCT04536233","Effects of MSCs Derived Pleiotropic Factors on Wound Healing in Endonasal Surgeries",,"Not yet recruiting","No Results Available","MSCs Derived Pleiotropic Factors on Wound Healing in Endonasal Surgeries","Biological: MSCs Derived Pleiotropic Factors|Other: physiological saline","Wound healing evaluation","Chinese PLA General Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CHIN-PLAGH-MP-05","October 10, 2020","January 31, 2021","March 30, 2021","September 2, 2020",,"September 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04536233"
1052,"NCT04493242","Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS","EXIT-COVID19","Completed","No Results Available","Covid19|ARDS|Pneumonia, Viral","Biological: DB-001|Other: Intravenous normal saline","7 Day Improvement in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio|Time to Recovery|Incidence of Serious Adverse Events (SAE)|All-cause Mortality","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-001","September 24, 2020","May 1, 2021","May 22, 2021","July 30, 2020",,"July 14, 2021","Helen Keller Hospital, Sheffield, Alabama, United States|St. Joseph Hospital Heritage, Fullerton, California, United States|Donald Guthrie Foundation/ Robert Packer Hospital, Sayre, Pennsylvania, United States|Covenant Health, Lubbock, Texas, United States|PRX Research, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04493242"
1053,"NCT03828344","Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis","Biological: hUC-MSC suspension|Biological: Placebo","Frequency of Adverse Events (AE) and Serious Adverse Events (SAE)|Percentage of participants achieving ACR20 from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR50 response from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR70 response from Baseline at Week 12 and Week 24|Change from Baseline in the disease activity score 28-joint count using C reactive protein (DAS28-CRP) at Week 12 and Week 24|Change from Baseline in the health assessment questionnaire disability index (HAQ-DI) score at Week 12 and Week 24|Percentage of participants achieving remission by Simplified Disease Activity Index (SDAI) based criteria at Week 12 and Week 24|Change from Baseline of rheumatoid factor at Week 12 and Week 24|Change from Baseline of anti-cyclic citrullinated peptide (anti-CCP) at Week 12 and Week 24","Baylx Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BXU001-RA","December 2020","November 2022","December 2022","February 4, 2019",,"June 30, 2020",,,"https://ClinicalTrials.gov/show/NCT03828344"
1054,"NCT03473301","A Study of UCB and MSCs in Children With CP: ACCeNT-CP","ACCeNT-CP","Completed","Has Results","Cerebral Palsy","Biological: Infusion of allogeneic umbilical cord blood|Biological: Infusion of MSCs","Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change|Number of Adverse Events","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","24 Months to 60 Months   (Child)","Phase 1|Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00089362","April 10, 2018","February 26, 2020","May 31, 2021","March 22, 2018","February 17, 2021","August 19, 2021","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03473301/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03473301"
1055,"NCT04903327","Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress",,"Not yet recruiting","No Results Available","Covid19","Biological: COVI-MSC|Drug: Placebo","All-cause mortality rate at Day 28|All-cause mortality rate at Day 60 and Day 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-COV-201BR","July 2021","December 2021","February 2022","May 26, 2021",,"June 3, 2021",,,"https://ClinicalTrials.gov/show/NCT04903327"
1056,"NCT03887208","Therapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells","2ABC","Completed","No Results Available","Skin|Scar|Cutis Laxa|Keloid|Cicatrix","Procedure: Laser therapy|Biological: Autologous ADSC injection|Procedure: Normal saline injection","Change in patient's skin condition|Evaluation of skin problems. Assessment of skin related complaints since the last visit.|The assessment of the scar by the patient.|Changes in volume of the skin (USG)|Changes in skin surface morphology (digital imagining)|Record of adverse events","Medical University of Warsaw|Timeless Chirurgia Plastyczna-Janusz Jaworowski|Melitus sp. z o.o.|Polish Stem Cells Bank S.A.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2ABC Therapy|2016-004110-10|267976/13/NCBR/2015|PL008125|Z4217","January 31, 2018","January 31, 2019","January 31, 2019","March 22, 2019",,"January 28, 2020","Laboratory for Cell Research and Application, Medical University of Warsaw, Warsaw, Poland|Melitus sp. z o.o., Warsaw, Poland|Timeless Chirurgia Plastyczna Sp. z o. o., Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03887208"
1057,"NCT04482413","Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Drug: AstroStem and Donepezil Placebo|Drug: Donepezil and AstroStem Placebo","ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|MMSE (Mini-mental status examination)|C-SSRS (Columbia Suicide Severity Rating Scale)|NPI (Neuropsychiatric Inventory)|ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change)|Treatment related Adverse Events","Nature Cell Co. Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AST-ADP2-US02","December 1, 2021","December 1, 2022","December 20, 2023","July 22, 2020",,"March 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04482413"
1058,"NCT02378974","Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of Cordstem-ST in Patients With Cerebral Infarction",,"Completed","No Results Available","Cerebral Infarction","Biological: Cordstem-ST|Biological: Placebo","Number of treatment related-adverse events during the study period|Improvement in clinical function as assessed by Modified Rankin Score(mRS) compared to baseline at 6 months|Improvement in clinical function as assessed by National Institute of Health Stroke Scale (NIHSS) compared to baseline at 6 months|Improvement in clinical function as assessed by Barthel Index (BI) compared to baseline at 6 months|Improvement in clinical function as assessed by Brain MRI tratogram compared to baseline at 6 months","CHABiotech CO., Ltd","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CHA-CST-101","February 24, 2015","April 13, 2017","April 13, 2017","March 4, 2015",,"November 15, 2019","CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02378974"
1059,"NCT04452097","Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS",,"Not yet recruiting","No Results Available","COVID-19|ARDS|Acute Respiratory Distress Syndrome","Biological: Human umbilical cord mesenchymal stem cells + best supportive care|Other: Placebo control + best supportive care","Incidence of infusion-related adverse events|Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)|Selection of an appropriate dose of BX-U001 for the following Phase 2 study|All-cause mortality|Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.|Duration of ICU stay|Duration of hospital stay|Changes in blood cytokine levels","Baylx Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BXU001-COVID19","July 1, 2021","March 31, 2022","March 31, 2022","June 30, 2020",,"March 18, 2021",,,"https://ClinicalTrials.gov/show/NCT04452097"
1060,"NCT03117738","A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Drug: AstroStem|Other: Placebo-Control","Treatment Related Adverse Events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)|MMSE (Mini-mental Status Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale)","Nature Cell Co. Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AST-ADP2-US01","May 9, 2017","June 26, 2019","August 31, 2019","April 18, 2017","July 9, 2021","August 10, 2021","ATP Clinical Research, Costa Mesa, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Valden Medical, Honolulu, Hawaii, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03117738"
1061,"NCT01873547","Different Efficacy Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With SCI in China","SCI-III","Completed","No Results Available","Spinal Cord Injury","Biological: cell therapy|Other: rehabilitation","Assessment of changes in International Standards for Neurological Classification of Spinal Cord Injury according to American Spine Injury Association|Assessment of changes in score of pain index using Short-form McGill Pain Questionnaire|Assessment of changes in score of activity of daily living|Assessment of changes in sensory evoked potentials and motor evoked potentials","General Hospital of Chinese Armed Police Forces","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2013-03-04SCI-III","June 2012","October 2014","December 2015","June 10, 2013",,"May 25, 2018","General Hospital of Chinese People's Armed Police Forces, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01873547"
1062,"NCT02674399","A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis",,"Completed","Has Results","Osteoarthritis, Knee","Drug: JointStem|Drug: Synvisc-One","Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group|Change From Baseline on Visual Analog Scale (VAS) in JointStem Group|MRI Improvement Evaluation in JointStem Group|Change From Baseline on WOMAC Between JointStem and Positive Control Groups|Change From Baseline on VAS Between JointStem and Positive Control Groups|Change From Baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups|Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups|Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups|Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups|Change From Baseline on WOMAC in JointStem Group|Change From Baseline on VAS in JointStem Group|Comparison of MRI Improvement Evaluation in JointStem Group|Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12|Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group","Nature Cell Co. Ltd.|KCRN Research, LLC","All","22 Years to 60 Years   (Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JS-OAP2-US01","February 16, 2016","March 12, 2018","December 28, 2018","February 4, 2016","July 13, 2021","August 10, 2021","Orthopedic Pain Specialists, Santa Monica, California, United States|Walnut Creek, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02674399"
1063,"NCT02382874","Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)",,"Unknown status","No Results Available","Focal Segmental Glomerulosclerosis","Biological: Intravenous injection","Liver function|Serum creatinine|Proteinuria|Renal function|Increase in anti inflammatory factors|Increase in Treg","Royan Institute","All","2 Years to 14 Years   (Child)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Kidney-005","May 2015","June 2017","October 2017","March 9, 2015",,"December 4, 2015","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02382874"
1064,"NCT04297813","Efficacy in Alveolar Bone Regeneration With Autologous MSCs and Biomaterial in Comparison to Autologous Bone Grafting","Maxibone","Recruiting","No Results Available","Alveolar Bone Atrophy","Combination Product: Advanced medicinal Therapy (MSC combined with biomaterial)|Procedure: Autologous bone graft","Change in bone width|Pain postoperatively in the two different treatments|Radiological examination of bone volume","University of Bergen|Université de Nantes|University of Ulm|Universidad Complutense de Madrid|University of Aarhus|Universitat Internacional de Catalunya|Assistance Publique - Hôpitaux de Paris|European Commission","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-001227-39","March 2020","August 2022","September 2024","March 6, 2020",,"March 12, 2020","Syddansk Universitet SDU (University Hospital of Southern Denmark), Odense, Denmark|Assistance Publique - Hôpitaux De Paris, Créteil, France|CHU Nantes, Centre de Soins Dentaires, Nantes, France|University of Bergen, Institute of Clonical Dentistry, Bergen, Hordaland, Norway|Universidad Complutense De Madrid, Madrid, Calle Fernando De Castro Rodriguez,, Spain|Universitat Internacional De Catalunya, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04297813"
1065,"NCT04461925","Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs",,"Recruiting","No Results Available","COVID-19 Pneumonia","Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Drug: Antibiotics|Drug: Hormones|Drug: Anticoagulant Therapy|Device: Оxygen therapy","Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio.|Changes in length of hospital stay|Changes in mortality rate|Changes of С-reactive protein (CRP, mg/L)|Evaluation of Pneumonia Improvement|Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)|Peripheral blood count recovery time","Institute of Cell Therapy|Kyiv City Clinical Hospital # 4","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#4/24.04.2020","May 2, 2020","May 2, 2021","December 2021","July 8, 2020",,"July 8, 2020","Institute of Cell Therapy, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04461925"
1066,"NCT03424629","Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis",,"Unknown status","No Results Available","Moderate and Severe Plaque Psoriasis","Biological: Low-dose UC-MSCs|Biological: High-dose UC-MSCs|Drug: Methotrexate","Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 20|Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment（PGA0/1) at week 20|Proportion of subjects who have 90% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI90) at week 20|Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 12,16,36,52|Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment（PGA0/1) at week 12,16,36,52|Frequency of Adverse Events and Serious Adverse Events|Proportion of subjects who experience psoriasis relapse","Tianjin Ever Union Biotechnology Co., Ltd.","All","18 Years to 60 Years   (Adult)","Phase 1","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TianjinEverUnion","June 1, 2018","September 30, 2018","December 31, 2019","February 7, 2018",,"April 20, 2018","Peking University Third Hospital, Beijing, China|Tianjin Ever Union Biotechnology Co., Ltd., Beijing, China",,"https://ClinicalTrials.gov/show/NCT03424629"
1067,"NCT04494386","Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS","ULSC","Recruiting","No Results Available","Covid19|Corona Virus Infection|SARS-CoV Infection|ARDS|Coronavirus","Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control)","Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg/dL) from baseline|Changes in levels of sodium (mEq/L) from baseline|Changes in levels of potassium (mEq/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline|Changes in levels of alanine transaminase (ALT; U/L) from baseline|Change in Urinalysis (UA) from baseline","Restem, LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ULSC-CV-01","July 23, 2020","October 30, 2021","December 30, 2021","July 31, 2020",,"March 9, 2021","Miami Baptist Hospital, Miami, Florida, United States|Sanford Research, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT04494386"
1068,"NCT01393977","Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China",,"Unknown status","No Results Available","Spinal Cord Injuries","Procedure: rehabilitation of limb function|Procedure: Stem Cells Transplantation","Electromyogram and Electroneurophysiologic test","General Hospital of Chinese Armed Police Forces","All","20 Years to 50 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-01-19SCI","January 2011","December 2011","May 2012","July 14, 2011",,"October 10, 2011","Yihua An, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01393977"
1069,"NCT02648386","Stem Cell Therapy Combined With NeuroRegen Scaffold™ in Patients With Erectile Dysfunction After Rectal Cancer Surgery",,"Unknown status","No Results Available","Rectal Cancer|Erectile Dysfunction","Procedure: Laparoscopic surgery|Device: NeuroRegen scaffold transplantation|Biological: NeuroRegen scaffold/BMMCs transplantation|Biological: NeuroRegen scaffold/HUC-MSCs transplantation","Safety and Tolerability assessed by Adverse Events|IIEF-5 (International Index of Erectile Function)|Mean scores of the Sexual Encounter Profile (SEP) Question 2, 3|Penile cavernosal artery peak systolic velocity (PSV)|Nocturnal penile tumescence (NPT)|The change of results of Nerve electrophysiological examination|Maximum Flow Rate (Qmax)","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","Male","20 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-ED-IGDB","January 2016","December 2020","December 2020","January 7, 2016",,"January 25, 2019","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02648386"
1070,"NCT01661842","Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis",,"Unknown status","No Results Available","Autoimmune Hepatitis","Other: conventional plus UC-MSC treatment|Other: Conventional plus placebo treatment","Liver Histology change|Serum alanine aminotransferase (ALT)|Serum AST|Serum Tbil|Serum immunoglobulin G (IgG)|Serum γ-globulin|MELD score|Number of participants with treatment side effects|Number of participants with improvement of clinical symptoms","Beijing 302 Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Beijing302-006","October 2011","October 2014","October 2014","August 10, 2012",,"May 31, 2013","Beijing 302 Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01661842"
1071,"NCT03865394","Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells","1ABC","Completed","No Results Available","Diabetic Foot Ulcer","Biological: Application of allogeneic ADSC stem cells in fibrin gel|Procedure: Standard care in diabetic foot ulcer","Changes in wound size|Changes in wound morphology|Changes in pro-angiogenic factors expression|Changes in wound-associated pain|Changes in the quality of life|Record of adverse events","Medical University of Warsaw|Polish Stem Cells Bank S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1ABC Therapy|267976/13/NCBR/2015|2016-004109-15|PL008125|Z4217","July 1, 2019","March 31, 2021","September 30, 2021","March 6, 2019",,"October 14, 2021","Medical University of Warsaw, Department of Diabetology and Internal Diseases, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03865394"
1072,"NCT04484077","hCT-MSC Infusion in Adults With Autism Spectrum Disorder","AIMs","Not yet recruiting","No Results Available","Autism Spectrum Disorder|Autism","Biological: hCT-MSC","Incidence of infusion reactions|Incidence of product-related infections|Evidence of formation of anti-HLA antibodies|Incidence of graft vs. host disease|Incidence of unexpected adverse events, by severity and relation to study|The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form|Social Responsiveness Scale, Second Edition (SRS-2)|Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)|Repetitive Behavior Scale Revised - parent/guardian questionnaire|Pediatric Quality of Life Inventory General Core Scales|Pediatric Quality of Life Inventory Family Impact Measure|Pediatric Quality of Life Inventory General Core Scales - Adult Version","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","18 Years to 35 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00104691","November 2021","March 2023","March 2023","July 23, 2020",,"October 25, 2021","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04484077"
1073,"NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions",,"Recruiting","No Results Available","Autoimmune Diseases|Cardiovascular Disorders|Diabetes Complications|Integumentary Disease|Musculoskeletal Disorders|Neurodegenerative Disorders|Neurologic Disorders|Pulmonary Disorders|Sexual Dysfunction|Urologic Disorders|Viral Illness","Biological: PrimePro™/ PrimeMSK™","Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months.|Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months.|Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months.|Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months.|Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months.|Assessment of interstitial cystitis via O'Leary/Sant Questionnaire change from baseline at 6 and 12 months.|Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months.|Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.","Thomas Advanced Medical LLC|HeartStem Institute|NuStem","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5000","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICSS-2020-032","July 9, 2020","July 9, 2030","December 9, 2030","December 24, 2020",,"December 24, 2020","Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City, California, United States",,"https://ClinicalTrials.gov/show/NCT04684602"
1074,"NCT04223622","Effects of ASC Secretome on Human Osteochondral Explants","ASC-OA","Not yet recruiting","No Results Available","Osteoarthritis","Biological: ASC secretome","Validation of the cell-free approach based on the use of ASC secretome on an ex vivo OA model by evaluation of cell viability, histological features and gene/protein expression of cartilage and bone biomarkers","Istituto Ortopedico Galeazzi","All","18 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ASC-OA","February 2020","December 2022","December 2022","January 10, 2020",,"January 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04223622"
1075,"NCT04288934","Treatment of Spinal Cord Injuries With (AutoBM-MSCs)vs (WJ-MSCs).",,"Completed","No Results Available","Spinal Cord Injuries","Biological: Collection and expansion of BM-MSC|Diagnostic Test: VI-SCI evaluation and patients' follow up","SCI evaluation and patients follow up|SCI evaluation and MSCs transplantation","University of Jordan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCICTC","August 15, 2017","April 15, 2020","September 20, 2020","February 28, 2020",,"August 25, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04288934"
1076,"NCT02582775","MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs",,"Recruiting","No Results Available","Epidermolysis Bullosa","Drug: Thymoglobulin|Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Bone marrow infusion|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Biological: Donor mesenchymal stem cell infusions|Drug: Busulfan","Event-free survival|Percentage change of a patient's iscorEB|Transplant-related mortality|Quality of life|Lymphoid Chimerism|Myeloid Chimerism","Masonic Cancer Center, University of Minnesota","All","up to 25 Years   (Child, Adult)","Phase 2","84","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015LS076","March 2016","December 2021","September 2022","October 21, 2015",,"October 8, 2021","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02582775"
1077,"NCT04021394","Influence of EMT on CTCs and Disease Progression in Prostate Cancer",,"Active, not recruiting","No Results Available","Prostate Cancer","Diagnostic Test: CellSearch CTC platform|Diagnostic Test: Parsortix CTC platform","CTC enumeration capacity|CTC recovery capacity|Comparison of AR and EMT characteristics|Relationship of CTC count to disease features|CTC counts and prognosis of OS and PFS","Lawson Health Research Institute","Male","18 Years and older   (Adult, Older Adult)",,"31","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMT Prostate","June 5, 2019","December 2021","December 2025","July 16, 2019",,"June 9, 2021","London Regional Cancer Program, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04021394"
1078,"NCT01984450","A Study to Compare Two Techniques for Articular Cartilage Repair:ACIC Vs. MCIC",,"Unknown status","No Results Available","Articular Cartilage Defect","Procedure: ACIC|Procedure: MCIC|Device: implant with a collagen + fibrin gel mixture","Clinical outcome|Radiological outcome","Shetty-Kim Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKRF 002","January 2014","December 2016","June 2017","November 14, 2013",,"November 14, 2013","Kent Knee Unit, Walderslade, Kent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01984450"
1079,"NCT02017912","Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS","NurOwn","Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Biological: Autologous MSC-NTF cells|Biological: Placebo","Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation","Brainstorm-Cell Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BCT-001-US","May 2014","March 2016","July 2016","December 23, 2013",,"July 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02017912"
1080,"NCT01227694","Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis",,"Completed","No Results Available","Osteoarthritis, Knee|Knee Injuries|Joint Diseases|Rheumatic Diseases|Cartilage Diseases","Other: Autologous MSC knee implantation","Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Efficacy by imaging procedures.|Clinical outcomes.","Banc de Sang i Teixits|Centro Medico Teknon|Institut de Terapia Regenerativa Tissular|Cetir Sant Jordi, S.a..","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-M-09-01","October 2010","July 2012","January 2013","October 25, 2010",,"December 11, 2015","Centro Medico Teknon-ITRT, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01227694"
1081,"NCT00515307","Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia, Familial","Procedure: Cellular transplantation","Serum cholesterol and LDL levels|Tracking the infused cells","University of Tehran","Female","Child, Adult, Older Adult","Phase 1","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DDRC 85-15","June 2007","May 2008","June 2008","August 13, 2007",,"August 29, 2008","Digestive Disease Research Center, Shariati Hospital, North Kargar Ave., Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00515307"
1082,"NCT03280056","Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Biological: NurOwn® (MSC-NTF cells)|Other: Placebo|Other: Bone Marrow aspiration","To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers","Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM)","All","18 Years to 60 Years   (Adult)","Phase 3","263","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BCT-002-US","August 28, 2017","October 30, 2020","October 30, 2020","September 12, 2017",,"October 6, 2021","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03280056"
1083,"NCT04653077","MSCs Therapy for Cerebral Palsy",,"Not yet recruiting","No Results Available","Stem Cell Transplant Complications","Other: stem cells","Changes in Motor Performance.","Aljazeera Hospital|AMR KHALIL ORTHOPEDIC SURGERY CENTER","All","2 Years to 12 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","cerebral palsy","December 2, 2020","October 15, 2022","December 1, 2022","December 4, 2020",,"December 4, 2020","Aljazeera( Al Gazeera) hospital, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT04653077"
1084,"NCT03635450","Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE",,"Completed","No Results Available","Moderate to Severe Hypoxic-ischemic Encephalopathy","Biological: Infusion of hCT-MSC","Incidence of infusion reactions|Incidence of Infections post-infusion|Survival|Neurodevelopmental Assessments","Joanne Kurtzberg, MD|Duke Clinical and Translational Science Institute (CTSI), part of the NIH Clinical and Translational Science Awards (CTSA)|Duke University","All","up to 48 Hours   (Child)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00100253","December 27, 2018","July 28, 2019","December 28, 2020","August 17, 2018",,"March 22, 2021","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03635450"
1085,"NCT03404063","Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)",,"Completed","No Results Available","Myocardial Infarction","Drug: Cardiac Drug|Drug: Placebos","Reduction of infarct size|Infarct size reduction|Myocardial perfusion improvement|Increase of left ventricle ejection fraction (LVEF)|Left ventricle ejection fraction (LVEF) change against baseline.|Left ventricle end-systolic volume (ESV) change against baseline.|Left ventricle end-diastolic volume (EDV) change against baseline.|The occurrence of major adverse cardiovascular events|Quality of life improvement","John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CardioCell evaluation in AMI","October 20, 2017","July 2, 2020","March 31, 2021","January 19, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03404063"
1086,"NCT03672825","REcycled CartiLage Auto/Allo IMplantation",,"Recruiting","No Results Available","Cartilage Defect","Drug: REcycled CartiLage Auto/Allo IMplantation","Nature, incidence and severity of adverse events (AEs)","Mayo Clinic","All","18 Years to 50 Years   (Adult)","Phase 1","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000939","September 13, 2018","September 13, 2022","September 13, 2022","September 17, 2018",,"December 24, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03672825"
1087,"NCT00988338","Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion","TAF","Completed","No Results Available","Tibiotalar Arthrodesis|Subtalar Arthrodesis|Calcaneocuboid Arthrodesis|Talonavicular Arthrodesis|Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular)|Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)","Biological: Trinity Evolution","Fusion Success|Improvement in scores: Ankle-Hindfoot Scale (AHS), Visual Analog Scale (VAS), and Health Survey (SF-36v2).","Orthofix Inc.","All","18 Years and older   (Adult, Older Adult)",,"106","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TY01AF","September 2009","January 2013","January 2013","October 2, 2009",,"October 28, 2021","Orthopaedic Associates of South Broward, PA, Hollywood, Florida, United States|Sinai Hospital of Baltimore / Rubin Institute for Advanced Orthopedics, Baltimore, Maryland, United States|New Mexico Orthopedics, Albuquerque, New Mexico, United States|OrthoCarolina Research Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio Orthopedic Center of Excellence, Upper Arlington, Ohio, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|Central Tennessee Foot and Ankle Center, Sparta, Tennessee, United States|Franciscan Foot and Ankle Specialists, Burien, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00988338"
1088,"NCT00908856","Autologous Cell Therapy After Stroke",,"Withdrawn","No Results Available","Stroke","Biological: autologous bone marrow mononuclear cell transfusion|Biological: marrow stromal cells|Drug: placebo","death|myocardial infarction|pulmonary embolism|ischemic stroke|deep venous thrombosis|other arterial or venous thrombosis|Infection requiring IV antibiotics","University of California, Irvine|University of California, San Diego","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2003-3040","January 2016","December 2017","December 2017","May 27, 2009",,"February 4, 2016","UC Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00908856"
1089,"NCT02240992","MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment",,"Unknown status","No Results Available","Stem Cell Transplantation, Hematopoietic|Poor Graft Function|Delayed Platelet Engraftment|Hematological Diseases","Biological: PBSC|Biological: MSCs","Percentage of Participants with Hematopoietic Recovery|Incidence of graft-versus-host disease|Incidence of infections|Incidence of primary underlying disease relapse|Incidence of acute toxicity","Nanfang Hospital of Southern Medical University|Guangdong Provincial People's Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Guangzhou General Hospital of Guangzhou Military Command|Guangzhou First People's Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Southern Medical University, China|Peking University People's Hospital|Huazhong University of Science and Technology|Sun Yat-sen University|Academy Military Medical Science, China","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-PBSC-MSC-PGF-2014","September 2014","September 2018","December 2018","September 16, 2014",,"September 16, 2014","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02240992"
1090,"NCT01603836","Study Confirms or Refutes the Hypothesis That the Autologous Bone Marrow Concentrate Together With the Allograft is a Better Alternative for the Posterolateral Fusion in Spine Surgery Than the Allograft Alone",,"Completed","No Results Available","Spondyloarthrosis, Spondylosis","Biological: bone allogaft with bone marrow concentrate","The improvement of the fusion of the posterolateral fusion measured on X-rays|The improvement of the fusion of the posterolateral fusion measured on X-rays and CT scans.","Hospital Znojmo","All","45 Years to 89 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PLFBMC","February 2009","March 2010","March 2012","May 23, 2012",,"May 23, 2012",,,"https://ClinicalTrials.gov/show/NCT01603836"
1091,"NCT04397796","Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation",,"Active, not recruiting","No Results Available","COVID","Biological: BM-Allo.MSC|Biological: Placebo","Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs","ImmunityBio, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","QUILT-COVID-19-MSC","August 3, 2020","June 2021","June 2021","May 21, 2020",,"May 27, 2021","St. Francis Medical Center, Lynwood, California, United States",,"https://ClinicalTrials.gov/show/NCT04397796"
1092,"NCT04034615","The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars",,"Recruiting","No Results Available","Cicatrix","Biological: Mesenchyme Stem Cells low-dose group|Biological: Mesenchyme Stem Cells high-dose group|Biological: Placebo","Vancouver Scar Scale score|Erythema|Pigmentation|Scar Thickness and Uniformity|Subject's satisfaction","Maternal and Child Health Hospital of Foshan","Female","21 Years to 35 Years   (Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","MCHHFoshan-1902","May 20, 2021","December 1, 2021","June 1, 2022","July 26, 2019",,"June 9, 2021","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04034615"
1093,"NCT02563340","Effect of BM-MSCs on Chronic AMR After Kidney Transplantation",,"Unknown status","No Results Available","Kidney Transplantation","Other: BM-MSCs|Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)","Estimated glomerular filtration rate (eGFR)|Patient survival rate|Graft survival rate|Donor specific antibody (DSA) level|Pathological manifestation|Severe adverse events","First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital of Guangzhou Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSC-KTx-cAMR-150926","November 2015","October 2017","November 2017","September 30, 2015",,"September 30, 2015","The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02563340"
1094,"NCT04281797","Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients",,"Enrolling by invitation","No Results Available","Transplantation Infection|Kidney Transplant; Complications|Stem Cell Transplant Complications|Liver Transplant; Complications|Microbial Colonization","Diagnostic Test: Intestinal microbiome new generation sequencing","Gut microbiome composition|Infectious complications after transplantation|Organ or tissue rejection","Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","All","Child, Adult, Older Adult",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Microbiome Minsk_1","January 1, 2020","June 30, 2022","December 31, 2022","February 24, 2020",,"February 24, 2020","Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04281797"
1095,"NCT02772289","Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars",,"Completed","No Results Available","Cicatrix","Biological: Mesenchyme Stem Cells low-dose group|Biological: Mesenchyme Stem Cells high-dose group|Biological: Placebo","Change of Vancouver Scar Scale (VSS)|Wound healing status|Erythema measured by reflectance|Pigmentation measured by reflectance|Scar Thickness and Uniformity|Change of scar area|Immunoglobulin concentrations in breast milk|Subject's satisfaction|Adverse events occurrence","Maternal and Child Health Hospital of Foshan","Female","21 Years to 35 Years   (Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCHHFoshan-1602","November 2016","September 2018","March 2019","May 13, 2016",,"May 7, 2019","Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02772289"
1096,"NCT02789995","Dysfunctions of Human Muscle Stem Cells in Sepsis","DISCUSS","Completed","No Results Available","Sepsis","Procedure: Human biological samples","Muscle regenerative capacities|Satellite cell dysfunction after sepsis|Regenerative capacities of Human satellite cells in presence of mesenchymal stem cells","Institut Pasteur","All","18 Years and older   (Adult, Older Adult)","Not Applicable","93","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2015-015|ID-RCB number : 2015-A01022-47","June 23, 2016","June 28, 2018","June 28, 2018","June 3, 2016",,"November 1, 2019","Hopital Henri Mondor, Service de Réanimation chirurgicale polyvalente, Créteil, France|Hôpital Pitié Salpétrière, Salle de surveillance post-interventionnelle, Accueil des Polytraumatisés, Paris, France|Hôpital Pitié Salpêtrière, Anesthésie et Réanimation, Institut de Cardiologie, Paris, France|Hôpital Pitié Salpêtrière, Service de Chirurgie Générale, Viscérale et Endocrinienne, Paris, France|Hôpital Pitié Salpêtrière, Service de Chirurgie Hépatobiliaire et de Transplantation Hépatique, Paris, France|Hôpital Pitié Salpêtrière, Service de réanimation chirurgicale polyvalente, Paris, France|Hôpital Saint-Antoine, Département d'Anesthésie-réanimation, Paris, France",,"https://ClinicalTrials.gov/show/NCT02789995"
1097,"NCT04738981","Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT",,"Not yet recruiting","No Results Available","Graft Vs Host Disease","Drug: UC-MSC|Drug: Anti-CD25 mAb","Rate of complete remission|Overall survival|Rate of partial remission|Infusion toxicity","Peking University People's Hospital|Southern Medical University, China|Third Military Medical University|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GVHD-PKU2021","February 2021","December 2021","December 2021","February 4, 2021",,"February 4, 2021","Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04738981"
1098,"NCT01623453","Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)","ANTG","Terminated","No Results Available","Perianal Fistula|Primary; Complex","Biological: Autologous adipose derived stem cells(low dose group)|Biological: Autologous adipose derived stem cells(high dose group)","Number of patients with Sustained efficacy of complete closure of fistula|Number of patients with sustained efficacy of closure of fistula|Evaluation of Fecal Incontinence Score|Grade of Investigator's satisfaction|Number of patients with adverse events as a measure of systemic tolerance and physical examinations","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)",,"6","Industry","Observational","Time Perspective: Prospective","ANTG-ASC-211","September 2010","September 2014","September 2014","June 20, 2012",,"November 23, 2016","DaeHang Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01623453"
1099,"NCT01314092","Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula","ANTG-ASC-210","Terminated","No Results Available","Complex Perianal Fistula","Biological: Autologous cultured adipose derived stem cells(low dose group)|Biological: Autologous cultured adipose derived stem cells(high dose group)","Number of patients with complete closure of fistula (week 8)|Grade of investigator's satisfaction|Number of patients with closed fistula|Photo of target fistula|Number of patients with adverse events","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ANTG-ASC-210","January 2011","September 2014","September 2014","March 14, 2011",,"November 23, 2016","Soon cheun Hyang university bucheon hospital, Bucheon-si, Korea, Republic of|Ewha womwn university mokdong hospital, Seoul, Korea, Republic of|DaeHang Hospital, Seoul, Korea, Republic of|Samsung seoul Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01314092"
1100,"NCT01033552","Biochemical Correction of Severe EB by Allo HSCT and ""Off-the-shelf"" MSCs",,"Recruiting","No Results Available","Epidermolysis Bullosa","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Anti-thymocyte globulin|Drug: Cyclosporine A|Drug: Mycophenolate mofetil|Procedure: Mesenchymal stem cell transplantation|Radiation: Total body irradiation|Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation","Event-free survival rate|Transplant-related mortality (TRM)|Pattern of biochemical improvement|Quality of Life|Durability of HSC and third party MSC engraftment in the skin|Probability of Survival|Number of participants experiencing Acute GVHD","Masonic Cancer Center, University of Minnesota","All","up to 25 Years   (Child, Adult)","Phase 2","75","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT2009-09|0911M74035","January 2010","October 2021","October 2021","December 16, 2009",,"May 24, 2021","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01033552"
1101,"NCT04590118","Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)",,"Not yet recruiting","No Results Available","Ischemic Stroke","Drug: it-hMSC|Drug: Placebo","Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after it-hMSC infusion.|Modified Rankin Scale|National Institute of Health stroke scale|Mini-mental State Examination|Barthel Index|Geriatric Depression Scale","Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.|Beijing Tiantan Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STCMSC-CT-001","March 20, 2021","April 1, 2023","August 1, 2023","October 19, 2020",,"January 27, 2021","Beijing Tiantan Hospital, Capital Medical University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04590118"
1102,"NCT05126563","Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome","HBPCOVID02","Recruiting","No Results Available","Post COVID-19 Syndrome","Biological: HB-adMSCs (allogeneic)|Other: Placebo","Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue|Changes in Visual Analog Scale of Neurological Symptoms. - Brain fog|Changes in Visual Analog Scale of Neurological Symptoms. - Headache|Changes in Visual Analog Scale of Neurological Symptoms. - Sleep disturbances|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of taste|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of smell|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities.|AEs of special interest (serious or non-serious) - infections.|AEs of special interest (serious or non-serious) - hypersensitivities.|Changes in Laboratory values. - CBC.|Changes in Laboratory values. - CMP.|Changes in Laboratory values. - Coagulation Panel.|Changes in Vital Signs. - Respiratory Rate (breaths per minute)|Changes in Vital Signs. - Heart Rate (beats per minute)|Changes in Vital Signs. - Body Temperature (Fahrenheit )|Changes in Vital Signs. - Blood Pressure (mmHg)|Changes in Weight in lb.|Changes in Physical examination results. - General|Changes in Physical examination results. - Body Systems|Changes in Subject's energy - Fatigue Assessment form.|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea a rest|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea with activity|Changes in Visual Analog Scale of non -Neurological Symptoms. - Cough|Changes in Visual Analog Scale of non -Neurological Symptoms. - Body aches|Changes in Visual Analog Scale of non -Neurological Symptoms. - Joint pain|Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire|Changes in Subject's level of depression - PHQ 9 scale.","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HBPCOVID02","December 20, 2021","December 20, 2023","December 20, 2025","November 19, 2021",,"November 19, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05126563"
1103,"NCT01626625","Mesenchymal Stem Cells; Donor and Role in Management and Reconstruction of Nonunion Fracture",,"Unknown status","No Results Available","Healing of Fracture","Drug: stem cells + hydroxy apatite|Other: autograft taken from iliac crest","healing of fracture|VAS","Indonesia University","All","18 Years to 55 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NONUNISTEM1","April 2010","April 2015","January 2016","June 25, 2012",,"June 25, 2012","RSCM, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT01626625"
1104,"NCT03990805","A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis",,"Completed","No Results Available","Degenerative Arthritis|Knee Osteoarthritis","Biological: JOINTSTEM|Drug: saline","Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|Change of Visual Analog Scale (VAS) scores from baseline|WOMAC 3 subscale score|VAS score|KOOS|SF-36|IKDC|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan|Use of rescue medication","R-Bio","All","20 Years to 100 Years   (Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BSR-CTph3-JS1","June 11, 2019","December 15, 2020","December 15, 2020","June 19, 2019",,"January 29, 2021","Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, Korea, Republic of|Kyunghee University Medical Center, Seoul, Korea, Republic of|Yonsei University Health System, Seoul, Korea, Republic of|Soonchunhyang University Hospital Seoul, Seoul, Korea, Republic of|KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Chunang University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03990805"
1105,"NCT02563366","Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.",,"Unknown status","No Results Available","Kidney Transplantation|Acute Kidney Tubular Necrosis","Other: BM-MSCs|Other: Saline","Estimated glomerular filtration rate|Proportion of normal renal function recovery|Time to renal function recovery (days)|acute rejection rate|patient and graft survival rate|Incidence of severe adverse events","First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital of Guangzhou Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSCs-KTx-DCD-150925","November 2015","October 2017","December 2017","September 30, 2015",,"September 30, 2015","The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02563366"
1106,"NCT02079324","Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer","GX-051","Unknown status","No Results Available","Head and Neck Cancer","Biological: GX-051","MTD after GX-051 intratumoral injection|Adverse events after GX-051 intratumoral injection|Anti-tumor response by RECIST 1.1 on computed tomography|Changes of INF-γ and IL-12 levels in blood comparing to the baseline after GX-051 intratumoral injection|Changes of immune cell distribution in tumor tissue after GX-051 intratumoral injection|Evaluation of antibody generation against IL-12 which is active ingredient of GX-051|Evaluation of long term safety examined by vital sign, physical examination, clinical laboratory tests, CT etc","Genexine, Inc.","All","19 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GX-051_HNC_1","March 2014","September 2016","September 2016","March 5, 2014",,"April 30, 2015","Seoul St.Mary's Hospital of the Catholic University of Korea, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02079324"
1107,"NCT04007081","Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia",,"Completed","No Results Available","Xerostomia|Head and Neck Cancer","Procedure: Bone Marrow Aspiration|Diagnostic Test: Ultrasound Imaging of Salivary Glands|Other: Salivary Assay|Other: Quality of Life Instruments","Number of Participant's whose Marrow-Derived MSCs Can be Expanded in vitro to > 50 million cells within two weeks|Change in participant QoL: XeQOL|Change in participant QoL: MDADI|Change in participant QoL: VAS|Change in participant Salivary Function: Unstimulated|Change in participant Salivary Function: Stimulated|Change in participant Salivary Gland Size","University of Wisconsin, Madison","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UW19009|2019-0497|SMPH/HUMAN ONCOLOGY/HUMAN ONCO|A533300|Protocol Version 7/24/2020","October 18, 2019","March 10, 2021","March 10, 2021","July 5, 2019",,"March 24, 2021","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04007081"
1108,"NCT03943576","Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Drug: GXCPC1|Device: HA","WOMAC pain score|MRI|Visual Analogue Scale (VAS)|12-item Short Form (SF-12)","Gwo Xi Stem Cell Applied Technology Co., Ltd.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GXCPC1","December 1, 2019","December 31, 2021","October 31, 2022","May 9, 2019",,"March 17, 2020","GWOXI Stem Cell Applied Technology Co., Ltd., Hsinchu, Taiwan",,"https://ClinicalTrials.gov/show/NCT03943576"
1109,"NCT04392778","Clinical Use of Stem Cells for the Treatment of Covid-19",,"Completed","No Results Available","Covid19|Pneumonia|Multiple Organ Failure|Corona Virus Infection","Biological: MSC Treatment|Biological: Saline Control","Clinical improvement|Lung damage improvement|Sars-Cov-2 viral infection laboratory test|Blood test","SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi|Istinye University|Regenerative Medicine and Stem Cell Production Center Liv MedCell|Liv Hospital (Ulus)","All","40 Years to 60 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bak. Sadi Konuk-Istinye Uni.","April 1, 2020","November 1, 2020","November 30, 2020","May 19, 2020",,"May 25, 2021","Istinye University, Istanbul, Turkey|SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04392778"
1110,"NCT01213186","Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients",,"Unknown status","No Results Available","Human Immunodeficiency Virus|Disorder of Immune Reconstitution","Drug: high dose of MSC|Drug: low dose of MSC treatment","the total CD4 T cell counts compared with CD4 T cell counts at baseline|the CD38 expression on CD8 T cells|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|plasma RNA copies/mL|the ratio of CD4 and CD8 T cells|the HLA-DR expression on CD8 T cells|Quality of live|the occurring rate of tumor|occurring rate of opportunistic infections","Fu-Sheng Wang|Beijing 302 Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","beijing302-001","January 2013","December 2015","June 2016","October 1, 2010",,"May 29, 2013","Beijing 302 Hospital, Beijing, Beijing, China|Xinjiang Hospital of Infectious Diseases, Urumqi, Xinjiang, China|the Yunnan Hospital of Infectious Diseases, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT01213186"
1111,"NCT01541579","Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease","ADMIRE-CD","Completed","No Results Available","Crohn's Disease","Other: Cx601|Other: Saline solution","Combine remission of perianal fistulising Crohn's|Efficacy Assessment by week 24|Efficacy Assessment by week 52|Efficacy Assessment by week 104|Safety analysis throughout the study:","Tigenix S.A.U.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cx601-0302","July 2012","July 2015","November 2016","March 1, 2012",,"November 29, 2019","Univ.-Klinik Innsbruck, Innsbruck, Austria|Krankenhaus, St. Veit/Glan, Austria|Medizinische Universität, Wien, Austria|Hospital Oost-Limburg, Genk, Belgium|Gent University Hospital, Gent, Belgium|Leuven University Hospital, Leuven, Belgium|Hospital Hartziekenhuis, Roeselare, Belgium|CHU d'Amiens, Amiens, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Hôpital Beaujon, Clichy, France|CHRU de Lille, Lille, France|CHU de Marseille, Marseille, France|CHU de Nice, Nice, France|Hôpital Saint-Louis, Paris, France|Charite, Berlin, Germany|Krakenhaus Walfriede, Berlin, Germany|Klinikum Braunscheweig, Braunschweig, Germany|Klinikum Frankfurt, Frankfurt/Main, Germany|Evangelisches Krankenhaus Kalk, Köln, Germany|Klinikum Lüneburg, Lüneburg, Germany|Rambam MC, Haifa, Israel|Sharee Zedek MC, Jerusalem, Israel|Rabin MC, Petah Tikva, Israel|Tel Aviv Sourasky MC, Tel Aviv, Israel|Sheba MC, Tel Hashomer, Israel|Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Instituto Clinico Humanitas IRCCS, Milano, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy|Università Cattolica del Sacro Cuore, Rome, Italy|AMC, Amsterdam, Netherlands|VUMC, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|UMCU, Utrecht, Netherlands|Hospital de Manises, Manises, Valencia, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Juan Ramon Jimenez, Huelva, Spain|Hospital Ramón y Cajal, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Son Espases, Palma de Mallorca, Spain|Hospital de Montecelo, Pontevedra, Spain|Hospital Virgen del Rocio, Seville, Spain|Hospital de Sagunto, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01541579"
1112,"NCT04269525","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia",,"Recruiting","No Results Available","Pneumonia, Viral|Pneumonia, Ventilator-Associated","Biological: UC-MSCs","Oxygenation index|28 day mortality|Hospital stay|2019-nCoV antibody test|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)|C-reactive protein(CRP)|CD4+ T-Lymphocytopenia|CD8+ T-Lymphocytopenia|natural killer cell(NK)","ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020002","February 6, 2020","December 1, 2020","December 30, 2020","February 13, 2020",,"July 1, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04269525"
1113,"NCT03252535","Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease","ADORE-DH","Completed","No Results Available","Huntington Disease","Biological: Cellavita HD lower dose|Biological: Cellavita HD higher dose|Other: Placebo","Effective Dose|Clinical neurological worsening over the treatment|BMI assessment|Risk of suicidal ideation|CNS assessment|Clinical Interview Based impression of Severity (CIBIS)","Azidus Brasil|Cellavita Pesquisa Científica Ltda","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","35","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADORE-DH|52375916.1.0000.5412","January 15, 2018","March 23, 2021","April 30, 2021","August 17, 2017",,"June 23, 2021","Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03252535"
1114,"NCT03925649","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI",,"No longer available","No Results Available","Spinal Cord Injury at C5-C7 Level","Biological: HB-adMSCs",,"Hope Biosciences|The University of Texas Health Science Center, Houston","Male","18 Years and older   (Adult, Older Adult)",,,"Industry|Other","Expanded Access:Individual Patients|Intermediate-size Population|Treatment IND/Protocol",,"HBSCI01",,,,"April 24, 2019",,"July 6, 2021","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03925649"
1115,"NCT02742857","Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury",,"Completed","No Results Available","Brain Death","Biological: BQ-A Peptide Extract|Biological: Mesenchymal Stem Cells|Device: Transcranial Laser Therapy|Device: Median Nerve Stimulator","Reversal of brain death as noted in clinical examination or EEG|Cerebrospinal fluid (CSF) analysis of color consistency, cell counts, and microbial evaluation|MRI analysis to analyze any changes in meninges|Pulse|O2 saturation|Blood Pressure|Respiration changes","Bioquark Inc.|Revita Life Sciences|Anupam Hospital","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","BQ12016|AAH -01-2016","July 2016","August 2020","August 2020","April 19, 2016",,"October 1, 2020","Anupam Hospital, Rudrapur, Uttaranchal, India",,"https://ClinicalTrials.gov/show/NCT02742857"
1116,"NCT01496339","Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: MenSCs transplantation|Drug: exogenous indulin injection daily","Glycosylated hemoglobin (HbA1c)|The acute reaction and severity of adverse events related to the stem cell infusion procedure|Number of severe and documented hypoglycemic events|C-peptide release test|The reduction in fasting blood glucose (FBG)|The increase in basal C-peptide|The postprandial blood glucose|The random glucose level","S-Evans Biosciences Co., Ltd.|Zhejiang University|Wenzhou Medical University|Zhenjiang First People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SEB-1213-T1DM","January 2012","December 2013","May 2014","December 21, 2011",,"June 7, 2012","The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01496339"
1117,"NCT01351610","Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia|Peripheral Artery Disease","Biological: PTA + Infusion of MSC_Apceth|Procedure: PTA","Collection of adverse events|Safety laboratory values|ECG findings|Analysis of inflammation markers|Comparison of course of haemodynamic and vascular processes","Apceth GmbH & Co. KG","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC_Apceth_001","March 2011","October 2014","October 2015","May 11, 2011",,"December 15, 2015","Isar Medizin Zentrum, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT01351610"
1118,"NCT02290886","A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral",,"Active, not recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Other: Intravenous administration of placebo|Drug: Intravenous administration of 1 million of MSC|Drug: Intravenous administration of 2 million of MSC|Drug: Intravenous administration of 4 million of MSC","Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CeTMAd/ELA/2011","July 2014","February 2022","December 2022","November 14, 2014",,"July 22, 2021","Hospital Regional Universitario Reina Sofía, Cordoba, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen Macarena, Servicio de Neurología, Seville, Spain|Hospital Universitario Virgen del Rocío, Seville, Spain",,"https://ClinicalTrials.gov/show/NCT02290886"
1119,"NCT01547689","Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease","SEMAD","Unknown status","No Results Available","Alzheimer's Disease","Biological: Human Umbilical Cord Derived MSC","Number of participants with adverse event|Changes from the baseline in Alzheimer' s Disease Assessment Scale-cognitive subscale(ADAS-Cog) at 10 weeks post-dose","Affiliated Hospital to Academy of Military Medical Sciences|Peking University Third Hospital","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307-CTC-MSC-001|2011AA020114","March 2012","December 2016","December 2016","March 8, 2012",,"February 22, 2016","Department of Hematopoietic Stem Cell Transplantation, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01547689"
1120,"NCT02209311","Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs",,"Unknown status","No Results Available","Partially Edentulous Maxilla|Alveolar Bone Atrophy|Alveolar Bone Loss","Procedure: Oral mucosa biopsy|Procedure: Sinus lift with implantation of tissue engineered construction|Device: Dental implant","Number of serious adverse events (SAEs) and serious adverse reactions (SARs)|Quality of life monitoring|Changes in bone tissue volume|Correlation of morphometrical analysis using cone beam CT scan with absolute value of the newly formed bone","Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation","All","20 Years to 60 Years   (Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RU-CCH-06-01-14","September 2014","October 2017","March 2018","August 5, 2014",,"November 30, 2016","Federal State Budgetary Institution ""Central Clinical Hospital with Outpatient Health Center"" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies, Moscow, Russian Federation|A.I. Evdokimov Moscow State Medical Stomatological University, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02209311"
1121,"NCT03000712","Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients.",,"Completed","No Results Available","Degenerative Arthritis|Knee Osteoarthritis","Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml","MRI scan|WOMAC score|WOMAC sub-scale|Kellgren & Lawrence grade|EQ5D|ROM|KOOS (Knee Injury & Osteoarthritis Outcome Score)|PGIC(Patient Global Impression of Change)|PSQI(Pittsburgh Sleep Quality Index)|Biomarkers|Incidence of adverse reactions and characteristics associated with investigational product","R-Bio","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HTO-MSCs","November 2, 2016","May 22, 2020","May 22, 2020","December 22, 2016",,"January 29, 2021","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03000712"
1122,"NCT02917291","Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury","SPINE","Recruiting","No Results Available","Acute Traumatic Spinal Cord Injury","Drug: FAB117-HC|Other: Control group","Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord|Changes in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC|Changes in the functional assessment of Spinal Cord Independence Measure (SCIM III)|Changes in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test.|Changes in Motor-Evoked Potentials (MEP) electrophysiological assessment test","Ferrer Internacional S.A.|Histocell, S.L.","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","FAB117-CT-01","December 2016","July 2022","July 2023","September 28, 2016",,"September 16, 2021","Complexo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Complejo Hospitalario de Toledo (HNP y VS), Toledo, Spain|Hospital Universitari La Fe, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02917291"
1123,"NCT01697072","First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","RILOMET-1","Terminated","No Results Available","Gastric Cancer","Drug: Rilotumumab|Other: Placebo|Drug: Epirubicin|Drug: Cisplatin|Drug: Capecitabine","Overall Survival|PFS|TTP|ORR|DCR|TTR|Safety|Immunogenicity","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","609","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20070622|2011-004923-11","October 2012","November 2014","August 2015","October 2, 2012",,"February 9, 2016","Research Site, Tucson, Arizona, United States|Research Site, Aurora, Colorado, United States|Research Site, Pueblo, Colorado, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Woodbury, Minnesota, United States|Research Site, Henderson, Nevada, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Bedford, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Randwick, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Douglas, Queensland, Australia|Research Site, Elizabeth Vale, South Australia, Australia|Research Site, Kurralta Park, South Australia, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Ringwood East, Victoria, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Liege, Belgium|Research Site, Roeselare, Belgium|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Pelotas, Rio Grande do Sul, Brazil|Research Site, Santo Andre, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Horovice, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Copenhagen, Denmark|Research Site, Odense, Denmark|Research Site, Århus C, Denmark|Research Site, Bayonne, France|Research Site, Bordeaux, France|Research Site, Clermont Ferrand Cedex 1, France|Research Site, Dijon cedex, France|Research Site, Le Mans, France|Research Site, Limoges Cedex, France|Research Site, Lyon Cedex 03, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille cedex 5, France|Research Site, Montpellier Cedex 5, France|Research Site, Nice cedex 2, France|Research Site, Périgueux cedex, France|Research Site, Saint Priest en Jarez Cedex, France|Research Site, Saint Priest en Jarez, France|Research Site, Strasbourg, France|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Oldenburg, Germany|Research Site, Schweinfurt, Germany|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Larissa, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Szolnok, Hungary|Research Site, Aviano PN, Italy|Research Site, Brescia, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Toluca, Mexico|Research Site, Bialystok, Poland|Research Site, Elblag, Poland|Research Site, Gdansk, Poland|Research Site, Konin, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Aveiro, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Vila Real, Portugal|Research Site, Alba Iulia, Romania|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Lasi, Romania|Research Site, Timisoara, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Poprad, Slovakia|Research Site, Trencin, Slovakia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kraaifontein, South Africa|Research Site, Pretoria, South Africa|Research Site, Oviedo, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Terrassa, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Eskilstuna, Sweden|Research Site, Stockholm, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Chur, Switzerland|Research Site, Ankara, Turkey|Research Site, Gaziantep, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mariupol, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Belfast, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Salisbury, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01697072"
1124,"NCT00025441","Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors",,"Completed","No Results Available","Ovarian Cancer|Sarcoma|Small Intestine Cancer","Biological: dactinomycin|Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy",,"Societe Internationale d'Oncologie Pediatrique|Children's Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|National Cancer Institute (NCI)","All","6 Years to 17 Years   (Child)","Phase 2",,"Other","Interventional","Primary Purpose: Treatment","CDR0000068961|SIOP-MMT-98|SFOP-SIOP-MMT-98|CCLG-SIOP-MMT-98|EU-20126|STS-1998","November 1998",,"March 2010","January 27, 2003",,"December 4, 2013","Centre Leon Berard, Lyon, France|Our Lady's Hospital for Sick Children, Crumlin, Ireland|Birmingham Children's Hospital, Birmingham, England, United Kingdom|Bristol Royal Hospital for Children, Bristol, England, United Kingdom|Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom|Saint Bartholomew's Hospital, London, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, London, England, United Kingdom|Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom|Meyerstein Institute of Oncology at University College of London Hospitals, London, England, United Kingdom|Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, England, United Kingdom|Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Oxford Radcliffe Hospital, Oxford, England, United Kingdom|Children's Hospital - Sheffield, Sheffield, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00025441"
1125,"NCT03392467","PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants",,"Recruiting","No Results Available","Severe Bronchopulmonary Dysplasia","Biological: PNEUMOSTEM|Other: Placebo","Percentage of subjects who have severe BPD or are dead|Percentage of subjects who have moderate/severe BPD or are dead|Percentage of subjects by severity of BPD|Percentage of subjects in death due to lung disease|intubation duration|ventilation duration|continuous positive airway pressure (CPAP) treatment duration|treatment duration with supplemental oxygen|% of subjects treated with steroid for weaning ventilator|Retinopathy of prematurity (ROP) with stage III or higher|number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy|z-score|days in hospitalization|changes in tracheal suction fluid examination","Medipost Co Ltd.","All","up to 13 Days   (Child)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MP-CR-012","August 13, 2018","June 2021","July 2021","January 8, 2018",,"August 28, 2020","Asan medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03392467"
1126,"NCT04362189","Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19",,"Active, not recruiting","No Results Available","COVID-19","Biological: HB-adMSC|Other: Placebo","Interleukin-6|C Reactive protein|Oxygenation|TNF alpha|IL-10|Return to room air (RTRA)|EKG qt interval|Leukocyte differential|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|NK cell surface antigen (CD3-CD54+)|CD4+/CD8+ ratio|Myoglobin|Troponin|Creatinine kinase MB|Serum ferritin|Adverse events|7-point ordinal scale|D-dimer|Chest X-ray|CT scan|PCR test for SARS-CoV-2","Hope Biosciences Stem Cell Research Foundation|Advanced Diagnostics Healthcare|Hope Biosciences|United Memorial Medical Center","All","Child, Adult, Older Adult","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBCOV03","June 30, 2020","October 31, 2021","October 31, 2021","April 24, 2020",,"July 6, 2021","River Oaks Hospital and Clinics, Houston, Texas, United States|United Memorial Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04362189"
1127,"NCT04492501","Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan",,"Completed","No Results Available","Covid19|Cytokine Release Syndrome|Critical Illness|ARDS","Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy","survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications","UNICEF|Pak Emirates Military Hospital Rawalpindi","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sultan Mehmood Kamran 3","April 1, 2020","July 20, 2020","July 20, 2020","July 30, 2020",,"July 30, 2020","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04492501"
1128,"NCT02846883","Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms","VIVAAA","Terminated","No Results Available","Abdominal Aortic Aneurysm","Biological: MSC's|Drug: Placebo","Incidence of treatment related adverse events at 12 months post MSC administration as evidenced by the Investigator|Changes in circulating inflammatory cell phenotypes as measured by 18-FDG PET/CT","VA Office of Research and Development","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 1","28","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CLNB-06-15F|1510579216","December 5, 2016","September 30, 2021","September 30, 2021","July 27, 2016",,"November 8, 2021","Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02846883"
1129,"NCT02815423","Safety and Exploratory Efficacy Study of UCMSCs in Patients With Fracture and Bone Nonunion",,"Unknown status","No Results Available","Fracture|Bone Nonunion","Biological: UCMSCs|Biological: Percutaneous","Radiological progression of bone fusion|Comparison of the rate of complications between the 2 groups|Incidence of increased temperature sensitivity by questionnaire|Incidence and severity of infections at grafting sites by questionnaire","South China Research Center for Stem Cell and Regenerative Medicine|Guangzhou Panyu Central Hospital","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-6","January 2017","January 2019","January 2020","June 28, 2016",,"June 28, 2016",,,"https://ClinicalTrials.gov/show/NCT02815423"
1130,"NCT01041001","Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury",,"Completed","No Results Available","Cartilage Injury|Osteoarthritis","Biological: Cartistem|Procedure: Microfracture treatment","ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.|Degree of improvement in the grade of joint pain measured on a 100-mm VAS (Visual Analogue Scale)|Grade of cartilage regeneration in patients who agreed to a biopsy during arthroscopy at week 48|Changes in WOMAC scores|Changes in IKDC Subjective Score|ICRS scores","Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CRP-005","February 2009","December 2010","January 2011","December 30, 2009",,"April 20, 2017","Gachon University Gil Hospital, Incheon, Gyunggido, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Seoul Veterans Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01041001"
1131,"NCT03458819","EMT in Peritoneal Dialysis Patients",,"Completed","No Results Available","Peritoneal Dialysis Complication","Diagnostic Test: Isolation of peritoneal mesothelial cells","Changes in the protein expression of EMT markers","University of Colorado, Denver","All","18 Years to 90 Years   (Adult, Older Adult)",,"22","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-0401","March 20, 2018","May 22, 2019","May 22, 2019","March 8, 2018",,"February 25, 2021","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03458819"
1132,"NCT04042844","A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)",,"Not yet recruiting","No Results Available","Lumbar Disc Disease","Biological: BRTX-100|Drug: Saline","Number of study participants with treatment related adverse events (TEAES) and serious adverse events (SAEs) from baseline through Week 104.|Visual Analogue Scale for Pain Assessment - Changes from Baseline in pain as assessed with the VAS score through Week 52|Oswestry Disability Index for Functional Assessment -- Changes from Baseline in function as assessed with the Oswestry Disability Index through Week 52.","BioRestorative Therapies","All","18 Years to 60 Years   (Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLDD-001","March 2, 2021","June 2, 2023","August 31, 2023","August 2, 2019",,"July 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04042844"
1133,"NCT04798716","The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19","ARDOXSO","Not yet recruiting","No Results Available","Covid19|Novel Coronavirus Pneumonia|Acute Respiratory Distress Syndrome","Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Drug: MSC-exosomes delivered intravenously every other day (8:8:8)","Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.|Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.|Analyze and report organ failure, associated with ICU mortality in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO™ as an interventional exosome therapy.|Record and analyze respiratory measures (Berlin Score/PEEP) following treatment regime.","AVEM HealthCare","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","020582","September 2021","September 2021","December 2021","March 15, 2021",,"July 21, 2021","Mission Community Hospital, Panorama City, California, United States",,"https://ClinicalTrials.gov/show/NCT04798716"
1134,"NCT04772378","Individual Patient Expanded Access IND of HB-adMSCs for the Treatment of Parkinson's Disease","HBPD02","No longer available","No Results Available","Parkinson Disease","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","Male","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access:Individual Patients",,"HBPD02",,,,"February 26, 2021",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04772378"
1135,"NCT02543073","MSC for Treatment of Interstitial Lung Disease After Allo-HSCT",,"Unknown status","No Results Available","Lung Diseases, Interstitial|Hematopoietic Stem Cell Transplantation|Bronchiolitis Obliterans","Biological: MSCs|Drug: AZM|Drug: Glucocorticoid","Response rate of ILD|Overall Survival","Nanfang Hospital of Southern Medical University|Sun Yat-sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-ILD-2015","September 2014","December 2017","June 2018","September 7, 2015",,"May 10, 2017","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02543073"
1136,"NCT04247945","Co-transplantation of MSC in the Setting of Allo-HSCT",,"Recruiting","No Results Available","Allogeneic Hematopoietic Stem Cell Transplantation","Biological: Cotransplant with MSCs","Survival Rate|Cumulative Incidence of Graft-versus Host Disease|Incidence of Systemic Infections|Mean Time to Engraftment|Transplant-Related Mortality|Rates of Relapse","Fujian Medical University","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MSC-SCT-03","February 1, 2020","December 1, 2023","December 1, 2025","January 30, 2020",,"January 30, 2020","Union Hospital,Fujian Medical University, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04247945"
1137,"NCT04293692","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus",,"Withdrawn","No Results Available","COVID-19","Biological: UC-MSCs|Other: Placebo","Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes","Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pr20200225","February 24, 2020","February 25, 2020","February 25, 2020","March 3, 2020",,"March 18, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04293692"
1138,"NCT04713436","The Effects of Antibiotic Combinations on Stem Cells",,"Completed","No Results Available","Stem Cells|Anti-Bacterial Agents","Drug: Differentiation Markers","Measurment of Cell Viability and Apoptosis|Measurment of cell differantiation","Eskisehir Osmangazi University|TC Erciyes University","All","16 Years to 22 Years   (Child, Adult)",,"3","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2015-68","January 1, 2014","January 1, 2016","February 1, 2017","January 19, 2021",,"January 19, 2021","Eskişehir Osmangazi University, Eskişehir, Turkey",,"https://ClinicalTrials.gov/show/NCT04713436"
1139,"NCT02975960","ADMSCs for the Treatment of Systemic Sclerosis",,"Completed","No Results Available","Systemic Sclerosis","Biological: injection of autologous stromal vascular fraction","Change from baseline modified Rodnan Skin score (mRSS) of hands at 12 weeks|Change from baseline Raynaud's condition score at 12 weeks|Change from baseline Visual Analog Score for pain the hands at 12 weeks|Changes from baseline mRSS (total) at 12 weeks|Change from baseline Kapandji score at 12weeks|Change from baseline Cochin hand function scale at 12 weeks|Change from baseline Systemic sclerosis HAQ at 12 weeks|Change from baseline peripheral vasculature at 12 weeks|Change from baseline finger circumference at 12 weeks","The Catholic University of Korea|Seoul St. Mary's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KC16TISI0343","October 25, 2016","October 30, 2017","January 20, 2018","November 29, 2016",,"January 25, 2018","Seoul St. Mary's hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02975960"
1140,"NCT04545307","Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis","MSC","Completed","No Results Available","Pulp Necroses|Apical Periodontitis","Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis","Sings and Symptoms Absence|Root canal Narrowing|Elongation of the root|Sensitivity tests perception|Repair of the bone lesion produced by the apical periodontitis|Stability of bio ceramic cements used in the obturation of the access cavity|Evaluate blood circulation within the root canal","Universidad Central de Venezuela|Instituto Venezolano de Investigaciones Cientificas","All","6 Years to 16 Years   (Child)","Phase 2|Phase 3","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCYPPNAP001","November 27, 2019","December 27, 2019","January 27, 2020","September 11, 2020",,"September 16, 2020","Unidad de Terapia Celular del Instituto de Investigaciones Científicas, San Antonio de los Altos, Miranda, Venezuela",,"https://ClinicalTrials.gov/show/NCT04545307"
1141,"NCT04562025","Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy","UC-MSCs","Recruiting","No Results Available","Diabetic Nephropathy","Drug: UC-MSCs|Drug: Placebo","Adverse Events|Kidney function|SF-36 (The MOS item short from health survey)|Change in HbA1c","Renmin Hospital of Wuhan University|Wuhan Hamilton Biotechnology Co., Ltd","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200915HMD","September 25, 2020","September 25, 2021","December 31, 2021","September 24, 2020",,"September 24, 2020","Renmin Hospital of Wuhan university, Wuhan, Hubei China, China",,"https://ClinicalTrials.gov/show/NCT04562025"
1142,"NCT02685722","UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers","UC-MSCs","Completed","No Results Available","Difficult to Healing of Skin Ulcers","Biological: UC-MSCs Gel group|Other: Gel group","Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 6 Week","Chinese PLA General Hospital","All","17 Years to 78 Years   (Child, Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHIN-PLAGH-ST-008","January 2012","December 2015","December 2015","February 19, 2016",,"February 19, 2016","Chinese PLA General Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02685722"
1143,"NCT04137523","Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression",,"Recruiting","No Results Available","Multiple Myeloma",,"To strengthen preliminary data|Potential marker of PD|Analysis both MM cells and MM-BMSC compartment.|To investigate eNAMPT role|To determine the effects","University of Turin, Italy","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Other","eNAMPT","August 12, 2019","August 12, 2019","September 15, 2022","October 24, 2019",,"August 18, 2021","Aou Citta' Della Salute E Della Scienza Di Torino, Torino, TO, Italy",,"https://ClinicalTrials.gov/show/NCT04137523"
1144,"NCT04723303","Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)",,"Recruiting","No Results Available","Polymyositis|Dermatomyositis","Drug: Umbilical Cord Lining Stem Cells","Number of Subjects with Dose Limiting Toxicity (DLT) that begins during or following ULSC infusion as assessed within 24 hours.","University of Florida|Restem, LLC.","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","22","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM/PM V2.0|IRB201903442|OCR33722","October 6, 2021","April 20, 2022","April 20, 2022","January 25, 2021",,"November 18, 2021","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04723303"
1145,"NCT02025270","MSCs For Treatment of Azoospermic Patients",,"Unknown status","No Results Available","Male Infertility","Biological: Stem Cells","All Cases Improvement|All Cases Fertility Improvement","Al-Azhar University|Cairo University","Male","20 Years to 50 Years   (Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AZH010066099|Azhar23052011","October 2012","October 2016","October 2017","January 1, 2014",,"June 29, 2016","Al Azhar University , School of Medicine, Nasr City, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02025270"
1146,"NCT03838666","Utilization of AMSC to Enhance Rotator Cuff Repair - Safety and Efficacy","AMSC-RC-001","Terminated","No Results Available","Rotator Cuff Tear","Drug: Suspension of human autologous MSC 3P","Safety: To assess the occurrence of adverse events of treatment by hAMSC - systemic reactions.|Safety: To assess the occurrence of adverse events of treatment by autologous mesenchymal stem cells - local reactions.|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - Visual Analogue Score (VAS)|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - Constant Shoulder Score|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - UCLA Shoulder Rating Score|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - MRI imaging - Continuation / discontinuation of the rotator cuff|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - MRI imaging - Fatty degeneration","Bioinova, s.r.o.|Department of Neurology, University Hospital Motol, Prague, Czech Republic","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-RC-001","December 12, 2012","November 18, 2015","November 18, 2015","February 12, 2019",,"February 15, 2019",,,"https://ClinicalTrials.gov/show/NCT03838666"
1147,"NCT01646528","The Value of Black Spots in Diagnosing Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy",,"Unknown status","No Results Available","Gastric Intestinal Metaplasia","Procedure: CLE examination for upper gastrointestinal tract","Accuracy of black spots in diagnosis of gastric intestinal metaplasia","Shandong University","All","18 Years to 80 Years   (Adult, Older Adult)",,"30","Other","Observational","Time Perspective: Prospective","2012SDU-QILU-G01","June 2012","December 2012","December 2012","July 20, 2012",,"July 20, 2012","Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01646528"
1148,"NCT03839238","Safety Observation on hESC Derived MSC Like Cell for the Meniscus Injury",,"Unknown status","No Results Available","Meniscus Injury","Biological: hESC derived MSC like cell","The change in number of adverse events based on the National Cancer Institute-Common Terminology Criteria for Adverse Events|Ultrasound of knee joint|Visual Analog Score for pain（VAS）|Range of knee motion|Lysholm Knee Scale|MRI of knee|Global posture analysis system|Dynamic balance test","Tongji Hospital|Chinese Academy of Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Wuhan Tongji Hospital","January 4, 2019","June 30, 2020","September 30, 2020","February 15, 2019",,"February 15, 2019","Tongji Hospital, Tongji Medical College of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT03839238"
1149,"NCT02848131","Senescence in Chronic Kidney Disease",,"Enrolling by invitation","No Results Available","Chronic Kidney Disease","Drug: Group 2: Dasatinib|Drug: Group 2: Quercetin","Change in proportion of senescent cells (representing the total senescent cell burden) present|Change in proportion of senescent mesenchymal stem cells present|Change in mesenchymal stem cell function|Change in Frailty index score|Change in kidney function","Mayo Clinic","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-005843","July 2016","April 2, 2022","June 2, 2022","July 28, 2016",,"August 12, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02848131/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02848131"
1150,"NCT03968198","Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia","ACellDREAM2","Recruiting","No Results Available","Critical Limb Ischemia and Peripheral Artery Disease","Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell)","Number of patients alive without major amputation|Number of patients alive without critical limb ischemia|New vessels|Blood flow|Wound surface reduction|Ulcer healing|Pain reduction|Wound infection|Immuno measures in blood sample|Immuno measures in vitro","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Etablissement Français du Sang","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14 7441 01","March 4, 2020","December 2022","July 2023","May 30, 2019",,"July 30, 2020","CHU de BORDEAUX, Bordeaux, France|CHU de LIMOGES, Limoges, France|Rangueil Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03968198"
1151,"NCT04397471","A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis","COMET20d","Not yet recruiting","No Results Available","Healthy Volunteers for Bone Marrow Donation","Procedure: Bone Marrow Harvest","Determine feasibility of recruiting healthy volunteers in a clinically useful timeframe.|Manufacture a cell-based product suitable for clinical use|Establishment of a robust process of production|Production of stability data to be used in the MHRA dossier for the COMET clinical trial.|Production of cell-based products to be administered to COVID-19 patients with severe pneumonitis.|Analysis of cells for understanding production, manufacture and related research.","CCTU- Cancer Theme|Cambridge Cellular Therapies Laboratory|The Evelyn Trust|Cambridge University Hospitals NHS Foundation Trust","All","18 Years to 40 Years   (Adult)",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COMET20d","May 2020","December 2021","December 2021","May 21, 2020",,"May 21, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04397471"
1152,"NCT04763369","Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)",,"Recruiting","No Results Available","Retinitis Pigmentosa (RP)","Biological: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa|Biological: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa","Evaluation of safety related adverse ocular events including immune response|Ophthalmic examination for best-corrected visual acuity (BCVA) using early treatment of diabetic retinopathy study (ETDRS) chart|Measurement of electrical activity/function of retina using Electroretinography (ERG) test|Evaluation of outer retinal thickness using Optical Coherence Tomography (OCT) imaging test|Examination of retinal damage by Fundus Photography|Evaluation of visual field sensitivity using perimeter","Jinnah Burn and Reconstructive Surgery Centre, Lahore|The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township Lahore.|Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JB&RSC-02","February 2021","May 2022","June 2022","February 21, 2021",,"February 21, 2021","Stem Cell laboratory, Jinnah Burn & Reconstructive Surgery Centre, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04763369"
1153,"NCT04173650","MSC EVs in Dystrophic Epidermolysis Bullosa",,"Not yet recruiting","No Results Available","Dystrophic Epidermolysis Bullosa","Drug: AGLE 102","Dose Limiting Toxicity|Wound size evaluation","Aegle Therapeutics","All","6 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EB IND","April 2022","January 2023","July 2023","November 22, 2019",,"June 24, 2021",,,"https://ClinicalTrials.gov/show/NCT04173650"
1154,"NCT02104713","Stem Cell Therapy to Improve Burn Wound Healing",,"Completed","No Results Available","Skin Burn Degree Second","Biological: Allogeneic (MSC's) Application to the Burn Wounds","Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.","E.Badiavas|United States Department of Defense|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20120925","June 4, 2014","March 18, 2019","March 18, 2019","April 4, 2014",,"April 30, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02104713"
1155,"NCT03099239","hCT-MSCs for Children With Autism Spectrum Disorder (ASD)","hCT-MSCs","Completed","No Results Available","Autism|Autism Spectrum Disorder|ASD","Biological: hCT-MSC infusion","Incidence of Infusion reactions|Incidence of Infections","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","2 Years to 11 Years   (Child)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00079421","June 6, 2017","June 10, 2019","June 10, 2019","April 4, 2017",,"December 3, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03099239"
1156,"NCT02745379","Effect of Buccal Fat Pad Derived Stem Cells in Maxillary Sinus Augmentation",,"Unknown status","No Results Available","Alveolar Bone Loss","Procedure: BFPSCs+ DFDBA+ PRF|Procedure: DFDBA + PRF","amount of regenerated bone","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sbmu9212","January 2016","December 2016","December 2016","April 20, 2016",,"October 17, 2016","School of Dentristry at Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02745379"
1157,"NCT03939741","SVF (Adipose Tissue Derived MSC) Based Therapy for CKD.","StemCell&CKD","Recruiting","No Results Available","Chronic Kidney Diseases","Biological: SVF Containg Autologous Non Expanded ADSC","Incidence of minor adverse events (MAEs) , serious adverse events (SAEs) which may be immediate, early or late - for Phase I|Change from baseline to 24 week visit in glomerular filtration rate (GFR) and split renal function in all patients - for Phase II|Change from baseline to 24 week visit in estimated glomerular filtration rate (eGFR) with serum creatinine level in patients with CKD 4 and below - for Phase II|Change from baseline to 24 week visit in need for dialysis in patients with CKD 5 - for phase II|Change from baseline to all post-treatment visits in body weight|Change from baseline to all post-treatment visits in Blood-pressure|Change from baseline to all post-treatment visits in S.creatinine|Change from baseline to all post-treatment visits in blood urea.|Change from baseline to all post-treatment visits in Hemoglobin level|Change from baseline to all post-treatment visits in urine microalbumin-to-creatinine ratio (UMCR)|Change from baseline to all post-treatment visits in hemoglobin A1c|Change from baseline to all post-treatment visits in random blood sugar (RBS)|Change from baseline to all post-treatment visits in Anti-Hypertensive medication if there is any.|Change from baseline to all post-treatment visits in Hypoglycemic agent if there is any.|Change from baseline to post-treatment visits in urine total protein-creatinine ratio (UPCR)|Change from baseline to all post-treatment visits in urinary Protein-to-creatinine ratio PCR)|Change from baseline to post-treatment level of serum Alpha Feto Protein|Change from baseline to post-treatment level of serum CEA level|Change from baseline to post-treatment level of serum CA 19.9 level|Change from baseline to post-treatment level LDH level|Change from baseline to post-treatment level of Beta 2 Microglobulin level|Change from baseline to post-treatment level of serum CA 125 level (in case of female patients)|Change from baseline to post-treatment level of PSA level (in case of male patients)","Bangladesh Laser & Cell Surgery Institute & Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BangladeshLCS001","April 1, 2019","March 31, 2024","March 31, 2025","May 7, 2019",,"July 15, 2020","Bangladesh Laser And Cell Surgery Institute And Hospital, Dhaka, Bangladesh","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03939741/Prot_SAP_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03939741"
1158,"NCT03248466","PRG Combined With Autologous BMMSCs for Treatment of Diabetic Foot Ulcer",,"Unknown status","No Results Available","Diabetic Foot Ulcer","Biological: PRG combined with BMMSCs transplantation","Amputation rate|hospital stay|Wound healing time|Transcutaneous oxygen partial pressure","Third Military Medical University","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","endocrine department of TMMU","August 30, 2017","January 1, 2020","July 1, 2020","August 14, 2017",,"August 14, 2017","Southwest Hospital of the Third Military Medical University, Chongqing, Chongqing, China|Endocrine Department, the First Affiliated Hospital of the Third Military Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03248466"
1159,"NCT02745366","Buccal Fat Pad Derived Stem Cells With Cortical Tenting in Posterior Mandible Reconstruction",,"Unknown status","No Results Available","Alveolar Bone Loss|Atrophy","Procedure: BFPSC+FDBA+PRF|Procedure: FDBA+PRF","amount of regenerated bone","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sbmu9217","January 2016","December 2016","December 2016","April 20, 2016",,"October 17, 2016","School of Dentristry at Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02745366"
1160,"NCT01915927","Stem Cell Fistula Plug in Perianal Crohn's Disease","MSC-AFP","Completed","No Results Available","Perianal Crohn's Disease","Drug: MSC-AFP","To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.|To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC","William A. Faubion, M.D.|Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009716","July 2013","December 2019","December 2019","August 5, 2013",,"January 3, 2020","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01915927"
1161,"NCT03629015","Safety Study of Stemchymal® in Acute Liver Failure","ALF","Unknown status","No Results Available","Stem Cells|Adult Stem Cells|Acute Liver Failure|Acute-On-Chronic Liver Failure|Steminent","Biological: Stemchymal®","The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)","Steminent Biotherapeutics Inc.|Taipei Veterans General Hospital, Taiwan","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AA01","October 1, 2018","February 29, 2020","October 31, 2020","August 14, 2018",,"August 14, 2018","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03629015"
1162,"NCT03265444","Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy",,"Completed","No Results Available","Multiple System Atrophy","Biological: CS10BR05","Dose-Limiting Toxicity and Maximum Tolerated Dose of CS10BR05 Inj.|Adverse events, frequency and rate of vitals sign, laboratory test, physical examination, ECG, etc.|Unified Multiple System Atrophy Rating Scale(UMSARS)","Corestem, Inc.","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS10BR05-MSA101","April 13, 2018","December 5, 2019","December 5, 2019","August 29, 2017",,"August 7, 2020","Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03265444"
1163,"NCT03258164","Cosmetic Fat Transplantation Using Expanded ASC Enriched Fat Grafts",,"Unknown status","No Results Available","Breast Hypoplasia and Facial Ageing","Biological: ASC enriched lipofilling|Biological: Standard Lipofilling","Change in volume over time after breast augmentation|Change in cosmetic facial appearance over time after facial filling","Stemform|Aleris-Hamlet Hospitaler København","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","32","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","H-16046960","March 22, 2017","January 1, 2021","June 1, 2021","August 23, 2017",,"June 24, 2019","Stemform, Copenhagen, Søborg, Denmark",,"https://ClinicalTrials.gov/show/NCT03258164"
1164,"NCT04427930","Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial",,"Enrolling by invitation","No Results Available","Knee Osteoarthritis","Biological: JOINTSTEM|Drug: Saline","Adverse Events|Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|WOMAC 3 subscale score|SF-36|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan","R-Bio","All","20 Years and older   (Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BSR-CTph3-JS1_FU","April 13, 2020","December 23, 2026","December 30, 2027","June 11, 2020",,"September 25, 2020","Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04427930"
1165,"NCT01558908","Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia",,"Unknown status","No Results Available","Peripheral Vascular Diseases","Biological: Administration of ERC","Safety|Efficacy","Medistem Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDS-027","May 2012","May 2013","July 2013","March 20, 2012",,"March 20, 2012","Indiana University School of Medicine, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01558908"
1166,"NCT02468492","Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Platelet Rich Plasma|Other: Normal Saline","Biochemical Molecular Outcomes|Clinical Outcomes|Imaging Outcomes","Hunter Holmes Mcguire Veteran Affairs Medical Center|Foundation for Physical Medicine and Rehabilitation","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","18","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","IRB #01979/FDA IDE#15944","September 2014","November 2015","November 2015","June 10, 2015",,"August 16, 2017","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02468492"
1167,"NCT03462953","Identification of EMT Indicators in Healthy and Periodontally Diseased Gingival Samples",,"Unknown status","No Results Available","Chronic Periodontitis","Procedure: Gingival tissue samples will be harvested","Localization of EMT indicators TGF- β1, Vimenten, E-Cadherin","Cairo University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","CEBC-CU-2018-02-28","April 15, 2018","August 15, 2018","March 15, 2019","March 13, 2018",,"March 13, 2018",,,"https://ClinicalTrials.gov/show/NCT03462953"
1168,"NCT03902067","UC-MSC Transplantation for Left Ventricular Dysfunction After AMI",,"Not yet recruiting","No Results Available","Left Ventricular Dysfunction|Acute Myocardial Infarction","Biological: UC-MSC|Biological: Control Group","Safety measured as the number of Major Adverse Cardiac Events (MACE)|Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up","Shanghai Life Science & Technology|Shanghai Jiao Tong University Affiliated Sixth People's Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ShanghaiLST-ucmsc-ami01","December 1, 2020","December 31, 2021","December 31, 2021","April 3, 2019",,"October 22, 2020","Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03902067"
1169,"NCT02317458","Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL","CHART-2","Unknown status","No Results Available","Heart Failure","Biological: Experimental|Biological: Sham comparator","Efficacy of C3BS-CQR-1 injection based on a hierarchical composite score","Celyad Oncology SA","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C3BS-C-12-01","June 2017","March 2020",,"December 16, 2014",,"July 11, 2016",,,"https://ClinicalTrials.gov/show/NCT02317458"
1170,"NCT03067870","Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis",,"Active, not recruiting","No Results Available","RheumatoId Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip","Biological: Stem Cell Transplantation","Evaluation of Pain Reduction measured by VAS scaling|Evaluation of the Physical Activity measure by WOMAC scoring|Evaluation the resurfacing of articular cartilage by MRI","Stem Cells Arabia","All","17 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA-RA1","November 2016","December 2021","February 2022","March 1, 2017",,"March 17, 2020",,,"https://ClinicalTrials.gov/show/NCT03067870"
1171,"NCT02492308","Induction With SVF Derived MSC in Living-related Kidney Transplantation",,"Unknown status","No Results Available","Living-relative Kidney Transplantation","Procedure: SVF-MSC induction|Drug: Basiliximab induction","Effects of autologous SVF derived MSC transplantation on reducing the dosage of immunosuppressant in living-related kidney transplant recipients.|Changes in renal function|Incidence of acute rejection|Incidence of delayed graft function|Allograft survival|Infection adverse event|Non-hematologic toxicities|Hematologic toxicities","Fuzhou General Hospital","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SVF-LR","December 2014","December 2016","December 2017","July 8, 2015",,"July 8, 2015","Xi er huan road No.156, Fuzhou, Fujian, China|Xi er huan road No.156, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT02492308"
1172,"NCT02016508","Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration",,"Unknown status","No Results Available","Age Related Macular Degeneration","Drug: autologous bone marrow derived stem cells","number of subjects with adverse events|Assessment of visual function changes from the base line","Al-Azhar University|Hassan , Hosny , M.D. M.Sc|Samour , Hany M.D. M.Sc|Ismail , Mahmoud M.D. M.Sc|Higazy , Hasan M.D. M.Sc|Abou el kheir, Wael, M.D. M.Sc.|Gabr, Hala , M.D. M.Sc.|Bakry, Sayed , phD. M.Sc.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCT 4619792013|4619792013","March 2013","April 2015","June 2015","December 20, 2013",,"December 24, 2013","Al-Azhar university medical school (Benin-cairo) ophthalmology department, Cairo, Nasr city, Egypt",,"https://ClinicalTrials.gov/show/NCT02016508"
1173,"NCT02767817","Injectable Collagen Scaffold™ Combined With MSCs Transplantation for Brain Injury",,"Active, not recruiting","No Results Available","Brain Injury","Procedure: Stereotactic Hematoma Evacuation|Biological: MSCs Transplantation|Biological: Injectable Collagen Scaffold with MSCs Transplantation","Number of adverse events and participants with those adverse events|Change in functional outcomes as measured by National Institutes of Health stroke scale (NIHSS) score|Change in motor recovery evaluated by Brunnstrom stage|Change in self-care ability as measured by Barthel Index (BI)|Change in pain intensity as measured by Visual Analogue Scale (VAS)|Change in electrical brain activity as measured by Electroencephalography (EEG)|Changes in brain electrophysiology as measured by Somatosensory evoked potential (SSEP)|Change in brain pathology diagnosed by Head CT scan","Chinese Academy of Sciences|Affiliated Hospital of Logistics University of CAPF","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-BI/IGDB","March 2016","December 2021","December 2021","May 10, 2016",,"December 23, 2020","Affiliated Hospital of Logistics Universtiy of CAPF, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02767817"
1174,"NCT04410731","Allogeneic BM-MSCs in Patients With Lumbar Facet Arthropathy","Cellkine","Recruiting","No Results Available","Facet-Mediated Low Back Pain","Drug: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy","Clinical assessment of nature, incidence, and severity of adverse events (AEs)|Self-reported assessment of nature, incidence, and severity of AEs|Study personnel assessment of nature, incidence, and severity of AEs|Global Health Scale (GHS)|Visual Analog Scale (VAS) - back and leg pain|Oswestry Disability Index (ODI)|Patient Health Questionnaire-4 (PHQ-4)|Narcotic Use Questionnaire|Work Status Questionnaire|PROMIS-CAT|Changes from Baseline evaluated by MRI|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide","Mayo Clinic","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-000330","April 28, 2020","April 1, 2022","April 1, 2022","June 1, 2020",,"August 31, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04410731"
1175,"NCT02669199","MSCs Source of Sweat Gland Cells of Large Area Skin Injury Patients Transplant of the Wound","MSCs","Completed","No Results Available","MSCs","Biological: MSCs","Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 12 Week","Chinese PLA General Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHIN-PLAGH-ST-007","January 2012","December 2015","December 2015","February 1, 2016",,"February 1, 2016","Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02669199"
1176,"NCT04074408","Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration",,"Recruiting","No Results Available","Basal Ganglia Hematoma","Procedure: stereotactic surgery|Biological: hUMSCs|Biological: placebo","Frequency of dose limiting adverse events|Modified Rankin Scale (mRS) to measure the prognosis|National institute of Health Stroke Scale (NIHSS) to measure stroke recovery|Barthel Index (BI) to evaluate the self-care ability|Rate of muscle strength level of the hemiplegic limb|Mortality rate|Change in Glasgow coma scale (GCS) score|Change in Glasgow outcome scale (GOS) score|MRI (T1, T2, Flair, DWI) scanning","Second Affiliated Hospital, School of Medicine, Zhejiang University|The First Affiliated Hospital, University of Science and Technology of China|Huzhou Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Fujian Medical University|Jinhua Hospital, School of Medicine, Zhejiang University|Taizhou Hospital","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SAHZJU-hUMSCs","May 2020","November 2022","November 2023","August 30, 2019",,"May 26, 2020","Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04074408"
1177,"NCT03651791","In Vivo Tracking of USPIO Labeled MSC in the Heart","USPIO-MSC","Completed","No Results Available","Ischemic Heart Disease","Combination Product: USPIO labeled MSC injection","MSC identification using MRI in-vivo on day 0|MSC identification using MRI in-vivo on day 1|MSC identification using MRI in-vivo on day 7|MSC identification using MRI in-vivo after 2 weeks|MSC identification using MRI in-vivo after 4 weeks|MSC identification using MRI in-vivo after 8 weeks|MSC identification using MRI in-vivo after 12 weeks|MSC identification using MRI in-vivo after 26 weeks|Cardiac pump function changes|CCS class|Seattle Angina Questionnaire|Weekly number of angina attacks|Weekly nitroglycerin consumption|Adverse events","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USPIO-MSC1","May 2013","June 2014","October 2017","August 29, 2018",,"August 29, 2018",,,"https://ClinicalTrials.gov/show/NCT03651791"
1178,"NCT04126603","Impact of Semaglutide on CD34+ EPC and Fat Derived MSC",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebos","CD34+ Endothelial Progenitor Cell number|CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient|Gene Expression of CD34+ Endothelial Progenitor Cell number|Gene Expression of Subcutaneous Adipose cell|Arterial Stiffness: Pulse Wave Velocity|Arterial Stiffness: Pulse Wave Analysis|Body Composition: BMI|Body Composition: Body Fat Percent|Hip to Waist Ratio|Biochemistry: HbA1c|Biochemistry: LDL over HDl Ratio","Sabyasachi Sen|George Washington University","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCR191206","August 1, 2019","August 1, 2021","November 30, 2021","October 15, 2019",,"October 15, 2019","The GW Medical Faculty Associates, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04126603"
1179,"NCT02685046","Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy","ImPACCT","Terminated","No Results Available","Colonic Neoplasms","Drug: Imatinib","Effects of treatment on the mesenchymal gene expression profile|Extent of targeted inhibition of PDGFR and KIT phosphorylation in cancer cells|Correlation between plasma imatinib trough levels on day 14 and intratumoural concentration of imatinib in the resection specimen|Correlation between the extent of PDGFR and cKIT inhibition and systemic and intratumoural imatinib and CGP74588 concentration|Change in plasma CEA-concentrations|Change in plasma levels of circulating tumor DNA|Effects of imatinib on the ability of cancer cells to form in vitro 3D cell cultures (organoids)|Number of participants with treatment-related adverse events as assessed by CTCAEv4.02","UMC Utrecht|Meander Medical Center|Erasmus Medical Center|Hubrecht Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-TT-IMA-14|NL50620.041.15|2014-003965-11","April 2016","September 1, 2019","September 1, 2019","February 18, 2016",,"October 14, 2019","Meander Medical Center, Amersfoort, Utrecht, Netherlands|Diakonessenhuis, Utrecht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02685046"
1180,"NCT01709656","A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis",,"Completed","No Results Available","Ankylosing Spondylitis","Biological: MSC|Drug: ""celecoxib"", ""Celebrex®""","the proportion of patients which disease activity reaches ASAS(assessment in ankylosing Spondylitis)20 remission criteria|BASDAI score comparing to baseline|BASFI score comparing to baseline","Sun Yat-sen University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","[2012]2-31","March 2012","December 2014","December 2014","October 18, 2012",,"February 11, 2015","Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01709656"
1181,"NCT02145897","To Evaluate the Safety and Efficacy of IM and IV Administration of Autologous ADMSCs for Treatment of CLI",,"Unknown status","No Results Available","Critical Limb Ischemia","Biological: Autologous Stromal Vascular Fraction (SVF)|Biological: Autologous Adipose Derieved MSCs|Other: Control","To assess the safety|To assess the efficacy","Kasiak Research Pvt. Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KRPL/CLI/11-12/001","August 2014","August 2015",,"May 23, 2014",,"May 23, 2014","Kasiak Research Pvt Ltd, Thane, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02145897"
1182,"NCT02745808","Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes",,"Unknown status","No Results Available","Erectile Dysfunction|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus","Biological: HUC-MSCs|Biological: Injectable Collagen Scaffold + HUC-MSCs","Safety and Tolerability assessed by Adverse Events|Improvement in IIEF-5 (International Index of Erectile Function)|Improvement in penile colour Doppler ultrasonography","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","Male","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CAS-XDA-DEF/IGDB","September 2015","December 2020","December 2020","April 20, 2016",,"January 25, 2019","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02745808"
1183,"NCT04681118","Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS",,"Available","No Results Available","Amyotrophic Lateral Sclerosis","Biological: NurOwn (MSC-NTF cells)",,"Brainstorm-Cell Therapeutics","All","18 Years to 63 Years   (Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"BCT-003-US",,,,"December 23, 2020",,"December 23, 2020","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04681118"
1184,"NCT01686139","Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers",,"Unknown status","No Results Available","Type I Diabetes Mellitus With Ulcer|Type II Diabetes Mellitus With Ulcer","Biological: ABMD-MSC","Frequency of Adverse Events","Sheba Medical Center","All","18 Years to 81 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-11-8802-IS-SMC","March 2016","March 2017","December 2017","September 17, 2012",,"January 27, 2016","Orthopedic Rehabilitation out-patient clinic, Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT01686139"
1185,"NCT04664829","The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC",,"Recruiting","No Results Available","Metastatic Triple-Negative Breast Carcinoma","Drug: Bexarotene|Drug: Capecitabine","Tumour transcriptome by RNA sequencing|Tumour protein profile by multiplex immunohistochemistry|Incidences of treatment related adverse events","National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore","Female","21 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BEXMET","October 1, 2020","June 30, 2023","June 30, 2023","December 11, 2020",,"December 11, 2020","National Cancer Center Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04664829"
1186,"NCT02947191","Collagen Membrane Combined With HUC-MSCs Transplantation in Patients With Nasal Septum Perforation",,"Active, not recruiting","No Results Available","Chronic Nasal Septum Perforation","Biological: Collagen membrane + HUC-MSCs","The change of integrity of nasal septum assessed by endoscopic examination|The change of nasal mucosal physiology assessed by olfactory test|The change of nasal mucosal physiology assessed by nasal mucociliary clearance time (MCT)|The change of nasal airway resistance assessed by rhinomanometry|The change of nasal obstruction assessed by acoustic rhinometry|The change of nasal obstructive symptom assessed by visual analogue scale (VAS)|The change of nasal symptom severity assessed by total nasal symptom score (TNSS)|Change from baseline in computed tomography (CT)","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAS-XDA-NSP/IGDB","November 2016","December 2021","December 2021","October 27, 2016",,"January 5, 2021","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02947191"
1187,"NCT01409954","Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells",,"Enrolling by invitation","No Results Available","Pseudarthrosis After Fusion or Arthrodesis",,"Osteogenic Potential of Mesenchymal Stem Cells","University of Utah","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","46970","October 2011","January 2023","January 2023","August 4, 2011",,"March 10, 2021","University of Utah Orthopaedic Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01409954"
1188,"NCT03147976","QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors",,"Withdrawn","No Results Available","Solid Tumor","Drug: AMG 337","Objective Response Rate (ORR)|Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)|Progression-free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)|Disease Control Rate (DCR)","NantPharma, LLC","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QUILT-3.036","May 2, 2018","August 23, 2019","August 23, 2019","May 10, 2017",,"August 28, 2019","Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",,"https://ClinicalTrials.gov/show/NCT03147976"
1189,"NCT01768702","Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.","CHART-1","Completed","No Results Available","Heart Failure","Biological: Injection of C3BS-CQR-1|Biological: Sham, no injection","Efficacy between groups post-index procedure|Efficacy and safety between groups post-index procedure","Celyad Oncology SA","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","C3BS-C-11-01|2011-001117-13","November 2012","August 2017","August 2017","January 15, 2013",,"June 1, 2018","OLV Ziekenhuis Aalst, Aalst, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Hopital Civil Marie Curie, Lodelinsart, Belgium|AZ Glorieux, Ronse, Belgium|CHU Mont-Godinne, Yvoir, Belgium|City Clinic Cardiology Center Multiprofile Hospital for Active Treatment, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia', Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment 'Alexandrovska' EAD, Sofia, Bulgaria|Gottsegen György Országos Kardiológiai Intézet - Felnőtt Kardiológiai Osztály, Budapest, Hungary|Semmelweis Egyetem - Városmajori Szív- és Érgyógyászati Klinika, Budapest, Hungary|MH Egészségügyi Központ Kardiológiai Osztály, Budapest, Hungary|Debreceni Egyetem Orvos - és Egészségtudomanyi Centrum, Debrecen, Hungary|Pécsi Tudományegyetem Klinikai Központ - Szívgyógyászati Klinika, Pécs, Hungary|Barzilai Medical Center - Cardiology Unit, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Western Galilee Hospital, Nahariya, Israel|Nazareth Hospital EMMS, Nazareth, Israel|Ziv Medical Center - Heart Institute, Safed, Israel|A.O. Spedali Civili di Brescia, Brescia, Italy|AOUI Verona - Borgo Trento Hospital, Verona, Italy|Uniwersyteckie Centrum Kliniczne, KliniczneCentrum Kardiologii, Gdansk, Poland|Górnośląskie Centrum Medyczne Śląskiej Akademii Medycznej, Katowice, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Kraków, Poland|Biegański Hospital, Łódź, Poland|Clinic of Emergency Internal Medicinne Military Medical Academy, Belgrade, Serbia|Clinical Center of Serbia - Cardiology Clinic, Belgrade, Serbia|Clinical Centre of Serbia, Cardiology Clinic, Belgrade, Serbia|Clinical Hospital Center Zvezdara - Cardiology Clinic, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Cardiology Dept., Belgrade, Serbia|Clinical Center of Kragujevac,, Kragujevac, Serbia|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria - Campus de Teatinos s/n, Malaga, Spain|Cardiocentro Ticino, Lugano, Switzerland",,"https://ClinicalTrials.gov/show/NCT01768702"
1190,"NCT03747913","Oxidative Stress as an Acute Exercise-induced Mechanism of Stem and Progenitor Cell Mobilization","EISMO","Completed","No Results Available","Healthy","Dietary Supplement: Antioxidative supplementation","Changes in exercise-dependently mobilized stem and progenitor cell numbers in the peripheral blood with antioxidative supplementation|Changes in numbers of exercise-induced apoptotic cells and oxidative stress markers in the peripheral blood with antioxidative supplementation","Swiss Federal Institute of Technology","Male","18 Years to 35 Years   (Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EISMO","May 2, 2019","October 21, 2019","October 31, 2019","November 20, 2018",,"December 16, 2019","Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich, Zürich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03747913"
1191,"NCT04388982","the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Biological: low dosage MSCs-Exos administrated for nasal drip|Biological: mild dosage MSCs-Exos administrated for nasal drip|Biological: high dosage MSCs-Exos administrated for nasal drip","Number of participants with treatment-related abnormal laboratory values of Liver or kidney function|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Cognitive function|Quality of life evaluation|MRI Neuroimaging|PET-CT Neuroimaging","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBMG-AD-01","July 1, 2020","August 2021","August 2022","May 15, 2020",,"June 25, 2021","Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04388982"
1192,"NCT04040348","Alzheimer's Disease Stem Cells Multiple Infusions",,"Recruiting","No Results Available","Alzheimer Disease","Biological: Approximately 100 million cells allogeneic hMSC","Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)|Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11)|Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test|Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version|Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver|Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver|Neuropsychiatric Inventory-Q (NPI-Q) Scores over time|Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores|Biomarker levels over time|Serum ApoE level over time|Serum PRA level over time|Serum Tau protein level over time|Cerebrospinal Fluid (CSF) Biomarker levels over time|CSF ApoE level over time|CSF PRA level over time|CSF Tau protein level over time|Change in hippocampal volume","Bernard (Barry) Baumel|University of Miami","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20190438","October 8, 2019","September 1, 2022","September 1, 2022","July 31, 2019",,"July 19, 2021","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04040348"
1193,"NCT02492490","Effect of SVF Derived MSC in DCD Renal Transplantation",,"Unknown status","No Results Available","Uremia","Other: SVFderived MSC transplantations|Drug: Basiliximab","Effects of autologous SVF derived MSC transplantation on reducing the dosage of CNI by 30% in Kidney Transplantation from Chinese Donation after Citizen Death|Changes in renal function as determined by eGFR and proteinuria|Incidence of Acute rejection|Incidence of delayed graft function (DGF)|Allograft survival|SAE (severe adverse effects)|non-hematologic toxicities","Fuzhou General Hospital","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SVF-DCD","December 2014","November 2016","November 2016","July 8, 2015",,"July 8, 2015","Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT02492490"
1194,"NCT02641769","Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.",,"Recruiting","No Results Available","Non-obstructive Azoospermia","Biological: Stem Cell Transplantation","Appearance of different germ cells in testicles through the progress of spermatogenesis will be assessed by the count of cells using histological studies.|General improvements of testicular morphology will be assessed with histological studies.|Improvement in sexual function will be assessed using a questionnaire","Stem Cells Arabia","Male","21 Years to 50 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA-INF1","January 2014","June 2020","January 2021","December 29, 2015",,"March 17, 2020","Stem Cells of Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02641769"
1195,"NCT03838250","Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC",,"Recruiting","No Results Available","Alcoholic Liver Cirrhosis","Biological: Cellgram™ (Bone marrow-derived MSCs)","Incidence of Serious Adverse Events|Number of patients with Hepatocellular carcinoma (primary liver cancer) development|Incidence of Adverse Events|Liver stiffness measurement|How well the Liver is functioning|Chronic liver disease as assessed by the Child-Pugh score|Model for End-Stage Liver Disease (MELD) Score|Overall survival|Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire","Pharmicell Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-P-08","June 20, 2019","March 2021","June 2021","February 12, 2019",,"October 22, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03838250"
1196,"NCT03896568","Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",,"Recruiting","No Results Available","IDH1 wt Allele|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma","Biological: Oncolytic Adenovirus Ad5-DNX-2401|Procedure: Therapeutic Conventional Surgery","Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies","M.D. Anderson Cancer Center|DNAtrix, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0953|NCI-2019-01195","February 12, 2019","May 31, 2022","May 31, 2022","April 1, 2019",,"April 28, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03896568"
1197,"NCT02313415","Treatment of Infertility by Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchyma Stem Cells",,"Completed","No Results Available","Infertility|Intrauterine Adhesions","Procedure: UC-MSCs therapy","live birth rate|Reduction of intrauterine adhesion|The change of endometrial thickness|ongoing pregnant rate","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Institute of genetic development, Chinese Academy of Sciences|Institute of zoology, Chinese Academy of Sciences","Female","20 Years to 45 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20141206","November 28, 2014","January 28, 2015","August 31, 2017","December 10, 2014",,"October 24, 2017","Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02313415"
1198,"NCT01309061","The Effect of Human Adipose Tissue-derived MSCs in Romberg's Disease",,"Completed","No Results Available","Progressive Hemifacial Atrophy|Romberg's Disease","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","The volume change of fatty layer|Clinical lab tests|Fat absorption rate","R-Bio|Asan Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","5","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-Facial-Stem","March 2008","December 2009","February 2010","March 4, 2011",,"June 5, 2019","ASAN Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01309061"
1199,"NCT04953663","Clinical Plan of Ischemic Stroke",,"Recruiting","No Results Available","Stroke","Biological: it-hMSC","Adverse events and serious adverse events rate|Rate of clinical significant changes in laboratory|Rate of abnormal neurological physical examination results|Rate of imaging changes|Change of NIHSS scores|Change of BI scores|Change of mRS scores|Change of MMSE scores|Change of GDS scores","Peking University Third Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D2020093","January 1, 2021","January 1, 2022","January 1, 2023","July 8, 2021",,"July 8, 2021","Peking University Third Hospital, Beijin, China",,"https://ClinicalTrials.gov/show/NCT04953663"
1200,"NCT02644447","Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF",,"Completed","No Results Available","Premature Ovarian Failure","Biological: HUC-MSCs Transplantation|Biological: HUC-MSCs with Injectable Collagen Scaffold Transplantation","Safety and Tolerability assessed by Adverse Events|Number of Antral follicle development|Estradiol (E2) serum level|Follicle Stimulating Hormone (FSH) serum level|Anti-Mullerian Hormone (AMH) serum level|Pregnancy rate","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","Female","20 Years to 39 Years   (Adult)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-POF/IGDB","October 2015","October 2018","October 2018","December 31, 2015",,"January 13, 2020","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02644447"
1201,"NCT02544633","Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: MGCD265","Objective Response Rate|Duration of Response|Progression Free Survival|1-Year Survival Rate|Overall Survival|Number of Patients Experiencing Treatment-emergent Adverse Events|Blood Plasma Concentration of MGCD265 - AUC0-6|Blood Plasma Concentration of MGCD265 - Cmax|Blood Plasma Concentration of MGCD265 - Ctrough|Blood Plasma Concentration of MGCD265 - Accumulation Ratio AUC0-6|Blood Plasma Concentration of MGCD265 - Accumulation Ratio Cmax|Blood Plasma Concentration of MGCD265 - Peak to Trough Ratio|Blood Plasma Concentration of MGCD265 - Tmax|Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Activating Mutations|Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Gene Amplifications|Assess Change in Genetic Alteration Status in ctDNA With MGCD265 Treatment Over Time in the Selected Population|Blood Plasma Concentration of Soluble MET (sMET) Biomarker","Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","68","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","265-109","October 2015","April 30, 2018","January 2019","September 9, 2015","September 10, 2019","March 4, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Clearview Cancer Institute, Huntsville, Alabama, United States|Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Saint Joseph Heritage Healthcare, Fullerton, California, United States|University of California San Diego, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of California, San Francisco, San Francisco, California, United States|Innovative Clinical Reseach Institute, Whittier, California, United States|St. Mary's Regional Cancer Center, Grand Junction, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Boca Raton Regional Hospital - Eugene M. & Christine E. Lynn Cancer Institute, Boca Raton, Florida, United States|Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Mercy Cancer Center, Mason City, Iowa, United States|Oncology-Hematology Associates, PA, Danville, Kentucky, United States|Lexington Oncology Associates, LLC, Lexington, Kentucky, United States|Kentuckyone Health Cancer and Blood Speacialists, Louisville, Kentucky, United States|Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Queens Cancer Center, Jamaica, New York, United States|Clinical Research Alliance, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Cancer Center, Sayre, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Saint George Hospital, Kogarah, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Cancer Centre, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|Monash Health, Clayton, Australia|The Tweed Hospital, Tweed Heads, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|McGill University Health Centre, Montréal, Canada|Szent Borbála Kórház, Tatabánya, Komarom-esztergom, Hungary|Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary|Országos Onkológiai Intézet, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Ospedale Unico Versilia, Lucca, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Istituto Europeo di Oncologia Milano, Milano, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|Azienda Unita Sanitaria Locale di Ravenna, Ravenna, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Chungbuk National University Hospital, Cheongju, Chungcheongbuk-do, Korea, Republic of|National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Saint Vincent Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea Saint Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Veterans Health Service Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdańsk, Pomorskie, Poland|Samodzielny Publiczny Zespól Gruzlicy i Chorób Pluc w Olsztynie, Olsztyn, Warminsko-mazurskie, Poland|Med Polonia Sp. z o.o., Poznan, Wielkopolskie, Poland|National Cheng Kung University, Tainan, Tainan CITY, Taiwan|Chi Mei Hospital Liouying, Tainan City, Tainan, Taiwan|Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|North Bristol NHS Trust, Westbury on Trym, Bristol, England, United Kingdom|University College London Hospitals NHS Foundation Trust, London, England, United Kingdom|East and North Hertordshire NHS Trust, Northwood, England, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02544633/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02544633"
1202,"NCT02786017","Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis",,"Unknown status","No Results Available","Decompensated Cirrhosis","Biological: Conventional therapy|Biological: Injectable Collagen Scaffold + HUC-MSCs","Improvement of liver function measured by change in the model for end-stage liver disease (MELD) score|Improvement of liver function measured by change in Child-Pugh score|Change in clinical laboratory parameters of liver function|30-Day Survival|Change in the size of liver and spleen and inner diameter of spleen portal venous","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-DC/IGDB","May 2016","December 2020","December 2020","May 30, 2016",,"January 13, 2020","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02786017"
1203,"NCT03113747","Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs)","ADSCs-BWs","Unknown status","No Results Available","Second- or Third-degree Burns","Biological: ALLO-ASCs","The degree of healing of skin flap; The degree of epithelialization of burn wounds in the perforations of a skin graft|The dynamics of healing of skin flap|Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test.|Duration of treatment (days) to complete epithelialization of burn wounds;","A.A. Partners, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-P1","March 25, 2015","December 26, 2018","December 26, 2018","April 14, 2017",,"April 26, 2017","The Kyiv City Clinical Hospital №2, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03113747"
1204,"NCT03766139","Regenerative Potential of Supercell Glue and Platelet Rich Fibrin Matrix",,"Unknown status","No Results Available","Intrabony Periodontal Defect","Biological: SUPERCELL GLUE|Biological: PRFM ALONE","Early wound healing index (Supercell in early wound healing index)|Change in probing pocket depth and clinical attachment gain (Supercell as a regenerative novel material)|Change in the bone level (Supercell as a biological material)|Change in the clinical parameters of gingival index and plaque index (Supercell as a regenerative material using clinical indices)","KLE Society's Institute of Dental Sciences","All","25 Years to 60 Years   (Adult)","Early Phase 1","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PARVATHY61","December 2018","June 2019","November 2019","December 6, 2018",,"December 7, 2018","Kle Society'S Institute of Dental Sciences, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT03766139"
1205,"NCT03455335","Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia","Drug: 20 million hMSCs|Drug: 40 million hMSCs|Drug: 80 million hMSCs","The number of Serious Adverse Events that are attributable to the treatment|The severity of Serious Adverse Events that are attributable to the treatment|Amputation free survival|median time to amputation,|Change in Transcutaneous Pressure of Oxygen TcPO2|Change in Ankle Brachial Index|Collateral vessel formation|Change in Ischemic rest pain|Change in Ulcer size|Change in Quality of Life","National University of Ireland, Galway, Ireland|University Hospital of Limerick","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-001","March 23, 2015","October 31, 2019","October 31, 2019","March 6, 2018",,"March 4, 2021","Galway University Hospital, Galway City, Galway, Ireland",,"https://ClinicalTrials.gov/show/NCT03455335"
1206,"NCT03381326","CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.","IRSTB030","Active, not recruiting","No Results Available","Prostate Cancer|Metastatic Cancer|Castration-resistant Prostate Cancer|Circulating Tumor Cells","Procedure: blood and FFPE sample collection","Progression free survival (PFS)|Overall survival (OS)","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","Male","18 Years and older   (Adult, Older Adult)",,"94","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRSTB030","December 15, 2014","October 2019","June 2021","December 22, 2017",,"February 26, 2021","Ospedali Riuniti Umberto I, Ancona, AN, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy|IRCCS AOU San martino IST, Genova, GE, Italy|Ospedale Civile degli Infermi, Rimini, RN, Italy|Azienda Ospedaliera Cannizzaro, Catania, Italy|Ospedale Maggiore della Carità, Novara, Italy|Istituto Oncologico del Veneto (IOV) - Università di Padova, Padova, Italy|Policlinico Universitario Campus Bio-Medico, Roma, Italy|Ospedale Sacro Cuore Don Calabria (Negrar), Verona, Italy",,"https://ClinicalTrials.gov/show/NCT03381326"
1207,"NCT02221882","A Study of LY3164530 in Participants With Cancer",,"Completed","Has Results","Neoplasms|Neoplasm Metastasis","Drug: LY3164530","Recommended Phase 2 Dose of LY3164530: Maximum Tolerated Dose (MTD)|Maximum Serum Concentration (Cmax) of LY3164530 Epidermal Growth Factor Receptor (EGFR) Specific ELISA Assay|Maximum Serum Concentration (Cmax) of LY3164530 Mesenchymal-Epithelial Transition Factor (MET) Specific ELISA Assay|Area Under the Serum Concentration-Time Curve (AUC[0-τ]) of LY3164530 EGFR Specific ELISA Assay|Area Under the Serum Concentration-Time Curve (AUC[0-τ]) of LY3164530 MET Specific ELISA Assay|Number of Participants With Tumor Response","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15279|I7H-MC-JNBA","August 2014","March 7, 2017","March 7, 2017","August 21, 2014","October 23, 2019","October 23, 2019","Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The START Center for Cancer Care, San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02221882/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02221882/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02221882"
1208,"NCT00221130","Clinical Trials of Regeneration for Periodontal Tissue",,"Completed","No Results Available","Adult Periodontitis","Procedure: surgical operation of cell transplantation","Alveolar bone defect|Tooth mobility","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|ArBlast Co.,Ltd.|Nagoya University","All","35 Years to 60 Years   (Adult)","Phase 1|Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRI PDT03-01","July 2004",,"December 2005","September 22, 2005",,"February 9, 2009","Ｉｎstitute of Biomedical Research and Innovation, Kobe, Hyogo Pref., Japan",,"https://ClinicalTrials.gov/show/NCT00221130"
1209,"NCT01804153","Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO)","HULPURO","Unknown status","No Results Available","Urinary Incontinence","Drug: Adipose-derived expanded stem cells","Evaluate the feasability and security of the autologous ASC for the feminine stress urinary incontinence|Quality of life assessment using the SF-12 Questionnaire|Adverse events","Instituto de Investigación Hospital Universitario La Paz","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HULPURO-2010-01|2010-024331-16","September 2012","October 2013","April 2014","March 5, 2013",,"March 5, 2013","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01804153"
1210,"NCT00790764","Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)",,"Suspended","No Results Available","Heart Disease|Blocked Arteries|Coronary Ischemia|Coronary Disease|Coronary Artery Disease|Coronary Atherosclerosis","Biological: MESENDO|Other: placebo","Safety as measured by laboratory assessments, ecg and temperature.|Efficacy as measured by SPECT scan, MUGA scan and 2D Echogradiogram","TCA Cellular Therapy","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008--03-II","November 2008","May 2014","May 2014","November 13, 2008",,"May 9, 2014","TCA Cellular Therapy, Covington, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00790764"
1211,"NCT01663116","Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients",,"Completed","No Results Available","Rheumatoid Arthritis Aggravated","Genetic: Stem cells|Genetic: Placebo","Number of Adverse Events and Severe Adverse Events|Proportion of ACR20 patients/ACR50 patients/ACR70 patients (swollen joints*, tender joints**, physician global assessment***, patient global assessment***, patient´s assessment of pain ***, ESR/CRP, HAQ score)","Tigenix S.A.U.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Cx611-0101","March 2011","January 2013","January 2013","August 13, 2012",,"April 12, 2019","Hospital U. Central de Asturias, Oviedo, Asturias, Spain|Hospital General de Mérida, Mérida, Badajoz, Spain|Hospital U. de Canarias, La Laguna, Tenerife, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Complejo Hospitalario U. A Coruña, A Coruña, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. de Guadalajara, Guadalajara, Spain|Hospital de La Princesa, Madrid, Spain|Hospital U. Gregorio Marañon, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital U. La Paz, Madrid, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital U. Marques de Valdecilla, Santander, Spain|Hospital Ntra. Sª de Valme, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital La Fe, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01663116"
1212,"NCT00810238","C-Cure Clinical Trial",,"Completed","No Results Available","Heart Failure Class II or III","Biological: C-Cure","Change in left ventricular ejection fraction|6-min walking distance|Quality of Life|All cause mortality|Cardiovascular events","Celyad Oncology SA","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","C3BS-C-07-01|EudraCT 2007-007699-40","December 2008","July 2010","January 2012","December 18, 2008",,"September 5, 2012","CardioVascular Center, Aalst, Belgium|Université Catholique de Louvain, Saint-Luc, Brussels, Belgium|Centre Hospitalier Universitaire, Charleroi, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Ziekenhuis Oost Limburg, Genk, Belgium|Virga Jesse Ziekenhuis, Hasselt, Belgium|Centre Hospitalier Universitaire, Liège, Belgium|Clinical Center of Serbia, Belgrade, Serbia",,"https://ClinicalTrials.gov/show/NCT00810238"
1213,"NCT00615329","Huntsman Biopsy Study",,"Terminated","No Results Available","Soft Tissue Sarcoma|Osteosarcoma",,"Classification of sarcomas","State University of New York - Upstate Medical University|Huntsman Cancer Institute","All","Child, Adult, Older Adult",,"142","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Huntsman Cancer Institute|IRB 4795","April 2003","February 2014","February 2014","February 14, 2008",,"November 25, 2014","SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT00615329"
1214,"NCT00956891","Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation",,"Completed","No Results Available","Liver Failure|Mesenchymal Stem Cells",,"Short-term therapeutic effects of transplantation.|Long-term outcomes of transplantation.","Sun Yat-sen University","All","15 Years to 70 Years   (Child, Adult, Older Adult)",,"158","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","SunYat-senU 5010 hepatitisB","May 2005","June 2009","July 2010","August 11, 2009",,"December 7, 2010","The Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT00956891"
1215,"NCT01392625","PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)","PoseidonDCM","Completed","Has Results","Non-ischemic Dilated Cardiomyopathy","Biological: Autologous hMSCs|Biological: Allogeneic hMSCs","Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20100968|1R01HL110737-01","May 19, 2011","August 28, 2016","August 28, 2017","July 12, 2011","February 15, 2018","February 15, 2018","University of Miami School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01392625"
1216,"NCT01585857","ADIPOA - Clinical Study",,"Completed","No Results Available","Osteoarthritis","Biological: Autologous adipose derived stem cells administrated for intra-articular use","Recording of Serious Adverse Events|Functional status of the knee|Quality of life","University Hospital, Montpellier","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8606","April 2012","December 2014","December 2014","April 26, 2012",,"December 4, 2014","UH Montpellier, Montpellier, France|Orthopädische Klinik, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT01585857"
1217,"NCT01803347","Clinical Trial to Evaluate the Efficacy and Safety of Stem Cells","FISPAC","Completed","No Results Available","Anal Fistula","Drug: ◦Drug: ASCs. + fibrin glue|Drug: fibrin glue","Safety/efficacy","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2012-001178-28","February 2013","October 2017","October 2017","March 4, 2013",,"April 19, 2018","Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Clínico Universitario, Salamanca, Castilla-Leon, Spain|Hospital General Universitario, Valencia, Comunidad Valenciana, Spain|Hospital Universitario La Paz, Madrid, Spain|Clínica Universitaria de Navarra, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT01803347"
1218,"NCT03138083","OMO-1 in Solid Malignancies",,"Terminated","No Results Available","Neoplasms","Drug: OMO-1","Incidence of treatment-emergent adverse events including dose-limiting toxicities|Incidence of clinically significant abnormal measurements in physical examination, ophthalmological examination, vital signs, electrocardiogram (ECG), pregnancy test, lab tests and ECOG performance status|Objective Response Rate|Percentage change in tumour size|Maximal OMO-1 plasma concentration Cmax|Area under the OMO-1 plasma concentration curve (AUC)|'Proof of mechanism' and 'proof of principle' pharmacodynamic biomarkers, including markers of tumour cell proliferation and apoptosis.","Octimet Oncology N.V.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OMO1.01.02","August 8, 2017","May 25, 2020","May 25, 2020","May 3, 2017",,"June 11, 2020","Mary Crowley Cancer Research, Dallas, Texas, United States|University Hospital Antwerp, Edegem, Belgium|Institut Bergonie, Bordeaux, France|Hôpital La Timone, Marseille, France|lnstitut Gustave Roussy, Villejuif, France|Erasmus MC, Rotterdam, Netherlands|UMCU Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|University of Oxford, Department of Oncology, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03138083"
1219,"NCT01091701","Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke",,"Withdrawn","No Results Available","Stroke","Biological: Ex vivo cultured adult allogenic MSCs|Other: Plasmalyte-A","The type of AE(s), number of AE(s) and proportion of patients with AE(s).|Improvement of neurological recovery as assessed by NIH Stroke Scale (NIHSS).|Improvement of the Functional recovery - assessed by Barthel's Index for activities of daily living.|Improvement of Global outcome as assessed by the Modified Rankin Scale|MRI Parameters - Change in infarct size T2 - weighted images and blood flow in infarct area as evaluated by Diffusion Weighted Index","Stempeutics Research Pvt Ltd|Stempeutics Research Malaysia SDN BHD","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SRM/CS/09-10/001","December 2011","May 2013","May 2013","March 24, 2010",,"May 12, 2016","Hospital Raja Permaisuri Bainun, Jalan Hospital, 30990,, Ipoh, Perak, Malaysia|Hospital Kuala Lumpur, Jalan Pahang, 50586, Kuala Lumpur, Malaysia|Hospital Melaka, Jalan Mufti Haji Khalil, 75400, Melaka, Malaysia|Hospital Seberang jaya Jalan Tun Hussein Onn, 13700, Prai, Pulau Pinang, Malaysia|Hospital Sungai Buloh, Jalan Hospital, 47000, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Bahiyah, Km 6 Jalan Langgar, 5460 Alor Setar, Kedah, Malaysia",,"https://ClinicalTrials.gov/show/NCT01091701"
1220,"NCT02483364","A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure)","Bonecure","Completed","No Results Available","Pseudoarthrosis","Other: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)","Safety of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of atrophic nonunion in long bones by recording of adverse events.|Effectiveness by mean of radiological methods on the appearance of signs of osseous setting formation.|Comparative statistical analysis","Salvat","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STEMQUIRI/12ES01","November 10, 2015","May 18, 2020","October 20, 2020","June 26, 2015",,"March 17, 2021","Laboratorios Salvat, S.A., Esplugues de Llobregat, Barcelone, Spain",,"https://ClinicalTrials.gov/show/NCT02483364"
1221,"NCT03678467","Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction","EB-CMF","Recruiting","No Results Available","Mandible Tumor|Mandibular Injuries|Mandible; Deformity","Combination Product: EB-CMF","Number of participants with treatment-related adverse events|Bone regeneration as assessed by high-resolution CT scans|Quality of life as measured by the Glasgow Benefit Inventory","Epibone, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EB-CMF-02","March 31, 2021","March 2023","June 2023","September 19, 2018",,"April 12, 2021","Cleveland Clinic, Cleveland, Ohio, United States|UT Health San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03678467"
1222,"NCT01468064","Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke","AMETIS","Completed","No Results Available","Stroke|Infarction, Middle Cerebral Artery","Genetic: Autologous BMSCs transplantation|Genetic: Autologous EPCs transplantation|Genetic: IV infusion of placebo","Number of adverse events after infusion of BMSCs or EPCs.|Changes in functional outcomes measured by the modified Rankin Scale (mRS) and the Barthel index (BI).","Southern Medical University, China|The Second People's Hospital of Nanhai District of Foshan|The First People's Hospital of Haizhu District Guangzhou|Cellonis Biotechnology Co. Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ZJH-001|2011A030400007","November 2011","December 2015","March 2017","November 9, 2011",,"April 2, 2021","Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01468064"
1223,"NCT00705120","Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation",,"Completed","No Results Available","Osteogenesis Imperfecta","Other: Bone Marrow Cell Transplantation|Radiation: Irradiation, Total Body|Drug: Cyclophosphamide|Drug: Cyclosporin|Procedure: Mesenchymal Stem Cell Transplantation|Drug: Busulfan","To investigate the safety and toxicity of allogeneic bone marrow transplantation (BMT) in children with severe Osteogenesis Imperfecta (OI)","St. Jude Children's Research Hospital","All","3 Years and older   (Child, Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOIT","November 1995","July 2000","October 2007","June 25, 2008",,"June 25, 2008","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00705120"
1224,"NCT04798066","Intermediate Size Expanded Access Protocol Evaluating HB-adMSC's for the Treatment of Post-COVID-19 Syndrome","LongHaulers","No longer available","No Results Available","Post COVID-19 Syndrome","Biological: HB-adMSC's",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years to 65 Years   (Adult, Older Adult)",,,"Other|Industry","Expanded Access:Intermediate-size Population",,"HBPCOV01",,,,"March 15, 2021",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04798066"
1225,"NCT00951210","Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)",,"Completed","No Results Available","Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia","Biological: PLX-PAD","Adverse events; Amputation incidence, Death incidence & Rehospitalization incidence|Immunological reaction","Pluristem Ltd.","All","40 Years to 81 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1202-2","August 2009","January 2011","October 2011","August 4, 2009",,"May 27, 2015","Cardiology PC, Birmingham, Alabama, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00951210"
1226,"NCT03418233","Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)",,"Completed","No Results Available","Heart Failure","Drug: CardioCell|Drug: Placebos","Left ventricle ejection fraction (LVEF) increase|An increase the result of 6 minute walk test|Myocardial perfusion improvement|An improvement the result of spiroergometric test|Left ventricle ejection fraction (LVEF) change against baseline|Left ventricle end-systolic volume (ESV) change against baseline|Left ventricle end-diastolic volume (EDV) change against baseline|NT pro-BNP level|The occurrence of major adverse cardiovascular events|Quality of life improvement","John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CardioCell in CIHF","April 19, 2018","January 27, 2021","March 31, 2021","February 1, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|The University Hospital in Cracow, Cracovia, Poland|Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego, Katowice, Poland|Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Katowice, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03418233"
1227,"NCT03423732","Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)",,"Active, not recruiting","No Results Available","Critical Limb Ischemia","Drug: CardioCell|Drug: Placebos","Change in pain-free walking distance|Amputation-free survival period|Ulcer-free survival|Ulcer-extension free survival|Change in tissue oxygen/CO2 tension|An improvement of tissue perfusion|Change in transcutaneous pressure of O2|Change in ABI score|Quality of life improvement, assessed by SF-36 questionnaire","John Paul II Hospital, Krakow|KCRI|National Center for Research and Development, Poland","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CardioCell in N-O CLI","April 19, 2018","May 31, 2021","September 30, 2021","February 6, 2018",,"April 9, 2021","The John Paul II Hospital, Cracovia, Poland|Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Katowice, Poland",,"https://ClinicalTrials.gov/show/NCT03423732"
1228,"NCT04745299","Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS","ALSummit","Recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Biological: Lenzumestrocel|Drug: Riluzole|Drug: Placebo Comparator","Joint rank scores (CAFS, Combined Assessment of Functional and Survival)|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score|Time to event","Corestem, Inc.","All","25 Years to 75 Years   (Adult, Older Adult)","Phase 3","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEURONATA-R_ALS301","March 23, 2021","October 30, 2023","May 3, 2026","February 9, 2021",,"October 11, 2021","Pusan National University Yangsan Hospital, Yangsan, Kyungsangnam-do, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Hanyang university hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04745299"
1229,"NCT03267784","Allogeneic ABCB5-positive Stem Cells for Treatment of DFU ""Malum Perforans""",,"Completed","No Results Available","Diabetic Neuropathic Ulcer","Biological: allo-APZ2-DFU","Percentage of wound surface area reduction|Assessment of adverse event (AE) occurrence|Percentage of invisible and visible wound surface area reduction|Absolute wound surface area reduction|Absolute invisible and visible wound surface area reduction|Assessment of wound infection|Time to first complete wound closure|Proportion of patients achieving complete wound closure|Time to first 30% reduction of wound surface area|Proportion of patients achieving 30% reduction of wound surface area|Assessment of wound exudation, epithelialization and formation of granulation tissue|Time to amputation at target leg until Week 12|Pain assessment as per numerical rating scale (NRS)|Assessment of Quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of Dermatology-specific QoL based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs|Time to amputation of target leg until month 12","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","23","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","allo-APZ2-DFU-II-01","November 21, 2017","June 29, 2020","June 29, 2020","August 30, 2017",,"September 10, 2020","Universitätsmedizin Greifswald; Klinik und Poliklinik für Hautkrankheiten, Greifswald, Germany|St. Josefskrankenhaus Heidelberg GmbH; Klinische Studienabteilung, Heidelberg, Germany|Diabetologikum Raab, Privatärztliche Facharztpraxis, Kassel, Germany|pro scientia med im Mare Klinikum, Department Klinische Forschung und Entwicklung, Kronshagen, Germany|Studienambulanz Leipzig, medamed GmbH, Leipzig, Germany|Diabetologikum Ludwigshafen, Gemeinschaftspraxis, Ludwigshafen, Germany|Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03267784"
1230,"NCT03257098","Allogeneic ABCB5-positive Stem Cells for Treatment of CVU",,"Completed","No Results Available","Skin Ulcer Venous Stasis Chronic","Biological: allo-APZ2-CVU","Percentage of wound size reduction|Assessment of adverse event (AE) occurrence|Absolute wound size reduction|Proportion of patients achieving complete wound closure|Time to first complete wound closure|Proportion of patients achieving 30% wound closure|Time to first 30% wound closure|Epithelialization|Assessment of further wound healing parameters: formation of granulation tissue and wound exudation|Pain assessment as per numerical rating scale (NRS)|Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs at Week 6.1 and Week 12","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services","All","35 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","allo-APZ2-CVU-II-01","November 16, 2017","June 25, 2020","June 25, 2020","August 22, 2017",,"September 10, 2020","Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria Hilf Krankenhaus, Bochum, Germany|Universitätsklinikum Erlangen, Hautklinik, Erlangen, Germany|Klinik und Poliklinik für Hautkrankheiten, Universitätsmedizin Greifswald, Greifswald, Germany|Klinische Forschung Hamburg GmbH, Dermatologie / Allergologie, Hamburg, Germany|pro scientia med im Mare Klinikum; Department Klinische Forschung und Entwicklung, Kiel, Germany|Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie, Münster, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Germany|Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie, Ulm, Germany|Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03257098"
1231,"NCT03676400","Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia",,"Completed","No Results Available","Androgenic Alopecia","Other: conditioned media of umbilical cord blood-derived stem cells|Other: Placebo","Change in mean total hair density (hair/cm2)|Compare visual assessment before and after cosmetic treatment|Change in mean Telogen hair density|Change in mean Anagen hair density|Change in hair growth speed|Change in hair diameter","Medipost Co Ltd.","All","18 Years to 60 Years   (Adult)","Not Applicable","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","MP-CM-001","October 2, 2018","July 22, 2019","July 24, 2019","September 18, 2018",,"August 12, 2019","Dankook University Hospital, Cheonan, Chung Nam, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03676400"
1232,"NCT00919958","Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia",,"Completed","No Results Available","Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia","Biological: PLX-PAD IM injection","Adverse events, Safety laboratory values and ECG findings|Immunological reaction|Tumorigenesis","Pluristem Ltd.","All","40 Years to 81 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLX-PAD 1202-1","June 2009","June 2012","June 2012","June 12, 2009",,"June 19, 2012","Franziskus-Krankenhaus, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00919958"
1233,"NCT02582489","Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy",,"Recruiting","No Results Available","Osteoarthritis Post-meniscectomy","Biological: Bone Marrow Aspirate Concentrate|Procedure: Standard Meniscectomy","International Knee Documentation Committee (IKDC) Score|Patient reported outcomes throughout follow-up period|Synovial fluid analysis|Radiographic analysis","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","15090903","December 22, 2017","November 2021","January 2022","October 21, 2015",,"December 3, 2020","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02582489"
1234,"NCT04308213","Study on Shoulder Arthritis Treatment With Intra-articular Injections of Autologous Bone Marrow Aspirate.","Stemshoulder","Recruiting","No Results Available","Shoulder Arthritis","Device: Marrow Cellution System","Change of the Constant-Murley score|Change of the VAS pain score|Change of range of motion (ROM)|clinical change based on the DASH scale (disability of the arm, shoulder and Hand)|clinical change based on the , American Shoulder and Elbow Surgeons (ASES) score|evaluation of shoulder MRI results|evaluation of shoulder X-ray (XR) results","Istituto Clinico Humanitas","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","955","November 12, 2019","April 30, 2024","September 30, 2024","March 13, 2020",,"March 17, 2020","Humanitas Research Hospital, Rozzano, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04308213"
1235,"NCT03112122","Study for the Treatment of the Bone Marrow Edema:Core Decompression VS Bone Marrow Concentrate (BMC) VS Bone Substitute","BME-TARGET","Terminated","No Results Available","Bone Marrow Edema","Biological: autologous bone marrow concentrate|Biological: bone substitute i-FactorTM|Procedure: core decompression","change of Visual Analogue Scale (VAS) score|International Knee Documentation Committee (IKDC) subjective score|Knee Injury and Osteoarthritis Outcome (KOOS) Score|Tegner Activity Level Scale","Istituto Ortopedico Rizzoli","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BME-TARGET","March 11, 2016","December 31, 2017","December 31, 2017","April 13, 2017",,"August 9, 2018","Rizzoli Orthopaedic Institute, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT03112122"
1236,"NCT02899091","Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Biological: CB-AC-02|Biological: Placebo","Number of Adverse Events|Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score|Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score|Changes from the baseline in GDS (Global Deterioration Scale)|Changes from the baseline in CDR (Clinical Dementia Rating) Score|Changes from the baseline in K-IADL (Korean Instrumental Activities of Daily Living) Score|Changes from the baseline in CGA-NPI (Caregiver Administered-Neuropsychiatric Inventory) Score|Change in CIBIC (Clinician Interview Based Impression of Change)-plus|Changes from the baseline in SF-36|Changes in Amyloid Beta and Tau amount (pg/mL) in CSF (Cerebrospinal fluid)|Change in Brain MRI (Magnetic Responance imaging)|Change from the baseline of CMRglc (cerebral metabolic rate for glucose ) analyzed with SPM (statistical parametric mapping) with Brain FDG PET imaging|Changes from the baseline of Amyloid amount analyzed with SPM (statistical parametric mapping) with amyloid PET imaging|Changes of band power in qEEG (Quantitative electroencephalography)","CHABiotech CO., Ltd","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CHA-PAD-101","September 2016","December 2021","December 2021","September 14, 2016",,"September 6, 2019","Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02899091"
1237,"NCT01065337","Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia",,"Completed","No Results Available","Diabetic Foot","Biological: tissue repair cells (TRC)|Biological: bone marrow stem cells (BMC)","The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred|Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion","Ruhr University of Bochum","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HDZ-SBE-2004","August 2005","February 2009","February 2009","February 9, 2010",,"May 25, 2012","Herz- und Diabeteszentrum Nordrhein Westfalen, Bad Oeynhausen, Germany",,"https://ClinicalTrials.gov/show/NCT01065337"
1238,"NCT02829216","Graft-versus-host Disease Associated Myelosuppression",,"Unknown status","No Results Available","Abnormal Hematopoiesis|Allogenic Disease|Graft vs Host Disease",,"Changes in the amount of mesenchymal stromal cells after allogeneic hematopoietic stem cell transplantation","Technische Universität Dresden","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Bone marrow GvHD","April 2016","April 2017",,"July 12, 2016",,"July 12, 2016","Medizinische Klinik und Poliklinik I, Universitätsklinikum, TU Dresden, Dresden, Germany",,"https://ClinicalTrials.gov/show/NCT02829216"
1239,"NCT02525432","Autologous Stem Cell Study for Adult TBI (Phase 2b)",,"Enrolling by invitation","No Results Available","Brain Injuries, Traumatic|Brain Injuries, Acute|TBI (Traumatic Brain Injury)","Biological: Placebo Infusion|Biological: Autologous BMMNC Infusion","Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.","The University of Texas Health Science Center, Houston|United States Department of Defense|U.S. Army Medical Research and Development Command","All","18 Years to 55 Years   (Adult)","Phase 2","55","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0283","November 21, 2016","October 2022","December 2022","August 17, 2015",,"April 28, 2021","UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02525432"
1240,"NCT03258515","A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers",,"Completed","No Results Available","Solid Tumors","Drug: AZD6094 200 mg|Other: Placebo|Drug: Moxifloxacin","Effect of AZD6094 at single therapeutic dose (600 mg) on ventricular repolarization by analysis of change from baseline-corrected QT|Effect of AZD6094 at therapeutic dose (600 mg) on additional time-matched ECG variables|Effect of moxifloxacin 400 mg on Fridericia-corrected QT interval (QTcF) compared to placebo.|Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUC(0-∞)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Area under the plasma concentration-time curve from time zero to t hours after dosing (AUC(0-t)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Observed maximum concentration (Cmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Time to reach maximum concentration (tmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Lag-time (tlag - from the individual concentration-time curve) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal rate constant (λz) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal half-life (t½) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent clearance for parent drug estimated as dose divided by AUC (CL/F) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent volume of distribution for parent drug at terminal phase (Vz/F, extravascular administration) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Assessment of relationship between the plasma concentration of AZD6094 and moxifloxacin and ECG variables, including baseline-adjusted and placebo-subtracted QTc interval.|Number of participants with adverse events (AEs) of AZD6094|Systolic blood pressure [SBP]|Diastolic blood pressure [DBP]|Pulse rate|Twelve-lead (12-Lead) electrocardiograms (ECGs)|Physical examination|Laboratory assessments of Hematology|Laboratory assessments of Clinical chemistry|Laboratory assessments of urinalysis|Effect of AZD6094 at therapeutic dose (600 mg) on time-matched ECG variable - heart rate (HR)","AstraZeneca|Parexel","Male","18 Years to 55 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5084C00001","September 6, 2017","March 24, 2018","March 24, 2018","August 23, 2017",,"February 20, 2020","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03258515"
1241,"NCT02396056","Enhancing Guided Bone Regeneration by Modifying a Resorbable Membrane",,"Unknown status","No Results Available","Alveolar Ridge Augmentation","Other: BioMend Extend|Other: Modified BioMend Extend","Clinical horizontal bone augmentation results through direct measurement.|Volumetric measurements with CBCT","Stony Brook University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","StonyBrookU","December 2014","December 2017","December 2017","March 24, 2015",,"October 17, 2016","School of Dental Medicine of Stony Brook University, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT02396056"
1242,"NCT00418418","Combined CABG and Stem-Cell Transplantation for Heart Failure",,"Unknown status","No Results Available","Heart Failure|Myocardial Infarction|Coronary Artery Disease","Procedure: Coronary bypass operation|Procedure: Bone marrow aspiration (crista iliaca)|Biological: Intramyocardial mesenchymal stem cell transplantation|Biological: Intramyocardial injection of autologous serum","Does a bone marrow transplantation therapy increase the ejection fraction of the heart measured with MRI, when compared with placebo treatment?|Does a bone marrow transplantation therapy increase any cardiac function parameter measured by a an echocardiography, MRI or PET ischemia area, when compared with no treatment group?|Does a bone marrow transplantation therapy improve BNP-value?|Does a bone marrow transplantation therapy decrease hospitalization or the days stayed in hospital?|Does pericardial fluid growth factor concentrations correlate to left ventricular function improvement?|Does autologous cardiac stem cell quality correlate to left ventricular function improvement?","University of Helsinki","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TYH 6220","October 2006","December 2009","December 2010","January 4, 2007",,"August 19, 2008","Department of Cardiothoracic Surgery, Meilahti Hospital, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT00418418"
1243,"NCT05113342","Descartes-25 in Relapsed/Refractory Multiple Myeloma",,"Not yet recruiting","No Results Available","Multiple Myeloma|Relapse Multiple Myeloma","Drug: Descartes-25","Maximum tolerated dose of Descartes-25|Overall Response Rate according to the IMWG response criteria|Median Duration of Response","Cartesian Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DC25-1A","November 2021","December 2022","January 2023","November 9, 2021",,"November 9, 2021",,,"https://ClinicalTrials.gov/show/NCT05113342"
1244,"NCT03909139","Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear",,"Recruiting","No Results Available","Acetabular Labrum Tear|Femoro Acetabular Impingement|Chondral Defect|Bone Marrow Aspirate Concentrate|Mesenchymal Stromal Cell","Biological: BMAC","Change iHOT--33 Surveys from preoperative to various postoperative timepoints|Change HOS Surveys from preoperative to various postoperative timepoints|Change NAHS Surveys from preoperative to various postoperative timepoints|Change LEFS Surveys from preoperative to various postoperative timepoints|Change mHHS Surveys from preoperative to various postoperative timepoints|Change RAND-36 Surveys from preoperative to various postoperative timepoints|Degree of Improvement on Hip VAS Pain Score|Patient Satisfaction Questionnaires","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019P002191","September 6, 2019","June 30, 2023","June 30, 2025","April 9, 2019",,"November 19, 2021","MGH, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03909139"
1245,"NCT04524962","Study of Descartes-30 in Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|Covid19","Biological: Descartes 30","To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.","Cartesian Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DC30-1A","September 15, 2020","September 25, 2021","September 25, 2022","August 24, 2020",,"February 10, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California-Irvine, Irvine, California, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland Medical Center Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT04524962"
1246,"NCT03339973","Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD",,"Terminated","No Results Available","Peripheral Arterial Occlusive Disease","Biological: allo-APZ2-PAOD|Drug: Placebo","Percent change from baseline to week 12 in total wound size of the target leg|Assessment of adverse event (AE) occurrence|Time to total healing of all relevant ulcers at target leg|Percent change in total wound size of the target leg|Absolute change in total wound size of the target leg|Ankle-brachial index (ABI) of target leg;|Number of amputated toes at target leg|Time to major amputation at target leg until week 12;|Assessment of epithelialization in % of wound area of all relevant ulcers of the target leg|Assessment of further wound healing parameters: formation of granulation tissue in % of wound area and wound exudation of all relevant ulcers of the target leg|Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire|Pain assessment as per numerical rating scale (NRS).|Physical examination at week 12;|Vital signs: Body temperature at week 12;|Vital signs: Blood pressure at week 12;|Vital signs: Heart rate at week 12;|Assessment of Laboratory values (Hematology) at Week 12:|Assessment of Laboratory values (Clinical chemistry) at Week 12|Time to major amputation","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","allo-APZ2-PAOD-II-01","March 5, 2018","May 15, 2020","May 15, 2020","November 13, 2017",,"June 29, 2020","LKH-Univ. Klinikum Graz, Graz, Austria|Konventhospital der Barmherzigen Brüder Linz, Linz, Austria|Hanusch-Krankenhaus Wien, Wien, Austria|Krajská zdravotní a.s. - Masarykova nemocnice v Ústí nad Labem, o.z., Ústí Nad Labem, Czechia|Franziskus-Krankenhaus Berlin, Berlin, Germany|Universitätsklinikum ""Carl Gustav Carus"" der TU Dresden, Dresden, Germany|Helios Weißeritztal-Kliniken Klinikum Freital, Freital, Germany|Universitäres Herzzentrum Hamburg GmbH (UHZ), Hamburg, Germany|Asklepios Klinikum Harburg, Hamburg, Germany|St. Josefskrankenhaus Heidelberg GmbH, Heidelberg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|SRH Klinikum Karlsbad-Langensteinbach GmbH, Karlsbad, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Universitätsklinikum Mannheim, Mannheim, Germany|Klinikum der Universität München, Campus Innenstadt, München, Germany|Medizinisches Versorgungszentrum der Barmherzigen Brüder Trier, Trier, Germany|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust, Redhill, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03339973"
1247,"NCT04522505","Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis",,"Active, not recruiting","No Results Available","Lupus Nephritis",,"Incidence of adverse events|Incidence of abnormal results of Physical examination|Percentage of abnormal Vital signs|Percentage of abnormal results of Laboratory tests|SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2000)|BILAG 2004 (British Isles Lupus Assessment Group 2004)|SDI (Systemic Lupus International Collaborating Clinics/Americans College of Rheumatology (SLICC/ACR) Damage Index|Disease activity assessed by PGA (Physician Global Assessment)","Corestem, Inc.|Hanyang University","All","17 Years to 70 Years   (Child, Adult, Older Adult)",,"7","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CS20AT04-LN101-E","November 29, 2017","January 24, 2024","January 24, 2024","August 21, 2020",,"August 25, 2020","Hanyang university hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04522505"
1248,"NCT04825626","""Individual Patient Expanded Access IND Using HB-adMSCs to Treat of Spinal Cord Injury""",,"Temporarily not available","No Results Available","Spinal Cord Injuries","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","Male","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access",,"HBSCI03",,,,"April 1, 2021",,"April 1, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04825626"
1249,"NCT04825613","""Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis","HBPLS","Temporarily not available","No Results Available","Primary Lateral Sclerosis, Adult, 1","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","Male","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access",,"HBPLS01",,,,"April 1, 2021",,"April 1, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04825613"
1250,"NCT03912480","Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function",,"Unknown status","No Results Available","Type1diabetes","Biological: Stem cells from human exfoliated teeth","Total daily insulin dose|glucose-c peptide release test|Islet function|Composite index of glycosylated hemoglobin (HbAlc) and frequency of hypoglycemia|Continuous dynamic blood glucose","CAR-T (Shanghai) Biotechnology Co., Ltd.","All","25 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KTLC002","January 5, 2019","December 30, 2020","March 31, 2021","April 11, 2019",,"April 22, 2019","Changhai hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03912480"
1251,"NCT02135380","Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis",,"Unknown status","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: Autologous Stromal Vascular Fraction (SVF)|Biological: Autologous Adipose Derived MSCs (ADMSCs)|Other: Control","Safety|Efficacy","Kasiak Research Pvt. Ltd.","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KRPL/IPF/11-12/002","August 2014","August 2015",,"May 9, 2014",,"May 13, 2014","Kasiak Research Pvt Ltd, Thane, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02135380"
1252,"NCT03252340","Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis",,"Active, not recruiting","No Results Available","Atopic Dermatitis","Drug: ADSTEM Inj.","Tumor formation|Adverse events","EHL Bio Co., Ltd.","All","19 Years to 70 Years   (Adult, Older Adult)",,"11","Industry","Observational","Observational Model: Case-Only|Time Perspective: Other","AD-CP-17-1|30902","September 19, 2017","August 17, 2021","August 16, 2022","August 17, 2017",,"December 27, 2019","Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03252340"
1253,"NCT04514952","Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis",,"No longer available","No Results Available","Amyotrophic Lateral Sclerosis","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","Child, Adult, Older Adult",,,"Other|Industry","Expanded Access:Individual Patients",,"HBALS01",,,,"August 17, 2020",,"July 7, 2021","River Oaks Hospital and Clinics, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04514952"
1254,"NCT05081921","Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases","BioMiStem-CT","Not yet recruiting","No Results Available","Osteoarthritis of Knee","Drug: MesoCellA-Ortho administration|Drug: HA administration","Nature, incidence and severity of adverse events (AEs)|Change in Numerical Rating Scale (NRS)|Change in joint swelling|Change in the 36-Item Short Form Survey (SF-36)|Change in Knee injury and Osteoarthritis Outcome Score (KOOS)|Change in the International Knee Documentation Committee (IKDC 2000)|Change in cartilage morphology|Change in cartilage T2 relaxation time mapping in MRI|Changes in bone marrow edema-like lesions (BMLs)|Change in weight distribution on stable platform|Change in Range of motion (ROM)|Change in ultrasonographic findings in knee joint","Jagiellonian University|National Center for Research and Development, Poland|KCRI","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JU-BioMiStem-01|2019-005000-17","October 2021","March 2023","September 2023","October 18, 2021",,"October 18, 2021","Galen - Ortopedia Sp. Z O.O., Bieruń, Silesia, Poland",,"https://ClinicalTrials.gov/show/NCT05081921"
1255,"NCT04956744","A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis",,"Recruiting","No Results Available","Multiple Sclerosis","Biological: IMS001","Safety and tolerability","ImStem Biotechnology|Rho, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMS001-01","August 31, 2021","December 2027","December 2027","July 9, 2021",,"September 21, 2021","Shepherd Center, Atlanta, Georgia, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Rocky Mountain MS Clinic, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04956744"
1256,"NCT02274428","Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage",,"Completed","No Results Available","Mesenchymal Stromal Cells","Drug: pneumostem","unsuspected death or anaphylactic shock|Death or hydrocephalus required shunt operation","Samsung Medical Center","All","23 Weeks to 34 Weeks   (Child)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-06-103","October 2014","February 2016","December 2016","October 24, 2014",,"April 19, 2017","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02274428"
1257,"NCT04569409","Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Procedure: Vehicle Sheet","Proportions of subjects who achieved complete wound closure|Time taken to complete wound closure|Proportions of subjects who achieved complete wound closure at every visit|Change rates in wound size and depth compared to baseline groups","Anterogen Co., Ltd.","All","19 Years to 75 Years   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALLO-ASC-DFU-302","July 14, 2020","December 31, 2021","December 31, 2021","September 29, 2020",,"September 29, 2020","Bucheon ST. Mary's Hospital, Gyeonggi-do, Bucheon, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Seongnam-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Borame Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04569409"
1258,"NCT04614025","Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19",,"Active, not recruiting","No Results Available","COVID|ARDS","Biological: PLX-PAD","Number of ventilator-free days|All-cause mortality|Duration of mechanical ventilation","Pluristem Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLX-COV-03","October 19, 2020","August 4, 2021","September 2022","November 3, 2020",,"August 10, 2021","Charite Campus Virchow, Berlin, Germany|Campus Benjamin Franklin - CBF Charité - Universitätsmedizin, Berlin, Germany|University of hospital Bonn, Bonn, Germany|Hospital Cologne-Merheim, Köln, Germany|Emek Medical Center, Afula, Israel|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Galilee Medical Center, Nahariya, Israel|Baruch Padeh Medical Center, Poriya, Tiberias, Israel",,"https://ClinicalTrials.gov/show/NCT04614025"
1259,"NCT03961243","Lentiviral FIX Gene Therapy",,"Not yet recruiting","No Results Available","Hemophilia B","Biological: YUVA-GT-F901","Number of participants experiencing drug-related adverse events|Changes from baseline in circulating FIX activity (IU/dL or % normal)","Shenzhen Geno-Immune Medical Institute","All","2 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-19002","June 1, 2020","May 31, 2022","June 1, 2022","May 23, 2019",,"May 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03961243"
1260,"NCT03183648","A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-201 Clinical Trial",,"Active, not recruiting","No Results Available","Burn","Biological: ALLO-ASC-DFU","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Vancouver Burn Scar Scale","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALLO-ASC-BI-202","August 2016","December 2022","June 2023","June 12, 2017",,"July 21, 2021","Hallym university Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03183648"
1261,"NCT03183622","A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial",,"Completed","No Results Available","Burn","Biological: ALLO-ASC-DFU","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Vancouver Burn Scar Scale","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)",,"5","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALLO-ASC-BI-102","November 2015","July 2017","December 2017","June 12, 2017",,"January 10, 2018","Hallym university Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03183622"
1262,"NCT03183934","A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial",,"Unknown status","No Results Available","Dystrophic Epidermolysis Bullosa","Biological: ALLO-ASC-DFU","Safety assessed by clinically measured abnormality of laboratory tests and adverse events|Area of re-epithelization","Anterogen Co., Ltd.","All","2 Years to 60 Years   (Child, Adult)",,"5","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALLO-ASC-EB-102","July 2017","December 2019","June 2020","June 12, 2017",,"June 12, 2017","Gangnam Severence Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03183934"
1263,"NCT03563495","Tissue Engineered Constructs for Alveolar Cleft Repair",,"Completed","No Results Available","Cleft Lip and Palate","Other: tissue engineered group|Procedure: autogenous bone graft group","Assessment of changes in the bone volume at the grafted alveolar cleft site from the immediate postoperative to 6 months|Assessment of changes in the bone density at the grafted alveolar cleft site from the immediate postoperative to 6 months","Cairo University","All","8 Years to 14 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","MSCs in alveolar cleft repair","February 2015","July 2017","September 2017","June 20, 2018",,"June 20, 2018",,,"https://ClinicalTrials.gov/show/NCT03563495"
1264,"NCT03217032","Lentiviral FVIII Gene Therapy",,"Not yet recruiting","No Results Available","Hemophilia A","Biological: YUVA-GT-F801","Number of participants experiencing drug-related adverse events|Changes from baseline in circulating FVIII activity (IU/dL or % normal)","Shenzhen Geno-Immune Medical Institute","All","2 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-17007","June 1, 2020","May 31, 2022","June 1, 2022","July 13, 2017",,"May 23, 2019","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03217032"
1265,"NCT03645460","Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)",,"Recruiting","No Results Available","Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)","Genetic: TYF-ADA gene-modified autologous stem cells","Overall survival up to a year|1. Success of immune reconstitution|2. Change of infection status","Shenzhen Geno-Immune Medical Institute","All","1 Month and older   (Child, Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-18003","October 30, 2018","December 31, 2020","December 31, 2021","August 24, 2018",,"September 20, 2019","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03645460"
1266,"NCT01435434","Mononucleotide Autologous Stem Cells and Demineralized Bone Matrix in the Treatment of Non Union/Delayed Fractures",,"Unknown status","No Results Available","Non Union/Delayed Fractures","Device: the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.","clinical and radiological bony union at 3 months and 6 months.","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable",,"Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","lieb001-CTIL-HMO",,,,"September 16, 2011",,"March 4, 2014","Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01435434"
1267,"NCT03264573","Role of Stem Cells, Platelet Rich Plasma in Treatment of Scars",,"Completed","No Results Available","Atrophic Scar","Biological: Stem cell|Device: MSCs","Patient satisfaction (Patient Assessment Scar Scale)|Doctor satisfaction (Vancouver Scar Scale)","Heba Mohamed Saad Eldien|M.A. Eloteify|Ahmed Kamal Osman|G.M. Hafsa|Assiut University","All","10 Years to 35 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCs, PRP, Scar","July 2016","February 2017","July 2017","August 29, 2017",,"August 29, 2017",,,"https://ClinicalTrials.gov/show/NCT03264573"
1268,"NCT02729298","First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Advanced Solid Tumors|EGFR Positive Non-small Cell Lung Cancer|Colorectal Carcinoma|Recurrent Ovarian Carcinoma|BRAF-Mutated Melanoma","Drug: TP-0903","Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events|Area under the plasma concentration-time curve from zero to infinity [AUC(0-inf)] of oral TP-0903|Area under the plasma concentration-time curve from zero to last measured time point [AUC(0-last)] of oral TP-0903|Peak plasma concentration (Cmax) of oral TP-0903|Activity of TP-0903 on predictive biomarkers|Objective response rate using RECIST v1.1 and iRECIST","Sumitomo Dainippon Pharma Oncology, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1","177","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TP-0903-101","December 14, 2016","December 2022","December 2022","April 6, 2016",,"November 24, 2021","Mayo Clinic Arizona, Phoenix, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|University of Colorado Denver, Denver, Colorado, United States|US Oncology - Rocky Mountain Cancer Centers, LLP (RMCC), Denver, Colorado, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|US Oncology - Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|US Oncology - Texas Oncology Austin, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|US Oncology - Texas Oncology - Fort Worth, Fort Worth, Texas, United States|University of Texas Science Center at San Antonio (UTHSCSA), San Antonio, Texas, United States|US Oncology - Texas Oncology - Tyler, Tyler, Texas, United States|US Oncology - Virginia Cancer Specialists (VCS), Fairfax, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02729298"
1269,"NCT00702741","Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy",,"Completed","No Results Available","Recovery Following Partial Medial Meniscectomy","Drug: Chondrogen|Drug: Placebo","Comparison of treatment adverse event rates|Concomitant Medications|Visual Analog Scale","Mesoblast International Sàrl|Mesoblast, Ltd.","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","551","June 2008","September 2011","September 2011","June 20, 2008",,"June 2, 2020","University of Southern California Keck School of Medicine, Los Angeles, California, United States|OrthoIndy, Indianapolis, Indiana, United States|TRIA Orthopaedic Center, Bloomington, Minnesota, United States|Unlimited Research, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00702741"
1270,"NCT03351868","FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector",,"Recruiting","No Results Available","Fanconi Anemia","Genetic: Gene-modified autologous stem cells","Safety in patients using CTCAE version 4.0 standard to evaluate the level of adverse events|Treatment responses|Quality of life","Shenzhen Geno-Immune Medical Institute","All","2 Years to 20 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-17021","December 1, 2017","December 31, 2020","December 31, 2021","November 24, 2017",,"September 19, 2019","Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China|Beijing Children's Hospital, Beijing, Beijing, China|Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03351868"
1271,"NCT02127710","A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)",,"Completed","Has Results","Papillary Renal Cell Cancer","Drug: AZD6094","Objective Response Rate (RECIST Version 1.1)|Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set|Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set|Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set|Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set|Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set|Overall Survival Stratified by c-MET Status in the Safety Analysis Set|Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set|Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.|Duration of Response|Peak Plasma Concentration of AZD6094 Following Single Dose|Time to Peak Plasma Concentration of AZD6094 After Single Dose|Apparent Volume of Distribution of AZD6094 Following Single Dose|Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose|Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)|Apparent Total Clearance of AZD6094 From Plasma After Single Dose|Mean Residence Time of AZD6094 After Single Dose|Elimination Half-Life of AZD6094 After Single Dose","AstraZeneca|SCRI Development Innovations, LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","111","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5082C00002|GU 111","April 30, 2014","April 14, 2016","April 20, 2020","May 1, 2014","October 12, 2017","April 19, 2021","Research Site, Birmingham, Alabama, United States|Research Site, Duarte, California, United States|Research Site, Palo Alto, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Barcelona, Spain|Research Site, Cambridge, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02127710"
1272,"NCT03696485","Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS",,"Unknown status","No Results Available","Secondary Progressive Multiple Sclerosis (SPMS)","Biological: SCM-010","Adverse Events (AEs) reported during the trial|Change in MRI scans from baseline|Change from baseline in EDSS score|Time to Confirmed Disease Progression (CDP)","Stem Cell Medicine Ltd.","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPMS-SCM-010","February 1, 2019","February 1, 2021","February 1, 2021","October 4, 2018",,"October 17, 2018","Tel Aviv Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT03696485"
1273,"NCT03855631","Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders","Epi-KAB","Completed","No Results Available","Kabuki Syndrome 1","Genetic: Intervention on primary cultured cells","success rate of fibroblasts culture|success rate of turning fibroblasts into mesenchymal stem cells|success rate of CRISPR/Case9 gene therapy treatment on patients' cells","University Hospital, Montpellier|Association Française contre les Myopathies Telethon","All","6 Years and older   (Child, Adult, Older Adult)",,"8","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL18_0242","September 28, 2020","November 27, 2020","November 27, 2020","February 27, 2019",,"December 1, 2020","Arnaud de villeneuve Hospital, Montpellier, Herault, France",,"https://ClinicalTrials.gov/show/NCT03855631"
1274,"NCT04138017","ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis","ViviGen","Unknown status","No Results Available","Ankle Deformity|Ankle Arthritis","Device: ViviGen","Fusion|Failure of hardware or obvious non-union|Foot and Ankle Ability Measure (FAAM)|Vitamin D levels|Visual Analog Pain Scale|American Orthopaedic Foot and Ankle Society(AOFAS) hindfoot score|VR-12 (Veterans RAND 12)|Patient-Reported Outcomes Measurement Information System Physical Function-Short Form 8b (PROMIS Item Bank v2.0-Physical Function -Short Form 8b)","University of Virginia|DePuy Synthes","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20532","October 23, 2018","October 2020","October 2020","October 24, 2019",,"October 24, 2019","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04138017"
1275,"NCT02287974","Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin",,"Terminated","No Results Available","Critical Limb Ischemia (CLI)","Drug: Stem cell infusion","Serious Adverse Events|Efficacy measured by: The changes in the requirements of insulin, Peptide C, Resistance to the insulin, inflammatory Cytokines, pancreatic Reservation, Quantification of the degree of neovascularization (angio/arteriogenesis and vasculogenesis)","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CeTMMoTa/ICPDI/2010","September 2011","July 2018","July 2018","November 11, 2014",,"December 19, 2018","Hopsital U. Virgen Macarena, Sevilla, Seville, Spain|CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine), Seville, Spain",,"https://ClinicalTrials.gov/show/NCT02287974"
1276,"NCT01624701","Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells",,"Terminated","No Results Available","Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Lymphoma|Myeloma","Other: Ex vivo expanded cord blood cells","Safety|Engraftment","Singapore General Hospital|Whitehead Institute for Biomedical Research|Blood Services Group, Health Sciences Authority of Singapore","All","12 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009/925/B","March 2012","July 2015","July 2016","June 21, 2012",,"November 30, 2015","Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01624701"
1277,"NCT05060107","Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)","ExoOA-1","Not yet recruiting","No Results Available","Osteoarthritis, Knee","Biological: Exosomes (sEVs)","Adverse Event|Incidence of injection-related pain according to VAS scale (0-100mm)|Incidence of injection-related sinovitis according to effusion grading scale of knee joint|Pain reduction|Disability reduction|Percentage of responders","Francisco Espinoza|Universidad de los Andes, Chile","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C4C060921","October 5, 2021","April 5, 2023","October 5, 2023","September 28, 2021",,"September 28, 2021",,,"https://ClinicalTrials.gov/show/NCT05060107"
1278,"NCT01755195","Cabozantinib for Adults With Advanced Soft Tissue Sarcoma",,"Active, not recruiting","Has Results","Refractory Soft Tissue Sarcomas","Drug: Cabozantinib","Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas|Percentage of Participants With 6 Month Progression Free Survival (PFS)|Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)|Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)|Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)|Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","55","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130044|13-C-0044","January 15, 2013","September 30, 2020","October 16, 2022","December 24, 2012","September 16, 2021","November 10, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01755195/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01755195/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01755195"
1279,"NCT04310215","Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus",,"Active, not recruiting","No Results Available","Chondral or Osteochondral Lesion of Talus","Biological: CARTISTEM®|Procedure: Microfracture","ICRS-Cartilage Repair Assessment Total Score|ICRS-Cartilage Repair Assessment Overall Grade|Improvement degree of Cartilage Repair by MRI|Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)|Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)|Degree of Functional improvement in Tegner activity score|Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)|Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)","Hyundai Bioland Co., Ltd.|Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CARTISTEM_2019_01","March 3, 2020","June 2022","June 2022","March 17, 2020",,"June 14, 2021","Kyunghee University Medical Center, Seoul, Dongdaemun-gu, Korea, Republic of|Gangnam Severance Hospital, Seoul, Gangnam-gu, Korea, Republic of|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of|Inha University Hospital, Incheon, Jung-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04310215"
1280,"NCT01301664","Cartilage Tissue Engineering",,"Available","No Results Available","Mesenchymal Stem Cells","Other: total knee / hip replacement",,"Chin-Hung Chang|Far Eastern Memorial Hospital","All","30 Years to 70 Years   (Adult, Older Adult)",,,"Other","Expanded Access",,"97022",,,,"February 23, 2011",,"March 7, 2013",,,"https://ClinicalTrials.gov/show/NCT01301664"
1281,"NCT02645305","Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease",,"Unknown status","No Results Available","COPD","Biological: Adipose derived stem cells","SGOT|SGPT|Respiration rate|6 min walk test|rates of panic attacks|CRP concentration","University of Science Ho Chi Minh City|Van Hanh General Hospital|Nguyen Tri Phuong Hospital, Ho Chi Minh city, Viet Nam|GeneWorld Ltd Co, Ho Chi Minh city, Viet Nam","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2555/QD-BYT","June 2015","September 2016","December 2016","January 1, 2016",,"January 1, 2016","Van Hanh Hospital, Ho Chi Minh City, Vietnam|Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University, Ho Chi Minh, Ho Chi Minh, Vietnam|Nguyen Tri Phuong Hospital, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT02645305"
1282,"NCT04976140","Evaluate the Safety, Tolerability and Efficacy of PN-101 in Patients With Refractory Polymyositis or Dermatomyositis",,"Not yet recruiting","No Results Available","Polymyositis|Dermatomyositis","Biological: PN-101","Dose Limiting Toxicity(DLT)|International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)|Response rate of IMACS-TIS|Changes of Core Set Activity Measures(CSAM)|Changes of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)|Changes of Peak Pruritus Numeral Rating Scale(PPNRS)","Paean Biotechnology Inc.","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PN-101-101","August 2021","December 2022","December 2022","July 26, 2021",,"August 27, 2021",,,"https://ClinicalTrials.gov/show/NCT04976140"
1283,"NCT03109301","Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)",,"Withdrawn","No Results Available","Neoplasms, Nerve Tissue|Neurofibromatosis 1|Heredodegenerative Disorders, Nervous System|Peripheral Nervous System Diseases","Drug: Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Drug: Selumetinib (AZD6244 hyd sulfate) 25mg/m2","Efficacy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170084|17-C-0084","April 7, 2017","March 27, 2019","March 27, 2019","April 12, 2017",,"April 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03109301"
1284,"NCT03103295","3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects","3-D-TEBE","Unknown status","No Results Available","Bone Defects","Biological: 3D-Tissue Engineered Bone Equivalent","Radiographic and MRI assessment in progression|Reduction of pain using VAS|Cost analysis based on length of hospital stay","A.A. Partners, LLC","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-P2-14","November 20, 2015","December 20, 2018","December 20, 2018","April 6, 2017",,"May 11, 2017","LIMITED LIABILITY COMPANY ""A.A. PARTNERS"" (Medical company ilaya®), Kiev, Ukraine",,"https://ClinicalTrials.gov/show/NCT03103295"
1285,"NCT04847739","Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas",,"Not yet recruiting","No Results Available","Perianal Fistula|Crohn's Disease","Procedure: Seton Placement|Drug: AVB-114","Change in proportions of subjects with combined remission of treated perianal fistula between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula clinical remission between the AVB-114 and standard of care groups.|Change in the means of durability of clinical remission between the AVB-114 and standard of care groups.|Change in means of time to clinical remission between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula relapse between the AVB-114 and standard of care groups.|Change in means of time to fistula relapse between the AVB-114 and standard of care groups.|Change in proportions of radiologic response of treated fistula between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the Perianal Disease Activity Index (PDAI) between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the short Crohn's Disease Activity Index (sCDAI) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Euroqol 5 Diumention 5, level measure of health status (Eq-5Q-5L) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Inflammatory Bowel Disease Questionnaire (IBDQ) between the AVB-114 and standard of care groups.|Change in patient assessment of impact to daily functionality related to treated fistula between the AVB-114 and standard of care groups.|Change in the evaluations of patient care trajectory related to treated fistula between the AVB-114 and standard of care groups.|Change in number of adverse events between the AVB-114 and standard of care groups.|Change in number of serious adverse events between the AVB-114 and standard of care groups.","Avobis Bio, LLC|Alimentiv Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STOMP-II","August 2021","August 2023","January 2025","April 19, 2021",,"July 21, 2021",,,"https://ClinicalTrials.gov/show/NCT04847739"
1286,"NCT01874665","A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor","GIST","Completed","Has Results","GIST","Drug: Ponatinib","Clinical Benefit Rate (CBR) in Cohort A|Clinical Benefit Rate (CBR) in Cohort B|Progression-free Survival (PFS)|Percentage of Participants With Objective Response Rate (ORR)|Overall Survival (OS)|Number of Participants With Physical Examination|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Sign Measurements|Number of Participants With Worst Shift From Baseline Values to Post-baseline Values in Laboratory Parameters|Number of Participants With TEAEs Related to Electrocardiogram (ECG) Findings|Number of Participants With TEAEs Related to Echocardiography Parameter|Number of Participants Reporting One or More TEAEs and Serious Adverse Event (SAE)|Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib","Ariad Pharmaceuticals|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP24534-12-202","June 5, 2013","February 28, 2015","July 31, 2016","June 11, 2013","May 17, 2016","May 18, 2018","Massachusetts General Hospital, Site #047, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Site #008, Boston, Massachusetts, United States|Oregon Health & Sciences University, Site #048, Portland, Oregon, United States|Fox Chase Cancer Center, Site #012, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01874665"
1287,"NCT01298830","GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage",,"Terminated","No Results Available","Intracerebral Hemorrhage (ICH)","Drug: GLP-1 CellBeads","The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage|Neurological conditions","CellMed AG, a subsidiary of BTG plc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CM GLP-1/01|2007-004516-31","October 2008","June 2011","June 2011","February 18, 2011",,"March 26, 2013","Neurochirurgische Klinik und Neurologische Klinik des Universitätsklinikums Heidelberg, Heidelberg, Baden-Württemberg, Germany|Neurochirurgische Klinik der Universität Erlangen-Nürnberg, Erlangen, Bavaria, Germany|Klinik für Neurochirurgie Klinikum Bogenhausen Akademisches Lehrkrankenhaus der Technischen Universität München, München, Bavaria, Germany|Klinikum Region Hannover Krankenhaus Nordstadt, Klinik für Neurologie, Hannover, Lower Saxony, Germany|International Neuroscience Institute, Hannover, Lower Saxony, Germany|Klinik für Neurochirurgie Medizinische Hochschule Hannover, Hannover, Lower Saxony, Germany",,"https://ClinicalTrials.gov/show/NCT01298830"
1288,"NCT03794622","Autologous Bone Marrow Concentration for Femoral Shaft Fracture Union",,"Recruiting","No Results Available","Bone Marrow|Femoral Shaft Fracture","Other: intramedullary nail fixation with bone marrow concentration|Other: intramedullary nail fixation","1-month postoperative degree of union evaluated by plain radiograph|2-month postoperative degree of union evaluated by plain radiograph|3-month postoperative degree of union evaluated by plain radiograph|6-month postoperative degree of union evaluated by plain radiograph|12-month postoperative degree of union evaluated by plain radiograph","Pei-Yuan Lee, MD|Aeon Biotechnology Corporation|Show Chwan Memorial Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RD106049","June 14, 2017","December 2020","December 2020","January 7, 2019",,"April 14, 2020","Show Chwan Memorial Hospital, Changhua City, Changhua, Taiwan",,"https://ClinicalTrials.gov/show/NCT03794622"
1289,"NCT03793530","Autologous Bone Marrow Concentrate in Elective Tranforaminal Lumbar Interbody Fusion Surgery",,"Recruiting","No Results Available","Bone Marrow|Spinal Fusion","Other: Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Other: Transforaminal lumbar interbody fusion with local bone graft","3-month postoperative spinal function evaluated by Oswestry Disability Index|6-month postoperative spinal function evaluated by Oswestry Disability Index|12-month postoperative spinal function evaluated by Oswestry Disability Index|3-month postoperative degree of pain evaluated by visual analogue scale|6-month postoperative degree of pain evaluated by visual analogue scale|12-month postoperative degree of pain evaluated by visual analogue scale|3-month postoperative degree of bone healing evaluated by plain radiograph|6-month postoperative degree of bone healing evaluated by plain radiograph|12-month postoperative degree of bone healing evaluated by plain radiograph|12-month postoperative degree of bone healing evaluated by computed tomograph","Pei-Yuan Lee, MD|Aeon Biotechnology Corporation|Show Chwan Memorial Hospital","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","RD106050","August 1, 2017","December 2020","December 2020","January 4, 2019",,"April 14, 2020","Show Chwan Memorial Hospital, Changhua City, Changhua, Taiwan",,"https://ClinicalTrials.gov/show/NCT03793530"
1290,"NCT03792594","Autologous Bone Marrow Concentration for Rotator Cuff Tear",,"Recruiting","No Results Available","Rotator Cuff Tear|Bone Marrow","Other: arthroscopic repair with bone marrow concentration|Other: arthroscopic repair","3-month postoperative shoulder function evaluated by Constant Shoulder Score|6-month postoperative shoulder function evaluated by Constant Shoulder Score|12-month postoperative shoulder function evaluated by Constant Shoulder Score|3-month postoperative degree of healing evaluated by plain radiograph|6-month postoperative degree of healing evaluated by plain radiograph|12-month postoperative degree of healing evaluated by plain radiograph|6-month postoperative degree of healing evaluated by MRI|12-month postoperative degree of healing evaluated by MRI","Pei-Yuan Lee, MD|Aeon Biotechnology Corporation|Show Chwan Memorial Hospital","All","40 Years to 70 Years   (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RD106055","May 12, 2017","December 2020","December 2020","January 3, 2019",,"April 14, 2020","Show Chwan Memorial Hospital, Changhua City, Changhua, Taiwan",,"https://ClinicalTrials.gov/show/NCT03792594"
1291,"NCT03787329","Autologous Bone Marrow Concentration for Avascular Necrosis of Femoral Head",,"Recruiting","No Results Available","Avascular Necrosis of Femur|Bone Marrow","Other: Core decompression surgery with bone marrow concentration|Other: Core decompression surgery","3-month postoperative hip function evaluated by Harris Hip Score|6-month postoperative hip function evaluated by Harris Hip Score|12-month postoperative hip function evaluated by Harris Hip Score|3-month postoperative degree of collapse evaluated by plain radiograph|6-month postoperative degree of collapse evaluated by plain radiograph|12-month postoperative degree of collapse evaluated by plain radiograph|6-month postoperative degree of collapse evaluated by MRI","Pei-Yuan Lee, MD|Aeon Biotechnology Corporation|Show Chwan Memorial Hospital","All","30 Years to 60 Years   (Adult)",,"40","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RD-106057","April 14, 2017","December 2020","December 2020","December 26, 2018",,"April 14, 2020","Show Chwan Memorial Hospital, Changhua City, Changhua, Taiwan",,"https://ClinicalTrials.gov/show/NCT03787329"
1292,"NCT04261335","The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy","SHIELD","Active, not recruiting","No Results Available","Hypoxia-Ischemia, Brain","Biological: CL2020 cells","Incidence of adverse events|Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)|Mortality|Overall survival|Duration of continuous respiratory support|Duration of continuous use of vasopressors or pulmonary vasodilators|The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition|The developmental quotient in Kyoto Scale of Psychological Development 2001|Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words|Presence of spasticity|Presence of epilepsy|MRI score|Gross Motor Function Classification System (GMFCS) score","Nagoya University|Life Science Institute, Inc.","All","up to 14 Days   (Child)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAMCR-014|jRCT2043190112","March 4, 2020","December 2021","September 2023","February 7, 2020",,"September 5, 2021","Nagoya University Hospital, Nagoya, Aich, Japan",,"https://ClinicalTrials.gov/show/NCT04261335"
1293,"NCT02240823","Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy",,"Unknown status","No Results Available","Delayed Graft Function","Other: adipose derived stem cells","Safety and Tolerability|Improvement in erectile function, measured i IIEF-5 score","Martha Haahr M.D|Odense University Hospital","Male","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-Afd-L","April 2014","October 2015","September 2016","September 16, 2014",,"October 16, 2015","Odense Universitet Hospital, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT02240823"
1294,"NCT02161003","Stem Cells Therapy for Fecal Incontinence in Children After Posterior Sagittal Ano-rectoplasty",,"Unknown status","No Results Available","Fecal Incontinence","Procedure: Stem Cells Injection Technique|Procedure: Stem Cell Isolation","Main outcome measures|Assessment of Clinical Parameters|Clinical Assessment|Assessment of Urinary sphin Assessment of Urinary Sphincter (Electrophysiology Study)","Al-Azhar University|Cairo University|Ain Shams University|Affiliated Hospital to Academy of Military Medical Sciences|Wake Forest University Health Sciences","Male","2 Years to 12 Years   (Child)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Azhar52980070","October 2013","September 2016","December 2016","June 11, 2014",,"June 11, 2014","Pediatric Surgery Outpatients Clinics - Al Hussien Hospital, Nasr City, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02161003"
1295,"NCT02831075","A Clinical Study Using Adipose-derived Stem Cells for Diabetic Foot",,"Unknown status","No Results Available","Peripheral Vascular Disease|Ischemia|Diabetic Foot","Biological: Adipose-derived stem cell|Biological: saline","Area of diabetic foot ulcers|Improvement of transcutaneous oxygen partial pressure (TcPO2)|Improvement of microvascular cutaneous reactivity by laser Doppler perfusion monitoring (LDPM)|Pain (Visual-Analog Scale)|Walking distance (treadmill) if possible","Jie Shen|Nanfang Hospital of Southern Medical University|Academy Military Medical Science, China|The Fifth Affiliated Hospital of Southern Medical University|Southern Medical University, China|The Third Affiliated Hospital of Southern Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Southern Medical University","January 2015","December 2017","December 2018","July 13, 2016",,"April 7, 2017","the Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02831075"
1296,"NCT01932021","Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting","Angiolipo","Unknown status","No Results Available","Skin Ulcer","Procedure: adipose tissue grafting","Treatment of hypertensive leg ulcer by adipose tissue grafting|treatment of angiodermatitis necrotitis by lipofilling","University Hospital, Caen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-A01613-40","April 2013","April 2014","December 2014","August 30, 2013",,"April 9, 2014","University Hospital, Caen, Caen, France",,"https://ClinicalTrials.gov/show/NCT01932021"
1297,"NCT05120726","A Novel Therapeutic Treatment of Pyoderma Gangrenosum",,"Recruiting","No Results Available","Pyoderma Gangrenosum","Biological: Dehydrated human amnion/chorion membrane","Gene Measurements|Wound Size|Infection|Pain Level","Louisiana State University Health Sciences Center in New Orleans","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB: #1579","June 2, 2021","August 1, 2022","August 1, 2022","November 15, 2021",,"November 15, 2021","LSU Healthcare Network Clinic, Metairie, Louisiana, United States|University Medical Center, New Orleans, Louisiana, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT05120726/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05120726"
1298,"NCT02504437","Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease","TPAABPIHD","Unknown status","No Results Available","Myocardial Infarction|Acute Myocardial Infarction|Ischemic Cardiomyopathy","Biological: BMMSCs","LVEF (left ventricular ejection fraction)","Academy Military Medical Science, China|Sun Yat-sen University","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","200","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BMMSC-1","November 2015","December 2017","December 2017","July 22, 2015",,"July 22, 2015",,,"https://ClinicalTrials.gov/show/NCT02504437"
1299,"NCT04340284","Adipose Tissue Derived Stromal Vascular Fraction (SVF) Application in Treatment of Long Bones Nonunion",,"Completed","No Results Available","Nonunion of Fracture","Biological: autologous adipose tissue derived stromal vascular fraction (SVF)","Union|Short Form 12 Physical Component Summary scale.","Dr. Himanshu Bansal Foundation","All","25 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HimanshubansalFoundation","November 10, 2019","February 14, 2020","February 14, 2020","April 9, 2020",,"April 9, 2020","Anupam Hospital, Rudrapur, Uttrakhand, India",,"https://ClinicalTrials.gov/show/NCT04340284"
1300,"NCT03957564","Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer",,"Recruiting","No Results Available","Gastric Cancer|Gastro-oesophageal Junction Cancer","Drug: Neoadjuvant chemotherapy with PSOX regimen.|Other: Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Other: Detect the tumor related DNA in pathological tissues after operation.|Other: Follow-up of DFS and OS in patients with gastric cancer after operation.","Numbers of CTC pre- and post- neoadjuvant chemotherapy and after operation.|Types of CTC pre- and post- neoadjuvant chemotherapy and after operation.|Mutation rate of ctDNA pre- and post- neoadjuvant chemotherapy and after operation.|Concentration of cfDNA pre- and post- neoadjuvant chemotherapy and after operation.|The relationship between tumor response and changes in numbers of CTC pre- and post-neoadjuvant chemotherapy and after operation.|The relationship between tumor response and mutation of ctDNA pre- and post-neoadjuvant chemotherapy and after operation.|Disease Free Survival(DFS)|Overall survival(OS)|Types of tumor-associated DNA in tumor tissues after operation.","Affiliated Hospital of Qinghai University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHQU-2019002","May 28, 2019","May 20, 2022","May 20, 2024","May 21, 2019",,"January 22, 2020","Jiuda Zhao, Xining, Qinghai, China",,"https://ClinicalTrials.gov/show/NCT03957564"
1301,"NCT03325322","Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Diseases|Diabetes Mellitus|Diabetic Nephropathies","Dietary Supplement: Fisetin|Drug: Placebo oral capsule","Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization","Mayo Clinic","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16-010521","January 2, 2018","January 2023","April 2025","October 30, 2017",,"September 14, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03325322"
1302,"NCT01929434","Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis","CP","Completed","No Results Available","Cerebral Palsy","Other: rehabilitation|Biological: stem cell injection","Gross Motor Function Measure Score|Routine Blood Test and Biochemical Test","General Hospital of Chinese Armed Police Forces","All","1 Year to 14 Years   (Child)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2013-05-13 CP III","October 2013","December 2015","December 2016","August 28, 2013",,"December 27, 2017","General Hospital of Chinese People's Armed Police Forces, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01929434"
1303,"NCT04389450","Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",,"Active, not recruiting","No Results Available","COVID|ARDS","Biological: PLX-PAD|Biological: Placebo","Number of ventilator free days|All-cause mortality|Duration of mechanical ventilation","Pluristem Ltd.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PLX-COV-01","October 1, 2020","May 17, 2021","June 2022","May 15, 2020",,"August 10, 2021","University of California Irvine, Irvine, California, United States|University of Southern California (USC) - Keck School of Medicine (KSOM), Los Angeles, California, United States|University Of California Davis,4860 Y Street, Sacramento, California, United States|Baptist Health Medical Center, Jacksonville, Florida, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|Sarah Cannon Research Institute, LLC (Mercer University School of Medicine), Macon, Georgia, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper Research Institute, Camden, New Jersey, United States|Holy Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, New York, New York, United States|Maimonides Medical Center, New York, New York, United States|Mercy Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04389450"
1304,"NCT02566681","Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis","MSC/ONM","Unknown status","No Results Available","Osteonecrosis of Jaw","Biological: MSC construct for Osteonecrosis","Rate of serious adverse events related to the procedure.|Rate of non-serious adverse events related to the procedure.|Time to Repair the injury|Local pain assessed by visual analog scale|Bone formation, measured by Computed tomography (mm)|Quality of life, measured by EuroQol-5D.","Red de Terapia Celular|Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Hospital Universitario Virgen de la Arrixaca|Spanish National Health System|Public Health Service, Murcia","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC/ONM|2012-005813-38","September 2015","December 2018","December 2018","October 2, 2015",,"March 30, 2017","Hospital Clínico Virgen de la Arrixaca, El Palmar, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT02566681"
1305,"NCT04685577","Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients",,"Not yet recruiting","No Results Available","Burn; Multiple Body Regions, Max. Second Degree|Third-Degree Burn|Burn Degree Second","Drug: Nefopam|Other: Placebo (Vehicle)","Assessment of efficacy by measuring scar/wound area at day 1.|Assessment of efficacy by measuring scar/wound area at day 21.|Assessment of efficacy by measuring scar/wound area at day 27.|Assessment of efficacy by measuring scar/wound area at day 48.|Assessment of efficacy by measuring scar/wound area at day 76.|Assessment of efficacy by measuring scar/wound area at day 104.|Assessment of efficacy by measuring scar/wound depth at day 1.|Assessment of efficacy by measuring scar/wound depth at day 21.|Assessment of efficacy by measuring scar/wound depth at day 27.|Assessment of efficacy by measuring scar/wound depth at day 48.|Assessment of efficacy by measuring scar/wound depth at day 76.|Assessment of efficacy by measuring scar/wound depth at day 104.|Assessment of efficacy by measuring scar erythema and pigmentation at day 1.|Assessment of efficacy by measuring scar erythema and pigmentation at day 21.|Assessment of efficacy by measuring scar erythema and pigmentation at day 27.|Assessment of efficacy by measuring scar erythema and pigmentation at day 48.|Assessment of efficacy by measuring scar erythema and pigmentation at day 76.|Assessment of efficacy by measuring scar erythema and pigmentation at day 104.|Assessment of efficacy by assessing scar/wound healing at day 6 (during Nefopam cream treatment).|Assessment of efficacy by assessing scar/wound healing at day 13 (during Nefopam cream treatment).|Assessment of efficacy by assessing scar/wound healing at day 20 (during Nefopam cream treatment).|Assessment of efficacy by assessing scar/wound healing at day 27 (after completion of Nefopam cream application).|Assessment of efficacy by assessing scar/wound healing at day 48 (after completion of Nefopam cream application).|Assessment of efficacy by assessing scar/wound healing at day 104 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 27 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 48 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 76 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 104 (after completion of Nefopam cream application).|Assessment of efficacy by performing qPCR of the fibrotic molecules at day 27 (after completion of Nefopam cream application).|Assessment of efficacy by performing qPCR of the fibrotic molecules at day 104(after completion of Nefopam cream application).|Assessment of efficacy by performing Immunohistochemistry at day 27(after completion of Nefopam cream application).|Assessment of efficacy by performing Immunohistochemistry at day 104 (after completion of Nefopam cream application).|Assessment of Safety by assessing drug tolerability.|Assessment of heart rate.|Assessment of temperature.|Assessment of blood pressure.|Assessment of respiration.|Measurement of routine hematology parameters.|Measurement of routine clinical chemistry parameters.|Serum Nefopam absorption assessment.","University of Alberta","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NEFOPAM-1|W81XWH-19-2-0048|CDMRP-MB170036","January 2022","December 2023","December 2024","December 28, 2020",,"October 6, 2021",,,"https://ClinicalTrials.gov/show/NCT04685577"
1306,"NCT01413061","Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft",,"Completed","No Results Available","Degenerative Osteoarthritis|Post-traumatic; Arthrosis|Rheumatoid Arthritis & Other Inflammatory Polyarthropathies|Rheumatoid Arthritis of Subtalar Joint","Procedure: Subtalar Arthrodesis","Fusion Rate (%)(as determined by CT assessment)|Radiographic outcome assessments|Functional outcome measurements","AlloSource","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AlloSource Subtalar Fusion RCT","June 2010","February 2017","March 2018","August 10, 2011",,"April 13, 2018","Institute for Foot and Ankle Reconstruction at Mercy, Baltimore, Maryland, United States|Orthopaedic Associates of Michigan, Grand Rapids, Michigan, United States|Minnesota Orthopedic Sports Medicine Institute (MOSMI), Edina, Minnesota, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Campbell Clinic, Germantown, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01413061"
1307,"NCT01860495","Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Perforated Membrane","MPM","Completed","No Results Available","Periodontal Pocket","Procedure: perforated membrane|Procedure: G2","gingival cervicular fluid BMP-2 level|intrabony components (defect bony filling)","Al-Azhar University","All","31 Years to 51 Years   (Adult)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ahmedgamal","March 2012","May 2012","December 2012","May 22, 2013",,"May 22, 2013","Al azhar universty, Cairo Governorate, Egypt",,"https://ClinicalTrials.gov/show/NCT01860495"
1308,"NCT03042143","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)","REALIST","Active, not recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148)","Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality","Belfast Health and Social Care Trust|Queen's University, Belfast|Northern Ireland Clinical Trials Unit|NHS Blood and Transplant","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16154DMcA-AS","January 7, 2019","July 2022","March 2024","February 3, 2017",,"August 20, 2021","Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03042143"
1309,"NCT04189432","Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease",,"Recruiting","No Results Available","Chronic Graft-versus-host-disease","Biological: SCM-CGH|Other: Placebo","Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR])|Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR]).|Organ-specific Assessments|Patient-Reported Outcomes|Clinician-Assessed Global Rating/Scale|Failure-free Survival","SCM Lifescience Co., LTD.","All","19 Years and older   (Adult, Older Adult)","Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SCM-CGH2001","September 28, 2016","March 31, 2022","December 31, 2022","December 6, 2019",,"September 28, 2021","National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Seoul, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04189432"
1310,"NCT04189419","Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis",,"Recruiting","No Results Available","Pancreatitis, Acute","Biological: SCM-AGH|Other: Placebo","The change from baseline in modified Marshall score on Day 7 for organ failure subject|The change from baseline in CTSI Score on Day 28|Percentage of subjects whose organ failure was resolved at 3 days, 7 days, 14 days and 28 days|The change from baseline in modified Marshall score at each assessment point up to Day 28|The change from baseline in sequential organ failure assessment (SOFA) at each assessment point up to Day 28|Duration of Systemic inflammatory response syndrome (SIRS)|Time to resolution of organ failure|The change from baseline value of C-Reactive Protein(CRP) which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of Tumor Necrosis Factor(TNF)-α which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-6 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-8 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of lymphocyte count ratio which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|Duration of intensive care unit (ICU) stay|The change from baseline in Computed Tomography Severity Index(CTSI) on Day 28|Incidence of pancreatic complication|Requirement of drainage or surgery|Rate of infection|Mortality on Day 28 and 90","SCM Lifescience Co., LTD.","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APT2001","August 12, 2019","June 30, 2022","June 30, 2022","December 6, 2019",,"October 4, 2021","Soonchunhyang University Hosptial Bucheon, Bucheon, Gyenggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04189419"
1311,"NCT04179760","Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis",,"Recruiting","No Results Available","Dermatitis, Atopic","Biological: SCM-AGH|Other: Placebo","over 50% reduction ratio of Eczema Area and Severity Index (EASI) as contrasted with baseline value (EASI-50)|Score change from Baseline in Eczema Area and Severity Index(EASI) score|Percentage of subjects who have EASI-75 (improvement of ≥75% in EASI score from Baseline)|Percentage of subjects who have EASI-90 (improvement of ≥90% in EASI score from Baseline)|Percentage of subjects who have the Investigator's Global Assessment (IGA) score of 0 or 1|Percentage of subjects whose Investigator Global Assessment (IGA) score is decreased by 2 points or more|Score change from Baseline on Pruritus Numerical Rating Scale (NRS)|Percentage of subjects whose Pruritus Numerical Rating Scale (NRS) is improved by 3 points or more|Percentage change from Baseline in Body Surface Area (BSA) affected by Atopic Dermatitis (AD)|Score change from Baseline in the SCORing Atopic Dermatitis (SCORAD) index|Score change from Baseline in the Dermatology Life Quality Index (DLQI)|Score change from Baseline the Patient-Oriented Eczema Measure (POEM)|Change from Baseline in biomarker (Immunoglobulin E [IgE])|Change from Baseline in biomarker (eosinophil count)|Change from Baseline in biomarker (interleukin [IL]-13)|Change from Baseline in biomarker (interleukin [IL]-17)|Change from Baseline in biomarker (thymus and activation-regulated chemokine [TARC])|Change from Baseline in biomarker (interleukin [IL]-22)","SCM Lifescience Co., LTD.","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADT2002","March 24, 2020","June 30, 2022","December 30, 2022","November 27, 2019",,"November 19, 2021","Inha University Hospital, Incheon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04179760"
1312,"NCT04364620","AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)",,"Recruiting","No Results Available","NSCLC Stage IV","Drug: AB-16B5|Drug: Docetaxel","Objective response rate (ORR)|Safety and tolerability of the combination of AB-16B5 and docetaxel: number of subjects with an adverse event|Clinical benefit rate (CBR)|Duration of response (complete response and partial response)|Duration of stable disease|Progression free survival (PFS)|Overall survival (OS)|Determination of plasma concentrations of AB-16B5","Alethia Biotherapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AB-16B5-201","February 23, 2021","February 2022","July 2022","April 28, 2020",,"April 21, 2021","The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Quebec, Canada|Centre Intégré de Santé et de Services Sociaux des Laurentides (Hôpital Régional de St-Jérôme), Saint-Jérôme, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04364620"
1313,"NCT03197623","Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids",,"Completed","No Results Available","Osteopenia|Osteoporosis|Osteonecrosis","Drug: LLP2A-ALENDRONATE|Drug: Placebo","Dose limiting Adverse events|Severe infusion reactions|Grade 2 elevated creatinine","Nancy E. Lane, MD|California Institute for Regenerative Medicine (CIRM)|University of California, Davis","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 1","58","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20161825|LLP2A-001","October 14, 2016","March 15, 2021","March 31, 2021","June 23, 2017",,"August 6, 2021","West Coast Clinical Trials (WCCT), Cypress, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03197623"
1314,"NCT04638868","Silicon Microsieve Device vs Cell Surface Marker-based Platform for the Isolation of Pancreatic Cancer CTCs",,"Not yet recruiting","No Results Available","Pancreatic Cancer","Device: Microsieve device|Device: Cell surface marker-based platform","Number of circulating tumor cells","Singapore General Hospital|Agency for Science, Technology and Research","All","21 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2019/2502|03/FY2018/P1/13-A28FY2019PFF02","November 17, 2020","December 31, 2021","December 31, 2021","November 20, 2020",,"November 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04638868"
1315,"NCT04557514","Comparative Study Between Fat Injection And Platelet Rich Plasma In Post Burn Facial Scar",,"Not yet recruiting","No Results Available","Burn Scar","Procedure: platelet rich plasma injection in post burn facial scar|Procedure: fat injection in post burn facial scar","vancouver scale","Assiut University","All","15 Years to 60 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","facial burn scar","October 1, 2020","October 1, 2023","December 1, 2023","September 21, 2020",,"September 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04557514"
1316,"NCT03555357","Platelet Rich Therapy for Scar Revision",,"Unknown status","No Results Available","Abdominoplasty Scar Revision","Other: Platelet Rich Fibrin|Other: Platelet Rich Plasma","Global Aesthetics Improvement Scale (GAIS)","Rejuva Medical Aesthetics","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PRF02","July 2018","January 2019","July 2019","June 13, 2018",,"June 13, 2018",,,"https://ClinicalTrials.gov/show/NCT03555357"
1317,"NCT01436123","Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting","NANOM PCI","Terminated","No Results Available","Coronary Artery Disease|Atherosclerosis","Other: Stenting and micro-infusion of NP|Device: Implantation of everolimus-eluting stent","Total atheroma volume|Composite end-point of any MACE (major acute cardiovascular events), all-cause death, any revascularization|Composition of plaque|Major and minor bleeding|Restenosis rate|Stent thrombosis rate|Coronary flow-mediated vasodilatation|Coronary intima-media thickness|Minimum diameter stenosis|Minimum lumen diameter","Ural State Medical University|Ural Institute of Cardiology|De Haar Research Foundation|Ural Federal University","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NANOM PCI","December 2010","July 2012","October 2012","September 19, 2011",,"May 19, 2015","De Haar Research Foundation, Rotterdam, South Holland, Netherlands|Ural Center of Modern Nanotechnologies, Institute of Natural Sciences, Ural Federal University, Yekaterinburg, Sverdlovsk oblast, Russian Federation|Ural Institute of Cardiology, Yekaterinburg, Sverdlovsk oblast, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01436123"
1318,"NCT03618784","Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis",,"Recruiting","No Results Available","Rheumatoid Arthritis","Biological: FURESTEM-RA Inj|Other: sterile saline","Safety of FURESTEM-RA Inj. - number of adverse events|Efficacy as measured by ACR(American College of Rheumatology)20,50,70 reaction rate|Efficacy as measured by EULAR (European League Against Rheumatism)reaction rate|Efficacy as measured by DAS(Disease activity scores)28-ESR|Efficacy as measured by KHAQ(Korean Health assessment questionnaire)|Efficacy as measured by CDAI (clinical disease activity index)|Efficacy as measured by 100mm Pain VAS(Visual analogue scale)|Total number of use and consumed amount of rescue medicine|Change in Cytokine(TNF-a, Interleukin (IL)-1b, IL-4,IL-6,IL-8,IL-10,IL-13,IL-17A,IL-21,IL-22)","Kang Stem Biotech Co., Ltd.","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","K0202","July 11, 2018","February 2021","April 2021","August 7, 2018",,"July 13, 2020","Chonnam National University Hospital, Gwangju, Korea, Republic of|Gangdong Kyung Hee University Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Seoul Hospital attached to Soonchunhyang University, Seoul, Korea, Republic of|Seoul national University Boramae, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03618784"
1319,"NCT04274543","Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military",,"Recruiting","No Results Available","Tibial Meniscus Injuries|Knee Injuries|Knee Injuries and Disorders","Device: Lipogems|Drug: Normal Saline","Change in Numerical Rating Scale|Patient Global Impression of Change|Knee Injury and Osteoarthritis Outcome Score|PROMIS-Physical Functioning Short Form","Kessler Foundation|Walter Reed National Military Medical Center|Uniformed Services University of the Health Sciences","All","18 Years to 45 Years   (Adult)","Phase 2","80","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R-1065-19","July 1, 2019","September 30, 2021","September 2022","February 18, 2020",,"February 18, 2020","Kessler Foundation, West Orange, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04274543"
1320,"NCT04136743","Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury","MFAT-SCI","Recruiting","No Results Available","Spinal Cord Injuries|Tendinopathy|Rotator Cuff Tears|Shoulder Pain","Device: Lipogems|Drug: Dexamethasone","Change in Numerical Rating Scale|Wheelchair User's Shoulder Pain Index|Patient Global Impression of Change|Physical Examination of the Shoulder Scale|Ultrasound Shoulder Pathology Rating Scale|Quantitative Ultrasound of the Supraspinatus Tendon","Kessler Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R-1066-19","June 14, 2019","April 30, 2022","April 30, 2022","October 23, 2019",,"February 18, 2020","Kessler Foundation, West Orange, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04136743"
1321,"NCT03410355","Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis","BMAC","Terminated","No Results Available","Osteoarthritis, Hip","Procedure: BMAC/PRP Injection|Procedure: Cortisone Injection","Functional Benefit and Pain Level Changes using iHOT33 Questionnaire|Functional Benefit and Pain level Changes using the modified Harris Hip Score (HHS)|Functional Benefit and Pain level Changes using the The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Burden of Disease and Quality of Life Changes using the Veterans RAND 12 Item Health Survey (VR-12)|Pain Changes using the Visual Analogue Scale (VAS)","Nova Scotia Health Authority","All","16 Years to 60 Years   (Child, Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IW-001","February 1, 2018","May 17, 2019","May 17, 2019","January 25, 2018",,"August 2, 2021","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT03410355"
1322,"NCT00562497","Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)",,"Completed","No Results Available","Graft Versus Host Disease","Drug: Prochymal|Other: Placebo","Percentage of Participants with Treatment Success|Percentage of Participants with Overall Response|Percentage of Participants with Induction of a 2-grade decrease in (Graft Versus Host Disease) GVHD by Study Day 28 with maintenance of a 2-grade decrease in GVHD through Study Day 56|Percentage of Participants with Induction of CR lasting for greater than or equal to 14 Days|Percentage of Participants with Induction of a CR after Study Day 28 and clinically managed with steroids with second line/escalation therapy through Study Day 56|Percentage of Participants with Induction of PR during the first 28 days|Time to achieve CR|Number of CR per organ|Total corticosteroid dose administered|Number of corticosteroid-related complications|Number of Infectious complications|Number of Days of Hospitalization|Average Daily Corticosteroid Dose","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","265","January 31, 2008","July 14, 2009","May 20, 2010","November 22, 2007",,"March 10, 2020","University of Alabama Birmingham (UAB) Hospital, Birmingham, Alabama, United States|UCLA Medical Center, Los Angeles, California, United States|University of California Medical Center, San Francisco, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northwestern Center for Clinical Research, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Hospitals, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|St. Francis Cancer Center, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Tufts New England Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Medical Center, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Kansas City Cancer Center, Lee's Summit, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|University of North Carolina Hospitals, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Jewish Hospital, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Oncology Hematology Association, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Centers, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina(MUSC), Charleston, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St. Vincent's Hospital, Darlinghurst, Australia|Royal Brisbane Hospital, Herston, Australia|Peter Lougheed Centre, Calgary, Alberta, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00562497"
1323,"NCT02951897","Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma","CTCs detection","Unknown status","No Results Available","Lung Adenocarcinoma, Stage I|Diagnoses Diseases|Circulating Tumor Cells|Treatment","Procedure: lobectomy|Procedure: segmentecomy|Drug: chemotherapy（pemetrexed+CISPLATIN）|Procedure: Lymphadenectomy|Other: CanPatrolTM to detect CTCs","Disease free survival","Third Military Medical University","All","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMMU-DP-2016-4-25","April 2016","December 2019","December 2019","November 1, 2016",,"November 2, 2016","Daping hospital, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT02951897"
1324,"NCT05019287","Menstrual Blood Stem Cells in Severe Covid-19",,"Completed","No Results Available","Covid19|Cytokine Storm","Biological: Allogeneic human menstrual blood stem cells secretome|Other: Intravenous saline injection","Adverse reactions incidence|Time to clinical improvement|Assessment of serum CRP (mg/L) levels|Assessment of serum LDH (U/L) levels|Assessment of serum Ferritin (ng/ml) levels|Assessment of serum D-dimer (microgr/ml) levels|Immunological changes on CD4+ T and CD8+ T|Lung Involvement|Changes in Inflammatory cytokine IL 6|Changes in anti-Inflammatory cytokine IL10","Avicenna Research Institute|Tehran University of Medical Sciences","All","25 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","990308-026|99/3436","April 17, 2021","May 21, 2021","June 9, 2021","August 24, 2021",,"September 2, 2021","Avicenna Research Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05019287"
1325,"NCT04750499","Treatment of Perianal Fistulas by Endorectal Advancement Flap Associated With Adipose Tissue Injection","Fistula_CM1","Recruiting","No Results Available","Anal Fistula","Procedure: Adipose tissue injection associated with endorectal advancement flap.","Healing rate|Incontinence rate|Treatment related adverse events","Hospital Plató","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Fistula_CM1","September 1, 2020","September 2022","September 2022","February 11, 2021",,"February 15, 2021","Hospital Plato, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04750499"
1326,"NCT05054803","Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury",,"Not yet recruiting","No Results Available","Spinal Cord Injury Cervical","Drug: WJ-MSC (XCEL-UMC-BETA)|Drug: Placebo","Safety assessment|ASIA punctuation|Motor evoked potentials|Somatosensory evoked potentials|Electrical pain threshold perception|Handgrip Strength|Walk test WISCIII|Numerical scale for neuropathic pain assessment|Modified Ashworth scale for spasticity|SCIM III scale for functionality|Quality of life questionnaire (WHOQOL-BREF)|Psychological general well-being index (PGWBI)|Hospital Anxiety and Depression Scale (HADS)|Community Integration Questionaire (CIQ-IG)|AntiHLA antibodies in cerebrospinal fluid (CSF)|Detection of donor cells in CSF","Banc de Sang i Teixits|Institut Guttmann|Academic Research Organization (ARO) - VHIR","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BST-SCI-02","October 2021","October 2023","October 2025","September 23, 2021",,"September 23, 2021","Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain|Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain",,"https://ClinicalTrials.gov/show/NCT05054803"
1327,"NCT04749758","Assessment of the Efficacy of Stromal Vascular Fraction Treatment for Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: SVF treatment","Change from baseline knee pain measured with a Visual Analogue Scale (VAS) at 1 year|Change from baseline functionality measured with Knee Injury and Osteoarthritis Outcome Score (KOOS) at 1 year|Change from baseline quality of life measured with SF-36 questionnaire at 1 year.|Change from baseline disability measured with WHODAS 2.0 questionnaire at 1 year.|Change from baseline joint cartilage characteristics measured with Magnetic Resonance Imaging at 1 year.","University of Andorra","All","18 Years and older   (Adult, Older Adult)","Not Applicable","77","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UA003GRCSSS","September 20, 2018","December 2021","December 2022","February 11, 2021",,"February 11, 2021","CelularClinic, Escaldes-Engordany, Andorra",,"https://ClinicalTrials.gov/show/NCT04749758"
1328,"NCT03643614","Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula",,"Completed","No Results Available","Rectovaginal Fistula","Procedure: Injection of autologous regenerative cells of adipose tissue","Serious adverse events|Serious adverse reactions|Changes of fistula size|Changes in rectovaginal soft tissue density and flexibility|Quality of life monitoring - 1|Quality of life monitoring - 2","South Ural State Medical University","Female","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RU SUSMU 310855.210617.1","August 1, 2017","November 15, 2019","January 22, 2020","August 23, 2018",,"January 27, 2020","South Ural State Medical University, Chelyabinsk, Chelyabinsk Oblast, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03643614"
1329,"NCT01626677","Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect",,"Completed","No Results Available","Degenerative Osteoarthritis|Defect of Articular Cartilage","Biological: CARTISTEM|Procedure: Microfracture","Degree of improvement in knee assessments compared to the active control (microfracture)|Number of subjects with adverse events","Medipost Co Ltd.|Dong-A Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CARTISTEM_CR_F/U","June 2012","May 2015","May 2015","June 25, 2012",,"April 20, 2017","Inha University Hospital, Incheon, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Seoul Veterans Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01626677"
1330,"NCT03060551","Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients",,"Completed","Has Results","Systemic Sclerosis","Procedure: SVF injection","Raynaud's Condition Scale|Hand Visual Analogue Scale|Colchin Hand Function Scale|Kapandji Score (Ranging 0 to 10) - Dominant Hand|Kapandji Score (Non-dominant Hand)|Disease-related QOL (Quality of Life) : EuroQol-5 Dimensions Time Trade-off (EQ-5D TTO)|Disease-related QOL (Quality of Life) : EuroQol Visual Analog Scale (EQ VAS)|Disease-related QOL (Quality of Life) : Health Assessment Questionnaire (HAQ)|The Degree of Hand Edema (Right)|The Degree of Hand Edema (Left)|Changes of Nailfold Capillary Microscopic Findings (Irregularly Enlarged Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Giant Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Hemorrhages)|Changes of Nailfold Capillary Microscopic Findings (Loss of Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Disorganization of the Vascular Array)|Changes of Nailfold Capillary Microscopic Findings (Capillary Ramifications)","Suk-Ho Moon|Seoul St. Mary's Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SVF treatment in SSc","July 1, 2018","December 30, 2019","December 30, 2019","February 23, 2017","October 8, 2020","October 8, 2020","Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03060551/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03060551"
1331,"NCT01071577","Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products",,"Completed","No Results Available","Bone Marrow Stromal Cells",,"Tissue Collection","National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)",,"65","NIH","Observational","Observational Model: Other|Time Perspective: Prospective","100053|10-CC-0053","March 17, 2010",,,"February 19, 2010",,"October 18, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01071577"
1332,"NCT03913910","Perianal Fistula Treatment With Autologous Adipose Tissue Injection",,"Unknown status","No Results Available","Perianal Fistula","Procedure: Lipogems","Healing|Safety collecting all types of adverse events|Pain assessed using the Visual Analogue Scale (VAS) for pain|Continence|Patient's satisfaction|Non inferiority compared with the Advancement flap technique","Azienda Ospedaliero, Universitaria Pisana","All","18 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AOUPisana_1","February 1, 2019","December 31, 2019","June 30, 2020","April 12, 2019",,"May 14, 2019","AOU Pisana - Cisanello, Pisa, Toscana, Italy",,"https://ClinicalTrials.gov/show/NCT03913910"
1333,"NCT03226015","Autologous Oral Mucosa Transplantation for Limbal Stem Cell Deficiency",,"Completed","No Results Available","Limbal Stem-cell Deficiency",,"change in number of acute surgeries|change in days of acute inpatient treatment|change in number of curative surgical procedures after oral mucosa transplantation|change in conjunctival inflammation","Klinikum Chemnitz gGmbH|Institute of Anatomy TU Dresden","All","18 Years and older   (Adult, Older Adult)",,"27","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EK-BR-64/15-1","July 2015","April 2017","May 2017","July 21, 2017",,"July 21, 2017",,,"https://ClinicalTrials.gov/show/NCT03226015"
1334,"NCT01366911","Stem Cells Predicting Orthopedic Outcomes",,"Completed","No Results Available","Hip Arthroplasty",,"Can Stem Cells Predict Orthopaedic Outcomes?","University of Nebraska","All","Child, Adult, Older Adult",,"203","Other","Observational","Observational Model: Other|Time Perspective: Prospective","168-11-FB","April 2011","January 10, 2014","January 10, 2014","June 6, 2011",,"September 14, 2017","Dept of Orthopaedic Surgery at University of Nebraska Medical Center, Omaha, Nebraska, United States|Dept. of Orthopaedic Surgery, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01366911"
1335,"NCT01088191","Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction",,"Completed","No Results Available","Anterior Cruciate Ligament Injury|Osteoarthritis","Biological: MSB-CAR001 Combined With Hyaluronan|Drug: Hyaluronan","To determine the overall safety of MSB-CAR001 plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).|To evaluate the overall efficacy with MSB-CAR001 plus Hyaluronan compared to Hyaluronan alone using MRI scans and x-ray of the involved knee joint and access the change in outcomes (KOOS, SF-36) and pain (VAS)","Mesoblast, Ltd.","All","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MSB-CAR001","March 2009","November 2013","October 2014","March 17, 2010",,"August 15, 2018","Emeritus Research, Malvern East, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01088191"
1336,"NCT03021642","Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Tepotinib test (Treatment Period 1)|Drug: Tepotinib reference (Treatment Period 2)|Drug: Tepotinib reference (Treatment Period 1)|Drug: Tepotinib test (Treatment Period 2)","Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) at Concentration at or Above Lower Limit of Quantitation (LLOQ) of Tepotinib|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tepotinib|Maximum Plasma Concentration Observed (Cmax) of Tepotinib|Time to Reach the Maximum Plasma Concentration (Tmax) of Tepotinib|Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Maximum Plasma Concentration Observed (Cmax) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Time to Reach the Maximum Plasma Concentration (Tmax) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Apparent Terminal Half-Life (t1/2) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A) in Plasma|Apparent Terminal Rate Constant (λz) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A) in Plasma|Total Body Clearance of Drug From Plasma (CL/f) for Tepotinib|Apparent Volume of Distribution (Vz/f) for Tepotinib|Extrapolated Area Under the Plasma Concentration-Time Curve From Time t to Infinity (%AUCextra) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A)|Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Metabolite (MSC2571109A or MSC2571107A) to AUC0-inf of Tepotinib|Ratio of Maximum Plasma Concentration Observed (Cmax) of Metabolite (MSC2571109A or MSC2571107A) to Cmax of Tepotinib|Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, TEAEs Leading to Discontinuation|Number of Subjects With Clinically Significant Change From Baseline in Vital Signs, Electrocardiogram (ECG) and Laboratory Parameters","Merck KGaA, Darmstadt, Germany","All","18 Years to 60 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS200095-0012|2015-004369-95","January 31, 2016","March 31, 2016","March 31, 2016","January 16, 2017","January 25, 2019","January 25, 2019","For Recruiting Locations outside US, please Contact Merck KGaA Communication Center, Darmstadt, Germany",,"https://ClinicalTrials.gov/show/NCT03021642"
1337,"NCT02940977","Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique",,"Unknown status","No Results Available","Prostatic Neoplasms|Prostatic Adenoma","Other: Blood draws","Circulating tumor cell (CTC) total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique|Pathological findings (whether the patient has: 1.OC, organ confined; 2.EPE, extraprostatic extension; 3. SVI, seminal vesicle invasion; 4. LNI, lymph node invasion) during the radical prostectomy, confirmed by pathology section result|CTC total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique|Prostate specific antigen (PSA) level measurement using peripheral venous blood|PSA level measurement using peripheral venous blood|Radiological evaluation including isotope bone scanning and pelvic magnetic resonance imaging (MRI) scan","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Shen Kang Hospital Development Center","Male","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","XH-16-028","October 1, 2016","March 30, 2019","March 30, 2019","October 21, 2016",,"July 10, 2018","Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02940977"
1338,"NCT03276312","Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot",,"Completed","No Results Available","Diabetic Foot","Device: Lipogems","Healing time|Safety: All types of adverse events will be collected|Incidence of relapse|Pain assessed using the Visual Analogue Scale (VAS) for pain|Total time of hospitalization|Total time of immobility|Quality of Life using the Short Form 36 (SF-36) questionnaire","University of Modena and Reggio Emilia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADF01","April 2015","March 2018","March 2018","September 8, 2017",,"June 8, 2018","University of Modena and Reggio Emilia, Modena, Italy",,"https://ClinicalTrials.gov/show/NCT03276312"
1339,"NCT01111422","Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients",,"Unknown status","No Results Available","End-Stage Kidney Disease|Peritoneal Dialysis","Drug: N-acetylcysteine","Peritoneal membrane function|Oxydative stress status|Mesothelial cell transformation (Epithelial to Mesenchymal Transition)|Residual renal function","Ewha Womans University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ewha 219-3-40","March 2010","December 2010","December 2011","April 27, 2010",,"April 27, 2010","Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01111422"
1340,"NCT04735185","Stem Cells vs. Steroids for Discogenic Back Pain",,"Not yet recruiting","No Results Available","Chronic Low Back Pain|Degenerative Disc Disease","Other: Autologous stem cells|Drug: Corticosteroid|Drug: Local anesthetic","Mean change in average low back pain score on 0-10 numerical rating scale|Hospital Anxiety and Depression Scale score|Athens Insomnia Scale score|Patient global impression of change (PGIC) score|Oswestry disability index score|Disc Degeneration based on MRI|Average low back pain score on 0-10 numerical rating scale|Mean change in worst low back pain score on 0-10 numerical rating scale|Worst low back pain score on 0-10 numerical rating scale|Positive categorical outcome","Johns Hopkins University|The Geneva Foundation|United States Department of Defense","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","106","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00250806","November 30, 2021","November 30, 2024","November 30, 2025","February 3, 2021",,"May 10, 2021",,,"https://ClinicalTrials.gov/show/NCT04735185"
1341,"NCT01927354","Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.",,"Unknown status","No Results Available","Head-and-Neck Squamous Cell Carcinoma",,"The interplay between Twist1 and other EMT regulators throigh microRNA-29 family","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort","201112085RID","December 2012","March 2014","March 2014","August 22, 2013",,"September 16, 2013","National Taiwan University Hospital research Ethics Committee, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01927354"
1342,"NCT01223664","Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Procedure: Allogenic bone marrow stem cells transplantation|Drug: Conserved therapy","Liver Function|Immunity","Sun Yat-sen University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SYS-1012","October 2010","November 2011","November 2011","October 19, 2010",,"October 19, 2010","Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01223664"
1343,"NCT01221454","Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure",,"Unknown status","No Results Available","Liver Failure","Procedure: Allogenic bone marrow stem cells transplantation|Drug: Conserved therapy","Liver Function|Immune function","Sun Yat-sen University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SYS-LF","October 2010","November 2011","November 2011","October 15, 2010",,"October 18, 2010","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01221454"
1344,"NCT02859025","Concomitant Use of Buccal Fat Pad Derived Cells and Autogenous Bone in Alveolar Cleft Osteoplasty",,"Completed","No Results Available","Cleft of Alveolar Ridge","Biological: anterior iliac crest graft|Biological: lateral ramus cortical bone+BFPSC+NBBM|Biological: anterior iliac crest graft+BFPSC+NBBM","change in bone volume","Shahid Beheshti University of Medical Sciences","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sbmu9221","January 2015","January 2016","February 2016","August 8, 2016",,"August 8, 2016","School of Dentristry at Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02859025"
1345,"NCT02301039","SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas",,"Completed","Has Results","Soft Tissue Sarcoma|Bone Sarcoma","Drug: Pembrolizumab","Objective Response Rate|Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient|The Progression-free Survival (PFS)|Response Rate by Immune-related Response Criteria (Ir-RC)|Overall Survival (OS)","Sarcoma Alliance for Research through Collaboration|Merck Sharp & Dohme Corp.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","144","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARC028","March 2015","July 1, 2020","July 1, 2020","November 25, 2014","September 29, 2020","September 29, 2020","University of Southern California, Los Angeles, California, United States|Medstar Health Research Institute, Washington, District of Columbia, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02301039/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02301039"
1346,"NCT00081055","OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies",,"Withdrawn","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes","Biological: autologous expanded mesenchymal stem cells OTI-010|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Incidence of acute GVHD grade II-IV of skin, liver and gut (stomach to rectum) through Day 84 post-PBSC transplantation|Safety as measured by infusional toxicity, relapse nd survival, formation of potential ectopic tissue foci","Mesoblast International Sàrl|National Cancer Institute (NCI)|Mesoblast, Ltd.","All","18 Years to 55 Years   (Adult)","Phase 2","0","Industry|NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care","Mesoblast|UCLA-0303036|CDR0000358809",,,,"April 8, 2004",,"December 4, 2014","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00081055"
1347,"NCT01524016","68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia",,"Unknown status","No Results Available","Oncogenic Osteomalacia|Mesenchymal Tumor","Drug: 68Ga-DOTATATE","Number and location of lesions detected by 68GA-DOTATATE PET/CT compared to 99mTc-HYNIC-TOC SPECT/CT and/or 18F-FDG PET/CT|Number of participants and kinds of adverse events as a measure of safety","Peking Union Medical College Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM001","December 2011","December 2017","December 2017","February 1, 2012",,"April 7, 2017","Department of Nuclear Medicine, Peking Union Medical College Hopital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01524016"
1348,"NCT00790413","Haploidentical Stem Cell Transplantation in Neuroblastoma",,"Active, not recruiting","No Results Available","Neuroblastoma","Drug: iodine I 131 metaiodobenzylguanidine|Drug: Fludarabine|Drug: Thiotepa|Procedure: T-cell depletion|Procedure: Haploidentical stem cell transplantation|Procedure: Donor Lymphocyte Infusion|Drug: Rituximab|Procedure: Co-transplantation of mesenchymal stem cells","Engraftment rate|Overall survival|Immunological reconstitution|Incidence of acute graft versus host disease","Lund University Hospital","All","6 Months to 21 Years   (Child, Adult)","Early Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","385/2005","August 2005","December 31, 2022","December 31, 2022","November 13, 2008",,"February 21, 2021","Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT00790413"
1349,"NCT02015065","Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors",,"Completed","Has Results","GIST","Drug: Vandetanib","Number of Participants With a Clinical Activity-radiographic Response|Count of Participants With Serious and Non-serious Adverse Events|Percentage of Participants Overall Survival|Progression Free-Survival|Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","9","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130208|13-C-0208","December 14, 2013","May 4, 2016","December 10, 2019","December 19, 2013","July 23, 2019","March 30, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/Prot_SAP_000.pdf|""Informed Consent Form: Standard consent"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/ICF_001.pdf|""Informed Consent Form: Parent QOL consent"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02015065"
1350,"NCT03379168","Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.",,"Unknown status","No Results Available","Knee Osteoarthritis","Device: Microfragmented Adipose Tissue (Lipogems)|Drug: Corticosteroid injection|Drug: Saline","Change in Visual Analog Pain Scale (VAS) Over Time|Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Over Time|Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Over Time","Dustin L. Richter, MD|University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17-146","April 1, 2018","March 31, 2019","July 2019","December 20, 2017",,"April 23, 2018","UNM Hospital, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT03379168"
1351,"NCT03296501","Intraspinal Transplantation of Autologous ADRC in ALS Patients","ADIPOSTEM","Active, not recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Biological: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients","Functional progression rate|Electrophisiological progression rate","Mossakowski Medical Research Centre Polish Academy of Sciences|Medical University of Warsaw","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DPO/014/33/09/2015","October 13, 2015","October 31, 2020","October 31, 2022","September 28, 2017",,"April 15, 2020","Medical University of Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03296501"
1352,"NCT03555773","Micro-fragmented Adipose Tissue and Complex Crohns' Anal Fistulas",,"Completed","No Results Available","Crohn Disease|Perianal Fistula","Procedure: Lipogems","Healing|Health-related quality of life assessed by a disease specific questionnaire|Health-related quality of life assessed by a generic questionnaire","IRCCS Azienda Ospedaliero-Universitaria di Bologna","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Lipogems-crohn2","May 11, 2016","June 28, 2017","June 28, 2017","June 14, 2018",,"June 14, 2018","S. Orsola-Malpighi Hospital, Bologna, BO, Italy",,"https://ClinicalTrials.gov/show/NCT03555773"
1353,"NCT05120700","Synovial Tissue and Fat Pad Stromal Vascular Fraction Bioengineering in Patients With Knee Articular Cartilage Injury",,"Not yet recruiting","No Results Available","Cell- and Tissue-Based Therapy|Cartilage Injury|Knee Injuries","Biological: Synovial Tissue and Fat Pad Stromal Vascular Fraction","Cartilage Repair|Visual Analog Score for pain|International Knee Documentation Committee Questionnaire|Western Ontario and McMaster Universities Osteoarthritis Index|Perioperative and post-operative complications|Measurement of health resources expenses","University of Sao Paulo General Hospital","All","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4.285.308","April 2022","April 2025","May 2025","November 15, 2021",,"November 15, 2021",,,"https://ClinicalTrials.gov/show/NCT05120700"
1354,"NCT04980261","Freeze-dried Bovine Hydroxyapatite/Secretome Composite for Bone Defects",,"Recruiting","No Results Available","Bone Loss","Procedure: ORIF + autograft|Procedure: ORIF + FD BHA/Secretome","X-ray evaluation immediately following surgery.|X-ray evaluation at 4 weeks following surgery|X-ray evaluation at 8 weeks following surgery.|X-ray evaluation at 12 weeks following surgery.|X-ray evaluation at 16 weeks following surgery.|Ultrasonography evaluation at 2 weeks|Ultrasonography evaluation at 4 weeks|Ultrasonography evaluation at 8 weeks|Ultrasonography evaluation at 12 weeks|Ultrasonography evaluation at 16 weeks|Functional evaluation at 8 weeks following surgery.|Functional evaluation at 12 weeks following surgery.|Functional evaluation at 16 weeks following surgery.","Dr. Soetomo General Hospital|Dr. Ramelan Naval Hospital|Airlangga University Hospital|Sidoarjo General Hospital|Cell & Tissue Bank, Dr. Soetomo General Hospital","All","18 Years to 50 Years   (Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0045/KEPK/VIII/2020","July 1, 2020","July 1, 2022","December 31, 2022","July 28, 2021",,"July 28, 2021","Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04980261"
1355,"NCT03030417","Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas",,"Recruiting","No Results Available","Solid Tumors|Lymphoma","Drug: LMP744","To establish the safety, tolerability and the maximum tolerated dose (MTD) of LMP744 (NSC 706744)|Characterize the pharmacokinetic (PK) profile of LMP744","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","53","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170045|17-C-0045","February 27, 2017","October 2, 2022","October 2, 2022","January 25, 2017",,"October 18, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03030417"
1356,"NCT02619734","Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease",,"Unknown status","No Results Available","Chronic Leg Ulcer|Sickle Cell Disease","Biological: Infusion of Autologous Bone Marrow Mononuclear Cells","Safety of Treatment - Determined by changes in vital signs, electrocardiographic, biochemical, hematological, and urinalysis measures, and reported adverse events|Change in Leg Ulcer|Numeric pain intensity scale (0-10)|Ulcer Healing|Quality of Life","Federal University of Bahia|Oswaldo Cruz Foundation","All","18 Years to 55 Years   (Adult)","Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11738","August 2006","July 2016","August 2016","December 2, 2015",,"December 2, 2015",,,"https://ClinicalTrials.gov/show/NCT02619734"
1357,"NCT03066245","Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC)",,"Unknown status","No Results Available","Aneurysmal Bone Cyst","Biological: MSC-PLGA","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the MSC-PLGA engraftment|Effectiveness of using PLGA scaffolds seeded with autologous bone marrow MSCs by Radiograph","Sophia Al-Adwan|University of Jordan","All","4 Years to 28 Years   (Child, Adult)","Phase 1|Phase 2","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABCUJCTC","May 3, 2018","December 2019","March 2020","February 28, 2017",,"July 24, 2019","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03066245"
1358,"NCT00815217","The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers",,"Unknown status","No Results Available","Diabetic Wounds|Venous Stasis Wounds","Procedure: injection of lipoaspirate|Other: control","wound measurements, healing of wounds, pictures of wounds","Washington D.C. Veterans Affairs Medical Center","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","250","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","01194","February 2009","February 2010","February 2010","December 29, 2008",,"December 29, 2008","Veterans Affairs Medical Center, Washington D.C., Washington D.C., District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00815217"
1359,"NCT02138331","Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM)",,"Unknown status","No Results Available","Diabetes Mellitus Type 1","Biological: MSC exosomes.","Total daily insulin dose|Pancreatic β-cell Mass","General Committee of Teaching Hospitals and Institutes, Egypt","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","666666|Cell Free MSC Exo","April 2014","July 2014","September 2014","May 14, 2014",,"May 14, 2014","Sahel Teaching Hospital, Sahel, Cairo, Egypt|Sahel Teaching Hospital - General Committee of Teaching Hospitals and Institutes, Shubra, Cairo, Egypt|Sahel Teaching Hospital, General Commettee of Teaching Hospitals and Institutes., Shubra, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02138331"
1360,"NCT00629096","Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy",,"Completed","No Results Available","Dilated Cardiomyopathy","Procedure: Intracoronary infusion of autologous bone marrow cells","Improvement of left ventricular function|Functional status","Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCMR0007/2006|EudraCT 2007-003088-36","February 2008","August 2010","December 2010","March 5, 2008",,"December 5, 2014","Reina Sofía University Hospital, Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT00629096"
1361,"NCT04132076","Treatment Outcome After Ankle Joint Surgeries",,"Unknown status","No Results Available","Osteochondral Lesion of Talus|Ankle Arthritis|Instability; Ankle (Ligaments) (Old Injury)|Impingement Syndrome of Ankle",,"FAOS questionnaire|EQ-5D questionnaire|Tegner activity score|Kellgren and Lawrence score","University Medical Centre Ljubljana","All","18 Years to 90 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","0120-99/2019/4","April 17, 2019","March 2020","January 2021","October 18, 2019",,"October 18, 2019","Department of orthopaedic surgery, University medical centre Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT04132076"
1362,"NCT04695522","ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery",,"Recruiting","No Results Available","D017202","Biological: ADR-002K administration","Number of participants with Adverse event|Amount of change in late gadolinium contrast-enhanced area at the time of screening and 6 months after surgery|Number of complication associated with drug administration method","Osaka University|Rohto Pharmaceutical Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CVSR0006","November 27, 2019","April 30, 2021","October 31, 2021","January 5, 2021",,"January 5, 2021","Osaka University Hospital, Suita, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT04695522"
1363,"NCT01967186","Intraportal or Intramuscular Site for Islets in Simultaneous Islet and Kidney Transplantation",,"Unknown status","No Results Available","Type 1 Diabetes|End Stage Renal Disease","Procedure: Intraportal islet transplantation|Procedure: Intramuscular islet transplantation|Procedure: Intramuscular transpl with stemcells|Procedure: Kidney transplantation","C-peptide derived from the Mixed Meal Tolerance Test (MMTT)","The Nordic Network For Clinical Islet Transplantation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIK01","April 2007","January 2016","July 2016","October 22, 2013",,"October 6, 2015",,,"https://ClinicalTrials.gov/show/NCT01967186"
1364,"NCT03217461","Corneal Epithelial Autograft for Limbal Dermoid",,"Unknown status","No Results Available","Corneal Dermoid","Procedure: CorneaL epithelial autograft|Device: Femtosecond laser|Procedure: Limbal autograft","Restoration of corneal surface|Cosmetic improvement|Corneal Thickness|Best corrected visual acuity|Corneal power, astigmatism and aberration|Density of stromal nerve and stromal keratocytes|Corneal haze","Chunxiao Wang|Sun Yat-sen University","All","1 Year to 30 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017KYPJ056","July 18, 2017","December 30, 2019","June 30, 2020","July 14, 2017",,"September 19, 2019","Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03217461"
1365,"NCT04043819","Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis",,"Active, not recruiting","No Results Available","Knee Osteoarthritis","Drug: PSC-01","Incidence of Adverse Events|Changes in KOOS Measurement","Personalized Stem Cells, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","125","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSC-CP-001","September 7, 2019","January 2021","January 2021","August 2, 2019",,"September 16, 2020","San Diego Orthobiologics Medical Group, Carlsbad, California, United States|Grossmont Orthopedic Medical Group, La Mesa, California, United States|Synergy Orthopedic Specialists Medical Group, San Diego, California, United States|The Orthohealing Center, Santa Monica, California, United States|Cellular Orthopedics, Des Plaines, Illinois, United States|New Jersey Regenerative Institute, Cedar Knolls, New Jersey, United States|RestorePDX, Beaverton, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04043819"
1366,"NCT04495582","Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)",,"Active, not recruiting","No Results Available","Multiple System Atrophy",,"Safety assessment(evaluation)|Efficacy assessment(evaluation)","Corestem, Inc.","All","Child, Adult, Older Adult",,"8","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","CS10BR05-MSA101-E","August 28, 2018","November 2024","November 2024","August 3, 2020",,"August 5, 2020","Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04495582"
1367,"NCT04230902","Effects of α MAT Versus Steroid Injection in Knee Osteoarthritis (STα MAT-knee Study)",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Microfragmented Adipose Tissue Transplant|Drug: Corticosteroid injection","Comparing the total pain score pre- and post-injection differences between the two arms|Comparing MOAKS pre-and post-injection differences between the two arms|Clinical outcomes-extension|Clinical outcomes-flexion|Clinical outcomes-stability|Cartilage thickness|Patient-based outcomes|Pain score-other follow-ups","American University of Beirut Medical Center","All","45 Years and older   (Adult, Older Adult)","Phase 3","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BIO-2017-0440","March 4, 2019","March 31, 2021","March 31, 2021","January 18, 2020",,"January 18, 2020","American University of Beirut Medical Center, Beirut, Lebanon",,"https://ClinicalTrials.gov/show/NCT04230902"
1368,"NCT01270139","Plasmonic Nanophotothermal Therapy of Atherosclerosis","NANOM-FIM","Completed","Has Results","Stable Angina|Heart Failure|Atherosclerosis|Multivessel Coronary Artery Disease","Procedure: Transplantation of nanoparticles|Procedure: Transplantation of iron-bearing nanoparticles|Device: Stenting","Total Atheroma Volume|MACE (Major Adverse Cardiovascular Events)-Free Survival|Per Cent of Fibro-fatty Component|Event Free Survival|Restenosis Rate|Late Definite Thrombosis|Coronary Vasomotion - Mean Lumen Diameter After Infusion of Acetylcholine 10-6 M|Per Cent Atheroma Volume|Target Lesion Revascularization|Per Cent of Fibrous Component|Per Cent of Necrotic Core|Per Cent of Calcium|Minimal Lumen Diameter|MACE|Cardiac Death|TLR (Target Lesion Revascularization)|TVR (Target Vessel Revascularization)|Mean Number of Membrane Defects on Membrane of Red Blood Cells","Ural State Medical University|Ural Institute of Cardiology|De Haar Research Task Force|Ural Federal University|Transfiguration Clinic","All","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NANOM-FIM","April 1, 2007","April 1, 2009","August 1, 2016","January 5, 2011","August 30, 2012","March 17, 2021","De Haar Research Task Force, Amsterdam, North Holland, Netherlands|Ural Center of Modern Nanotechnologies, Institute of Natural Sciences, Ural Federal University, Yekaterinburg, Sverdlovsk Oblast, Russian Federation|Transfiguration Clinic, Yekaterinburg, Sverdlovsk Oblast, Russian Federation|Ural Institute of Cardiology, Yekaterinburg, Sverdlovsk Oblast, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01270139"
1369,"NCT03167138","Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury",,"Active, not recruiting","No Results Available","Shoulder Pain|Shoulder Impingement Syndrome|Rotator Cuff Impingement Syndrome|Rotator Cuff Tendinitis|Rotator Cuff Syndrome of Shoulder and Allied Disorders|Spinal Cord Injuries","Biological: Autologous micro-fragmented adipose tissue|Device: Lipogems system","Numerical Rating Scale|Wheelchair User's Shoulder Pain Index (WUSPI)|Patient Global Impression of Change|Brief Pain Inventory interference items (BPI-I7)|Physical Examination of the Shoulder Score (PESS)","Kessler Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R-957-17","July 14, 2017","September 6, 2019","February 21, 2020","May 25, 2017",,"February 17, 2020","Kessler Institute for Rehabilitation, West Orange, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03167138"
1370,"NCT03790189","Subchondral and Intra-articular Application of Bone Marrow Concentrate for Knee Unicompartmental OA","MarrowMule","Unknown status","No Results Available","Osteoarthritis, Knee|Cartilage Degeneration","Biological: Subchondral and intra-articular injection of BMC","Change in IKDC (International Knee Documentation Committee) subjective score|Variation in KOOS (Knee Injury and Osteoarthritis Outcome) Score|VAS (Visual Analogue Scale) for pain|MRI (Magnetic Resonance Imaging) Changes in subchondral bone edema and cartilage status from basal to 12 months' follow-up","Istituto Clinico Humanitas","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","172797","January 2019","July 2021","November 2021","December 31, 2018",,"December 31, 2018","Istituto Clinico Humanitas, Rozzano, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT03790189"
1371,"NCT01739504","Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.",,"Terminated","No Results Available","Osteoarthritis","Procedure: Liposuction with Local Anesthesia|Biological: Intra articular infusion of AD-SVF","Change from Baseline in Visual Analogue Scale (VAS)|Change from Baseline of Quality of life scores|Change from Baseline of Reduction in analgesics|Number of adverse events reported|Change from Baseline in x-ray, sonogram, or MRI imaging of affected joint compared to baseline.","Ageless Regenerative Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AD-US-OR-001","March 1, 2014","April 1, 2017","April 1, 2017","December 3, 2012",,"November 24, 2017","Ageless Institute LLC, Aventura, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01739504"
1372,"NCT01544712","Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow",,"Completed","No Results Available","Non Traumatic Osteonecrosis of the Femoral Head (Hip)","Procedure: core decompression with autologous bone marrow implantation|Procedure: core decompression of the femoral head","reduction of total prosthesis|Pain reduction|functional status","University of Liege","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ref 2004/08 st 3","August 2004","September 2010","September 2010","March 6, 2012",,"March 6, 2012","University of Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT01544712"
1373,"NCT01892514","Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head","AVN-13","Unknown status","No Results Available","Osteonecrosis","Procedure: core decompression","Reduction of the total necrotic area by Magnetic Resonance Imaging (MRI)|Pain reduction by measurement of the Visual Analog Scale (VAS)|Functional status evaluated by Harris Hip Score (HHS) and Western Ontario McMaster Universities Arthritis Index (WOMAC)|maintenance of structural integrity of the joint by Radiography (RX)","Istituto Ortopedico Rizzoli","All","18 Years to 60 Years   (Adult)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AVN-13","April 2013","April 2018","April 2018","July 4, 2013",,"October 30, 2017","3rd Orthopaedic and Traumatologic Clinic, prevalently oncologic, Rizzoli Orthopaedic Institute, Bologna, Italy|S.S.D. Conservative Orthopaedic Surgery and Innovative Techniques, Rizzoli Orthopaedic Institute, Bologna, Italy|Orthopaedic and Traumatologic Department Policlinico di Modena, Modena, Italy",,"https://ClinicalTrials.gov/show/NCT01892514"
1374,"NCT04077099","REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","NSCLC","Drug: REGN5093","Number of patients with Dose Limiting Toxicities|Incidence and severity of treatment-emergent adverse events|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of grade ≥3 laboratory abnormalities|REGN5093 concentrations in serum over time|Objective response rate (ORR) per RECIST 1.1|ORR per RECIST 1.1|Incidence and severity of TEAEs|Incidence and severity of AESIs|Incidence and severity of SAEs|REGN5093 Pharmacokinetics (PK)|Duration of response (DOR) per RECIST 1.1.|Disease control rate (DCR) per RECIST 1.1.|Progression free survival (PFS) per RECIST 1.1.|Overall survival (OS)|Immunogenicity as measured by Anti-drug antibodies (ADA) to REGN5093","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","111","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5093-ONC-1863|2019-001908-38","January 7, 2020","October 20, 2024","October 20, 2024","September 4, 2019",,"October 29, 2021","Regeneron Research Facility, Birmingham, Alabama, United States|Regeneron Research Facility, Orange, California, United States|Regeneron Research Facility, Washington, District of Columbia, United States|Regeneron Research Facility, Tampa, Florida, United States|Regeneron Research Facility, Lexington, Kentucky, United States|Regeneron Research Facility, Boston, Massachusetts, United States|Regeneron Research Facility, Detroit, Michigan, United States|Regeneron Research Facility, Saint Louis, Missouri, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Durham, North Carolina, United States|Regeneron Research Facility, Oklahoma City, Oklahoma, United States|Regeneron Research Facility, Philadelphia, Pennsylvania, United States|Regeneron Research Facility, Pittsburgh, Pennsylvania, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Bordeaux Cedex 9, France|Regeneron Research Facility, Dijon Cedex, France|Regeneron Research Facility, Grenoble, France|Regeneron Research Facility, Montpellier, France|Regeneron Research Facility, Rennes Cedex 9, France|Regeneron Research Facility, Gyeonggi do, Gyeonggi, Korea, Republic of|Regeneron Research Facility, Suwon, Gyeonggi, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04077099"
1375,"NCT04821102","Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration",,"Not yet recruiting","No Results Available","Degenerative Arthritis|Knee Arthritis","Biological: JOINTSTEM|Drug: Saline","Arthroscopy|WOMAC total score|WOMAC subscale score|VAS score|RAND-36|IKDC|Biopsy|Use of rescue medication|Kellgren-Lawrence grade","R-Bio","All","20 Years and older   (Adult, Older Adult)","Not Applicable","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BS-JS-IIT1","July 1, 2021","February 1, 2022","December 31, 2023","March 29, 2021",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04821102"
1376,"NCT03797391","A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors",,"Recruiting","No Results Available","Neoplasms|Neoplasm Metastasis|Non-Small-Cell Lung Cancer","Drug: EMB-01","Maximum tolerated dose (MTD) (phase 1 only)|Adverse Events (AEs), and Serious Adverse Events (SAEs)|Overall Response Rate (ORR) (phase 2 only)|Maximum Serum Concentration (Cmax)|Area Under the Plasma Concentration-Time Curve (AUC)|Trough Serum Concentration (Ctrough)|Elimination half-life (t1/2)|Clearance (CL)|Volume of distribution at steady state (Vss)|Accumulation Ratio (AR)|Dose Proportionality|Anti-Drug Antibodies (ADA)|Duration Of Response (DOR)|Progression-Free Survival (PFS)","Shanghai EpimAb Biotherapeutics Co., Ltd.|Covance","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","186","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMB01X101","December 13, 2018","March 14, 2023","March 14, 2023","January 9, 2019",,"September 5, 2021","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Guangdong General Hospital, Guangzhou, Guang Dong, China|Shanghai Chest Hosptial, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03797391"
1377,"NCT02658344","Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis",,"Completed","No Results Available","Degenerative Arthritis|Knee Osteoarthritis","Biological: JOINTSTEM|Drug: Saline solution","WOMAC score|WOMAC 3 subscale|KOOS (Knee Injury & Osteoarthritis Outcome Score)|SF(Short Form)-36 Score|Global assessment of disease activity|Overall satisfaction|X-ray|MRI scan|Arthroscopy evaluation|Histological evaluation|VAS|IKDC|ROM|Quadriceps power|effusion|Crepitus|Ligament laxity|Medial joint line tenderness|Pes tenderness","R-Bio","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Jointstem2b","July 2015","November 2016","December 2016","January 18, 2016",,"June 5, 2019","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|GangNam Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02658344"
1378,"NCT04222140","Early Regenerative Intervention for Post-Traumatic Osteoarthritis","ERIPTO","Not yet recruiting","No Results Available","Post-Traumatic Osteoarthritis of Knee","Combination Product: ERIPTO Protocol|Biological: BMAC Only","Radiographic Changes|Subjective Knee Symptom Changes","Affinity Health Research Institute|Genesis Orthopedics and Sports Medicine|The Center for Primary Care and Sports Medicine","All","25 Years to 60 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ERIPTO","August 1, 2020","August 1, 2021","September 1, 2021","January 9, 2020",,"January 9, 2020","The Center for Primary Care and Sports Medicine, Aurora, Illinois, United States|Affinity Health Research Institute, Oak Brook, Illinois, United States|Genesis Orthopedics and Sports Medicine, Oak Brook, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04222140"
1379,"NCT02412462","Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy",,"Completed","No Results Available","Solid Tumor|Metastatic Cancer","Drug: AB-16B5","Number of participants with an adverse event as a measure of safety and tolerability|Determination of plasma concentrations of AB-16B5|Objective tumor responses in subjects with measurable disease according to RECIST|Monitoring of epithelial-to-mesenchymal (EMT) and stem cells biomarkers in peripheral blood circulating tumor cells and paired tumor biopsies","Alethia Biotherapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AB-16B5-101","April 2015","January 2017","January 2017","April 9, 2015",,"June 28, 2017","Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02412462"
1380,"NCT02932852","Autologous Adipose-Derived Adult Stem Cell Transplantation for Corneal Diseases","A-ADAS-CT-CD","Unknown status","No Results Available","Hereditary Corneal Dystrophy|Keratoconus","Procedure: Lipoaspiration|Procedure: Transplantation","Vision recovery (Corrected Distance Visual Acuity)|Corneal Thickness|Topopgraphy|Anterior segment Optical Coherence Tomography|Slit Lamp Observation|refraction measurement","Vissum, Instituto Oftalmológico de Alicante|Reviva Pharmaceuticals|Hospital Universitario La Paz|LASER VISION CENTER IN LIBANON|OPTICA GENERAL IN LIBANON","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTP-007/15","November 2015","April 2017",,"October 13, 2016",,"October 13, 2016","Optica General, Saida, Lebanon",,"https://ClinicalTrials.gov/show/NCT02932852"
1381,"NCT04604288","Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Hip Osteoarthritis",,"No longer available","No Results Available","Arthritis|Hip Osteoarthritis|Degenerative Arthritis|Hip Arthritis","Biological: HB-adMSC",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences",,"Child, Adult, Older Adult",,,"Other|Industry","Expanded Access:Individual Patients",,"HBHOA01",,,,"October 27, 2020",,"July 6, 2021","River Oaks Hospital and Clinics, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04604288"
1382,"NCT02742844","Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers",,"Terminated","No Results Available","Skin Ulcer Venous Stasis Chronic","Biological: APZ2 application","Percentage of wound size reduction|Assessment of adverse event (AE) occurrence|Absolute wound size reduction|Proportion of patients achieving complete wound closure|Time to first complete wound closure|Proportion of patients achieving 30% wound closure|Time to first 30% wound closure|Percentage of wound epithelialization|Formation of granulation tissue and wound exudation|Pain assessment as per numerical rating scale (NRS)|Quality of life (QoL) assessment using the SF-36 questionnaire|Dermatologic quality of life assessment using the DLQI questionnaire|Physical examination and vital parameters","RHEACELL GmbH & Co. KG|Ticeba GmbH|FGK Clinical Research GmbH|Granzer Regulatory Consulting & Services","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","13","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APZ2-II-01","August 2016","January 15, 2019","January 15, 2019","April 19, 2016",,"July 7, 2020","Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria-Hilf-Krankenhaus, Bochum, Germany|Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT02742844"
1383,"NCT02037204","IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.","IMPACT","Completed","Has Results","Foreign-Body Reaction|Inflammation|Effusion (L) Knee|Knee Pain Swelling","Other: Cartilage repair surgery","Safety: Adverse Events|Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score","UMC Utrecht","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPACT","March 2013","April 2016","April 2016","January 15, 2014","January 2, 2019","January 2, 2019","University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02037204"
1384,"NCT01771913","Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts",,"Completed","Has Results","Breast Reconstruction|Contour Irregularities|Volume Insufficiency","Genetic: centrifuged fat graft|Genetic: ADSCs enriched fat graft","Volume Maintenance|Immunophenotyping","University of Sao Paulo","Female","20 Years to 70 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","boosteredADSCs","March 2012","September 2014","May 2015","January 18, 2013","August 24, 2015","August 24, 2015","Hospital Municipal Carmino Caricchio, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01771913"
1385,"NCT03011541","Stem Cell Ophthalmology Treatment Study II","SCOTS2","Recruiting","No Results Available","Retinal Disease|Age-Related Macular Degeneration|Retinitis Pigmentosa|Stargardt Disease|Optic Neuropathy|Nonarteritic Ischemic Optic Neuropathy|Optic Atrophy|Optic Nerve Disease|Glaucoma|Leber Hereditary Optic Neuropathy|Blindness|Vision Loss Night|Vision Loss Partial|Vision, Low|Retinopathy|Maculopathy|Macular Degeneration|Retina Atrophy","Procedure: Arm 1|Procedure: Arm 2|Procedure: Arm 3","Visual Acuity|Visual Fields|Optical Coherence Tomography (OCT)","MD Stem Cells","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCOTS2","January 2016","January 2023","January 2024","January 5, 2017",,"September 10, 2021","MD Stem Cells, Westport, Connecticut, United States|MD Stem Cells, Coral Springs, Florida, United States|Medcare Orthopaedics & Spine Hospital, Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03011541"
1386,"NCT04323917","Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential",,"Recruiting","No Results Available","Pancreatic Cancer","Diagnostic Test: Liquid biopsy","Assessments of diagnosis of PC by EMT-TF mRNA levels in blood|Prediction of prognosis of PC by EMT-TF mRNA levels in blood","Istituto Clinico Humanitas|IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"850","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EMT PC 1.1","November 2, 2017","November 2021","November 2022","March 27, 2020",,"August 10, 2020","Istituto Clinico humanitas, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT04323917"
1387,"NCT04323813","""High Levels of EMT-TFs for the Diagnosis of Colorectal Cancer (CRC)""",,"Recruiting","No Results Available","Colorectal Cancer","Diagnostic Test: Liquid biopsy","Assessments of diagnosis of CRC by EMT-TF mRNA levels in blood|Prediction of prognosis of CRC by EMT-TF mRNA levels in blood","Istituto Clinico Humanitas|Cliniche Gavazzeni spa - Bergamo (BG)|Istituto Clinico Mater Domini - Castellanza (VA)|Humanitas Gradenigo - Torino","All","18 Years and older   (Adult, Older Adult)",,"900","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EMT CRC 1.1","September 1, 2017","September 2021","September 2022","March 27, 2020",,"March 27, 2020","Istituto Clinico Humanitas, Rozzano, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04323813"
1388,"NCT02918123","Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis",,"Recruiting","No Results Available","Psoriasis","Biological: FURESTEM-CD Inj.","number of adverse events|safety lab tests, physical examination, ECG, vital signs|variation of Cytokine, PASI, BSA","Kang Stem Biotech Co., Ltd.","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSB-PsO","January 17, 2018","December 2021","December 2021","September 28, 2016",,"March 14, 2018","The Catholic Univ. Korea Seoul, St. Marry's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02918123"
1389,"NCT02448121","Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease",,"Unknown status","No Results Available","Avascular Necrosis of Bone|Sickle Cell Disease","Procedure: Autologous bone marrow stem cell graft","Change in Functional / Clinical Score of 10 points or more|Numeric pain intensity scale (0-10)|Disease progression defined as progression to a fractural stage of osteonecrosis|Reoperation rate|Radiological progression","Federal University of Bahia|Hospital Universitário Professor Edgard Santos|Oswaldo Cruz Foundation","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAAE 25000039812/2005-99|11738","August 2006","July 2018","August 2018","May 19, 2015",,"November 20, 2017",,,"https://ClinicalTrials.gov/show/NCT02448121"
1390,"NCT02926300","Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)",,"Unknown status","No Results Available","Crohn's Disease","Biological: stem cells","all kinds of adverse events which occur during the clinical sutdy|ratio of patients who is applicable to CDAI<150|ratio of patients who reduce CDAI over 70 as contrasted witd baseline(V7)","Kang Stem Biotech Co., Ltd.","All","19 Years to 70 Years   (Adult, Older Adult)",,"24","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","KSTHD_FURESTEM-CD-EXT","November 2015","October 2021","November 2021","October 6, 2016",,"September 6, 2017","Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Seoul National Universtiy Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Soeul National University Hospital, Soeul, Korea, Republic of|The Catholic University of Korea, St. Vincent'S Hospital., Suwon-si, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02926300"
1391,"NCT02849613","Regenerative Stem Cell Therapy for Stroke in Europe","RESSTORE","Withdrawn","No Results Available","Stroke","Other: Adipose Derived Stem Cells|Other: Vehicle media","Between-group difference of NIHSS (stroke severity score)","University Hospital, Grenoble|Horizon 2020 - European Commission|University Grenoble Alps|Servicio Madrileño de Salud, Madrid, Spain|St. Anne's University Hospital Brno, Czech Republic|Andaluz Health Service|University of Glasgow|University of Eastern Finland|Etablissement Français du Sang|Tampere University|Histocell SL, Spain|Medfiles CRO, Finland|Institut National de la Santé Et de la Recherche Médicale, France|Hospices Civils de Lyon|Association Groupe ESSEC|NOVADISCOVERY SAS, France|Finovatis|Centre Hospitalier Universitaire de Besancon|Assistance Publique - Hôpitaux de Paris|University Hospital, Toulouse|University Hospital, Bordeaux|University Hospital, Caen|Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Servicio de Salud de Castilla La Mancha, Albacete, Spain|Servizo Galego de Saude, Santiago de Compostela, Spain|Pirkanmaa Hospital District, Tampere, Finland|Hospital Vall d'Hebron|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","38RC15.337","March 2016","September 2017","September 2017","July 29, 2016",,"October 6, 2021","University Grenoble Hospital / EFS, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT02849613"
1392,"NCT01920867","Stem Cell Ophthalmology Treatment Study","SCOTS","Unknown status","No Results Available","Retinal Disease|Macular Degeneration|Hereditary Retinal Dystrophy|Optic Nerve Disease|Glaucoma","Procedure: RB (Retrobulbar)|Procedure: ST (Subtenon)|Procedure: IV (Intravenous)|Procedure: IVIT (Intravitreal)|Procedure: IO (Intraocular)","Visual acuity|Visual fields","MD Stem Cells","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICMS-2013-0019.","August 2012","July 2020","July 2020","August 12, 2013",,"October 23, 2019","MD Stem Cells, Westport, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01920867"
1393,"NCT04515394","Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)",,"Active, not recruiting","No Results Available","Colorectal Neoplasms","Drug: Tepotinib|Biological: Cetuximab","Number of Participants Experiencing Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events (AEs) Version 5.0|Number of Participants with Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators|Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators|Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators|Overall Survival (OS) Assessed by Investigators|Number of Participants with Adverse Events (AEs) and Treatment Related Adverse Events (TRAEs)|Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings|Number of Participants With Anti-Drug Antibodies (ADAs) for Cetuximab","EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS202202_0002|2020-001776-15","January 28, 2021","March 23, 2023","March 23, 2023","August 17, 2020",,"November 24, 2021","Mayo Clinic, Phoenix, Arizona, United States|Moores Cancer Center, La Jolla, California, United States|University of California, Los Angeles (UCLA), Santa Monica, California, United States|Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Mayo Clinic Hospital, Jacksonville, Florida, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|North Shore-LIJ Monter Cancer Center, Lake Success, New York, United States|Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Scott & White Vasicek Cancer Treatment Center, Temple, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Aurora Cancer Care - Milwaukee West, Wauwatosa, Wisconsin, United States|Antwerp University Hospital, Antwerp, Belgium|UZ Leuven, Leuven, Belgium|Universtity Hospital Brno, Brno, Czechia|University Hospital Olomouc, Olomouc, Czechia|Dept. of Oncology Faculty Hospital Motol, Prague, Czechia|Hospital Na Bulovce, Prague, Czechia|CHU Besançon Hôpital Jean Minjoz, Besancon Cedex, France|University Hospital of Besançon, Besançon, France|CHU Estaing, Clermont Ferrand Cedex 1, France|CHU Estaing, Clermont-Ferrand, France|CHU Hôpital Henri Mondor, Créteil, France|Clinique Victor Hugo, Le Mans Cedex 02, France|Clinique Victor Hugo, Le Mans, France|CHU de Poitiers, Poitiers, France|Curie Institute, Saint Cloud, France|Institut Curie - René-Huguenin Hospital, Saint-Cloud, France|Istituto Scientifico Romagnolo per lo Studio e la Cura die Tumori, Meldona, Italy|Fondazione IRCCS - Istituto Tumori Milano, Milan, Italy|Grande Ospedale Metropolitano Niguarda, Milan, Italy|Istituto Europeo di Oncologia, Milan, Italy|Istituto Nazionale Tumori, Fondazione G. Pascale Napoli, Napoli, Italy|UOC Oncoematologia AOU Vanvitelli, Napoli, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chiara, Pisa, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy|Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy|Arkangelsk Clinical Oncological Dyspensary, Arkhangelsk, Russian Federation|Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russian Federation|Kursk Regional Clinical Oncology Dispensary, Kislino, Russian Federation|FSBI ""National Medical Research Center of Oncology n.a. N.N. Blokhina"" of the MoH of the RF, Moscow, Russian Federation|Limited Liability Company Medicine 24/7, Moscow, Russian Federation|Russian Cancer research center n.a. N.N. Blokhin, Moscow, Russian Federation|Omsk Regional Oncology Dispensary, Omsk, Russian Federation|LLC Clinica UZI 4D, Pyatigorsk, Russian Federation|Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation|Tomsk National Research Medical Center, Tomsk, Russian Federation|MKMC Medical City, Tyumen, Russian Federation|SAHI Republican Clinical Oncology Dispensary, Ufa, Russian Federation|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|VHIO Valle de Hebron Instituto de Oncologia, Barcelona, Spain|H.U. Ramon y Cajal, Madrid, Spain|HM-CIOCC, Madrid, Spain|Hospital de Madrid Norte Sanchinarro, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital UNiversitario La Paz, Madrid, Spain|H.U.Marqués de Valdecilla, Santander, Spain|HUVirgen del Rocio, Sevilla, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|Bristol Oncology Centre, Bristol, United Kingdom|Beatson WJSCC, Glasgow, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04515394"
1394,"NCT02000362","Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)",,"Unknown status","No Results Available","Crohn's Disease","Biological: Stem cells","Number of Participants with Adverse Events, Ratio of patients who is applicable to CDAI<150|the ratio of patients who reduce CDAI over 70 as contrasted with baseline value|a variation of CRP value as contrasted with baseline|a variation of MR enterographic score as contrasted with baseline|a variation of fecal calprotectin as contrasted with baseline|a variation of IBDQ score as contrasted with baseline|a variation of SF-36 score as contrasted with baseline|reduction of the number of draining fistula|all kinds of adverse effects which occur during the clinical study","Kang Stem Biotech Co., Ltd.","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSTHD_FURESTEM-CD","August 2014","September 2018","October 2018","December 4, 2013",,"September 6, 2017","Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Seoul National Universtiy Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Soeul National University Hospital, Soeul, Korea, Republic of|The Catholic University of Korea, St. Vincent'S Hospital., Suwon-si, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02000362"
1395,"NCT04137562","Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis",,"Recruiting","No Results Available","Atopic Dermatitis","Biological: ADSTEM Inj.|Other: Placebo","EASI-50|EASI-75|EASI score|SCORAD-50|SCORAD-75|SCORAD score|SCORAD subgroup|Severity|IGA grade|IGA -1 or more grade|IGA -2 or more grade|Total IgE|PGE2 and ECP|Immune cytokine|Remedy used days and frequency|Remedy used subjects","EHL Bio Co., Ltd.","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 2","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AD-CP-18-1|30902","December 11, 2019","February 14, 2025","May 31, 2027","October 24, 2019",,"January 6, 2020","Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of|Korea University AnSan Hospital, Ansan, Gyeonggi-do, Korea, Republic of|Chung-Ang University Hospital, Seoul, Seoulteukbyeolsi, Korea, Republic of|Kyunghee University Medical Center, Seoul, Seoulteukbyeolsi, Korea, Republic of|Seoul National University Hospital, Seoul, Seoulteukbyeolsi, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Seoulteukbyeolsi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04137562"
1396,"NCT04817501","Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System","CTCs","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Endometrial Cancer","Other: Taking 5 ml of venous blood at different time intervals|Other: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any","CTC phenotype","Tomsk National Research Medical Center of the Russian Academy of Sciences","Female","18 Years to 80 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CTC Phenotyping","February 14, 2014","December 1, 2022","December 1, 2022","March 26, 2021",,"March 26, 2021","Evgeniya Kaigorodova, Tomsk, Tomskaya Oblast, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04817501"
1397,"NCT00710411","Inflammatory Response After Muscle and Skeleton Trauma","IRAMST","Completed","No Results Available","Multiple Trauma",,"Inflammatory pattern of complement activation, biomarkers and complement-regulating proteins (CRegs)on leukocytes|inflammatory biomarkers, cell surface markers, apoptosis, functional polymorphisms, mesenchymal stem cells, severity of injury (ISS), infections, SIRS, sepsis, shock, organ dysfunctions, severity of disease, ICU length of stay, wound healing, mortality","University of Ulm|German Research Foundation","All","18 Years to 80 Years   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","DFG KFO-200","April 2009","October 2015","December 2015","July 4, 2008",,"December 17, 2015","Clinic of Anesthesiology and Clinic of Traumatology, Hand-, Plastic-, and Reconstructive Surgery, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT00710411"
1398,"NCT00512434","Percutaneous Autologous Bone-marrow Grafting for Open Tibial Shaft Fracture","IMOCA","Completed","No Results Available","Tibial Fractures|Fractures, Open","Procedure: Osteosynthesis","Proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve month post fracture.|Relation between the number of the progenitor available injected with concentrated bone marrow aspirated and the rate of bone union.|Comparison of the rate of complications between the 2 groups.|Economic impact study.","University Hospital, Tours","All","17 Years and older   (Child, Adult, Older Adult)","Not Applicable","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRN/06/PR/IMOCA|ID RCB 2007 - A00032 - 51","September 2007","September 2012","September 2013","August 7, 2007",,"October 22, 2018","UH Angers, Angers, France|UH Besançon Jean Minjoz, Besancon, France|UH Brest Cavale Blanche, Brest, France|UH Clermont Ferrand Gabriel Montpied, Clermont Ferrand, France|UH Grenoble Michallon Hospital, Grenoble, France|UH Grenoble South Hospital, Grenoble, France|UH Nancy Central Hospital, Nancy, France|UH Nantes Hôtel Dieu, Nantes, France|UH Pitié Salpétrière AH HP, Paris, France|UH Tours CHRU Trousseau, Tours, France|UHTOURS, Tours, France",,"https://ClinicalTrials.gov/show/NCT00512434"
1399,"NCT00538850","Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",,"Completed","Has Results","Cancer","Drug: Fentanyl sublingual spray|Drug: Placebo","Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)|Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing|Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing|Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing","INSYS Therapeutics Inc|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","130","Industry|NIH","Interventional","Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INS-05-001|CDR0000581128","October 2007","February 2010","October 2010","October 3, 2007","March 5, 2014","March 5, 2014","InSys Therapeutics, Incorporated, Chandler, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00538850"
1400,"NCT04407039","Establishment and Evaluation of Multimodal Image Recognition System of Glioma Based on Deep Learning",,"Not yet recruiting","No Results Available","Glioma","Device: PET/CT, H-MRS and MRI","The data of multimodal image recognition system|Molecular subsets in in diffuse gliomas|Overall survival","Tao Xin|Qianfoshan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","YXLL-KY-2020 (009)","December 30, 2021","August 30, 2022","December 30, 2022","May 29, 2020",,"September 9, 2021",,,"https://ClinicalTrials.gov/show/NCT04407039"
1401,"NCT02048371","SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes",,"Recruiting","No Results Available","Liposarcoma|Osteogenic Sarcoma|Ewing/Ewing-like Sarcoma|Rhabdomyosarcoma|Mesenchymal Chondrosarcoma","Drug: Regorafenib|Drug: Placebo","Progression-free survival (PFS). Cohort A|Progression-free survival (PFS). Cohort B|Progression-free survival (PFS). Cohort C|Progression-free survival (PFS). Cohort D|Progression-free survival (PFS). Cohort E|The incidence of reported CTCAE (Common Terminology Criteria for Adverse Events) version 4.03 adverse events. All cohorts.|Overall response rate (ORR). All cohorts.|Progression-free survival (PFS), Cohorts A and B, after crossover.|Response rate (RR), Cohorts A and B, after crossover.|Time to tumor progression (TTP), Cohorts A and B, after crossover.|overall survival (OS). Cohorts A and B, after crossover.|Disease Specific Survival (DSS). Cohorts A and B, after crossover.","Sarcoma Alliance for Research through Collaboration","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SARC024","July 2014","December 2021","February 2022","January 29, 2014",,"August 10, 2021","City of Hope National Medical Center, Duarte, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|Stanford University, Stanford, California, United States|Mayo Clinic - Florida, Jacksonville, Florida, United States|H. Lee Moffitt, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Dana Farber/Partners Cancer Care, Boston, Massachusetts, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02048371"
1402,"NCT01441128","-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer",,"Terminated","No Results Available","Carcinoma, Non-Small Cell Lung|Adenocarcinoma|Carcinoma, Squamous Cell|Carcinoma, Large Cell","Drug: PF-02341066/PF-00299804","Overall safety profile of combined PF 02341066 plus PF 00299804 including adverse events (AE), as defined and graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], and first cycle Dose Limiting Tox...|Plasma concentrations and pharmacokinetic (PK) parameters of PF 02341066 and PF 00299804 including AUCtau, Cmax, Ctrough, Tmax, and CLss/F|Clinical activity of combined PF 02341066 plus PF 00299804 including objective response (OR) and stable disease (SD) as defined by RECIST version 1.1, duration of response (DR) and progression free survival (PFS).|Biomarkers in tumor and blood that are potentially predictive for drug activity: for example, KRAS mutations, EGFR mutations (eg, T790M), EGFR and HER2 amplifications, c Met amplification and mutations, ALK, PTEN and PIK3A status in tumor biopsi...|Pharmacodynamic biomarkers in tumor biopsies (e.g., phospho c Met, c Met, EGFR, phospho EGFR) and in blood (e.g., HGF and s Met) that are modulated following drug exposure.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","20","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110250|11-C-0250","September 1, 2011","February 28, 2014","February 26, 2015","September 27, 2011",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01441128"
1403,"NCT02609776","Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","CHRYSALIS","Recruiting","No Results Available","Non-Small-Cell Lung Cancer","Drug: Amivantamab|Drug: Lazertinib|Drug: Carboplatin|Drug: Pemetrexed","Part 1: Number of Participants With Dose Limiting Toxicity (DLT)|Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs|Part 2: Overall Response Rate (ORR)|Part 2: Duration of Response (DOR)|Part 2: Percentage of Participants With Clinical Benefit|Trough Serum Concentration (Ctrough) of Amivantamab|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab|Maximum Serum Concentration (Cmax) of Amivantamab|Time to Reach Maximum Observed Serum Concentration (Tmax) of Amivantamab|Area Under the Serum Concentration-Time Curve From t1 to t2 Time (AUC[t1-t2]) of Amivantamab|Maximum Serum Concentration (Cmax) of Lzertinib|Time to Reach Maximum Observed Serum Concentration (Tmax) of Lazertinib|Trough Serum Concentration (Ctrough) of Lazertinib|Accumulation ratio (R) of Amivantamab|Number of Participants With Anti-Drug Antibodies (ADA)|Progression-Free Survival (PFS)|Time to Treatment Failure (TTF)|Overall Survival (OS)","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","780","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108064|61186372EDI1001|2018-003908-38","May 24, 2016","January 15, 2024","January 31, 2024","November 20, 2015",,"November 4, 2021","City of Hope, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|UCLA, Santa Monica, California, United States|Samuel Oschin Comprehensive Cancer Center Cedars-Sinai Medical Center, West Hollywood, California, United States|H. Lee Moffitt Cancer & Research Institute, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan - Rogel Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Langone Health at NYC University, NYU School of Medicine, New York, New York, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Sanford Cancer Center - Sanford Hematology Oncology, Sioux Falls, South Dakota, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Chris O'Brien Lifehouse, Camperdown, Australia|Austin Hospital, Heidelberg, Australia|St George Hospital, Kogarah, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|BC Cancer Agency - Vancouver BC, Vancouver, British Columbia, Canada|University Health Network, Toronto, Ontario, Canada|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China|Beijing Shijitan Hospital, Capital Medical University, Beijing, China|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Jilin cancer hospital, Changchun, China|The First Bethune Hospital of Jilin University, Changchun, China|Hunan Cancer hospital, Changsha, China|Sichuan Cancer Hospital, Chengdu, China|West China Hospital Sichuan University, Chengdu, China|Chongqing University Cancer Hospital, Chongqing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Anhui Province Hospital, Hefei, China|The First Affiliated Hospital of NanChang University, Nanchang, China|Jiangsu Cancer Hospital, Nanjing, China|Nantong Tumor Hospital, Nantong, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|The first affiliated hospital of xiamen university, Xiamen, China|Henan Cancer Hospital, Zhengzhou, China|Institut Bergonié, Bordeaux, France|Centre Georges-François Leclerc, Dijon, France|Centre Leon Bérard, Lyon Cedex 8, France|Hopital de la Timone, Marseille, France|Institut Curie, Paris, France|Institut de cancerologie de l'ouest, Saint-Herblain Cedex, France|Institut Gustave Roussy, Villejuif Cedex, France|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|National Cancer Center Hospital, Chuo-Ku, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-city, Japan|Hyogo Cancer Center, Hyogo, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Kurume University Hospital, Kurume, Japan|Aichi Cancer Center Hospital, Nagoya-Shi, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka City General Hospital, Osaka, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|Tottori University Hospital, Yonago, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hosp. Univ. Quiron Dexeus, Barcelona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Virgen Del Rocio, Seville, Spain|E-DA Hospital, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|The Christie Nhs Foundation Trust, Manchester, United Kingdom|Sir Bobby Robson Unit, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02609776"
1404,"NCT02412735","Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Subjects With Chronic Low Back Pain","MSB-DR003","Completed","No Results Available","Degenerative Disc Disease","Drug: rexlemestrocel-L|Drug: rexlemestrocel-L + HA|Drug: Placebo","Treatment Success (composite responder analysis of low back pain Visual Analogue Scale (VAS) score, Oswestry Disability Index (ODI) score and no post-treatment interventions)|Effectiveness (Pain Responder analysis)|Effectiveness (Functional Responder analysis)|Effectiveness (Treatment Success at 24 months)|Effectiveness (Minimal Pain Responder at 24 months)|Effectiveness (Time to first intervention)","Mesoblast, Ltd.|Quintiles, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","404","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSB-DR003","March 2015","May 15, 2020","April 1, 2021","April 9, 2015",,"May 26, 2021","Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Tennessee Valley Pain Consultants, Huntsville, Alabama, United States|Arizona Pain Specialists, Scottsdale, Arizona, United States|Physicians Research Group, Tempe, Arizona, United States|TriWest Research Associates, LLC, El Cajon, California, United States|Memorial Orthopaedics Surgical Group, Long Beach, California, United States|Newport Beach Headache and Pain, Newport Beach, California, United States|Institute for Regenerative Medicine and Clinical Research, Pasadena, California, United States|UC Davis Spine Center, Sacramento, California, United States|Orthopedic Pain Specialists, Santa Monica, California, United States|The Spine Institute, Santa Monica, California, United States|Summit Pain Alliance, Santa Rosa, California, United States|Integrated Pain Management, Walnut Creek, California, United States|Denver Back Pain Specialists, LLC, Greenwood Village, Colorado, United States|George Washington University Medical Center, Washington, District of Columbia, United States|Coastal Clinical Research Specialists, Fernandina Beach, Florida, United States|Shrock Orthopedic Research, LLC, Fort Lauderdale, Florida, United States|Holy Cross Orthopedics Institute, Oakland Park, Florida, United States|Emory Orthopaedics & Spine Center, Atlanta, Georgia, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States|Injury Care Medical Center, Boise, Idaho, United States|Millennium Pain Center, Bloomington, Illinois, United States|Otrimed Clinical Research, Edgewood, Kentucky, United States|Orthopedic Specialists of Louisiana, Shreveport, Louisiana, United States|Mayo Clinic, Rochester, Minnesota, United States|MAPS Applied Research Center, Shakopee, Minnesota, United States|Innovative Pain Care Center, Las Vegas, Nevada, United States|University Clinical Research, Somerset, New Jersey, United States|Ainsworth Institute of Pain Management, New York, New York, United States|Rochester Regional Health, Rochester, New York, United States|Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina, United States|On Site Clinical Solutions, LLC, Morrisville, North Carolina, United States|The Center for Clinical Research/ Carolinas Pain Institute, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|DOC Clinical Research, Dayton, Ohio, United States|Clinical Investigations, LLC, Edmond, Oklahoma, United States|Orthopaedic and Spine Specialists, York, Pennsylvania, United States|RI Hospital-Comprehensive Spine Center, Providence, Rhode Island, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Greenville Pharmaceutical Research, Inc., Charleston, South Carolina, United States|Texas Back Institute, Plano, Texas, United States|Spine Team Texas, Southlake, Texas, United States|Precision Spine Care, Tyler, Texas, United States|Ericksen Research & Development, LLC, Bountiful, Utah, United States|the SMART Clinic, Draper, Utah, United States|Hope Research Institute, Saint George, Utah, United States|Virginia iSpine Physicians, PC, Richmond, Virginia, United States|Monash Medical Center, Clayton, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02412735"
1405,"NCT02323477","Human Umbilical Cord Stroma MSC in Myocardial Infarction","HUC-HEART","Terminated","No Results Available","Chronic Ischemic Cardiomyopathy|Coronary Artery Bypass Surgery","Biological: stem cell transplantation","ventricular remodeling","Ankara University|Hacettepe University|Turkiye Yuksek Ihtisas Education and Research Hospital|Atigen-Cell and Tissue Center|Dr. Sami Ulus Children's Hospital|Ankara Yildirim Beyazıt University","Male","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","741.STZ.2014","February 2, 2015","September 30, 2018","December 30, 2018","December 23, 2014",,"July 10, 2020","Alp Can, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT02323477"
1406,"NCT05110196","Phase IV Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.",,"Not yet recruiting","No Results Available","Non-Small Cell Lung Carcinoma","Drug: Capmatinib 150 mg|Drug: Capmatinib 200 mg","Percentage of participants with Adverse Events (AEs)|Percentage of participants with dose modifications|Dose intensity|Overall Response Rate (ORR)|Overall Intracranial Response Rate (OIRR)|Duration of Response (DOR|Time To response (TTR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC280AIN01","December 1, 2021","July 1, 2024","July 1, 2024","November 5, 2021",,"November 5, 2021",,,"https://ClinicalTrials.gov/show/NCT05110196"
